Table of Contents

As filed with the Securities and Exchange Commission on June 22, 2010

Registration No. 333-166135

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Amendment No. 2 to

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

Amyris, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   8731   55-0856151

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

 

5885 Hollis Street, Suite 100

Emeryville, CA 94608

(510) 450-0761

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

 

John G. Melo

President and Chief Executive Officer

Amyris, Inc.

5885 Hollis Street, Suite 100

Emeryville, CA 94608

(510) 450-0761

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

 

Copies to:

 

Gordon K. Davidson, Esq.

Daniel J. Winnike, Esq.

Sayre E. Stevick, Esq.

Fenwick & West LLP

801 California Street

Mountain View, California 94041

(650) 988-8500

 

Jeffrey D. Saper, Esq.

Allison B. Spinner, Esq.

Wilson Sonsini Goodrich & Rosati, P.C.

650 Page Mill Road

Palo Alto, California 84304

(650) 493-9300

 

 

 

Approximate date of commencement of proposed sale to the public: as soon as practicable after this registration statement is declared effective.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.   ¨

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.   ¨

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.   ¨

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.   ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer      ¨    Accelerated filer      ¨
Non-accelerated filer      x     (Do not check if a smaller reporting company)    Smaller reporting company      ¨

 

 

 

CALCULATION OF REGISTRATION FEE

 

          

Title of Each Class of

Securities To Be Registered

   Proposed Maximum
Aggregate  Offering
Price (1)(2)
  Amount of
Registration Fee

Common Stock, $0.0001 par value per share

   $100,000,000   $7,130 (3)
          
  (1)   Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended.
  (2)   Includes shares which may be purchased by the underwriters pursuant to their option to purchase additional shares.
  (3)   Previously paid.

 

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to Section 8(a), may determine.

 

 


Table of Contents

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any state where the offer or sale is not permitted.

 

PROSPECTUS (Subject to Completion)

Issued June 22, 2010

 

             Shares

 

LOGO

 

COMMON STOCK

 

 

 

Amyris, Inc. is offering              shares of its common stock. This is our initial public offering and no public market currently exists for our shares. We anticipate that the initial public offering price of our common stock will be between $              and $              per share.

 

 

 

We have applied to list our common stock on The Nasdaq Global Market under the symbol “AMRS”.

 

 

 

Investing in our common stock involves substantial risks. See “ Risk Factors ” beginning on page 13.

 

 

 

PRICE $              A SHARE

 

 

 

      

Price to

Public

    

Underwriting

Discounts and
Commissions

    

Proceeds to

Amyris

Per Share

     $               $               $         

Total

     $                          $                          $                    

 

We have granted the underwriters the right to purchase up to an additional              shares of common stock.

 

The Securities and Exchange Commission and state securities regulators have not approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

The underwriters expect to deliver the shares of common stock to purchasers on                     , 2010.

 

 

 

MORGAN STANLEY     GOLDMAN, SACHS & CO.
  J.P. MORGAN  

 

 

 

BANCO ITAÚ     THOMAS WEISEL PARTNERS LLC

 

                    , 2010


Table of Contents

LOGO


Table of Contents

TABLE OF CONTENTS

 


 

 

 

You should rely only on the information contained in this prospectus or in any free-writing prospectus we may specifically authorize to be delivered or made available to you. We have not and the underwriters have not authorized anyone to provide you with additional or different information. We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information in this prospectus or a free-writing prospectus is accurate only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date.

 

Until                          , 2010 (25 days after the commencement of this offering), all dealers that buy, sell or trade shares of our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

 

For investors outside the U.S.: We have not and the underwriters have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the U.S. Persons outside the U.S. who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the U.S.

 

 

 

i


Table of Contents

PROSPECTUS SUMMARY

 

This summary highlights information appearing elsewhere in this prospectus and does not contain all of the information you should consider in making your investment decision. You should read this entire prospectus carefully, especially the “Risk Factors” section beginning on page  13 and our consolidated financial statements and the related notes appearing elsewhere in this prospectus, before making an investment decision.

 

AMYRIS, INC.

 

Business Overview

 

Our Company

 

We are building an integrated renewable products company by applying our industrial synthetic biology platform to provide alternatives to select petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. We genetically modify microorganisms, primarily yeast, and use them as living factories in established fermentation processes to convert plant-sourced sugars into potentially thousands of target molecules. Our first commercialization efforts have been focused on a molecule called farnesene, which forms the basis for a wide range of products varying from specialty chemical applications such as detergents, cosmetics, perfumes and industrial lubricants, to transportation fuels such as diesel. We call these No Compromise ® products because we design them to perform comparably to or better than currently available products. While our platform is able to utilize a wide variety of feedstocks, we have focused our initial research and development, business development and production operations on the use of Brazilian sugarcane as our primary feedstock because of its abundance, low cost and relative price stability. We intend to secure access to this feedstock and expand our production capacity in a “capital light” manner. Under this approach, we expect to work with Brazilian sugar and ethanol producers to build new, “bolt-on” facilities adjacent to their existing mills instead of building entirely new “greenfield” facilities, thereby reducing the capital required to establish and scale our production. Our first such arrangement is our joint venture with Usina São Martinho, a subsidiary of São Martinho S.A., one of the largest sugar and ethanol producers in Brazil.

 

Technology

 

We have developed genetic engineering and screening technologies that enable us to modify the way microorganisms, or microbes, process sugar. By controlling these metabolic pathways, we design microbes to serve as living factories, or biorefineries, to produce target molecules that we seek to commercialize. Our platform utilizes proprietary high-throughput processes to create and test as many as 1,000 yeast strains a day in order to select those yeast strains which are most efficient. We first developed and applied our technology to create microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial therapeutic. This work was funded by a five year grant awarded by the Bill & Melinda Gates Foundation to the Institute for OneWorld Health. We have granted a royalty-free license to this technology to sanofi-aventis for the commercialization of artemisinin-based drugs.

 

Feedstock

 

We are focusing on Brazilian sugarcane as our primary feedstock. Brazil is the world’s largest producer of sugarcane, crushing over 600 million tons of sugarcane annually to provide feedstock to approximately 400 sugar and ethanol mills. According to UNICA, the Brazilian Sugarcane Industry Association, sugarcane is the lowest cost feedstock to produce renewable products at scale and using it enables us to leverage the established Brazilian infrastructure. Common to both our process and the sugarcane-to-ethanol process is the use of fermentation, a well-established process that combines a sugar source and yeast to produce beer, wine and, more recently, ethanol fuels. We plan to establish production capacity taking as input the same sugar source that is routinely processed by existing sugar and ethanol mills and directing it to customized fermentors, where it will be combined with our genetically engineered yeast.

 

 

1


Table of Contents

Scale-Up

 

We operate research and development laboratories in Emeryville, California, and have built an adjacent pilot facility that tests our yeast strains in 300 liter scale fermentors. We have an identical pilot plant in Campinas, Brazil, to facilitate the adaptation of our technology to the Brazilian production environment. We established a 5,000 liter demonstration facility in Brazil in September 2009 to further validate our processes and equipment as we move toward commercialization of our products. We have also completed production runs using our strains to produce farnesene in a 60,000 liter fermentor at a contract manufacturing facility in the U.S.

 

Commercial Production

 

We expect to access feedstock and expand our production through our capital light strategy. Our first such arrangement is our joint venture with Usina São Martinho, SMA Indústria Quimica S.A. This facility is located at Usina São Martinho, the world’s largest sugarcane processing facility, which crushed 8.1 million tons of sugarcane during the 2009-2010 harvest. We have also provided Usina São Martinho with an option to produce our products at a second production facility. We have non-binding letters of intent in place with Bunge Limited, Cosan S.A. and Açúcar Guarani, a subsidiary of Tereos, which are leading Brazilian sugar and ethanol producers, to build new, bolt-on facilities adjacent to specified existing mills to produce our products. We expect that these mill owners will make a substantial capital or operating contribution to fund these facilities in return for a share of the higher gross margin we believe we will realize from the sale of our renewable products. We expect these arrangements to provide us with access to over 10 million tons of sugarcane crush capacity annually, which we intend to expand over time with these and other mills. As of the first quarter of 2010, this capacity represented approximately 10% of the total crush capacity of these sugar and ethanol producers.

 

Commercialization and Distribution

 

We plan to commence commercialization of our products starting in 2011 using contract manufacturers, and to have our first capital light production facility, our joint venture with Usina São Martinho, operational in the second quarter of 2012. As we commence commercial production of our initial molecule, farnesene, we expect to target specialty chemical markets. We recently entered into the following agreements related to the initial commercialization of our products:

 

   

Cosan : a term sheet with Cosan for the formation of a joint venture to develop and commercialize farnesene-based specialty chemicals for industrial and automotive applications.

 

   

M&G : a collaboration agreement with M&G Finanziaria S.R.L. that establishes the terms under which M&G may purchase our farnesene for use in M&G’s polyethylene terephthalate, or PET, resins to be incorporated into containers for food, beverages and other products.

 

   

P&G : a supply agreement with The Procter & Gamble Company that establishes terms under which P&G may purchase our farnesene for use in its products.

 

   

Soliance : an agreement with Soliance for the development and commercialization of farnesene-based squalane for use as an ingredient in cosmetics products.

 

   

Total : a collaboration agreement with Total Gas & Power USA Biotech, Inc., an affiliate of Total S.A., that covers the research, development and commercialization of chemical and fuel products.

 

Production and sale of our products pursuant to these relationships will depend on the achievement of contract-specific technical, development and commercial milestones.

 

For distribution of our diesel in the U.S., we expect to sell directly, primarily to corporations with large trucking fleets. For distribution of our diesel in other geographies, we expect to sell indirectly through third

 

 

2


Table of Contents

parties. We recently entered into an agreement with Shell Western Supply and Trading Limited, a subsidiary of Royal Dutch Shell plc, which establishes terms under which Shell may purchase our diesel fuel, commencing 18 months after we notify Shell that we intend to export diesel from Brazil. To build our U.S. distribution capabilities we established our subsidiary Amyris Fuels, LLC, which currently generates revenues through the sale of third party ethanol to wholesale customers through a network of terminals in the southeastern U.S.

 

Our Industry

 

Petroleum is a fundamental building block for products, such as consumer products, chemicals, plastics and transportation fuels, that are essential to modern economies. According to the U.S. Energy Information Administration, in 2008 the total worldwide demand for petroleum was over $3 trillion, or 5% of worldwide gross domestic product. Recently, however, the increased demand for petroleum in the face of limited supply, supply chain uncertainty and negative environmental impacts has created challenges to the current petroleum infrastructure. As a result, there have been many attempts to create products comparable to petroleum derivatives without these drawbacks. However, initial approaches have faced a number of challenges that have limited their success, including:

 

   

Exposure to volatile feedstock pricing. Many U.S. renewable fuels companies have focused on the conversion of commodity feedstocks, such as corn or vegetable oil, into ethanol or biodiesel. These companies were exposed to swings in the market prices for their feedstocks, which at times made production unprofitable for a number of producers in these industries.

 

   

Limited product portfolio . Companies engaging in early attempts to create renewable fuels typically focused on one end product, such as ethanol or biodiesel. These companies generally lacked product diversity and, therefore, were vulnerable to variability of market prices and the degree of government support for their primary product. Further, the products these companies made were imperfect substitutes for the products they were intended to replace, as neither ethanol nor biodiesel can be stored or transported conventionally and both are subject to blend limits.

 

   

Capital intensity . Many initial U.S. ethanol companies utilized a vertically integrated business model that required hundreds of millions of dollars to construct and own mills. This left them with limited ability to enter new geographies and to access new feedstock, as they were tied to their existing facilities.

 

   

Dependence on policy . The economic viability of many alternative fuels is based on government regulations and support, making it difficult to build a business with long term sustainability.

 

Other efforts to develop alternatives to petroleum-sourced products include the use of non-food-based feedstocks, such as cellulosic sugars sourced from wood chips, corn stalks and sugarcane bagasse. Some of these approaches have shown promise and may not be influenced by commodity markets and food versus fuel concerns. However, they are not complete solutions to the challenges above, and to date, these approaches have been limited by cost and technical considerations, among others.

 

Our Solution

 

Our proprietary technology enables us to engineer microbes, such as yeast, to produce target molecules, and our business model is designed to produce these products and bring them to market in a capital light manner. Our industrial synthetic biology platform is designed to produce competitive products from widely available plant-derived feedstocks using genetically modified yeast strains in a well-established fermentation process. We are focusing our initial production efforts in Brazil, positioning us to access sugarcane feedstock and to leverage the substantial infrastructure of existing sugar and ethanol mills.

 

 

3


Table of Contents

Competitive Strengths

 

Our key competitive strengths are:

 

   

Abundant, low-cost and relatively price stable feedstock. Brazilian sugar and ethanol mills typically grow much of their own sugarcane, and sugarcane in Brazil does not compete as a food source. As a result, this industry enjoys a low production cost structure and is insulated from feedstock price volatility.

 

   

Broad range of potential products . Our initial molecule, farnesene, can serve as the basis for a wide range of products, enabling us to optimize our product mix and reduce our exposure to any one end market. Our technology platform gives us the ability to produce potentially thousands of additional target molecules.

 

   

Scalable, capital light approach. Our technology platform enables us to leverage the large existing sugar and ethanol industry infrastructure in Brazil.

 

   

Not policy dependent. While we benefit from regulations, such as the Renewable Fuels Standard provided for by the U.S. Energy Policy Act of 2005, that encourage the use of renewable products, we expect our products to be offered on a cost-competitive basis with existing products without reliance on subsidies.

 

Our Solution for our Customers

 

The key benefits we intend to provide to our customers include:

 

   

No Compromise product offerings. We refer to our products as No Compromise because we design them to perform comparably to or better than currently available products. For example, we expect that our diesel will not require engine or distribution infrastructure modifications, will have better performance at low temperatures and will generally have a higher cetane number than biodiesel.

 

 

   

Greater pricing stability . We believe that our use of Brazilian sugarcane, and our ability over time to utilize a wide variety of other plant-based feedstocks, will enable us to offer our specialty chemical customers greater pricing protection from the level of price volatility generally associated with exposure to petroleum-sourced products.

 

   

“Green” alternative. Our products are derived from renewable sources, enabling our customers to reduce the environmental impact of their products and, in some cases, increase the loyalty consumers have for these products.

 

Our Value Proposition to Sugar and Ethanol Producers

 

The key benefits we intend to provide to sugar and ethanol producers that will work with us to produce our products include:

 

   

Product diversification. By producing our products, sugar and ethanol mills would be able to diversify their business beyond their current sugar or ethanol production and potentially mitigate volatility in their financial performance caused by changes in the market prices for sugar or ethanol.

 

   

Opportunity for growth. By diversifying their product base to address additional market opportunities, producers may be able to expand the amount of sugarcane grown and processed at their mills.

 

   

Potential for improved margins. We intend to offer these producers a share of the higher gross margin we believe we will realize from the sale of our renewable products relative to their existing products, potentially improving their gross margins and the return they realize on their feedstock.

 

 

4


Table of Contents

Our Strategy

 

Our objective is to become the leading provider of renewable specialty chemicals and transportation fuels worldwide. Key elements of our strategy include:

 

   

Pursuing market opportunities that maximize our returns. We intend to commercialize initially in select specialty chemical markets and then as we lower our production costs, to expand into broader specialty chemical and transportation fuels markets. We also intend to enter into collaborative research, development and commercialization agreements to accelerate our entry into select new product opportunities such as the agreements we have entered into with Cosan, M&G, P&G, Soliance and Total.

 

   

Leveraging our technology platform to improve efficiency. We intend to continually apply our technology platform to lower the cost of production of our products through yield improvements and other efficiencies.

 

   

Focusing on Brazilian sugarcane. We are initially focusing on Brazilian sugarcane as our primary feedstock because of its abundance, low cost and relative price stability.

 

   

Advancing capital light production. We expect to partner with existing sugar and ethanol mills to establish and scale production at a lower cost than the cost of greenfield mill construction such as our joint venture with Usina São Martinho.

 

   

Continuing to develop our fuels distribution network. We will continue to expand the size and geographic scope of our Amyris Fuels distribution network in the U.S. and establish arrangements with third parties for distribution in other countries such as our supply agreement with Shell.

 

Our Risks

 

Our business is subject to numerous risks and uncertainties that you should understand before making an investment decision. These risks are discussed more fully in the section entitled “Risk Factors” beginning on page 13 of this prospectus. These include:

 

   

we have a limited operating history and have not generated revenues from the sale of any of our renewable products, and our business may fail if we are not able to successfully commercialize these products;

 

   

we have incurred losses to date, anticipate continuing to incur losses in the future and may never achieve or sustain profitability;

 

   

if we are unable to decrease our production costs, we may not be able produce our products at competitive prices and our business will not succeed;

 

   

we have no experience producing our products at the commercial scale needed for the development of our business, and we will not succeed if we cannot effectively scale our technology and processes;

 

   

our ability to commence commercial sales of our products in 2011 is subject to a number of risks, any of which could delay our sales and adversely impact our customer relationships, business and results of operations;

 

   

the agreements for the initial commercialization of our products that we recently entered into are subject to technical, commercial and production milestones that we may fail to achieve;

 

   

if our joint venture production facility with Usina São Martinho in Brazil does not successfully commence operations in the second quarter of 2012, our customer relationships, business and results of operations may be adversely affected;

 

   

our joint venture with Usina São Martinho contemplates that we will make significant capital expenditures and subjects us to certain legal and financial terms that could adversely affect us;

 

 

5


Table of Contents
   

we plan to enter into additional arrangements with Brazilian sugar and ethanol producers to produce our products, and if we are not able to complete these arrangements in a timely manner and on terms favorable to us, our business will be adversely affected;

 

   

building new bolt-on facilities adjacent to existing sugar and ethanol mills for production of our products requires significant capital, and if mill owners are unwilling to contribute, or do not have or have access to this capital, production of our products would be more limited or expensive than expected and our business would be harmed;

 

   

our strategy of relying on existing Brazilian sugar and ethanol producers to produce our products will make us substantially dependent on these owners, and they may not perform their obligations under agreements with us or otherwise perform to our standards;

 

   

our reliance on contract manufacturers to produce our products during construction of our Usina São Martinho joint venture production facility and periodically for additional short-term production capacity exposes us to risks relating to the price and availability of that contract manufacturing and could adversely affect our growth;

 

   

the production of our products will require sugar feedstock, and the inability to obtain such feedstock in sufficient quantities or in a timely manner may limit our ability to produce our products;

 

   

an increase in the price and profitability of ethanol and sugar relative to our products could adversely affect our arrangements with sugar and ethanol producers;

 

   

the price of sugarcane feedstock can be volatile as a result of changes in industry policy and may increase the cost of production of our products;

 

   

most of our planned initial production capacity will be in Brazil, and our business will be adversely affected if we do not operate effectively in that country;

 

   

we may face risks relating to the use of our genetically modified yeast strains and if we are not able to secure regulatory approval for the use of our yeast strains or if we face public objection to our use of them, our business could be adversely affected;

 

   

we may not be able to obtain regulatory approval for the sale of our renewable products; and

 

   

we cannot assure you that our products will be approved or accepted by customers in specialty chemical markets.

 

Company Information

 

We were formed as a California corporation in 2003 under the name Amyris Biotechnologies, Inc. and have maintained our headquarters and research facilities in the San Francisco Bay Area since that time. In June 2010, we reincorporated in Delaware and changed our name to Amyris, Inc. We commenced research activities in 2005, focusing on the development of an alternative source of artemisinic acid for the treatment of malaria and launched research efforts for production of farnesene in 2006. In 2008, we began to sell third party ethanol to wholesale customers through our Amyris Fuels subsidiary. We first established a presence in Brazil in 2008 through the opening of laboratories in Campinas.

 

Our corporate headquarters are located at 5885 Hollis Street, Suite 100, Emeryville, CA 94608, and our telephone number is (510) 450-0761. Our website address is www.amyris.com. The information contained on our website or that can be accessed through our website is not part of this prospectus, and investors should not rely on any such information in deciding whether to purchase our common stock.

 

 

6


Table of Contents

Except where the context requires otherwise, in this prospectus, “Amyris,” “our company,” “the Company,” “we,” “us” and “our” refer to Amyris, Inc. and its subsidiaries. These subsidiaries include Amyris Brasil S.A., a majority-owned Brazilian company through which we conduct our Brazilian operations, and Amyris Fuels, LLC, a wholly-owned subsidiary through which we are building our U.S. fuels distribution capabilities. In connection with the completion of this offering, Amyris Brasil S.A. will become a wholly-owned subsidiary through the conversion of third-party held stock in that subsidiary into our common stock. Amyris Brasil holds our equity interest in our joint venture with Usina São Martinho, SMA Indústria Química S.A.

 

Amyris ® , No Compromise ® and our logo are our trademarks. This prospectus also contains trademarks and trade names of other businesses that are the property of their respective holders.

 

 

7


Table of Contents

THE OFFERING

 

Common stock offered by us

  

             shares

Common stock to be outstanding after this offering

  

             shares

Use of proceeds

   We intend to use the net proceeds from this offering for capital expenditures, working capital and other general corporate purposes, including for building engineering services capabilities and growing our chemistry capabilities. We may also use a portion of our proceeds to expand our current business through acquisitions of other companies, assets or technologies. See “Use of Proceeds.”

Risk factors

   You should read the “Risk Factors” section of this prospectus beginning on page  13 for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.

Proposed stock exchange trading symbol

  

“AMRS”

 

 

 

The number of shares of our common stock to be outstanding after this offering is based on 34,972,688 shares of our common stock outstanding as of March 31, 2010, after giving effect to the conversion of our outstanding convertible preferred stock into 29,000,821 shares of common stock and the conversion of shares of Amyris Brasil held by third party investors in this subsidiary into 550,044 shares of our common stock. It includes 311,111 shares of common stock issuable upon the conversion of 1,111,111 shares of Amyris Brasil issued after March 31, 2010 and 7,101,548 shares of common stock issuable upon conversion of the shares of Series D preferred stock issued after March 31, 2010, and gives effect to the forfeiture of 10,000 shares of restricted stock after March 31, 2010. In the event the actual initial public offering price is lower than $             per share, the shares of Series D preferred stock will convert into a larger number of shares of common stock; if the initial public offering price is equal to the midpoint of the range on the cover of this prospectus, the Series D preferred stock would convert into an additional              shares of common stock. A $1.00 decrease in the initial public offering price would increase by             , and a $1.00 increase in the initial public offering price would decrease by             , the number of shares of common stock issuable upon conversion of the Series D preferred stock. The number of shares of our common stock to be outstanding after this offering excludes:

 

   

5,819,455 shares of common stock issuable upon the exercise of stock options outstanding as of March 31, 2010, at a weighted average exercise price of $4.62 per share;

 

   

509,454 shares of common stock issuable upon exercise of stock options granted after March 31, 2010 and before June 21, 2010, with a weighted average exercise price of $20.41 per share;

 

   

195,604 shares of common stock issuable upon the exercise of outstanding warrants as of March 31, 2010, that will remain outstanding after the completion of this offering through various dates from one year from the effective date of this offering to January 2017, with a weighted average exercise price of $18.76 per share;

 

   

176,272 shares of common stock subject to restricted stock units outstanding as of March 31, 2010;

 

   

4,200,000 shares of common stock reserved for future issuance under our 2010 Equity Incentive Plan, which will become effective upon the completion of this offering and will contain provisions that will automatically increase its share reserve each year, as more fully described in “Management—Stock Option and Other Compensation Plans;” and

 

 

8


Table of Contents
   

168,627 shares of common stock reserved for future issuance under our 2010 Employee Stock Purchase Plan, which will become effective upon the completion of this offering and will contain provisions that will automatically increase its share reserve each year, as more fully described in “Management—Stock Option and Other Compensation Plans.”

 

Unless otherwise indicated, the information in this prospectus assumes:

 

   

the filing of our restated certificate of incorporation and the adoption of our restated bylaws immediately prior to the completion of this offering; and

 

   

no exercise by the underwriters of their option to purchase additional shares.

 

All references in this prospectus to “U.S. dollars,” “dollars,” “US$” or “$” are to U.S. dollars. All references to the “real”, “reais” or “BRL$” are to the Brazilian real, the official currency of Brazil. All conversions of Brazilian reais into U.S. dollars in this document are based on the BRL$/US$ exchange rate as of June 11, 2010, reported by The Wall Street Journal of BRL$1.8096 : US$1.0000.

 

 

9


Table of Contents

SUMMARY CONSOLIDATED FINANCIAL DATA

 

The following table summarizes our consolidated financial data. We have derived the following consolidated statement of operations data for the fiscal years ended December 31, 2007, 2008 and 2009 and the consolidated balance sheet data as of December 31, 2009 from our audited consolidated financial statements appearing elsewhere in this prospectus. We have derived the summary consolidated statement of operations data for the three months ended March 31, 2009 and 2010 and the summary consolidated balance sheet as of March 31, 2010 from our unaudited consolidated financial statements appearing elsewhere in this prospectus. You should read the summary of our consolidated financial data set forth below together with the more detailed information contained in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and the related notes appearing elsewhere in this prospectus. Our historical results presented below are not necessarily indicative of financial results to be achieved in the future.

 

    Years Ended December 31,     Three Months Ended March 31,  
             2007                        2008                        2009                        2009                        2010            
   

(in thousands, except share and per share amounts)

 
          (Unaudited)  

Consolidated Statement of Operations Data:

         

Total revenues

  $ 6,184      $ 13,892      $ 64,608      $ 2,091      $ 13,655   
                                       

Cost and operating expenses

         

Cost of product sales

           10,364        60,428        1,424        10,003   

Research and development (1)

    8,662        30,306        38,263        8,603        11,178   

Sales, general and administrative (1)

    10,522        16,622        23,558        4,402        9,216   

Restructuring and asset impairment charges

                  5,768                 
                                       

Total cost and operating expenses

    19,184        57,292        128,017        14,429        30,397   
                                       

Loss from operations

    (13,000     (43,400     (63,409     (12,338     (16,742

Total other income (expense)

    1,226        857        (1,391     (55     407   
                                       

Loss before income taxes

    (11,774     (42,543     (64,800     (12,393     (16,335

Benefit from income taxes

           (207                     
                                       

Net loss

    (11,774     (42,336     (64,800     (12,393     (16,335

Loss attributable to noncontrolling interest

           (472     (341     (221     (183
                                       

Net loss attributable to Amyris, Inc. stockholders

  $ (11,774   $ (41,864   $ (64,459   $ (12,172   $ (16,152
                                       

Net loss per share of common stock attributable to Amyris, Inc. stockholders, basic and diluted (2)

  $ (3.28   $ (9.91   $ (13.56   $ (2.65   $ (3.22
                                       

Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted (2)

    3,592,932        4,223,533        4,753,085        4,592,400        5,010,569   
                                       

Pro forma net loss per share of common stock attributable to Amyris, Inc. stockholders, basic and diluted (unaudited) (2)

      $ (3.16     $ (0.67
                     

Weighted-average shares of common stock outstanding used in computing pro forma net loss per share of common stock, basic and diluted (unaudited) (2)

        20,279,433          24,794,446   
                     

 

 

10


Table of Contents

 

     As of March 31, 2010
     Actual     Pro Forma   (3)    Pro Forma  as
Adjusted  (4)
   Pro Forma as
Adjusted  for

this Offering (5)
    

(in thousands)

     (Unaudited)     (Unaudited)    (Unaudited)    (Unaudited)

Consolidated Balance Sheet Data:

          

Cash, cash equivalents, short term investments and restricted cash

   $ 105,256      $ 105,256    $ 243,773    $              

Working capital

     85,994        85,994      85,994   

Total assets

     158,182        158,182      158,182   

Total indebtedness (6)

     20,307        20,307      20,307   

Convertible preferred stock warrant liability

     2,705               

Convertible preferred stock

     230,606               

Redeemable noncontrolling interest

     7,094               

Total equity (deficit)

   $ (128,690   $ 111,715    $ 250,232    $  

 

  (1)   Includes stock-based compensation expense as follows:

 

     Years Ended
December 31,
   Three Months Ended
March  31,
     2007    2008    2009    2009    2010
    

(in thousands)

          (Unaudited)

Research and development

   $ 117    $ 632    $ 773    $ 136    $ 453

Sales, general and administrative

        429      1,395      2,526         466      1,346
                                  

Total stock-based compensation expense

   $ 546    $ 2,027    $ 3,299    $ 602    $ 1,799
                                  

 

  (2)   See Note 2 to our Consolidated Financial Statements appearing elsewhere in this prospectus for an explanation of the method used to calculate basic and diluted net loss per share of common stock, the pro forma basic and diluted net loss per share of common stock and the weighted-average number of shares used in computation of the per share amounts.
  (3)   On a pro forma basis to reflect the conversion of all shares of our convertible preferred stock outstanding as of March 31, 2010 into common stock, the conversion of shares of Amyris Brasil outstanding as of March 31, 2010 held by investors in that subsidiary into shares of our common stock and the reclassification of the convertible preferred stock warrant liability to additional paid-in capital immediately prior to the completion of this offering.
  (4)   On a pro forma as adjusted basis to reflect the adjustments described in footnote 3 above and as further adjusted to reflect 311,111 shares of common stock issuable upon the conversion of 1,111,111 shares of Amyris Brasil issued after March 31, 2010 and 7,101,548 shares of common stock issuable upon conversion of shares of Series D preferred stock issued after March 31, 2010, and gives effect to the forfeiture of 10,000 shares of restricted common stock after March 31, 2010. In the event the actual initial public offering price is lower than $             per share, the shares of Series D preferred stock will convert into a larger number of shares of common stock; if the initial public offering price is equal to the midpoint of the range on the cover of this prospectus, the Series D preferred stock would convert into an additional              shares of common stock.
  (5)  

On a pro forma as adjusted for this offering basis to reflect the sale of              shares of our common stock by us in this offering at an assumed initial public offering price of $             per share (which is the midpoint of the price range set forth on the cover page of this prospectus), after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us in connection with this offering. A $1.00 increase (decrease) in the assumed initial

 

 

11


Table of Contents
 

public offering price of $             per share of common stock would increase (decrease) cash, cash equivalents and short-term investments by $ million, working capital by $             million, total assets by $             million and total stockholders’ equity (deficit) by $             million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us in connection with this offering. The pro forma as adjusted information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing.

  (6)   Total indebtedness includes a $7.6 million credit facility associated with our student loan auction rate securities holdings, $7.5 million in capital lease obligations, a $4.1 million note payable and a $1.0 million loan payable (see Note 5 and Note 6 to our Consolidated Financial Statements).

 

 

12


Table of Contents

RISK FACTORS

 

Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this prospectus, including the consolidated financial statements and the related notes appearing elsewhere in this prospectus, before making an investment decision. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects could be materially and adversely harmed. The trading price of our common stock could decline due to any of these risks, and, as a result, you may lose all or part of your investment.

 

Risks Related to Our Business

 

We have a limited operating history and have not generated revenues from the sale of any of our renewable products, and our business may fail if we are not able to successfully commercialize these products.

 

We are an early stage company with a limited operating history, and we have not yet commercialized any of our renewable products. To date, our revenues have consisted of sales of ethanol produced by third parties, funding from third party collaborative research services and government grants. We are subject to the substantial risk of failure facing businesses seeking to develop products based on a new technology. Certain factors that could, alone or in combination, prevent us from successfully commercializing our renewable products include:

 

   

technical challenges with our production processes that we are not able to overcome;

 

   

our ability to achieve commercial scale production of our specialty chemical and fuel products on a cost effective basis;

 

   

our ability to secure access to low-cost feedstock;

 

   

our ability to establish and maintain successful relationships for the production of our products with the owners of sugar and ethanol mills;

 

   

our ability to secure and maintain all necessary regulatory approvals for the production, distribution and sale of our products and to comply with applicable laws and regulations;

 

   

our ability to develop customer relationships and build a cost-effective distribution network for our products;

 

   

actions of direct and indirect competitors that may seek to enter the renewable products markets in competition with us or that may seek to impose barriers to one or more aspects of the renewable products businesses that we intend to pursue; and

 

   

public concerns about the ethical, legal, environmental and social ramifications of genetically engineered products and processes, use of land and renewable carbon sources for the production of renewable products and diversion of resources from food production.

 

We have incurred losses to date, anticipate continuing to incur losses in the future and may never achieve or sustain profitability.

 

We have incurred substantial net losses since our inception, including net losses of $11.8 million, $42.3 million, and $64.8 million for the years ended December 31, 2007, 2008 and 2009, respectively and $16.3 million for the three months ended March 31, 2010. We expect these losses to continue. As of March 31, 2010, we had an accumulated deficit of $136.6 million. We expect to incur additional costs and expenses related to the continued development and expansion of our business, including our research and development operations, continued operation of our pilot plants and demonstration facility and engineering and design work. Further, we expect to incur costs related to the facility that we are developing with Usina São Martinho and adoption of our technology at other sugar and ethanol mills. There can be no assurance that we will ever achieve or sustain profitability on a quarterly or annual basis.

 

13


Table of Contents

If we are unable to decrease our production costs, we may not be able to produce our products at competitive prices and our business will not succeed.

 

We have developed the ability to create yeast strains that are capable of converting feedstocks into desired target molecules that form the basis of our products. The successful development of our business depends on our ability to increase the efficiency with which we produce these target molecules from feedstock. Our production costs are primarily driven by our ability to increase the yield from our yeast strains and other production factors.

 

Yield refers to the amount of the desired molecule that can be produced from a fixed amount of feedstock. We believe that we will be able to enter certain specialty chemical markets with farnesene if we can attain at commercial production scale the 15% yield that we have achieved at two liter scale. While we believe that we will be able to attain this level of yield of farnesene in commercial production, we cannot assure you that we will do so on the timeline we have planned or at all. If we cannot, it is likely that we will not be able to commercialize farnesene in a timely manner, and in that event, our business would be materially and adversely affected.

 

In order to successfully enter transportation fuels and certain other specialty chemical markets, our yeast strains must produce those products at substantially higher yields than we have achieved to date. We have produced and screened several hundred thousand yeast strains to reach our current farnesene yield levels and anticipate having to produce and screen hundreds of thousands of additional strains as we seek to achieve the requisite yield levels to enter these larger markets. We may never achieve the yields needed for us to profitably enter these markets. Further, yield improvement is generally not achieved on a linear basis over time, which makes it difficult for us to predict with a high level of specificity when, if ever, new yield levels will be attained. If we are delayed, or are not successful, in improving the yield of farnesene with our yeast strains, our ability to enter a number of the markets that we are currently targeting will similarly be delayed or precluded and our ability to grow our business will be impaired.

 

Additional factors that impact our production cost include productivity, separation efficiency and chemical process efficiency. Productivity represents the rate at which our product is produced by a given yeast strain. Separation efficiency refers to the amount of desired product produced in the fermentation process that we are able to extract and the time that it takes to do so. Chemical process efficiency refers to the cost and yield for the chemical finishing steps that convert our target molecule into a desired product. Our ability to lower our production costs to enter and successfully compete in our target markets over time is contingent on efficiency gains of yield and these additional factors.

 

Our ability to commence commercial sales of our products in 2011 is subject to many risks, any of which could delay our sales and adversely impact our customer relationships, business and results of operations.

 

We are seeking to commence commercial sales of our initial products for specialty chemical applications in 2011. Our sales and marketing efforts are focused on a small number of target customers and we will need to convince them that our products are comparable to or better than the specialty chemicals they currently use that we seek to replace. In addition, these customers will need to complete product qualification procedures, which may not be achieved in a timely manner or at all. In order to commence sales in 2011, we must secure production capacity with contract manufacturers. Such capacity may not be available to us at prices or on terms acceptable to us, or at all. We do not currently have definitive agreements with contract manufacturers that would provide the production capacity required to achieve commercialization of our products in 2011 at the volumes we intend, or at all. In addition, some contract manufacturers may not have the equipment required for the production of our products and we cannot be assured that such equipment can be ordered or installed on a timely basis or at all. In addition, we will need to transfer our yeast strains and production processes to the contract manufacturing facilities, and we may face technical or operational challenges that delay the start-up of production or increase our costs. The failure of our contract manufacturers to produce our initial products on a timely basis or at all, or to produce our products in accordance with quality specifications or in volumes sufficient to meet our customer demand, could harm our relationships with our customers. Additionally, we have not tested our current yeast

 

14


Table of Contents

strains at commercial scale production levels, and our production costs will be impacted by the progress we make in improving the yield, productivity, separation efficiency and chemical process efficiency of our production process before we commence 2011 production. If we are unable to make the necessary progress, we may nonetheless decide to commence sales of our products at a loss in order to establish demand for our products and develop customer relationships, which could adversely affect our results of operations.

 

We recently entered into several agreements and a term sheet for the initial commercialization and sale of our products that contain important technical, development and commercial milestones. If we do not meet those milestones our future revenue and financial results will be harmed.

 

In June 2010, we entered into several agreements and a term sheet regarding arrangements for the further development of our products and, in some cases, for ultimate sale to the customer under the agreement. None of these agreements affirmatively obligates the other party to purchase specific quantities of any products at this time, and these agreements contain important conditions that must be satisfied before any such purchases may be made. These conditions include technical specifications that must be achieved to the satisfaction of our customer, which we cannot be certain we will be able to achieve. Some agreements provide that we will not seek to initiate sales until we achieve advances in yield and other production efficiencies to lower the cost of producing our products. In addition, these agreements contain exclusivity and other terms that may limit our ability to commercialize our products and technology in ways that we do not currently envision. If we do not achieve these contractual milestones, our revenues and financial results will be harmed.

 

We have limited experience in structuring arrangements with customers for the purchase of our renewable products, and we may not be successful in this essential aspect of our business.

 

We expect that our customers will be large companies that sell chemical products for consumer and other applications, and large users of diesel fuel. Because we have not yet completed development of our products, we have limited experience operating in our customers’ industries and interacting with the customers that we intend to target. Developing that expertise may take longer than we expect and will require that we expand and improve our sales and marketing infrastructure. These activities could delay our ability to capitalize on the opportunities that our technology and products present, and may prevent us from achieving commercialization of our initial products in 2011. Further, we expect ultimately to sell large amounts of our products to specific customers, and this will require that we effectively negotiate and manage contracts for these purchase and sale relationships. The companies with which we expect to have customer arrangements are generally much larger than we are and have substantially longer operating histories and more experience in target industries than we have. As a result, we may not be effective in negotiating or managing the terms of our relationships with these companies, which could adversely affect our future results of operations.

 

We have no experience producing our products at the commercial scale needed for the development of our business, and we will not succeed if we cannot effectively scale our technology and processes.

 

In addition to developing our yeast strains further to lower our production costs, we must demonstrate the ability to utilize our yeast strains to produce desired products at the commercial scale and on an economically viable basis. Such production will require that our technology and processes be scalable from laboratory, pilot and demonstration projects to commercial-scale production. Our technology may not perform as expected when applied at commercial scale, or we may encounter operational challenges for which we are unable to devise a workable solution. For example, contamination in the production process could decrease process efficiency, create delays and increase our costs. We may not be able to scale up our production in a timely manner, if at all, even if we successfully complete product development in our laboratories and pilot and demonstration facilities. If this occurs, our ability to commercialize our technology will be adversely affected, and, with respect to any products that we do bring to market, we may not be able to lower the cost of production, which would adversely affect our ability to increase the future profitability of our business.

 

15


Table of Contents

If our joint venture production facility with Usina São Martinho in Brazil does not successfully commence operations in the second quarter of 2012, our customer relationships, business and results of operations may be adversely affected.

 

We have selected Brazil as the optimal geography for the initial commercial production of our products, largely because of the availability of sugarcane as a feedstock and the existing infrastructure for producing, gathering and processing this sugarcane. Our business plan envisions that we will develop our production capacity in Brazil by demonstrating to existing sugar and ethanol producers the economic advantages of producing our products in addition to, or in lieu of, their current products. In order to have control over the development of our first commercial production facility in Brazil, we entered into an agreement with Usina São Martinho, one of the largest sugar and ethanol producers in Brazil, for the joint ownership and development of a production facility at the Usina São Martinho mill.

 

In order for our production facility at Usina São Martinho to meet our goal of commencing production in the second quarter of 2012, we must successfully complete the designs and other plans needed for the construction of this facility and secure in a timely manner the requisite permits, licenses and other governmental approvals in Brazil for doing so. Issuance of permits is subject to government review and may require, among other conditions, modification of plans or remediation of environmental impacts at the Usina São Martinho site. Construction of the facility must also be completed on a timely basis and within the budget. Once the facility is operational, it must perform as we have designed it. If we encounter significant delays, cost overruns, engineering problems, equipment supply constraints or other serious challenges in bringing this facility online, we may be unable to produce our initial renewable products in the time frame we have planned, or we may continue to use contract manufacturing sources, which would reduce our expected gross margins. Further, if our efforts to complete, and commence production at, this facility are not successful, other mill owners in Brazil may decide not to work with us to develop additional production facilities, demand more favorable terms or delay their commitment to invest capital in our production.

 

Our joint venture with Usina São Martinho contemplates that we will make significant capital expenditures and subjects us to certain legal and financial terms that could adversely affect us.

 

In April 2010, we entered into a joint venture with Usina São Martinho to build a new production facility for the production of our products at the Usina São Martinho sugar and ethanol mill located in São Paulo state. The terms of this joint venture are complex and are set forth in agreements that include several schedules that the parties anticipate will be converted into definitive agreements. If we and Usina São Martinho are unable to complete the agreements contemplated by these schedules, our ability to commence operations under the joint venture will be delayed and may never occur. Further, if we and Usina São Martinho disagree over the interpretation of the joint venture documents, the future success of the joint venture may be impaired and any amount that we have invested in it may be at risk.

 

The construction of the facility at Usina São Martinho will be the first project of this nature which we will design and manage. We expect the construction costs of the new facility to total between $80 million to $100 million. Under the terms of our joint venture agreements, construction of the production facility will take place in two phases. Phase I is designed to construct a facility capable of producing farnesene from up to one million tons of crushed sugarcane and Phase II will add capacities of up to a second million tons. Within one year of the commencement of Phase I commercial operations, Usina São Martinho will be required to reimburse us for half of the cost of Phase I, up to a cap of 30.9 million reais ($17.1 million based on the exchange rate at June 11, 2010). Thereafter, Usina São Martinho will co-fund the construction of Phase II and, as necessary, make a final payment at completion such that their total contribution will be 61.8 million reais ($34.2 million based on the exchange rate at June 11, 2010).

 

The difference in the amounts and timing of our capital contributions relative to Usina São Martinho’s could leave us vulnerable in the event we encounter challenges in building the facility or bringing it online, delays in achieving commercial viability with our farnesene production process, disputes with Usina São Martinho or other

 

16


Table of Contents

unanticipated events that may occur prior to the time Usina São Martinho makes its capital contribution. In addition, because Usina São Martinho’s contribution is capped, we will bear the responsibility for construction costs in excess of those anticipated.

 

The joint venture will be managed by a three member executive committee, of which we appoint two members, including the plant director who is the most senior executive. The executive committee will be responsible for managing the construction and operation of the production facility. The joint venture will be governed by a four member board of directors, of which we and Usina São Martinho will each appoint two members. The board of directors has certain protective rights which include final approval of the engineering designs and project work plan developed and recommended by the executive committee. If our directors and the Usina São Martinho directors fail to reach agreement on approval of the engineering designs or project work plans, construction of the facility could be delayed or terminated. Further, Usina São Martinho has the right to terminate the joint venture under certain circumstances. If the joint venture is terminated, we would be required to buy the joint venture’s assets at fair value and transfer them to another location. In that event, we could incur significant unexpected costs and be required to find alternative locations for our facility, which would substantially delay the commencement of production.

 

Under the terms of the joint venture agreements, if Amyris Brasil becomes controlled, directly or indirectly, by a competitor of Usina São Martinho, then Usina São Martinho has the right to acquire our interest in the joint venture. If Usina São Martinho becomes controlled, directly or indirectly, by a competitor of ours, then we have the right to sell our interest in the joint venture to Usina São Martinho. In either case, the purchase price shall be determined in accordance with the joint venture agreements, and we would continue to have the obligation to acquire products produced by the joint venture for the remainder of the term of the supply agreement then in effect even though we would no longer be involved in the joint venture’s management.

 

The joint venture has agreed to purchase, and Usina São Martinho has agreed to provide, feedstock for a price that is based on the average return that Usina São Martinho could receive from the production of its current products, sugar and ethanol. If the cost of these products increases relative to the price at which we can sell the output that we are required to purchase from the joint venture, our return on sales of products produced by the joint venture would be adversely affected. We are required to purchase the output of the joint venture for the first four years at a price that guarantees the return of Usina São Martinho’s investment plus a fixed interest rate. We may not be able to sell the output at a price that allows us to achieve anticipated, or any, level of profitability on the product we acquire under these terms. Similarly, the return that we are required to provide the joint venture for products after the first four years may have an adverse effect on the profitability we achieve from acquiring the mill’s output. Finally, our purchase obligation with the mill requires us to purchase the output regardless of whether we have a customer for such output, and our results of operations and financial condition would be adversely affected if we are unable to sell the output that we are required to purchase.

 

We consolidate our joint venture with Usina São Martinho in accordance with the guidance for consolidation of variable interest entities, which requires an ongoing assessment of whether we have the power to direct the activities that most significantly impact the joint venture’s economic performance. We may be unable to consolidate this joint venture in the future, if we determine that consolidation as a variable interest entity is no longer appropriate.

 

We plan to enter into arrangements with Brazilian sugar and ethanol producers to produce our products, and if we are not able to complete these arrangements in a timely manner and on terms favorable to us, our business will be adversely affected.

 

To expand our production in Brazil beyond that of our initial production facility with Usina São Martinho, we intend to enter into agreements with sugar and ethanol producers in Brazil that require them to make a substantial capital or operating contribution to produce our renewable products. In return, we expect to provide them with a share of the higher gross margin we believe we will realize from the sale of these products relative to

 

17


Table of Contents

their existing products. There can be no assurance that a sufficient number of Brazilian sugar and ethanol mill owners will accept the opportunity to partner with us for the production of our products, whether on those terms or at all. Reluctance on the part of mill owners may be caused, for example, by their failure to understand our technology or product opportunities or agree with the greater economic benefits that we believe they can achieve from partnering with us. Mill owners may also be reluctant or unable to obtain needed capital, or they may be limited by existing contractual obligations with other third parties, liability, health and safety concerns, and additional maintenance, training, operating and other ongoing expenses. We have entered into letters of intent with three Brazilian sugar and ethanol producers to produce our products and Usina São Martinho has the option for production at a second mill, but these do not bind either the mill owner or us to enter into and proceed with a formal relationship. There are numerous issues regarding these mill relationships that must be successfully negotiated with each of the mill owners and we may not be successful in completing these negotiations. Even if sugar and ethanol producers are willing to build new facilities and produce our products, they may do so only on economic terms that place more of the cost, or confer less of the economic return, on us than we currently anticipate. If we are not successful in negotiations with sugar and ethanol mill owners, our cost of gaining this production capacity may be higher than we anticipate in terms of up-front costs, capital expenditure or lost future returns, and we may not gain the production base that we need in Brazil to allow us to grow our business.

 

Building new, bolt-on facilities adjacent to existing sugar and ethanol mills for production of our products requires significant capital, and if mill owners are unwilling to contribute, or do not have or have access to this capital, production of our products would be more limited or more expensive than expected and our business would be harmed.

 

We expect to expand our production capacity using a capital light approach, through which mill owners would invest a substantial portion or all of the capital needed to build our bolt-on production facilities, in exchange for a share of the higher gross margin from the sale of our renewable chemicals and fuels, as compared to their current products. Mill owners may perceive this construction as a costly process requiring substantial capital or operating contribution. Mill owners may not have sufficient capital of their own for this purpose or may not be willing or able to secure financing. As a result, they may choose not to contribute the amount of capital that we anticipate or may need to seek external sources of financing, which may not be available. If the mill owner needs to obtain financing through debt, we may be required to provide a guarantee.

 

Even if sugar and ethanol producers are attracted to the opportunity, they may not attract the credit that they need or want to do so. In the past, Brazil has experienced very high rates of inflation, and the government’s measures to control inflation have often included maintaining a tight monetary policy with high interest rates, restricting the availability of credit. Limitations in the credit markets that would impede or prevent this kind of financing could adversely affect our ability to develop the production capacity needed to allow us to grow our business.

 

Our strategy of relying on existing Brazilian sugar and ethanol producers to produce our products will make us substantially dependent on these owners, and they may not perform their obligations under agreements with us or otherwise perform to our standards.

 

Even if we reach agreements with Brazilian sugar and ethanol producers to produce our products, initially the mill owners will be unfamiliar with our technology and production processes. We cannot be sure that the owners will have or develop the operational expertise needed to run the additional equipment and processes required to produce our products. Further, we may have limited control over the application of our specifications and quality requirements and the amount or timing of resources that any mill owner is able or willing to devote to production of our products. Mill owners may fail to perform their obligations as expected or may breach or terminate key terms of their agreements with us, such as the obligation to provide the agreed-upon amount of sugarcane feedstock for the production of our products. Moreover, disagreements with one or more mill owners could develop, and any conflict with a mill owner could negatively impact our relationship, and reduce our ability to enter into future agreements, with other sugar and ethanol mill owners. Furthermore, the sugar and ethanol mills may be subject to unanticipated disruptions to operations such as unscheduled down times,

 

18


Table of Contents

operational hazards, equipment failures, labor disruptions, land reform movements, political disruptions and natural disasters, thus preventing or delaying the production of our products. If our sugar and ethanol mill partners in Brazil fail to successfully operate the production facilities for our products, or terminate their relationships with us, such operational difficulties could adversely impact the timely and efficient production of our products. As a result, our business, results of operations and financial condition could be harmed.

 

Our reliance on contract manufacturers to produce our products during construction of our Usina São Martinho joint venture production facility and periodically for additional short-term production capacity exposes us to risks relating to the price and availability of that contract manufacturing and could adversely affect our growth.

 

We anticipate commencing production of certain of our products in 2011 through the use of contract manufacturers prior to the time that our joint venture facility in Brazil is ready to commence production. Similarly, as we grow and look to bring new facilities on line, it is possible that there will be periods when the demand for our products exceeds our production capacity. We intend to seek to enter into relationships with contract manufacturers for these purposes. We cannot be sure that contract manufacturers with this capacity will be available when we need their services, that they will be willing to dedicate a portion of their production capacity to our products or that we will be able to reach acceptable price and other terms with them for the provision of their production services. If we are unable to secure the services of such third parties when and as needed, we may lose customer opportunities and the growth of our business may be impaired. In addition, we expect that our costs to produce products using contract manufacturers will be higher than the costs to produce our products in sugar and ethanol mills with which we have entered into long term relationships.

 

The production of our products will require sugar feedstock, and the inability to obtain such feedstock in sufficient quantities or in a timely manner may limit our ability to produce our products.

 

We anticipate that the production of our products will require large volumes of feedstock, initially Brazilian sugarcane. We cannot predict the future availability of such feedstock or be sure that our mill partners, which we expect to supply the sugarcane necessary to produce our products, will be able to supply it in sufficient quantities or in a timely manner. Crop yields and sugar content depend on weather conditions, such as rainfall and temperature, that vary. Weather conditions have historically caused volatility in the ethanol and sugar industries by causing crop failures or reduced harvests. Excessive rainfall can adversely affect the supply of sugarcane available for the production of our products by reducing the sucrose content and limiting growers’ ability to harvest. Crop disease and pestilence can also occur from time to time and can adversely affect sugarcane growth, potentially rendering useless or unusable all or a substantial portion of affected harvests. The limited amount of time during which sugarcane keeps its sugar content after harvest and the fact that sugarcane is not itself a traded commodity increases these risks and limits our ability to substitute supply in the event of such an occurrence. If Brazilian sugarcane production is adversely affected by these or other conditions, our ability to produce our products will be impaired, and our business will be adversely affected.

 

An increase in the price and profitability of ethanol and sugar relative to our products could adversely affect our arrangements with sugar and ethanol producers.

 

In order to induce owners of sugar and ethanol facilities to produce our products, we plan to compensate them for the feedstock consumed in the production of our products in an amount equal to the revenue they would have realized had they instead produced their traditional products, plus any incremental costs incurred in the production of our products over their usual production costs. Finally, as we sell our products, we expect to share a portion of the realized gross margin with these mill owners. An increase in the price of ethanol or sugar relative to the price at which we can sell our products could result in the cost of our products increasing without a corresponding increase in the price at which we can sell our products. In this event our results of operations would be adversely affected. If ethanol prices are sufficiently high so that the return from converting a given amount of sugarcane to ethanol exceeds the return from converting that amount of sugarcane into our products, then we will have to compensate the mill owner for that loss or risk the mill owner reverting to the production of ethanol and not produce our products at all.

 

19


Table of Contents

Many factors could cause this unfavorable price dislocation. If sugar prices increase over a sustained period of time, this may encourage sugar production at the expense of ethanol in mills with flexibility to produce both products, which in turn could cause domestic prices in Brazilian reais for ethanol to increase. In addition, the Brazilian government currently requires the use of anhydrous ethanol as a gasoline additive. Any change in these government policies could affect ethanol demand in a way that discourages mill owners from producing our products.

 

The price of sugarcane feedstock can be volatile as a result of changes in industry policy and may increase the cost of production of our products.

 

In Brazil, sugarcane prices may increase due, among other things, to changes in the criteria set by the Conselho dos Produtores de Cana, Açúcar e Álcool (Council of Sugarcane, Sugar and Ethanol Producers), or Consecana. Consecana is an industry association of producers of sugarcane, sugar and ethanol that sets market terms and prices for general supply, lease and partnership agreements and may change such prices and terms. Such changes could result in higher sugarcane prices and/or a significant decrease in the volume of sugarcane available for the production of our products, which could adversely our business and results of operations.

 

Most of our planned initial production capacity will be in Brazil, and our business will be adversely affected if we do not operate effectively in that country.

 

For the foreseeable future, we will be subject to risks associated with the concentration of essential product sourcing and operations in Brazil. In the past, the Brazilian economy was characterized by frequent and occasionally extensive intervention by the Brazilian government and unstable economic cycles. The Brazilian government has changed in the past, and may change in the future, monetary, taxation, credit, tariff and other policies to influence the course of Brazil’s economy. For example, the government’s actions to control inflation have at times involved setting wage and price controls, adjusting interest rates, imposing taxes and exchange controls and limiting imports into Brazil. We have no control over, and cannot predict, what policies or actions the Brazilian government may take in the future. For example, the Brazilian government may take actions to support state-controlled entities in our industry that could adversely affect us. Our business, financial performance and prospects may be adversely affected by, among others, the following factors:

 

   

delays or failures in securing licenses, permits or other governmental approvals necessary to build and operate facilities and use our yeast strains to produce products;

 

   

rapid consolidation in the sugar and ethanol industries in Brazil, which could result in a decrease in competition;

 

   

political, economic, diplomatic or social instability in or affecting Brazil;

 

   

changing interest rates;

 

   

tax burden and policies;

 

   

effects of changes in currency exchange rates;

 

   

exchange controls and restrictions on remittances abroad;

 

   

inflation;

 

   

land reform movements;

 

   

export or import restrictions that limit our ability to move our products out of Brazil or interfere with the import of essential materials into Brazil;

 

   

changes in or interpretations of foreign regulations that may adversely affect our ability to sell our products or repatriate profits to the U.S.;

 

   

tariffs, trade protection measures and other regulatory requirements;

 

20


Table of Contents
   

successful compliance with U.S. and foreign laws that regulate the conduct of business abroad;

 

   

an inability, or reduced ability, to protect our intellectual property in Brazil including any effect of compulsory licensing imposed by government action; and

 

   

difficulties and costs of staffing and managing foreign operations.

 

Such factors could have a material adverse impact on our results of operations and financial condition.

 

In addition, Brazilian presidential and parliamentary elections will take place in October 2010. The Brazilian president has significant power to determine public policies and introduce measures affecting the Brazilian economy and companies such as ours. The new government, whether or not controlled by the current president’s political party, may seek to implement changes to existing public policies. For example, the current or future government may face pressure to reduce public investments (including investments in infrastructure), due to increasing inflation and public debt. This could have a material adverse impact on our operations.

 

We cannot predict whether the current or future Brazilian government will implement changes to existing policies on taxation, exchange controls, monetary strategy and social security, among others. We cannot estimate the impact of any such changes on the Brazilian economy or our operations.

 

We may face risks relating to the use of our genetically modified yeast strains and if we are not able to secure regulatory approval for the use of our yeast strains or if we face public objection to our use of them, our business could be adversely affected.

 

The use of genetically modified microorganisms (“GMMs”), such as our yeast strains, is subject to laws and regulations in many countries, some of which are new and some of which are still evolving. Public attitudes about the safety and environmental hazards of, and ethical concerns over, genetic research and GMMs could influence public acceptance of our technology and products. In the U.S., the Environmental Protection Agency (“EPA”) regulates the commercial use of GMMs as well as potential products from the GMMs. While the strain of genetically modified yeast that we currently use for the development and anticipate using for the commercial production of our target molecules, S. cerevisiae , is eligible for exemption from EPA review because it is recognized as posing a low risk, we must satisfy certain criteria to achieve this exemption, including but not limited to use of compliant containment structures and safety procedures, and we cannot be sure that we will meet such criteria in a timely manner, or at all. If exemption of S. cerevisiae is not obtained, our business may be substantially harmed.

 

In addition to S. cerevisiae , we may seek to use different GMMs in the future that will require EPA approval. If approval of different GMMs is not secured, our ability to grow our business could be adversely affected.

 

In Brazil, GMMs are regulated by the National Biosafety Technical Commission, or CTNBio. We have obtained approval from CTNBio to use GMMs in a contained environment in our Campinas facilities for research and development purposes. In addition, we have obtained initial commercial approval from CTNBio for one of our current yeast strains. As we continue to develop new yeast strains, we will be required to obtain further approvals from CTNBio in order to use these strains in commercial production in Brazil. We may not be able to obtain approvals from relevant Brazilian authorities on a timely basis, or at all, and if we do not, our ability to produce our products in Brazil would be impaired, which would adversely affect our results of operations and financial condition.

 

We expect to encounter GMM regulations in most if not all of the countries in which we may seek to establish production capabilities, and the scope and nature of these regulations will likely be different from country to country. If we cannot meet the applicable requirements in other countries in which we intend to produce products using our yeast strains, or if it takes longer than anticipated to obtain such approvals, our business could be adversely affected.

 

21


Table of Contents

We may not be able to obtain regulatory approval for the sale of our renewable products.

 

Our renewable chemical products may be subject to government regulation in our target markets. In the U.S., the EPA administers the Toxic Substances Control Act, or TSCA, which regulates the commercial registration, distribution, and use of chemicals. Before an entity can manufacture or distribute significant volumes of a chemical, it needs to determine whether that chemical is listed in the TSCA inventory. If the substance is listed, then manufacture or distribution can commence immediately. If not, then a pre-manufacture notice must be filed with the EPA for a review period of up to 180 days including extensions. Some of the products we produce or plan to produce, such as farnesene and squalane, are already in the TSCA inventory. Others, such as our lubricant s, diesel and jet fuel, are not yet listed. We may not be able to expediently receive approval from the EPA to list the molecules we would like to make on the TSCA registry, resulting in delays or significant increases in testing requirements. A similar program exists in the European Union, called REACH (Registration, Evaluation, Authorization, and Restriction of Chemical Substances). We similarly need to register our products with the European Commission, and this process could cause delays or significant costs. To the extent that other geographies, such as Brazil, may rely on TSCA or REACH for chemical registration in their geographies, delays with the U.S. or European authorities may subsequently delay entry into these markets as well.

 

Our diesel fuel is subject to regulation by various government agencies, including the EPA and the California Air Resources Board in the U.S. and Agencia Nacional do Petroleo, or ANP, in Brazil. To date, we have obtained registration with the EPA for the use of our diesel in the U.S. at a 20% blend rate with petroleum diesel. We are currently seeking supplemental EPA registration for a 35% blend rate and working to secure ANP approval for use of our diesel in Brazil at a 10% blend rate. We are currently in process of registration of our fuel with the California Air Resources Board and the European Commission. Registration with each of these bodies is required for the sale and use of our fuels within their respective jurisdictions.

 

We expect to encounter regulations in most if not all of the countries in which we may seek to sell our renewable chemical and fuel products, and we cannot assure you that we will be able to obtain necessary approvals in a timely manner or at all. If our chemical and fuel products do not meet applicable regulatory requirements in a particular country or at all, then we may not be able to commercialize our products and our business will be adversely affected.

 

We cannot assure you that our products will be approved or accepted by customers in specialty chemical markets.

 

The markets we intend to enter first are those for specialty chemical products used by large consumer products or specialty chemical companies. In entering these markets, we intend to sell our products as alternatives to chemicals currently in use, and in some cases the chemicals that we seek to replace have been used for many years. The potential customers for our molecules generally have well developed manufacturing processes and arrangements with suppliers of the chemical components of their products and may have a resistance to changing these processes and components. These potential customers frequently impose lengthy and complex product qualification procedures on their suppliers, influenced by consumer preference, manufacturing considerations such as process changes and capital and other costs associated with transitioning to alternative components, supplier operating history, regulatory issues, product liability and other factors, many of which are unknown to, or not well understood by, us. Satisfying these processes may take many months or years. If we are unable to convince these potential customers that our products are comparable to the chemicals that they currently use or that the use of our products is otherwise to their benefits, we will not be successful in entering these markets and our business will be adversely affected.

 

If we are unable to satisfy the significant product certification requirements of equipment manufacturers, we may not be able to successfully enter markets for transportation fuels, and our business would be adversely affected.

 

In order for our diesel fuel product to be accepted in various countries around the world, diesel engine manufacturers must certify that the use of our fuels in their equipment will not invalidate product warranties and that they otherwise regard our diesel as an acceptable fuel. In addition, we must successfully demonstrate to these manufacturers that our fuel does do not degrade the performance or reduce the lifecycle of their engines or cause

 

22


Table of Contents

them to fail to meet emissions standards. Meeting these suitability standards can be a time consuming and expensive process, and we may invest substantial time and resources into such qualification efforts without ultimately securing approval. To date, our diesel fuel products have achieved limited approvals from certain engine manufacturers, but we cannot be assured that other engine or vehicle manufacturers or fleet operators, will approve usage of our fuels. Although our diesel fuel satisfies existing pipeline operator and fuel distributor requirements, such fuel has not been reviewed nor transported by such operators as of this date. If these operators impose volume limitations on the transport of our fuels, our ability to sell our fuels may be impaired.

 

Our ability to sell a jet fuel product will be subject to the same types of qualification requirements as our diesel fuel, although we believe the qualification process will take longer and will be more expensive than the process for diesel.

 

We expect our international operations to expose us to the risk of fluctuation in currency exchange rates and rates of foreign inflation, which could adversely affect our results of operations.

 

We currently incur some costs and expenses in Brazilian reais and may in the future incur additional expenses in foreign currencies and derive a portion of our revenues in the local currencies of customers throughout the world. As a result, our revenues and results of operations are subject to foreign exchange fluctuations, which we may not be able to manage successfully. During the past few decades, the Brazilian currency in particular faced frequent and substantial exchange rate fluctuations in relation to the U.S. dollar and other foreign currencies. For example, the real appreciated 12.3%, 8.7% and 17.0% against the U.S. dollar in 2005, 2006, and 2007 respectively. As a result of the global financial crisis in mid-2008, the real depreciated 31.9% against the U.S. dollar. In 2009, due in part to the recovery of the Brazilian economy at a faster rate than the global economy, the real once again appreciated 25% against the U.S. dollar. In the first quarter of 2010, the real depreciated 2.6% against the U.S. dollar. There can be no assurance that the real will not significantly appreciate or depreciate against the U.S. dollar in the future.

 

We bear the risk that the rate of inflation in the foreign countries where we incur costs and expenses or the decline in value of the U.S. dollar compared to those foreign currencies will increase our costs as expressed in U.S. dollars. Future measures by the Central Bank of Brazil to control inflation, including interest rate adjustments, intervention in the foreign exchange market and changes to the fixed the value of the real, may trigger increases in inflation. Whether in Brazil or otherwise, we may not be able to adjust the prices of our products to offset the effects of inflation on our cost structure, which could increase our costs and reduce our net operating margins. If we do not successfully manage these risks through hedging or other mechanisms, our revenues and results of operations could be adversely affected.

 

We expect to face competition for our specialty chemical and transportation fuels products from providers of petroleum-based products and from other companies seeking to provide alternatives to these products, and if we cannot compete effectively against these companies or products we may not be successful in bringing our products to market or further growing our business after we do so.

 

We expect that our renewable products will compete with both the traditional, largely petroleum-based specialty chemical and fuels products that are currently being used in our target markets and with the alternatives to these existing products that established enterprises and new companies are seeking to produce. Amyris Fuels competes with other ethanol distributors in buying and selling third party ethanol.

 

In the specialty chemical markets that we will seek to enter initially, and in other chemical markets that we may seek to enter in the future, we will compete with the established providers of chemicals currently used in these products. Producers of these incumbent products include global oil companies, large international chemical companies and other companies specializing in specific products, such as squalane or essential oils. We may also compete in one or more of these markets with products that are offered as alternatives to the traditional petroleum-based or other traditional products being offered in these markets.

 

23


Table of Contents

In the transportation fuels market, we expect to compete with independent and integrated oil refiners, advanced biofuels companies and biodiesel companies. These refiners compete with us by selling traditional fuel products and some are also pursuing hydrocarbon fuel production using non-renewable feedstocks, such as natural gas and coal, as well as processes using renewable feedstocks, such as vegetable oil and biomass. We also expect to compete with companies which are developing the capacity to produce diesel and other transportation fuels from renewable resources in other ways. These include advanced biofuels companies using specific enzymes that they have developed to convert cellulosic biomass, which is non-food plant material such as wood chips, corn stalks and sugarcane bagasse, into fermentable sugars. Similar to us, some companies are seeking to use engineered enzymes to convert sugars, in some cases from cellulosic biomass and in others from natural sugar sources, into renewable diesel and other fuels. Biodiesel companies convert vegetable oils and animal oils into diesel fuel and some are seeking to produce diesel and other transportation fuels using thermochemical methods to convert biomass into renewable fuels.

 

We believe the primary competitive factors in both the chemicals and fuels markets are:

 

   

product price;

 

   

product performance and other measures of quality;

 

   

infrastructure compatibility of products;

 

   

sustainability; and

 

   

dependability of supply.

 

The oil companies, large chemical companies and well-established agricultural products companies with whom we compete are much larger than we are, have, in many cases, well developed distribution systems and networks for their products, have valuable historical relationships with the potential customers we are seeking to serve and have much more extensive sales and marketing programs in place to promote their products. In order to be successful, we must convince customers that our products are at least as effective as the traditional products they are seeking to replace and must provide our products on a cost-competitive basis with these traditional products and other available alternatives. Some of our competitors may use their influence to impede the development and acceptance of renewable products of the type that we are seeking to produce.

 

We believe that for our chemical products to succeed in the market, we must demonstrate that our products are comparable alternatives to existing products and to any alternative products that are being developed for the same markets based on some combination of product cost, availability, performance and consumer preference characteristics. With respect to our diesel and other transportation fuels products, we believe that our product must perform as effectively as petroleum-based fuel, or alternative fuels, and be available on a cost-competitive basis. In addition, with the wide range of renewable fuels products under development, we must be successful in reaching potential customers and convincing them that ours are effective and reliable alternatives.

 

Amyris Fuels currently competes with regional ethanol distributors in its purchase, distribution and sale of third party ethanol in the southeastern U.S. and competes with other suppliers based on price, convenience and reliability of supply.

 

A decline in the price of petroleum and petroleum-based products may reduce demand for many of our renewable products and may otherwise adversely affect our business.

 

We anticipate that most of our renewable products, and in particular our fuels, will be marketed as alternatives to corresponding petroleum-based products. If the price of oil falls, we may be unable to produce products that are cost-effective alternatives to their petroleum-based products. Declining oil prices, or the perception of a future decline in oil prices, may adversely affect the prices we can obtain from our potential customers or prevent potential customers from entering into agreements with us to buy our products. During sustained periods of lower oil prices we may be unable to sell our products, which could materially and adversely affect our operating results.

 

24


Table of Contents

Our pursuit of new product opportunities may not be technically feasible, which would limit our ability to expand our product line and sources of revenues.

 

Our technology provides us with the capability to genetically engineer microbes to produce potentially thousands of molecules. In order to grow our business over time we will need to, and we intend to, commit substantial resources to the development and analysis of these new molecules and the new pathways, or microbial strains, required to produce them. There is no guarantee that we will be successful in creating microbial strains that are capable of producing each target molecule. For example, some target molecules may be “toxic” to the microbe, which means that the production of the molecule kills the microbe. Other molecules may be biologically producible in small amounts but cannot be produced in quantities adequate for commercial production. In addition, some of our microbes may have longer production cycles that may make production of the target molecules more costly. If we are unable to resolve issues of this nature, we may not be able to expand our product line to introduce new sources of revenues.

 

Changes in government regulations, including subsidies and economic incentives, could have a material adverse effect upon our business and results of operations.

 

The market for renewable fuels is heavily influenced by foreign, federal, state and local government regulations and policies. Changes to existing or adoption of new domestic or foreign federal, state and local legislative initiatives that impact the production, distribution or sale of renewable fuels may harm our business. For example, in 2007, the U.S. Congress passed an alternative fuels mandate that currently calls for 13 billion gallons of liquid transportation fuels sold in 2010 to come from alternative sources, including renewable fuels, a mandate that grows to 36 billion gallons by 2022. Of this amount, a minimum of 21 billion gallons must be advanced biofuels. In the U.S. and in a number of other countries, these regulations and policies have been modified in the past and may be modified again in the future. Any reduction in mandated requirements for fuel alternatives and additives to gasoline may cause demand for biofuels to decline and deter investment in the research and development of renewable fuels. In addition, the U.S. Congress has passed legislation that extends tax credits to blenders of certain renewable fuel products. However, there is no assurance that this or any other favorable legislation will remain in place. For example, the biodiesel tax credit expired in December 2009, and its extension was not approved until March 2010. Any reduction in, or phasing out or elimination of existing tax credits, subsidies and other incentives in the U.S. and foreign markets for renewable fuels, or any inability of our customers to access such credits, subsidies and incentives, may adversely affect demand for our products and increase the overall cost of commercialization of our renewable fuels, which would adversely affect our business. In addition, market uncertainty regarding future policies may also affect our ability to develop new renewable products or to license our technologies to third parties and to sell products to our end customers. Any inability to address these requirements and any regulatory or policy changes could have a material adverse effect on our business, financial condition and results of operations.

 

Concerns associated with renewable fuels, including land usage, national security interests and food crop usage, are receiving legislative, industry and public attention. This could result in future legislation, regulation and/or administrative action that could adversely affect our business. Any inability to address these requirements and any regulatory or policy changes could have a material adverse effect on our business or the business of our partners or customers, financial condition and results of operations.

 

Furthermore, the production of our products will depend on the availability of feedstock, especially sugarcane. Agricultural production and trade flows are subject to government policies and regulations. Governmental policies affecting the agricultural industry, such as taxes, tariffs, duties, subsidies, incentives and import and export restrictions on agricultural commodities and commodity products, can influence the planting of certain crops, the location and size of crop production, whether unprocessed or processed commodity products are traded, the volume and types of imports and exports, and the availability and competitiveness of feedstocks as raw materials. Future government policies may adversely affect the supply of sugarcane, restrict our ability to use sugarcane to produce our products, and negatively impact our revenues and results of operations.

 

25


Table of Contents

We may incur significant costs complying with environmental laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.

 

We use hazardous chemicals and radioactive and biological materials in our business and are subject to a variety of federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of these materials both in the U.S. and overseas. Although we have implemented safety procedures for handling and disposing of these materials and waste products in an effort to comply with these laws and regulations, we cannot be sure that our safety measures are compliant or capable of eliminating the risk of accidental injury or contamination from the use, storage, handling or disposal of hazardous materials. In the event of contamination or injury, we could be held liable for any resulting damages, and any liability could exceed our insurance coverage. There can be no assurance that violations of environmental, health and safety laws will not occur in the future as a result of human error, accident, equipment failure or other causes. Compliance with applicable environmental laws and regulations may be expensive, and the failure to comply with past, present, or future laws could result in the imposition of fines, third party property damage, product liability and personal injury claims, investigation and remediation costs, the suspension of production, or a cessation of operations, and our liability may exceed our total assets. Liability under environmental laws can be joint and several and without regard to comparative fault. Environmental laws could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations, which could impair our research, development or production efforts and harm our business.

 

Our financial results could vary significantly from quarter to quarter and are difficult to predict.

 

Our revenues and results of operations could vary significantly from quarter to quarter because of a variety of factors, many of which are outside of our control. As a result, comparing our results of operations on a period-to-period basis may not be meaningful. Factors that could cause our quarterly results of operations to fluctuate include:

 

   

achievement, or failure to achieve, technology or product development milestones needed to allow us to enter identified markets on a cost effective basis;

 

   

delays or greater than anticipated expenses associated with the completion of new production facilities, and the time to complete scale-up of production following completion of a new production facility;

 

   

disruptions in the production process at any facility where we produce our products;

 

   

the timing, size and mix of sales to customers for our products;

 

   

increases in price or decreases in availability of our feedstocks;

 

   

the unavailability of contract manufacturing capacity altogether or at anticipated cost;

 

   

fluctuations in foreign currency exchange rates;

 

   

gains or losses associated with our hedging activities, especially in Amyris Fuels;

 

   

fluctuations in the price of and demand for sugar, ethanol, and petroleum-based and other products for which our products are alternatives;

 

   

seasonal production and sale of our products;

 

   

the effects of competitive pricing pressures, including decreases in average selling prices of our products;

 

   

unanticipated expenses associated with changes in governmental regulations and environmental, health and safety requirements;

 

   

reductions or changes to existing fuel and chemical regulations and policies;

 

   

departure of executives or other key management employees;

 

   

our ability to use our net operating loss carry forwards to offset future taxable income;

 

26


Table of Contents
   

business interruptions such as earthquakes and other natural disasters;

 

   

our ability to integrate businesses that we may acquire;

 

   

risks associated with the international aspects of our business; and

 

   

changes in general economic, industry and market conditions, both domestically and in our foreign markets.

 

Due to these factors and others the results of any quarterly or annual period may not meet our expectations or the expectations of our investors and may not be meaningful indications of our future performance.

 

Disruption of transportation and logistics services or insufficient investment in public infrastructure could adversely affect our business.

 

We initially intend to manufacture most of our renewable products in Brazil, where existing transportation infrastructure is underdeveloped. Substantial investments required for infrastructure changes and expansions may not be made on a timely basis or at all. Any delay or failure in making the changes to or expansion of infrastructure could harm demand or prices for our renewable products and impose additional costs that would hinder their commercialization.

 

In Brazil, a substantial portion of commercial transportation is by truck, which is significantly more expensive than the rail transportation available to U.S. and other international producers. Our dependence on truck transport may affect our production cost and, consequently, impair our ability to compete with petroleum-sourced products in local and world markets.

 

We may require additional financing in the future and may not be able to obtain such financing on favorable terms, if at all.

 

We will continue to fund our research and development and related activities and to provide working capital to fund production, storage, distribution and other aspects of our business. In addition, we plan to make significant capital expenditures in connection with our joint venture with Usina São Martinho and other potential mill arrangements. While we plan to enter into relationships with sugar and ethanol producers for them to provide some portion or all of the capital needed to build the new, adjacent bolt-on production facility, we may determine that it is more advantageous for us to provide some portion or all of the financing that we currently expect to be provided by these owners.

 

If our capital resources are insufficient to meet our capital requirements, we will have to raise additional funds. If future financings involve the issuance of equity securities, our existing stockholders would suffer dilution. If we are able to raise additional debt financing, we may be subject to restrictive covenants that limit our ability to conduct our business. We may not be able to raise sufficient additional funds on terms that are favorable to us, if at all. If we fail to raise sufficient funds and continue to incur losses, our ability to fund our operations, take advantage of strategic opportunities, develop and commercialize products or technologies, or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate research and development programs or the commercialization of products resulting from our technologies, curtail or cease operations or obtain funds through collaborative and licensing arrangements that may require us to relinquish commercial rights, or grant licenses on terms that are not favorable to us. If adequate funds are not available, we will not be able to successfully execute our business plan or continue our business.

 

Our fuels marketing and distribution business depends, and will depend for the foreseeable future, on purchasing and reselling ethanol produced by third parties, which may not be available to us on favorable terms or at all and which we may be unable to resell.

 

Amyris Fuels currently purchases and sells ethanol under short-term agreements and in spot transactions. In the future, we plan to continue the purchase and sale of ethanol and to hedge the price volatility of ethanol using futures contracts. We cannot predict the future market price of ethanol or the price or other terms of any supply contracts that

 

27


Table of Contents

Amyris Fuels may enter into. We cannot assure you that Amyris Fuels will be able to purchase ethanol at favorable prices, allowing our ethanol marketing activities to be profitable. In addition, there can be no guarantee that futures contracts to hedge the risks from the purchase and sale of ethanol will effectively mitigate risk as intended, that such hedging instruments will always be available, or that counterparties to such hedging contracts will honor their obligations. As a result of these pricing and hedging uncertainties, Amyris Fuels may incur operating losses, harming our results of operations and financial condition. If Amyris Fuels is unable to conduct sales of ethanol on favorable volume, price and other terms, our results of operations and financial condition will be harmed.

 

The success of our fuels marketing and distribution business depends on our ability to expand our access to financial and infrastructure assets.

 

In June 2008, we began to distribute ethanol produced by third parties in the U.S. through our wholly-owned subsidiary, Amyris Fuels. Amyris Fuels currently has secured access to certain terminal and other storage capacity for ethanol, and it engages providers of transportation and transloading services for the movement of ethanol. If Amyris Fuels is unable to access sufficient terminal and other storage capacity and/or to obtain transportation and transloading services on favorable terms, its business will be substantially harmed, which will reduce our revenues and adversely affect our results of operations and financial condition.

 

Growth may place significant demands on our management and our infrastructure.

 

We have experienced, and may continue to experience, expansion of our business as we continue to make efforts to develop and bring our products to market. We have grown from 18 employees at the end of 2005 to 221 employees at the end of 2009 and 257 at the end of April 2010. We work simultaneously on multiple projects to develop, produce and commercialize several types of renewable chemicals and fuels. Our growth and diversified operations have placed, and may continue to place, significant demands on our management and our operational and financial infrastructure. In particular, continued growth could strain our ability to:

 

   

develop and improve our operational, financial and management controls;

 

   

enhance our reporting systems and procedures;

 

   

recruit, train and retain highly skilled personnel;

 

   

develop and maintain our relationships with existing and potential business partners;

 

   

maintain our quality standards; and

 

   

maintain customer satisfaction.

 

Managing our growth will require significant expenditures and allocation of valuable management resources. If we fail to achieve the necessary level of efficiency in our organization as it grows, our business, results of operations and financial condition would be harmed.

 

If we fail to maintain an effective system of internal controls, we might not be able to report our financial results accurately or prevent fraud; in that case, our stockholders could lose confidence in our financial reporting, which would harm our business and could negatively impact the price of our stock.

 

Effective internal controls are necessary for us to provide reliable financial reports and prevent fraud. In addition, Section 404 of the Sarbanes-Oxley Act of 2002 will require us and our independent registered public accounting firm to evaluate and report on our internal control over financial reporting beginning with our Annual Report on Form 10-K for the year ending December 31, 2011. The process of implementing our internal controls and complying with Section 404 will be expensive and time consuming, and will require significant attention of management. We cannot be certain that these measures will ensure that we implement and maintain adequate controls over our financial processes and reporting in the future. Even if we conclude, and our independent registered public accounting firm concurs, that our internal control over financial reporting provides reasonable

 

28


Table of Contents

assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, because of its inherent limitations, internal control over financial reporting may not prevent or detect fraud or misstatements. Failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm our results of operations or cause us to fail to meet our reporting obligations. If we or our independent registered public accounting firm discover a material weakness, the disclosure of that fact, even if quickly remedied, could reduce the market’s confidence in our financial statements and harm our stock price. In addition, a delay in compliance with Section 404 could subject us to a variety of administrative sanctions, including SEC action, ineligibility for short form resale registration, the suspension or delisting of our common stock from the stock exchange on which it is listed and the inability of registered broker-dealers to make a market in our common stock, which would further reduce our stock price and could harm our business.

 

Our proprietary rights may not adequately protect our technologies and product candidates.

 

Our commercial success will depend substantially on our ability to obtain patents and maintain adequate legal protection for our technologies and product candidates in the U.S. and other countries. To date, we have 24 issued U.S. and foreign patents and 195 pending U.S. and foreign patent applications that are owned by or licensed to us. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies and future products are covered by valid and enforceable patents or are effectively maintained as trade secrets.

 

We apply for patents covering both our technologies and product candidates, as we deem appropriate. However, we may fail to apply for patents on important technologies or product candidates in a timely fashion, or at all. Our existing and future patents may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products or technologies. In addition, the patent positions of companies like ours are highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of patent claims has emerged to date in the U.S. and the landscape is expected to become even more uncertain in view of recent rule changes by the Patent and Trademark Office, the introduction of patent reform legislation in Congress and recent decisions in patent law cases by the U.S. Supreme Court. In addition, certain key U.S. patents were obtained using a procedure for accelerated examination recently implemented by the U.S. Patent and Trademark Office (“USPTO”) which requires special activities and disclosures that may create additional risks related to the validity or enforceability of the U.S. patents so obtained. The patent situation outside of the U.S. is even less predictable. As a result, the validity and enforceability of patents cannot be predicted with certainty. Moreover, we cannot be certain whether:

 

   

we or our licensors were the first to make the inventions covered by each of our issued patents and pending patent applications;

 

   

we or our licensors were the first to file patent applications for these inventions;

 

   

others will independently develop similar or alternative technologies or duplicate any of our technologies;

 

   

any of our or our licensors’ patents will be valid or enforceable;

 

   

any patents issued to us or our licensors will provide us with any competitive advantages, or will be challenged by third parties;

 

   

we will develop additional proprietary products or technologies that are patentable; or

 

   

the patents of others will have an adverse effect on our business.

 

We do not know whether any of our patent applications or those patent applications that we license will result in the issuance of any patents. Even if patents are issued, they may not be sufficient to protect our technology or product candidates. The patents we own or license and those that may be issued in the future may

 

29


Table of Contents

be challenged, invalidated, rendered unenforceable, or circumvented, and the rights granted under any issued patents may not provide us with proprietary protection or competitive advantages. In particular, U.S. patents we obtained using the USPTO accelerated examination program may introduce additional risks to the validity or enforceability of some or all of these specially-obtained U.S. patents if validity or enforceability are challenged. Moreover, third parties could practice our inventions in territories where we do not have patent protection or in territories where they could obtain a compulsory license to our technology where patented. Such third parties may then try to import products made using our inventions into the U.S. or other territories. Additional uncertainty may result from potential passage of patent reform legislation by the U.S. Congress, legal precedent by the U.S. Federal Circuit and Supreme Court as they determine legal issues concerning the scope and construction of patent claims and inconsistent interpretation of patent laws by the lower courts. Accordingly, we cannot ensure that any of our pending patent applications will result in issued patents, or even if issued, predict the breadth, validity and enforceability of the claims upheld in our and other companies’ patents.

 

Unauthorized parties may attempt to copy or otherwise obtain and use our products or technology. Monitoring unauthorized use of our intellectual property is difficult, and we cannot be certain that the steps we have taken will prevent unauthorized use of our technology, particularly in certain foreign countries where the local laws may not protect our proprietary rights as fully as in the U.S. or may provide, today or in the future, for compulsory licenses. If competitors are able to use our technology, our ability to compete effectively could be harmed. Moreover, others may independently develop and obtain patents for technologies that are similar to, or superior to, our technologies. If that happens, we may need to license these technologies, and we may not be able to obtain licenses on reasonable terms, if at all, which could cause harm to our business.

 

We rely in part on trade secrets to protect our technology, and our failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

 

We rely on trade secrets to protect some of our technology, particularly where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to maintain and protect. Our strategy for scale-up of production would require us to share confidential information with our Brazilian business partners and other parties. While we use reasonable efforts to protect our trade secrets, our or our business partners’ employees, consultants, contractors or scientific and other advisors may unintentionally or willfully disclose our proprietary information to competitors. Enforcement of claims that a third party has illegally obtained and is using trade secrets is expensive, time consuming and uncertain. In addition, foreign courts are sometimes less willing than U.S. courts to protect trade secrets. If our competitors independently develop equivalent knowledge, methods and know-how, we would not be able to assert our trade secrets against them. We require new employees and consultants to execute confidentiality agreements upon the commencement of an employment or consulting arrangement with us. These agreements generally require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties. These agreements also generally provide that inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. Nevertheless, our proprietary information may be disclosed, or these agreements may be unenforceable or difficult to enforce. Additionally, trade secret law in Brazil differs from that in the U.S. which requires us to take a different approach to protecting our trade secrets in Brazil. We may employ approaches to trade secret protection that are novel and untested under Brazilian law and we cannot guarantee that we would prevail if our trade secrets are contested in Brazil. If any of the above risks materializes our failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

 

Third parties may misappropriate our yeast strains.

 

Third parties, including sugar and ethanol mill owners, contract manufacturers, other contractors and shipping agents, often have custody or control of our yeast strains. If our yeast strains were stolen, misappropriated or reverse engineered, they could be used by other parties who may be able to reproduce the yeast strains for their own commercial gain. If this were to occur, it would be difficult for us to challenge and prevent this type of use, especially in countries with limited intellectual property protection.

 

30


Table of Contents

If we are sued for infringing intellectual property rights or other proprietary rights of third parties, litigation could be costly and time consuming and could prevent us from developing or commercializing our future products.

 

Our commercial success depends on our ability to operate without infringing the patents and proprietary rights of other parties and without breaching any agreements we have entered into with regard to our technologies and product candidates. We cannot determine with certainty whether patents or patent applications of other parties may materially affect our ability to conduct our business. Our industry spans several sectors, including biotechnology, renewable fuels, renewable specialty chemicals and other renewable compounds, and is characterized by the existence of a significant number of patents and disputes regarding patent and other intellectual property rights. Because patent applications can take several years to issue, there may currently be pending applications, unknown to us, that may result in issued patents that cover our technologies or product candidates. We are aware of a significant number of patents and patent applications relating to aspects of our technologies filed by, and issued to, third parties. The existence of third-party patent applications and patents could significantly reduce the coverage of patents owned by or licensed to us and limit our ability to obtain meaningful patent protection. If we wish to make, use, sell, offer to sell, or import the technology or compound claimed in issued and unexpired patents owned by others, we will need to obtain a license from the owner, enter into litigation to challenge the validity of the patents or incur the risk of litigation in the event that the owner asserts that we infringe its patents. If patents containing competitive or conflicting claims are issued to third parties and these claims are ultimately determined to be valid, we may be enjoined from pursing research, development, or commercialization of products, or be required to obtain licenses to these patents, or to develop or obtain alternative technology.

 

If a third-party asserts that we infringe upon its patents or other proprietary rights, we could face a number of issues that could seriously harm our competitive position, including:

 

   

infringement and other intellectual property claims, which could be costly and time consuming to litigate, whether or not the claims have merit, and which could delay getting our products to market and divert management attention from our business;

 

   

substantial damages for past infringement, which we may have to pay if a court determines that our product candidates or technologies infringe a competitor’s patent or other proprietary rights;

 

   

a court prohibiting us from selling or licensing our technologies or future products unless the holder licenses the patent or other proprietary rights to us, which it is not required to do; and

 

   

if a license is available from a third party, we may have to pay substantial royalties or grant cross licenses to our patents or proprietary rights.

 

The industries in which we operate, and the biotechnology industry in particular, are characterized by frequent and extensive litigation regarding patents and other intellectual property rights. Many biotechnology companies have employed intellectual property litigation as a way to gain a competitive advantage. If any of our competitors have filed patent applications or obtained patents that claim inventions also claimed by us, we may have to participate in interference proceedings declared by the relevant patent regulatory agency to determine priority of invention and, thus, the right to the patents for these inventions in the U.S. These proceedings could result in substantial cost to us even if the outcome is favorable. Even if successful, an interference may result in loss of certain claims. Our involvement in litigation, interferences, opposition proceedings or other intellectual property proceedings inside and outside of the U.S., to defend our intellectual property rights or as a result of alleged infringement of the rights of others, may divert management time from focusing on business operations and could cause us to spend significant resources, all of which could harm our business and results of operations.

 

Many of our employees were previously employed at universities, biotechnology, specialty chemical or oil companies, including our competitors or potential competitors. We may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending

 

31


Table of Contents

such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel and be enjoined from certain activities. A loss of key research personnel or their work product could hamper or prevent our ability to commercialize our product candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and demand on management resources.

 

We may need to commence litigation to enforce our intellectual property rights, which would divert resources and management’s time and attention and the results of which would be uncertain.

 

Enforcement of claims that a third party is using our proprietary rights without permission is expensive, time consuming and uncertain. Litigation would result in substantial costs, even if the eventual outcome is favorable to us and would divert management’s attention from our business objectives. In addition, an adverse outcome in litigation could result in a substantial loss of our proprietary rights and we may lose our ability to exclude others from practicing our technology or producing our product candidates.

 

The laws of some foreign countries do not protect intellectual property rights to the same extent as do the laws of the U.S. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology and/or bioindustrial technologies. This could make it difficult for us to stop the infringement of our patents or misappropriation of our other intellectual property rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Moreover, our efforts to protect our intellectual property rights in such countries may be inadequate.

 

Loss of key personnel, including key management personnel, and/or failure to attract and retain additional personnel could delay our product development programs and harm our research and development efforts and our ability to meet our business objectives.

 

Our business involves complex, global operations across a variety of markets and requires a management team and employee workforce that is knowledgeable in the many areas in which we operate. The loss of any key member of our management or key technical and operational employees, or the failure to attract or retain such employees could prevent us from developing and commercializing our products for our target markets and executing our business strategy. We may not be able to attract or retain qualified employees in the future due to the intense competition for qualified personnel among biotechnology and other technology-based businesses, particularly in the renewable fuels area, or due to the availability of personnel with the qualifications or experience necessary for our business. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience staffing constraints that will adversely affect our ability to meet the demands of our collaborators and customers in a timely fashion or to support our internal research and development programs. In particular, our product and process development programs are dependent on our ability to attract and retain highly skilled technical and operational personnel. Competition for such personnel from numerous companies and academic and other research institutions may limit our ability to do so on acceptable terms. All of our employees are at-will employees, which means that either the employee or we may terminate their employment at any time.

 

As we expand our operations, we will need to hire additional qualified research and development and management personnel to succeed. The process of hiring, training and successfully integrating qualified personnel into our operation is a lengthy and expensive one. The market for qualified personnel is very competitive because of the limited number of people available with the necessary technical skills and understanding of our technology and anticipated products. Our failure to hire and retain qualified personnel could impair our ability to meet our research and development and business objectives and adversely affect our results of operations and financial condition.

 

32


Table of Contents

We may be sued for product liability.

 

The design, development, production and sale of our products involve an inherent risk of product liability claims and the associated adverse publicity. We may be named directly in product liability suits relating to our products, even for defects resulting from errors of our commercial partners, contract manufacturers or chemical finishers. These claims could be brought by various parties, including customers who are purchasing products directly from us or other users who purchase products from our customers. We could also be named as co-parties in product liability suits that are brought against the sugar and ethanol mills who produce our products in Brazil. Insurance coverage is expensive, may be difficult to obtain and may not be available in the future on acceptable terms. We cannot assure you that our contract manufacturers or the sugar and ethanol producers who produce our products will have adequate insurance coverage to cover against potential claims. This insurance may not provide adequate coverage against potential losses, and if claims or losses exceed our liability insurance coverage, we may go out of business. In addition, insurance coverage may become more expensive, which would harm our results of operations.

 

During the ordinary course of business, we may become subject to lawsuits or indemnity claims, which could materially and adversely affect our business and results of operations.

 

From time to time, we may in the ordinary course of business be named as a defendant in lawsuits, claims and other legal proceedings. These actions may seek, among other things, compensation for alleged personal injury, worker’s compensation, employment discrimination, breach of contract, property damages, civil penalties and other losses of injunctive or declaratory relief. In the event that such actions or indemnities are ultimately resolved unfavorably at amounts exceeding our accrued liability, or at material amounts, the outcome could materially and adversely affect our reputation, business and results of operations. In addition, payments of significant amounts, even if reserved, could adversely affect our liquidity position.

 

Our ability to use our net operating loss carry forwards to offset future taxable income may be subject to certain limitations.

 

In general, under Section 382 of the Internal Revenue Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change net operating loss carry forwards, or NOLs, to offset future taxable income. If the Internal Revenue Service challenges our analysis that our existing NOLs are not subject to limitations arising from previous ownership changes, or if we undergo an ownership change in connection with or after this public offering, our ability to utilize NOLs could be limited by Section 382 of the Internal Revenue Code. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Internal Revenue Code. Furthermore, our ability to utilize NOLs of companies that we may acquire in the future may be subject to limitations. For these reasons, we may not be able to utilize a material portion of the NOLs reflected on our balance sheet, even if we attain profitability.

 

Loss of our government grant funding could impair our research and development efforts.

 

We have been awarded a $24.3 million “Integrated Bio-Refinery” grant from the U.S. Department of Energy (“DOE”). The terms of this grant make the funds available to us to leverage and expand our existing Emeryville, California, pilot plant and support laboratories to develop U.S.-based production capabilities for renewable fuels and chemicals derived from sweet sorghum. Generally, government grant agreements have fixed terms and may be terminated, modified or recovered by the granting agency under certain conditions. If the DOE later terminates its grant agreement with us, our U.S.-based research and development activities could be impaired, which could harm our business.

 

33


Table of Contents

Our headquarters and other facilities are located in an active earthquake zone, and an earthquake or other types of natural disasters affecting us or our suppliers could cause resource shortages and disrupt and harm our results of operations.

 

We conduct our primary research and development operations in the San Francisco Bay Area in an active earthquake zone, and certain of our suppliers conduct their operations in the same region or in other locations that are susceptible to natural disasters. In addition, California and some of the locations where certain of our suppliers are located have experienced shortages of water, electric power and natural gas from time to time. The occurrence of a natural disaster, such as an earthquake, drought or flood, or localized extended outages of critical utilities or transportation systems, or any critical resource shortages, affecting us or our suppliers could cause a significant interruption in our business, damage or destroy our facilities, production equipment or inventory or those of our suppliers and cause us to incur significant costs or result in limitations on the availability of our raw materials, any of which could harm our business, financial condition and results of operations. The insurance we maintain against fires, earthquakes and other natural disasters may not be adequate to cover our losses in any particular case.

 

Risks Related to this Offering and Ownership of Our Common Stock

 

An active trading market for our common stock may not develop, and you may not be able to resell your shares at or above the initial public offering price.

 

Prior to this offering, there has been no public market for shares of our common stock. Although we will apply to have our common stock approved for quotation on a stock exchange, an active trading market for our shares may never develop or be sustained following this offering. The initial public offering price of our common stock will be determined through negotiations between us and the underwriters. This initial public offering price may not be indicative of the market price of our common stock after this offering. In the absence of an active trading market for our common stock, investors may not be able to sell their common stock at or above the initial public offering price or at the time that they would like to sell.

 

Our stock price may be volatile, and the market price of our common stock after this offering may drop below the price you pay.

 

The market price of our common stock could be subject to significant fluctuations after this offering and it may decline below the initial public offering price. Market prices for securities of early stage companies have historically been particularly volatile. As a result of this volatility, you may not be able to sell your common stock at or above the initial public offering price. Such fluctuations could be in response to, among other things, the factors described in this “Risk Factors” section or elsewhere in this registration statement, or other factors, some of which are beyond our control, such as:

 

   

fluctuations in our financial results or outlook or those of companies perceived to be similar to us;

 

   

changes in estimates of our financial results or recommendations by securities analysts;

 

   

changes in market valuations of similar companies;

 

   

changes in the prices of commodities associated with our business such as sugar, ethanol and petroleum;

 

   

changes in our capital structure, such as future issuances of securities or the incurrence of debt;

 

   

announcements by us or our competitors of significant contracts, acquisitions or strategic alliances;

 

   

regulatory developments in the U.S., Brazil, and/or other foreign countries;

 

   

litigation involving us, our general industry or both;

 

   

additions or departures of key personnel;

 

   

investors’ general perception of us; and

 

   

changes in general economic, industry and market conditions.

 

34


Table of Contents

Furthermore, the stock markets have experienced price and volume fluctuations that have affected, and continue to affect, the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market fluctuations, as well as general economic, political and market conditions, such as recessions, interest rate changes and international currency fluctuations, may negatively affect the market price of our common stock.

 

In the past, many companies that have experienced volatility in the market price of their stock have become subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business.

 

We will incur increased costs and demands upon management as a result of complying with the laws and regulations affecting public companies, which could harm our results of operations.

 

As a public company, we will incur significant additional accounting, legal and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements. We also have incurred and will incur costs associated with corporate governance requirements, including requirements under Section 404 and other provisions of the Sarbanes-Oxley Act, as well as rules implemented by the Securities and Exchange Commission and the exchange on which we list our common stock. The expenses incurred by public companies for reporting and corporate governance purposes have increased dramatically in recent years. We expect these rules and regulations to substantially increase our financial and legal compliance costs. We also expect that as we become a public company it will be more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage previously available. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as our executive officers.

 

The concentration of our capital stock ownership with insiders upon the completion of this offering will limit your ability to influence corporate matters.

 

We anticipate that our executive officers, directors, current five percent or greater stockholders and entities affiliated with them will together beneficially own approximately     % of our common stock outstanding after this offering. A single stockholder—Total Gas & Power USA, SAS (“Total”)—will hold approximately     % of our common stock outstanding after this offering, assuming an initial public offering price of $            , which is the midpoint of the price range set forth on the cover page of this prospectus. This significant concentration of share ownership may adversely affect the trading price for our common stock because investors often perceive disadvantages in owning stock in companies with controlling stockholders. Also, these stockholders, acting together, will be able to control our management and affairs and matters requiring stockholder approval, including the election of directors and the approval of significant corporate transactions, such as mergers, consolidations or the sale of substantially all of our assets. Consequently, this concentration of ownership may have the effect of delaying or preventing a change of control, including a merger, consolidation or other business combination involving us, or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control, even if that change of control would benefit our other stockholders.

 

A significant portion of our total outstanding shares may be sold into the public market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.

 

Sales of a substantial number of shares of our common stock in the public market could occur at any time after the expiration of the lock-up agreements described in the “Underwriters” and “Shares Eligible for Future Sale—Lock-Up Agreements” sections of this prospectus. These sales, or the market perception that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we will have              shares of common stock outstanding based on the number of shares outstanding as of March 31, 2010, including the shares of common stock issuable upon conversion of our Series D preferred

 

35


Table of Contents

stock sold after March 31, 2010 (assuming an initial offering price of $            , which is the midpoint of the price range on the cover of this prospectus) and assuming the conversion of all shares of Amyris Brasil held by investors into shares of our common stock and no exercise of outstanding options or warrants after March 31, 2010. This includes the              shares that we are selling in this offering, which may be resold in the public market immediately. The remaining 34,972,688 shares, or     % of our outstanding shares after this offering, are currently restricted as a result of securities laws or lock-up agreements but will be able to be sold, subject to any applicable volume limitations under federal securities laws, in the near future as set forth below:

 

   

89,872 shares will be eligible for sale immediately upon completion of this offering;

 

   

34,571,705 shares will be eligible for sale upon the expiration of 180-day lock-up and/or market standoff agreements, subject in some cases to the volume and other restrictions of Rule 144 and Rule 701 promulgated under the Securities Act of 1933, as amended, or the Securities Act, and upon the lapse of our right of repurchase with respect to any unvested shares; and

 

   

311,111 shares are not subject to a lock-up or market standoff agreement and will be eligible for sale upon completion of this offering, subject to the restrictions of Rule 144 promulgated under the Securities Act.

 

The lock-up agreements expire 180 days after the date of this prospectus, except that the 180-day period may be extended in certain cases for up to 34 additional days under certain circumstances where we announce or pre-announce earnings or a material event occurs within approximately 17 days prior to, or approximately 16 days after, the termination of the 180-day period. The representatives of the underwriters may, in their sole discretion and at any time without notice, release all or any portion of the securities subject to lock-up agreements.

 

Following this offering, holders of 34,266,433 of the shares of our common stock (including shares issuable upon exercise of certain stock options) not sold in this offering and holders of warrants to purchase an aggregate of 24,101 shares of common stock not sold in this offering will be entitled to rights with respect to the registration of these shares under the Securities Act. See “Description of Capital Stock—Registration Rights.” If we register their shares of common stock following the expiration of the lock-up agreements, these stockholders could sell those shares in the public market without being subject to the volume and other restrictions of Rule 144 and Rule 701.

 

After the closing of this offering, we intend to register approximately 10,562,572 shares of common stock that have been reserved for future issuance under our stock incentive plans. Of these shares,              shares will be eligible for sale upon the exercise of outstanding options that will be vested after the expiration of the lock-up agreements.

 

Purchasers in this offering will experience immediate and substantial dilution in the book value of their investment.

 

The assumed initial public offering price of our common stock is substantially higher than the net tangible book value per share of our outstanding common stock immediately after this offering. Therefore, if you purchase our common stock in this offering, you will incur immediate dilution of approximately $              in net tangible book value per share from the price you paid. In addition, investors purchasing common stock in this offering will own only approximately     % of our shares outstanding after this offering even though they will have contributed     % of the total consideration received by us in connection with our sales of common stock. Moreover, we issued options and warrants in the past to acquire our stock at prices significantly below the assumed initial public offering price. As of June 21, 2010, 6,287,980 shares of common stock were issuable upon exercise of outstanding stock options with a weighted average exercise price of $5.89 per share. As of June 21, 2010, warrants to purchase 195,604 shares of common stock (assuming conversion of all shares of preferred stock into common stock as of June 21, 2010) were issuable upon exercise of outstanding warrants with a weighted average exercise price of $18.76 per share. To the extent that these outstanding options and warrants are ultimately exercised, you will incur further dilution. For a further description of the dilution that you will experience immediately after this offering, see the “Dilution” section of this prospectus.

 

36


Table of Contents

If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.

 

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our market or our competitors. If any of the analysts who may cover us change their recommendation regarding our stock adversely, or provide more favorable relative recommendations about our competitors, our stock price would likely decline. If any analyst who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

 

Our management will have broad discretion over the use of the proceeds we receive in this offering and might not apply the proceeds in ways that increase the value of your investment.

 

Our management will have broad discretion in the application of the net proceeds from this offering, and you will be relying on the judgment of our management regarding the application of these proceeds. Our management might not apply our net proceeds of this offering in ways that increase the value of your investment. We expect to use the net proceeds to us from this offering for working capital, and other general corporate purposes, which may in the future include expansion of production facilities, investments in, or acquisitions of, complementary businesses, joint ventures, partnerships, services or technologies. Our management might not be able to yield a significant return, if any, on any investment of these net proceeds. You will not have the opportunity to influence our decisions on how to use our net proceeds from this offering.

 

After the completion of this offering, we do not expect to declare any dividends in the foreseeable future.

 

After the completion of this offering, we do not anticipate declaring any cash dividends to holders of our common stock in the foreseeable future. In addition, our equipment lease with TriplePoint Capital LLC and our letter of credit facility currently restrict our ability to pay dividends. Consequently, investors may need to rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investment. Investors seeking cash dividends should not purchase our common stock.

 

Anti-takeover provisions contained in our certificate of incorporation and bylaws, as well as provisions of Delaware law, could impair a takeover attempt.

 

Our amended and restated certificate of incorporation and our amended and restated bylaws to be effective upon the completion of this offering will contain provisions that could delay or prevent a change in control of our company. These provisions could also make it more difficult for stockholders to elect directors and take other corporate actions. These provisions include:

 

   

staggered board of directors;

 

   

authorizing the board to issue, without stockholder approval, preferred stock with rights senior to those of our common stock;

 

   

authorizing the board to amend our bylaws and to fill board vacancies until the next annual meeting of the stockholders;

 

   

prohibiting stockholder action by written consent;

 

   

limiting the liability of, and providing indemnification to, our directors and officers;

 

   

not authorizing our stockholders to call a special stockholder meeting;

 

   

eliminating the ability of our stockholders to call special meetings; and

 

   

requiring advance notification of stockholder nominations and proposals.

 

37


Table of Contents

Section 203 of the Delaware General Corporation Law prohibits, subject to some exceptions, “business combinations” between a Delaware corporation and an “interested stockholder,” which is generally defined as a stockholder who becomes a beneficial owner of 15% or more of a Delaware corporation’s voting stock, for a three-year period following the date that the stockholder became an interested stockholder. We have agreed to opt out of Section 203 through an amendment of our certificate of incorporation, but, following the amendment, our certificate of incorporation will contain substantially similar protections to our company and stockholders as those afforded under Section 203, except that we have agreed with Total that it will not be deemed an “interested stockholder” under such protections.

 

In addition, we have an agreement with Total, which provides that, so long as Total holds at least 10% of our voting securities, we must inform Total of any offer to acquire us or any decision of our Board of Directors to sell our company, and we must provide Total with information about the contemplated transaction. In such events, Total will have an exclusive negotiating period of 15 business days in the event the Board of Directors authorizes us to solicit offers to buy Amyris, or five business days in the event that we receive an unsolicited offer to purchase us. This exclusive negotiation period will be followed by an additional restricted negotiation period of 10 business days, during which we are obligated to continue to negotiate with Total and will be prohibited from entering into an agreement with any other potential acquirer.

 

These and other provisions in our amended and restated certificate of incorporation and our amended and restated bylaws to be effective upon the completion of this offering under Delaware law and in our agreement with Total could discourage potential takeover attempts, reduce the price that investors might be willing to pay in the future for shares of our common stock and result in the market price of our common stock being lower than it would be without these provisions. See “Description of Capital Stock—Preferred Stock” and “Description of Capital Stock—Anti-Takeover Provisions.”

 

38


Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus contains forward-looking statements. All statements, other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “continue” or other similar words.

 

These forward-looking statements are only predictions. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to materially differ from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We have described in the “Risk Factors” section and elsewhere in this prospectus the principal risks and uncertainties that we believe could cause actual results to differ from these forward-looking statements. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as guarantees of future events.

 

In particular, forward looking statements in this prospectus include statements about:

 

   

achievement of advances in our technology platform, including yield;

 

   

target molecules we intend to produce from our synthetic biology platform;

 

   

the expected applications of our molecules and addressable markets;

 

   

the expected cost-competitiveness and relative performance attributes of our products;

 

   

timing of commercial sales of our products;

 

   

the acceptance and success of our capital light model for production of our products at sugar and ethanol mills;

 

   

the timing and capacity of manufacturing available to us, including from contract manufacturing partners, our joint venture with Usina São Martinho and sugar and ethanol mill owners;

 

   

government regulatory and industry certification approval and acceptance of our products and genetically modified microorganisms;

 

   

the availability of suitable and cost-competitive feedstock;

 

   

the commercial scale-up of our production;

 

   

our access to distribution infrastructure and services and chemical processing;

 

   

government policymaking and incentives relating to renewable fuels;

 

   

the future price and volatility of petroleum; and

 

   

our ability to manage operations in Brazil.

 

The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future or to conform these statements to actual results or revised expectations, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus.

 

39


Table of Contents

USE OF PROCEEDS

 

We estimate that our net proceeds from the sale of the common stock that we are offering will be approximately $             million, assuming an initial public offering price of $             per share, which is the midpoint of the price range listed on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A $1.00 increase (decrease) in the assumed initial public offering price of $             per share would increase (decrease) our net proceeds from this offering by approximately $             million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their option to purchase additional shares in full, we estimate that our net proceeds will be approximately $              million after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

We expect to use the net proceeds from this offering for capital expenditures, working capital and general corporate purposes, including building engineering services capabilities to support sugar and ethanol mill adoption of our technology and growing our chemistry capabilities to accelerate customer use of our chemical products. With regard to capital expenditures, we will bear the construction costs of Phase I of the facility to be completed under our joint venture agreements with Usina São Martinho, and Usina São Martinho will be required to reimburse us for a portion of these costs after commencement of commercial operations. We and Usina São Martinho will jointly fund the construction of Phase II of this facility, subject to certain limitations on Usina São Martinho’s funding requirements. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Recent Developments” for a further description of the joint venture, and “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” for a discussion of our expectation of the amount that we will invest in the construction of the joint venture facility and the time period over which we will do so and for additional information about our anticipated use of cash resources. We expect to enter into agreements with owners of other sugar and ethanol mills for the construction of bolt-on facilities for the production of our products, and we anticipate that we will agree to fund a portion of these construction costs. The amount of our capital expenditures for future production facilities will be a function of the number of such facilities that we undertake to develop and the terms of our agreements with the mill owners related to the financing of these construction costs. We also anticipate that our capital expenditures will include expenditures for capital equipment purchases associated with contract manufacturing arrangements. We may also use a portion of the net proceeds to expand our business through acquisitions of other companies, assets or technologies. However, at this time, we do not have any commitment to any specific acquisitions.

 

Some of the other principal purposes of this offering are to create a public market for our common stock, increase our visibility in the marketplace and provide liquidity to existing stockholders. A public market for our common stock will facilitate future access to public equity markets and enhance our ability to sell our common stock as a means of attracting and retaining key employees and as consideration for acquisitions.

 

We will have broad discretion in the way that we use the net proceeds of this offering. The amounts that we actually spend for the purposes described above may vary significantly and will depend, in part, on the timing and amount of our future revenues, our future expenses and any potential acquisitions that we may propose. Pending the uses of the net proceeds of this offering, as described above, we intend to invest the net proceeds in investment-grade, interest-bearing securities. See “Risk Factors—Risks Related to This Offering and Ownership of our Common Stock—Our management will have broad discretion over the use of the proceeds we receive in this offering and might not apply the proceeds in ways that increase the value of your investment.”

 

DIVIDEND POLICY

 

We have never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings and do not expect to declare or pay any dividends in the foreseeable future. Any further determination to pay dividends on our capital stock will be at the discretion of our Board of Directors and will depend on our financial condition, results of operations, capital requirements and other factors that our Board of Directors considers relevant. In addition, our equipment lease with TriplePoint Capital LLC and our letter of credit facility currently restrict our ability to pay dividends.

 

40


Table of Contents

CAPITALIZATION

 

The following table sets forth our cash and cash equivalents and capitalization as of March 31, 2010:

 

   

on an actual basis;

 

   

on a pro forma basis to reflect:

 

   

the conversion of all of our outstanding shares of convertible preferred stock into 21,899,273 shares of common stock upon the completion of this offering;

 

   

the conversion of 1,964,444 shares of Amyris Brasil held by third party investors in this subsidiary into 550,044 shares of our common stock at the completion of this offering;

 

   

the reclassification of the preferred stock warrant liability to additional paid-in capital immediately prior to the completion of this offering; and

 

   

the reclassification of redeemable noncontrolling interest to common stock and additional paid-in capital immediately prior to the completion of this offering;

 

   

On a pro forma as adjusted basis to reflect:

 

   

the issuance of 7,101,548 shares of Series D preferred stock after March 31, 2010 and the conversion of those shares into common stock;

 

   

the issuance of 1,111,111 shares of Amyris Brasil after March 31, 2010 and the conversion of those shares into 311,111 shares of our common stock at the completion of this offering; and

 

   

the forfeiture of 10,000 shares of restricted common stock after March 31, 2010.

 

   

on a pro forma as adjusted for this offering basis as adjusted to reflect the pro forma adjustments described above and the sale by us of              shares of our common stock that we are offering at an assumed initial public offering price of $             per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

41


Table of Contents

Our capitalization following the closing of this offering will be adjusted based upon the actual initial public offering price and other terms of the offering determined at pricing. In the event the actual initial public offering price is lower than $         per share, the shares of Series D preferred stock will convert into a larger number of shares of common stock; if the initial public offering price is equal to the midpoint of the range on the cover of this prospectus, the Series D preferred stock would convert into an additional              shares of common stock. A $1.00 decrease in the initial public offering price would increase by             , and a $1.00 increase in the initial public offering price would decrease by             , the number of shares of common stock issuable upon conversion of the Series D preferred stock. If the actual initial public offering price is greater than $18.75 per share, we will be entitled to a cash payment from the purchaser of our Series D preferred stock; for every $1.00 per share in excess of $18.75 per share we would receive approximately $         million, to a maximum of approximately $14.3 million at an initial public offering price of $28.84 per share or above. You should read the following table together with our Consolidated Financial Statements and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing elsewhere in this prospectus.

 

     As of March 31, 2010
     Actual     Pro Forma     Pro Forma as
Adjusted
    Pro Forma as
Adjusted for
this Offering
     (in thousands, except share and per share data)
     (Unaudited)     (Unaudited)     (Unaudited)     (Unaudited)

Cash, cash equivalents, short term investments and restricted cash

   $ 105,256      $ 105,256      $ 243,773     
                          

Total indebtedness (1)

   $ 20,307      $ 20,307      $ 20,307     
                          

Convertible preferred stock warrant liability

     2,705                   
                          

Convertible preferred stock—$0.0001 par value: 23,862,355 shares authorized, 21,385,969 shares issued and outstanding, actual; 23,862,355 shares authorized, no shares issued and outstanding pro forma; 30,963,903 shares authorized, no shares issued and outstanding, pro forma as adjusted and pro forma as adjusted for this offering

     230,606                   

Redeemable noncontrolling interest

     7,094                   
                          

Stockholders’ Equity (Deficit):

        

Preferred stock—$0.0001 par value:
no shares authorized, issued and outstanding, actual; 5,000,000 shares authorized, no shares issued and outstanding, pro forma, pro forma as adjusted and pro forma as adjusted for this offering

           

  
        

Common stock—$0.0001 par value:
38,000,000 shares authorized, 5,120,712 shares issued and outstanding, actual; 38,000,000 shares authorized, 27,570,029 shares issued and outstanding, pro forma; 61,862,355 shares authorized, 34,972,688 shares issued and outstanding, pro forma as adjusted; and 100,000,000 shares authorized,              shares issued and outstanding pro forma as adjusted for this offering

     1        3        3     

Additional paid-in capital

     7,180        247,583        386,100     

Accumulated other comprehensive income

     729        729        729     

Accumulated deficit

     (136,600     (136,600     (136,600  
                          

Total equity (deficit)

     (128,690     111,715        250,232     
                          

Total capitalization

   $ 132,022      $ 132,022      $ 270,539     
                          

 

42


Table of Contents

 

  (1)   Total indebtedness includes a $7.6 million credit facility associated with our student loan auction rate securities holdings, $7.5 million in capital lease obligations, a $4.1 million note payable and a $1.0 million loan payable (see Note 5 and Note 6 to our Consolidated Financial Statements).

 

A $1.00 increase (decrease) in the assumed initial public offering price of $             per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) each of cash and cash equivalents, working capital, total assets and total stockholders’ deficit by $             million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase of 1.0 million shares in the number of shares of common stock offered by us would increase each of cash and cash equivalents, working capital, total assets and total stockholders’ equity (deficit) by approximately $             million. Similarly, each decrease of 1.0 million shares in the number of shares offered by us would decrease each of cash and cash equivalents, working capital, total assets and total stockholders’ equity by approximately $             million. The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering.

 

If the underwriters’ option to purchase additional shares were exercised in full, pro forma as adjusted cash, cash equivalents, common stock and additional paid-in capital, stockholders’ equity (deficit) and shares issued and outstanding as of December 31, 2009, would be $             million, $             million, $             million and $             million.

 

The table above does not include:

 

   

5,819,455 shares of common stock issuable upon the exercise of stock options outstanding as of March 31, 2010, at a weighted average exercise price of $4.62 per share;

 

   

509,454 shares of common stock issuable upon the exercise of stock options granted after March 31, 2010, with a weighted average exercise price of $20.41 per share;

 

   

195,604 shares of common stock issuable upon the exercise of outstanding warrants as of March 31, 2010, that will remain outstanding after the completion of this offering through various dates from one year from the effective date of this offering to January 2017, with a weighted average exercise price of $18.76 per share;

 

   

176,272 shares of common stock subject to restricted stock units outstanding as of March 31, 2010;

 

   

4,200,000 shares of common stock reserved for future issuance under our 2010 Equity Incentive Plan, which will become effective upon the completion of this offering and will contain provisions that will automatically increase its share reserve each year, as more fully described in “Management—Stock Option and Other Compensation Plans”; and

 

   

168,627 shares of common stock reserved for future issuance under our 2010 Employee Stock Purchase Plan, which will become effective upon the completion of this offering and will contain provisions that will automatically increase its share reserve each year, as more fully described in “Management—Stock Option and Other Compensation Plans.”

 

43


Table of Contents

DILUTION

 

If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per share and the net tangible book value per share of our common stock after this offering. As of March 31, 2010, our net tangible book value was $             million, or $             per share of common stock, and our pro forma net tangible book value was $             million, or $             per share of our common stock. Pro forma net tangible book value per share represents the amount of our total tangible assets less our total liabilities, divided by the total number of shares of our common stock outstanding, after giving effect to the conversion at the completion of this offering of shares of Amyris Brasil held by investors in that subsidiary, the automatic conversion of all of our outstanding convertible preferred stock into shares of common stock upon the completion of this offering and the reclassification of preferred stock warrant liability to additional paid-in capital immediately prior to the completion of this offering.

 

After giving effect to the sale by us of              shares of our common stock in this offering at an assumed initial public offering price of $             per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of March 31, 2010, would have been approximately $             million, or $             per share of our common stock. This amount represents an immediate increase in our pro forma net tangible book value of $             per share to our existing stockholders and an immediate dilution in our pro forma net tangible book value of $             per share to new investors purchasing shares of our common stock in this offering at the initial public offering price.

 

The following table illustrates this dilution on a per share basis:

 

Assumed initial public offering price per share

      $             

Pro forma net tangible book value per share as of March 31, 2010, before giving effect to this offering

     

Increase in pro forma net tangible book value per share attributable to new investors

     
       

Pro forma as adjusted net tangible book value per share after this offering

     
         

Dilution per share to investors in this offering

      $  
         

 

A $1.00 increase (decrease) in the initial public offering price of $             per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) our pro forma as adjusted net tangible book value per share after this offering by approximately $             and would increase (decrease) dilution per share to new investors by approximately $            , assuming that the number of shares offered by us, as listed on the cover page of this prospectus, remains the same. In addition, to the extent any outstanding options or warrants are exercised, new investors will experience further dilution.

 

If the underwriters exercise their over-allotment option in full, the pro forma as adjusted net tangible book value will increase to $             per share, representing an immediate increase to existing stockholders of $             per share and an immediate dilution of $             per share to new investors.

 

The following table summarizes, as of March 31, 2010, the number of shares purchased or to be purchased from us, the total consideration paid or to be paid to us, and the average price per share paid or to be paid to us by existing stockholders and new investors purchasing shares of our common stock in this offering at an assumed initial public offering price of $             per share before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. As the table below shows, new investors purchasing shares of our common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid.

 

44


Table of Contents
     Shares Purchased     Total Consideration     Average
Price

Per  Share
       Number    Percent     Amount    Percent    
     (In thousands other than percentages and
per share data)

Existing stockholders

             $                        $             

New investors

            
                              

Total

      100   $      100  
                          

 

A $1.00 increase (decrease) in the assumed initial public offering price of $             per share would increase (decrease) the total consideration paid to us by new investors by $             million and increase (decrease) the percent of total consideration paid to us by new investors by     % assuming that the number of shares offered by us, as listed on the cover page of this prospectus, remains the same.

 

The number of shares purchased from us by existing stockholders is based on our common stock outstanding as of March 31, 2010, after giving effect to the conversion of all of our convertible preferred stock outstanding as of March 31, 2010 into common stock and the conversion of shares of Amyris Brasil outstanding as of March 31, 2010 held by third party investors in this subsidiary into shares of our common stock upon the completion of this offering. This number excludes:

 

   

5,819,455 shares of common stock issuable upon the exercise of stock options outstanding as of March 31, 2010, at a weighted average exercise price of $4.62 per share;

 

   

195,604 shares of common stock issuable upon the exercise of outstanding warrants as of March 31, 2010, that will remain outstanding after the completion of this offering through various dates from one year from the effective date of this offering to January 2017, with a weighted average exercise price of $18.76 per share;

 

   

176,272 shares of common stock subject to restricted stock units outstanding as of March 31, 2010;

 

   

7,101,548 shares of Series D preferred stock issued after March 31, 2010 and the conversion of those shares into common stock;

 

   

1,111,111 shares of Amyris Brasil issued after March 31, 2010 and the conversion of these shares into 311,111 shares of our common stock;

 

   

10,000 shares of common stock that were forfeited after March 31, 2010;

 

   

4,200,000 shares of common stock reserved for future issuance under our 2010 Equity Incentive Plan, which will become effective upon the completion of this offering and will contain provisions that will automatically increase its share reserve each year, as more fully described in “Management— Stock Option and Other Compensation Plans;” and

 

   

168,627 shares of common stock reserved for future issuance under our 2010 Employee Stock Purchase Plan, which will become effective upon the completion of this offering and will contain provisions that will automatically increase its share reserve each year, as more fully described in “Management—Stock Option and Other Compensation Plans.”

 

If all our outstanding stock options and outstanding warrants had been exercised as of March 31, 2010, our pro forma net tangible book value as of March 31, 2010, would have been approximately $             million or $             per share of our common stock, and the pro forma net tangible book value after giving effect to this offering would have been $             per share, representing dilution in our pro forma net tangible book value per share to new investors of $            .

 

45


Table of Contents

SELECTED CONSOLIDATED FINANCIAL DATA

 

The selected consolidated statement of operations data for the years ended December 31, 2007, 2008 and 2009 and the selected consolidated balance sheet data as of December 31, 2008 and 2009 are derived from our audited Consolidated Financial Statements, appearing elsewhere in this prospectus. The selected consolidated statement of operations data for 2005 and 2006 and the selected consolidated balance sheet data as of December 31, 2005, 2006 and 2007 have been derived from our audited consolidated financial statements, which are not included in this prospectus. We derived the selected consolidated statement of operations data for the three months ended March 31, 2009 and 2010 and the selected consolidated balance sheet as of March 31, 2010 from our unaudited consolidated financial statements appearing elsewhere in this prospectus. The historical results presented below are not necessarily indicative of financial results to be achieved in future periods. You should read the following selected consolidated financial data in conjunction with “Management’s Discussion Analysis of Financial Condition and Results of Operations” and our Consolidated Financial Statements appearing elsewhere in this prospectus.

 

    Years Ended December 31,     Three Months Ended
March 31,
 
    2005     2006     2007     2008     2009     2009     2010  
   

(in thousands, except share and per share amounts)

 
          (Unaudited)  

Consolidated Statement of Operations Data:

             

Revenues

             

Product sales

  $      $      $      $ 10,680      $ 61,689      $ 1,534      $ 9,954   

Collaborative research services

    2,235        3,804        6,046        3,008        2,919        557        1,378   

Government grants

    255        198        138        204                      2,323   
                                                       

Total revenues

    2,490        4,002        6,184        13,892        64,608        2,091        13,655   
                                                       

Cost and operating expenses

             

Cost of product sales

                         10,364        60,428        1,424        10,003   

Research and development (1)

    1,866        3,633        8,662        30,306        38,263        8,603        11,178   

Sales, general and administrative (1)

    610        2,787        10,522        16,622        23,558        4,402        9,216   

Restructuring and asset impairment charges

                                5,768                 
                                                       

Total cost and operating expenses

    2,476        6,420        19,184        57,292        128,017        14,429        30,397   
                                                       

Income (loss) from operations

    14        (2,418     (13,000     (43,400     (63,409     (12,338     (16,742

Other income (expense)

             

Interest income

    50        213        1,178        1,378        448        237        276   

Interest expense

                  (28     (377     (1,218     (234     (384

Other income (expense), net

           36        76        (144     (621     (58     515   
                                                       

Total other income (expense)

    50        249        1,226        857        (1,391     (55     407   
                                                       

Income (loss) before income taxes

    64        (2,169     (11,774     (42,543     (64,800     (12,393     (16,335

Provision for (benefit from) income taxes

    556        (354            (207                     
                                                       

Net loss

    (492     (1,815     (11,774     (42,336     (64,800     (12,393     (16,335

Loss attributable to noncontrolling interest

                         (472     (341     (221     (183
                                                       

Net loss attributable to Amyris, Inc. stockholders

  $ (492   $ (1,815   $ (11,774   $ (41,864   $ (64,459   $ (12,172   $ (16,152
                                                       

Net loss per share of common stock attributable to Amyris, Inc. stockholders, basic and diluted (2)

  $ (0.25   $ (0.60   $ (3.28   $ (9.91   $ (13.56   $ (2.65   $ (3.22
                                                       

Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted (2)

    1,954,900        3,049,761        3,592,932        4,223,533        4,753,085        4,592,400        5,010,569   
                                                       

Pro forma net loss per share of common stock attributable to Amyris, Inc. stockholders, basic and diluted (unaudited) (2)

          $ (3.16     $ (0.67
                         

Weighted-average shares of common stock outstanding used in computing pro forma net loss per share of common stock, basic and diluted (unaudited) (2)

            20,279,433          24,794,446   
                         

 

46


Table of Contents

 

     As of December 31,     As of March 31,  
     2005     2006     2007     2008     2009     2010  
     (in thousands)  
                                   (Unaudited)  

Consolidated Balance Sheet Data:

            

Cash, cash equivalents, investments and restricted cash

   $ 3,767      $ 6,706      $ 45,862      $ 52,888      $ 71,716      $ 105,256   

Working capital (deficit)

     (1,222     2,287        31,045        32,356        51,062        85,994   

Total assets

     4,678        8,580        50,889        98,823        122,159        158,182   

Total indebtedness (3)

                   655        6,747        20,608        20,307   

Convertible preferred stock warrant liability

                          2,132        2,740        2,705   

Convertible preferred stock

            6,397        58,126        121,436        179,651        230,606   

Redeemable noncontrolling interest

                                 5,506        7,094   

Total deficit

   $ (521   $ (2,301   $ (13,301   $ (52,143   $ (113,745   $ (128,690

 

 
  (1)   Includes stock-based compensation expense.
  (2)   See Note 2 to our Consolidated Financial Statements for an explanation of the method used to calculate basic and diluted net loss per share of common stock, the pro forma basic and diluted net loss per share of common stock and the weighted-average number of shares used in computation of the per share amounts.
  (3)   Total indebtedness includes a $7.6 million credit facility associated with our student loan auction rate securities holdings, $7.5 million in capital lease obligations, a $4.1 million note payable and a $1.0 million loan payable (See Note 5 and Note 6 to our Consolidated Financial Statements).

 

47


Table of Contents

MANAGEMENT’S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the other financial information appearing elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of various factors, including those discussed below and those discussed in the section entitled “Risk Factors” included elsewhere in this prospectus.

 

Overview

 

We are building an integrated renewable products company by applying our industrial synthetic biology platform to provide alternatives to select petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. We genetically modify microorganisms, primarily yeast, and use them as living factories in established fermentation processes to convert plant-sourced sugars into potentially thousands of molecules. Our first commercialization efforts have been focused on a molecule called farnesene, which forms the basis for a wide range of products varying from specialty chemical applications such as detergents, cosmetics, perfumes and industrial lubricants, to transportation fuels such as diesel. We have focused our research and development, business development and production operations on the use of Brazilian sugarcane as our primary feedstock for the foreseeable future, because it is abundant, low cost and relatively price stable. We intend to secure access to this feedstock and expand our production capacity in a “capital light” manner. Under this approach, we expect to work with Brazilian sugar and ethanol producers to build a new, “bolt-on” facility adjacent to their existing mills instead of building new “greenfield” facilities, thereby reducing the capital required to establish and scale our production. Our first such arrangement is our joint venture with Usina São Martinho, one of the largest sugar and ethanol producers in Brazil.

 

We commenced research activities in January 2005 to build our platform, focusing on development of microbial strains to provide an alternative, lower cost source of artemisinic acid, a precursor of artemisinin, an anti-malarial therapeutic. This work was funded by a five-year grant awarded by the Bill & Melinda Gates Foundation to the Institute for OneWorld Health to support a research collaboration with Amyris and the University of California, Berkeley. In 2008, we entered into an agreement to license our artemisinic acid-producing yeast strains to sanofi-aventis on a royalty free basis for the purpose of manufacturing and commercializing artemisinin-based drugs for the treatment of malaria.

 

As we embark on new research programs, we first identify the molecule that we want to produce based on its market opportunity, and then engineer yeast strains capable of producing the target molecule. Thereafter, we focus on improving the yeast strains so they can produce the desired end product at commercially viable levels. We gauge our production efficiency by measuring a number of production metrics, of which “yield” is the primary metric. Yield quantifies the amount of target molecule produced from a given amount of sugar. To improve yield, our strain development and screening technology utilizes proprietary high-throughput processes to create and test as many as 1,000 yeast strains a day in order to select those yeast strains which are most efficient.

 

In 2006, leveraging our research on artemisinin, we launched formal research programs to produce farnesene, a molecule which can be used as a renewable chemical ingredient for consumer and industrial products and as a fuel. We believe that we will be able to enter certain specialty chemical markets with farnesene if we can attain at commercial production scale the 15% yield that we have achieved at two liter scale. We will continue to seek to improve our yield of farnesene and other molecules in order to enter additional markets profitably and improve our production economics.

 

One of our priorities is to evolve our production processes to transition from laboratory to commercial scale. To do this, we expect to initiate commercial production through the use of contract manufacturing as we complete our joint venture facility with Usina São Martinho which will be located in Brazil. While our yeast

 

48


Table of Contents

strains can use a wide variety of feedstocks, we are focusing on the use of sugarcane as our predominant feedstock and seeking to leverage Brazil’s existing sugar and ethanol infrastructure. In 2008, we established a base of operations in Brazil to move our strains from the laboratory toward commercial production and to oversee Brazilian commercialization of our products. Key milestones to date include:

 

   

In March 2008, we established our subsidiary Amyris Brasil S.A. in Campinas, Brazil, and opened laboratories at this site in August 2008.

 

   

In November 2008, we began operation of our first 300 liter scale pilot plant, in Emeryville, California. This facility enables us to test our strains at a significantly larger volume than the two liter scale we use in our laboratories, which is the first step in our scale-up process.

 

   

In June 2009, we began operation of our second 300 liter scale pilot plant in Campinas, Brazil. This pilot plant is a replica of our plant in Emeryville, which enables us to control transfer of our strains and processes to Brazil, where we can test them with commercial production feedstock.

 

   

In June 2009, through the use of a contract manufacturer, we completed our first initial production runs in 60,000 liter scale fermentors to evaluate results at a larger scale and to produce renewable diesel fuel to support our certification efforts.

 

   

In September 2009, we began operation of our 5,000 liter scale demonstration facility in Campinas, Brazil. We refine large scale equipment design and processes at this scale, the final step before transitioning to a full commercial facility.

 

   

In January 2010, we ordered four 600,000 liter commercial plant fermentors for the purpose of commencing commercial production in the second quarter of 2012 in our Usina São Martinho joint venture facility.

 

   

In February 2010, we received approval from the Brazilian government to use one of our current yeast strains in broad commercial production and we will seek to amend this approval from time to time as we develop new strains.

 

   

In April 2010, we signed a definitive agreement with Usina São Martinho to establish a joint venture for our first production facility in Brazil.

 

We expect to commercialize our products through the use of contract manufacturing in 2011. Starting in the second quarter of 2012, we intend to transition this production to our joint venture with Usina São Martinho. We have also provided Usina São Martinho with an option to produce our products at a second production facility, and we have non-binding letters of intent in place with three leading Brazilian sugar and ethanol producers, Bunge Limited, Cosan S.A. and Açúcar Guarani, a subsidiary of Tereos, to establish production at certain of their existing mills.

 

We intend to work with Brazilian sugar and ethanol producers to increase our production on a capital light basis as follows:

 

   

We would provide mill owners with design and engineering services to build the facility and with access to our yeast strains and processes;

 

   

The mill owners would make a substantial contribution of capital to enable construction of our bolt-on facility or make other substantial operating contributions;

 

   

We would enter into agreements to purchase the products produced and retain exclusive distribution and sales rights; and

 

   

We plan to compensate the mill owner for the feedstock consumed in the production of our products in an amount equal to the revenue they would have realized had they instead produced their traditional products, plus any incremental costs incurred in the production of our products over their usual production costs. Further, as we sell our products, we expect to share a portion of the higher gross margin we expect to realize from the sale of our renewable products with these mill owners.

 

49


Table of Contents

We believe that our capital light approach should enable us to increase production capacity without needing to invest the amount of upfront capital that would be required for the construction of new greenfield facilities.

 

To build the capabilities we will need to distribute our renewable fuels products in the U.S., we have established our subsidiary Amyris Fuels, LLC. Amyris Fuels currently generates revenues by selling third party ethanol to wholesale customers through a network of 13 storage terminals in the southeastern U.S., including in Georgia, North Carolina, South Carolina, Virginia and Tennessee.

 

To date we have not generated any revenues from the commercialization of our own products. Our revenues have come from ethanol sales by Amyris Fuels, which accounted for 77%, 95% and 73% of our total revenues in 2008, 2009 and the three months ended March 31, 2010, respectively, and from collaborative research services and grants.

 

We continue to experience significant losses as we invest in research and development, commercial facility design, sales and marketing and administrative infrastructure. As of March 31, 2010, we had an accumulated deficit of $136.6 million . We incurred net losses attributable to Amyris stockholders of $11.8 million, $41.9 million and $64.5 million in 2007, 2008 and 2009, respectively and $16.2 million for the three months ended March 31, 2010.

 

Recent Developments

 

On April 14, 2010, we entered into a joint venture with Usina São Martinho to build a new production facility for the production of our products at the Usina São Martinho sugar and ethanol mill located in São Paulo state. The joint venture, SMA Indústria Química S.A., was created to build the first facility in Brazil fully dedicated to the production of Amyris renewable products. The new company will be located at Usina São Martinho in Pradópolis, São Paulo state.

 

The joint venture will be managed by a three-member executive committee, of which we appoint two members, including the plant director who is the most senior executive. The executive committee will be responsible for managing the construction and operation of the production facility. The joint venture will be governed by a four-member board of directors, of which we and Usina São Martinho will each appoint two members. The board of directors has certain protective rights which include final approval of the engineering designs and project work plan developed and recommended by the executive committee.

 

The construction of the facility at Usina São Martinho will be the first project of this nature that we will design and manage. We expect the construction costs of the new facility to total between $80 million to $100 million. Under the terms of our joint venture agreements, construction of the production facility will take place in two phases. Phase I is designed to construct a facility capable of producing farnesene from one million tons of crushed sugarcane annually, and Phase II will expand that capacity to two million tons annually. We will provide the initial funding for Phase I and within one year of the commencement of Phase I commercial operations, Usina São Martinho will be required to reimburse us for half of the cost of Phase I, up to a cap of 30.9 million reais ($17.1 million based on the exchange rate on June 11, 2010). Thereafter, Usina São Martinho will co-fund the construction of Phase II and, as necessary, make a final payment at completion such that their total contribution will be 61.8 million reais ($34.2 million based on the exchange rate on June 11, 2010).

 

Post commercialization, Amyris will market and distribute the Amyris renewable products. São Martinho will sell feedstock and provide certain other services to the joint venture. The cost of the feedstock to the joint venture is a price that is based on the average return that Usina São Martinho could receive from the production of its current products, sugar and ethanol. We are required to purchase the output of the joint venture for the first four years at a price that guarantees the return of Usina São Martinho’s investment plus a fixed interest rate.

 

Under the terms of the joint venture agreements, if Amyris Brasil becomes controlled, directly or indirectly, by a competitor of Usina São Martinho, then Usina São Martinho has the right to acquire our interest in the joint

 

50


Table of Contents

venture. If Usina São Martinho becomes controlled, directly or indirectly, by a competitor of ours, then we have the right to sell our interest in the joint venture to Usina São Martinho. In either case, the purchase price shall be determined in accordance with the joint venture agreements, and we would continue to have the obligation to acquire products produced by the joint venture for the remainder of the term of the supply agreement then in effect even though we would no longer be involved in the joint venture’s management.

 

On June 21, 2010, we entered into an agreement with Total Gas & Power USA, SAS (“Total”), pursuant to which we sold 7,101,548 shares of our Series D preferred stock to Total for an aggregate of $133.2 million. The shares of Series D preferred stock are convertible into shares of our common stock on a one-for-one basis, representing approximately 20.8% of our common stock (and representing approximately 17% of our outstanding capital stock when calculated on a “fully diluted basis” which gives effect to (i) all outstanding shares of common stock, (ii) all shares of common stock into which our outstanding securities are convertible, and (iii) the total number of shares remaining available for issuance outstanding under our 2005 Stock Option/Stock Issuance Plan) after giving effect to the conversion of all of our preferred stock prior to this offering, and more shares if the initial public offering price is below $         per share. If the initial public offering price is above $18.75, then Total will make an additional payment to us. See “Capitalization.”

 

In connection with Total’s equity investment, we agreed to appoint a person designated by Total to serve as a member of our Board of Directors in the class subject to the latest reelection date, and to use our reasonable efforts, consistent with the Board’s fiduciary duties, to cause the director designated by Total to be re-nominated by the Board in the future. These Board membership rights terminate upon the earlier of Total holding less than half of the shares of common stock originally issuable upon conversion of the Series D preferred stock or a sale of our company.

 

We also agreed with Total that, so long as Total holds at least 10% of our voting securities, we will notify Total if our Board of Directors seeks to cause the sale of our company or if we receive an offer to be acquired. In the event of such decision or offer, we must provide Total with all information given to an offering party and certain other information, and Total will have an exclusive negotiating period of 15 business days in the event the Board authorizes us to solicit offers to buy Amyris, or five business days in the event that we receive an unsolicited offer to be acquired. This exclusive negotiation period will be followed by an additional restricted negotiation period of 10 business days, during which we will be obligated to negotiate with Total and will be prohibited from entering into an agreement with any other potential acquirer.

 

Total has also entered into a standstill agreement pursuant to which it agreed for a period of three years not to acquire in excess of the greater of 20% or the number of shares of Series D preferred stock purchased by Total (during the initial two years) or 30% (during the third year) of our common stock without the prior consent of our Board of Directors, except that, among other things, if another person acquires more than Total’s then current holdings of our common stock, then Total may acquire up to that amount plus one share.

 

We also entered into a technology license, development, research and collaboration agreement with Total Gas & Power USA Biotech, Inc., an affiliate of Total S.A. The agreement sets forth the terms for the research, development, production and commercialization of certain to be determined chemical and/or fuel products made through the use of our synthetic biology platform. The agreement establishes a multi-phased process through which projects are identified, screened, studied for feasibility, and ultimately selected as a project for development of an identified lead compound using an identified microbial strain. The agreement also contemplates that we and Total would work together on projects making microbial strains using pathways not currently under development by Amyris. Subject to agreement between Total and Amyris on the initial projects and associated expenses, Total has agreed to pay up to the first $50.0 million in research and development costs for the selected projects; thereafter the parties will share such costs equally. Amyris has agreed to dedicate the laboratory resources needed for collaboration projects. Total also plans to second employees at Amyris to work on the projects. Once a development project has commenced, the parties are obliged to work together exclusively to develop the lead compound during the project development phase. After a development project is completed, Amyris and Total expect to form one or more joint ventures to commercialize any products that are developed.

 

51


Table of Contents

Each party has certain rights to independently produce commercial quantities of these products under certain circumstances, subject to paying royalties to the other party. In addition, Amyris has retained rights to produce and commercialize products in the following markets: flavors and fragrances; cosmetics; pharmaceuticals; consumer packaged goods; food additives; and pesticides. Total has the right of first negotiation with respect to exclusive commercialization arrangements we would propose to enter into with certain third parties. In addition, Total has certain rights to require Amyris to work on non-collaboration projects. The collaboration agreement has an initial term of 12 years.

 

Financial Operations Overview

 

Revenues

 

To date, our revenues have consisted of sales of ethanol, collaborative research services and government grants.

 

   

Product sales.  Product sales are derived from sales of ethanol purchased from third parties under short-term agreements at prevailing market prices.

 

   

Collaborative research services . Collaborative research service revenues generally consist of payments for research and development activities for specific projects. These payments may include a combination of cost plus reimbursement, up-front payments or milestone payments.

 

   

Government grants. Government grant revenues consist of payments from government entities. The terms of these grants generally provide us with reimbursement for research and development services and certain types of capital expenditures over a contractually defined period.

 

Ethanol sales by Amyris Fuels accounted for 77%, 95% and 73% of our total revenues in 2008, 2009 and the three months ended March 31, 2010, respectively. The balance of our revenues has come from collaborative research services and grants. Prior to commercialization of our products, we expect to increase revenues from grants and collaborations. We expect to receive approximately $24.3 million in funding for 2010 through 2012 under a grant from the DOE, of which we received payment of $2.3 million in May 2010. Under this grant, we would be required to fund an additional $10.6 million in cost sharing expenses. We expect revenues from the sale of our renewable products to comprise an increasing portion of our total revenues.

 

We expect to commercialize our renewable products starting in 2011. We anticipate that our revenues from sales of our renewable products may be significantly lower in the first quarter of each year, as we expect to produce and sell the majority of our products during the sugarcane harvesting period, which typically begins in April or May and ends in November or December in the region of Brazil where we intend to locate the majority of our production capacity.

 

Cost and Operating Expenses

 

Cost and operating expenses consist of cost of product sales, research and development expenses, sales, general and administrative expenses and restructuring and asset impairment charges. Cost of product sales and personnel-related expenses comprise the most significant components of these expenses. We expect to continue to hire new employees, particularly in process development and manufacturing and general and administration in order to support our anticipated growth.

 

Cost of Product Sales. Our cost of product sales consists primarily of cost of purchased ethanol products, terminal fees paid for storage and handling, transportation costs between terminals, product losses and changes in the fair value of the derivative contracts used for hedging the price volatility of ethanol. To date gross margins on product sales have been nominal given the relatively high cost of ethanol compared to the price at which ethanol is sold. We expect gross margins to improve once we are producing through the joint venture with Usina São Martinho and additional sugar and ethanol mills. We expect lower margins on products produced by contract manufacturers than on products produced by our joint venture or by sugar and ethanol mills with whom we are

 

52


Table of Contents

partnering, due primarily to the fees we pay to the contract manufacturer and, as applicable, to the extent we use feedstock with such contract manufacturers that is more expensive to us than the sugarcane we expect to use in our joint venture mill or in other mills with whom we are partnering. In the future, gross margins may vary depending on the mix of specialty chemicals and renewable fuels that we produce. We expect that the cost of our products will be comprised primarily of the cost of the products paid to the mill owners or the contract manufacturer and, if applicable, chemical finishing and distribution costs.

 

Research and Development.  Research and development expenses consist primarily of expenses for personnel engaged in the development of new products, the expansion of product applications and the improvement in yield. These expenses also consist of facilities costs and other related overhead and lab materials. We expense all of our research and development costs as they are incurred. In the near term, we expect to hire additional employees, as well as incur contract-related expenses as we continue to invest in the development of our products. Accordingly, we expect that our research and development expenses will continue to increase.

 

Sales, General and Administrative. Sales, general and administrative expenses consist primarily of personnel-related expenses related to our executive, legal, finance, human resource and information technology functions, as well as fees for professional services and allocated facility overhead expenses. These expenses also include costs related to our sales function, including marketing programs and other allocated costs. Professional services consist principally of external legal, accounting, tax, audit and other consulting services. We expect sales, general and administrative expenses to increase as we incur additional costs related to operating as a publicly-traded company, including increased legal fees, accounting, costs of compliance with securities, corporate governance and other regulations, investor relations expenses and higher insurance premiums, particularly those related to director and officer insurance. In addition, we expect to incur additional costs as we hire personnel and enhance our infrastructure to support the anticipated growth of our business.

 

Restructuring and Asset Impairment Charges. Restructuring and asset impairment charges consist primarily of non-cash charges relating to the consolidation of our headquarters in a single facility in Emeryville, California, and asset impairment charges related to the vacated facility.

 

Other Income (Expense), Net

 

Interest Income.  Interest income consists primarily of interest income earned on investments and cash balances. Our interest income will vary each reporting period depending on our average investment balances during the period and market interest rates. We expect interest income to fluctuate in the future with changes in average investment balances and market interest rates.

 

Interest Expense.  We recognize interest expense on all of our capital leases, loans payable and debt obligations. We expect interest expense to fluctuate in the future with changes in our debt obligations.

 

Other Income (Expense), Net.  Other income (expense), net consists primarily of the change in the fair value of our convertible preferred stock warrants, change in the fair value of our auction rate securities (“ARS”) and our rights to sell our ARS. Our outstanding convertible preferred stock warrants are classified as a liability and the change in the fair value of these warrants will vary based on multiple factors, but will generally increase if the fair value of underlying stock increases. We will continue to record adjustments to the fair value of the warrants until they are exercised, converted into warrants to purchase common stock or expire, at which time the warrants will no longer be remeasured at each balance sheet date and the then-current aggregate fair value of these warrants will be reclassified from liabilities to common stock and we will cease to record any related periodic fair value adjustments.

 

Income Taxes

 

Provision for (Benefit from) Income Taxes.  Since inception, we have incurred net losses and have not recorded any U.S. federal and state and non-U.S. income tax provisions, with limited exceptions in several years, since the tax benefits of our net losses have been offset by valuation allowances.

 

53


Table of Contents

Critical Accounting Policies and Estimates

 

Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. We base our estimates and assumptions on historical experience and on various other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The results of our analysis form the basis for making assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.

 

We believe the following critical accounting policies involve significant areas of management’s judgments and estimates in the preparation of our financial statements.

 

Revenue Recognition

 

We currently recognize revenues from the sale of ethanol, the delivery of collaborative research services and from government grants. Revenues are recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable and collectability is reasonably assured.

 

If sales arrangements contain multiple elements, we evaluate whether the components of each arrangement represent separate units of accounting. We have determined that all of our revenue arrangements should be accounted for as a single unit of accounting. Application of revenue recognition standards requires subjective determination and requires management to make judgments about the fair values of each individual element and whether it is separable from other aspects of the contractual relationship.

 

For each source of revenues, we apply the above revenue recognition criteria in the following manner:

 

Product Sales

 

We sell ethanol under short-term agreements and in spot transactions at prevailing market prices. Revenues are recognized, net of discounts and allowances, once passage of title and risk of loss have occurred, provided all other revenue recognition criteria have also been met.

 

Shipping and handling costs charged to customers are recorded as revenues. Shipping costs are included in cost of product revenues. Such charges were not significant in any of the periods presented.

 

Collaborative Research Services

 

Revenues from collaborative research services are recognized as the services are performed consistent with the performance requirements of the contract. In cases where the planned levels of research services fluctuate over the research term, we recognize revenues using the proportionate performance method based upon actual efforts to date relative to the amount of expected effort to be incurred by us. When up-front payments are received and the planned levels of research services do not fluctuate over the research term, revenues are recorded on a ratable basis over the arrangement term, up to the amount of cash received. When up-front payments are received and the planned levels of research services fluctuate over the research term, revenues are recorded using the proportionate performance method, up to the amount of cash received. Where arrangements include milestones that are determined to be substantive and at risk at the inception of the arrangement, revenues are recognized upon achievement of the milestone and is limited to those amounts whereby collectability is reasonably assured.

 

54


Table of Contents

Government Grants

 

Government grants are made pursuant to agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. Revenues from government grants are recognized in the period during which the related costs are incurred, provided that the conditions under which the government grants were provided have been met and only perfunctory obligations are outstanding.

 

Impairment of Long-Lived Assets

 

We assess impairment of long-lived assets, which include property and equipment, on at least an annual basis and test long-lived assets for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to, significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; or expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.

 

Recoverability is assessed based on the fair value of the asset, which is calculated as the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. An impairment loss is recognized in the consolidated statements of operations when the carrying amount is determined to be not recoverable and exceeds fair value, which is determined on a discounted cash flow basis.

 

We make estimates and judgments about future undiscounted cash flows and fair values. Although our cash flow forecasts are based on assumptions that are consistent with our plans, there is significant exercise of judgment involved in determining the cash flow attributable to a long-lived asset over its estimated remaining useful life. Our estimates of anticipated cash flows could be reduced significantly in the future. As a result, the carrying amounts of our long-lived assets could be reduced through impairment charges in the future.

 

Convertible Preferred Stock Warrants

 

Freestanding warrants to purchase shares of our convertible preferred stock are classified as liabilities on our consolidated balance sheets at fair value because the warrants may conditionally obligate us to redeem the underlying convertible preferred stock at some point in the future. The warrants are subject to remeasurement at each balance sheet date, and any change in fair value is recognized as a component of other income (expense), net in the consolidated statements of operations. We estimated the fair value of these warrants at the respective balance sheet dates using the Black-Scholes option pricing model. We use a number of assumptions to estimate the fair value including the remaining contractual terms of the warrant, risk-free interest rates and expected dividend yield and expected volatility of the price of the underlying common stock. These assumptions are highly judgmental and could differ significantly in the future.

 

For 2007, 2008 and 2009, we recorded charges of $0, $0.1 million and $0.4 million through other income (expense), net to reflect the change in the fair value of the warrants. During the three months ended March 31, 2009 and 2010, the reduction in the expected term and in the estimated per share fair value of the underlying preferred stock, offset by the increase in expected volatility, resulted in an estimated fair value of the warrants based on the Black-Scholes valuation model to be less that the valuation in prior periods. As a result, we recorded a gain of $138,000 and $542,000 during the three months ended March 31, 2009 and 2010, respectively, in other income (expense), net to reflect the change in fair value of the warrants.

 

We will continue to record adjustments to the fair value of the warrants until they are exercised, converted into warrants to purchase common stock or expire, at which time the warrants will no longer be remeasured at each balance sheet date. At that time, the then-current aggregate fair value of these warrants will be reclassified from liabilities to common stock and we will cease to record any related periodic fair value adjustments.

 

55


Table of Contents

Stock-Based Compensation

 

Our stock-based compensation expense is as follows:

 

     Years Ended
December 31,
   Three Months Ended
March 31,
     2007    2008    2009    2009    2010
    

(Dollars in thousands)

          (Unaudited)

Research and development

   $ 117    $ 632    $ 773    $ 136    $ 453

Sales, general and administrative

        429      1,395      2,526         466      1,346
                                  

Total stock-based compensation expense

   $ 546    $ 2,027    $ 3,299    $ 602    $ 1,799
                                  

 

We recognize compensation expense related to share-based transactions, including the awarding of employee stock options, based on the grant date estimated fair value. We amortize the fair value of the employee stock options on a straight-line basis over the requisite service period of the award, which is generally the vesting period.

 

In future periods, our stock-based compensation expense is expected to increase as a result of our existing unrecognized stock-based compensation still to be recognized and as we issue additional stock-based awards in order to attract and retain employees and nonemployee consultants.

 

Significant Factors, Assumptions and Methodologies Used In Determining Fair Value

 

We utilize the Black-Scholes option pricing model to estimate the fair value of our share-based payment awards. The Black-Scholes option pricing model requires inputs such as the expected term of the grant, expected volatility and risk-free interest rate. Further, the forfeiture rate also affects the amount of aggregate compensation that we are required to record as an expense. These inputs are subjective and generally require significant judgment.

 

The fair value of employee stock options was estimated using the following weighted-average assumptions:

 

     Years Ended
December 31,
     Three Months
Ended March 31,
     2007            2008                  2009                2009              2010    
                          (Unaudited)

Expected dividend yield

   0%      0%      0%      *      0%

Risk-free interest rate

   3.9%-4.7%      3.2%      2.8%      *      2.8%

Expected term (in years)

   6.0      6.0      6.0      *      6.0

Expected volatility

   70%      70%      97%      *      98%

 

  *   No options were granted during the quarter ended March 31, 2009.

 

Our expected term is derived from a comparable group of publicly listed companies that has a similar industry, life cycle, revenue and market capitalization.

 

Our expected volatility is derived from the historical volatilities of several unrelated public companies within our industry over a period equal to the expected term of our options because we do not have any trading history to use for calculating the volatility of our own common stock.

 

Our risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to each option’s expected term.

 

Our expected dividend yield was assumed to be zero as we have not paid, and do not anticipate paying, cash dividends on our shares of common stock.

 

56


Table of Contents

We estimate our forfeiture rate based on an analysis of our actual forfeitures and will continue to evaluate the appropriateness of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover and other factors. Quarterly changes in the estimated forfeiture rate can have a significant effect on reported stock-based compensation expense, as the cumulative effect of adjusting the rate for all expense amortization is recognized in the period the forfeiture estimate is changed. If a revised forfeiture rate is higher than the previously estimated forfeiture rate, an adjustment is made that will result in a decrease to the stock-based compensation expense recognized in the consolidated financial statements. If a revised forfeiture rate is lower than the previously estimated forfeiture rate, an adjustment is made that will result in an increase to the stock-based compensation expense recognized in the consolidated financial statements.

 

We will continue to use judgment in evaluating the expected term, volatility and forfeiture rate related to our own stock-based compensation on a prospective basis and incorporating these factors into the Black-Scholes option pricing model.

 

Each of these inputs is subjective and generally requires significant management and director judgment to determine. If, in the future, we determine that another method for calculating the fair value of our stock options is more reasonable, or if another method for calculating these input assumptions is prescribed by authoritative guidance, and, therefore, should be used to estimate expected volatility or expected term, the fair value calculated for our employee stock options could change significantly. Higher volatility and longer expected terms generally result in an increase to stock-based compensation expense determined at the date of grant.

 

The following table summarizes the options granted from January 1, 2008, through the date of this prospectus:

 

Grant Date

   Number of Options
Granted
   Exercise Price
Per Share
   Estimated Fair Value
Per Share
    Intrinsic Value
Per Share

January 2, 2008

   51,700    $ 3.93    $ 4.26   $ 0.33

February 1, 2008

   103,900      3.93      4.35     0.42

February 27, 2008

   210,000      3.93      4.43     0.50

March 7, 2008

   49,000      3.93      4.58     0.65

April 1, 2008

   285,970      3.93      5.08     1.15

May 7, 2008

   113,500      3.93      5.80     1.87

June 2, 2008

   135,500      3.93      6.33     2.40

August 25, 2008

   279,979      3.93      7.95     4.02

September 15, 2008

   60,000      3.93      8.36     4.43

September 14, 2009

   965,153      4.31      4.31       

October 27, 2009

   144,400      4.31      4.31       

January 7, 2010

   1,178,810      9.32      9.32       

March 19, 2010

   236,500      14.28      14.28       

April 20, 2010

   509,454      20.41      20.40    

 

  *   We reassessed the fair value of our common stock subsequent to the grant date of these options.

 

The intrinsic value of the options outstanding as of March 31, 2010 was $         million, of which $         million related to vested options, based on an assumed initial public offering price of $         per share, the midpoint of the range set forth on the cover page of the prospectus.

 

All options granted by our board of directors on the dates noted above were intended to be exercisable at the fair value of our stock based on information known at that time. For the purposes of recording stock-based compensation expense, we reviewed the historical pattern of our common stock, and subsequently reassessed the fair value of our stock for the options granted from January 2, 2008, through September 15, 2008.

 

57


Table of Contents

The fair values of the common stock underlying our stock options have historically been determined by our Board of Directors with input from management. In the absence of a public trading market for our common stock, our Board has determined the fair value of the common stock utilizing methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation , (referred to herein as the “AICPA Practice Guide”). In addition, our Board of Directors considered numerous objective and subjective factors including:

 

   

the prices for our convertible preferred stock sold to outside investors in arm’s-length transactions;

 

   

the prices of our common stock sold to investors in arm’s-length transactions;

 

   

rights, preferences and privileges of that convertible preferred stock relative to those of our common stock;

 

   

valuations using the methodologies described below;

 

   

actual operating and financial performance based on management’s estimates;

 

   

the execution of strategic and development agreements;

 

   

the hiring of key personnel;

 

   

status of product development;

 

   

the risks inherent in the development and expansion of our products and services;

 

   

our stage of development and revenue growth;

 

   

achievement of various product certifications;

 

   

the lack of an active public market for our common and convertible preferred stock;

 

   

the likelihood of achieving a liquidity event, such as an initial public offering or a sale of our company given prevailing market conditions and the nature and history of our business;

 

   

the performance of similarly-situated companies in our industry;

 

   

trends in the renewable chemicals and fuels industries;

 

   

industry information such as market growth and volume; and

 

   

macro-economic events.

 

Our Board of Directors considered common stock valuations performed as of September 16, 2008, August 7, 2009, December 29, 2009, March 9, 2010 and April 16, 2010, in determining or confirming the grant date fair value of common stock. Using these valuations, and the other factors described above, our Board of Directors made the following estimates of fair value of our common stock.

 

Valuation Date

   Fair Value Per Share

September 16, 2008

   $ 8.38

August 7, 2009

     4.31

December 29, 2009

     9.32

March 9, 2010

     14.28

April 16, 2010

     20.40

 

The valuations that our Board of Directors considered in determining the fair value of our common stock from September 2008 through October 2009 were based on the estimated aggregate enterprise value at the valuation date using the implied equity value from our convertible preferred stock financings, as the probability of a sale or merger occurring in the foreseeable future were deemed to be highly uncertain. In order to arrive at the fair value of our common stock, the indicated enterprise value of our company calculated at the valuation date was allocated to the shares of convertible preferred stock and the warrants to purchase convertible preferred

 

58


Table of Contents

stock, and shares of common stock and the options to purchase common stock using an option pricing methodology. The option pricing method treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company’s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the liquidation preference at the time of a liquidity event, such as a strategic sale, merger or initial public offering, assuming the enterprise has funds available to make a liquidation preference meaningful and collectible by the holders of preferred stock. The common stock is modeled as a call option on the underlying equity value at a predetermined exercise price. In the model, the exercise price is based on a comparison with the total equity value rather than, as in the case of a regular call option, a comparison with a per share stock price. Thus, common stock is considered to be a call option with a claim on the enterprise at an exercise price equal to the remaining value immediately after the preferred stock is liquidated. The option pricing method uses the Black-Scholes option pricing model to price the call options. This model defines the securities’ fair values as functions of the current fair value of a company and uses assumptions such as the anticipated timing of a potential liquidity event and the estimated volatility of the equity securities. The anticipated timing of a liquidity event utilized in these valuations was based on then-current plans and estimates of our Board of Directors and management regarding a liquidity event. The aggregate value of the common stock derived from the option pricing method was then divided by the number of shares of common stock outstanding to arrive at the per share value. A discount for lack of marketability was applied to reflect the increased risk arising from the inability to readily sell the shares. This approach is consistent with the methods outlined in the AICPA Practice Guide.

 

The common stock valuation as of September 16, 2008, was performed following the commencement of sale of shares of our Series B-1 preferred stock sold during the period from February 2008 to January 2009 at a price of $25.26 per share to several venture capital and private equity firms. The price per share for the Series B-1 shares and the terms of the transactions were the result of negotiations between us and the Series B-1 investors.

 

The common stock valuation as of August 7, 2009, was performed following the commencement of our sale of shares of our Series C preferred stock in July 2009 at a price of $12.46 per share to several venture capital and private equity firms. The price per share for the Series C shares and the terms of the transactions were the result of negotiations between us and the Series C investors.

 

Commencing in December 2009, the valuations that our Board of Directors considered in determining the fair value of our common stock were based on the market approach and the income approach to estimate our aggregate enterprise value at each valuation date. The market approach measures the value of a company through the analysis of recent sales of comparable companies. Consideration is given to the financial condition and operating performance of the company being valued relative to those of publicly traded companies operating in the same or similar lines of business. When choosing the comparable companies to be used for the market approach, we focused on companies in our industry. Some of the specific criteria used to select comparable companies within this industry include the business description, business size, projected growth, financial condition and historical earnings. The income approach measures the value of a company as the present value of its future economic benefits by applying an appropriate risk-adjusted discount rate to expected cash flows, based on forecasted revenues and costs. We prepared a financial forecast for each valuation to be used in the computation of the enterprise value for both the market approach and the income approach. The financial forecasts took into account our past experience and future expectations. The risks associated with achieving these forecasts were assessed in selecting the appropriate discount rate.

 

These contemporaneous valuations used two equity allocation scenarios to derive our common stock fair value as follows: (i) a sale or merger scenario and (ii) an initial public offering scenario. Under both scenarios, we used an options-based methodology for allocating the estimated aggregate value to each of our securities using the Black-Scholes option-pricing model. We also considered the price per share of common stock established in recent transactions among our stockholders. Each of the aggregate values of the common stock derived from the two option pricing models was then divided by the number of shares of common stock

 

59


Table of Contents

outstanding to arrive at a per share value. A discount for lack of marketability was applied to reflect the increased risk arising from the inability to readily sell the shares.

 

There is inherent uncertainty in these estimates and if we had made different assumptions than those described above, the amount of our stock-based compensation expense, net loss and net loss per share amounts could have been significantly different.

 

Discussion of Specific Valuation Inputs

 

We granted stock options in 2008, 2009 and 2010 with exercise prices between $3.93 and $20.41 per share. No single event caused the valuation of our common stock to increase or decrease from January 2008 to April 2010; rather, it has been a combination of the following factors that led to the changes in the fair value of the underlying common stock:

 

January to March 2008: In January 2008, we appointed a Chief Financial Officer. In February 2008, we closed the first round of our Series B-1 convertible preferred stock financing, at a price of $25.26 per share. In March 2008, we announced a development agreement for artemisinin with One World Health and sanofi-aventis. In March 2008 we also established our subsidiary Amyris Brasil S.A. in Campinas, Brazil. For option grants from January to March 2008, the Board of Directors deemed the fair market value of the common stock to be $3.93. However, for purposes of computing the related stock compensation expense the fair value of our common stock was subsequently reassessed at $4.26-$4.58 per share for options granted from January 2008 to March 2008.

 

April to September 2008: During this period, we completed subsequent rounds of our Series B-1 convertible preferred stock financing at a price of $25.26 per share. In June 2008, we began generating revenues through our Amyris Fuels, LLC subsidiary. For option grants from April to September 2008, the board deemed the fair market value of the option grants to be $3.93. However, for purpose of computing the related stock compensation expense the fair value of our common stock was subsequently reassessed at $5.08-$8.36 per share for options granted from April 2008 to September 2008.

 

October 2008 to June 2009: In November 2008, we completed our first test runs at our pilot plant in Emeryville, California, to produce renewable products. In November 2008, we appointed a Senior Vice President of Research Programs and Operations. In December 2008, we determined market conditions had deteriorated and reduced our workforce by 12%. In January 2009, we closed the final round of our Series B-1 convertible preferred stock financing at a price of $25.26 per share. In April 2009, we received EPA registration for our renewable diesel fuel. In June 2009, we completed our initial production runs at our 300 liter scale fermentors in our pilot plant in Campinas, Brazil, to transition our yeast and processes into Brazil. Additionally in June 2009, through the use of a contract manufacturer, we completed our first initial production runs in 60,000 liter scale fermentors to evaluate results at a larger scale and to produce renewable diesel fuel to support our certification efforts. No options were granted during the period from October 2008 to August 2009.

 

July to October 2009: In July 2009, we closed the first round of our Series C convertible preferred stock financing at a price of $12.46 per share, which was 51% lower than the price per share we received from our Series B-1 convertible preferred stock financing in 2008 resulting from unfavorable market conditions related to the availability of private funding at the time. In September 2009, we began operations of our 5,000 liter scale demonstration facility in Campinas, Brazil. As a result of these transactions, and applying the Common Stock valuation methodology described above, we estimated the fair value of our common stock to be $4.31 per share as of August 7, 2009, and it remained at that price through the end of October 2009 because there were no significant developments in our business.

 

November to December 2009: In November 2009, we secured a patent covering our second potential jet fuel product and another patent covering our lubricant products. We also signed a memorandum of understanding with two international corporations to evaluate the technical and sustainability aspects of our renewable jet fuel. In addition, we signed a binding letter of intent related to the construction and launch of our first commercial facility at an ethanol mill owned by Usina São Martinho in Brazil. In December 2009, we received notification of

 

60


Table of Contents

a conditional award from the DOE, authorizing a grant for $24.3 million. Further, we announced letters of intent with Bunge Limited, Cosan and Açúcar Guarani for the purpose of partnering for the production of renewable chemicals and fuels. We also appointed a Chief Commercial Officer and a Chief Operating Officer. In December, three of our founders and our CEO sold to four existing investors shares of common stock representing in each case less than 10% of their overall common stock and options holdings at a price of $7.00 per share. Due to the change in the equity markets, in December we also deemed the probability of completing an initial public offering to be probable in the next eighteen months. As a result of these transactions, and applying the Common Stock valuation methodology described above, we estimated the fair value of our common stock to be $9.32 per share as of December 31, 2009. No options were granted during the period from November to December 2009.

 

January 2010 to February 2010: From December 29, 2009, to January 10, 2010, our valuation remained at $9.32 per share because there were no significant developments in our business. In January 2010, we ordered four 600,000 liter commercial fermentors for the purpose of commencing commercial production in our Usina São Martinho joint venture facility. Also in January 2010, we commenced negotiations to receive $3.9 million from a DOE grant, which is being made to the NREL, and under which we would be a subcontractor. Additionally, in January we closed the final round of our Series C convertible preferred stock financing at a price of $12.46 per share. In February 2010, we received approval from the Brazilian government to use our current yeast strain in commercial production. During this period we began discussions with investment banks regarding an IPO.

 

March 2010 to April 2010: In March 2010, we received an additional $1.7 million investment from an investor in Amyris Brasil and we completed our $47.8 million Series C-1 preferred stock financing at a price of $17.56 per share. In April 2010, we entered into a joint venture with Usina São Martinho. Also in April 2010, we filed a registration statement on Form S-1 with the SEC for a potential initial public offering. As a result of these events and applying the common stock valuation methodology described above, we estimated the fair value of our common stock to be $20.40 per share as of April 16, 2010.

 

May 2010 to June 2010: In May 2010, we received a $5.4 million investment from an investor in Amyris Brasil. In June 2010, we sold 7,101,548 shares of our Series D preferred stock, at $18.75 per share for an aggregate purchase price of approximately $133.2 million, to Total Gas & Power USA, SAS, or Total. We also entered into a technology license, development, research and collaboration agreement with Total. In June 2010, we entered into agreements with The Procter & Gamble Company and M&G Finanziaria S.R.L. that establish terms under which they may purchase our farnesene for use in their products. In June 2010, we also entered into an agreement with Soliance for the development and commercialization of farnesene-based ingredients for cosmetics products and into a term sheet with Cosan for the formation of a joint venture to develop and commercialize farnesene-based specialty chemicals for industrial and automotive applications. In June 2010, we entered into an agreement with Shell Western Supply and Trading Limited, a subsidiary of Royal Dutch Shell plc, that establishes terms under which Shell may purchase our diesel fuel. No options were granted during the period from May to June 2010.

 

Nonemployee Stock-Based Compensation

 

We account for stock options issued to nonemployees based on the estimated fair value of the awards using the Black-Scholes option pricing model. We account for restricted stock units (“RSUs”) issued to nonemployees based on the estimated fair value of our common stock. The measurement of stock based compensation is subject to periodic adjustments as the underlying equity instruments vest, and the resulting change in value, if any, is recognized in our consolidated statement of operations during the period the related services are rendered.

 

Stock-based compensation expense for options and RSUs granted to nonemployees for 2007, 2008 and 2009 was $0.2 million, $0.7 million and $0.7 million, respectively, and for the three months ended March 31, 2009 and 2010, was $0.1 million and $0.5 million, respectively.

 

61


Table of Contents

There is inherent uncertainty in these estimates and if different assumptions had been used, the fair value of the equity instruments issued to nonemployee consultants could have been significantly different.

 

Income Taxes

 

We are subject to income taxes in both the U.S. and foreign jurisdictions, and we use estimates in determining our provisions for income taxes. We use the liability method of accounting for income taxes, whereby deferred tax assets or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect for the year in which the differences are expected to affect taxable income.

 

Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. We recognize a valuation allowance against our net deferred tax assets if it is more likely than not that some portion of the deferred tax assets will not be fully realizable. This assessment requires judgment as to the likelihood and amounts of future taxable income by tax jurisdiction. At December 31, 2009, we had a full valuation allowance against all of our deferred tax assets.

 

Effective January 1, 2007, we adopted ASC 740-10 to account for uncertain tax positions. As of December 31, 2007, 2008 and 2009, our total unrecognized tax benefits were $0.1, $0.6 and $1.0 million, of which none of the tax benefits, if recognized, would affect the effective income tax rate due to the valuation allowance that currently offsets deferred tax assets. We do not anticipate the total amounts of unrecognized income tax benefits will significantly increase or decrease in the next 12 months.

 

We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.

 

62


Table of Contents

Results of Operations

 

The following table sets forth our consolidated results of operations for the periods shown:

 

     Years Ended December 31,     Three Months Ended March 31,  
         2007             2008             2009                 2009                     2010          
    

(Dollars in thousands)

 
           (Unaudited)  

Consolidated Statements of Operations Data:

          

Revenues

          

Product sales

   $      $ 10,680      $ 61,689      $ 1,534      $ 9,954   

Collaborative research services

     6,046        3,008        2,919        557        1,378   

Government grants

     138        204                      2,323   
                                        

Total revenues

     6,184        13,892        64,608        2,091        13,655   
                                        

Cost and operating expenses

          

Cost of product sales

            10,364        60,428        1,424        10,003   

Research and development

     8,662        30,306        38,263        8,603        11,178   

Sales, general and administrative

     10,522        16,622        23,558        4,402        9,216   

Restructuring and asset impairment charges

                   5,768                 
                                        

Total cost and operating expenses

     19,184        57,292        128,017        14,429        30,397   
                                        

Loss from operations

     (13,000     (43,400     (63,409     (12,338     (16,742

Other income (expense)

          

Interest income

     1,178        1,378        448        237        276   

Interest expense

     (28     (377     (1,218     (234     (384

Other income (expense), net

     76        (144     (621     (58     515   
                                        

Total other income (expense)

     1,226        857        (1,391     (55     407   
                                        

Loss before income taxes

     (11,774     (42,543     (64,800     (12,393     (16,335

Benefit from income taxes

            (207                     
                                        

Net loss

     (11,774     (42,336     (64,800     (12,393     (16,335

Net loss attributable to noncontrolling interest

            (472     (341     (221     (183
                                        

Net loss attributable to Amyris, Inc. stockholders

   $ (11,774   $ (41,864   $ (64,459   $ (12,172   $ (16,152
                                        

 

Comparison of Three Months Ended March 31, 2010 and 2009

 

Revenues

 

     Three Months Ended March 31,    Change in 2010
         2009            2010        $
     (Dollars in thousands)
     (Unaudited)

Product sales

   $ 1,534    $ 9,954    $ 8,420

Collaborative research services

     557      1,378      821

Government Grants

          2,323      2,323
                    

Total revenue

   $ 2,091    $ 13,655    $ 11,564
                    

 

Our total revenue increased $11.6 million to $13.7 million in the three months ended March 31, 2010 compared to the comparable period the prior year. The increase was primarily the result of the increase of $8.4 million in sales of third party ethanol. We sold 4.9 million gallons of ethanol in the first quarter of fiscal 2010

 

63


Table of Contents

compared to 0.7 million gallons in the first quarter of fiscal 2009, as we had an increase in the number of customers and accessed additional terminal space in 2010. We also had an increase of $2.3 million resulting from revenue recognized from our DOE grant in the three months ended March 31, 2010 compared to zero revenue from government grants in the same period the prior year.

 

Cost and Operating Expenses

 

     Three Months Ended March 31,    Change in 2010
         2009            2010        $
     (Dollars in thousands)
     (Unaudited)

Cost of product sales

   $ 1,424    $ 10,003    $ 8,579

Research and development

     8,603      11,178      2,575

Sales, general and administrative

     4,402      9,216      4,814
                    

Total costs and operating expenses

   $ 14,429    $ 30,397    $ 15,968
                    

 

Cost of Product Sales

 

Our cost of product sales increased by $8.6 million to $10.0 million in the three months ended March 31, 2010 primarily due to higher volumes of ethanol sales.

 

Research and Development Expenses

 

Our research and development expenses increased by $2.6 million to $11.2 million in the three months ended March 31, 2010, primarily the result of increased personnel-related expenses of $1.3 million and higher depreciation costs of $0.6 million. Research and development expense included stock-based compensation expense of $0.5 million compared to $0.1 million in the three months ended March 31, 2010 and 2009, respectively.

 

Sales, General and Administrative Expenses

 

Our sales, general and administrative expenses increased by $4.8 million to $9.2 million in three months ended March 31, 2010, primarily the result of higher personnel-related costs of $2.7 million and higher consulting expenses of $1.3 million related primarily to the initial engineering design work for a commercial production facility in Brazil. Sales, general and administrative expenses included stock-based compensation of $1.3 million compared to $0.5 million in the three months ended March 31, 2010 and 2009, respectively.

 

Other Income (Expense)

 

     Three Months Ended March 31,     Change in 2010  
         2009             2010         $  
     (Dollars in thousands)  
    

(Unaudited)

 

Other income (expense)

      

Interest income

   $ 237      $ 276      $ 39   

Interest expense

     (234     (384     (150

Other income (expense), net

     (58     515        573   
                        

Total other income (expense)

   $ (55   $ 407      $ 462   
                        

 

Total other interest income (expense) increased by $0.5 million to $0.4 million in the three months ended March 31, 2010 primarily the result of $0.5 million change in fair value of preferred stock warrants.

 

64


Table of Contents

Comparison of Years Ended December 31, 2008 and 2009

 

Revenues

 

     Years Ended December 31,    Change in 2009  
         2008            2009        $  
     (Dollars in thousands)  

Revenues

        

Product sales

   $ 10,680    $ 61,689    $ 51,009   

Collaborative research services

     3,008      2,919      (89

Government grants

     204           (204
                      

Total revenues

   $ 13,892    $ 64,608    $ 50,716   
                      

 

Our total revenues increased by $50.7 million to $64.6 million in 2009 from $13.9 million in 2008. The increase was primarily the result of the $51.0 million increase in sales of ethanol purchased from third parties to $61.7 million in 2009 from $10.7 million in 2008, as we commenced our ethanol trading business in the second half of 2008. We sold 29.9 million gallons of ethanol in 2009 compared to 4.7 million gallons in 2008, as we had an increase in the number of customers and accessed additional terminal space in 2009.

 

Revenues from collaborative research services were relatively flat in 2009 compared to 2008. Collaborative research service revenues in 2009 included $1.6 million for contracted research services focused on strain improvement performed on behalf of Sanofi Chimie. Additionally, 2009 collaborative research services included $1.3 million related to the completion of our work under an agreement with One World Health and sanofi-aventis related to the anti-malaria product. Collaborative research service revenues in 2008 included $3.0 million associated with the same agreement.

 

Cost and Operating Expenses

 

     Years Ended December 31,    Change in 2009
          2008              2009         $
     (Dollars in thousands)

Cost and operating expenses

        

Cost of product sales

   $ 10,364    $ 60,428    $ 50,064

Research and development

     30,306      38,263      7,957

Sales, general and administrative

     16,622      23,558      6,936

Restructuring and asset impairment charges

          5,768      5,768
                    

Total cost and operating expenses

   $ 57,292    $ 128,017    $ 70,725
                    

 

Cost of Product Sales

 

Our cost of product sales increased by $50.1 million in 2009, primarily due to higher volumes of ethanol sales.

 

Research and Development Expenses

 

Our research and development expenses increased by $8.0 million in 2009 over 2008, primarily the result of $5.0 million in additional expenses from a full year of facility-related expenses and depreciation costs for our headquarters, that includes lab and office space, and our pilot plant in Emeryville, California, both of which we occupied in the second and third quarter of 2008, respectively, and the growth of our operations in Brazil. Our 2009 research and development expenses also included facility-related expenses and depreciation costs relating to our pilot plant and demonstration facility in Campinas, Brazil, that opened in 2009. The increase was also

 

65


Table of Contents

attributable to increased personnel-related expenses of $4.3 million, due in part to an increase in research and development personnel in Brazil associated with the expansion of the Brazil operations. These increases were offset in part by lower professional services fees of $1.5 million incurred in 2009 compared to 2008 when we used consultants to facilitate our research efforts. Research and development expenses included stock-based compensation expense of $0.6 million and $0.8 million during 2008 and 2009.

 

Sales, General and Administrative Expenses

 

Our sales, general and administrative expenses increased by $6.9 million in 2009 primarily as a result of increased personnel-related expenses of $3.0 million, and higher consulting and professional fees of $3.1 million. The increase in consulting and professional fees was due to the expansion of our Brazilian operations and the use of consultants to negotiate other contracts during the year in addition to consulting costs associated with the initial design work for a commercial production facility in Brazil. To a lesser extent, the increase was due to an increase in depreciation costs due to leasehold improvements associated with a full year of depreciation for our headquarters in Emeryville, California. Sales, general and administrative expenses included stock-based compensation expense of $1.4 million and $2.5 million during 2008 and 2009.

 

Restructuring and Asset Impairment Charges

 

Restructuring and asset impairment charges were $5.8 million and consisted primarily of non-cash charges related to consolidation of our headquarters in a single facility in Emeryville, California, and asset impairment charges related to the vacated facility in 2009. These costs represent future rent expense, write off of leasehold improvements and the reversal of deferred rent associated with the leased facility.

 

Other Income (Expense)

 

     Years Ended December 31,     Change in 2009  
         2008             2009         $  
     (Dollars in thousands)  

Other income (expense)

      

Interest income

   $ 1,378      $ 448      $ (930

Interest expense

     (377     (1,218     (841

Other income (expense), net

     (144     (621     (477
                        

Total other income (expense)

   $ 857      $ (1,391   $ (2,248
                        

 

Interest Income

 

Interest income decreased by $0.9 million in 2009. The decrease was a result of lower interest rates, partially offset by higher average investment balances.

 

Interest Expense

 

Interest expense increased by $0.8 million in 2009. The increase resulted primarily from higher outstanding principal balances on our capital leases in 2009 compared to 2008.

 

Other Income (Expense), Net

 

Other income (expense), net increased by $0.5 million in 2009 primarily due to higher expense related to the increase in the fair value of our convertible preferred stock warrants.

 

66


Table of Contents

Comparison of Years Ended December 31, 2007 and 2008

 

Revenues

 

     Years Ended December 31,    Change in 2008  
         2007            2008        $  
     (Dollars in thousands)  

Revenues

        

Product sales

   $    $ 10,680    $ 10,680   

Collaborative research services

     6,046      3,008      (3,038

Government grants

     138      204      66   
                      

Total revenues

   $ 6,184    $ 13,892    $ 7,708   
                      

 

Our total revenues increased $7.7 million to $13.9 million in 2008 from $6.2 million in 2007. The increase was primarily the result of the $10.7 million in sales of third party ethanol in 2008 for 4.7 million gallons of ethanol sold compared to zero in 2007.

 

Revenues from government grants increased by $0.1 million in 2008 primarily as a result of a professional services contract with a research institution compared to a lower level of grant funding from Small Business Innovation Research in 2007.

 

Revenues from collaborative research services decreased by $3.0 million in 2008 primarily as a result of the substantial completion of the anti-malaria product development, which was completed in 2009.

 

Cost and Operating Expenses

 

     Years Ended December 31,    Change in 2008
         2007            2008        $
     (Dollars in thousands)

Cost and operating expenses

        

Cost of product sales

   $    $ 10,364    $ 10,364

Research and development

     8,662      30,306      21,644

Sales, general and administrative

     10,522      16,622      6,100
                    

Total cost and operating expenses

   $ 19,184    $ 57,292    $ 38,108
                    

 

Cost of Product Sales

 

Our cost of product sales increased to $10.4 million in 2008 from zero in 2007 as a result of the commencement of ethanol sales in 2008.

 

Research and Development Expenses

 

Our research and development expenses increased by $21.6 million in 2008, primarily as a result of higher facility-related expenses and depreciation costs of $9.4 million. In May 2008, we entered into an operating lease for our facility in Campinas, Brazil. Also contributing to this increase was higher facility-related expenses and depreciation costs for our new headquarters in Emeryville, California, which includes lab and office space, and costs associated with the pilot plant also in located in Emeryville. Additionally, we incurred higher personnel-related expenses of $6.8 million attributable to a 91% increase in employee headcount in our research and development functions over the prior year. We also incurred higher professional fees of $3.0 million as we leveraged consultants during this expansion phase as well as $1.9 million in higher expenses associated with lab supplies. Research and development expenses included stock-based compensation expense of $0.1 million and $0.6 million during 2007 and 2008.

 

67


Table of Contents

Sales, General and Administrative Expenses

 

Our sales, general and administrative expenses increased by $6.1 million in 2008 primarily as a result of $5.4 million in increased personnel-related expenses attributable to higher sales and general and administrative headcount, which increased 48% over the prior year. We increased our headcount in Emeryville and in Chicago, where we established Amyris Fuels, LLC. We also had an increase of $1.8 million in higher professional and consulting fees. Sales, general and administrative expenses included stock-based compensation expense of $0.4 million and $1.4 million during 2007 and 2008.

 

Other Income (Expense)

 

     Years Ended December 31,     Change in 2008  
         2007             2008         $  
     (Dollars in thousands)  

Other income (expense)

      

Interest income

   $ 1,178      $ 1,378      $ 200   

Interest expense

     (28     (377     (349

Other income (expense), net

     76        (144     (220
                        

Total other income (expense)

   $ 1,226      $ 857      $ (369
                        

 

Interest Income

 

Interest income increased by $0.2 million in 2008. The increase resulted from our higher average investment balances and higher interest rates in 2008 compared to 2007.

 

Interest Expense

 

Interest expense increased by $0.3 million in 2008 due primarily to higher outstanding principal balances on our capital leases in 2008 compared to 2007.

 

Other Income (Expense), Net

 

Other income (expense), net decreased by $0.2 million. Other income (expense), net in 2008 included $0.1 million expense related to the increase in the fair value of our convertible preferred stock warrants.

 

Liquidity and Capital Resources

 

     December 31,    March 31,
     2008    2009    2010
    

(Dollars in thousands)

          (Unaudited)

Working capital

   $ 32,356    $ 51,062    $ 85,994

Cash and cash equivalents and short-term investments

   $ 37,190    $ 67,210    $ 100,741

 

     Years Ended December 31,     Three Months Ended March 31,  
     2007     2008     2009           2009                 2010        
     (Dollars in thousands)  
           (Unaudited)  

Net cash used in operating activities

   $ (9,526   $ (38,879   $ (45,718   $ (12,762   $ (15,177

Net cash used in investing activities

   $ (41,643   $ (14,660   $ (25,422   $ 13,559      $ (29,243

Net cash provided by financing activities

   $ 51,539      $ 67,979      $ 71,473      $ 13,814      $ 52,358   

 

68


Table of Contents

Since our inception, we have financed our operations primarily through an aggregate of $382.9 million from private placements of equity securities, $19.6 million of collaborative research services revenues and $14.4 million of equipment financing.

 

As of March 31, 2010, we had cash, cash equivalents and short-term investments of $100.7 million compared to $67.2 million and $37.2 million as of December 31, 2009 and December 31, 2008, respectively. As of March 31, 2010, we had total debt, including capital lease obligations of $20.3 million. In addition, we had total borrowing capacity of $2.4 million under our Credit Agreement, which we currently utilize in connection with our Amyris Fuels business.

 

During the years ended December 31, 2007, 2008 and 2009 and in the three months ended March 31, 2010 we used cash of $2.5 million, $22.0 million, $7.6 million and $3.1 million, respectively, to fund capital expenditures. We currently anticipate making aggregate capital expenditures of between 140 million Brazilian reais and 180 million Brazilian reais for the Usina São Martinho joint venture facility, of which we expect São Martinho to reimburse us for 61.8 million Brazilian reais. Of this expenditure, we expect to incur approximately 50 to 60 million Brazilian reais in 2010 (approximately $28 million to $33 million), approximately 80 to 110 million Brazilian reais in 2011 (approximately $44 million to $61 million) and approximately 10 million Brazilian reais in 2012 (approximately $6 million). During 2010 and 2011 we expect to incur $15 million to $20 million in fees associated with engineering design plans that we expect to use for our joint venture and other capital light mill construction and approximately $10 million in capital expenditures for capital equipment purchases associated with contract manufacturing. Additionally, we anticipate making approximately $6.0 million in capital expenditures for research and scale-up equipment and tenant improvements in 2010.

 

Beyond our investment in Usina São Martinho, we expect to invest capital in additional production arrangements as we seek to add capacity for the production of our products. The timing and amount of capital expenditures for additional production facilities will depend on our business and financial outlook and the specifics of the opportunity. For example, we believe that the amount of financing that we agree to provide for the construction of bolt-on, or other, production facilities may influence the other terms of the arrangements that we establish with the facility owner, and, accordingly, expect to evaluate the optimal amount of capital expenditures that we agree to fund on a case-by-case basis. As such, we believe that having, or having access to, capital to fund capital expenditures will better position us to realize the value of our technology as we seek to add additional production capacity. We may also consider additional strategic investments or acquisitions. These events may require us to access additional capital through equity or debt offerings. If we are unable to access additional capital, our growth will be limited due to the inability to invest in additional production facilities.

 

We believe that our existing cash, cash equivalents, and short term investments, the net proceeds of this offering and funding under the two grants from the DOE will be sufficient to fund our operations and other capital expenditures for at least the next 12 months.

 

Credit Agreement. In November 2008, we entered into an uncommitted facility letter (the “Credit Agreement”) with a financial institution to secure letters of credit and to finance short term advances for the purchase of ethanol and associated margin requirements as needed. In October 2009, the agreement was amended to decrease the maximum amount that we may borrow under such facility. The Credit Agreement, as amended, provides an aggregate maximum availability up to the lower of $20.0 million or the borrowing base as defined in the agreement. We may use this line to secure letters of credit for product purchases in an aggregate amount up to $5.7 million. In addition, we may borrow cash for the purchase of product, which is determined by our borrowing base. As of April 2, 2010 we had sufficient borrowing base levels to draw up to a total of $2.4 million in short-term cash advances and had $1.7 million available for letters of credit in addition to those outstanding at year end. As of December 31, 2008 and 2009 and March 31, 2010, we had no outstanding advances and had $0.7 million, $1.1 million and $4.0 million, respectively in outstanding letters of credit under the Credit Agreement which are guaranteed by Amyris, Inc. and payable on demand. The Credit Agreement is collateralized by a first priority security interest in certain of our present and future assets. (See Note 6 to the Consolidated Financial Statements).

 

69


Table of Contents

Auction Rate Securities. Our investment portfolio includes auction rate securities (“ARS”), which are issued principally by student loan entities and rated AAA by a major credit rating agency. In February 2008, auctions failed for $12.95 million in par value of ARS that we held because sell orders exceeded buy orders. During the year ended December 31, 2009, a total of $250,000 of the ARS held by us were called at par by the issuer. As of December 31, 2009 and March 31, 2010, we owned $12.7 million and $12.1 million par value of these securities, respectively.

 

In October 2008, UBS AG (“UBS”) offered to repurchase all of the ARS that we purchased from them. We formally accepted the settlement offer and entered into a repurchase agreement with UBS in November 2008. By accepting the agreement, we received the right (“Put Option”) to sell our ARS at par value to UBS between June 30, 2010, and July 2, 2012. We expect to sell the ARS under the Put Option. However, if the Put Option is not exercised before July 2, 2012, it will expire and UBS will have no further rights or obligation to buy the ARS. (See Note 3 to the Consolidated Financial Statements.)

 

Three Months Ended March 31, 2010 and 2009

 

Cash Flows from Operating Activities

 

Net cash used in operating activities of $15.2 million in the three months ended March 31, 2010 reflected a net loss of $16.3 million and a $1.9 million net change in our operating assets and liabilities partially offset by non cash-charges of $3.1 million. Non-cash charges primarily included $1.8 million of stock-based compensation and $1.6 million of depreciation and amortization.

 

Net cash used in operating activities of $12.8 million in the three months ended March 31, 2009 reflected a net loss of $12.4 million and a $2.3 million net change in our operating assets and liabilities partially offset by non-cash charges of $1.9 million. Non-cash charges primarily included $1.4 million of depreciation and amortization.

 

Cash Flows from Investing Activities

 

For the three months ended March 31, 2010 cash used in investing activities was $29.2 million as a result of $26.1 million in net investment purchases and $3.1 million of capital expenditures. This compares to cash provided by investing activities of $13.6 million in the three months ended March 31, 2009 as the result of $16.5 million in net investment sales offset by $2.8 million of capital expenditures.

 

Cash Flows from Financing Activities

 

In the three months ended March 31, 2010 cash provided by financing activities was $52.4 million, primarily the result of a net receipt of $47.8 million from our sale of Series C-1 convertible preferred stock, net receipt of $3.7 million from our sale of Series C convertible preferred stock and the receipt of $1.7 million from investors for the sale of a noncontrolling interest in Amyris Brasil.

 

In the three months ended March 31, 2009 cash provided by financing activities was $13.8 million, primarily the result of the receipt of $8.1 million from debt from an advance on student loan auction rate securities held at UBS, $4.3 million from proceeds from equipment financing and $1.8 million proceeds from the sale of Series B-1 convertible preferred stock.

 

Years Ended December 31, 2007, 2008 and 2009

 

Cash Flows from Operating Activities

 

Our primary uses of cash from operating activities are for cost of product sales and personnel-related expenditures offset by cash received from product sales. Cash used in operating activities was $9.5 million, $38.9 million and $45.7 million for the years ended December 31, 2007, 2008 and 2009.

 

70


Table of Contents

Cash used in operating activities of $45.7 million in 2009 reflected a net loss of $64.8 million, partially offset by aggregate non-cash charges of $10.4 million and a net change of $8.7 million in our net operating assets and liabilities. Non-cash charges primarily included $5.8 million of depreciation and amortization and $3.3 million of stock-based compensation. The net change in our operating assets and liabilities was primarily a result of our restructuring activity of $5.1 million, the increase in accrued and other liabilities of $4.5 million and the decrease in prepaid and other assets of $1.0 million, partially offset by the increase in inventory of $0.9 million and the decrease in accounts payable of $1.0 million.

 

Cash used in operating activities of $38.9 million in 2008 reflected a net loss of $42.3 million, partially offset by aggregate non-cash charges of $4.8 million, and net change of $1.3 million in our net operating assets and liabilities. Non-cash charges primarily included $2.6 million of depreciation and amortization and $2.0 million of stock-based compensation. The net change in our operating assets and liabilities was primarily a result of the increase in prepaid expenses and other assets of $1.9 million, the increase in inventory of $1.4 million and the decrease in deferred revenue of $1.4 million, partially offset by the increase in accrued and other liabilities of $2.1 million and the increase in accounts payable of $1.3 million.

 

Cash used in operating activities of $9.5 million in 2007 reflected a net loss of $11.8 million, partially offset by aggregate non-cash charges of $1.8 million and a net change of $0.4 million in our net operating assets and liabilities. Non-cash charges primarily included $0.6 million of depreciation and amortization and $0.5 million of stock-based compensation. The net change in our operating assets and liabilities was primarily a result of the increase in accrued and other liabilities of $2.3 million, partially offset by the decrease in deferred revenue of $1.9 million.

 

Cash Flows from Investing Activities

 

Our investing activities consist primarily of net investment purchases, maturities and sales and capital expenditures.

 

In 2009, cash used in investing activities was $25.4 million as a result of $16.0 million in net investment purchases and $7.6 million of capital expenditures, and a $1.8 million increase in restricted cash.

 

In 2008, cash used in investing activities was $14.7 million as a result of $22.0 million of capital expenditures and $2.0 million increase in restricted cash, partially offset by $9.3 million in net investment sales and maturities.

 

In 2007, cash used in investing activities was $41.6 million as a result of $38.4 million in net investment purchases, $2.5 million of capital expenditures and $0.7 million increase in restricted cash.

 

Cash Flows from Financing Activities

 

In 2009, cash provided by financing activities was $71.5 million, primarily as a result of the net receipt of $56.5 million from our sale of Series C convertible preferred stock, the net receipt of $1.8 million from our sale of Series B-1 convertible preferred stock, the receipt of $9.6 million from debt, primarily from an advance on student loan auction rate securities held at UBS, $4.8 million in proceeds from equipment financing and the receipt of $3.1 million from investors for their noncontrolling interest in Amyris Brasil, partially offset by our purchase of the noncontrolling interest in Amyris Brasil for $2.3 million, our principal payments on our equipment financing facilities of $1.1 million and principal repayments on our debt of $1.0 million.

 

In 2008, cash provided by financing activities was $68.0 million, primarily as a result of the receipt of $61.4 million from our sale of Series B-1 convertible preferred stock, the receipt of $3.7 million from our sale of Series B convertible preferred stock, the receipt of $1.6 million from the sale of the noncontrolling interest in Amyris Brasil and $1.2 million in proceeds from equipment financing.

 

71


Table of Contents

In 2007, cash provided by financing activities was $51.5 million, primarily as a result of the receipt of $13.9 million from our sale of Series A convertible preferred stock and the receipt of $37.6 million from our sale of Series B convertible preferred stock.

 

Contractual Obligations

 

The following is a summary of our contractual obligations as of December 31, 2009 and March 31, 2010:

 

      Total   2010   2011   2012   2013   2014 and
beyond
    (Dollars in thousands)

As of December 31, 2009

           

Principal payments on long term debt

  $ 13,380   $ 9,018   $ 1,348   $ 655   $ 533   $ 1,826

Interest payments on long-term debt, fixed rate (1)

    1,618     442     381     251     193     351

Interest payments on long-term debt, variable rate (2)

    55     55                

Operating leases

    34,747     3,161     4,021     4,669     4,328     18,568

Principal payments on capital leases

    7,228     2,251     2,469     2,241     267    

Interest payments and executor costs on capital leases

    1,303     710     436     153     4    

Terminal storage costs

    2,059     934     805     320        
                                   

Total

  $ 60,390   $ 16,571   $ 9,460   $ 8,289   $ 5,325   $ 20,745

As of March 31, 2010

 

Principal payments on long term debt

  $ 12,775   $ 8,356   $ 1,384   $ 660   $ 538   $ 1,837

Interest payments on long-term debt, fixed rate (1)

    1,525     343     383     253     195     351

Interest payments on long-term debt, variable rate (2)

    24     24                

Operating leases

    34,551     2,446     4,091     4,742     4,402     18,870

Principal payments on capital leases

    7,531     1,946     2,724     2,525     336    

Interest payments and executor costs on capital leases

    1,280     583     506     185     6    

Terminal storage costs

    2,537     889     1,216     432        

Purchase obligations

    2,856     2,856                
                                   

Total

  $ 63,079   $ 17,443   $ 10,304   $ 8,797   $ 5,477   $ 21,058

 

  (1)   For fixed rate facilities, the interest rates are more fully described in Note 6 of our consolidated financial statements.
  (2)   For variable rate facilities, amounts are based on weighted average interest rate which was 1.32% and 1.28% as of December 31, 2009 and March 31, 2010, respectively.

 

This table does not reflect that portion of the expenses that we expect to incur from 2010 through 2012 in connection with research activities under the DOE Integrated Bio-Refinery grant for which we will not be reimbursed. We have the right to be reimbursed for up to $24.3 million of a total of up to $34.9 million of expenses for research activities that we undertake under this grant.

 

Amyris Brasil S.A. Transactions

 

Between December 2009 and March 2010, we entered into agreements with certain investors to sell a noncontrolling equity interest in Amyris Brasil S.A. (See Note 16 to our Consolidated Financial Statements included elsewhere in this prospectus for a description of these transactions.) Under the terms of these agreements, we have the right to require the investors to convert their shares of Amyris Brasil into shares of our common stock. We intend to exercise this right prior to the completion of this offering, and as a result we will issue 550,044 shares of our common stock to these investors.

 

72


Table of Contents

Off-Balance Sheet Arrangements

 

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules, such as relationships with unconsolidated entities or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating financing transactions that are not required to be reflected on our consolidated balance sheets.

 

Quantitative and Qualitative Disclosures about Market Risk

 

We are exposed to financial market risks, primarily changes in interest rates, currency exchange rates and commodity prices. On a limited basis we use derivative financial instruments primarily to manage commodity price risk. All of the potential changes noted below are based on sensitivity analyses performed on our financial positions as of March 31, 2010. Actual results may differ materially.

 

Interest Rate Risk

 

Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio and our outstanding debt obligations. We generally invest our cash in investments with short maturities or with frequent interest reset terms. Accordingly, our interest income fluctuates with short-term market conditions. As of March 31, 2010, our investment portfolio consisted primarily of money market funds, government bonds and notes and ARS. With the exception of our ARS, these were highly liquid investments. Due to the short-term nature of our investment portfolio, our exposure to interest rate risk is minimal.

 

Interest rate risk is present with both fixed- and variable-rate debt. As of March 31, 2010, approximately 38 percent of our debt portfolio was comprised of variable-rate debt and 62 percent was fixed-rate debt. If interest rates had increased by 100 basis points related to the outstanding amounts as of March 31, 2010, our interest expense would have changed by $19,000 on an annual basis.

 

Foreign Currency Risk

 

Most of our sales contracts are principally denominated in U.S. dollars and, therefore, our revenues are not currently subject to significant foreign currency risk. We do incur certain operating expenses in currencies other than the U.S. dollar in relation to Amyris Brasil and, therefore, are subject to volatility in cash flows due to fluctuations in foreign currency exchange rates, particularly changes in the Brazilian reais. To date, we have not entered into any hedging contracts since exchange rate fluctuations have had minimal impact on our results of operations and cash flows.

 

Commodity Price Risk

 

Our exposure to market risk for changes in commodity prices currently relates primarily to our purchases of ethanol. When possible, we manage our exposure to this risk primarily through the use of supplier pricing agreements. We also, at times, use standard derivative commodity instruments to hedge the price volatility of ethanol, principally through ethanol futures contracts. The changes in fair value of these contracts are recorded on the balance sheet and recognized immediately in cost of product sales. We recognized (losses) gains of $0, $752,000 and ($1,910,000) as the change in fair value for the years ended December 31, 2007, 2008 and 2009, and we recognized gains of $647,000 as the change in fair value for the three months ended March 31, 2010, respectively. (See Note 3 to the Consolidated Financial Statements).

 

Recent Accounting Pronouncements

 

In June 2009, the FASB issued a new accounting standard that requires a qualitative approach to identifying a controlling financial interest in a variable interest entity (“VIE”), and requires ongoing assessment of whether

 

73


Table of Contents

an interest in a VIE makes the holder the primary beneficiary of the VIE. The new accounting standard became effective for us on January 1, 2010. The adoption of the standard had no impact on the Company’s consolidated financial position, results of operations or cash flows.

 

In October 2009, the FASB issued a new accounting standard that changes the accounting for arrangements with multiple deliverables. Specifically, the new accounting standard requires an entity to allocate arrangement consideration at the inception of an arrangement to all of its deliverables based on their relative selling prices. In addition, the new standard eliminates the use of the residual method of allocation and requires the relative- selling-price method in all circumstances in which an entity recognizes revenue for an arrangement with multiple deliverables. In October 2009, the FASB also issued new accounting standard that changes revenue recognition for tangible products containing software and hardware elements. Specifically, if certain requirements are met, revenue arrangements that contain tangible products with software elements that are essential to the functionality of the products are scoped out of the existing software revenue recognition accounting guidance and will be accounted for under these new accounting standards. Both standards will be effective for us in the first quarter of 2011. Early adoption is permitted. We are currently assessing the impact that the adoption of these standards will have on our consolidated financial statements.

 

In January 2010, the FASB issued an amendment to an accounting standard which requires new disclosures for fair value measures and provides clarification for existing disclosure requirements. Specifically, this amendment requires an entity to disclose separately the amounts of significant transfers in and out of Level 1 and Level 2 fair value measurements and to describe the reasons for the transfers; and to disclose separately information about purchases, sales, issuances and settlements in the reconciliation for fair value measurements using significant unobservable inputs, or Level 3 inputs. This amendment clarifies existing disclosure requirements for the level of disaggregation used for classes of assets and liabilities measured at fair value and requires disclosure about the valuation techniques and inputs used to measure fair value for both recurring and nonrecurring fair value measurements using Level 2 and Level 3 inputs. The adoption of this amendment will not impact the Company’s consolidated financial statements.

 

74


Table of Contents

BUSINESS

 

Business Overview

 

Our Company

 

We are building an integrated renewable products company by applying our industrial synthetic biology platform to provide alternatives to select petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. We genetically modify microorganisms, primarily yeast, and use them as living factories in established fermentation processes to convert plant-sourced sugars into potentially thousands of target molecules. Our first commercialization efforts have been focused on a molecule called farnesene, which forms the basis for a wide range of products varying from specialty chemical applications such as detergents, cosmetics, perfumes, and industrial lubricants, to transportation fuels such as diesel. We call these No Compromise products because we design them to perform comparably to or better than currently available products. While our platform is able to utilize a wide variety of feedstocks, we have focused our initial research and development, business development and production operations on the use of Brazilian sugarcane as our primary feedstock, because it is abundant, low cost and relatively price stable. We intend to secure access to this feedstock and expand our production capacity in a “capital light” manner. Under this approach, we expect to work with Brazilian sugar and ethanol producers to build new, “bolt-on” facilities adjacent to their existing mills instead of building new “greenfield” facilities, thereby reducing the capital required to establish and scale our production. Our first such arrangement is our joint venture with Usina São Martinho, a subsidiary of São Martinho S.A., one of the largest sugar and ethanol producers in Brazil.

 

Technology

 

We have developed genetic engineering and screening technologies which enable us to modify the way microbes process sugar. By controlling these metabolic pathways, we design microbes to serve as living factories, or biorefineries, to produce target molecules that we seek to commercialize. Our platform utilizes proprietary high-throughput processes to create and test as many as 1,000 yeast strains a day in order to select those yeast strains which are most efficient. We first developed and applied our technology to create microbial strains that produce artemisinic acid, a precursor of artemisinin, an anti-malarial therapeutic. We have granted a royalty-free license to this technology to sanofi-aventis for the commercialization of artemisinin-based drugs.

 

Feedstock

 

We are focusing on Brazilian sugarcane as our primary feedstock given its abundance, low cost and relative price stability. Brazil is the world’s largest producer of sugarcane, crushing over 600 million tons of sugarcane annually to provide feedstock to approximately 400 sugar and ethanol mills. According to UNICA, the Brazilian Sugarcane Industry Association, sugarcane is the lowest cost feedstock to produce renewable products at scale and using it enables us to leverage the established Brazilian infrastructure. Common to both our process and the sugarcane-to-ethanol process is the use of fermentation, a well-established process that combines a sugar source and yeast to produce beer and wine and, more recently, ethanol fuels. We plan to establish production capacity by partnering with sugar and ethanol producers, and then taking as input the same sugar source that is routinely processed by these mills and directing it to customized fermentors, where it would be combined with our genetically engineered yeast.

 

Scale-Up

 

We operate research and development laboratories in Emeryville, California, and have built an adjacent pilot facility that tests our yeast strains in 300 liter scale fermentors. We have an identical pilot plant in Campinas, Brazil, to facilitate the adaptation of our technology to the Brazilian production environment. We established a 5,000 liter demonstration facility in Brazil in September 2009 to further validate our processes and equipment as we move toward commercialization of our products. We have also completed production runs using our strains to produce farnesene at a contract manufacturing facility in a 60,000 liter fermentor in the U.S.

 

75


Table of Contents

Commercial Production

 

We expect to access feedstock and scale our production through our capital light strategy. Our first such arrangement is our joint venture with Usina São Martinho, SMA Industrio Quimico S.A. This facility is located at Usina São Martinho, the world’s largest sugarcane processing facility, which crushed 8.1 million tons of sugarcane in the 2009-2010 harvest. We have also provided Usina São Martinho with an option to produce our products at a second production facility. We have non-binding letters of intent in place with Bunge Limited, Cosan S.A. and Açúcar Guarani, a subsidiary of Tereos, which are leading Brazilian sugar and ethanol producers, to build new, bolt-on facilities adjacent to specified existing mills to produce our products. We expect that these mill owners will make a substantial contribution of capital or operating contribution to fund these facilities in return for a share of the higher gross margin we believe we will realize from the sale of our renewable products. We expect these arrangements to provide us with access to over 10 million tons of sugarcane crush capacity annually, which we intend to expand over time with these and other mills. As of the first quarter of 2010, this capacity represented approximately 10% of the total crush capacity of these sugar and ethanol producers.

 

Products and Distribution

 

As we commence commercial production of our initial molecule, farnesene, we expect to target specialty chemical markets. We have entered into agreements with The Procter & Gamble Company, a consumer products company, and M&G Finanziaria S.R.L., a chemical engineering and manufacturing company, that establish terms under which each of these companies may purchase our farnesene for use in their products. We have also entered into an agreement with Soliance, a cosmetics ingredients company, for the development and commercialization of farnesene-based squalane for use as an ingredient in cosmetics products. We have signed a term sheet with Cosan for the formation of a joint venture to develop and commercialize farnesene-based specialty chemicals for industrial and automotive applications. We recently entered into a technology license, development, research and collaboration agreement with Total Gas & Power USA Biotech, Inc., an affiliate of Total S.A., for the research, development and commercialization of chemical and fuel products.

 

For distribution of our fuel products in the U.S., we expect to sell directly, primarily to corporations with large trucking fleets. For distribution of our fuel products in other geographies, we expect to sell indirectly through third parties. We recently entered into an agreement with Shell Western Supply and Trading Limited, a subsidiary of Royal Dutch Shell plc, that establishes terms under which Shell may purchase our diesel fuel, commencing 18 months after we notify Shell that we intend to export diesel from Brazil. To build our U.S. distribution capabilities, we established our subsidiary Amyris Fuels, LLC, which currently generates revenues through the sale of ethanol to wholesale customers through a network of terminals in the southeastern U.S.

 

76


Table of Contents

Industry Background

 

Petroleum is a fundamental building block for products, such as consumer products, chemicals, plastics and transportation fuels, that are essential to modern economies. According to U.S. Energy Information Administration, in 2008 the total worldwide demand for petroleum was over $3 trillion, or 5% of worldwide gross domestic product. The graphic below outlines some of the markets that currently rely on petroleum as a precursor:

 

LOGO

 

Historically, the abundance of petroleum has made it a convenient and inexpensive source of many chemicals and transportation fuels. Recently, however, changes in the economics of petroleum production and consumer preferences have created challenges for the current infrastructure, such as:

 

   

Increased demand for petroleum but limited supply. Petroleum is a finite resource, and locating and extracting new petroleum resources is becoming more challenging and expensive. At the same time, population growth, economic development and urbanization in emerging countries such as Brazil, Russia, India and China are significantly increasing the demand for petroleum.

 

   

Volatility of petroleum prices. Petroleum prices are highly volatile, which reduces petroleum’s attractiveness as a building block for products. For instance, the price per barrel of petroleum ranged from $145.66 in July 2008 to $30.81 in December 2008. This variability adds a level of price uncertainty to providers and customers of goods that rely on petroleum.

 

   

Supply chain uncertainty and inconsistency . Secure and stable access to petroleum is increasingly threatened by a variety of factors, including the political instability of several large oil producing countries, competition over energy sources and attacks on supply infrastructure, as well as accidents and natural disasters. Concerns with dependence on current petroleum producing countries are spurring private and public initiatives to reduce petroleum use and develop effective alternatives.

 

 

77


Table of Contents
   

Negative environmental impact and changing consumer sentiment . The production of petroleum and its use as a fossil fuel create emissions that are harmful to the environment. This has led to changes in consumer attitudes towards consumption and raised the likelihood of regulatory frameworks that will continue to challenge the economics of petroleum-based products.

 

To address the foregoing challenges, countries have taken various actions to promote environmentally-friendly alternatives to petroleum. The U.S. Energy Policy Act of 2005 mandated that 7.5 billion gallons of renewable fuels be produced in the U.S. by 2012 as part of the Renewable Fuels Standard (“RFS”). The RFS was amended by the Energy Independence and Security Act of 2007, which calls for 36 billion gallons of renewable fuels—including 21 billion gallons from cellulosic ethanol and other advanced biofuels—by 2022. According to the U.S. Energy Information Administration, this is approximately 11% of the 2022 forecast for total U.S. petroleum demand. Similar mandates have been enacted in Europe, where the Renewable Energy Directive calls for 20% of energy to come from renewable sources by 2020. These and other policies, such as tariffs on petroleum inputs and subsidies for renewable energy research, provide meaningful incentives for the development and acceptance of alternative sources for petroleum and petroleum derivatives.

 

Petroleum Alternatives

 

There have been many attempts to create equivalent products to petroleum-based products that avoid the difficulties listed above. However, these initial approaches have faced challenges that have limited, or may limit, their success:

 

   

Exposure to volatile feedstock pricing. Many U.S. renewable fuels companies have focused on the conversion of commodity feedstocks, such as corn or vegetable oil, into ethanol or biodiesel. These companies were exposed to potential swings in the market prices for their feedstocks. According to The World Bank, the price of maize rose over 60% from 2005 to 2007, due largely to the U.S. ethanol program combined with reduced stocks in major exporting countries. In addition to significantly impacting food prices and availability, we believe such increases reduced or eliminated the profitability of these businesses, and at various times have made production unprofitable for a number of producers in these industries.

 

   

Limited product portfolio . Companies engaging in early attempts to create renewable fuels typically focused on one end product, such as ethanol or biodiesel. These companies generally lacked product diversity and therefore were vulnerable to variability of market prices and the degree of government support for their primary products. Further, these companies’ products were imperfect substitutes for the transportation fuels they were intended to replace. For example, neither ethanol nor biodiesel can be transported in conventional petroleum pipelines or stored in blended form with petroleum-sourced fuels for any significant time due to their corrosive and viscous properties. In addition, ethanol has a lower energy content than petroleum-sourced fuels, resulting in reduced fuel economy. In many countries, ethanol and biodiesel can be blended with petroleum-based fuels only in limited quantities without requiring engine modifications or risking invalidation of engine or vehicle warranties. In the U.S., current blend limits set by the EPA restrict ethanol blending to 10% or less of gasoline.

 

   

Capital intensity . Many initial U.S. ethanol companies utilized a business model that included the construction and ownership of mills to control their production process. A new ethanol mill requires capital outlays of hundreds of millions of dollars. These significant capital outlays tied ethanol producers to their existing facilities and construction plans, which we believe limited their ability to opportunistically and rapidly enter new geographies and access new feedstock.

 

   

Dependence on policy . The economic viability of many alternative fuel and energy resources is based on government regulations and support. For instance, corn based ethanol and biodiesel are both heavily dependent on government subsidies to blenders and refineries. For example, in response to the U.S. Senate’s delay in extending a biodiesel tax credit beyond its expiration in December 2009, many biodiesel producers laid off workers and suspended operations until the extension was approved in March 2010.

 

78


Table of Contents

As a result of these challenges, many corn ethanol and biodiesel solutions have not been successful. Other efforts to develop alternatives to petroleum-sourced products include the use of non-food-based feedstocks, such as cellulosic sugars sourced from wood chips, corn stalks and sugarcane bagasse. Some of these approaches have shown promise and may not be influenced by commodity markets and food versus fuel concerns. However, they are not complete solutions to the challenges above, and to date, these approaches have been limited by cost and technical considerations, among others.

 

The Amyris Solution

 

We are building an integrated renewable products company by applying our industrial synthetic biology platform to provide alternatives to select petroleum-based products used in specialty chemical and transportation fuel markets worldwide. Our proprietary technology enables us to engineer microbes, such as yeast, to produce target molecules, and our business model is designed to produce these products and bring them to market in a capital light manner. Our technology platform is designed to produce competitive products from widely available plant-derived feedstocks, using genetically modified yeast strains in a well-established fermentation process. We are focusing our initial production efforts in Brazil, positioning us to access abundant, low-cost and relatively price stable sugarcane feedstock sources and to leverage the substantial infrastructure of existing sugar and ethanol mills.

 

Competitive Strengths

 

Our key competitive strengths are:

 

   

Abundant, low-cost and relatively price stable feedstock. The Brazilian sugarcane industry enjoys a low production cost structure and is insulated from feedstock price volatility. The sugar and ethanol industries are vertically integrated with most mills growing much or all of their own sugarcane. Hence, they are generally exposed only to these agricultural production costs, rather than the market price of a volatile, traded commodity feedstock. Even when cane is procured from third-party growers the contract price is a formula derived from the selling price of the resultant sugar or ethanol production, insulating the mill from any substantial disconnect between its feedstock price and ultimate product selling price. Furthermore, Brazilian sugarcane does not compete for use as a food source. According to the U.S. Department of Agriculture, roughly 50% of Brazilian sugarcane is used for sugar production, and the production of cane is expected to substantially increase over the next 10 years.

 

   

Broad range of potential products . Our technology platform gives us the ability to produce potentially thousands of target molecules. This capability enables us to focus on the development of promising, high-value products, optimizing our overall mix of products and mitigating our exposure to any one end market. Our farnesene molecule, on which we are initially focusing, forms the basis for a wide range of chemical and fuels applications.

 

   

Scalable, capital light approach. We are developing production capacity by entering into agreements with sugar and ethanol producers to build new, bolt-on facilities adjacent to their existing mills to produce our products. Under these agreements, the producers will make a substantial capital or operating contribution in return for a share in the higher gross margin that we believe we will realize from the sale of our products. With approximately 400 sugar and ethanol mills operating in Brazil, we believe that this model will allow us to take advantage of the large infrastructure that is already in place. While we and/or the mill owner will be required to make a substantial capital investment to complete the new facility under these arrangements, we refer to these arrangements as capital light because we believe that the cost of constructing a bolt-on facility will be substantially less than the construction cost of an entirely new, or greenfield, facility.

 

   

Not policy dependent. We do not intend to rely on subsidies, mandates or tariffs to make our products commercially viable. While we benefit from policies such as the Renewable Fuels Standard that encourage the use of renewable products, and while we will seek to access incentives available for the production of our products, we expect our products to be offered on a cost-competitive basis with existing products without reliance on subsidies.

 

79


Table of Contents

Our Solution for our Customers

 

The key benefits we intend to provide to our customers include:

 

   

No Compromise product offerings . We refer to our products as No Compromise because we design them to perform comparably to or better than currently available products. For example, in initial testing our squalane, a natural emollient used in high-end cosmetics, has exhibited characteristics comparable to currently available squalane. In addition, our diesel will not require engine or distribution infrastructure modifications, will have better performance at low temperatures and generally will have a higher cetane number than biodiesel.

 

   

Greater pricing stability . We expect that our use of Brazilian sugarcane will make our products less susceptible to price volatility than petroleum-sourced, corn-based ethanol and biodiesel products. Our yeast strains are designed to utilize a wide variety of feedstocks, which will allow us to seek other low-cost sugar sources for our process over time. We believe that this will help protect our customers from the level of volatility generally associated with exposure to petroleum and other commodities.

 

   

“Green” alternative. Our products are derived from renewable sources, enabling our customers to reduce the environmental impact of their products. For example, we believe we can provide our prospective customers in the specialty chemical market with a competitive advantage by offering “greener” products than those that are based on petroleum. We also believe that our diesel offers a number of environmental benefits, including the elimination of sulfur and greatly reduced nitrogen oxides, particulate matter, carbon monoxide and hydrocarbon exhaust emissions.

 

Our Value Proposition to Sugar and Ethanol Producers

 

The key benefits we intend to provide to sugar and ethanol producers that will work with us to produce our products include:

 

   

Product diversification. By producing our products, sugar and ethanol mills would be able to diversify their business beyond their current sugar or ethanol production and potentially mitigate volatility in their financial performance caused by changes in the market prices for sugar or ethanol.

 

   

Opportunity for growth. By diversifying their product base to address expanded market opportunities, producers may be able to expand the amount of sugarcane grown and processed at their mills.

 

   

Potential for improved margins. We intend to offer these producers a share of the higher gross margin we believe we will realize from the sale of our renewable products relative to their existing products, potentially improving their gross margins and the return they realize on their feedstock.

 

Our Strategy

 

Our objective is to become the leading provider of renewable specialty chemicals and transportation fuels worldwide. These specialty chemical and transportation fuels markets are some of the largest addressable markets in the world, aggregating to well above $1 trillion annually. However, for decades there has been little success in developing alternatives to the petroleum-sourced products that serve these markets. We believe this to be the case because incumbents have significant advantages in the form of established production processes, access to historically low cost and plentiful petroleum feedstock and significant financial resources, which together form high barriers to entry. As a result, we believe that in order for a new company to offer products that effectively compete with petroleum-based products for these end markets, it is important to build a company that can fundamentally innovate and differentiate to achieve a long-term sustainable competitive advantage.

 

Since inception we focused our company on achieving a sustainable competitive advantage by abiding by three strategic principles. First, we select target markets where we can deliver products that perform comparably to existing offerings on a cost-competitive basis. Second, we will continue to advance our technology such that we can scale our business using a wide variety of feedstocks in a capital light fashion. Finally, we intend to participate in the distribution and sale of our products, either directly or with partners, to maximize the value we can capture from

 

80


Table of Contents

sales of our products. By selectively participating in the supply chain for each of our end markets, we intend to position our company to capture the greatest value across each end market.

 

Activities that we are pursuing to support these elements of our strategy include:

 

   

Pursuing market opportunities that maximize our returns. We expect to be able to produce numerous specialty chemicals as well as renewable diesel from our farnesene molecule and other molecules that we can produce. We intend to expand our chemistry capabilities in order to expand market applications and support customer adoption of our products. We are focusing our initial sales and marketing efforts on a small number of high value specialty chemicals applications, such as detergents, cosmetics, perfumes and industrial lubricants, for which there exists an attractive business case for our products. We recently entered into agreements with P&G and M&G that establish terms under which they may purchase our farnesene for use in their products. We also entered into an agreement with Soliance for the development and commercialization of farnesene-based squalane for use as an ingredient in cosmetics products and into a term sheet with Cosan for the formation of a joint venture to develop and commercialize farnesene-based specialty chemicals for industrial and automotive applications. We intend initially to sell and market these products in the U.S., Europe and potentially Brazil. As we lower our production costs and increase our production capacity, we believe our ability to address a wide range of target markets will provide us with significant flexibility in adjusting product mix in order to maximize our returns. We intend to enter into collaborative research, development and commercialization agreements to accelerate our entry into select new product opportunities. We recently entered into a technology license, development, research and collaboration agreement with an affiliate of Total S.A. for the research, development and commercialization of chemical and fuel products. We are in active discussions with other companies for similar arrangements.

 

   

Leveraging our technology platform to improve efficiency. We intend to continually leverage our technology platform to lower the cost of production of our products through continued strain improvement and gains in other production process efficiencies. For example, since we first engineered a yeast strain capable of producing farnesene in 2006, we have substantially increased our yield and have achieved a 15% yield at two liter scale which we believe, if replicated at commercial production scale, will enable us to enter certain specialty chemical markets. We intend to further develop our strains to enable us to address transportation fuels markets.

 

   

Focusing on Brazilian sugarcane . We are focusing on Brazilian sugarcane as our primary feedstock given its abundance, low cost and relative price stability. We formed Amyris Brasil in March 2008 to establish local visibility to enhance our ability to access sugarcane. We have entered into non-binding letters of intent for production relationships with three sugar and ethanol producers in Brazil, Bunge Limited, Cosan and Açúcar Guarani. If successfully consummated, we believe these production relationships, together with the Usina São Martinho mill, would provide us with access to over ten million tons of annual crushing capacity. We will continue to develop relationships to secure additional feedstock sources.

 

   

Advancing capital light production. We expect to partner with existing sugar and ethanol mills to establish and scale production at a lower cost than the cost of greenfield mill construction. While we are constructing our first capital light facility in Brazil, our joint venture with Usina São Martinho, we expect to initiate commercial production starting in 2011 through the use of contract manufacturing. We then expect to begin to operate the joint venture facility starting in the second quarter of 2012. We also intend to build engineering services capabilities to support sugar and ethanol mill adoption of our technology.

 

   

Continuing to develop our fuels distribution network. We will continue to invest in our Amyris Fuels distribution network, expanding our footprint in the U.S. We believe this strategy builds capabilities for future distribution and sales of our renewable products in the U.S. We recently entered into an agreement with Shell Western Supply and Trading Limited, a subsidiary of Royal Dutch Shell plc, that establishes terms under which Shell may purchase our diesel fuel, commencing 18 months after we notify Shell that we intend to export diesel from Brazil, and running for two years after the date specified in such notice, up to the end of March 2016 at the latest, with an option to renew for

 

81


Table of Contents
 

a further year. We will seek to establish similar arrangements with other large oil companies for distribution of our renewable fuels in other countries.

 

Technology

 

We believe that our technology enables us to genetically engineer microorganisms that will perform as effectively in commercial manufacturing conditions as they perform in the laboratory. We accomplish this by maintaining a constant feedback loop between our laboratory, where strains are initially created and modified, and our two pilot plants, where we expose those strains to conditions that simulate a commercial production environment. This allows us to focus our microbe development resources on those strains that demonstrate the potential to scale effectively. The key components of our industrial synthetic biology platform are strain engineering, process development and scale-up and chemical finishing.

 

Strain Engineering

 

The process by which a living organism converts sugar to molecules is comprised of many individual steps that together form a pathway. We focus on engineering microorganisms to build pathways that are specifically designed to produce target molecules for which we believe there may be significant market opportunities. The primary biological pathway within the microbe that we currently use to produce our target molecules is the isoprenoid pathway. Isoprenoids constitute a large, diverse class of molecules with current product applications in a wide range of industries, including specialty chemicals and fuels. The microorganisms we currently use are strains of yeast, although we have demonstrated that our technology can be applied in E. coli bacteria and we believe it can also be used in other microbes.

 

The following chart illustrates the use of our engineered yeast cells to produce target molecules in a variety of applications:

 

LOGO

 

82


Table of Contents

The key steps in our strain engineering process are:

 

Identifying target molecules. We start our process by identifying the commercial application that we want to pursue. We identify the key molecular properties that are essential to product performance in a specific commercial application and then analyze the chemical structures that drive those key performance characteristics. Finally, we identify target molecules or simple derivatives of molecules that are comprised of these key chemical structures and that may be produced by our yeast strains.

 

Developing initial strains. Once we have chosen a target molecule, we identify the steps required for its production in a biological pathway. We then seek to design a pathway to produce the target, either directly or by producing a molecule that can, through simple chemical steps, be synthesized, or converted, into the target. Once this pathway is identified, we undertake to engineer it into our yeast strains by employing the processes discussed below.

 

Improving strain performance to achieve commercial viability. After we have established a pathway and verified that it can produce the target molecule, the yeast strain must be improved to increase the level of efficiency of production. The two key measures of yeast strain efficiency are yield and productivity. Our focus to date has been on maximizing yield, which is the measurement of the amount of a specified molecule that is produced by our yeast from a given amount of sugar. Yield is measured both at laboratory scale, where production occurs in a controlled environment with highly uniform feedstock, and at commercial scale where products are produced on-site using commercially available feedstock, such as sugarcane juice. Yield is expressed as a percentage, with, for example, a yield of 10% indicating that of one gram of product is produced from ten grams of sugar input. Yeast strain productivity represents the rate at which our product is produced by a given yeast strain. The higher productivity a strain has, the more product can be produced in the same size fermentor in a given period of time.

 

We seek to achieve yield gains primarily by means of two different scientific approaches—random mutagenesis and rational design. In random mutagenesis, a mutagen, such as ultraviolet light, is applied to a strain that already produces some amount of a target molecule. The goal is to mutagenize, or genetically change, the strain so it will produce a greater amount of that target molecule. In order to identify strains that are more productive than the parent, or starting strain, large numbers of mutagenized strains must be screened. We have developed assays for screening tens of thousands of strains per week, and we frequently evolve the assays we use for this rapid, or high-throughput, analysis of production.

 

We augment our efforts to identify improved yeast strains via random mutagenesis by employing a process we refer to as rational design, in which we specifically design strains to achieve a desired effect. Through the use of techniques like genomics, which is the analysis of nucleic acids within the cell, metabolomics, which is the analysis of reaction intermediates inside the cell, and proteomics, which is the analysis of enzymes inside the cell, we can identify potential bottlenecks in the flow of the sugar feedstock to the target molecules. We can then explore solutions to those bottlenecks and test them by making targeted, or rational, genetic changes to the pathway. In order to increase the efficiency of these rational design efforts, we have developed and implemented a series of automated processes:

 

   

Rapid strain engineering . This is a method of engineering strains in which we break the strain engineering process into a series of modular steps, which allows for more rapid construction of strains than do conventional methods.

 

   

Automated strain engineering . We are able to take the strain engineering processes normally undertaken by people and implement them on standard molecular biology and liquid handling robotics equipment.

 

   

High-throughput assays . We implement the previous two steps in conjunction with the same high-throughput assays used to screen mutagenized strains in order to identify those strains with improved production capabilities.

 

83


Table of Contents

Our two primary strain engineering approaches, random mutagenesis and rational design, also intersect in a way that enables us to leverage both. In addition to using random mutagenesis to generate strains, we also use it to identify hypotheses about further improvements that can be implemented through rational design techniques. By comparing the DNA sequence of a newly identified, improved microorganism to the DNA sequence of its parent strain, we can identify the specific mutations in the improved strain that we believe led to the improvements, and then rationally design them into other strains. Additionally, we can use these identified mutations to generate new hypotheses for rational design.

 

Our progress to date with farnesene demonstrates results obtained from the application of our technology platform. After identifying farnesene as a molecule with commercial potential, we developed a farnesene producing yeast strain and began to apply our strain improvement processes. We increased the peak yield for farnesene from approximately 6% to 15% in 2009 at the two liter laboratory scale.

 

We have selectively transitioned from our laboratories to our pilot plants several strains that we believe have the potential to scale effectively. In doing so, we have demonstrated the ability of certain strains to achieve farnesene yields at the 300 liter pilot scale that are comparable to those achieved at the two liter laboratory scale. Similarly, we have selectively transitioned two of these strains to the 5,000 liter demonstration scale, and these strains have demonstrated yields comparable to those achieved at the two liter and 300 liter scales. We plan to continue to transition our most promising strains to demonstration scale, with the goal of achieving no, or minimal, drop-off in yield levels.

 

The two graphs below show, on the left, our progress in improving farnesene yield at laboratory scale with our increasingly productive yeast strains over the course of 2009 and, on the right, the yields obtained at each of the two liter and 300 liter scales in Emeryville for three of our strains and also at the 300 liter and 5,000 liter scales in Campinas for the two strains that have been further tested there.

 

LOGO

 

We believe that we will be able to enter certain specialty chemical markets with farnesene if we can attain at commercial production scale the 15% yield that we have achieved at two liter scale. Based on our success in matching at the 5,000 liter scale the yields achieved by earlier generation strains at the two liter and 300 liter scales, we believe we can achieve the 15% yield at commercial scale, although we cannot be assured that we will do so until we have fully transitioned to that scale. In order to enter substantially larger markets such as those for diesel and certain specialty chemical products, we must achieve substantially higher farnesene yields than we have achieved to date. We may never achieve the yields needed to address these larger markets.

 

84


Table of Contents

Process Development and Scale-up

 

The basis of our production process is a well established fermentation process that uses our genetically engineered yeast strains to convert the sugar source into target molecules like farnesene. We employ a multi-stage scale-up approach, to progress from laboratory scale to commercial production scale. This approach is depicted in the diagram below.

 

LOGO

 

   

Laboratory scale. This first stage of scale-up evaluates the performance of promising new strains in a fermentation process under conditions approximating our pilot plant conditions. A limited number of strains are selected for further scale-up, and the fermentation process is further optimized to improve performance of each selected strain.

 

   

U.S. pilot plant. Our 300 liter U.S. pilot plant is located in Emeryville, California, adjacent to our laboratories. At this facility, we develop and test complete production processes that will eventually form the basis of processes used for commercial production. The activities we conduct at this pilot plant include feedstock preparation, fermentation runs and product separation. At the Emeryville pilot plant, we use commercially available sucrose as the feedstock.

 

   

Brazil pilot plant. We have a second 300 liter pilot plant located in Campinas, Brazil, which is substantially identical to our pilot plant in Emeryville. Using an identical design and process between the Emeryville and Campinas pilot plants allows us to replicate our processes while incorporating Brazilian sugarcane as our feedstock.

 

   

Brazil demonstration plant . In addition to our two pilot facilities, we have a demonstration facility in Campinas, Brazil, which contains two 5,000 liter fermentors. Here, the production process we developed at the 300 liter scale is further adapted to perform at the 5,000 liter scale, allowing for additional validation of production processes and equipment as we move toward full scale commercial

 

85


Table of Contents
 

production. This facility will provide technology support for development and continuous improvement of our commercial facilities.

 

   

Contract manufacturing . We have also run certain of our strains for farnesene production at contract manufacturing facilities in 60,000 liter fermentors. Thus far, the primary purpose of these operations has been the production of sufficient volumes for product testing. To date, we have produced approximately 50 barrels (or approximately 10,000 liters) of our renewable diesel for testing and certification purposes. However, production at this scale also serves as an indication of the performance of our strains at scales that are larger than that of our demonstration plant, and we anticipate using contract manufacturers for this purpose in the future. We intend to use larger fermentors on a contract manufacturing basis to initiate commercial production and in the future as needed to meet demand.

 

Chemical Finishing Steps

 

Although our product development process starts with identification and development of a target molecule for a specific product application, we also enhance the value of our biologically-derived molecules by finding multiple uses for them. In certain cases, the biologically-derived molecule will itself be the end product and in others it serves as an intermediary molecule that can then be converted into other products by means of simple chemistry steps such as hydrogenation and polymerization. For example, our diesel molecule farnesane is derived by hydrogenating the biologically derived farnesene. However, farnesene can also be converted into other applications such as lubricants, surfactants and squalane by one or more other simple chemistry steps.

 

Production

 

Commercial Production

 

We expect to initiate commercial production through the use of contract manufacturing as we complete our facility at our planned joint venture facility with Usina São Martinho. Following completion of the facility, we will seek to expand our production capacity by entering into agreements with owners of additional sugar and ethanol mills in Brazil. We may also use alternative production resources in other geographies. We anticipate that for many applications chemical finishing processes will be applied to the molecules that we produce in order to create desired products.

 

We are currently developing the engineering designs and technical capabilities to build out facilities at existing sugar and ethanol mills to produce our products. Because the bulk of our production process leverages the same equipment and process steps used to produce ethanol, we will be able to utilize much of the existing infrastructure. We expect this capital light approach will allow us to scale production at a lower cost than the cost of greenfield mill construction. The mill operator will retain the ability to direct the crushed sugarcane to produce either their current products or our products.

 

The manner in which we intend to develop our manufacturing capacity is as follows:

 

Contract manufacturing. To date, we have used contract manufacturing facilities to produce quantities of farnesene needed for certification and fleet testing. We are currently seeking to enter into relationships with additional contract manufacturers that will enable us to commercialize our products beginning in 2011. Depending primarily on the manufacturer’s location and preferences, the most likely feedstocks to be used are corn based dextrose, sugarcane syrup or sugar beets. In addition, we may use contract manufacturing to supplement our production capacity as new facilities are coming online and as otherwise needed to help us meet demand for our products.

 

86


Table of Contents

First production in Brazil through joint venture with Usina São Martinho. We have formed a joint venture with Usina São Martinho, a subsidiary of a leading sugar and ethanol company in Brazil, São Martinho S.A., to establish our first commercial-scale production facility at Usina São Martinho, located in São Paulo state, Brazil, which crushed 8.1 million tons of sugarcane in the 2009-2010 harvest season. We expect that production of our products will commence at the facility in the second quarter of 2012.

 

Increasing production in Brazil through arrangements with sugar and ethanol mill owners. We anticipate increasing our commercial production through arrangements with other ethanol and sugar producers in Brazil. We have entered into non-binding letters of intent for production relationships with three sugar and ethanol producers in Brazil, Bunge Limited, Cosan and Açúcar Guarani. If successfully consummated, we believe these production relationships together with the Usina São Martinho mill would provide us with access to over ten million tons of annual crushing capacity, which we expect to expand over time with these and other mills. As of the first quarter of 2010, this capacity represented approximately 10% of the total crush capacity of these producers.

 

Alternative geographies for production. Although we have identified the use of new bolt-on facilities adjacent to existing sugar and ethanol mills in Brazil as the optimal source for our primary production efforts, we may use facilities in alternative geographies for certain products. We currently do not have specific plans for the use of a feedstock other than Brazilian sugar cane, other than as described above for contract manufacturing, but may in the future elect to use additional feedstocks, particularly if we produce our products in other geographies. We are exploring production options in the U.S. Through our “Integrated Biorefinery Grant” from the DOE, which we were awarded in early April 2010, we are evaluating the potential for the production of our renewable products from sweet sorghum grown in Florida, Louisiana, Alabama, Texas and Hawaii.

 

Chemical finishing steps. For each product requiring additional chemical finishing steps, we will evaluate the optimal geographies and facilities for the completion of these steps. These chemical finishing steps may be performed either by our customers or outsourced by us.

 

Cost of Production

 

The primary focus of our research and development efforts at this time is on the refinement of our production processes, particularly the yield level of our farnesene strains, so that we are able to produce our products economically at commercial scale. Other important measures of production efficiency include yeast strain productivity, separation efficiency and chemical process efficiency. Productivity represents the rate at which our product is produced by a given yeast strain. The higher productivity a strain has, the more product can be produced in the same size fermentor in a given period of time. Separation yield refers to the amount of desired product produced in the fermentation process that we are able to extract and the time that it takes to do so. Chemical process efficiency refers to the cost and yield for the chemical finishing steps that convert our target molecule into a desired product.

 

Our Products

 

We are focused on bringing a broad range of products to market, including specialty chemicals and renewable transportation fuels. Our current product development efforts focus on the development and production of a limited number of chemical products and on diesel as our initial transportation fuel. Over time we plan to develop additional chemical and fuel products. We have already begun initial product development and testing efforts with regard to several of these products. Our technology license, development, research and collaboration agreement with an affiliate of Total S.A. establishes a multi-phased process through which compounds are identified, screened, selected for product feasibility study, and then ultimately selected as a lead compound for development. To commercialize any strains and compounds that are developed, Amyris and Total expect to form one or more joint ventures. Both Amyris and Total would retain certain rights to make covered products independently subject to making royalty payments to the non-producing party, and Total has certain

 

87


Table of Contents

rights to require Amyris to work on non-collaboration projects. We have retained rights to produce and commercialize products in the following markets: flavors and fragrances; cosmetics; pharmaceuticals; consumer packaged goods; food additives; and pesticides.

 

For the foreseeable future, the products that we develop will seek to replace petroleum-sourced, or other biological or chemical-derived, components of existing consumer and commercial products in target markets. Our No Compromise commitment is based on the premise that while our customers will value products made from renewable resources, each product must be economically viable and competitive in terms of product quality relative to the existing product that it is seeking to replace. We believe that this philosophy of targeting existing attractive markets with a “green” alternative that is cost-competitive with the current product components and provides comparable or better performance will position our products to achieve acceptance as they become available.

 

A common characteristic of many of the products on which we are initially concentrating is that they are derived from farnesene, which is a 15-carbon molecule produced in our fermentation process. We have the ability to perform finishing processes to chemically convert farnesene into a variety of products, providing significant end market flexibility to our process. Since we first produced farnesene in a microbial system we have been concentrating on decreasing the production costs primarily by increasing the yield. We believe that we will be able to enter certain specialty chemical markets with farnesene if we can attain at commercial production scale the 15% yield that we have achieved at two liter scale. Our ability to enter other specialty chemical markets and the diesel market will depend on our continuing to reduce the production cost of the farnesene molecule.

 

Chemical Products

 

Our first commercialization efforts have been focused on the molecule farnesene, which forms the basis for a wide range of products including specialty chemical applications such as emollients, flavors and fragrances, surfactants for various consumer and commercial purposes, isoprene, industrial and automotive oils and lubricants. We recently entered into agreements with P&G and M&G that establish terms under which we expect to develop new farnesene-based products. We also entered into an agreement with Soliance for the development and commercialization of farnesene-based ingredients for cosmetics products and into a term sheet with Cosan for the formation of a joint venture to develop and commercialize farnesene-based specialty chemicals for industrial and automotive applications. We continue to seek to identify additional uses of farnesene and to select those uses that enhance our ability to optimize the return on our technology and our production capacity.

 

In addition to farnesene-derived chemicals, we are seeking to develop additional chemical products through modifications to our engineered yeast strains to produce different molecules. These include flavors and fragrances chemicals, such as patchouli oil and sandalwood oil, used widely in perfumery and household products. We are also investigating the production of molecules such as isoprene, which is used extensively for the production of tires, among other uses.

 

While we currently expect to initially pursue the markets described above in the order and with the partners that we have indicated, we may slow or accelerate the development of one or more of our products based on a variety of factors. Among these will be our ability to continue to lower the production costs of our products. Other contributing factors may include our ability to complete product qualification processes required by our partners or customers and to satisfy any applicable regulatory requirements. Product qualification processes for our chemical products will vary from product to product. These qualification processes generally include measurement against both widely accepted industry criteria for the specific product as well as specific protocols designed by the customer. Product qualification processes generally will include one or more of the following steps: testing the basic chemical properties to confirm properties or substitutability; testing the formulation to ensure compatibility, performance or effectiveness; and sampling and testing by end users to demonstrate acceptability. We may also elect to change or redirect the pace of development of our chemical products as we continue to evaluate opportunities available to us in the chemical and fuels markets.

 

88


Table of Contents

Transportation Fuels

 

We have selected diesel as our primary area of focus within the transportation fuels market because of its projected global demand growth, the lack of a scalable, competitive renewable product and our belief that our fuel product has properties superior to those of existing renewable alternatives. Testing to date indicates that our diesel will not require engine or distribution infrastructure modifications. An independent third party that we engaged has tested certain critical ASTM International (formerly known as the American Society for Testing and Materials, or ASTM) certification metrics of our diesel fuel, the results of which are shown in the following chart along with corresponding metrics for petroleum diesel and a current biodiesel formulation:

 

LOGO

 

We will produce our renewable diesel by the simple chemical step of hydrogenating our farnesene. Hydrogenation is a common chemical process currently used in the production of liquid transportation fuels, margarine and numerous other products. We plan to complete this process in one or more locations to be determined based on a variety of factors, including cost, reliability and proximity to the production site and end customer.

 

We have completed significant steps to validate our ability to produce a market-accepted diesel product. By design, our product is a hydrocarbon of similar size to many of the hydrocarbons in petroleum-sourced diesel fuel. Due to the similarity of its chemical composition to that of existing petroleum-sourced diesel, our product has the properties required of diesel fuel and thereby satisfies the ASTM D975 Table 1 specifications for petroleum-derived diesel fuel oils. The EPA has registered our diesel for use as a 20% blend with petroleum diesel in standard engines and we are working to obtain registration for a higher blend with petroleum diesel. Our blend ratio compares, by way of example, with the typical 3-5% blend of other bio-diesel products with petroleum diesel. We have completed successful engine testing of our diesel fuel with Cummins and Mercedes-Benz Brasil at a blend of up to 10%, and we continue to work with other diesel engine manufacturers to qualify our product for use in their engines.

 

The prices at which we expect to be able to sell our diesel fuel are lower than those of many of the chemical products that we may sell. Consequently, our ability to successfully enter the diesel fuels market is particularly dependent upon our ability to continue to lower our production costs. Our ability to enter the diesel market is also dependent on our continuing to achieve the required regulatory approvals in the global markets in which we will seek to sell our diesel products. These approvals primarily involve clearance by the relevant environmental agencies in the particular jurisdiction. We must also be certified by a sufficient number of diesel engine manufacturers, vehicle manufacturers or operators of large trucking fleets so that our diesel will have an appropriately large and accessible addressable market. These certification processes include fuel analysis

 

89


Table of Contents

modeling and the testing of engines and their components to ensure that the use of our diesel fuel does not degrade performance or reduce the lifecycle of the engine or cause it to fail to meet emissions standards. Our experience with Cummins and Mercedes-Benz Brasil supports our belief that because our fuel is substantially similar to petroleum diesel fuel, OEMs are receptive to investing the time and resources needed for the certification process.

 

We believe that we will also have the capacity to produce a jet fuel that is competitive with existing petroleum-sourced jet fuel. Through a different combination of fermentation and chemical finishing steps, we have produced fuels that have the chemical properties required of jet fuel. We have begun testing a series of jet fuels that we have produced through this process with major engine and aircraft manufacturers.

 

Ethanol Sales and Collaborative Research Services

 

Since the second quarter of 2008 we have generated revenues from the purchase and sale of third party ethanol in the U.S. We expect to continue to engage in these purchases and sales to further develop our fuel distribution capabilities in the U.S. We have also derived revenues from providing collaborative research services under agreements with the Bill and Melinda Gates Foundation and sanofi-aventis.

 

Product Distribution and Sales

 

We intend to distribute and sell our products either directly or with partners, depending on the market. For most chemical applications, we intend to sell directly to specialty chemical and consumer products companies. For example, we expect to sell directly to P&G and M&G under our agreements with them. Neither P&G nor M&G has any specific purchase obligations under these agreements, and sales are contingent upon achievement of technical and commercial milestones. In addition, we expect to enter into joint venture arrangements, including with Cosan, Soliance and Total, pursuant to which the joint ventures may be distributors of the joint ventures’ products.

 

Our approach to the diesel market will vary by the different regions in which we intend to market our renewable diesel. For Brazil and other markets outside the U.S., we intend to sell indirectly through third parties. Our agreement with Shell Western Supply and Trading Limited, a subsidiary of Royal Dutch Shell plc, contemplates that Shell may purchase our diesel fuel, commencing 18 months after we notify Shell that we intend to export diesel from Brazil. Shell has no obligation to purchase any specific amount of our diesel fuel under this agreement, and we are not obligated to sell any specific quantities to Shell, but the parties will be subject to obligations to purchase and sell if and to the extent formal notices and orders are submitted under the agreement in the future. If we seek to export our diesel fuel from Brazil, we agreed to provide Shell the first right to purchase the fuel.

 

In the U.S., we expect that our customers will be large purchasers of diesel transportation fuels, including corporations with large trucking fleets. We plan to vertically integrate our commercialization efforts in the U.S. by retaining ownership and control of the diesel product from production through sale to customers. Vertical integration will involve transportation of our diesel from the manufacturing site in Brazil to a port terminal in the U.S., storage in Brazil and the U.S. pending further transport, and delivery to terminals located more closely to customers within the U.S. We anticipate leveraging the experience, capabilities and relationships established by our subsidiary, Amyris Fuels, to help us to achieve this vertical integration. We believe that our maintaining control of the diesel product in the U.S. in this manner may make us eligible to receive certain blend credits in the U.S. Blend credits are federal subsidies made available to an entity that purchases both the renewable fuel and equivalent petroleum product, blends them in prescribed ratios and sells the blended product to end customers.

 

Since 2008, we have been developing a fuels distribution network and capabilities in the U.S. through Amyris Fuels, through which we currently purchase ethanol produced by third parties and sell it to wholesale customers. For 2009, Murphy Oil USA, Inc. and The Pantry, Inc. each accounted for more than 10% of our

 

90


Table of Contents

reported revenues by virtue of their purchases of ethanol from Amyris Fuels. Our customers purchase ethanol from us under short term agreements and spot transactions, and we currently do not have any contractual commitments from customers to purchase ethanol from us over a period of time.

 

Intellectual Property

 

Our success depends in large part upon our ability to obtain and maintain proprietary protection for our products and technologies, and to operate without infringing the proprietary rights of others. We seek to avoid the latter by monitoring patents and publications in our product areas and technologies to be aware of developments that may affect our business, and to the extent we identify such developments, evaluate and take appropriate courses of action. With respect to the former, our policy is to protect our proprietary position by, among other methods, filing for patent applications on inventions that are important to the development and conduct of our business with the U.S. Patent and Trademark Office (“USPTO”) and its foreign counterparts.

 

To date, we have 24 issued U.S. and foreign patents and 195 pending U.S. and foreign patent applications that are owned by or licensed to us. We also use other forms of protection (such as trademark, copyright, and trade secret) to protect our intellectual property, particularly where we do not believe patent protection is appropriate or obtainable. We aim to take advantage of all of the intellectual property rights that are available to us and believe that this comprehensive approach provides us with a strong proprietary position.

 

Notwithstanding the increasing backlog and patent pendency at the USPTO, we have obtained U.S. patents for many of our potential products through the use of a recently introduced accelerated examination program by the USPTO. Using this procedure, we have obtained patents for various fuel products: U.S. Patent No. 7,399,323 directed to our renewable diesel fuel composition; U.S. Patent No. 7,540,888 directed to our renewable gasoline fuel composition; and U.S. Patents No. 7,589,243 and No. 7,671,245, which are directed to our renewable jet products. Since obtaining our fuels patents, we have expanded the use of this program to our chemicals portfolio and have recently obtained U.S. Patent Nos. 7,592,295 and 7,691,792 for our lubricant products, and U.S. Patent No. 7,655,739, for our adhesive products.

 

We also protect our proprietary information by requiring our employees, consultants, contractors and other advisers to execute nondisclosure and assignment of invention agreements upon commencement of their respective employment or engagement. Agreements with our employees also prevent them from bringing the proprietary rights of third parties to us. In addition, we also require confidentiality or material transfer agreements from third parties that receive our confidential data or materials.

 

Competition

 

We expect that our renewable products will compete with both the traditional, largely petroleum-based specialty chemical and fuels products that are currently being used in our target markets and with the alternatives to these existing products that established enterprises and new companies are seeking to produce. Amyris Fuels competes with other ethanol distributors.

 

Chemical Products

 

The chemical products that we initially plan to produce include emollients, flavors and fragrances, surfactants, for various consumer and commercial purposes, isoprene, industrial and automotive oils and lubricants. In these markets, and other chemical markets that we may seek to enter in the future, we will compete with the established providers of components currently used in these products. Producers of these incumbent products include global oil companies, large international chemical companies and other companies specializing in specific products, such as squalane or essential oils. We may also compete in one or more of these markets with products that are offered as alternatives to the traditional petroleum-based or other traditional products being offered in these markets. We believe that there may be a number of companies seeking to develop renewable alternatives for existing chemical markets products, including those that we are initially targeting.

 

91


Table of Contents

Transportation Fuel Products

 

Independent and Integrated oil refiners . Our competitors with respect to traditional fuel products are independent and integrated oil refiners. These companies are also our primary competitors with respect to fuels, including jet fuel currently in use in other transportation markets. We compete with these companies because an increasing penetration of renewable fuels reduces the need for fuels derived from traditional petroleum sources.

 

Many of these companies are seeking to provide alternative transportation fuel products through investing in internal research and development programs or in emerging technology companies. These efforts include processes that use non-renewable feedstocks, such as natural gas and coal, and renewable feedstocks, such as vegetable oil and biomass. These technologies are in varying states of development, the most advanced of which are those using non-renewable feedstocks, such as coal. The application of refining technologies to renewable feedstocks is less developed, with demonstration units in operation using vegetable oil or animal fats at a number of oil companies and active research on refining of biomass at other companies.

 

Advanced biofuels . Many other companies are exploring options for the production of diesel and other transportation fuels from renewable resources in other ways. These include companies using enzymes to convert cellulosic biomass, which is non-food plant material such as wood chips, corn stalks and sugarcane bagasse, into fermentable sugars to be converted into renewable fuels.

 

Biodiesel . Another source of renewable fuels products is the biodiesel industry, which is served by large, well-established agricultural products companies that convert vegetable oils, and in some cases animal oils, into diesel fuel. Other companies are seeking to produce diesel and other transportation fuels using thermochemical methods to convert biomass into renewable fuels.

 

We believe the primary competitive factors in both the chemical and fuel markets are:

 

   

product price;

 

   

product performance and other measures of quality;

 

   

infrastructure compatibility of products;

 

   

sustainability; and

 

   

dependability of supply.

 

The oil companies, large chemical companies and well-established agricultural products companies with which we compete are much larger than we are, in many cases have well developed distribution systems and networks for their products, have historical relationships with the potential customers we are seeking to serve and have sales and marketing programs in place to promote their products. In order to be successful, we must convince customers that our products are at least as effective as the products we are seeking to replace and we must provide our products on a cost-competitive basis. Some of our competitors may use their influence to impede the development and acceptance of renewable products of the type that we are seeking to produce

 

We believe that for our chemical products to succeed in the market, we must demonstrate that they are comparable to both existing products and other alternative products that are being developed for the same markets based on some combination of product cost, availability, performance and consumer preference characteristics. With respect to our diesel and other transportation fuels products, we believe that our product must perform as effectively as the petroleum-sourced fuel and be available on a cost-competitive basis. Given the size of the traditional transportation fuels markets and the developing stage of alternatives fuels markets, we do not believe that our success will necessarily prevent other renewable diesel or other fuels products from achieving commercial success, or that the success of other renewable products will prevent our fuels products from being successful. However, with the wide range of renewable fuels products under development, we must be successful in reaching potential customers and convincing them that ours are effective and reliable alternatives.

 

92


Table of Contents

Amyris Fuels

 

Amyris Fuels competes with regional ethanol distributors in the southeastern U.S. The primary competitive factors in the Amyris Fuels business are price, convenience, and reliability of supply.

 

Environmental and Other Regulatory Matters

 

Our development and production processes involve the use, generation, handling, storage, transportation and disposal of hazardous chemicals and radioactive and biological materials. We are subject to a variety of federal, state, local and international laws, regulations and permit requirements governing the use, generation, manufacture, transportation, storage, handling and disposal of these materials in the U.S., Brazil and other countries where we operate or may operate or sell our products in the future. These laws, regulations and permits can require expensive fees, pollution control equipment or operational changes to limit actual or potential impact of our technology on the environment and violation of these laws could result in significant fines, civil sanctions, permit revocation or costs from environmental remediation. We believe we are currently in substantial compliance with applicable environmental regulations and permitting. However, future developments including our commencement of commercial manufacturing of one or more of our products, more stringent environmental regulation, policies and enforcement, the implementation of new laws and regulations or the discovery of unknown environmental conditions may require expenditures that could have a material adverse effect on our business, results of operations or financial condition. See “Risk Factors—Risks Relating to Our Business—We may incur significant costs complying with environmental laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.”

 

The use of GMMs like our yeast strains, is subject to laws and regulations in many countries. In the U.S., the EPA regulates the commercial use of GMMs as well as potential products from the GMMs. The strain of genetically modified yeast that we use, S. cerevisiae , is eligible for exemption from EPA review because the EPA recognizes it as posing a low risk given its long history of safe use and will qualify for such exemption provided that it meets certain criteria, including but not limited to use of compliant containment structures and safety procedures. In Brazil, GMMs are regulated by CTNBio under its Biosafety Law No. 11.105-2005. We have obtained approval from CTNBio to use GMMs in our Campinas facilities for research and development purposes. In addition, we have obtained initial commercial approval from CTNBio for one of our current yeast strains. We expect to encounter GMM regulations in most if not all of the countries in which we may seek to make our products, however, the scope and nature of these regulations will likely be different from country to country. If we cannot meet the applicable requirements in countries in which we intend to use produce our products using our yeast strains, then our business will be adversely affected. See “Risk Factors—Risks Relating to Our Business—We may face risks relating to the use of our genetically modified yeast strains and if we are not able to secure regulatory approval for the use of our yeast strains or if we face public objection to our use of them, our business could be adversely affected.”

 

Our renewable chemical products may be subject to regulation by government agencies in our target markets. The EPA administers the requirements of the TSCA, which regulates the commercial use of chemicals. Before an entity can manufacture a chemical, it needs to determine whether that chemical is listed in the TSCA inventory. If the substance is listed, then manufacture can commence immediately. If not, then a pre-manufacture notice must be filed with the EPA which has 90 days to review.

 

Our diesel fuel is subject to regulation by various government agencies. In the U.S., this includes the EPA and the California Air Resources Board. In Brazil, this includes Agencia Nacional do Petroleo, or ANP. To date we have obtained registration with the EPA for the use of our diesel in the U.S. at a 20% blend rate. We are currently seeking supplemental EPA registration for a 35% blend rate and working to secure ANP approval for use of our diesel in Brazil at a 10% blend rate. We are currently exploring registration of our fuel with the California Air Resources Board and the European Commission. Registration with each of these bodies is required for the sale and use of our fuels within their respective jurisdictions. “Risk Factors—Risks Relating to Our Business—We may not be able to obtain regulatory approval for the sale of our renewable products.”

 

93


Table of Contents

Amyris Fuels is subject to various U.S. federal regulations relating to its marketing and distribution of ethanol, and it is registered with the EPA in connection with its use of ethanol as a fuel additive. In addition, Amyris Fuels is subject to various state regulations, including regulations regarding excise tax payments and the posting of surety bonds in connection with ethanol sales.

 

Research and Development

 

We devote substantial resources to our research and development efforts. Our research and development organization is comprised of approximately 190 employees, 60 of whom hold Ph.D.s. Our technology development is currently focused primarily on improving the performance of our production strains and on developing strains that produce new molecules. To facilitate the transfer of our fermentation technology to production, we operate pilot-scale fermentation facilities in both Emeryville, California, and Campinas, Brazil, and transfer strains on a regular basis through this process. Our process consists of a number of discrete steps including:

 

   

identifying new target molecules

 

   

creating new microbial strains capable of producing the target molecule

 

   

increasing product yield and productivity from microbial strains through strain modification or fermentation improvements

 

   

increasing efficiency of product separation and purification

 

   

continuous translation of these steps from lab to commercial scale production.

 

Our research and development expenditures were approximately $8.7 million, $30.3 million and $38.3 million for the fiscal years ended December 31, 2007, 2008 and 2009, respectively and $8.6 million and $11.2 million for the three months ended March 31, 2009 and 2010, respectively.

 

Employees

 

As of June 11, 2010, we had 259 full-time employees. Of these employees, 194 were in the U.S. and 65 were in Brazil. None of our employees is represented by a labor union or is covered by a collective bargaining agreement. We have never experienced any employment-related work stoppages and consider relations with our employees to be good.

 

Facilities

 

We lease approximately 114,000 square feet of space in two adjacent buildings in Emeryville, California, pursuant to two leases. Of this, we use approximately 91,000 square feet for general office purposes and lab space, and approximately 23,000 square feet comprise our pilot plant. Approximately 20,000 square feet of office space was vacated in the restructuring that we completed in August 2009. The leases expire in May 2018. We have an option to extend these leases for five years.

 

Amyris Brasil leases approximately 13,000 square feet of space in Campinas, Brazil, pursuant to a lease that will expire in May 2013. Of this, approximately 9,000 square feet comprise a pilot plant and demonstration facility, and the remainder is general office and lab space. Amyris Brasil has a right of first refusal to purchase the space if the landlord elects to sell it and an option to extend the lease for five additional years.

 

Amyris Fuels has secured the use of ethanol storage tanks with an aggregate capacity of 32,500 barrels at various locations in Virginia, North Carolina, South Carolina, Georgia and Tennessee. The agreements have initial terms of approximately three years, which begin expiring in 2011. Upon expiration of the respective initial term, each agreement will continue for successive one-year terms until terminated by one of the parties.

 

We also use a small amount of office space in Oakbrook Terrace, Illinois.

 

We believe that our current facilities are suitable and adequate to meet our needs and that suitable additional space will be available to accommodate the foreseeable expansion of our operations.

 

94


Table of Contents

MANAGEMENT

 

Executive Officers and Directors

 

The following table sets forth information regarding our executive officers, directors and key employees as of June 21, 2010.

 

Name

   Age   

Position

Directors:

     

John Melo

   44    Director, President and Chief Executive Officer

Ralph Alexander (1)

   55    Director

John Doerr (2)

   58    Director

Geoffrey Duyk, M.D., Ph.D. (1) (2)

   51    Director

Samir Kaul (2)

   36    Director

Arthur Levinson, Ph.D.

   60    Director

Patrick Pichette (1)

   47    Director

Carole Piwnica

   52    Director

Keith Kinkead Reiling, Ph.D.

   36   

Director, Senior Vice President of Corporate Development

Fernando de Castro Reinach, Ph.D.

   54    Director

Other Executive Officers:

     

Jeryl Hilleman

   52    Chief Financial Officer

Peter Boynton

   56    Chief Commercial Officer

Joel Cherry, Ph.D.

   49    Senior Vice President, Research Programs and Operations

Jefferson Lievense, Ph.D.

   55   

Senior Vice President, Process Development and Manufacturing

Mario Portela

   49    Chief Operating Officer

Neil Renninger, Ph.D.

   36    Chief Technical Officer

Tamara Tompkins

   45    Senior Vice President, General Counsel and Secretary

Key Employees:

     

Jack Newman, Ph.D.

   43    Senior Vice President, Research

 

  (1)   Member of Audit Committee
  (2)   Member of Leadership Development and Compensation Committee

 

Directors

 

John Melo

 

John Melo has served as our President and Chief Executive Officer and a director since January 2007 and our President since January 2008. Before joining Amyris, Mr. Melo served in various senior management positions at BP Plc (formerly British Petroleum), one of the world’s largest energy firms, from 1997 to 2006, most recently as President of U.S. Fuels Operations from 2004 until December 2006, and previously as Chief Information Officer of the refining and marketing segment from 2001 to 2003, Senior Advisor for e-business strategy to Lord Browne, BP Chief Executive, from 2000 to 2001, and Director of Global Brand Development from 1999 to 2000. Before joining BP, Mr. Melo was with Ernst & Young, an accounting firm, from 1996 to 1997, and a member of the management teams of several startup companies, including Computer Aided Services, a management systems integration company, and Alldata Corporation, a provider of automobile repair software to the automotive service industry. Mr. Melo currently serves on the board of directors of U.S. Oil Company. Mr. Melo’s experience as a senior executive at one of the world’s largest energy companies provides critical leadership in designing the fuels value chain, shaping strategic direction and business transactions, and in building teams to drive innovation.

 

95


Table of Contents

Ralph Alexander

 

Ralph Alexander has been a member of our Board of Directors since May 2007. Mr. Alexander has been a Managing Director at Riverstone Holdings, LLC, an energy and power-focused private equity firm, since September 2007. Previously, he served in various senior management positions with affiliates and subsidiaries of BP Plc (formerly British Petroleum), most recently as Chief Executive Officer of Innovene, BP’s olefins and derivatives subsidiary, from 2004 to December 2005, as Chief Executive Officer of BP’s Gas, Power and Renewables and Solar segment from 2001 to 2004, and as a Group Vice President in BP’s Exploration and Production segment and BP’s Refinery and Marketing segment. Mr. Alexander has served on the board of directors of Stein Mart, Inc. since August 2007. Mr. Alexander previously served on the boards of directors Anglo-American Plc from April 2005 to October 2007 and of Foster Wheeler from May 2006 to February 2007. He is currently deputy-chairman of the board of Polytechnic University. Mr. Alexander holds a Bachelor of Science degree and a Master of Science degree in Nuclear Engineering from Brooklyn Polytech (now Polytechnic University), and a Master of Science degree in Management Science from Stanford University. Mr. Alexander’s extensive experience with the energy industry generally and renewable fuels in particular enables him to provide important insight and guidance to our management team and Board of Directors.

 

John Doerr

 

John Doerr has been a member of our Board of Directors since May 2006. Mr. Doerr has been a Partner at Kleiner Perkins Caufield & Byers, a venture capital firm, since 1980. Mr. Doerr currently serves on the board of directors of Google Inc., as well as on the boards of directors of several private companies. Previously, Mr. Doerr served on the boards of directors of Amazon.com, Inc., Move, Inc., drugstore.com, Inc., Homestore.com, Inc., palmOne, Inc. and Sun Microsystems, Inc. Mr. Doerr holds a Bachelor of Science and a Master of Science in Electrical Engineering and Computer Science degrees from Rice University and a Master of Business Administration degree from Harvard University. Mr. Doerr’s global business leadership as general partner of Kleiner Perkins Caufield & Byers, as well as his outside board experience as director of several public companies enable him to provide valuable insight and guidance to our management team and Board of Directors.

 

Geoffrey Duyk, M.D., Ph.D.

 

Dr. Geoffrey Duyk has been a member of our Board of Directors since May 2006. Dr. Duyk is a partner of TPG Growth, LLC, an affiliate of TPG Biotechnology Partners II, L.P. Previously, he served on the board of directors and was President of Research and Development at Exelixis, Inc., a biopharmaceutical company focusing on drug discovery, from 1996 to 2003. Prior to Exelixis, Dr. Duyk was Vice President of Genomics and one of the founding scientific staff at Millennium Pharmaceuticals, from 1993 to 1996. Before that, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of several private companies and the non-profit Wesleyan University Board of Trustees. He served on the board of directors of Agria Corporation from August 2007   to May 2009, Cardiovascular Systems, Inc. (formerly Replidyne, Inc.) from 2004 to February 2009, Exelixis, Inc. from 1996 to 2003, and several private companies. Dr. Duyk holds a Bachelor of Arts degree in Biology from Wesleyan University and Doctor of Philosophy and Medicine degrees from Case Western Reserve University. Mr. Duyk’s experience with the biotechnology industry enables him to provide insight and guidance to our management team and Board of Directors.

 

Samir Kaul

 

Samir Kaul has been a member of our Board of Directors since May 2006. Mr. Kaul has been a General Partner at Khosla Ventures, a venture capital firm focusing on clean technologies, since February 2006. Previously, Mr. Kaul was a member of Flagship Ventures, a venture capital firm, from 2002 to May 2006. Prior to Flagship, Mr. Kaul worked at The Institute for Genomic Research (TIGR). Mr. Kaul currently serves on the boards of directors of several private companies. Mr. Kaul holds a Bachelor of Science degree in Biology from the University of Michigan, a Master of Science degree in Biochemistry from the University of Maryland and a

 

96


Table of Contents

Master of Business Administration degree from Harvard University. Mr. Kaul provides our Board of Directors with wide-ranging experience in synthetic biology and high throughput system development and insight in the management of startup companies.

 

Arthur Levinson, Ph.D.

 

Dr. Arthur Levinson has been a member of our Board of Directors since April 2010. Dr. Levinson has been an advisor to the Research and Early Development Center and a member of the Scientific Resource Board of Genentech, Inc., a biotechnology company, since May 2009. Previously, he served as Chief Executive Officer of Genentech, Inc. from 1995 to April 2009. Dr. Levinson has served as Chairman of the board of directors of Genentech, Inc. since 1999, and as a member of the boards of directors of Apple, Inc. since 2000, Hoffman La Roche, Inc. since March 2010 and NGM Biopharmaceutical, Inc. since October 2009. Dr. Levinson previously served on the board of directors of Google, Inc. from 2004 to October 2009. He holds a Bachelor of Arts degree in Biology from the University of Washington, Seattle and a Doctor of Philosophy degree in Biochemical Sciences from Princeton University. Dr. Levinson’s experience with the biotechnology industry enables him to provide insight and guidance to our management team and Board of Directors.

 

Patrick Pichette

 

Patrick Pichette has been a member of our Board of Directors since March 2010. Mr. Pichette has been a Senior Vice President and the Chief Financial Officer of Google Inc., an internet search company, since August 2008. Previously, he served in various senior financial management positions at Bell Canada, a telecommunications firm, from 2001 to July 2008, most recently as President, Operations from 2004 to July 2008 and, from 2002 to 2003, as Chief Financial Officer. Mr. Pichette was a partner at McKinsey & Company, a consulting firm, from 1996 to 2000, and served as Vice President and Chief Financial Officer of Call-Net Enterprises, a Canadian telecommunications company, from 1994 to 1996. Mr. Pichette served on the board of directors of Alaska Communication Systems, Inc. from 2004 to August 2008 and Aliant Communications Systems Group, Inc. from 2006 to August 2008. He currently serves on the boards of the non-profit organizations Engineers Without Borders and the Trudeau Foundation. Mr. Pichette holds a Bachelor of Arts degree in Business Administration from Université du Québec à Montréal and a Master of Arts degree in Philosophy, Politics and Economics from Oxford University, where he attended as a Rhodes Scholar. Mr. Pichette’s expertise in accounting, finance, international financial operations and management enables him to provide important insight and guidance to our management team and Board of Directors and to serve as a member of our Audit Committee.

 

Carole Piwnica

 

Carole Piwnica has been a member of our Board of Directors since September 2009. Ms. Piwnica has been Director of NAXOS UK, a consulting firm advising private equity, since January 2008. Previously, Ms. Piwnica served as a director, from 1996 to July 2006, and Vice-Chairman of Governmental Affairs, from 2000 to 2006, of Tate & Lyle Plc, a European food and agricultural ingredients company. She was a director of S.A. Spadel N.V., a European soft drink company, from 1998 to 2004, and a chairman of Amylum Group, a European food ingredient company and subsidiary of Tate & Lyle Plc, from 1996 to 2000. From 1992 to 1996, Ms. Piwnica held general management positions and board memberships in various other European food companies, including Cacao Barry and Vital Sogéviandes. Ms. Piwnica currently serves on the boards of directors of Dairy Crest Group Plc, Aviva Plc and Toepfer International GmbH. She was a member of the Biotech Advisory Council of Monsanto from May 2006 to October 2009. Ms. Piwnica holds a Law degree from the Université Libre de Bruxelles and a Master of Laws degree from New York University. Ms. Piwnica provides the Board of Directors and management with significant experience in corporate leadership in multinational firms.

 

Keith Kinkead Reiling, Ph.D.

 

Dr. Reiling is a co-founder of Amyris and has been a member of our Board of Directors since July 2008 and from 2003 to May 2006. Dr. Reiling has served as our Senior Vice President, Corporate Development since

 

97


Table of Contents

January 2008 and also served as our President from 2003 to January 2008. He holds a Bachelor of Science degree in Physics from the University of California, Los Angeles, a Master of Science degree in Applied Physics from Columbia University and a Doctor of Philosophy degree in Biophysics from the University of California, San Francisco. Dr. Reiling provides our Board of Directors with insight into the fundamental science behind Amyris’ technology and the application of that technology in the chemicals and fuels sectors.

 

Fernando de Castro Reinach, Ph.D.

 

Dr. Fernando de Castro Reinach has been a member of our Board of Directors since September 2008. Dr. Reinach has been a General Partner at Votorantim Novos Negócios Ltda., the private equity arm of Votorantim Group, a large Brazilian industrial group, since 2001. Before joining Votorantim, he was involved in the creation of two companies, Genomic Engenharia Molecular Ltda., a molecular diagnostic laboratory, and .ComDominio S/A, a datacenter company. Dr. Reinach currently serves on the board of directors of Tivit Terceirização de Processos, Serviços e Tecnologia S/A, a Brazilian IT company which is publicly traded in Brazil. Dr. Reinach holds Bachelor of Science degree in biology from the University of São Paulo and a Doctor of Philosophy degree in Cell and Molecular Biology from Cornell University Medical College. Dr. Reinach’s experience with Brazilian business practices and startup companies enable him to provide important insight and guidance to our management team and Board of Directors and to assist management with establishing and developing operations in Brazil.

 

Other Executive Officers

 

Jeryl Hilleman

 

Jeryl Hilleman has served as our Chief Financial Officer since January 2008. Before joining Amyris, from 1997 to June 2007, she was Executive Vice President and Chief Financial Officer of Symyx Technologies, Inc., a research and development infrastructure company providing scientific software and research services to technology companies. Before Symyx, Ms. Hilleman worked with two biotechnology companies, Geron Corporation, a biopharmaceutical company, as Vice President, Finance from 1992 to 1997, and Cytel Corporation, a provider of clinical trial design tools, services and statistics applications, as Chief Financial Officer from 1987 to 1992. Ms. Hilleman holds a Bachelor of Arts degree in History from Brown University and a Master of Business Administration degree from the Wharton Graduate School of Business.

 

Peter Boynton

 

Peter P. Boynton has served as our Chief Commercial Officer since December 2009. Mr. Boynton joined Amyris from Tate & Lyle Plc, a global food and agricultural ingredients company, where he served in various positions from 1999 to December 2009, most recently as Senior Vice President, Bio-products and Fermentation. Previously, he held multiple positions at Cargill, Inc., a privately held food and agriculture company, from 1980 to 1998, lastly as Vice President NACM. Mr. Boynton holds a Bachelor of Science degree in Economics from the University of Georgia.

 

Joel Cherry, Ph.D.

 

Dr. Joel Cherry has served as our Senior Vice President of Research Programs and Operations since November 2008. Before joining Amyris, Dr. Cherry was Senior Director of Bioenergy Biotechnology at Novozymes, a biotechnology company focusing on development and manufacture of industrial enzymes from 1992 to November 2008. At Novozymes, he served in a variety of R&D scientific and management positions, including membership in Novozymes’ International R&D Management team, and as Principal Investigator and Director of the BioEnergy Project, a U.S. Department of Energy-funded $18 million effort initiated in 2000. Dr. Cherry holds a Bachelor of Arts degree in Chemistry from Carleton College and a Doctor of Philosophy degree in Biochemistry from the University of New Hampshire.

 

98


Table of Contents

Jefferson Lievense, Ph.D.

 

Dr. Jefferson Lievense has served as our Senior Vice President of Process Development and Manufacturing since December 2007. Before joining Amyris, he was the Vice President of Technology and Process Development and served in other technology management positions for the Research and Development organization of Tate & Lyle Plc, a European food and agricultural ingredients company, from 1994 to November 2007. Prior to that, he was Vice President of Research and Operations and President of the Bio-Business Incubator of Michigan for Michigan Biotechnology Institute from 1993 to 1994, Director of Chemical Programs and Pathway Engineering for Genencor International from 1990 to 1993, and held various process engineering, research scientist and product management positions at Eastman Kodak Company from 1982 to 1989. Dr. Lievense holds a Bachelor of Science degree in Chemical Engineering from The University of Michigan and a Doctor of Philosophy degree in Chemical Engineering from Purdue University.

 

Mario Portela

 

Mario Portela joined us as our Chief Operating Officer in December 2009. He also serves as Chair of the Board of Directors of Amyris Brasil. He has also worked since December 2008 as an advisor to TPG Capital on strategy, mergers and acquisitions. From December 2007 to December 2008, Mr. Portela was Vice President and Officer, Corporate Development, with LyondellBasell Industries, a leading manufacturer of polymers, petrochemicals, fuels and technology licensing. He held a similar position with Lyondell Chemical Company from 2003 until its merger with Basell in December 2007. Mr. Portela holds a degree in Mechanical Engineering from the IMPE Institute in Lisbon, Portugal.

 

Neil Renninger, Ph.D.

 

Dr. Neil Renninger is a co-founder of Amyris and has served as our Chief Technical Officer since January 2008, and has also served as our Vice President of Development from 2003 to March 2007 and as our Senior Vice President of Development from March 2007 to January 2008. Dr. Renninger holds a Bachelor of Science degree in Chemical Engineering from the Massachusetts Institute of Technology, a Master of Science degree in Environmental Engineering and a Doctor of Philosophy degree in Chemical Engineering from the University of California, Berkeley.

 

Tamara Tompkins

 

Tamara Tompkins has served as our General Counsel since February 2005, Secretary since November 2005 and Senior Vice President since July 2007. Before joining Amyris, she practiced as an attorney at Morgan, Lewis & Bockius LLP, a law firm, from 2003 to February 2005. Previously, Ms. Tompkins worked as an attorney at Brobeck, Phleger & Harrison LLP, a law firm, from 1996 to 1999 and from 2000 to 2003, and Shearman & Stearling LLP, a law firm, from 1994 to 1996. From 1999 to 2000, she was the Director of the Berkeley Center for Law and Technology at the Boalt Hall School of Law. Ms. Tompkins holds a Bachelor of Arts degree in History from Middlebury College and a Juris Doctor degree from Georgetown University Law Center.

 

Key Employee

 

Jack Newman, Ph.D.

 

Dr. Jack Newman is a co-founder of Amyris and has served as our Senior Vice President of Research since July 2007, and also served as our Director, Biology from 2004 to June 2007. Dr. Newman holds a Bachelor of Arts degree in Molecular and Cell Biology from the University of California, Berkeley and a Doctor of Philosophy degree from the University of Wisconsin-Madison in the field of microbial physiology and gene regulation.

 

Our executive officers are elected by, and serve at the discretion of, our Board of Directors. There are no family relationships among any of our directors and executive officers.

 

99


Table of Contents

Board of Directors

 

Under our amended and restated certificate of incorporation that will become effective immediately prior to the closing of this offering, our Board of Directors may set the authorized number of directors. Each director currently serves until our next annual meeting or until his or her successor is duly elected and qualified. Upon the completion of this offering, our common stock will be listed on The Nasdaq Stock Market. The rules of The Nasdaq Stock Market require that a majority of the members of our Board of Directors be independent within specified periods following the closing of this offering. We believe that seven of our directors are independent as determined under these rules: Ralph Alexander, John Doerr, Dr. Geoffrey Duyk, Samir Kaul, Dr. Arthur Levinson, Patrick Pichette, Carole Piwnica and Dr. Fernando de Castro Reinach.

 

Pursuant to a voting agreement as most recently amended and restated on June 21, 2010, Messrs. Kaul and Doerr and Dr. Duyk were appointed to our Board of Directors by certain of our investors. As of the date of this prospectus, Messrs. Kaul and Doerr and Dr. Duyk continue to serve on our Board of Directors and will continue to serve as directors until their resignation or until their successors are duly elected by the holders of our common stock, despite the fact that the voting agreement will terminate upon the completion of this offering.

 

Immediately prior to the completion of this offering, we will file our amended and restated certificate of incorporation. We anticipate that the amended and restated certificate of incorporation will divide our Board of Directors into three classes, with staggered three-year terms:

 

   

Class I directors, whose initial term will expire at the annual meeting of stockholders to be held in 2011;

 

   

Class II directors, whose initial term will expire at the annual meeting of stockholders to be held in 2012; and

 

   

Class III directors, whose initial term will expire at the annual meeting of stockholders to be held in 2013.

 

At each annual meeting of stockholders after the initial classification, the successors to directors whose terms have expired will be elected to serve from the time of election and qualification until the third annual meeting following such election. Upon the completion of this offering, the Class I directors will consist of             ,              and             ; the Class II directors will consist of             ,              and             ; and the Class III directors will consist of             ,              and             . As a result, only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.

 

In connection with Total’s equity investment, we agreed to appoint a person designated by Total to serve as a member of our Board of Directors in the class subject to the latest re-election date and to use our reasonable efforts, consistent with the Board’s fiduciary duties, to cause the director designated by Total to be re-nominated as a director in the future. These rights of Total terminate upon the earlier of Total holding fewer than half of the shares of common stock originally issuable upon conversion of the Series D preferred stock or a sale of our company.

 

In addition, we intend to amend and restate our certificate of incorporation and bylaws immediately prior to the completion of this offering to provide that only our Board of Directors may fill vacancies on our Board of Directors until the next annual meeting of stockholders. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the total number of directors.

 

The classification of our Board of Directors and provisions described above may have the effect of delaying or preventing changes in our control or management. See “Description of Capital Stock—Anti-Takeover Provisions—Restated Certificate of Incorporation and Restated Bylaw Provisions.”

 

100


Table of Contents

Board Committees

 

Our Board of Directors has an Audit Committee, a Leadership Development and Compensation Committee and a Nominating and Governance Committee, each of which has the composition and responsibilities described below as of the closing of this offering. Members serve on these committees until their resignations or until otherwise determined by our Board of Directors.

 

Audit Committee

 

Our Audit Committee is comprised of Mr. Alexander, Dr. Duyk and Mr. Pichette, who is the chair of the Audit Committee. The composition of our Audit Committee meets the requirements for independence under the current Nasdaq Stock Market and SEC rules and regulations. Each member of our Audit Committee is financially literate. In addition, Mr. Pichette is an “audit committee financial expert” as defined in Item 407(d)(5)(ii) of Regulation S-K promulgated under the Securities Act of 1933, as amended, or the Securities Act. Being an “audit committee financial expert” does not impose on Mr. Pichette any duties, obligations or liabilities that are greater than are generally imposed on him as a member of our Audit Committee and our Board of Directors. Our Board of Directors adopted a charter for our Audit Committee. Our Audit Committee, among other things, will:

 

   

oversee our accounting and financial reporting processes and audits of our consolidated financial statements;

 

   

oversee our relationship with our independent auditors, including appointing and changing our independent auditors and ensuring their independence;

 

   

review and approve the audit and permissible non-audit services to be provided to us by our independent auditors;

 

   

facilitate communication among the independent auditors, our financial and senior management and the Board of Directors; and

 

   

monitor the periodic reviews of the adequacy of the accounting and financial reporting processes and systems of internal control.

 

Leadership Development and Compensation Committee

 

Our Leadership Development and Compensation Committee is comprised of Messrs. Alexander, Kaul and Pichette. The composition of our Leadership Development and Compensation Committee meets the requirements for independence under the current Nasdaq Stock Market and SEC rules and regulations. The purpose of our Leadership Development and Compensation Committee is to provide guidance and periodic monitoring for all of our compensation, benefit, perquisite and employee equity programs. Our Board of Directors adopted a new charter for our Leadership Development and Compensation Committee. Our Leadership Development and Compensation Committee will discharge the responsibilities of our Board of Directors relating to compensation of our executive officers, and will, among other things:

 

   

review and approve the compensation of our executive officers;

 

   

review and recommend to our Board of Directors the compensation of our directors;

 

   

review and approve the terms of any compensation agreements with our executive officers;

 

   

administer our stock and equity incentive plans;

 

   

review and make recommendations to our Board of Directors with respect to incentive compensation and equity plans; and

 

   

establish and review our overall compensation strategy.

 

101


Table of Contents

Nominating and Governance Committee

 

Our Nominating and Governance Committee is comprised of Mr. Doerr and Ms. Piwnica. The composition of our Nominating and Governance Committee meets the requirements for independence under the current Nasdaq Stock Market and SEC rules and regulations. Our Board of Directors adopted a charter for our Nominating and Governance Committee. Our Nominating and Governance Committee, among other things, will:

 

   

identify, consider and recommend to the Board of Directors for nomination candidates for membership on the Board of Directors;

 

   

develop and recommend to our Board of Directors corporate governance guidelines and policies; and

 

   

advise the Board of Directors on corporate governance matters and Board of Directors performance matters, including recommendations regarding the structure and composition of the Board of Directors and its committees.

 

We intend to post the charters of our audit, compensation, and nominating and governance committees, and any amendments that may be adopted from time to time, on our website.

 

Leadership Development and Compensation Committee Interlocks and Insider Participation

 

During fiscal 2009, our Leadership Development and Compensation Committee consisted of Messrs. Doerr and Kaul and Dr. Duyk. None of them has at any time in the last fiscal year been one of our officers or employees, and none has had any relationships with our company of the type that is required to be disclosed under Item 404 of Regulation S-K. None of our executive officers has served as a member of the Board of Directors, or as a member of the compensation or similar committee, of any entity that has one or more executive officers who served on our Board of Directors or Leadership Development and Compensation Committee during fiscal 2009. Messrs. Doerr and Kaul have pecuniary interests in their respective affiliated venture funds and may be deemed to have an interest in certain transactions with us, as more fully described in “Certain Relationships and Related Party Transactions” below.

 

Code of Business Ethics and Conduct

 

Our Board of Directors has adopted a code of business conduct. The code of business conduct applies to all of our employees, officers and directors. The full text of our code of business conduct will be posted on our website. We intend to disclose future amendments to certain provisions of our code of business conduct, or waivers of these provisions, on our website and also in public filings.

 

Director Compensation

 

Our employee directors, Messrs. Melo and Reiling, have not received any compensation in connection with their service as directors. The compensation that we pay to Mr. Melo is discussed in the “Executive Compensation” section of this prospectus. As described under “Management—Executive Officers and Directors,” Mr. Reiling is employed in the capacity of Senior Vice President of Corporate Development and receives cash compensation and equity awards in such capacity, as determined by our Leadership Development and Compensation Committee.

 

We pay our non-employee directors who are not affiliated with any of our stockholders a $5,000 fee for each meeting attended by them. This policy currently applies to Mr. Ralph Alexander, Dr. Arthur Levinson and Ms. Carole Piwnica. In fiscal year 2009, pursuant to this policy, Mr. Alexander and Ms. Piwnica earned the fees described in the table below.

 

Name

   Fees Earned or Paid in Cash ($)

Ralph Alexander

   $ 10,000

Carole Piwnica

   $ 5,000

 

Except for meeting attendance fees in accordance with the policy described above, since our incorporation we have not paid any cash compensation to any of our directors for their service on the Board of Directors or on committees of the Board of Directors.

 

102


Table of Contents

Certain of our non-employee directors were granted options to purchase shares of our common stock, as follows:

 

Name

   Date of Grant    Number of  Shares
Underlying
Unexercised
Option (1)
    Exercise
Price Per
Share($)
   Vesting Start
Date
    Grant Date Fair
Value of Option
Awards ($) (2)

Ralph Alexander

   9/27/2007    45,000 (3)       3.93    7/20/2007 (4)     116,649

Dr. Arthur Levinson

   4/20/2010    100,000 (3)     $ 20.41    4/20/2010 (5)     1,610,790

Patrick Pichette

   3/19/2010    100,000 (3)       14.28    3/4/2010 (5)     1,126,040
Dr. Fernando de Castro Reinach (6)    9/15/2008    60,000 (7)       3.93    9/15/2008 (8)     387,906

 

  (1)   None of the options reported in this table have been exercised as of the date of this prospectus.
  (2)   The amount in this column reflects the aggregate grant date fair value computed in accordance with ASC Topic 718. The assumptions used by us in determining the grant date fair value of option awards are set forth in Note 13 to our Consolidated Financial Statements included elsewhere in this prospectus. These amounts do not correspond to the actual value that will be recognized by the directors. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our Consolidated Financial Statements.
  (3)   These options are immediately exercisable without regard to vesting schedule. We retain a right of repurchase of unvested shares resulting from exercise of such options.
  (4)   This option vested over two years from the vesting start date.
  (5)   This option will vest in quarterly increments over three years from the vesting start date at a rate of 1/12 per quarter.
  (6)   This option was granted in consideration for Dr. Reinach’s service on the Board of Directors and was issued in the name of Lit Tele LLC whose parent is an affiliate of Dr. Reinach, as more fully described in the “Certain Relationships and Related Party Transactions” section below.
  (7)   These options are not immediately exercisable and can be exercised only with respect to vested underlying shares.
  (8)   This option will vest in equal quarterly increments over three years from the vesting start date at a rate of 1/12th per quarter.

 

John Doerr, Dr. Geoffrey Duyk, Samir Kaul and Carole Piwnica have not to date received any options to purchase shares of our common stock or other equity awards in connection with their service on our Board of Directors.

 

Executive Compensation

 

Compensation Discussion and Analysis

 

The following discussion describes and analyzes our compensation for our named executive officers for 2009, which include our President and Chief Executive Officer (“CEO”), our Chief Financial Officer (“CFO”) and the three most highly compensated executive officers other than the CEO and CFO as set forth in the “ Summary Compensation Table ” below (our “named executive officers”).

 

We are building an integrated renewable products company by applying our industrial synthetic biology platform to provide alternatives to select petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. Since our formation we have conducted substantial efforts to, and we continue to, further develop our technology platform. We have also engaged in extensive discussions and negotiations with third parties that we expect will provide facilities and feedstock for the production of our products and other third parties that we expect will purchase products that we produce. We have raised a substantial amount of capital from investors to support our growth as we seek to bring our products to market as well as from research institutions and other entities for the provision of collaborative research services and from

 

103


Table of Contents

government grants. Our success depends, among other things, on attracting and retaining executive officers with experience and skills in a number of different areas as we continue to further develop our products and seek to commercialize them.

 

We were formed in 2003. While our founders continue to serve us in key capacities, we have added a number of executive officers since our formation, including our CEO, CFO and other executives. These additional officers have joined us at various times from 2005 through December 2009.

 

Compensation Philosophy and Objectives and Elements of Compensation

 

Our intent and philosophy in designing compensation packages at the time of hiring new executives has been based in part on providing compensation that we thought was sufficient to enable us to attract the talent necessary to further develop our business while at the same time being prudent in the management of our cash and equity in light of the early stage of the development of our company. Compensation of our executive officers after the initial period following their hiring has been influenced by the amounts of compensation that we initially agreed to pay them as well as by our evaluation of their subsequent performance, changes in their levels of responsibility, prevailing market conditions, the financial condition and prospects of our company and our attempt to maintain some level of internal equity in the compensation of existing executives relative to the compensation paid to more recently hired executives.

 

We have compensated our executives with a combination of salaries, cash bonuses and stock option awards. We think this combination of cash and equity is largely consistent with the forms of compensation provided by other companies with which we compete for executive talent, and as such is a package that matches the expectations of our executives and of the market for executive talent. We also believe that it provides an appropriate blend of compensation to retain our executives, reward them for performance in the short term and induce them to contribute to the creation of value in the Company over the long term.

 

We view the different components of our executive compensation as distinct. We believe we must maintain a salary that is sufficiently competitive to position us to attract the executives that we need and that it is important that our executives perceive that over time they will continue to have the opportunity to earn a salary that they regard as competitive.

 

The ability to earn cash bonuses should incentivize executives to effectively pursue goals established by our Board of Directors and should be regarded by executives as appropriately rewarding effective performance against these goals. We have in the past sought to establish target bonus levels and performance goals for executives at the beginning of the year to help ensure that our performance goals, and the bonus attainable for achieving these goals, were well understood by executives.

 

Our equity awards are also designed to be sufficiently competitive to allow us to attract executives. We have used stock options as the form of equity award for executives. Because our executive officers are awarded stock options with an exercise price equal to the fair market value of our common stock on the date of grant, these options will have value to our named executive officers only if the market price of our common stock increases after the date of grant. Typically, since November 2007 our stock option awards to executive officers vested and became exercisable at a rate of 20% upon the one-year anniversary of grant and then monthly over the following four years. Our Board of Directors believes that these stock option awards align the interests of our named executive officers with those of the stockholders, because they create the incentive to build stockholder value over the long-term. In addition, our Board of Directors believes the five-year vesting provision of our equity awards improves our ability to retain our executives. We have also determined that in order to attract qualified executives in our market it is highly desirable to provide equity compensation that is regarded as competitive relative to the compensation provided by other privately held, venture-backed companies.

 

We grant stock options to executive officers in connection with their hiring. The size of the initial stock option award is determined based on the executive’s position with us and takes into consideration the executive’s

 

104


Table of Contents

base salary and other compensation as well as an analysis of the grant and compensation practices of the companies that participate in the survey that we have reviewed in the past in connection with establishing our overall compensation policies. The initial stock option awards are intended to provide the executive with an incentive to build value in the organization over an extended period of time, while remaining consistent with our overall compensation philosophy. Insofar as we have to date incurred operating losses and consumed substantial amounts of cash in our operations, we have sought to attract executives to join us by compensating for cash salaries and cash bonus opportunities that were, in certain cases, lower than the salaries and bonuses they earned in their prior positions with stock options having the potential to provide significant value if we were successful.

 

We may also grant additional stock option grants in recognition of a commendable performance and in connection with a significant change in responsibilities. Typically, our Board of Directors determines to make equity awards upon the recommendation of the Leadership Development and Compensation Committee. In making its recommendation or determination, the Committee or Board takes into account various factors. These factors include the responsibilities, past performance and anticipated future contribution of the executive officer, the executive’s overall compensation package and the executive’s existing equity holdings.

 

Stock options are granted with an exercise price equal to the fair value of our stock on the applicable date of grant. Upon completion of this offering, we expect to determine fair value for purposes of stock option pricing based on the most recent closing price of our common stock on the stock exchange on which our common stock is listed.

 

As further discussed below, our compensation philosophy for 2009 was significantly influenced by the deteriorating global economic circumstances that began to materialize in late 2008.

 

Compensation Decision Process

 

Historic. Since our formation, our Board of Directors has overseen the compensation of our executive officers and our executive compensation programs and initiatives. While we have had a Compensation Committee of the Board, this committee has acted in an advisory role, assisting the Board of Directors in compensation matters. The Board of Directors has also sought, and received, significant input from our CEO with regard to the performance and compensation of executives other than himself.

 

In making compensation decisions for executive officers, we have referred to compensation survey data of competitive conditions in our market. With regard to annual base salaries and annual cash incentive bonus opportunity targets for fiscal year 2009, our Board of Directors reviewed comprehensive compensation data from the Radford Global Life Sciences Survey, which aggregated survey results from 130 biotechnology, pharmaceutical and medical device companies in Northern California with revenues of less than $1 billion. In addition, certain of our directors have significant experience with privately held venture-backed companies such as our and the executive compensation practices of such companies, and have applied this knowledge and experience to their judgments regarding our compensation decisions.

 

Post-offering . Prior to the completion of this offering, we anticipate that our Leadership Development and Compensation Committee will recommend, and our Board of Directors will adopt, a new charter for our Leadership Development and Compensation Committee which will expand the committee’s responsibilities. Currently, our Leadership Development and Compensation Committee is comprised of Messrs. Doerr and Kaul and Dr. Duyk. In accordance with the amended charter, the Committee will determine the annual compensation of our CEO and other executive officers and will regularly report its compensation decisions to the full Board of Directors. The Committee will also administer our equity compensation plans, including our 2010 Equity Incentive Plan and 2010 Employee Stock Purchase Plan, which will become effective on or shortly after the date of this prospectus.

 

The Committee has not yet made significant decisions about the process that it will employ in performing these functions. All of our named executive officers continue to be paid the same salary that was in place at the

 

105


Table of Contents

end of 2009. We have retained Compensia, a compensation advisory firm, to support the Leadership Development and Compensation Committee in developing our compensation structure as a publicly-held company. We expect that the Leadership Development and Compensation Committee, with assistance from Compensia, will develop a peer group of companies to which it will refer in making compensation decisions regarding executive compensation.

 

2009 Compensation

 

In the final months of 2008, our Board of Directors recognized that the dramatically deteriorating condition of the global economy was likely to have an adverse affect on our business and prospects, at least in the near term. In the face of the challenging conditions of the financial markets at that time, our ability to continue to fund our operations through private placements of equity securities was uncertain.

 

In light of these conditions, in late 2008 our Board of Directors elected to forego our customary year-end process of considering changes in salaries for executive officers. Instead, the Board of Directors froze salaries at the time for all executive officers, as salaries were frozen for virtually all our employees. As a result, Mr. Melo’s and Ms. Tompkins’ salaries remained at the same level as had been in place since January 2008, the last previous time that their salaries were increased. The salaries of Ms. Hilleman and Messrs. Cherry and Lievense remained at the same levels as had been established at the times that they were hired by us, between December 2007 and November 2008.

 

The Board of Directors also elected at this time not to put in place a cash bonus program for executives as it had in 2007-2008. In addition, the Board of Directors determined not to pay any cash bonuses to executives for services rendered in 2008.

 

Later in 2009, it appeared that the deterioration in global economic conditions had slowed, if not ceased. Activity in the public equity markets in the U.S. and in venture capital financings began to suggest that the ability for privately held companies to raise capital, while still challenging, was improving from the conditions existing in late 2008 and most of 2009. Recognizing this improvement, the Board approved an increase in the annual salary of our CEO by $100,000, to $500,000, effective December 1, 2009. This salary increase was made in recognition of raising private equity through the sale of our Series C convertible preferred stock, progress that was made with sugar and ethanol producers for securing production capacity in Brazil and expansion of the management team through the hiring of a chief operating officer and chief commercial officer. In addition, the Board of Directors approved, also effective December 1, 2009, an increase in the annual salary of our General Counsel of $29,500, to $300,000, recognizing that Ms. Tompkins’ responsibilities had increased substantially as we continued to increase the size and scope of our operations and that her salary was lower than that of the other named executive officers by approximately this amount. The Board of Directors also took into account that each of these officers last received a salary increase effective January 1, 2008.

 

In the second half of 2009, the Board of Directors also approved a bonus payment to Mr. Melo of $200,000 in recognition of the factors described above that were considered in approving Mr. Melo’s salary increase. Mr. Melo and the Board of Directors approved the amounts of cash bonus payments to each of the other named executive officers as are set forth in the Summary Compensation Table appearing below. The bonuses were made in recognition of the support of these executives in the achievement of the factors considered by the Board in approving Mr. Melo’s salary increase. In awarding these bonuses, the Board of Directors also took account of the fact that, other than Ms. Tompkins, none of these executive officers had received a salary increase or bonus since joining us.

 

In 2009, we granted stock options to three of our named executive officers. In September 2009, we granted options for the purchase of 210,000 shares to Mr. Cherry pursuant to the commitment we made at the time of hiring Mr. Cherry to grant him this number of stock options. Options for the purchase of 50,000 shares were granted to Mr. Leivense in recognition of the substantial and effective efforts made to oversee the development of our pilot and demonstration facilities in Brazil in 2009. Options for the purchase of 10,000 shares were granted

 

106


Table of Contents

to Ms. Tompkins in order to bring her aggregate option position closer in line with the option holdings of more recently hired executives and in recognition of efforts made in connection with the further development of Amyris Brasil and the joint venture with Usina São Martinho.

 

Severance and Change of Control Agreements

 

We have entered into offer letters, or amendments to offer letters, with each of our named executive officers providing for certain payments upon termination of their employment with us without cause and upon termination without cause following a change of control. These payments, and the definition for this purpose of change of control, are described in detail below under Potential Severance Payments upon Termination and upon Termination Following a Change in Control .

 

We believe that these agreements appropriately balance our needs to offer a competitive level of severance protection to our executives and to induce our executives to remain in our employ through the potentially disruptive conditions that may exist around the time of a change in control, while not unduly rewarding executives for a termination of their employment. We note that our change in control terms include so-called “double trigger” provisions, so that the executive is not entitled to the severance payment by the mere occurrence of the change in control. We believe this feature, will be an incentive to the executive to remain in the employ of the company if such continuation is required by our partner in a change in control transaction. We also believe that it is appropriate that our executives’ equity awards be treated, in the event of a change of control, like those of other employees and not accelerated if the executive’s employment continues following the change in control event.

 

Other Executive Benefits and Perquisites

 

We provide the following benefits to our executive officers on the same basis as other eligible employees:

 

   

health insurance;

 

   

vacation, personal holidays and sick days;

 

   

life insurance and supplemental life insurance;

 

   

short-term and long-term disability; and

 

   

a 401(k) plan.

 

We believe these benefits are generally consistent with those offered by other companies with which we compete for executive talent.

 

Some of the executives whom we have hired, including Mr. Melo, held positions in locations outside of Northern California at the time that they agreed to join us. We have agreed in these instances to pay relocation expenses to these executives, including costs associated with commuting from our facilities to their family’s home outside of Northern California. The amounts paid in 2009 to named executive officers are included in the “All Other Compensation” column in the Summary Compensation Table below. Given the cost of living in the San Francisco Bay Area relative to most other metropolitan areas in the U.S., we believe that in order for us not to be limited to hiring executives located near our headquarters in Emeryville, California, that we must be willing to offer to pay an agreed upon amount of relocation costs.

 

Other Compensation Practices and Policies

 

Tax Considerations.  Section 162(m) of the Internal Revenue Code disallows a tax deduction for any publicly held corporation for individual compensation exceeding $1.0 million in any taxable year for our president and chief executive officer and each of the other named executive officers (other than our chief financial officer), unless compensation is performance based. As we are not currently publicly-traded, our board of directors has not previously taken the deductibility limit imposed by Section 162(m) into consideration in

 

107


Table of Contents

setting compensation. We expect that our Leadership Development and Compensation Committee will adopt a policy at some point in the future that, where reasonably practicable, we will seek to qualify the variable compensation paid to our executive officers for an exemption from the deductibility limitations of Section 162(m). Until such policy is implemented, our Leadership Development and Compensation Committee may, in its judgment, authorize compensation payments that do not consider the deductibility limit imposed by Section 162(m) when it believes that such payments are appropriate to attract and retain executive talent.

 

Policy regarding the timing of equity awards.  As a privately-owned company, there has been no market for our common stock. Accordingly, in fiscal 2009, we had no program, plan or practice pertaining to the timing of stock option grants to executive officers coinciding with the release of material non-public information. We do not, as of yet, have any plans to implement such a program, plan or practice after becoming a public company. However, we intend to implement policies to ensure that equity awards are granted at fair market value on the date that the grant action occurs.

 

Policy regarding restatements.  We do not have a formal policy regarding adjustment or recovery of awards or payments if the relevant performance measures upon which they are based are restated or otherwise adjusted in a manner that would reduce the size of the award or payment. Under those circumstances, our Board of Directors or the Leadership Development and Compensation Committee would evaluate whether adjustments or recoveries of awards were appropriate based upon the facts and circumstances surrounding the restatement.

 

Stock Ownership Policies . We have not established stock ownership or similar guidelines with regards to our executive officers. All of our executive officers currently have a direct or indirect, through their stock option holdings, equity interest in our company, and we believe that they regard the potential returns from these interests as a significant element of their potential compensation for services to us.

 

Summary Compensation Table

 

The following table sets forth information regarding compensation earned by our chief executive officer, our chief financial officer and each of our three other most highly compensated executive officers during 2009. We refer to these executive officers as our “named executive officers” elsewhere in this prospectus:

 

Name and Principal Position

   Year    Salary($)    Bonus($) (1)    Option
Awards($) (2)
   All Other
Compensation($)
    Total($)

John Melo

   2009    408,333    200,000       $ 221,617 (3)     829,950

President and Chief Executive Officer

                

Joel Cherry, Ph.D.

   2009    310,000    74,683    709,737           1,094,420

Senior Vice President, Research Programs and Operations

                

Jeryl Hilleman

   2009    300,000    149,365         18,833 (4)     468,198

Chief Financial Officer

                

Jefferson Lievense, Ph.D.

   2009    300,000    44,810    168,985      76,048 (5)     589,843

Senior Vice President, Process Development and Manufacturing

                

Tamara Tompkins

   2009    272,867    37,341    33,797      18,743 (6)     362,748

Senior Vice President and General Counsel

                

 

  (1)   The amounts reported in this column represent discretionary bonuses determined by the Board of Directors.
  (2)  

The amounts in the “Option Awards” column reflect the aggregate grant date fair value computed in accordance with ASC Topic 718. The assumptions used by us in determining the grant date fair

 

108


Table of Contents
 

value of option awards are set forth in Note 13 to our Consolidated Financial Statements included elsewhere in this prospectus. See the “Grants of Plan-Based Awards” table for information on stock option grants made in fiscal 2009. These amounts do not correspond to the actual value that may be recognized by the named executive officers.

  (3)   Includes $145,907 for reimbursement for temporary housing and relocation expenses, $56,877 gross-up to pay associated taxes and $18,833 of health and life insurance premiums paid on behalf of Mr. Melo.
  (4)   Represents health and life insurance premiums paid on behalf of Ms. Hilleman.
  (5)   Includes $38,390 for reimbursement for temporary housing and relocation expenses, $18,825 gross-up to pay associated taxes and $18,833 of health and life insurance premiums paid on behalf of Mr. Lievense.
  (6)   Represents health and life insurance premiums paid on behalf of Ms. Tompkins.

 

Grants of Plan-Based Awards

 

The following table sets forth information regarding grants of compensation in the form of plan-based awards made during 2009 to our named executive officers.

 

Name

   Grant Date    All Other
Option  Awards:
Number of  Securities
Underlying
Options (#) (1)
   Exercise or
Base Price
of Option
Awards

($/Sh) (2)
   Grant Date
Fair Value
of Option
Awards ($) (3)

John Melo

           

Joel Cherry, Ph.D.

   09/14/2009    210,000    4.31    709,737

Jeryl Hilleman

           

Jefferson Lievense, Ph.D.

   09/14/2009    50,000    4.31    168,985

Tamara Tompkins

   09/14/2009    10,000    4.31    33,797

 

  (1)   Grants vest as to 20% of the original number of shares on the first anniversary of the vesting commencement date, which is a date fixed by our Board of Directors when granting options, and as to an additional 1/60th of the original number of shares each month thereafter until the fifth anniversary of the vesting commencement date, subject to continued service through each relevant vesting date. Notwithstanding, grants are subject to certain rights to acceleration of vesting upon a change in control of our company and termination of employment following a change in control, as further described below in “Executive Compensation—Potential Payments upon Termination and upon Termination Following a Change in Control.” All options were granted under our 2005 Stock Option/Stock Issuance Plan, which is described below under “Executive Compensation—Stock Option and Other Compensation Plans.”
  (2)   Represents the fair market value of a share of our common stock, as determined by our Board of Directors, on the respective option grant date. For a discussion of our methodology for determining the fair value of our common stock, see the “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates” section of this prospectus.
  (3)   Reflects the grant date fair value of each award computed in accordance with FASB ASC Topic 718. These amounts do not correspond to the actual value that will be recognized by the named executive officers. Our assumptions with respect to the calculation of stock-based compensation expenses are set forth above in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates—Stock-Based Compensation”. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our Consolidated Financial Statements included elsewhere in this prospectus.

 

109


Table of Contents

Outstanding Equity Awards at Fiscal Year End

 

The following table sets forth information regarding outstanding equity awards held as of December 31, 2009 by our named executive officers.

 

Name

   Number of
Securities
Underlying
Unexercised
Options that are
Exercisable  (#) (1) (2)
    Number of
Securities
Underlying
Unexercised
Options that are
Unexercisable (#)
   Option
Exercise
Price ($/Sh)
   Option
Expiration
Date

John Melo

   279,979 (3)        3.93    8/26/2018
   925,000 (4)        0.28    1/18/2017

Joel Cherry, Ph.D.

   210,000 (5)        4.31    9/13/2019

Jeryl Hilleman

   184,555 (6)        3.93    2/26/2018

Jefferson Lievense, Ph.D.

   50,000 (7)        4.31    9/13/2019
   200,000 (8)        3.93    12/12/2017

Tamara Tompkins

   10,000 (9)        4.31    9/13/2019
   100,000 (10)        0.28    5/8/2017

 

  (1)   All options granted to our named executive officers are immediately exercisable, regardless of vesting schedule.
  (2)   All options vest as to 20% of the original number of shares on the first anniversary of the vesting commencement date, which is a date fixed by our Board of Directors when granting options, and as to an additional 1/60th of the original number of shares each month thereafter until the fifth anniversary of the vesting commencement date.
  (3)   The vesting commencement date of this grant is 6/3/2008.
  (4)   The vesting commencement date of this grant is 10/23/2006.
  (5)   The vesting commencement date of this grant is 11/3/2008.
  (6)   The vesting commencement date of this grant is 1/28/2008.
  (7)   The vesting commencement date of this grant is 10/1/2008.
  (8)   The vesting commencement date of this grant is 12/3/2007.
  (9)   The vesting commencement date of this grant is 10/1/2008.
  (10)   The vesting commencement date of this grant is 11/6/2006.

 

Stock Option Exercises During Fiscal Year 2009

 

The following table shows information regarding option exercises by our named executive officers during fiscal year 2009.

 

     Option Awards

Name

   Number of
Shares Acquired
on Exercise (#)
   Value Realized
on Exercise
($) (1)

John Melo

   75,000    302,250

 

  (1)   The aggregate dollar value realized upon exercise of an option represents the difference between the aggregate fair market value of our common stock underlying the option on the date of exercise, which was determined by our Board of Directors to be approximately $4.31 per share, and the aggregate exercise price of the option, which was $21,000, based on a $0.28 exercise price per share.

 

110


Table of Contents

Pension Benefits

 

None of our named executive officers participates in, or has an account balance in, a qualified or non-qualified defined benefit plan sponsored by us.

 

Non-Qualified Deferred Compensation

 

None of our named executive officers participates in, or has account balances in, a traditional non-qualified deferred compensation plan or other deferred compensation plans maintained by us.

 

Potential Severance Payments upon Termination and upon Termination Following a Change in Control

 

The initial offer letters and amendments of the offer letters of Messrs. Melo, Cherry and Lievense, Ms. Hilleman and Ms. Tompkins provide that, if we terminate the employment of the respective named executive officer for any reason other than for cause, he or she will receive severance equal to 12 months of base salary, payable in accordance with our regular payroll practices. These payments will be terminated as of the date of commencement of employment with another employer. In addition, in the event of such termination, the respective named executive officer will receive COBRA benefits until the earlier of (i) 12 months from termination and (ii) commencement of employment with another employer.

 

We have also agreed that in the event we terminate any of our named executive officers without cause or constructively terminate the employment of any of our named executive officers, in either case within six months of a change of control of Amyris, the terminated individual will receive the benefits described in the preceding paragraph and accelerated vesting of 50% of any of his or her unvested options as of the date of termination.

 

As a condition to receipt of any of the benefits set forth in the preceding two paragraphs, the respective named executive officer must execute a release of claims in our favor and return to us any of our property and confidential information in his or her possession. In addition, to receive his severance and change of control benefits, Mr. Melo must resign from our Board of Directors.

 

For purposes of the above benefits, a change of control includes (i) any transaction after which our then current stockholders own less than 50% of the voting power of the surviving entity or its parent; (ii) a merger, reorganization or consolidation or other acquisition of Amyris after which our then-current stockholders transfer more than a majority of the voting power of the Company; and (iii) a sale of all or substantially all of our assets. Constructive termination means resignation of employment within 120 days after any of the following events, each of which must occur within five months of our change of control with respect to Jeryl Hilleman and John Melo and within six months of our change of control with respect to Joel Cherry, Tamara Tompkins and Jeff Lievense: a material reduction in responsibilities or base salary (unless the reduction is comparable to and part of a reduction of all executive officers) or a relocation of principal office more than 50 miles from the location of the named executive officer’s office immediately before a change of control. If an event constituting grounds for constructive termination occurs, the respective named executive officer must give us notice of it within 90 days and we have 30 days to remedy the condition caused by that event. Cause is determined by our Board of Directors and includes any of the following: (i) failure or refusal to comply in any material respect with any of our policies; (ii) a violation of law or regulation applicable to our business; (iii) conviction or plea of no contest to a felony and in addition, in some instances a misdemeanor involving moral turpitude under the laws of the United States or any state; (iv) fraud or misappropriation of our property; (v) non-performance, non-compliance or interference with the other party’s performance under the terms of any confidentiality, invention assignment or proprietary information agreement with us or with a former employer, (vi) failure to satisfactorily perform duties after having received written notice of such failure and at least 30 days to cure such failure, or (vii) misconduct or gross negligence in connection with the performance of employment duties to us.

 

To the extent any severance benefits to a named executive officer constitute deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended, and that officer is deemed a “specified

 

111


Table of Contents

employee” under Section 409A, then we will defer payment of these benefits to the extent necessary to avoid adverse tax treatment.

 

The following table summarizes the potential payments and benefits payable to each of our named executive officers upon (i) termination of employment other than for cause and (ii) termination without cause or constructive termination following a change in our control, modeling, in each situation, that termination and change of control, where applicable, occurred on December 31, 2009.

 

     Qualifying Termination Other Than for
Cause not in Connection with a Change
of Control
   Qualifying Change of Control and Termination
Without Cause or Constructive Termination
Within 6 Months Following a Change of
Control

Name

   Base
Salary($) (1)
   COBRA
Benefits($) (1)
   Value of
Accelerated
Options or
Shares($)
   Base
Salary($) (1)
   COBRA
Benefits($) (1)
   Value of
Accelerated
Options or
Shares($) (2)

John Melo

   408,333    24,608       408,333    24,608    4,371,034

Joel Cherry, Ph.D.

   310,000    275       310,000    275    824,145

Jeryl Hilleman

   300,000    24,608       300,000    24,608    613,431

Jefferson Lievense, Ph.D.

   300,000    24,608       300,000    24,608    838,853

Tamara Tompkins

   272,867    24,608       272,867    24,608    384,951

 

  (1)   The amounts in this column assume that the respective named executive officer has not started employment with another company before the expiration of 12 months from termination of his or her employment with us.
  (2)   With respect to outstanding options as of December 31, 2009, this amount is equal to (a) the number of shares underlying unexercised options that would vest as a direct result of employment termination without cause or constructive termination following a change of control, assuming a December 31, 2009, change of control and employment termination, multiplied by (b) the excess of $9.32, which represents our Board of Directors’ determination of the fair market value of our common stock as of December 31, 2009, over the exercise price of the option. With respect to unvested shares held by the named executive officer, this amount is equal to (a) the number of unvested shares that would vest as a direct result of employment termination without cause or constructive termination following a change of control, assuming a December 31, 2009, change of control and employment termination, multiplied by (b) $9.32.

 

Agreements with Executives

 

We do not have formal employment agreements with any of our named executive officers. The initial compensation of each named executive officer was set forth in an offer letter that we executed with him or her at the time his or her employment with us commenced and that was later amended. Each offer letter provides that the named executive officer’s employment is at will.

 

As a condition to their employment, our named executive officers entered into non-competition, non-solicitation and proprietary information and inventions assignment agreements. Under these agreements, each named executive officer has agreed (i) not to solicit our employees during his or her employment and for a period of 12 months after the termination of his or her employment, (ii) not to compete with us or assist any other person to compete with us during the officer’s employment with us and (iii) to protect our confidential and proprietary information and to assign to us intellectual property developed during the course of his or her employment.

 

See above “Executive Compensation—Potential Payments upon Termination and upon Termination Following a Change in Control” for a description of potential payments to our named executive officers on a change of control.

 

112


Table of Contents

Stock Option and Other Compensation Plans

 

2005 Stock Option/Stock Issuance Plan

 

Background . Our Board of Directors adopted, and our stockholders approved, our 2005 Stock Option/Stock Issuance Plan in September 2005. We reserved a pool of shares of our common stock for issuance to employees and other service providers pursuant to awards granted under our 2005 Stock Option/Stock Issuance Plan, as amended. It provides for awards under two separate equity programs: (i) the Option Grant Program, under which eligible persons may be granted options, and (ii) the Stock Issuance Program, under which eligible persons may be granted stock purchase rights, awards of shares as a bonus for services rendered, or restricted stock units or other share awards which vest upon completion of a service period or performance milestones. The 2005 Stock Option/Stock Issuance Plan is administered by our Board of Directors, which may delegate administrative responsibilities to a committee.

 

Option Grant Program . Our 2005 Stock Option/Stock Issuance Plan provides for the grant of both incentive stock options, or ISOs, that qualify for favorable tax treatment under Section 422 of the Internal Revenue Code for their recipients and nonqualified stock options, or NSOs. ISOs may be granted only to our employees or employees of any of our subsidiaries. NSOs may be granted to employees, officers, non-employee directors, consultants and other independent advisors who provide services to us or any of our subsidiaries. The options’ exercise price must be at least equal to the fair market value of our common stock on the date of grant. The exercise price of options granted to 10% stockholders must be at least equal to 110% of the fair market value of our common stock on the date of grant. Payment of the option exercise price may be made in cash (including by check), with a full-recourse promissory note if authorized by the plan administrator, or following the registration of our common stock under the Securities Exchange Act, by surrender of shares or through a broker-assisted cashless exercise program. The maximum permitted term of options granted under our 2005 Stock Option/Stock Issuance Plan is ten years from the date of grant (five years for incentive stock options granted to 10% stockholders). The plan administrator may grant options subject to vesting restrictions but options granted to individuals who are not officers, non-employee directors or independent contractors cannot vest less than 20% per year. In the event of a change in control, the 2005 Stock Option/Stock Issuance Plan provides that unvested options that are not assumed or replaced by the successor corporation will vest in full immediately prior to such change in control and all options will expire on the consummation of the change in control or subject to other treatment imposed by the Board of Directors or the committee administering the 2005 Stock Option/Stock Issuance Plan in connection with a change in control. Our Board of Directors or Leadership Development and Compensation Committee has authority to grant additional acceleration rights upon change of control to holders of options issued pursuant to the 2005 Stock Option/Stock Issuance Plan.

 

As of June 21, 2010, options to purchase 6,227,980 shares of our common stock granted from the 2005 Stock Option/Stock Issuance Plan remained outstanding and 134,592 shares of our common stock remained available for issuance upon the exercise of awards that may be granted from the 2005 Stock Option/Stock Issuance Plan. The options outstanding as of June 21, 2010, had a weighted-average exercise price of approximately $5.91 per share.

 

Stock Issuance Program . Our 2005 Stock Option/Stock Issuance Plan provides for direct issuances of shares of our common stock and issuances of share right awards or restricted stock units which entitle the recipients to receive the underlying shares upon completion of specified service periods or performance goals. We may issue stock, share right awards and restricted stock units to employees, officers, directors, consultants and other independent advisors who provide services to us or any of our subsidiaries. The issue price per share must be equal to at least the fair market value per share of our common stock on the issue date. The recipient may pay the purchase price of the shares in cash (including by check), in past services rendered to us or any of our subsidiaries, or by tendering any other valid consideration under the California Corporations Code. The shares that we issue pursuant to the Stock Issuance Program may be subject to vesting restrictions based on length of service or attainment of specified performance goals, as determined by our Board of Directors or Leadership Development and Compensation Committee, but no awards made to individuals who are not officers, non-employee directors, or independent consultants may vest less than 20% per year. In the event of a change in control, the 2005 Stock Option/Stock Issuance Plan provides that unvested shares issued pursuant to the plan will vest in full immediately prior to such

 

113


Table of Contents

change in control unless the repurchase rights underlying such awards are assigned to the successor corporation, continued, or unless accelerated vesting is precluded by the documents evidencing the award.

 

Our 2010 Equity Incentive Plan will be effective upon the completion of this offering. As a result, no awards will be granted from the 2005 Stock Option/Stock Issuance Plan after the date of this prospectus and the 2005 Stock Option/Stock Issuance Plan will terminate. However, any outstanding awards granted from the 2005 Stock Option/Stock Issuance Plan will remain outstanding, subject to the terms of our 2005 Stock Option/Stock Issuance Plan and the applicable award agreements, until the awards are exercised or until they terminate or expire by their terms.

 

2010 Equity Incentive Plan

 

Background. Our Board of Directors has adopted a 2010 Equity Incentive Plan that will serve as the successor equity compensation plan to our 2005 Stock Option/Stock Issuance Plan. We have reserved 4,200,000 shares of our common stock to be issued under our 2010 Equity Incentive Plan. Our 2010 Equity Incentive Plan will become effective on the date of our initial public offering and will terminate in 2020. Our 2010 Equity Incentive Plan will provide for the grant of incentive stock options, nonqualified stock options, restricted stock awards, stock bonuses, stock appreciation rights, restricted stock units and performance awards.

 

Administration. Our 2010 Equity Incentive Plan will be administered by our Leadership Development and Compensation Committee, all of the members of which are non-employee directors under applicable federal securities laws and outside directors as defined under applicable federal tax laws. This Leadership Development and Compensation Committee will act as the plan administrator and will have the authority to construe and interpret the plan, grant awards, determine the terms and conditions of awards and make all other determinations necessary or advisable for the administration of the plan (subject to the limitations set forth in our 2010 Equity Incentive Plan).

 

Share Reserve. We have reserved 4,200,000 shares of our common stock for issuance under our 2010 Equity Incentive Plan plus:

 

   

all shares of our common stock reserved under our 2005 Stock Option/Stock Issuance Plan that are not issued or subject to outstanding grants as of the completion of this offering;

 

   

any shares issuable upon exercise of options granted under our 2005 Stock Option/Stock Issuance Plan that cease to be subject to such stock options; and

 

   

any shares of our common stock issued under our 2005 Stock Option/Stock Issuance Plan that are forfeited or repurchased by us at the original purchase price.

 

The number of shares available for grant and issuance under the 2010 Equity Incentive Plan will be increased on January 1 of each of the calendar years that commence after our initial public offering by an amount equal to the lesser of (1) five percent of our shares outstanding on the immediately preceding December 31 and (2) a number of shares as may be determined by our Board of Directors or Leadership Development and Compensation Committee in their discretion. In addition, shares will again be available for grant and issuance under our 2010 Equity Incentive Plan that are:

 

   

subject to issuance upon exercise of an option or stock appreciation right granted under our 2010 Equity Incentive Plan and that cease to be subject to such award for any reason other than the award’s exercise;

 

   

subject to an award granted under our 2006 Equity Incentive Plan and that are subsequently forfeited or repurchased by us at the original issue price;

 

   

surrendered pursuant to an exchange program; or

 

   

subject to an award granted under our 2010 Equity Incentive Plan that otherwise terminates without shares being issued.

 

114


Table of Contents

Equity Awards. Our 2010 Equity Incentive Plan will permit us to grant the following types of awards:

 

Stock Options. Our 2010 Equity Incentive Plan will provide for the grant of incentive stock options, or ISOs, to employees, and nonqualified stock options, or NSOs, to employees, non-employee directors and consultants. We will be able to issue no more than 30,000,000 shares pursuant to the grant of ISOs under the 2010 Equity Incentive Plan. The Leadership Development and Compensation Committee will determine the terms of each option award, provided that ISOs will be subject to statutory limitations. The Leadership Development and Compensation Committee will determine the exercise price for a stock option, provided that the exercise price of an option may not be less than 100% (or 110% in the case of recipients of ISOs who hold more than 10% of our stock on the option grant date) of the fair market value of our common stock on the date of grant. Options granted under our 2010 Equity Incentive Plan will vest at the rate specified by the Leadership Development and Compensation Committee and such vesting schedule will be set forth in the stock option agreement to which such stock option grant relates. Generally, the Leadership Development and Compensation Committee will determine the term of stock options granted under our 2010 Equity Incentive Plan, up to a term of ten years (or five years in the case of ISOs granted to 10% stockholders).

 

After termination of an optionee, he or she will be able to exercise his or her vested option for the period of time stated in the stock option agreement to which such option relates, up to a maximum of five years from the date of termination. Generally, if termination is due to death or disability, the vested option will remain exercisable for 12 months. If an optionee is terminated for cause (as defined in our 2010 Equity Incentive Plan), then the optionee’s options will expire on the optionee’s termination date or at such later time and on such conditions as determined by our Leadership Development and Compensation Committee. In all other cases, the vested option will generally remain exercisable for three months. However, an option may not be exercised later than its expiration date.

 

Restricted Stock Awards. A restricted stock award is an offer by us to sell shares of our common stock subject to restrictions that the Leadership Development and Compensation Committee may impose. These restrictions may be based on completion of a specified period of service with us or upon the completion of performance goals during a performance period. The Leadership Development and Compensation Committee will determine the price of a restricted stock award. Unless otherwise set forth in the award agreement, vesting will cease on the date the participant no longer provides services to us, and at that time unvested shares are forfeited to us or subject to repurchase by us.

 

Stock Bonus Awards. A stock bonus is an award of shares of our stock for past or future services to us. Stock bonuses will be granted as additional compensation for performance and, therefore, will not be issued in exchange for cash. The Leadership Development and Compensation Committee will determine the number of shares to be issued as stock bonus and any restrictions on those shares. These restrictions may be based on completion of a specified period of service with us or upon the completion of performance goals during a performance period. Unless otherwise set forth in the award agreement, vesting will cease on the date the participant no longer provides services to us, and at that time unvested shares will be forfeited to us or will be subject to repurchase by us.

 

Stock Appreciation Rights. Stock appreciation rights provide for a payment, or payments, in cash or shares of our common stock to the holder based upon the difference between the fair market value of our common stock on the date of exercise and the stated exercise price. Stock appreciation rights may vest based on time or achievement of performance conditions.

 

Restricted Stock Units. Restricted stock units represent the right to receive shares of our common stock at a specified date in the future, subject to forfeiture of such right due to termination of employment or failure to achieve specified performance conditions. If the restricted stock unit has not been forfeited, then on the date specified in the restricted stock unit agreement we will deliver to the holder of the restricted stock unit shares of our common stock, cash or a combination of our common stock and cash.

 

115


Table of Contents

Performance Awards . A performance award is an award of a cash bonus or a bonus denominated in shares that are subject to performance factors. The award of performance shares may be settled in cash or by issuance of those shares (which may consist of restricted stock).

 

Change in Control. If we undergo a corporate transaction (as defined in our 2010 Equity Incentive Plan), our 2010 Equity Incentive Plan provides that the successor company (if any) may assume, convert, replace or substitute outstanding awards. Outstanding awards that are not so assumed, converted, replaced or substituted will have their vesting accelerate and become exercisable in full.

 

Transferability of Awards. Unless the Leadership Development and Compensation Committee provides otherwise, our 2010 Equity Incentive Plan does not allow for the transfer of awards, other than by will or the laws of descent and distribution, and generally only the recipient of an award may exercise it during his or her lifetime. The Leadership Development and Compensation Committee will have discretion to determine and implement award transfer programs to give participants the opportunity to transfer any outstanding awards to a financial institution or other person or entity approved by the Leadership Development and Compensation Committee. As part of such a program, the Leadership Development and Compensation Committee will have the authority to amend any terms of awards included in the program, including expiration date, post-expiration exercise period, vesting and forfeiture conditions, permitted payment methods, and adjustments in the event of capitalization changes and other similar events.

 

Eligibility. The individuals eligible to participate in our 2010 Equity Incentive Plan will include our employees, officers, directors, consultants, independent contractors and advisors or any parent or subsidiary of ours, provided the consultants, independent contractors and advisors render services not in connection with the offer and sale of securities in a capital-raising transaction.

 

Payment for Purchase of Shares of our Common Stock. Payment for shares of our common stock purchased pursuant to our 2010 Equity Incentive Plan may be made by any of the following methods (provided such method is permitted in the applicable award agreement to which such shares relate): (1) cash (including by check); (2) cancellation of indebtedness; (3) surrender of shares; (4) waiver of compensation due or accrued for services rendered; (5) through a broker-assisted sale or other cashless exercise program, or (6) by any other method approved by our Board of Directors.

 

Limit on Awards. Under our 2010 Equity Incentive Plan, during any calendar year, no person will be eligible to receive more than 1,000,000 shares of our common stock, and in the case of new employees during their first fiscal year of employment with us 2,000,000 shares of our common stock.

 

Amendment and Termination. Our Board of Directors will be able to amend or terminate our 2010 Equity Incentive Plan at any time, subject to stockholder approval where required. In addition, we cannot make an amendment that is detrimental to an outstanding award without the consent of the affected participant.

 

2010 Employee Stock Purchase Plan

 

Background. Our Board of Directors has adopted a 2010 employee stock purchase plan designed to enable eligible employees to periodically purchase shares of our common stock at a discount. Our 2010 employee stock purchase plan will become effective on the date of our initial public offering. Purchases will be accomplished through participation in discrete offering periods. Our 2010 employee stock purchase plan will be intended to qualify as an employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended.

 

Share Reserve. We have reserved 168,627 shares of our common stock for issuance under our 2010 Employee Stock Purchase Plan. During the first eight years of the life of the plan, the number of shares reserved for issuance will increase automatically on the first day of each January, starting with January 1, 2011, by the number of shares equal to one percent of our total outstanding shares as of the immediately preceding December 31st. Our Board of Directors or Leadership Development and Compensation Committee will be able to reduce the amount of the increase in any particular year. No more than 10,000,000 shares of our common

 

116


Table of Contents

stock may be issued under our 2010 Employee Stock Purchase Plan and no other shares may be added to this plan without the approval of our stockholders.

 

Administration. Our Leadership Development and Compensation Committee will administer our 2010 Employee Stock Purchase Plan. Employees who are five percent stockholders, or would become five percent stockholders as a result of their participation in our 2010 Employee Stock Purchase Plan, are ineligible to participate in our 2010 Employee Stock Purchase Plan. We may impose additional restrictions on eligibility as well. Under our 2010 Employee Stock Purchase Plan, eligible employees will be able to acquire shares of our common stock by accumulating funds through payroll deductions. Our eligible employees will be able to select a rate of payroll deduction between one percent and 15% of their cash compensation. We will also have the right to amend or terminate our 2010 Employee Stock Purchase Plan, except that, subject to certain exceptions, no such action may adversely affect any outstanding rights to purchase stock under the plan. Our 2010 Employee Stock Purchase Plan will terminate on the tenth anniversary of the first offering date, unless it is terminated earlier by our Board of Directors.

 

Purchase Rights. When an offering period commences, our employees who meet the eligibility requirements for participation in that offering period will be automatically granted a non-transferable option to purchase shares in that offering period. Each offering period may run for no more than 24 months and consist of no more than five purchase periods. An employee’s participation will automatically end upon termination of employment for any reason.

 

No participant will have the right to purchase our shares at a rate which, when aggregated with purchase rights under all our employee stock purchase plans that are also outstanding in the same calendar year(s), have a fair market value of more than $25,000, determined as of the first day of the applicable offering period, for each calendar year in which such right is outstanding. The purchase price for shares of our common stock purchased under our 2010 Employee Stock Purchase Plan will be 85% of the lesser of the fair market value of our common stock on (1) the first trading day of the applicable offering period and (2) the last trading day of each purchase period in the applicable offering period.

 

Change in Control. In the event of a corporate transaction (as defined in our 2010 Employee Stock Purchase Plan), the successor company may assume or substitute the outstanding rights to purchase shares under our 2010 Employee Stock Purchase Plan. If the successor company refuses to assume or substitute the outstanding rights, the offering period for such purchase rights will be shortened and end on a new purchase date on or prior to the consummation of the corporate transaction and no new offering period will commence.

 

401(k) Plan

 

We maintain a deferred savings retirement plan for our U.S. employees. The deferred savings retirement plan is intended to qualify as a tax-qualified plan under Section 401 of the Internal Revenue Code. Contributions to the deferred savings retirement plan are not taxable to employees until withdrawn from the plan. The deferred savings retirement plan provides that each participant may contribute his or her pre-tax compensation (up to a statutory limit, which is $16,500 in 2010). For employees 50 years of age or older, an additional catch-up contribution of $5,500 is allowable. Under the plan, each employee is fully vested in his or her deferred salary contributions. The deferred savings retirement plan also permits us to make additional discretionary contributions, subject to established limits and a vesting schedule.

 

Limitation of Liability and Indemnification

 

Our certificate of incorporation, which will become effective immediately prior to the completion of this offering, limits the personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the Delaware General Corporation Law and provides that no director will have personal liability to us or to our stockholders for monetary damages for breach of fiduciary duty or other duty as a director. However, these provisions do not eliminate or limit the liability of any of our directors:

 

   

for any breach of the director’s duty of loyalty to us or our stockholders;

 

117


Table of Contents
   

for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;

 

   

for voting or assenting to unlawful payments of dividends, stock repurchases or other distributions; or

 

   

for any transaction from which the director derived an improper personal benefit.

 

Any amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to such amendment or repeal. If the Delaware General Corporation Law is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of our directors will be further limited to the greatest extent permitted by the Delaware General Corporation Law.

 

In addition, our amended and restated bylaws, which will become effective immediately prior to the completion of this offering, provide that we must indemnify our directors and officers and we must advance expenses, including attorneys’ fees, to our directors and officers in connection with legal proceedings, subject to very limited exceptions.

 

We maintain an insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.

 

Certain of our non-employee directors may, through their relationships with their employers, be insured and/or indemnified against certain liabilities incurred in their capacity as members of our Board of Directors.

 

Prior to completion of this offering, we intend to enter into indemnification agreements with each of our directors and executive officers that may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements may require us, among other things, to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements may also require us to advance all expenses incurred by the directors and executive officers in investigating or defending any such action, suit or proceeding. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.

 

At present, we are not aware of any pending litigation or proceeding involving any person who is or was one of our directors, officers, employees or other agents or is or was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, for which indemnification is sought, and we are not aware of any threatened litigation that may result in claims for indemnification.

 

The underwriting agreement provides for indemnification by the underwriters of us and our officers, directors and employees for certain liabilities arising under the Securities Act or otherwise.

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling our company pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

 

Rule 10b5-1 Sales Plans

 

Our directors and executive officers may adopt written plans, known as Rule 10b5-1 plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or officer when entering into the plan, without further direction from them. The director or officer may amend or terminate the plan in some circumstances. Our directors and executive officers may also buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information.

 

118


Table of Contents

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

 

In addition to the compensation arrangements, including employment, termination of employment and change-in-control and indemnification arrangements, discussed, when required, above under “Management,” and the registration rights described below under “Description of Capital Stock—Registration Rights,” the following is a description of each transaction since January 1, 2007, and each currently proposed transaction in which:

 

   

we have been or are to be a participant;

 

   

the amount involved exceeds $120,000; and

 

   

any of our directors, executive officers or holders of more than 5% of any class of our capital stock at the time of the transactions in issue, or any immediate family member of or person sharing the household with any of these individuals, had or will have a direct or indirect material interest.

 

Warrants

 

From March 2008 through March 2009, we issued warrants to purchase an aggregate of 104,558 shares of our Series B-1 preferred stock at an exercise price of $25.26 per share.

 

In January 2010, we issued warrants to purchase an aggregate of 49,157 shares of our Series C preferred stock at an exercise price of $12.46 per share.

 

The holders of our warrants are entitled to specified registration rights. The following table summarizes the warrants issued in connection with the transactions described in this section, all of which were issued to holders of more than 5% of any class of our capital stock at the time of the transactions in issue.

 

Investor

   Warrants to Purchase Shares
of Series B-1 Preferred Stock
(#)
   Warrants to Purchase Shares
of Series C Preferred Stock
(#)
Entities associated with Advanced Equities Financial Corp.    104,558    49,157

 

Preferred Stock Financings

 

In April and May 2007, we sold an aggregate of 6,482,824 shares of our Series A preferred stock at $2.174 per share for an aggregate purchase price of approximately $14.1 million. In September 2007 and April 2008, we sold an aggregate of 1,667,817 shares of our Series B preferred stock at $24.88 per share for an aggregate purchase price of approximately $41.5 million. In February 2008, April 2008, May 2008, July 2008, September 2008, November 2008, December 2008 and January 2009, we sold an aggregate of 2,615,721 shares of our Series B-1 preferred stock at $25.26 per share for an aggregate purchase price of approximately $66.1 million. In July 2009, September 2009, October 2009, November 2009, December 2009 and January 2010, we sold an aggregate of 4,902,665 shares of our Series C preferred stock at $12.46 per share for an aggregate purchase price of approximately $61.1 million. In March 2010, we sold an aggregate of 2,724,766 shares of our Series C-1 preferred stock at $17.56 per share for an aggregate purchase price of approximately $47.8 million. In June 2010, we sold an aggregate of 7,101,548 shares of our Series D preferred stock at $18.75 per share for an aggregate purchase price of approximately $133.2 million.

 

Although none of our executive officers or directors purchased Series A, B, B-1, C, C-1 or D preferred stock, pursuant to a voting agreement last amended and restated on June 21, 2010, (i) KPCB Holdings, Inc., as nominee, TPG Biotechnology Partners II, L.P. and entities affiliated with Khosla Ventures had representatives serving on our Board of Directors at the time the Series B, B-1 or C preferred stock were purchased, and these directors may have been considered to beneficially own any Series B, B-1 or C preferred stock purchased by the entities with which they were affiliated, and (ii) Lit Tele LLC had a representative serving on our Board of Directors at the time the Series C preferred stock was purchased, and this director may have been considered to beneficially own any Series C preferred stock purchased by the entity with which he is affiliated. These directors disclaim beneficial ownership of these securities. The terms of these purchases were the same as those made available to unaffiliated purchasers.

 

119


Table of Contents

The purchasers of these shares of our preferred stock are entitled to specified registration rights. See “Description of Capital Stock—Registration Rights.” The following table summarizes the Series A, B, B-1, C and C-1 preferred stock, reflected on an as-issued and as-converted to common stock basis, assuming conversion occurred on June 21, 2010 and assuming an initial public offering price at the midpoint of the price range set forth on the cover of this prospectus, purchased by our executive officers, directors and holders of more than 5% of any class of our capital stock at the time of the transactions in issue, since January 1, 2007, in connection with the transactions described above in this section. The terms of these purchases were the same as those made available to unaffiliated purchasers.

 

Name

  Shares of
Series A
Preferred
Stock (#)
  Shares of
Series A
Preferred
Stock (on

an as-
converted
basis) (#)
  Shares of
Series B
Preferred
Stock (#)
  Shares of
Series B
Preferred
Stock (on
an as-

converted
basis) (#)
  Shares of
Series

B-1
Preferred
Stock (#)
  Shares of
Series
B-1
Preferred
Stock (on

an as-
converted
basis) (#)
  Shares of
Series C
Preferred
Stock (#)
  Shares of
Series C
Preferred
Stock (on

an as-
converted
basis) (#)
  Shares of
Series

C-1
Preferred
Stock (#)
  Shares of
Series

C-1
Preferred
Stock (on

an as-
converted
basis) (#)
  Shares of
Series D
Preferred
Stock (#)
  Shares of
Series D
Preferred
Stock (on
an as-
converted
basis) (#)
KPCB Holdings, Inc., as nominee (1) (5)   3,449,861   3,449,861   150,723   168,508       419,688   419,688        
TPG Biotechnology Partners II, L.P. (2) (5)   2,299,907   2,299,907   401,929   449,357       419,687   419,687        
Entities affiliated with Khosla Ventures II, L.P. (3) (5)   3,449,861   3,449,861   150,723   168,508       419,687   419,687        
Entities associated with Advanced Equities Financial Corp.           1,301,312   1,458,771   174,675   174,675        
Lit Tele LLC (4) (5)           395,883   443,785   802,568   802,568        
Maxwell (Mauritius) Pte Ltd.                   2,724,766   2,724,766    
Entities associated with DAG Ventures II, L.P.       803,859   898,714       220,707   220,707        
Total Gas & Power USA, SAS                       7,101,548   7,101,548

 

  (1)   John Doerr, one of our directors, is a manager of the general partners of entities affiliated with KPCB Holdings, Inc.
  (2)   Dr. Geoffrey Duyk, one of our directors, is a partner of TPG Growth, LLC, an affiliate of TPG Biotechnology Partners II, L.P.
  (3)   Samir Kaul, one of our directors, is a member of Khosla Ventures II, L.P.
  (4)   Dr. Fernando de Castro Reinach, one of our directors, is an affiliate of the parent company of Lit Tele LLC.
  (5)   The directors listed in the notes above disclaim beneficial ownership of these securities.

 

Stockholder Agreements

 

In connection with the sale of our Series A, B, B-1, C, C-1 and D preferred stock, we entered into agreements that grant customary preferred stock rights to all of our major preferred stock investors, including holders of more than 5% of our preferred stock at the time of the transactions in issue. The rights include registration rights, rights of first refusal, co-sale rights with respect to stock transfers, a voting agreement providing for the election of investor designees to our Board of Directors, information rights and other similar rights. The Amended and Restated Investors Rights Agreement dated June 21, 2010, which contains the registration rights and many of the other rights described above, is filed as an exhibit to the registration statement of which this prospectus is a part. All of these rights, other than the registration rights, will terminate upon the completion of this offering.

 

120


Table of Contents

Upon the completion of this offering, holders of 34,266,433 shares of our common stock (including shares issuable upon exercise of certain stock options) and holders of warrants to purchase an aggregate of 24,101 shares of common stock, or their permitted transferees, will be entitled to rights with respect to the registration of these shares under the Securities Act. For more detailed description of these registration rights, see “Description of Capital Stock—Registration Rights.”

 

In connection with the sale of our Series D preferred stock, we granted additional rights to Total Gas & Power USA, SAS. The agreements containing such rights are filed as exhibits to the registration statement of which this prospectus is a part. For more detailed description of these rights, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Recent Developments.”

 

Other Transactions

 

On September 15, 2008, we entered into a Stock Option Agreement with Lit Tele LLC, whereby Lit Tele LLC received an option to purchase up to 60,000 shares of our common stock at an exercise price of $3.93 per share, outside the terms of our 2005 Stock Option/Stock Issuance Plan.

 

On April 9, 2008 and November 25, 2008, we entered into Placement Agent Agreements with Advanced Equities, Inc., pursuant to which Advanced Equities acted as our exclusive placement agent in obtaining financing through a private placement of our Series B-1 preferred stock. Under the terms of these agreements, as compensation for its placement services, Advanced Equities received: (i) $2,641,149 in cash, and (ii) warrants to purchase 104,558 shares of our Series B-1 preferred stock as discussed in “Warrants” above. In addition, under the terms of these agreements, we are required to indemnify Advanced Equities and its affiliates for (a) any misrepresentations or untrue statements made by us to Advanced Equities, (b) any breach or alleged breach of any representation, warranty or covenant made by us in these agreements, and (c) any misrepresentations or untrue statements made by us in any document furnished to the investors placed by Advanced Equities. Furthermore, Advanced Equities is required to indemnify us for (a) any misrepresentations or untrue statements made by Advanced Equities to the investors it placed with us (except to the extent such misrepresentations or untrue statements are based on information provided to Advanced Equities by us), (b) any breach or alleged breach of any representation, warranty or covenant made by Advanced Equities in these agreements, and (c) Advanced Equities’ bad faith, gross negligence or willful misconduct in performing its services.

 

On September 28, 2009, we entered into a Placement Agent Agreement with Advanced Equities pursuant to which Advanced Equities acted as our exclusive placement agent in obtaining financing through a private placement of our Series C preferred stock. Under the terms of this agreement, as compensation for its placement services Advanced Equities received: (i) $619,965 in cash, and (ii) a warrant to purchase 49,157 shares of our Series C preferred stock as discussed in “Warrants” above. This agreement contains mutual indemnification obligations similar to the indemnification obligations contained in our Series B-1 placement agent agreements with Advanced Equities described above.

 

On July 31, 2009, we entered into an Amended and Restated Restricted Stock Issuance Agreement with Lit Tele LLC, which amended and restated the Restricted Stock Issuance Agreement between the parties dated September 15, 2008. Pursuant to this agreement, Lit Tele LLC was awarded 50,000 restricted stock units outside the terms of our 2005 Stock Option/Stock Issuance Plan, and each unit entitles Lit Tele LLC to receive one share of our common stock. These restricted stock units granted to Lit Tele LLC were in exchange for advisory services provided to us pursuant to the Amended and Restated Advisory Services Agreement dated July 31, 2009, between us and Lit Tele LLC, as amended by Amendment No. 1 dated February 11, 2010. Under the terms of Amendment No. 1, we issued to Lit Tele LLC additional 126,272 restricted stock units outside the terms of our 2005 Stock Option/Stock Issuance Plan, and each unit entitles Lit Tele LLC to receive one share of our common stock.

 

Dr. Fernando de Castro Reinach, one of our directors, is an affiliate of the parent company of Lit Tele LLC.

 

121


Table of Contents

 

Indemnification Arrangements

 

Please see “Management—Limitation of Liability and Indemnification” for information on our indemnification arrangements with our directors and executive officers.

 

Executive Compensation and Employment Arrangements

 

Please see “Management—Executive Compensation” and “Management—Agreements with Executives” for information on compensation arrangements with our executive officers, including option grants and agreements with executive officers.

 

Related Person Transaction Policy

 

Our policy adopted by our Board of Directors requires that any transaction with a related party that must be reported under applicable SEC rules, other than compensation related matters, must be reviewed and approved or ratified by our Audit Committee. Another independent body of our Board of Directors must provide such approval or ratification if the related party is, or is associated with, a member of the Audit Committee or if it is otherwise inappropriate for the Audit Committee to review the transaction. The Audit Committee has not adopted policies or procedures for review of, or standards for approval of, these transactions.

 

122


Table of Contents

PRINCIPAL STOCKHOLDERS

 

The following table sets forth information with respect to the beneficial ownership of our common stock, as of June 21, 2010, by:

 

   

each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our voting securities;

 

   

each of our directors;

 

   

each of our named executive officers; and

 

   

all of our directors and executive officers as a group.

 

Beneficial ownership is determined in accordance with the rules of the SEC and generally includes any shares over which the individual or entity has sole or shared voting power or investment power. The information does not necessarily indicate beneficial ownership for any other purpose. Except as indicated in the footnotes to this table and pursuant to applicable community property laws, to our knowledge the persons named in the table below have sole voting and investment power with respect to all shares of common stock beneficially owned. The number of shares beneficially owned by each person or group as of June 21, 2010, includes shares of common stock that such person or group had the right to acquire on or within 60 days after June 21, 2010, upon the exercise of options and warrants or the settling of restricted stock units. References to options and warrants in the footnotes of the table below include only options and warrants outstanding as of June 21, 2010, that were exercisable on or within 60 days after June 21, 2010, and references to restricted stock units in the footnotes of the table below include only restricted stock units outstanding as of June 21, 2010, that would vest and could settle on or within 60 days after June 21, 2010. For the purposes of calculating each person’s or group’s percentage ownership, stock options and warrants exercisable and restricted stock units that would vest within 60 days after June 21, 2010, are included for that person or group but not the stock options, warrants or restricted stock units of any other person or group.

 

Percentage ownership of our common stock in the table before this offering is based on 34,118,866 shares of our common stock outstanding on June 21, 2010. This number and the numbers of beneficially owned shares reported in the table below assume the automatic conversion of all outstanding shares of our preferred stock into 29,000,821 shares of common stock. Percentage ownership of our common stock after this offering also assumes our sale of the              shares in this offering. Except as otherwise set forth below, the address of the beneficial owner is c/o Amyris, Inc., 5885 Hollis Street, Suite 100, Emeryville, CA 94608.

 

     Shares beneficially
owned prior to offering
   Shares beneficially
owned after offering

Name and address of beneficial owner

   Number (#)    Percentage
(%)
   Number (#)    Percentage
(%)

5% Stockholders

           

Total Gas & Power USA, SAS (1)

   7,101,548    20.8      

Entities affiliated with Kleiner Perkins Caufield & Byers (2)

   4,158,224    12.2      

Entities affiliated with Khosla Ventures (3)

   4,158,222    12.2      

TPG Biotechnology Partners II, L.P. (4)

   3,262,450    9.6      

Maxwell (Mauritius) Pte Ltd. (5)

   2,724,766    8.0      

Entities affiliated with Advanced Equities Financial Corp. (6)

   1,799,813    5.2      

Directors and Named Executive Officers

           

John Melo (7)

   1,502,983    4.2      

Ralph Alexander (8)

   45,000    *      

John Doerr (2) (9)

   3,913,688    11.5      

Geoffrey Duyk, M.D., Ph.D. (4)(10)

           

 

123


Table of Contents
     Shares beneficially owned
prior to offering
   Shares beneficially
owned after offering

Name and address of beneficial owner

   Number (#)    Percentage
(%)
   Number (#)    Percentage
(%)

Samir Kaul (3)

   4,158,222    12.2      

Arthur Levinson, Ph.D. (11)

   100,000
   *      

Patrick Pichette (12)

   100,000    *      

Carole Piwnica

           

Kinkead Reiling (13)

   985,000    2.9      

Fernando de Castro Reinach, Ph.D. (14)

   35,000    *      

Jeryl Hilleman (15)

   250,000    *      

Joel Cherry, Ph.D. (16)

   230,000    *      

Jefferson Lievense, Ph.D. (17)

   280,000    *      

Tamara Tompkins (18)

   240,000    *      

All directors and executive officers as a group
(16 persons) (19)

   13,284,893    35.5      

 

   *   Represents beneficial ownership of less than 1%.
  (1)   The address of Total Gas & Power USA, SAS is 2, Place Jean Millier, 92078 Paris La Défense CEDEX, France.
  (2)   Includes 3,702,178 shares of common stock held by KPCB XII, LLC and 67,666 shares held by KPCB XII Founders Fund, LLC, 143,844 shares beneficially held by Clarus, LLC, whose manager is L. John Doerr, and 244,536 shares held by other individual managers. Mr. Doerr is a manager of the general partners of these entities and has shared voting and investment authority over these shares. Mr. Doerr disclaims beneficial ownership of these shares except to the extent of his pecuniary interest arising therein. The shares are held for convenience in the name of “KPCB Holdings, Inc. as nominee” for the account of entities affiliated with Kleiner Perkins Caufield & Byers and others. KPCB Holdings, Inc. has no voting, dispositive or pecuniary interest in any such shares. The address for Mr. Doerr and these entities is 2750 Sand Hill Road, Menlo Park, CA 94025.
  (3)   Includes 3,618,369 shares of common stock held by Khosla Ventures II, L.P. and 539,853 shares of common stock held by Khosla Ventures III, L.P. Mr. Kaul, one of our directors, is the general partner of the general partners of these entities and as such may be deemed to have voting and investment power with respect to shares held by these entities. Mr. Kaul disclaims beneficial ownership of these shares except to the extent of his individual pecuniary interest in these entities. The address for Mr. Kaul and these entities is 3000 Sand Hill Road, Building 3, Suite 170, Menlo Park, CA 94025.
  (4)   Includes 3,262,450 shares of common stock (the “TPG Stock”) held by TPG Biotechnology Partners II, L.P. (“Partners II”), a Delaware limited partnership, whose general partner is TPG Biotechnology GenPar II, L.P., a Delaware limited partnership (“GenPar II”), whose general partner is TPG Biotech Advisors II, LLC, a Delaware limited liability company (“Advisors II”), whose sole member is TPG Ventures Holdings, LLC, a Delaware limited liability company (“Venture Holdings II”), whose managing member is TPG Ventures Partners, L.P., a Delaware limited partnership (“Venture Partners II” and, together with Partners II, GenPar II, Advisors II and Venture Holdings II, the “TPG Funds”), whose general partner is Tarrant Advisors, Inc., a Texas corporation (“Tarrant”), whose sole shareholder is Tarrant Capital Advisors, Inc., a Delaware corporation (“TCA”). Messrs. David Bonderman and James G. Coulter are directors, officers and sole shareholders of TCA, and may therefore be deemed to be the beneficial owners of the TPG Stock. The address of each of the TPG Funds, Tarrant, TCA, and Messrs. Bonderman and Coulter is c/o TPG Capital, L.P., 301 Commerce Street, Suite 3300, Fort Worth, TX 76102.
  (5)   The address of Maxwell (Mauritius) Pte Ltd is 60B Orchard Road, #06-18 Tower 2, The Atrium @ Orchard, Singapore 238891.

 

124


Table of Contents
  (6)   Entities affiliated with Advanced Equities Financial Corp. (“AEFC”) beneficially own the following numbers of shares of common stock and shares of common stock issuable upon the exercise of warrants.

 

Entity

   Common Stock    Warrants

Advanced Equities Amyris Investments I, LLC

   289,074   

Advanced Equities Amyris Investments II, LLC

   844,112   

Advanced Equities Amyris Investments III, LLC

   38,753   

Advanced Equities Amyris Investments IV, LLC

   81,403   

AEI 2008 CleanTech Investments I, LLC

   120,299   

AEI 2008 CleanTech Investments II, LLC

   259,805   

Advanced Equities Financial Corp.

      166,367

 

All of the above entities other than AEFC (collectively, the “AEI Funds”) are controlled by managing members that are wholly-owned subsidiaries of AEFC. AEFC exercises voting and dispositive control over all of the AEI Funds. AEFC disclaims beneficial ownership of all of these shares, except to the extent of its pecuniary interest therein. The business address for AEFC and all of the AEI Funds is 311 S. Wacker Drive, Suite 1650, Chicago, IL 60606.

  (7)   Represents 1,502,983 shares of common stock issuable upon exercise of options that are exercisable within 60 days of June 21, 2010. If these options were exercised in full, 686,793 of these shares would be subject to vesting and a right of repurchase in our favor upon Mr. Melo’s cessation of service prior to vesting.
  (8)   Represents 45,000 shares of common stock issuable upon exercise of vested options that are exercisable within 60 days of June 21, 2010.
  (9)   Represents shares held by entities affiliated with Kleiner Perkins Caufield & Byers of which Mr. Doerr is an affiliate but excludes 244,536 of these shares over which Mr. Doerr has no voting or investment power.
  (10)   Dr. Duyk, who is one of our directors, is a partner of TPG Growth, LLC, which is an affiliate of Partners II. Dr. Duyk has no voting or investment power over and disclaims beneficial ownership of the TPG Stock. The address of Dr. Duyk is c/o TPG Capital, L.P., 301 Commerce Street, Suite 3300, Fort Worth, TX 76102.
  (11)   Represents 100,000 shares of common stock issuable upon exercise of options that are exercisable within 60 days of June 21, 2010. If these options were exercised in full, 91,667 of the shares resulting from such exercise would be subject to vesting and a right of repurchase in our favor upon Dr. Levinson’s cessation of service prior to vesting.
  (12)   Represents 100,000 shares of common stock issuable upon exercise of options that are exercisable within 60 days of June 21, 2010. If these options were exercised in full, 91,667 of the shares resulting from such exercise would be subject to vesting and a right of repurchase in our favor upon Mr. Pichette’s cessation of service prior to vesting.
  (13)   Includes (i) 863,000 shares of common stock held by Dr. Reiling, (ii) an aggregate of 37,000 shares of common stock held by transferees of Dr. Reiling, over which shares be retains shared voting power and (iii) 85,000 shares issuable upon exercise of options of Dr. Reiling that are exercisable within 60 days of June 21, 2010. If these options were exercised in full 36,835 of the shares resulting from such exercise would be subject to vesting and a right of repurchase in our favor upon Dr. Reiling’s cessation of service prior to vesting.
  (14)   Represents shares issuable upon exercise of options exercisable within 60 days of June 21, 2010. Dr. Reinach does not have any voting or investment power with respect to shares held by Lit Tele, LLC. The address for Dr. Reinach is Rua Jeronimo de Veiga, 384 12° andar, São Paulo, Brazil.
  (15)  

Includes (i) 25,445 shares of common stock, of which 12,723 are unvested as of June 21, 2010, and subject to a lapsing right of repurchase in our favor and (ii) 224,555 shares issuable upon exercise of options that are exercisable within 60 days of June 21, 2010. If these options were

 

125


Table of Contents
 

exercised in full, 128,945 of the shares resulting from such exercise would be subject to vesting and a right of repurchase in our favor upon Ms. Hilleman’s cessation of service prior to vesting.

  (16)   Represents 230,000 shares of common stock issuable upon exercise of options that are exercisable within 60 days of June 21, 2010. If these options were exercised in full, 153,500 of the shares resulting from such exercise would be subject to vesting and a right of repurchase in our favor upon Dr. Cherry’s cessation of service prior to vesting.
  (17)   Represents 280,000 shares of common stock issuable upon exercise of options that are exercisable within 60 days of June 21, 2010. If these options were exercised in full, 150,501 of the shares resulting from such exercise would be subject to vesting and a right of repurchase in our favor upon Dr. Lievense’s cessation of service prior to vesting.
  (18)   Includes (i) 100,000 shares of common stock and (ii) 140,000 shares issuable upon exercise of options that are exercisable within 60 days of June 21, 2010. If these options were exercised in full, 56,834 of the shares resulting from such exercise would be subject to vesting and a right of repurchase in our favor upon Ms. Tompkins’ cessation of service prior to vesting.
  (19)   Includes the shares described in footnotes (2) through (4) and (7) through (18) above. Also includes (i) 900,000 shares of common stock held by executive officers and (ii) 545,000 shares issuable upon exercise of options beneficially owned by executive officers within 60 days after June 21, 2010, of which 496,835 shares, if these options were exercised in full, would be subject to vesting and a right of repurchase in our favor upon the executive officer’s cessation of service prior to vesting.

 

126


Table of Contents

DESCRIPTION OF CAPITAL STOCK

 

Upon the completion of this offering, our authorized capital stock will consist of 100,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of preferred stock, par value $0.0001 per share. A description of the material terms and provisions of our restated certificate of incorporation and restated bylaws affecting the rights of holders of our capital stock is set forth below. The description is intended as a summary, and is qualified in its entirety by reference to the form of our restated certificate of incorporation and the form of our restated bylaws to be adopted prior to the completion of this offering that will be filed with the registration statement relating to this prospectus. The descriptions of our common stock and preferred stock reflect changes to our capital structure that will occur upon the completion of this offering.

 

Common Stock

 

Dividend Rights

 

Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our Board of Directors, in its discretion, determines to issue dividends, and only then at the times and in the amounts that our Board of Directors may determine.

 

Voting Rights

 

Each holder of common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Our restated certificate of incorporation eliminates the right of stockholders to cumulate votes for the election of directors. Our restated certificate of incorporation establishes a classified Board of Directors, to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.

 

No Preemptive or Similar Rights

 

Our common stock is not entitled to preemptive rights and is not subject to conversion, redemption or sinking fund provisions.

 

Right to Receive Liquidation Distributions

 

Upon our dissolution, liquidation or winding-up, the assets legally available for distribution to our stockholders are distributable ratably among the holders of our common stock, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding shares of preferred stock.

 

Preferred Stock

 

Immediately upon the completion of this offering, each outstanding share of preferred stock will be converted into common stock.

 

Following this offering, we will be authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions. Our Board of Directors also can increase or decrease the number of shares of any series, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our Board of Directors may authorize the issuance of preferred stock with voting

 

127


Table of Contents

or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and may adversely affect the market price of our common stock and the voting and other rights of the holders of common stock. We have no current plan to issue any shares of preferred stock.

 

Options

 

As of June 21, 2010, we had options to purchase 6,227,980 shares of our common stock outstanding pursuant to our 2005 Stock Option/Stock Issuance Plan. In addition, as of June 21, 2010, we had granted an option to purchase up to 60,000 shares of our common stock outside of our 2005 Stock Option/Stock Issuance Plan.

 

Warrants

 

As of March 31, 2010, we had one warrant to purchase 2,580 shares of our Series B preferred stock with an exercise price of $24.88 per share. The warrant has a net exercise provision under which the holder in lieu of payment of the exercise price in cash can surrender the warrant and receive a net number of shares of Series B preferred stock based on the fair market value of such stock at the time of exercise of the warrant after deduction of the aggregate exercise price. Unless earlier exercised, this warrant will expire on the first anniversary of the closing of this offering. After the closing of this offering, this warrant will become exercisable for a number of shares of common stock determined by multiplying 2,580 by the conversion ratio of the Series B Preferred Stock in effect at the closing of this offering.

 

As of March 31, 2010, we had six warrants to purchase an aggregate of 106,567 shares of our Series B-1 preferred stock with an exercise price of $25.26 per share. Each of these warrants has a net exercise provision under which the holder in lieu of payment of the exercise price in cash can surrender the warrant and receive a net number of shares of Series B-1 preferred stock based on the fair market value of such stock at the time of exercise of the warrant after deduction of the aggregate exercise price. Unless earlier exercised, one warrant to purchase 2,009 shares of Series B-1 preferred stock will expire on the first anniversary of the closing of this offering and five warrants to purchase an aggregate of 104,558 shares of our Series B-1 preferred stock will expire on various dates from March 2015 to March 2016. After the closing of this offering, these warrants will become exercisable for an aggregate number of shares of common stock determined by multiplying 106,567 by the conversion ratio of the Series B-1 preferred stock in effect at the closing of this offering.

 

As of March 31, 2010, we had three warrants to purchase an aggregate of 73,258 shares of our Series C preferred stock with an exercise price of $12.46 per share. Each of these warrants has a net exercise provision under which the holder in lieu of payment of the exercise price in cash can surrender the warrant and receive a net number of shares of Series C preferred stock based on the fair market value of such stock at the time of exercise of the warrant after deduction of the aggregate exercise price. Unless earlier exercised, two of these warrants to purchase an aggregate of 24,101 will expire on the first anniversary of the closing of this offering and one warrant to purchase an aggregate of 49,157 shares will expire January 7, 2017. After the closing of this offering, these warrants will become exercisable for an aggregate number of shares of common stock determined by multiplying 73,258 by the conversion ratio of the Series C preferred stock in effect at the closing of this offering.

 

Restricted Stock Units

 

As of June 21, we had granted 176,272 restricted stock units outside our 2005 Stock Option/Stock Issuance Plan. Each restricted stock unit represents the right to receive one share of our common stock.

 

128


Table of Contents

Registration Rights

 

Demand Registration Rights

 

At any time beginning 180 days after the completion of this offering and ending on March 12, 2013, the holders of at least 30% of the shares having registration rights under our investors’ rights agreement may request that we file a registration statement under the Securities Act covering the shares of the requesting holders. We will be obligated to use our commercially reasonable efforts to register such shares if they represent at least 20% of the shares resulting from conversion of our preferred stock and if the anticipated aggregate price to the public is at least $5,000,000. We are required to effect no more than two registration statements upon exercise of these demand registration rights. We may postpone the filing of a registration statement for up to 90 days once in a 12-month period if we determine that the filing would be seriously detrimental to us and our stockholders.

 

Piggyback Registration Rights

 

If we register any of our securities for public sale, the stockholders with registration rights will have the right to include their shares in the registration statement. However, this right does not apply to a registration relating to any of our employee benefit plans, the offer and sale of debt securities, or a registration on any registration form that does not include the information required for registration of the shares having piggyback registration rights. The managing underwriter of any underwritten offering will have the right to limit, due to marketing reasons, the number of shares registered by these holders to 25% of the total shares covered by the registration statement.

 

Form S-3 Registration Rights

 

The holders of shares having registration rights can request that we register all or a portion of their shares on Form S-3 if we are eligible to file a registration statement on Form S-3 and the aggregate price to the public of the shares offered is at least $2,000,000. We are required to file no more than one registration statement on Form S-3 upon exercise of these rights in any 12-month period. We may postpone the filing of a registration statement on Form S-3 for up to 90 days once in a 12-month period if we determine that the filing would be seriously detrimental to us and our stockholders.

 

Registration Expenses

 

We will pay all expenses incurred in connection with exercise of demand and piggyback registration rights, except for underwriting discounts and commissions. However, we will not pay for any expenses of any demand registration if the request is subsequently withdrawn by the holders of a majority of the shares requested to be included in such a registration statement, subject to limited exceptions. The expenses associated with exercise of Form S-3 registration rights will be borne pro rata by the holders of the shares registered on such Form S-3.

 

Expiration of Registration Rights

 

The registration rights described above will expire five years after this offering is completed.

 

Holders of substantially all of our shares with these registration rights have signed agreements with the underwriters prohibiting the exercise of their registration rights for 180 days, subject to a possible extension of up to 34 additional days beyond the end of such 180-day period, following the date of this prospectus. These agreements are described below under “Underwriting.”

 

Anti-Takeover Provisions

 

The provisions of Delaware law, our restated certificate of incorporation and our restated bylaws may have the effect of delaying, deferring or discouraging another person from acquiring control of our company.

 

129


Table of Contents

Delaware Law

 

Section 203 of the Delaware General Corporation Law prevents some Delaware corporations from engaging, under some circumstances, in a business combination, which includes a merger or sale of at least 10% of the corporation’s assets with any interested stockholder, meaning a stockholder who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of the corporation’s outstanding voting stock, unless:

 

   

the transaction is approved by the Board of Directors prior to the time that the interested stockholder became an interested stockholder;

 

   

upon consummation of the transaction which resulted in the stockholder’s becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced; or

 

   

at or subsequent to such time that the stockholder became an interested stockholder the business combination is approved by the Board of Directors and authorized at an annual or special meeting of stockholders by at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.

 

If Section 203 applied to us, the restrictions could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, could discourage attempts to acquire us.

 

A Delaware corporation may “opt out” of the restrictions on business combinations contained in Section 203 with an express provision in its original certificate of incorporation or an express provision in its certificate or incorporation or bylaws resulting from a stockholders’ amendment approved by at least a majority of the outstanding voting shares. We have agreed to opt out of Section 203 through an amendment of our certificate of incorporation, but, following the amendment, our certificate of incorporation will contain substantially similar protections to our company and stockholders as those afforded under Section 203, except that we have agreed with Total that it will not be deemed an “interested stockholder” under such protections.

 

Restated Certificate of Incorporation and Restated Bylaw Provisions

 

Our restated certificate of incorporation and our restated bylaws will include a number of provisions that may have the effect of deterring hostile takeovers or delaying or preventing changes in control of our management team, including the following:

 

   

Board of Directors Vacancies.  Our restated certificate of incorporation and restated bylaws will authorize only our Board of Directors to fill vacant directorships. In addition, the number of directors constituting our Board of Directors will be set only by resolution adopted by a majority vote of our entire Board of Directors. These provisions prevent a stockholder from increasing the size of our Board of Directors and gaining control of our Board of Directors by filling the resulting vacancies with its own nominees.

 

   

Classified Board.  Our restated certificate of incorporation and restated bylaws will provide that our Board of Directors is classified into three classes of directors. The existence of a classified board could delay a successful tender offeror from obtaining majority control of our Board of Directors, and the prospect of that delay might deter a potential offeror. Pursuant to Delaware law, the directors of a corporation having a classified board may be removed by the stockholders only for cause. In addition, stockholders will not be permitted to cumulate their votes for the election of directors.

 

   

Stockholder Action; Special Meeting of Stockholders.  Our restated certificate of incorporation will provide that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. Our restated bylaws will further provide that special meetings of our stockholders may be called only by a majority of our Board of Directors, the chairman of our Board of Directors, our chief executive officer or our president.

 

130


Table of Contents
   

Advance Notice Requirements for Stockholder Proposals and Director Nominations.  Our restated bylaws will provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also will specify certain requirements regarding the form and content of a stockholder’s notice. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.

 

   

Issuance of Undesignated Preferred Stock.  After the filing of our restated certificate of incorporation, our Board of Directors will have the authority, without further action by the stockholders, to issue up to 5,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by the Board of Directors. The existence of authorized but unissued shares of preferred stock enables our Board of Directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.

 

In addition, we have an agreement with Total Gas & Power USA, SAS (“Total”) that, so long as Total holds at least 10% of our voting securities, we are required to notify Total if our Board of Directors seeks to cause the sale of the company or if we receive an offer to acquire us. In the event of such decision or offer, we are required to provide Total with all information given to an offering party and provide Total with an exclusive negotiating period of 15 business days in the event the Board of Directors authorizes us to solicit offers to buy our company, or five business days in the event that we receive an unsolicited offer to purchase us. These rights of Total may have the effect of delaying, deferring or discouraging another person from acquiring our company.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our common stock will be Wells Fargo Bank, National Association.

 

Stock Exchange Listing

 

We have applied to have our common stock listed on The Nasdaq Global Market under the symbol “AMRS.”

 

SHARES ELIGIBLE FOR FUTURE SALE

 

Prior to this offering, there has been no public market for our common stock, and we cannot assure you that a significant market for our common stock will develop or be sustained after this offering. Future public market sales or the possibility of such future sales, of substantial amounts of our common stock, including shares issued upon exercise of our options and warrants, could adversely affect the trading price of our common stock or could impair our ability to raise capital in the future. Furthermore, since only a limited number of shares will be available for sale shortly after this offering because of the contractual and legal restrictions on resale described below, sales of substantial amounts of our common stock in the public market after those restrictions lapse could also adversely affect the trading price of our common stock.

 

Sales of Restricted Securities

 

Upon the completion of this offering, a total of              shares of our common stock will be outstanding, based on the number of shares outstanding at March 31, 2010 but including 7,101,548 shares of common stock issuable upon conversion of Series D preferred stock issued after March 31, 2010 (assuming initial public offering price at the midpoint of the range set forth on the cover of this prospectus) and 311,111 shares of common stock issuable upon conversion of 1,111,111 shares of Amyris Brasil issued after March 31, 2010, and assuming no exercises of options or warrants after March 31, 2010, and the issuance of              shares of common stock in this offering.

 

131


Table of Contents

Of the shares to be outstanding after the closing of this offering, all shares sold in this offering will be freely tradable without restriction under the Securities Act, except that any shares purchased in this offering by our “affiliates,” as that term is defined in Rule 144 under the Securities Act generally may be sold in the public market only in compliance with Rule 144.

 

The remaining 34,972,688 shares of common stock will be “restricted securities,” as that term is defined in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule 144 or Rule 701 under the Securities Act, which are summarized below. In addition, substantially all of these restricted securities will be subject to the lock-up agreements described below.

 

As a result of the lock-up agreements and the provisions of our Amended and Restated Investors Rights Agreement described below, and subject to the provisions of Rules 144 and 701 under the Securities Act, these restricted securities will be available for sale in the public market as follows:

 

   

on the date of this prospectus, 89,872 of the shares will be available for sale in the public market without restriction; 

 

   

Beginning 91 days after the date of this prospectus, 311,111 shares not subject to a lock-up or market standoff agreement will become eligible for sale in the public market, all of which will be freely tradeable under Rule 144; and

 

   

beginning 181 days after the date of this prospectus, subject to extension as described in “Underwriters,” 34,571,705 shares will become eligible for sale in the public market, of which 12,715,295 shares will be freely tradable under Rule 144, and 21,856,410 shares will be freely tradable, subject to the limitations under Rules 144 and 701, of which 66,309 shares will be unvested and subject to our right of repurchase.

 

In addition, of the 6,015,059 shares of our common stock that were subject to stock options and warrants outstanding as of March 31, 2010, options and warrants to purchase              shares of common stock will be exercisable 181 days following the effective date of this prospectus and the shares resulting from any such exercises will be eligible for sale 181 days following the effective date of this prospectus, subject to extension as described in “Underwriters.”

 

As of March 31, 2010, 176,272 shares of common stock were subject to outstanding restricted stock units, all of which units will have settled 181 days after the effective date of this prospectus and will be freely tradable, subject to the limitations under Rule 144.

 

Rule 144

 

In general, under Rule 144 as currently in effect, once we have been subject to public company reporting requirements for at least 90 days, a person who is not deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and who has beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than our affiliates, is entitled to sell those shares without complying with the manner of sale, volume limitation or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then that person is entitled to sell those shares without complying with any of the requirements of Rule 144.

 

132


Table of Contents

In general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell upon the expiration of the lock-up agreements described below, within any three-month period beginning 90 days after the date of this prospectus, a number of shares that does not exceed the greater of:

 

   

1% of the number of shares of common stock then outstanding, which will equal approximately              shares immediately after this offering; or

 

   

the average weekly trading volume of the common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale.

 

Sales under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us.

 

Rule 701

 

Any of our employees, officers, directors or consultants who purchased shares under a written compensatory plan or contract may be entitled to sell them in reliance on Rule 701. Rule 701 permits affiliates to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. Rule 701 further provides that non-affiliates may sell these shares in reliance on Rule 144 without complying with the holding period, public information, volume limitation or notice provisions of Rule 144. All holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling those shares. However, all shares issued under Rule 701 are subject to lock-up agreements described below and/or to a 180-day market stand-off contractual restriction in our favor and will only become eligible for sale when the lock-up and/or market standoff period expires.

 

Investors’ Rights Agreement

 

Under our Amended and Restated Investors’ Rights Agreement, certain holders of our capital stock that are party to that agreement have agreed to not sell any of our securities owned by them for a period of 180 days after the date of effectiveness of the registration statement to which this prospectus is a part, and in specific circumstances, up to an additional 34 days. Such “market stand-off” rights are contingent upon all directors, officers and holders of at least one percent of our voting capital stock entering into a similar agreement.

 

Other Market Stand-off Provisions

 

In addition to the market-standoff restrictions described above, the stock purchase agreements entered into by all optionees who have exercised options under our 2005 Stock Option/Stock Issuance Plan contain a market stand-off restriction of 180 days, which is contingent upon all of our directors and officers being subject to a similar restriction.

 

Lock-Up Agreements

 

We and each of our directors, officers and a substantial majority of our other stockholders have agreed that, without the prior written consent of Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. on behalf of the underwriters, we and they will not, during the period ending 180 days after the date of this prospectus:

 

   

offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock beneficially owned by us or such persons or any securities convertible into or exercisable or exchangeable for shares of common stock; or

 

   

enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our common stock.

 

133


Table of Contents

The terms of the lock-up agreements, including exceptions to the prohibitions described above, as more fully described in “Underwriting” below.

 

Registration Rights

 

Upon the completion of this offering, the holders of an aggregate of 34,266,433 shares of our common stock (including shares issuable upon exercise of certain stock options) and the holders of warrants to purchase an aggregate of 24,101 shares of our common stock, or their permitted transferees, will be entitled to rights with respect to the registration of these shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See “Description of Capital Stock—Registration Rights” for additional information.

 

Registration Statements

 

We intend to file a registration statement on Form S-8 under the Securities Act covering all of the shares of common stock subject to options outstanding and reserved for issuance under our stock plans. We expect to file this registration statement as soon as practicable after this offering. However, none of the shares registered on Form S-8 will be eligible for resale until the expiration of the lock-up agreements to which they are subject.

 

134


Table of Contents

MATERIAL U.S. FEDERAL TAX CONSIDERATIONS

FOR NON-U.S. HOLDERS OF COMMON STOCK

 

This section summarizes the material U.S. federal income tax considerations relating to the ownership and disposition of common stock by non-U.S. holders. This summary does not discuss all potential tax considerations. The information provided below is based upon provisions of the Internal Revenue Code of 1986, as amended, or the Code, and Treasury regulations promulgated thereunder, administrative rulings and judicial decisions currently in effect. These authorities may change at any time, possibly on a retroactive basis, or the Internal Revenue Service, or IRS, might interpret the existing authorities differently. In either case, the tax considerations of owning or disposing of common stock could differ from those described below. For purposes of this summary, a “non-U.S. holder” is any holder other than:

 

   

an individual who is a citizen or resident of the U.S.;

 

   

a corporation created or organized under the laws of the U.S., any state or the District of Columbia;

 

   

a trust that is (1) subject to the primary supervision of a U.S. court and one of more U.S. persons have authority to control all substantial decisions of the trust or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person; or

 

   

an estate whose income is subject to U.S. income tax regardless of source.

 

If you are a non-U.S. holder that is an individual, you may, in many cases, be deemed to be a resident alien, as opposed to a nonresident alien, by virtue of being present in the U.S. for at least 31 days in the calendar year and for an aggregate of at least 183 days during a three-year period ending in the current calendar year. For these purposes, all the days present in the current year, one-third of the days present in the immediately preceding year, and one-sixth of the days present in the second preceding year are counted. Resident aliens are subject to U.S. federal income tax as if they were U.S. citizens. Such an individual is urged to consult his or her own tax advisor regarding the U.S. federal income tax consequences of the sale, exchange of other disposition of common stock. If a partnership or other pass-through entity is a beneficial owner of common stock, the tax treatment of a partner in the partnership or an owner of the entity will depend upon the status of the partner or other owner and the activities of the partnership or other entity. Any partner in a partnership or member in a pass-through entity holding shares of our common stock should consult its own tax advisor.

 

This discussion assumes that a non-U.S. holder will hold our common stock as a capital asset (generally, property held for investment). The summary generally does not address tax considerations that may be relevant to particular investors because of their specific circumstances, or because they are subject to special rules, including if the investor is a U.S. expatriate, “controlled foreign corporation,” “passive foreign investment company,” corporation that accumulates earnings to avoid U.S. federal income tax, dealer in securities or currencies, financial institution, regulated investment company, real estate investment trust, tax-exempt entity, insurance company, person holding our common stock as part of a hedging, integrated, conversion or constructive sale transaction or a straddle, trader in securities that elects to use a mark-to-market method of accounting, person liable for the alternative minimum tax, and partner or beneficial owner in a pass-through entity. Finally, the summary does not describe the effects of any applicable foreign, state or local laws, or, except to the extent discussed below, the effects of any applicable gift or estate tax laws.

 

INVESTORS CONSIDERING THE PURCHASE OF COMMON STOCK SHOULD CONSULT THEIR OWN TAX ADVISORS REGARDING THE APPLICATION OF THE U.S. FEDERAL INCOME AND ESTATE TAX LAWS TO THEIR PARTICULAR SITUATIONS AND THE CONSEQUENCES OF FOREIGN, STATE OR LOCAL LAWS, AND TAX TREATIES.

 

135


Table of Contents

Dividends

 

We do not expect to declare or pay any dividends on our common stock in the foreseeable future. If we do pay dividends on shares of our common stock, however, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that is applied against and reduces, but not below zero, a non-U.S. holder’s adjusted tax basis in shares of our common stock. Any remaining excess will be treated as gain realized on the sale or other disposition of our common stock. See “—Sale of Common Stock.”

 

Any dividend paid to a non-U.S. holder on our common stock will generally be subject to U.S. withholding tax at a 30% rate. The withholding tax might not apply, however, or might apply at a reduced rate, under the terms of an applicable income tax treaty between the U.S. and the non-U.S. holder’s country of residence. You should consult your tax advisors regarding your entitlement to benefits under a relevant income tax treaty. Generally, in order for us or our paying agent to withhold tax at a lower treaty rate, a non-U.S. holder must certify its entitlement to treaty benefits. A non-U.S. holder generally can meet this certification requirement by providing a Form W-8BEN (or any successor form) or appropriate substitute form to us or our paying agent. If the holder holds the stock through a financial institution or other agent acting on the holder’s behalf, the holder will be required to provide appropriate documentation to the agent. The holder’s agent will then be required to provide certification to us or our paying agent, either directly or through other intermediaries. For payments made to a foreign partnership or other pass-through entity, the certification requirements generally apply to the partners or other owners rather than to the partnership or other entity, and the partnership or other entity must provide the partners’ or other owners’ documentation to us or our paying agent. If you are eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty, you may obtain a refund or credit of any excess amounts withheld by filing an appropriate claim for a refund with the IRS in a timely manner.

 

Dividends received by a non-U.S. holder that are effectively connected with a U.S. trade or business conducted by the non-U.S. holder, or, if an income tax treaty between the U.S. and the non-U.S. holder’s country of residence apply, are attributable to a permanent establishment you maintain in the U.S., are not subject to such withholding tax. To obtain this exemption, a non-U.S. holder must provide us with an IRS Form W-8ECI properly certifying such exemption. Such effectively connected dividends, although not subject to withholding tax, are taxed at the same graduated rates applicable to U.S. persons, net of certain deductions and credits, subject to any applicable tax treaty providing otherwise. In addition to the graduated tax described above, dividends received by corporate non-U.S. holders that are effectively connected with a U.S. trade or business of the corporate non-U.S. holder may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable tax treaty.

 

Sale of Common Stock

 

Non-U.S. holders will generally not be subject to U.S. federal income tax on any gains realized on the sale, exchange or other disposition of common stock unless:

 

   

the gain (1) is effectively connected with the conduct by the non-U.S. holder of a U.S. trade or business and (2) if an income tax treaty applies between the U.S. and the non-U.S. holder’s country of residence, the gain is attributable to a permanent establishment (or, in the case of an individual, a fixed base) maintained by the non-U.S. holder in the U.S. (in which case the special rules described below apply);

 

   

the non-U.S. holder is an individual who is present in the U.S. for 183 days or more in the taxable year of the sale, exchange or other disposition of our common stock, and certain other requirements are met (in which case the gain would be subject to a flat 30% tax, or such reduced rate as may be specified by an applicable income tax treaty, which may be offset by U.S. source capital losses, even though the individual is not considered a resident of the U.S.); or

 

136


Table of Contents
   

the rules of the Foreign Investment in Real Property Tax Act, or FIRPTA, treat the gain as effectively connected with a U.S. trade or business.

 

The FIRPTA rules may apply to a sale, exchange or other disposition of common stock if we are, or were within the shorter of the five-year period preceding the disposition and the non-U.S. holder’s holding period, a “U.S. real property holding corporation,” or USRPHC. In general, we would be a USRPHC if interests in U.S. real estate comprised at least half of our assets. We do not believe that we are a USRPHC and we do not anticipate becoming one in the future. Even if we become a USRPHC, as long as our common stock is regularly traded on an established securities market, such common stock will be treated as U.S. real property interests only if a non-U.S. holder actually owns or constructively holds more than 5% of our outstanding common stock.

 

If any gain from the sale, exchange or other disposition of common stock, (1) is effectively connected with a U.S. trade or business conducted by a non-U.S. holder and (2) if an income tax treaty between the U.S. and the non-U.S. holder’s country of residence applies, is attributable to a permanent establishment (or, in the case of an individual, a fixed base) maintained by such non-U.S. holder in the U.S., then the gain generally will be subject to U.S. federal income tax at the regular graduated rates. If the non-U.S. holder is a corporation, under certain circumstances, that portion of its earnings and profits that is effectively connected with its U.S. trade or business, subject to certain adjustments, generally would be subject to a “branch profits tax.” The branch profits tax rate is generally 30%, although an applicable income tax treaty between the U.S. and the non-U.S. holder’s country of residence might provide for a lower rate.

 

U.S. Federal Estate Tax

 

The estates of nonresident alien individuals generally are subject to U.S. federal estate tax on property with a U.S. situs. Because we are a U.S. corporation, our common stock will be U.S. situs property and, therefore, will be included in the taxable estate of a nonresident alien decedent, unless an applicable estate tax treaty between the U.S. and the decedent’s country of residence provides otherwise.

 

Backup Withholding and Information Reporting

 

The Code and the Treasury regulations require those who make specified payments to report the payments to the IRS. Among the specified payments are dividends and proceeds paid by brokers to their customers. The required information returns enable the IRS to determine whether the recipient properly included the payments in income. This reporting regime is reinforced by “backup withholding” rules. These rules require the payors to withhold tax from payments subject to information reporting if the recipient fails to cooperate with the reporting regime by failing to provide his taxpayer identification number to the payor, furnishing an incorrect identification number, or failing to report interest or dividends on his returns. The backup withholding tax rate is currently 28%. The backup withholding rules do not apply to payments to corporations, whether domestic or foreign.

 

Payments to non-U.S. holders of dividends on common stock generally will not be subject to backup withholding, and payments of proceeds made to non-U.S. holders by a broker upon a sale of common stock will not be subject to information reporting or backup withholding, in each case so long as the non-U.S. holder certifies its nonresident status (and we or our paying agent do not have actual knowledge or reason to know the holder is a U.S. person or that the conditions of any other exemption are not, in fact, satisfied) or otherwise establishes an exemption. The certification procedures to claim treaty benefits described under “—Dividends” will satisfy the certification requirements necessary to avoid the backup withholding tax as well. We must report annually to the IRS any dividends paid to each non-U.S. holder and the tax withheld, if any, with respect to these dividends. Copies of these reports may be made available to tax authorities in the country where the non-U.S. holder resides.

 

Under the Treasury regulations, the payment of proceeds from the disposition of shares of our common stock by a non-U.S. holder made to or through a U.S. office of a broker generally will be subject to information reporting and backup withholding unless the beneficial owner certifies, under penalties of perjury, among other

 

137


Table of Contents

things, its status as a non-U.S. holder (and we or our paying agent do not have actual knowledge or reason to know the holder is a U.S. person) or otherwise establishes an exemption. The payment of proceeds from the disposition of shares of our common stock by a non-U.S. holder made to or through a non-U.S. office of a broker generally will not be subject to backup withholding and information reporting, except as noted below. Information reporting, but not backup withholding, will apply to a payment of proceeds, even if that payment is made outside of the U.S., if you sell our common stock through a non-U.S. office of a broker that is:

 

   

a U.S. person (including a foreign branch or office of such person);

 

   

a “controlled foreign corporation” for U.S. federal income tax purposes;

 

   

a foreign person 50% or more of whose gross income from certain periods is effectively connected with a U.S. trade or business; or

 

   

a foreign partnership if at any time during its tax year (a) one or more of its partners are U.S. persons who, in the aggregate, hold more than 50% of the income or capital interests of the partnership or (b) the foreign partnership is engaged in a U.S. trade or business;

 

unless the broker has documentary evidence that the beneficial owner is a non-U.S. holder and certain other conditions are satisfied, or the beneficial owner otherwise establishes an exemption (and the broker has no actual knowledge or reason to know to the contrary).

 

Backup withholding is not an additional tax. Any amounts withheld from a payment to a holder of common stock under the backup withholding rules can be credited against any U.S. federal income tax liability of the holder and may entitle the holder to a refund, provided that the required information is furnished to the IRS in a timely manner.

 

THE PRECEDING DISCUSSION OF U.S. FEDERAL TAX CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY. IT IS NOT TAX ADVICE. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, STATE, LOCAL AND FOREIGN TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS.

 

138


Table of Contents

UNDERWRITERS

 

Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below, for whom Morgan Stanley & Co. Incorporated, Goldman, Sachs & Co. and J.P. Morgan Securities Inc. are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of shares indicated below:

 

Name

         Number of
Shares

Morgan Stanley & Co. Incorporated

  

Goldman, Sachs & Co.

  

J.P. Morgan Securities Inc.

  

Itaú USA Securities Inc.

  

Thomas Weisel Partners LLC

  
      

Total:

  
    

 

The underwriters and the representatives are collectively referred to as the “underwriters” and the “representatives,” respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters’ over-allotment option described below.

 

The underwriters initially propose to offer part of the shares of common stock directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $             a share under the public offering price. After the initial offering of the shares of common stock, the offering price and other selling terms may from time to time be varied by the representatives. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters’ right to reject any order in whole or in part.

 

We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to              additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. To the extent the option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional shares of common stock as the number listed next to the underwriter’s name in the preceding table bears to the total number of shares of common stock listed next to the names of all underwriters in the preceding table.

 

The following table shows the per share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters’ option to purchase up to an additional              shares of common stock.

 

     Total
     Per Share    No Exercise    Full Exercise

Public offering price

   $                 $                 $             

Underwriting discounts and commissions to be paid by us

   $      $      $  

Proceeds, before expenses, to us

   $      $      $  

 

The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are approximately $            .

 

The underwriters have informed us that they do not intend sales to discretionary accounts to exceed five percent of the total number of shares of common stock offered by them.

 

139


Table of Contents

As of the completion of this offering our common stock will be approved for listing on The Nasdaq Global Market under the trading symbol “AMRS”.

 

We and all of our directors and officers, and the holders of substantially all of our outstanding stock and stock options have agreed that, without the prior written consent of Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. on behalf of the underwriters, we and they will not, during the period ending 180 days after the date of this prospectus:

 

   

offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock beneficially owned by us or such persons or any securities convertible into or exercisable or exchangeable for shares of common stock, or

 

   

enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our common stock;

 

whether any such transaction described above is to be settled by delivery of common stock or such other securities, in cash or otherwise. In addition, we have agreed that, without the prior written consent of Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. on behalf of the underwriters, we will not, during the period ending 180 days after the date of this prospectus, file any registration statement with the SEC relating to the offering of any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock, except for the filing of a registration statement on Form S-8 relating to the offering of securities in accordance with the terms of a plan in effect on the date hereof.

 

The restrictions described in the immediately preceding paragraph to do not apply to, among other things:

 

   

transactions relating to shares of our common stock or other securities acquired in open market transactions after the completion of this offering, provided that no filing under the Securities Exchange Act of 1934, or the Exchange Act (other than a filing on a Form 5, Schedule 13D or Schedule 13G (or 13D/A or 13G/A) made after the expiration of the restricted period), shall be required or shall be voluntarily made in connection with subsequent sales of common stock or other securities acquired in such open market transactions;

 

   

transfers of shares of our common stock or any security convertible into or exercisable for common stock as a bona fide gift;

 

   

transfers of shares of our common stock or any security convertible into or exercisable or exchangeable for common stock to us, pursuant to agreements under which we have the option to repurchase such shares or a right of first refusal with respect to transfers of such shares, provided that such transfers after the date of this prospectus shall be for less than market value of our common stock at the time of transfer;

 

   

the sale of shares of common stock to the underwriters;

 

   

the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act, provided that such plan does not provide for any transaction, including any sale, until the termination of the restricted period; or

 

   

the exercise of options, warrants or rights to acquire shares of our common stock or any security convertible into common stock, in accordance with their terms, provided that the acquired common stock is subject to the restricted period.

 

In addition, we, all of our directors and officers and the holders of substantially all of our outstanding stock and stock options have agreed that, without the prior written consent of Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. on behalf of the underwriters, we and they will not, during the period ending 180 days after the date of this prospectus, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock.

 

140


Table of Contents

The 180 day restricted period described in the preceding paragraphs will be extended if:

 

   

during the last 17 days of the 180 day restricted period we issue an earnings release or material news or a material event relating to us occurs; or

 

   

prior to the expiration of the 180 day restricted period, we announce that we will release earnings results during the 16-day period beginning on the last day of the 180 day period;

 

in which case the restrictions described in the preceding paragraph will continue to apply until the expiration of the 18 day period beginning on the issuance of the earnings release or the occurrence of the material news or material event.

 

In order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater than the number of shares available for purchase by the underwriters under the over-allotment option. The underwriters can close out a covered short sale by exercising the over-allotment option or purchasing shares in the open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under the over-allotment option. The underwriters may also sell shares in excess of the over-allotment option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. These activities may raise or maintain the market price of the common stock above independent market levels or prevent or retard a decline in the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time.

 

We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the other may be required to make because of any of these liabilities.

 

A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations.

 

The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates may in the future perform, various financial advisory and investment banking services for the issuer, for which they would receive customary fees and expenses.

 

In the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve securities and instruments of the issuer.

 

141


Table of Contents

Pricing of the Offering

 

Prior to this offering, there has been no public market for our common stock. The initial public offering price was determined by negotiations between us and the representatives. Among the factors considered in determining the initial public offering price were our future prospects and those of our industry in general, our sales, earnings and certain other financial and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain financial and operating information of companies engaged in activities similar to ours. We cannot assure you that the prices at which our shares will sell in the public market after this offering will not be lower than the initial public offering price or that an active trading market in our common stock will develop and continue after this offering.

 

European Economic Area

 

In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a Relevant Member State), each underwriter has represented and agreed that with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State (the Relevant Implementation Date) it has not made and will not make an offer of shares to the public in that Relevant Member State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant Member State or, where appropriate, approved in another Relevant Member State and notified to the competent authority in that Relevant Member State, all in accordance with the Prospectus Directive, except that it may, with effect from and including the Relevant Implementation Date, make an offer of shares to the public in that Relevant Member State at any time:

 

   

to legal entities which are authorised or regulated to operate in the financial markets or, if not so authorised or regulated, whose corporate purpose is solely to invest in securities;

 

   

to any legal entity which has two or more of (1) an average of at least 250 employees during the last financial year; (2) a total balance sheet of more than €43,000,000 and (3) an annual net turnover of more than €50,000,000, as shown in its last annual or consolidated accounts;

 

   

to fewer than 100 natural or legal persons (other than qualified investors as defined in the Prospectus Directive) subject to obtaining the prior consent of the representatives for any such offer; or

 

   

in any other circumstances which do not require the publication by the Issuer of a prospectus pursuant to Article 3 of the Prospectus Directive.

 

For the purposes of this provision, the expression an “offer of shares to the public” in relation to any shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State and the expression Prospectus Directive means Directive 2003/71/EC and includes any relevant implementing measure in each Relevant Member State.

 

United Kingdom

 

Each underwriter has represented and agreed that:

 

   

it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the FSMA) received by it in connection with the issue or sale of the shares in circumstances in which Section 21(1) of the FSMA does not apply to us; and

 

   

it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares in, from or otherwise involving the United Kingdom.

 

142


Table of Contents

Hong Kong

 

The shares may not be offered or sold by means of any document other than (i) in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), or (ii) to “professional investors” within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder, or (iii) in other circumstances which do not result in the document being a “prospectus” within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder.

 

Singapore

 

This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the “SFA”), (ii) to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

 

Where the shares are subscribed or purchased under Section 275 by a relevant person which is: (a) a corporation (which is not an accredited investor) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor, shares, debentures and units of shares and debentures of that corporation or the beneficiaries’ rights and interest in that trust shall not be transferable for 6 months after that corporation or that trust has acquired the shares under Section 275 except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275 of the SFA; (2) where no consideration is given for the transfer; or (3) by operation of law.

 

Japan

 

The securities have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (the Financial Instruments and Exchange Law) and each underwriter has agreed that it will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Law and any other applicable laws, regulations and ministerial guidelines of Japan.

 

143


Table of Contents

LEGAL MATTERS

 

The validity of the shares of common stock offered hereby will be passed upon for us by Fenwick & West LLP, Mountain View, California. Wilson Sonsini Goodrich & Rosati, P.C., Palo Alto, California, is acting as counsel for the underwriters in connection with certain legal matters related to this offering.

 

Certain investment partnerships comprised of members of, and persons associated with, Wilson Sonsini Goodrich & Rosati, P.C. beneficially hold an aggregate of 23,000 shares of our common stock, which represents less than 0.1% of our outstanding shares of common stock.

 

EXPERTS

 

The consolidated financial statements as of December 31, 2008 and 2009 and for each of the three years in the period ended December 31, 2009, included in this prospectus have been so included in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

 

WHERE YOU CAN FIND ADDITIONAL INFORMATION

 

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedule filed therewith. For further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. We currently do not file periodic reports with the SEC. Upon completion of this offering, we will be required to file periodic reports, proxy statements and other information with the SEC pursuant to the Securities Exchange Act of 1934. A copy of the registration statement and the exhibits filed therewith may be inspected without charge at the public reference room maintained by the SEC, located at 100 F Street, NE, Washington, DC 20549, and copies of all or any part of the registration statement may be obtained from that office. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room. The SEC also maintains an Internet website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the website is www.sec.gov.

 

144


Table of Contents

CONSOLIDATED FINANCIAL STATEMENTS

 

Index

 

Amyris, Inc.

 

     Page(s)

Report of Independent Registered Public Accounting Firm

   F-2

Consolidated Financial Statements

  

Consolidated Balance Sheets

   F-3

Consolidated Statements of Operations

   F-4
Consolidated Statements of Convertible Preferred Stock, Redeemable Noncontrolling Interest and Deficit    F-5

Consolidated Statements of Cash Flows

   F-7

Notes to Consolidated Financial Statements

   F-9

 

F-1


Table of Contents

Report of Independent Registered Public Accounting Firm

 

To the Board of Directors and Stockholders of

Amyris, Inc.

 

In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations, of convertible preferred stock, redeemable noncontrolling interest and deficit, and of cash flows present fairly, in all material respects, the financial position of Amyris, Inc. and its subsidiaries at December 31, 2009 and December 31, 2008, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2009 in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for noncontrolling interest in 2009.

 

/s/ PricewaterhouseCoopers LLP

 

San Jose, California

April 16, 2010, except for the eleventh

paragraph of Note 19 to the

consolidated financial statements

as to which the date is

June 22, 2010

 

F-2


Table of Contents

Amyris, Inc.

 

Consolidated Balance Sheets

In Thousands, Except Share and Per Share Amounts

 

    December 31,
2008
    December 31,
2009
    March 31,
2010
    Pro  Forma
Stockholders’

Equity as of
March 31,
2010
 
                (Unaudited)     (Unaudited)  

Assets

       

Current assets:

       

Cash and cash equivalents

  $ 17,899      $ 19,188      $ 26,800     

Short-term investments

    19,291        48,022        73,941     

Accounts receivable

    787        1,372        3,821     

Inventories

    1,420        2,298        1,973     

Prepaid expenses and other current assets

    1,556        3,983        2,040     
                         

Total current assets

    40,953        74,863        108,575     

Property and equipment, net

    41,565        42,560        43,913     

Restricted cash

    2,748        4,506        4,515     

Long-term investments

    12,950                   

Other assets

    607        230        1,179     
                         

Total assets

  $ 98,823      $ 122,159        158,182     
                         

Liabilities, Convertible Preferred Stock, Redeemable Noncontrolling Interest and Equity (Deficit)

       

Current liabilities:

       

Accounts payable

  $ 2,617      $ 1,709      $ 2,866     

Deferred revenue

           378            

Accrued and other current liabilities

    5,083        10,445        8,566     

Capital lease obligation, current portion

    557        2,251        2,615     

Debt, current portion

    340        9,018        8,534     
                         

Total current liabilities

    8,597        23,801        22,581     

Capital lease obligation, net of current portion

    3,041        4,977        4,916     

Long-term debt, net of current portion

    2,809        4,362        4,242     

Convertible preferred stock warrant liability

    2,132        2,740        2,705      $   

Deferred rent, net of current portion

    12,154        8,828        8,640     

Restructuring liability

           4,486        4,412     

Other liabilities

    797        1,553        1,676     
                         

Total liabilities

    29,530        50,747        49,172     
                         

Commitments and contingencies (Note 5)

       

Convertible preferred stock—$0.0001 par value, 16,104,641 authorized as of December 31, 2008, 21,080,641 shares authorized as of December 31, 2009 and 23,862,355 shares authorized as of March 31, 2010 (unaudited); 13,681,658 and 18,365,222 shares issued and outstanding as of December 31, 2008 and 2009, respectively (aggregate liquidation value of $126,225 and $185,566 as of December 31, 2008 and 2009, respectively); 21,385,969 shares issued and outstanding as of March 31, 2010 (unaudited) (aggregate liquidation value of $237,101) no shares issued and outstanding, pro forma (unaudited)

    121,436        179,651        230,606          

Redeemable noncontrolling interest

           5,506        7,094          

Stockholders’ Equity (Deficit):

       

Common stock— $0.0001 par value; 28,000,000 and 33,000,000 shares authorized as of December 31, 2008 and 2009, respectively and 38,000,000 authorized as of March 31, 2010; 5,015,576 and 5,114,205 shares issued and outstanding as of December 31, 2008 and 2009, respectively and 5,120,712 shares issued and outstanding as of March 31, 2010 (unaudited); 38,000,000 shares authorized, 27,570,029 shares issued and outstanding, pro forma (unaudited)

    1        1        1        3   

Additional paid-in capital

    3,164        5,366        7,180        247,583   

Accumulated other comprehensive income (loss)

    (468     1,336        729        729   

Accumulated deficit

    (55,989     (120,448     (136,600     (136,600
                               

Total Amyris, Inc. stockholders’ equity (deficit)

    (53,292     (113,745     (128,690     111,715   
                               

Noncontrolling interest

    1,149                        
                               

Total equity (deficit)

    (52,143     (113,745     (128,690   $ 111,715   
                               

Total liabilities, convertible preferred stock, redeemable noncontrolling interest and equity (deficit)

  $ 98,823      $ 122,159      $ 158,182     
                         

 

See accompanying notes to the consolidated financial statements.

 

F-3


Table of Contents

Amyris, Inc.

 

Consolidated Statements of Operations

In Thousands, Except Share and Per Share Amounts

 

      Years Ended December 31,     Three Months Ended March 31,  
    2007     2008     2009             2009                     2010          
                      (Unaudited)  

Revenues

         

Product sales

  $      $ 10,680      $ 61,689      $ 1,534      $ 9,954   

Collaborative research services

    6,046        3,008        2,919        557        1,378   

Government grants

    138        204                      2,323   
                                       

Total revenues

    6,184        13,892        64,608        2,091        13,655   

Cost and operating expenses

         

Cost of product sales

           10,364        60,428        1,424        10,003   

Research and development

    8,662        30,306        38,263        8,603        11,178   

Sales, general and administrative

    10,522        16,622        23,558        4,402        9,216   

Restructuring and asset impairment charges

                  5,768                 
                                       

Total cost and operating expenses

    19,184        57,292        128,017        14,429        30,397   
                                       

Loss from operations

    (13,000     (43,400     (63,409     (12,338     (16,742

Other income (expense):

         

Interest income

    1,178        1,378        448        237        276   

Interest expense

    (28     (377     (1,218     (234     (384

Other income (expense), net

    76        (144     (621     (58     515   
                                       

Total other income (expense)

    1,226        857        (1,391     (55     407   
                                       

Loss before income taxes

    (11,774     (42,543     (64,800     (12,393     (16,335

Benefit from income taxes

           (207                     
                                       

Net loss

  $ (11,774   $ (42,336   $ (64,800   $ (12,393   $ (16,335

Loss attributable to noncontrolling interest

           (472     (341     (221     (183
                                       

Net loss attributable to Amyris, Inc. stockholders

  $ (11,774   $ (41,864   $ (64,459   $ (12,172   $ (16,152
                                       

Net loss per share of common stock attributable to Amyris, Inc. stockholders, basic and diluted

  $ (3.28   $ (9.91   $ (13.56   $
(2.65

  $ (3.22
                                       

Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted

    3,592,932        4,223,533        4,753,085        4,592,400       
5,010,569
  
                                       

Pro forma net loss per share of common stock attributable to Amyris, Inc. stockholders, basic and diluted (unaudited)

      $ (3.16     $ (0.67
                     

Weighted-average shares of common stock outstanding used in computing pro forma net loss per share of common stock, basic and diluted (unaudited)

        20,279,433          24,794,446   
                     

 

See accompanying notes to the consolidated financial statements.

 

F-4


Table of Contents

Amyris, Inc.

 

Consolidated Statements of Convertible Preferred Stock, Redeemable Noncontrolling Interest and Deficit

    Convertible
Preferred Stock
    Redeemable
Noncontrolling
Interest
          Common Stock   Additional
Paid-in
Capital
    Accumulated
Deficit
    Accumulated
Other
Comprehensive
Income (Loss)
    Noncontrolling
Interest
    Total
Deficit
 
(In Thousands, Except Share and Per Share Amounts)   Shares   Amount         Shares     Amount          

January 1, 2007

  2,992,176   $ 6,397      $          4,503,917      $ 1   $ 50      $ (2,351   $      $      $ (2,300

Issuance of Series A convertible preferred stock at $2.174 per share for cash and services, net of issuance costs of $21

  6,482,824     14,073                                                          

Issuance of Series B convertible preferred stock at $24.88 per share for cash and services, net of issuance costs of $89

  1,517,093     37,656                                                          

Issuance of common stock upon exercise of stock options, net of restricted stocks

                      361,723            219                             219   

Repurchase of common stock

                      (20,625         (2                          (2

Stock-based compensation

                                 546                             546   

Components of other comprehensive income (loss)

                       

Change in unrealized gain on investments

                                               10               10   

Net loss

                                        (11,774                   (11,774
                             

Total comprehensive loss

                          (11,764
                                                                           

December 31, 2007

  10,992,093     58,126                 4,845,015        1     813        (14,125     10               (13,301

Issuance of Series B convertible preferred stock at $24.88 per share for cash, net of issuance costs of $80

  150,724     3,670                                                          

Issuance of Series B-1 convertible preferred stock at $25.26 per share for cash, net of issuance costs of $2,746

  2,538,841     61,385                                                          

Issuance of warrants in connection with issuance of Series B-1 convertible preferred stock

      (1,745                                                       

Issuance of common stock upon exercise of stock options, net of restricted stocks

                      172,059            326                             326   

Repurchase of common stock

                      (1,498         (2 )                            (2

Stock-based compensation

                                 2,027                             2,027   

Sale of noncontrolling interest

                                                      1,621        1,621   

Components of other comprehensive income (loss)

                       

Change in unrealized gain on investments

                                               77               77   

Foreign currency translation adjustment

                                               (555            (555

Net loss.

                                        (41,864            (472     (42,336
                             

Total comprehensive loss.

                          (42,814
                                                                           

December 31, 2008

  13,681,658     121,436                 5,015,576        1     3,164        (55,989     (468     1,149        (52,143

Issuance of Series B-1 convertible preferred stock at $25.26 per share for cash, net of issuance costs of $103

  76,880     1,840                                                          

Issuance of Series C convertible preferred stock at $12.46 per share for cash, net of issuance costs of $956

  4,606,684     56,443                                                          

Issuance of warrants in connection with issuance of Series B-1 convertible preferred stock

      (68                                                       

Issuance of common stock upon exercise of stock options, net of restricted stock

                      127,515            284                             284   

Repurchase of common stock

                      (28,886         (9 )                            (9

Stock-based compensation

                                 3,299                             3,299   

Proceeds from redeemable noncontrolling interest

             5,626                                                   

Purchase of noncontrolling interest

                                 (1,372                   (928     (2,300

Components of other comprehensive income (loss)

                       

Change in unrealized loss on investments

                                               (84            (84

Foreign currency translation adjustment

                                               1,888               1,888   

Net loss.

             (120                         (64,459            (221     (64,680
                             

Total comprehensive loss.

                          (62,876
                                                                           

December 31, 2009

  18,365,222   $ 179,651      $ 5,506          5,114,205      $ 1   $ 5,366      $ (120,448   $ 1,336      $      $ (113,745

 

F-5


Table of Contents

Amyris, Inc.

 

Consolidated Statements of Convertible Preferred Stock, Redeemable Noncontrolling Interest and Deficit—(Continued)

 

 

    Convertible
Preferred Stock
    Redeemable
Noncontrolling
Interest
          Common Stock   Additional
Paid-in
Capital
  Accumulated
Deficit
    Accumulated
Other
Comprehensive
Income (Loss)
    Noncontrolling
Interest
  Total
Deficit
 
(In Thousands, Except Share and Per Share Amounts)   Shares   Amount         Shares     Amount          

December 31, 2009

  18,365,222   $ 179,651      $ 5,506          5,114,205      $ 1   $ 5,366   $ (120,448   $ 1,336      $   $ (113,745

Issuance of Series C convertible preferred stock at $12.46 per shares of cash, net of issuance costs of $5 (unaudited)

  295,981     3,683                                                    

Issuance of Series C-1 convertible preferred stock at $17.56 per shares of cash, net of issuance costs of $68 (unaudited)

  2,724,766     47,779                                                    

Issuance of warrants in connection with issuance of Series C convertible preferred stock (unaudited)

      (507                                                 

Issuance of common stock upon exercise of stock options, net of restricted stock (unaudited)

                      6,707            15                       15   

Repurchase of common stock (unaudited)

                      (200                                 

Stock-based compensation (unaudited)

                            1,799                       1,799   

Proceeds from redeemable noncontrolling interest (unaudited)

             1,706                                             

Components of other comprehensive income (loss)

                       

Change in unrealized loss on investments (unaudited)

                                            (9         (9

Foreign currency translation adjustment (unaudited)

             65                                (598       (598

Net loss (unaudited)

             (183                      (16,152                (16,152
                             

Total comprehensive loss (unaudited)

                                                       (16,759
                                                                       

March 31, 2010

  21,385,969   $ 230,606      $ 7,094          5,120,712      $ 1   $ 7,180   $ (136,600   $ 729      $   $ (128,690
                                                                       

 

See accompanying notes to the consolidated financial statements.

 

F-6


Table of Contents

Amyris, Inc.

 

Consolidated Statements of Cash Flows

In Thousands

 

    Years Ended December 31,     Three Months Ended March 31,  
    2007     2008     2009         2009             2010      
                      (Unaudited)  

Operating activities

         

Net loss.

  $ (11,774   $ (42,336   $ (64,800   $ (12,393   $ (16,335

Adjustments to reconcile net loss to net cash used in operating activities:

         

Convertible preferred stock issued for services

    255                               

Convertible preferred stock warrants

           274        62               33   

Depreciation and amortization

    634        2,627        5,775        1,399        1,625   

Loss on disposal of property and equipment

           144        12                 

Loss on the sale of investments

                                (1

Stock-based compensation

    546        2,027        3,299        602        1,799   

Amortization of premium (discount) on investments

    402        (400     191        (39     161   

Change in fair value of convertible preferred stock warrant liability

           114        445        (138     (542

Restructuring and asset impairment charges

                  356                 

Other noncash expenses

                  219        58        20   

Changes in assets and liabilities:

         

Accounts receivable, net

           (787     (585     (229     (2,449

Inventories

           (1,420     (878     146        325   

Prepaid expenses and other assets

    (103     (1,943     972        370        1,180   

Accounts payable

    114        1,278        (997     (1,519     1,184   

Restructuring

                  5,078               (176

Accrued and other long-term liabilities

    2,303        2,114        4,470        (827     (1,510

Deferred revenue

    (1,903     (1,355     378               (378

Deferred rent

           784        285        (192     (113
                                       

Net cash used in operating activities

    (9,526     (38,879     (45,718     (12,762     (15,177
                                       

Investing activities

         

Purchase of short-term investments

    (120,901     (48,153     (47,996     (1,248     (38,645

Maturities of short-term investments

    88,258        52,746        31,690        17,750        4,150   

Sales of short-term investments

   
2,950
  
    8,905        250               8,407   

Purchases of long-term investments

    (8,750     (6,200                     

Sales and maturities of long-term investments

           2,000                        

Change in restricted cash

    (736     (1,962     (1,758     (130     (8

Purchase of property and equipment, net of disposals

    (2,464     (21,996     (7,608     (2,813     (3,147
                                       

Net cash provided by (used in) investing activities

    (41,643     (14,660     (25,422     13,559        (29,243
                                       

Financing activities

         

Proceeds from issuance of convertible preferred stock, net of issuance costs

    51,474        65,055        58,283        1,845        51,462   

Proceeds from issuance of common stock, net of repurchases

    217        586        113        1        5   

Purchase of noncontrolling interest

                  (2,300              

Proceeds from equipment financing

           1,220        4,763        4,280        850   

Principal payments on capital leases

    (152     (378     (1,134     (269     (547

Proceeds from debt

                  9,643        8,100          

Principal payments on debt

           (125     (985     (143     (974

Deferred offering costs

                                (144

Proceeds from sale of noncontrolling interest

           1,621        3,090               1,706   
                                       

Net cash provided by financing activities

    51,539        67,979        71,473        13,814        52,358   
                                       

Effect of exchange rate changes on cash and cash equivalents

           (555     956        34        (326
                                       

Net increase in cash and cash equivalents

    370        13,885        1,289        14,645        7,612   

Cash and cash equivalents at beginning of period

    3,644        4,014        17,899        17,899        19,188   
                                       

Cash and cash equivalents at end of period

  $ 4,014      $ 17,899      $ 19,188      $ 32,544      $ 26,800   
                                       

 

See accompanying notes to the consolidated financial statements.

 

F-7


Table of Contents

Amyris, Inc.

 

Consolidated Statements of Cash Flows—(Continued)

In Thousands

 

     Years Ended December 31,     Three Months Ended March 31,  
     2007    2008    2009         2009             2010      
                     (Unaudited)  

Supplemental disclosures of cash flow information:

            

Cash paid for interest

   $ 18    $ 320    $ 1,204      $ 235      $ 384   
                                      

Cash paid for income taxes, net of refunds

   $    $    $ 27      $ 3      $   
                                      

Supplemental disclosure of noncash investing and financing activities:

            

Convertible preferred stock issued for services

   $      255    $    $      $      $   
                                      

Stock receivable for noncontrolling interest

   $    $    $   2,536      $      $   
                                      

Additions to property and equipment under capital lease obligations

   $ 807    $ 2,101    $      $      $   
                                      

Additions to property and equipment under notes payable

   $    $ 3,274    $ 1,038      $ 677      $ 29   
                                      

Additions to property and equipment under tenant improvement allowances

   $    $ 11,370    $      $      $   
                                      

Acquisitions of assets under accounts payable

   $ 411    $ 731    $ 20      $ 133      $ 39   
                                      

Financing of insurance premium under notes payable

   $    $    $ 378      $      $ 101   
                                      

Change in unrealized gain (loss) on investments

   $ 10    $ 77    $ (84   $ (79   $ (9
                                      

Asset retirement obligation

   $    $ 470    $      $      $   
                                      

Warrants issued in connection with the issuance of convertible preferred stock

   $    $ 1,745    $ 68      $ 68      $ 507   
                                      

Accrued deferred offering costs

   $    $    $      $      $ 811   
                                      

Financing of rent payments under notes payable

   $    $    $      $      $ 239   
                                      

 

See accompanying notes to the consolidated financial statements.

 

F-8


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements

 

1. The Company and Basis of Presentation

 

Amyris, Inc. (the “Company”) was incorporated in the State of California on July 17, 2003 for the purpose of leveraging breakthroughs in synthetic biology to develop and provide renewable compounds for a variety of markets. The Company is currently building and applying its industrial synthetic biology platform to provide alternatives to select petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. The Company’s first commercialization efforts have been focused on a molecule called farnesene, which forms the basis for a wide range of products varying from specialty chemical applications to transportation fuels, such as diesel. While the Company’s platform is able to use a wide variety of feedstocks, the Company has focused initially on Brazilian sugarcane. The Company intends to secure access to this feedstock and to expand its production capacity by working with existing sugar and ethanol mill owners to build new, adjacent bolt-on facilities at their existing mills in return for a share of the higher gross margin the Company believes it will realize from the sale of our renewable products. The Company’s first such arrangement is its joint venture with Usina São Martinho (see Note 19).

 

In February 2008, the Company incorporated a wholly owned subsidiary, Amyris Fuels, Inc., a Delaware corporation, which is engaged in marketing and distribution of certain fuels. In September 2008, the Company established a wholly owned subsidiary, Amyris Fuels, LLC, a Delaware limited liability company into which it merged Amyris Fuels, Inc. In March 2008, the Company formed a subsidiary, Amyris Pesquisa e Desenvolvimento de Biocombustíveis Ltda., for the purpose of manufacturing and trading transportation fuels from sugarcane feedstock in Brazil and abroad (See Note 16). In March 2008, the Company sold a 30% interest to Crystalsev and the subsidiary was renamed Amyris-Crystalsev Pesquisa e Desenvolvimento de Biocombustiveis Ltda. (“ACB”). The Company invested $3.8 million of cash for a 70% interest in ACB, and Crystalsev contributed $1.6 million of cash for the remaining 30% interest.

 

In April 2009, the Company re-purchased Crystalsev’s 30% interest in ACB for $2.3 million resulting in Amyris Brasil becoming a wholly-owned subsidiary again. The purchase of the noncontrolling interest was treated as an equity transaction and the fair value of the consideration paid of $2.3 million was recorded as a reduction of the carrying value of the noncontrolling interest and additional paid-in capital. In December 2009, ACB was renamed Amyris Brasil S.A.

 

On December 22, 2009, the Company sold a 4.8% interest in Amyris Brasil for BRL$10.0 million. The redeemable noncontrolling interest is reported in the mezzanine equity section of the consolidated balance sheet because the Company is subject to a contingent put option under which it may be required to repurchase an interest in Amyris Brasil from the noncontrolling interest holder.

 

In March 2010, the Company sold an incremental 3.4% interest in Amyris Brasil for BRL $3.0 million (unaudited).

 

During December 2009, the Company received notification of a conditional award from the Department of Energy (“DOE”), pursuant to the Recovery Act-Demonstration of Integrated Biorefinery Operations Funding Opportunity Announcement, authorizing a grant for $24.3 million. Under this grant, the Company is required to fund an additional $10.6 million in cost sharing expenses. The Company’s obligation for this cost share is contingent on reimbursement for project costs incurred. As of December 31, 2009, no amounts had been provided from the DOE. During the quarter ended March 31, 2010 the Company recognized $2.3 million (unaudited) in revenue under this grant.

 

F-9


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

2. Summary of Significant Accounting Policies

 

Basis of Presentation and Use of Estimates

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s consolidated financial position, results of operations and cash flows for the periods presented. The consolidated financial statements include the accounts of the Company, wholly- owned subsidiaries and one majority-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. In preparing the consolidated financial statements, management must make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Unaudited Interim Financial Information

 

The consolidated financial statements as of March 31, 2010, and for the three months ended March 31, 2010 and March 31, 2009 are unaudited. All disclosures as of March 31, 2010, and for the three month periods ended March 31, 2009 and March 31, 2010, presented in the notes to the financial statements are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all normal recurring adjustments necessary for a fair statement of the Company’s financial position as of March 31, 2010 and results of operations and cash flows for the three months ended March 31, 2009 and March 31, 2010. The results of operations for the three months ended March 31, 2010 are not necessarily indicative of the results to be expected for the year ended December 31, 2010 or for other interim periods or for future years.

 

Unaudited Pro Forma Information

 

The March 31, 2010 unaudited pro forma stockholders’ equity has been prepared assuming that upon the completion of a qualifying initial public offering (i) all of the Company’s convertible preferred stock outstanding will automatically convert into shares of common stock, (ii) the Company’s convertible preferred stock warrants will become warrants for common stock (see Note 10), and (iii) shares of Amyris Brasil held by third parties will convert into shares of the Company’s common stock (see Note 16). The March 31, 2010 unaudited pro forma stockholders’ equity reflects the (i) the conversion of all 21,385,969 outstanding shares of preferred stock into 21,899,273 shares of common stock, the reclassification of the preferred stock warrant liability to additional paid-in capital and reclassification of redeemable noncontrolling interest to common stock and additional paid-in capital immediately prior to the completion of the initial public offering.

 

Significant Risks and Uncertainties

 

The Company is subject to certain risks and uncertainties that could have a material and adverse effect on the Company’s future financial position or results of operations. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, limited operating history, delays or greater than anticipated expenses associated with the completion of new production facilities and the time to complete scale up of production following completion of a new production facility, disruptions in the production process at any facility where we produce our products, the timing, size and mix of sales to customers for our products, fluctuations in foreign currency exchange rates, gains or losses associated with our hedging activities, especially in Amyris Fuels, fluctuations in the price of and demand for ethanol, as well as petroleum-based and other products for which our products are alternatives, seasonal production and sale of our products, the effects of competitive pricing pressures, including decreases in average

 

F-10


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

selling prices of our products, unanticipated expenses associated with changes in governmental regulations and environmental, health and safety requirements, reductions or changes to existing fuel and chemical regulations and policies, departure of executives or other key management employees, our ability to use our net operating loss carry forwards to offset future taxable income, our ability to integrate businesses that we may acquire and risks associated with the international aspects of our business.

 

Certain products developed by the Company may require approvals from the Environmental Protection Agency or other United States or international regulatory agencies prior to commercial sales. There can be no assurance the Company’s future products will receive the necessary approvals. If the Company was denied approval or approval was delayed, it may have a material adverse impact on the Company.

 

To achieve profitable operations, the Company must successfully develop, manufacture and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s future financial results.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, short-term and long-term investments, accounts receivable, derivatives and financial instruments. The Company places its cash equivalents and investments with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.

 

The Company’s accounts receivable are derived from customers located in the United States. The Company performs ongoing credit evaluation of its customers, does not require collateral, and maintains allowances for potential credit losses on customer accounts when deemed necessary. To date, there have been no such losses and the Company has not recorded an allowance for doubtful accounts.

 

Customers representing greater than 10% of accounts receivable were as follows (in percentages):

 

     December 31,    March 31,

Customers

   2008    2009    2010
               (Unaudited)

Customer A

   10    *    *

Customer B

   15    *    *

Customer C

   *    51    55

Customer D

   12    *    *

Customer E

   *    17    19

Customer F

   14    *    *

Customer G

   20    *    *

Customer H

   26    *    *

Customer I

   *    *    11

 

  *   Less than 10%

 

F-11


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Customers representing greater than 10% of revenues were as follows (in percentages):

 

     Years Ended
December 31,
   Three Months
Ended March  31,

Customers

   2008    2009    2010
               (Unaudited)

Customer A

   33    33    *

Customer B

   30    *    *

Customer C

   *    22    47

Customer D

   21    *    *

Customer E

   *    *    17

Customer I

   *    *    10

 

  *   Less than 10%

 

The Company is exposed to counterparty credit risk on all of its derivative commodity instruments. The Company has established and maintains strict counterparty credit guidelines and enters into agreements only with counterparties that are investment grade or better. The Company does not require collateral under these agreements.

 

Fair Value of Financial Instruments

 

The Company measures certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Financial instruments are primarily comprised of commercial paper, government bonds and notes, auction rate securities (“ARS”), rights to sell its ARS (“Put Option”), derivatives and convertible preferred stock warrants. Where available, fair value is based on or derived from observable market prices or other observable inputs. Where observable prices or inputs are not available valuation models are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the instruments or market and the instruments’ complexity.

 

The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities, and market interest rates if applicable. Based on the borrowing rates currently available to the Company for debt with similar terms, the carrying value of the notes payable and credit facility approximates its fair value. The carrying amount of the convertible preferred stock warrant liability represents its estimated fair value.

 

Cash and Cash Equivalents

 

All highly liquid investments purchased with an original maturity date of three months or less at the date of purchase are considered to be cash equivalents. Cash and cash equivalents consist of money market funds, commercial paper, U.S. Government agency securities and various deposit accounts.

 

Investments

 

Investments with original maturities greater than 90 days that mature less than one year from the consolidated balance sheet date are classified as short-term investments. The Company classifies investments as short-term or long-term based upon whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal cycle of business. The Company invests its excess cash balances primarily in short-

 

F-12


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

term investment grade commercial paper, U.S. Government agency securities and notes and ARS. The Company classifies all of its investments, other than ARS, as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of accumulated other comprehensive income (loss) in stockholders’ deficit. Debt securities are adjusted for amortization of premiums and accretion of discounts and such amortization and accretion are reported as a component of interest income. Realized gains and losses and declines in value that are considered to be other than temporary are recognized in the statements of operations. The cost of securities sold is determined on the specific identification method. There were no significant realized gains or losses from sales of debt securities during the years ended December 31, 2007, 2008 and 2009 and the three months ended March 31, 2010 (unaudited). As of December 31, 2008 and 2009 and March 31, 2010, the Company did not have any other-than-temporary declines in the fair value of its debt securities.

 

The Company classifies the ARS as trading securities and records all changes in fair value as component of other income (expense), net. The underlying securities have stated or contractual maturities that are generally greater than one year. The Company estimates the fair value of the ARS using a discounted cash flow model incorporating assumptions that market participants would use in their estimates of fair value. The Company has a Put Option to sell its ARS at par value. The Company has accounted for the Put Option as a freestanding financial instrument and elected to record it at fair value with changes in fair value recorded as a component of other income (expense), net (See Note 3).

 

Restricted Cash

 

Cash accounts that are restricted as to withdrawal or usage are presented as restricted cash. As of December 31, 2008 and 2009 and March 31, 2010, the Company had $2.7 million, $4.5 million and $4.5 million (unaudited), respectively, of restricted cash held by a bank in certificate of deposits as collateral for certain of its facility and capital lease agreements.

 

Inventories

 

Inventories, which consist of ethanol, are stated at the lower of cost or market. Cost is computed on a first-in, first-out basis. Inventory costs include costs such as transportation and storage costs incurred in bringing the inventory to its existing location.

 

Derivative Instruments

 

The Company is exposed to market risks related to price volatility of ethanol. The Company makes limited use of derivative instruments, which include futures positions on the New York Mercantile Exchange and the CME/Chicago Board of Trade. The Company does not engage in speculative derivative activities, and the majority of the Company’s activity in derivative commodity instruments is intended to manage the financial risk posed by physical transactions and inventory. Changes in the fair value of the derivative contracts are recognized currently in the consolidated statements of operations as specific hedge accounting criteria are not met.

 

Asset Retirement Obligations

 

The fair value of the asset retirement obligation is recognized in the period in which it is incurred if a reasonable estimate of fair value can be made. In addition, the associated asset retirement cost is added to the carrying amount of the associated asset and this additional carrying amount is amortized over the life of the asset. The Company’s asset retirement obligations are associated with its commitment to return property subject to the operating lease in Brazil to its original condition upon lease termination.

 

F-13


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

As of December 31, 2008 and 2009 and March 31, 2010 the Company has recorded asset retirement obligations of $499,000, $746,000 and $742,000 (unaudited), respectively. The related leasehold improvements are being amortized to depreciation expense over the term of the lease or the useful life of the assets, whichever is shorter. Related amortization expense was $0, $106,000 and $175,000 for the years ended December 31, 2007, 2008 and 2009, respectively, and $51,000 (unaudited) for the three months ended March 31, 2010.

 

Property and equipment

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the related assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized.

 

Leasehold improvements are amortized on a straight-line basis over the terms of the lease, or the useful life of the assets, whichever is shorter. Depreciation and amortization periods for the Company’s property and equipment are as follows:

 

Furniture and office equipment

   5 years

Computers and software

   3-5 years

Research and laboratory equipment

   7 years

 

Computers and software includes internal-use software that is acquired, internally developed or modified to meet the Company’s internal needs. Amortization commences when the software is ready for its intended use and the amortization period is the estimated useful life of the software, generally three to five years. Capitalized costs primarily include contract labor and payroll costs of the individuals dedicated to the development of internal-use software. Capitalized software totaled approximately $0, $0.6 million, and $1.1 million as of December 31, 2007, 2008 and 2009, respectively, and $1.2 million (unaudited) as of March 31, 2010 related to software development costs pertaining to the installation of a new financial reporting system.

 

Impairment of Long-Lived Assets

 

The Company periodically reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset are impaired or the estimated useful lives are no longer appropriate. If indicators of impairment exist and the undiscounted projected cash flows associated with such assets are less than the carrying amount of the asset, an impairment loss is recorded to write the asset down to their estimated fair values. Fair value is estimated based on discounted future cash flows. Impairment charges of $0, $0 and $3,075,000 were recorded during the years ended December 31, 2007, 2008 and 2009, respectively, and zero (unaudited) for three months ended March 31, 2010.

 

Convertible Preferred Stock Warrant Liability

 

The Company accounts for its freestanding warrants for shares of the Company’s convertible preferred stock that are contingently redeemable as liabilities at fair value on the consolidated balance sheets. The warrants are subject to re-measurement at each balance sheet date and the change in fair value, if any, is recognized as other income (expense), net. The Company will continue to adjust the liability for changes in fair value until the earlier of (i) exercise of the warrants, (ii) conversion into warrants to purchase common stock, or (iii) expiration of the warrants. Upon conversion, the convertible preferred stock warrant liability will be reclassified to additional paid-in capital.

 

F-14


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Convertible Preferred Stock

 

The holders of the Company’s outstanding convertible preferred stock, voting or consenting together as a separate class, control the vote of the Company’s stockholders. As a result, the holders of all series of the Company’s convertible preferred stock can force a change in control that would trigger liquidation. As redemption of the convertible preferred stock through liquidation is outside the control of the Company, all shares of convertible preferred stock have been presented outside of stockholders’ deficit in the Company’s consolidated balance sheets. All series of convertible preferred stock are collectively referred to in the consolidated financial statements as convertible preferred stock.

 

Noncontrolling Interest and Redeemable Noncontrolling Interest

 

As of January 1, 2009, the Company adopted the new accounting standard which establishes accounting and reporting standards for noncontrolling interests in consolidated financial statements. These provisions require that the carrying value of noncontrolling interests to be removed from the mezzanine equity section of the consolidated balance sheet and reclassified as equity, and that consolidated net income be recast to include net income attributable to the noncontrolling interests. The standard requires retrospective presentation and disclosure of existing noncontrolling interests. Accordingly, the Company presented noncontrolling interests as a separate component of equity (deficit) and has also presented net loss attributable to the noncontrolling interest in the consolidated statement of operations. Upon adoption, the noncontrolling interest of $1.1 million was reclassified to a component of total equity (deficit) in the consolidated balance sheet from the mezzanine equity section.

 

In accordance with accounting and reporting standards for redeemable equity instruments, a noncontrolling interest with redemption features (“redeemable noncontrolling interest”), such as a put option, that is not solely within the control of the Company, is required to be reported in the mezzanine equity section of the consolidated balance sheet.

 

Changes in noncontrolling interest ownership that do not result in a change of control and where there is a difference between fair value and carrying value are accounted for as equity transactions.

 

Revenue Recognition

 

The Company recognizes revenue from the sale of ethanol and delivery of research and development services and governmental grants. Ethanol sales consists of sales to customers through purchase from third-party suppliers in which the Company takes physical control of the ethanol and accepts risk of loss. Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable and collectability is reasonably assured.

 

If sales arrangements contain multiple elements, the Company evaluates whether the components of each arrangement represent separate units of accounting. To date the Company has determined that all revenue arrangements should be accounted for as a single unit of accounting.

 

Product Sales

 

The Company sells ethanol under short-term agreements at prevailing market prices. Revenues are recognized, net of discounts and allowances, once passage of title and risk of loss has occurred and contractually specified acceptance criteria have been met, provided all other revenue recognition criteria have also been met.

 

F-15


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Collaborative Research Services

 

Revenue from collaborative research services is recognized as the services are performed consistent with the performance requirements of the contract. In cases where the planned levels of research services fluctuate over the research term, the Company recognizes revenue using the proportionate performance method based upon actual efforts to date relative to the amount of expected effort to be incurred by the Company. When up-front payments are received and the planned levels of research services do not fluctuate over the research term, revenue is recorded on a ratable basis over the arrangement term, up to the amount of cash received. When up-front payments are received and the planned levels of research services fluctuate over the research term, revenue is recorded using the proportionate performance method, up to the amount of cash received. Where arrangements include milestones that are determined to be substantive and at risk at the inception of the arrangement, revenue is recognized upon achievement of the milestone and is limited to those amounts whereby collectability is reasonably assured.

 

Government grants

 

Government grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. Revenues from government grants are recognized in the period during which the related costs are incurred, provided that the conditions under which the government grants were provided have been met and only perfunctory obligations are outstanding.

 

Cost of Product Sales

 

Cost of product sales consists primarily of cost of purchased ethanol, terminal fees paid for storage and handling, transportation costs between terminals and changes in the fair value of the derivative commodity instruments.

 

Shipping and handling costs charged to customers are recorded as revenues. Shipping costs are included in cost of product revenues. Such charges were not significant in any of the periods presented.

 

Costs of Start-Up Activities

 

Start-up activities are defined as those one-time activities related to opening a new facility, introducing a new product or service, conducting business in a new territory, conducting business with a new class of customer or beneficiary, initiating a new process in an existing facility, commencing some new operation or activities related to organizing a new entity All the costs associated with a potential site are expensed, until the site is considered viable by management, at which time costs would be considered for capitalization based on authoritative accounting literature.

 

Research and Development

 

Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research activities on the Company’s behalf.

 

F-16


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Income taxes

 

The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized.

 

Effective January 1, 2007, the Company adopted the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording uncertain tax positions taken, or expected to be taken in a tax return, in the consolidated financial statements. Additionally, the guidance also prescribes new treatment for the derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained.

 

Currency Translation

 

The functional currency of the Company’s majority-owned subsidiary in Brazil is the Brazilian real. Accordingly, asset and liability accounts of those operations are translated into United States dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into United States dollars using historical rates. The revenues and expenses are translated using the average exchange rates in effect during the period, and gains and losses from foreign currency translation adjustments are included as a component of accumulated other comprehensive income (loss) in the consolidated balance sheets.

 

Comprehensive Income (Loss)

 

Comprehensive income (loss) represents all changes in stockholders’ deficit except those resulting from investments or contributions by stockholders. The Company’s unrealized gains and losses on available-for-sale securities and foreign currency translation adjustments represent the components of comprehensive income (loss) excluded from the Company’s net loss and have been disclosed in the consolidated statements of convertible preferred stock, redeemable noncontrolling interest and deficit for all periods presented.

 

The components of accumulated other comprehensive income (loss) are as follows (in thousands):

 

     December 31,    March 31, 2010  
     2008     2009        2009             2010      
                (Unaudited)  

Foreign currency translation adjustment

   $ (555   $ 1,333      (507     735   
                               

Accumulated unrealized gain (loss) on investment

     87        3      8        (6
                               

Total accumulated other comprehensive income (loss)

   $ (468   $ 1,336    $ (499   $ 729   
                               

 

Stock-Based compensation

 

The Company accounts for stock-based compensation arrangements with employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based

 

F-17


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

payment awards on the date of grant using an option pricing model. The Company uses the Black-Scholes pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the vesting period.

 

The Company accounts for stock options issued to nonemployees based on the estimated fair value of the awards using the Black-Scholes option pricing model. The Company accounts for restricted stock units (“RSUs”), issued to nonemployees based on the estimated fair value of the Company’s common stock. The measurement of stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest, and the resulting change in value, if any, is recognized in the Company’s consolidated statements of operations during the period the related services are rendered.

 

Net Loss per Share and Unaudited Pro Forma Net Loss per Share of Common Stock

 

Basic net loss per share of common stock is computed by dividing the Company’s net loss attributable to Amyris, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed by giving effect to all potentially dilutive securities, including stock options, restricted stock units, warrants and convertible preferred stock. Basic and diluted net loss per share of common stock attributable to Amyris, Inc. stockholders was the same for all periods presented as the inclusion of all potentially dilutive securities outstanding was anti-dilutive. As such, the numerator and the denominator used in computing both basic and diluted net loss are the same for each period presented.

 

The calculations for the unaudited pro forma basic and diluted net loss per share of common stock attributable to Amyris, Inc. stockholders assume the conversion of all outstanding shares of convertible preferred stock into shares of common stock, as if the conversions had occurred at the beginning of the period or the issuance date for Series B-1, Series C and Series C-1 convertible preferred stock issued during the year ended December 31, 2009 and the three months ended March 31, 2010 (unaudited), and the conversion of Amyris Brasil shares held by third parties. Also, the numerator in the pro forma basic and diluted net loss per share calculation has been adjusted to remove gains and losses resulting from re-measurements of the convertible preferred stock warrant liability as these measurements would no longer be required when the convertible preferred stock warrants become warrants to purchase shares of the Company’s common stock.

 

F-18


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

The following table presents the calculation of historical and pro forma basic and diluted net loss per share of common stock attributable to Amyris, Inc. stockholders (in thousands, except share and per share amounts):

 

    Years Ended December 31,     Three Months Ended
March 31,
 
    2007     2008     2009         2009             2010      
                      (Unaudited)  

Actual:

         

Numerator:

         

Net loss attributable to Amyris, Inc. stockholders

  $ (11,774   $ (41,864   $ (64,459   $ (12,172   $ (16,152
                                       

Denominator:

         

Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted

    3,592,932        4,223,533        4,753,085        4,592,400        5,010,569   
                                       

Net loss per share of common stock attributable to Amyris, Inc. stockholders, basic and diluted

  $ (3.28   $ (9.91   $ (13.56   $ (2.65   $ (3.22
                                       

Pro Forma:

         

Numerator:

         

Net loss attributable to Amyris, Inc. stockholders

      $ (64,459     $ (16,152

Less: Change in fair value of convertible preferred stock warrant liability (unaudited)

        (445       542   
                     

Net loss used in computing pro forma net loss per share of common stock attributable to Amyris, Inc. stockholders, basic and diluted (unaudited)

      $ (64,014     $ (16,694
                     

Denominator:

         

Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted

        4,753,085          5,010,569   

Add: Pro forma adjustment to reflect weighted-average effect of assumed conversion of convertible preferred stock (unaudited)

        15,517,824          19,455,593   

Add: Pro forma adjustment to reflect weighted-average effect of conversion of Amyris Brasil shares (unaudited)

        8,524          328,284   
                     

Weighted-average shares of common stock used in computing pro forma net loss per share of common stock, basic and diluted (unaudited)

        20,279,433          24,794,446   
                     

Pro forma net loss per share of common stock attributable to Amyris, Inc. stockholders, basic and diluted (unaudited)

      $ (3.16     $ (0.67
                     

 

F-19


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive:

 

     Years Ended December 31,    Three Months Ended March 31,
     2007    2008    2009    2009    2010
                    (Unaudited)

Convertible preferred stock (as converted basis)*

   11,171,110    14,185,660    18,878,526    14,271,842    21,899,273

Period-end stock options to purchase common stock

   2,628,910    3,628,169    4,446,894    3,556,756    5,819,455

Period-end common stock subject to repurchase

   964,525    505,035    132,038    363,777    76,861

Convertible preferred stock warrants (as converted basis)*

      129,272    146,447    133,580    195,604

Period-end restricted stock units

      50,000    50,000    50,000    176,272
                        

Total

   14,764,545    18,498,136    23,653,905    18,375,955    28,167,465
                        

 

  *   The convertible preferred stock and convertible preferred stock warrants were computed on an as converted basis using the conversion ratios in effect as of March 31, 2010 for all periods presented. See Note 9 for conversion ratios.

 

Recent accounting pronouncements

 

In June 2009, the FASB issued a new accounting standard that requires a qualitative approach to identifying a controlling financial interest in a variable interest entity (“VIE”) and requires ongoing assessment of whether an interest in a VIE makes the holder the primary beneficiary of the VIE. The new accounting standard is effective for the Company on January 1, 2010. The adoption of the standard had no impact on the Company’s consolidated financial position, results of operations or cash flows.

 

In October 2009, the FASB issued a new accounting standard that changes the accounting for arrangements with multiple deliverables. Specifically, the new accounting standard requires an entity to allocate arrangement consideration at the inception of an arrangement to all of its deliverables based on their relative selling prices. In addition, the new standard eliminates the use of the residual method of allocation and requires the relative-selling-price method in all circumstances in which an entity recognizes revenue for an arrangement with multiple deliverables. In October 2009, the FASB also issued a new accounting standard that changes revenue recognition for tangible products containing software and hardware elements. Specifically, if certain requirements are met, revenue arrangements that contain tangible products with software elements that are essential to the functionality of the products are scoped out of the existing software revenue recognition accounting guidance and will be accounted for under these new accounting standards. Both standards will be effective for the Company in the first quarter of 2011. Early adoption is permitted. The Company is currently assessing the impact that the adoption of these standards will have on its consolidated financial statements.

 

In January 2010, the FASB issued an amendment to an accounting standard which requires new disclosures for fair value measures and provides clarification for existing disclosure requirements. Specifically, this amendment require an entity to disclose separately the amounts of significant transfers in and out of Level 1 and Level 2 fair value measurements and to describe the reasons for the transfers; and to disclose separately information about purchases, sales, issuances and settlements in the reconciliation for fair value measurements

 

F-20


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

using significant unobservable inputs, or Level 3 inputs. This amendment clarifies existing disclosure requirements for the level of disaggregation used for classes of assets and liabilities measured at fair value and requires disclosure about the valuation techniques and inputs used to measure fair value for both recurring and nonrecurring fair value measurements using Level 2 and Level 3 inputs. The adoption of this amendment will not impact the Company’s consolidated financial statements.

 

3. Fair Value of Financial Instruments

 

Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows:

 

   

Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities.

 

   

Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

   

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The following tables set forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability. As of December 31, 2008, the Company’s fair value hierarchy for its financial assets and financial liabilities that are carried at fair value was as follows (in thousands):

 

     Quoted Prices
in Active
Markets for
Identical Assets

(Level 1)
   Other
Observable

Inputs
(Level 2)
   Significant
Unobservable

Inputs
(Level 3)
   Balance as of
December 31,

2008

Financial Assets

           

Money market funds

   $ 7,784    $    $    $ 7,784

Commercial paper

          2,850           2,850

US Government agency securities

          16,441           16,441

Auction rate securities

               10,907      10,907

Put Option

               2,043      2,043
                           

Total financial assets

   $ 7,784    $ 19,291    $ 12,950    $ 40,025
                           

Financial Liabilities

           

Derivative liabilities

   $    $ 45    $    $ 45

Convertible preferred stock warrant liability

               2,132      2,132
                           

Total financial liabilities

   $    $ 45    $ 2,132    $ 2,177
                           

 

F-21


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

As of December 31, 2009, the Company’s fair value hierarchy for its financial assets and financial liabilities that are carried at fair value was as follows (in thousands):

 

     Quoted Prices
in Active
Markets for
Identical
Assets

(Level 1)
   Other
Observable
Inputs

(Level 2)
   Significant
Unobservable
Inputs

(Level 3)
   Balance as of
December 31,
2009

Financial Assets

           

Money market funds

   $ 12,479    $    $    $ 12,479

US Government agency securities

          35,322           35,322

Auction rate securities

               11,235      11,235

Put Option

               1,465      1,465

Derivative assets

          13           13
                           

Total financial assets

   $ 12,479    $ 35,335    $ 12,700    $ 60,514
                           

Financial Liabilities

           

Convertible preferred stock warrant liability

   $    $    $ 2,740    $ 2,740
                           

Total financial liabilities

   $    $    $ 2,740    $ 2,740
                           

 

As of March 31, 2010, the Company’s fair value hierarchy for its financial assets and financial liabilities that are carried at fair value was as follows (in thousands):

 

     Quoted Prices
in Active
Markets for
identical
Assets

(Level 1)
   Other
Observable
Inputs
(Level 2)
   Significant
Unobservable
Inputs

(Level 3)
   Balance as of
March 31,
2010
     (Unaudited)

Financial Assets

           

Money market funds

   $ 22,085              $ 22,085

US Government agency securities

          61,891           61,891

Auction rate securities

               10,632      10,632

Put option

               1,418      1,418

Derivative assets

          43           43
                           

Total financial assets

   $ 22,085    $ 61,934    $ 12,050    $ 96,069
                           

Financial Liabilities

           

Convertible preferred stock warrant liability

   $    $    $ 2,705    $ 2,705
                           

Total financial liabilities

   $    $    $ 2,705    $ 2,705
                           

 

F-22


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

The change in the fair value of the Level 3 investments is summarized below (in thousands):

 

     Auction Rate
Securities
    Put Option  

Fair value as of December 31, 2007

   $ 18,750      $   

Unrealized loss recorded in other income (expense), net

     (2,043       

Recognition of the Put Option

            2,043   

Net purchases and sales/ maturities

     (5,800       
                

Fair value as of December 31, 2008

     10,907        2,043   

Redemption at par

     (250       

Change in fair value recorded in other income (expense), net

     578        (578
                

Fair value as of December 31, 2009

     11,235        1,465   
                

Redemption at par (unaudited)

     (650       

Change in fair value recorded in other income (expense), net (unaudited)

     47        (47
                

Fair value at March 31, 2009 (unaudited)

   $ 10,632      $ 1,418   
                

 

The change in the fair value of the convertible preferred stock warrant liability is summarized below:

 

Fair value as of December 31, 2007

   $   

Fair value of warrants issued

     2,018   

Change in fair value recorded in other income (expense), net

     114   
        

Fair value as of December 31, 2008

     2,132   

Fair value of warrants issued

     336   

Fair value of cancelled award

     (173

Change in fair value recorded in other income (expense), net

     445   
        

Fair value as of December 31, 2009

     2,740   

Fair value of warrant issued (unaudited)

     507   

Change in fair valued recorded in other income (expense), net (unaudited)

     (542
        

Fair value as of March 31, 2010 (unaudited)

   $ 2,705   
        

 

The Company’s investment portfolio includes ARS, which are issued principally by student loan entities and rated AAA by a major credit rating agency. ARS are structured to provide liquidity via an auction process that resets the applicable interest rate at predetermined calendar intervals, usually every 28 days. The underlying securities have stated or contractual maturities that are generally greater than one year. Typically, the carrying value of ARS approximates fair value due to the frequent resetting of the interest rates. In February 2008, auctions failed for $12.95 million in par value of ARS that the Company held because sell orders exceeded buy orders. These failures are not believed to be a credit issue, but rather caused by a lack of liquidity. The funds associated with these failed auctions may not be accessible until the issuer calls the security, a successful auction occurs, a buyer is found outside of the auction process, or the security matures. During the year ended December 31, 2009 and the three months ended March 31, 2009 and 2010, a total of $250,000, $0 (unaudited) and $650,000 (unaudited), respectively, of the ARS held by the Company were called at par by the issuer; therefore no realized losses were recognized on these securities.

 

The Company received notification from UBS AG (“UBS”), issued in connection with a settlement entered into between UBS and certain regulatory agencies, offering to repurchase all of the Company’s auction rate security holdings at par value. The Company formally accepted the settlement offer and entered into a repurchase

 

F-23


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

agreement with UBS in November 2008. By accepting the agreement, the Company (1) received the right (“Put Option”) to sell its ARS at par value to UBS between June 30, 2010 and July 2, 2012 and (2) gave UBS the right to purchase the ARS from the Company any time after the acceptance date as long as the Company receives the full par value. The agreement with UBS covers $12.7 million and $12.1 million (unaudited) par value (fair value of $11.2 million and $10.6 million (unaudited)) of the ARS held by the Company as of December 31, 2009 and March 31, 2010, respectively.

 

The Company expects to sell the ARS under the Put Option. However, if the Put Option is not exercised before July 2, 2012, it will expire and UBS will have no further rights or obligation to buy the ARS. UBS’s obligations under the Put Option are not secured by its assets and do not require UBS to obtain any financing to support its performance obligations under the Put Option. UBS has disclaimed any assurance that it will have sufficient financial resources to satisfy its obligations under the Put Option.

 

During the year ended December 31, 2008, the Company made an election to transfer the ARS from available-for-sale to trading securities. The transfer to trading securities reflects the Company’s intent to exercise the Put Option during the period from June 30, 2010 to June 30, 2012. Prior to entering into the agreement, the Company’s intent was to hold the ARS until the market recovered. At the time of transfer, the unrealized loss on the auction rate securities was $2.0 million. Prior to the transfer, this unrealized loss was included in accumulated other comprehensive income (loss). Upon transfer of the ARS from available-for-sale to trading securities, the Company immediately recognized an unrealized loss of $2.0 million, included in other income (expense), net, for the amount of the unrealized loss not previously recognized in earnings. The Company accounted for the Put Option as a freestanding financial instrument and recorded it at fair value. This allowed any changes in the fair value of the Put Option to be offset with changes in the fair value of the related ARS in the Company’s consolidated statements of operations. As a result, $2.0 million was initially recorded as a credit to other income (expense), net for the fair value of the Put Option.

 

The Company estimates the fair value of the ARS using a discounted cash flow model incorporating assumptions that market participants would use in their estimates of fair value. Some of these assumptions include estimates for interest rates, timing and amount of cash flows and expected holding periods of the ARS. The Company estimates the fair value of the Put Option using the expected value that the Company will receive from UBS which was calculated as the difference between the fair value and the par value of the ARS as of the option exercise date. This value is discounted by using UBS’s credit default swap rate to account for the credit considerations of the counterparty risk. The Company will reassess the fair values in future reporting periods based on several factors, including continued failure of auctions, failure of investments to be redeemed, deterioration of credit ratings of investments, market risk and other factors.

 

As of December 31, 2009, the Company has classified its ARS as short-term investments and they were classified as long-term investments as of December 31, 2008 based on its intention to liquidate the investments on June 30, 2010.

 

Derivative Instruments

 

The Company utilizes derivative financial instruments to mitigate its exposure to certain market risks associated with its ongoing operations. The primary objective for holding derivative financial instruments is to manage commodity price risk. The Company’s derivative instruments principally include ethanol futures. All derivative commodity instruments are recorded at fair value on the consolidated balance sheets. None of the Company’s derivative instruments are designated as a hedging instrument. Changes in the fair value of these non-designated hedging instruments are recognized in cost of product sales in the consolidated statements of operations.

 

F-24


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Derivative instruments measured at fair value as of December 31, 2008, 2009 and March 31, 2010, and their classification on the consolidated balance sheets and consolidated statements of operations, are presented in the following tables (in thousands) except contract amounts:

 

     Asset/Liability as of December 31,    Asset/Liability as of
March 31, 2010
     2008    2009    (Unaudited)

Type of Derivative Contract

   Quantity of Short
Contracts
   Fair Value    Quantity of Short
Contracts
   Fair Value    Quantity of Short
Contracts
   Fair Value

Regulated fixed price futures contracts, included in prepaid expenses and other current assets

      $    57    $ 13    68    $ 43

Regulated fixed price futures contracts, included in accrued and other current liabilities

   35    $ 45       $       $

 

Type of Derivative Contract

  

Income
Statement Classification

   Years Ended December 31,     Three Months
Ended
March 31, 2010
      2008    2009    
          Gains (Losses) Recognized     Gain (Losses)
Recognized
                (Unaudited)

Regulated fixed price futures contracts

   Cost of Product Sales    $ 752    $ (1,910   $ 647

 

4. Balance Sheet Components

 

Investments

 

The following table summarizes the Company’s investments as of December 31, 2008 (in thousands):

 

     December 31, 2008
     Amortized
Cost
   Unrealized Gain
(Loss)
    Fair Value

Short-term investments

       

Commercial paper

   $ 2,841    $ 9      $ 2,850

US Government agency securities

     16,363      78        16,441
                     

Total short-term investments

   $ 19,204    $ 87      $ 19,291
                     

Long-term investments

       

Auction rate securities

   $ 12,950    $ (2,043   $ 10,907

Put Option

          2,043        2,043
                     

Total long-term investments

   $ 12,950    $      $ 12,950
                     

 

F-25


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

The following table summarizes the Company’s investments as of December 31, 2009 (in thousands):

 

     December 31, 2009
     Amortized
Cost
   Unrealized Gain
(Loss)
    Fair Value

Short-term investments

       

US Government agency securities

   $ 35,319    $ 3      $ 35,322

Auction rate securities

     12,700      (1,465     11,235

Put Option

          1,465        1,465
                     

Total short-term investments

   $ 48,019    $ 3      $ 48,022
                     

 

The following table summarizes the Company’s investment as of March 31, 2010 (in thousands):

 

     March 31, 2010
     Amortized
Cost
   Unrealized Gain
(Loss)
    Fair Value
          (Unaudited)      

Short-term investments

       

US Government agency securities

   $ 61,897    $ (6   $ 61,891

Auction rate securities

     12,050      (1,418     10,632

Put Option

          1,418        1,418
                     

Total short-term investments

   $ 73,947    $ (6   $ 73,941
                     

 

Property and Equipment

 

Property and equipment, net is comprised of the following (in thousands):

 

     December 31,     March 31,  
     2008     2009     2010  
                 (Unaudited)  

Leasehold improvements

   $ 31,182      $ 29,575      $ 29,592   

Research and laboratory equipment

     9,422        16,904        18,031   

Computers and software

     1,159        1,472        2,683   

Furniture and office equipment

     1,355        1,468        1,517   

Construction in progress

     1,998        2,158        2,703   
                        
     45,116        51,577        54,526   

Less: accumulated depreciation and amortization

     (3,551     (9,017     (10,613
                        

Property and equipment, net

   $ 41,565      $ 42,560      $ 43,913   
                        

 

Depreciation and amortization expense was $634,000, $2.6 million and $5.8 million for the years ended December 31, 2007, 2008 and 2009, respectively. Depreciation and amortization expense was $1.4 million (unaudited) and $1.6 million (unaudited) for the three months ended March 31, 2009 and 2010, respectively.

 

Property and equipment includes $4.1 million, $8.9 million and $9.7 million (unaudited) of research and laboratory equipment and furniture and office equipment under capital leases as of December 31, 2008 and 2009 and March 31, 2010, respectively. Accumulated amortization of assets under capital leases totaled $626,000, $2.1 million and $2.5 million (unaudited) as of December 31, 2008 and 2009 and March 31, 2010, respectively.

 

F-26


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Accrued and Other Current Liabilities

 

Accrued and other current liabilities are comprised of the following (in thousands):

 

     December 31,    March 31,
     2008    2009    2010
               (Unaudited)

Professional services

   $ 1,635    $ 2,411    $ 3,664

Property and equipment

     731          

Accrued vacation

     636      1,471      1,754

Payroll and related expenses

     604      1,573      1,302

Tax-related liabilities

     431      330      107

Deferred rent, current portion

     100      893      729

Refundable exercise price on early exercise of stock options

     262      101      91

Refundable deposits

          2,177     

Restructuring charge, current portion

          592      490

Other

     684      897      429
                    

Total accrued and other current liabilities

   $ 5,083    $ 10,445    $ 8,566
                    

 

5. Commitments and Contingencies

 

Capital Leases

 

In March 2008, the Company executed an equipment financing agreement intended to cover certain qualifying research and laboratory hardware and software. In January 2009, the agreement was amended to increase the financing amount. During the years ended December 31, 2008 and 2009, the Company financed certain purchases of hardware equipment and software of approximately $3.3 million and $4.8 million, respectively. Pursuant to the equipment financing agreement, the Company financed the equipment with the transactions representing capital leases. Accordingly, fixed assets and capital lease liabilities were recorded at the present values of the future lease payments of $3.1 million and $6.9 million during the years ended December 31, 2008 and December 31, 2009. The incremental borrowing rates used to determine the present values of the future lease payments was 9.5%. Capital lease obligations expire at various dates, with the latest maturity in April 2013.

 

In connection with the capital lease entered into in 2008, the Company issued a warrant to purchase shares of the Company’s convertible preferred stock (See Note 10).

 

F-27


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

The recorded balance of capital lease obligations as of December 31, 2008 and 2009 and March 31, 2010 was $3.6 million, $7.2 million and $7.5 million (unaudited), respectively. The Company recorded interest expense in connection with its capital leases of $18,000, $175,000, $751,000, $206,000 (unaudited) for the years ended December 31, 2007, 2008 and 2009 and the three months ended March 31, 2010, respectively. Future minimum payments under capital leases as of December 31, 2009, are as follows (in thousands):

 

     Capital Leases  

Years ending December 31:

  

2010

   $ 2,961   

2011

     2,905   

2012

     2,394   

2013

     271   

2014

       

Thereafter

       
        

Total future minimum lease payments

     8,531   

Less: executory costs

     (19
        

Net minimum lease payments

     8,512   

Less: amount representing interest

     (1,284
        

Present value of minimum lease payments

     7,228   

Less: current maturities

     (2,251
        

Long-term portion

   $ 4,977   
        

 

Operating Leases

 

The Company has noncancelable operating lease agreements for office, research and development and manufacturing space in the United States and Brazil.

 

In August 2007, the Company entered into an operating lease for its new headquarters in Emeryville, California, with a term of ten years commencing in May 2008. As part of the operating lease agreement, the Company received a tenant improvements allowance of $11.4 million. The Company recorded the allowance as deferred rent and associated expenditures as leasehold improvements that are being amortized over the shorter of their useful life or the terms of the lease. In connection with the operating lease, the Company elected to defer a portion of the monthly base rent due under the lease and entered into notes payable agreements with the lessor for the purchase of certain tenant improvements (see Note 6).

 

In addition, the Company leases a facility in Brazil pursuant to a noncancelable operating lease that expires in May 2013 and the Company leases office space in the United States under noncancelable operating leases that expire at various dates, with the latest expiration in May 2018.

 

The Company recognizes rent expense on a straight-line basis over the noncancelable lease term and records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. Where leases contain escalation clauses, rent abatements, and/or concession, such as rent holidays and landlord or tenant incentives or allowances, the Company applies them in the determination of straight-line rent expense over the lease term. Rent expense for the years ended December 31, 2007, 2008 and 2009 was $1.0 million, $2.9 million and $3.6 million. Rent expense was $982,000 (unaudited) and $753,000 (unaudited) for the three months ended March 31, 2009 and 2010, respectively.

 

F-28


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

As of December 31, 2009, future minimum rental payments under the operating leases are as follows (in thousands):

 

     Operating Leases

Years ending December 31:

  

2010

   $ 3,161

2011

     4,021

2012

     4,669

2013

     4,328

2014

     4,051

Thereafter

     14,517
      

Total future minimum lease payments

   $ 34,747
      

 

Amyris Brasil S.A. Transactions

 

On December 22, 2009, the Company entered into an investment and stockholders’ agreement with third-party investors (“Investors”) to sell a 4.8% equity interest in Amyris Brasil. In the quarter ended March 31, 2010, Amyris Brasil sold an incremental 3.4% (unaudited) equity interest in Amyris Brasil to investors. Under the terms of the agreements, the Company is required to make additional capital investments in Amyris Brasil worth at least BRL $50.0 million. (See Note 16).

 

Guarantor Arrangements

 

The Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification period is for the officer or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future amounts paid. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of December 31, 2008 and 2009.

 

Other Matters

 

The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company, management does not believe any pending matter will be resolved in a manner that would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

 

F-29


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

6. Debt

 

Debt is comprised of the following (in thousands):

 

     December 31,     March 31,  
     2008     2009     2010  
                 (Unaudited)  

Credit facility

   $      $ 8,343      $ 7,638   

Notes payable

            4,038        4,143   

Loans payable

     3,149        999        995   
                        

Total debt

     3,149        13,380        12,776   

Less: current portion

     (340     (9,018     (8,534
                        

Long-term debt

   $ 2,809      $ 4,362      $ 4,242   
                        

 

Credit Facility

 

In January 2009, the Company entered into a credit facility with UBS associated with student loan auction rate securities holdings. In March and April 2009, the Company drew down $8.1 million and $0.5 million on the credit facility. The credit facility is collateralized by the auction rate securities held with the bank. The credit facility bears a variable interest rate of LIBOR plus 1.25% and the weighted average borrowing rate under the credit facility was 1.32% and 1.28% (unaudited) as of December 31, 2009 and March 31, 2010, respectively. As of December 31, 2009 and March 31, 2010, the total amount outstanding under the credit facility was $8.3 million and $7.6 million (unaudited), respectively.

 

Notes Payable

 

During the period between May 2008 and October 2008, the Company entered into notes payable agreements with the lessor of its headquarters under which the total amount of $3.3 million was borrowed for the purchase of tenant improvements, bearing an interest rate of 9.5% per annum and to be repaid over a period of 55 to 120 months. As of December 31, 2008 and 2009 and March 31, 2010, a principal amount of $3.1 million, $2.8 million and $2.7 million (unaudited) was outstanding under these notes payable, respectively.

 

During the period between January 2009 and December 2009, the Company entered into notes payable agreements with a service provider in connection with its software implementation under which the total amount of $1.2 million was borrowed for the payment of implementation services and software licenses, bearing an interest rate of 8.53% per annum and to be repaid over a period of 72 to 83 months. As of December 31, 2009 and March 31, 2010 (unaudited), a principal amount of $1.1 million was outstanding under these notes payable.

 

In July 2009, the Company entered into a notes payable agreement of $378,000 with its insurance provider. The notes payable are payable in monthly principal and interest installments of $45,300 through March 2010. The note payable accrues interest at 6%. As of December 31, 2009 and March 31, 2010, a principal amount of $125,000 and zero (unaudited) was outstanding under the notes payable, respectively.

 

In March 2010, the Company entered into a notes payable agreement of $101,000 (unaudited) with its insurance provider. The notes are payable in monthly principal and interest installments of $11,000 (unaudited) through November 2010. The note payable accrues interest at 5.50% (unaudited). As of March 2010 a principal amount of $90,000 (unaudited) was outstanding under these notes payable.

 

In February 2010, the Company entered into a notes payable agreement of $239,000 (unaudited) with its landlord. The notes are payable in monthly principal and interest installments of $31,000 from June 2010 through

 

F-30


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

January 2011. The notes payable accrue interest at 10.50%. As of March 31, 2010, a principal amount of $239,000 (unaudited) was outstanding under these notes payable.

 

Loans Payable

 

In August 2009, the Company entered into a loans payable agreement with the lessor of its headquarters under which $750,000 was borrowed. The loan is payable in monthly installments of interest only and unpaid interest and principle is payable in December 2011. Interest accrues at an interest rate of 10.5%. As of December 31, 2009 and March 31, 2010 (unaudited), a principal amount of $750,000 was outstanding under the loan. The notes payable agreement is secured by a $750,000 letter of credit.

 

In December 2009, the Company entered into a loan payable agreement with the lessor of its Emeryville, pilot plant under which the total amount of $250,000 was borrowed, bearing an interest rate of 10% per annum and to be repaid over a period of 96 months. As of December 31, 2009 and March 31, 2010, a principal amount of $249,000 and $244,000 (unaudited) was outstanding under the loan, respectively.

 

Future minimum payments under the debt agreements as of December 31, 2009 are as follows (in thousands):

 

       Credit Line     Notes Payable     Loans Payable  

Years ending December 31:

      

2010

   $ 8,398      $ 993      $ 123   

2011

            863        866   

2012

            861        45   

2013

            682        45   

2014

            592        45   

Thereafter

            1,406        134   
                        

Total minimum payments

     8,398        5,397        1,258   

Less: interest

     (55     (1,359     (259
                        

Present value of future minimum payments

     8,343        4,038        999   

Less: current portion

     (8,343     (653     (22
                        

Noncurrent portion of debt

   $      $ 3,385      $ 977   
                        

 

Letters of Credit

 

In November 2008, the Company entered into an uncommitted facility letter (the “Credit Agreement”) with a financial institution to finance the purchase and sale of fuel and for working capital requirements, as needed. In October 2009, the agreement was amended to decrease the maximum amount that the Company may borrow under such facility. The Credit Agreement, as amended, provides an aggregate maximum availability up to the lower of $20.0 million and the borrowing base as defined in the agreement, and is subject to a sub-limit of $5.7 million for the issuance of letters of credit and a sub-limit of $20 million for short-term cash advances for product purchases. Amyris has a parent guarantor for the payment of the outstanding balance under the Credit Agreement. Outstanding advances bear an interest rate at the Company’s option of the bank’s prime rate plus 1.0% or the bank’s cost of funds plus 3.5%. As of December 31, 2009, the Company had sufficient borrowing base levels to draw down up to a total of $2.8 million in short term cash advances and $4.6 million available for letters of credit in addition to those outstanding as of December 31, 2009. As of April 2, 2010 the Company could draw $2.4 million in short term advances and had $1.7 million available for letters of credit in addition to those outstanding at March 31, 2010. As of December 31, 2008 and 2009, and March 31, 2010 the Company had no outstanding advances and had $0.7 million, $1.1 million and $4.0 million (unaudited) in outstanding letters of credit under the Credit Agreement.

 

F-31


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

To the extent that amounts under the Credit Agreement remain unused, while the Credit Agreement is in effect and for so long thereafter as any of the obligations under the Credit Agreement are outstanding, the Company will pay an annual commitment fee of $300,000. The Credit Agreement requires compliance with certain customary covenants that require maintenance of certain specified financial ratios and conditions. As of December 31, 2009, the Company was in compliance with its financial covenants under the Credit Agreement. The Credit Agreement is collateralized by a first priority security interest in certain of the Company’s present and future assets.

 

In November 2009, the Company entered into an irrevocable standby letter of credit agreement for up to $4.5 million. As of March 31, 2010 five letters of credit had been issued totaling $3.8 million (unaudited) as security for certain facility and capital leases, each of which expires on November 9, 2010 and will be automatically extended for two one-year periods. As of December 31, 2009, the Company was in compliance with all financial covenants in the letter of credit agreements. In connection with the letter of credit agreements, the Company maintained a deposit balance with the financial institution, which amounted to $4.5 million as of December 31, 2009 and March 31, 2010 (unaudited), respectively. The availability of the letter of credit is dependent upon maintaining the cash deposits.

 

7. Income Taxes

 

The components of the provision for (benefit from) income taxes are as follows for the years ended December 31, 2007, 2008 and 2009 (in thousands):

 

     2007    2008     2009

Current:

       

Federal

   $    $      $

State

          (207    

Foreign

                
                     

Total current provision (benefit)

          (207    
                     

Deferred:

       

Federal

                

State

                

Foreign

                
                     

Total deferred provision (benefit)

                
                     

Total provision for (benefit from) income taxes

   $    $ (207   $
                     

 

A reconciliation between the statutory federal income tax and the Company’s effective tax rates as a percentage of loss before income taxes is as follows:

 

     Years Ended December 31,  
       2007         2008         2009    

Statutory tax rate

   34.0   34.0   34.0

State tax rate, net of federal benefit

   6.8      3.5      5.5   

Incentive stock option stock compensation

   (0.6   (0.5   (0.4

Federal R&D credit

   1.5      0.1      1.0   

Other

   (3.4   1.1      1.2   

Change in valuation allowance

   (38.3   (37.8   (41.3
                  

Effective income tax rate

   0   0.4   0
                  

 

F-32


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Temporary differences and carryforwards that gave rise to significant portions of deferred taxes are as follows (in thousands):

 

     December 31,
2008
    December 31,
2009
 

Net operating loss carry forwards

   $ 19,879      $ 37,118   

Fixed assets

            108   

Research and development credits

     208        2,409   

Accruals and reserves

     552        1,240   

Stock compensation

     719        1,602   

Other

            5,322   
                

Total deferred tax assets

     21,358        47,799   

Fixed assets

     (296       

Other

     (43       
                

Total deferred tax liabilities

     (339       
                

Net deferred tax asset prior to valuation allowance

     21,019        47,799   

Less: Valuation allowance

     (21,019     (47,799
                

Net deferred tax assets (liabilities)

   $      $   
                

 

Due to uncertainties surrounding the realization of deferred tax assets through future taxable income, the Company has provided a full valuation allowance and, therefore, has not recognized any benefits from the net operating losses and other deferred tax assets. The valuation allowance increased $4.5 million, $16.1 million and $26.8 million during the years ended December 31, 2007, 2008 and 2009, respectively.

 

Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. Based upon the weight of available evidence, the Company believes it is not yet more likely than not that the net deferred tax assets will be fully realizable. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets as of December 31, 2009.

 

As of December 31, 2009, the Company had federal and California net operating loss carryforwards of approximately $95.8 million and $67.4 million available to reduce future taxable income, if any, respectively.

 

The federal net operating loss carryforward begins expiring in 2025, and the California net operating loss carryforward begins expiring in 2015. The Company also had federal and California state research and development credit carryforwards of approximately $2.0 million and $2.1 million at December 31, 2009. The federal credits will expire starting 2024 if not utilized. The California tax credits can be carried forward indefinitely.

 

The Tax Reform Act of 1986 limits the use of net operating loss and tax credit carryforwards in certain situations where equity transactions result in a change of ownership as defined by Internal Revenue Code Section 382. In the event the Company should experience an ownership change, as defined, utilization of its United States net operating loss carryforwards and tax credits could be limited.

 

F-33


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Effective January 1, 2007, the Company adopted the accounting guidance on uncertainties in income taxes. A reconciliation of the beginning and ending amounts of unrecognized tax benefits since the adoption of accounting guidance on uncertainty in income taxes is as follows:

 

January 1, 2007

   $ 41

Increases in balances related to tax provisions taken during current period

     108
      

December 31, 2007

     149

Increases in balances related to tax provisions taken during current period

     423
      

December 31, 2008

     572

Increases in balances related to tax provisions taken during current period

     460
      

December 31, 2009

   $ 1,032
      

 

The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the provision for taxes. Management determined that no accrual for interest and penalties was required as of December 31, 2009.

 

As of December 31, 2009, the Company’s total unrecognized tax benefits were $1 million, of which none of the tax benefits, if recognized, would affect the effective income tax rate due to the valuation allowance that currently offsets deferred tax assets. The Company does not anticipate the total amounts of unrecognized income tax benefits will significantly increase or decrease in the next 12 months.

 

The Company’s primary tax jurisdiction is the United States. For United States federal and state tax purposes, tax years 2003 through 2009 remain open and subject to tax examination by the appropriate federal or state taxing authorities. Brazil tax years 2008 and 2009 remain open and subject to examination.

 

8. Research and Development Activities

 

Research and Collaboration Agreement

 

In November 2004, the Company entered into a research and collaboration agreement (the “Agreement”) with the Institute for One World Health (“IOWH”), a California nonprofit corporation, and the Regents of the University of California, Berkeley (“UC Berkeley”). Per the agreement, IOWH agreed to work in partnership with UC Berkeley and the Company. UC Berkeley agreed to conduct basic research to aid in the engineering of a microbe to make a biosynthetic precursor of artemisinin, currently the most effective treatment for malaria. The Company will optimize the strain for industrial fermentation and develop a follow-on chemical synthesis for artemisinin using the precursor. IOWH agreed to perform the drug development and regulatory work to demonstrate the bioequivalence of microbially produced artemisinin derivative to the drug’s natural form. The Company will receive no payments from the eventual use of the technology towards the production of antimalarial drugs for use in the developing world. The Agreement, however, allows the Company to develop and maintain ownership rights over a platform technology that is applicable towards the production of many other compounds.

 

During the year ended December 31, 2007, the Company received $4.1 million under this agreement. The Company recorded deferred revenue of $1.4 million and $0 million as of December 31, 2007 and 2008.

 

F-34


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Exclusive Development and Commercialization Agreement

 

In November 2004, the Company entered into an exclusive development and commercialization agreement, as amended in January 2008, with IOWH and sanofi-aventis (the “Parties”) under which the Parties agreed to develop and commercialize specific products (“anti-malarias”) in the IOWH field and territory (countries in the developing world). Under this amended agreement, the Company will grant IOWH and its affiliates a worldwide, exclusive, royalty-free license to develop and commercialize such anti-malaria products in those developing world countries.

 

During the year ended December 31, 2007, 2008 and 2009, the Company received $0, $1.7 million and $1.3 million related to these agreements. During the three months ended March 31, 2009 and 2010, the Company received $0.6 million (unaudited) and $0 (unaudited) related to these agreements.

 

Professional Services Contract

 

During the year ended December 31, 2008, the Company entered into a professional services contract (the “Contract”) with Auburn University. Per the contract, the Company will provide a portion of the activities required to plant, grow, harvest, and analyze a sugarcane nursery in Alabama. During the years ended December 31, 2008 and 2009, the Company recognized revenue of $204,000 and $0 related to this arrangement.

 

Development Services Agreement

 

In June 2009, the Company entered into a development services agreement with Sanofi Chimie, under which the Company agreed to perform molecular biology development services related to strain improvement on behalf of Sanofi Chimie. Under the terms of the agreement, Sanofi Chimie provided the Company with an up-front payment of $1.5 million which is being recognized on a ratable basis over the research period under the arrangement. The Company is also eligible to receive milestone payments totaling $1.5 million and a bonus payment of $0.3 million if a specified target is met. Milestones to be earned under the agreement have been determined to be at risk and substantive at the inception of the arrangement and are expected to be recognized upon achievement of the milestone and when collectability is reasonably assured. Research and development revenue of $1.6 million, including milestone revenue was recognized under the agreement during the year ended December 31, 2009 and $1.4 million (unaudited) was recognized under the agreement in the three months ended March 31, 2010. The Company recorded deferred revenue of $378,000 as of December 31, 2009 and $0 (unaudited) as of March 31, 2009 and 2010.

 

9. Convertible Preferred Stock

 

Under the Company’s amended and restated articles of incorporation, the Company’s convertible preferred stock is issuable in series.

 

A summary of convertible preferred stock issued and outstanding as of December 31, 2008 is as follows (in thousands, except share data):

 

     December 31, 2008
     Shares
Authorized
   Shares
Issued and
Outstanding
   Liquidation
Preference per
Share
   Liquidation
Amount
   Carrying
Value

Series A

   9,475,000    9,475,000    $ 2.174    $ 20,599    $ 20,470

Series B

   1,929,641    1,667,817      24.88      41,495      41,326

Series B-1

   4,700,000    2,538,841      25.26      64,131      59,640
                          

Total

   16,104,641    13,681,658       $ 126,225    $ 121,436
                          

 

F-35


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

A summary of convertible preferred stock issued and outstanding as of December 31, 2009 is as follows (in thousands, except share data):

 

     December 31, 2009
     Shares
Authorized
   Shares
Issued and
Outstanding
   Liquidation
Preference per
Share
   Liquidation
Amount
   Carrying
Value

Series A

   9,475,000    9,475,000    $ 2.174    $ 20,599    $ 20,470

Series B

   1,929,641    1,667,817      24.88      41,495      41,326

Series B-1

   4,700,000    2,615,721      25.26      66,073      61,412

Series C

   4,976,000    4,606,684      12.46      57,399      56,443
                          

Total

   21,080,641    18,365,222       $ 185,566    $ 179,651
                          

 

A summary of convertible preferred stock issued and outstanding as of March 31, 2010 is as follows (in thousands, except share data);

 

     March 31, 2010
     Shares
Authorized
   Shares
Issued and
Outstanding
   Liquidation
Preference per
Share
   Liquidation
Amount
   Carrying
Value
     (Unaudited)

Series A

   9,475,000    9,475,000    $ 2.174    $ 20,599    $ 20,470

Series B

   1,929,641    1,667,817      24.88      41,495      41,326

Series B-1

   4,700,000    2,615,721      25.26      66,073      61,412

Series C

   4,976,000    4,902,665      12.46      61,087      59,619

Series C-1

   2,781,714    2,724,766      17.56      47,847      47,779
                          

Total

   23,862,355    21,385,969       $ 237,101    $ 230,606
                          

 

The convertible preferred stock is recorded at fair value on the dates of issuance, net of issuance costs. The convertible preferred stock is classified outside of stockholders’ equity (deficit) because the shares contain liquidation features that are not solely within the control of the Company.

 

The rights, preferences and privileges of the convertible preferred stock are as follows:

 

Voting

 

Except as required by applicable law, each share of convertible preferred stock has voting rights equal to an equivalent number of shares of common stock into which it is convertible and votes together as one class with the common stock.

 

As long as at least 20% of the originally issued shares of the convertible preferred stock remain outstanding, consent of the holders of at least the majority of the convertible preferred stock are required for any action that includes among others (i) alters or changes the rights, preferences or privileges of the common stock and convertible preferred stock; (ii) results in the redemption of any shares of convertible preferred stock or common stock; (iii) results in a liquidation or other corporate reorganization; (iv) amends or waives any provision of the Company’s amended and restated articles of incorporation; (v) increases or decreases the authorized size of the Board of Directors; and (vi) results in the payment or declaration of any dividend on any shares of common or convertible preferred stock.

 

F-36


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Dividends

 

The holders of the convertible preferred stock are entitled to receive, in preference to any dividend on the common stock, noncumulative dividends, on a pari passu basis, at the rate of 8% of the original issue price per annum on each outstanding share of Series A, B, B-1, C and C-1 convertible preferred stock. Such dividends are payable when, as and if declared by the Board of Directors. No dividends have been declared to date.

 

Conversion Rights

 

Each share of preferred stock is convertible, at the option of the holder, at any time, into shares of common stock determined by dividing the issuance price per share by the conversion price in effect at the time of the conversion. The per share conversion prices are subject to adjustment for antidilution, stock splits and reclassifications. The per share conversion prices of Series A, B, B-1, C and C-1 convertible preferred stock are $2.174, $22.25, $22.53, $12.46 and $17.56, respectively. Accordingly, the conversion ratios for the Series A, B, B-1, C and C-1 convertible preferred stock to common stock are 1:1, 1:1.118, 1:1.121, 1:1 and 1:1, respectively.

 

Each share of Series A, B, B-1, C and C-1 convertible preferred stock shall automatically be converted into a number of shares of common stock upon the earlier to occur of (i) the date specified by the written consent or agreement of the holders of a majority of the then outstanding shares of Series A, B, B-1, C and C-1 convertible preferred stock, each such series voting together as a single class, or (ii) immediately upon the completion of the sale of the Company’s common stock in a firm commitment, underwritten public offering registered under the Securities Act of 1933, which results in aggregate proceeds to the Company equal to at least $30.0 million.

 

Liquidation Rights

 

In the event of any liquidation, dissolution, or winding up of the Company, the holders of the Series A, B, B-1, C and C-1 convertible preferred stock shall be entitled to receive, prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of the common stock, an amount equal to $2.174, $24.88, $25.26, $12.46 and $17.56 per share plus any declared but unpaid dividends on such share (the “Liquidation Preference”). After the payment of the Liquidation Preference, all remaining assets available for distribution, if any, shall be distributed ratably among the holders of the common stock. If available assets are insufficient to pay the full Liquidation Preference, the available assets will be distributed to the holders of Series A, B, B-1, C and C-1 convertible preferred stock, in proportion to the preferential amount each such holder is otherwise entitled to receive.

 

A merger, consolidation, sale or lease of all or substantially all of the assets of the Company which will result in the Company’s stockholders immediately prior to such transaction not holding at least 50% of the voting power of the surviving entity, shall be deemed to be a liquidation, dissolution or winding up. Upon this event, holders of all shares of Series A, B, B-1, C and C-1 convertible preferred stock shall receive the greater of (i) their liquidation preference including any declared but unpaid dividends as of the liquidation date or (ii) the amount that would have been payable had all shares of each such series been converted into common stock immediately prior to this event.

 

Redemption Rights

 

The convertible preferred stock is not redeemable.

 

The Company performs ongoing assessments of all terms and features of its convertible preferred stock in order to identify any potential embedded features that would require bifurcation or any beneficial conversion features. As part of this analysis, the Company assessed the economic characteristics and risks of its convertible

 

F-37


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

preferred stock, including conversion, liquidation and redemption features, as well as dividend and voting rights. Based on the Company’s determination that each series of its convertible preferred stock is an “equity host,” the Company determined that the features of the convertible preferred stock are most closely associated with an equity host and, although the convertible preferred stock includes conversion features, such conversion features do not require bifurcation as a derivative liability. The Company also determined that the conversion option with a contingent reduction in the conversion price, upon occurrence of certain dilutive events, is a potential contingent beneficial conversion feature. In accordance with certain antidilution provisions contained in the Series B and B-1 convertible preferred stock agreements, issuances of shares C and C-1 convertible preferred stock resulted in an antidilution adjustment of the conversion prices for the series B and B-1 convertible preferred stock during the year ended December 31, 2009 and three months ended March 31, 2010. As a result, the Company performed a calculation to determine if a beneficial conversion feature was triggered for the series B and B-1 convertible preferred stock at each issuance of series C and C-1 convertible preferred stock. The fair value of common stock, as determined by management and the Board of Directors, on the corresponding issuance dates of series B and B-1 convertible preferred stock in each instance was below the adjusted conversion prices. Therefore, no beneficial conversion feature was identified. The Company will continue to evaluate if a beneficial conversion feature needs to be recorded upon each subsequent adjustment of the conversion price based upon the difference between the adjusted conversion price and the fair market value of common stock at the original issuance date.

 

10. Warrants for Convertible Preferred Stock

 

The Company had the following unexercised convertible preferred stock warrants (in thousands, except for share data):

 

     Exercise
Price per
Share
   Shares as of
December 31,
   Fair Value as of
December 31,

Underlying Stock

        
      2008    2009    2008    2009

Series B Convertible Preferred Stock

   $ 24.88    12,628    2,580    $ 237    $ 48

Series B-1 Convertible Preferred Stock

   $ 25.26    102,724    106,567      1,895      2,267

Series C Convertible Preferred Stock

   $ 12.46       24,101           425
                          

Total

      115,352    133,248    $ 2,132    $ 2,740
                          

 

     Exercise
Price per
Share
   Shares as of
March 31,
   Fair Value
as of

March 31,
        2010    2010
          (Unaudited)     

Series B Convertible Preferred Stock

   $ 24.88    2,580    $ 33

Series B-1 Convertible Preferred Stock

   $ 25.26    106,567      1,597

Series C Convertible Preferred Stock

   $ 12.46    73,258      1,075
              

Total

      182,405    $ 2,705
              

 

Series B

 

In 2008, in connection with consulting services, the Company issued a warrant to purchase 2,580 shares of the Company’s Series B convertible preferred stock at an exercise price of $24.88 per share. The warrant is immediately exercisable and expires upon the earlier of (i) five years from the effective date; (ii) one year from the effective date of a public offering; or (iii) upon a change of control. The Company estimated the initial fair value of the warrant as of the date of issuance to be $39,000 and was recorded as consulting expense. The fair value was based on the contractual term of the warrants of five years, risk-free interest rate of 3.5%, expected volatility of 70% and 0% expected dividend yield.

 

F-38


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

In 2008, in connection with a capital lease agreement, the Company issued a warrant to purchase 10,048 shares of the Company’s Series B convertible preferred at an exercise price of $24.88 per share. The warrant was immediately exercisable and was due to expire upon the earlier of (i) ten years from the effective date; (ii) one year from the effective date of a public offering; or (iii) a merger event. The Company estimated the initial fair value of the warrant to be $196,000 and was recorded as other assets. The fair value was based on the contractual term of the warrants of ten years, risk-free interest rate of 4.04%, expected volatility of 70% and 0% annual dividend rate. In September 2009, the Company cancelled the warrant and issued a warrant to purchase 10,048 shares of the Company’s Series C convertible preferred stock.

 

Series B-1

 

In 2008, in connection with the Company’s issuance of Series B-1 convertible preferred stock, the Company issued warrants to purchase 100,715 shares of the Company’s Series B-1 convertible preferred stock at an exercise price of $25.26 per share to the placement agent. The warrants are immediately exercisable and expire seven years from the effective date. The Company estimated the initial fair value of these warrants as of the issuance dates to be $1.7 million and was recorded as a reduction to the carrying value of the Series B-1 convertible preferred stock. The fair value was based on the contractual term of the warrants of seven years, risk-free interest rates from 2.9% to 3.7%, expected volatility from 70% to 75%, and 0% expected dividend yield.

 

In 2008, in connection with an operating lease, the Company issued a warrant to purchase 2,009 shares of the Company’s Series B-1 convertible preferred stock at an exercise price of $25.26 per share. The warrant is exercisable immediately and expires upon the earlier of (i) ten years from the effective date; (ii) an underwritten public offering; or (iii) upon a change of control. The Company estimated the initial fair value of the warrant as of the date of issuance to be $40,000 and was recorded as rent expense. The fair value was based on the contractual term of the warrants of ten years, risk-free interest rate of 4.0%, expected volatility of 70% and 0% expected dividend yield.

 

In 2009, in connection with the Company’s issuance of Series B-1 convertible preferred stock, the Company issued a warrant to purchase 3,843 shares of the Company’s Series B-1 convertible preferred stock at an exercise price of $25.26 to the placement agent. The warrants are exercisable immediately and expire seven years from the effective date. The Company estimated the fair value of the warrant as of the date of issuance to be $68,000 and was recorded as a reduction to the carrying value of the Series B-1 convertible preferred stock. The fair value was based on the contractual term of the warrants of seven years, risk-free interest rate of 2.3%, expected volatility of 90% and 0% expected dividend yield.

 

Series C

 

In September 2009, the Company cancelled the warrant to purchase 10,048 shares of the Company’s Series B convertible preferred stock and issued a warrant to purchase 16,075 shares of the Company’s Series C convertible preferred stock with an exercise price of $12.46 per share. In connection with a capital lease arrangement, the Company issued a warrant to purchase 8,026 shares of the Company’s Series C convertible preferred stock at an exercise price of $12.46 per share. The warrants are exercisable immediately and expire upon the earlier of (i) September 2019; (ii) one year from the effective date of a public offering; or (iii) a merger event. The Company estimated the initial fair value of warrants as of the date of issuance to be $269,000 and was recorded as other assets and amortized over the capital lease draw-down period. The fair value was based on the contractual term of the warrants of ten years, risk-free interest rate of 3.3%, expected volatility of 97%, and 0% expected dividend yield.

 

In January 2010, in connection with the Company’s issuance of Series C convertible preferred stock, the Company issued a warrant to purchase 49,157 shares of the Company’s Series C convertible preferred stock at an

 

F-39


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

exercise price of $12.46 per share to the placement agent. The warrant is exercisable immediately and expires seven years from the effective date. The Company estimated the fair value of the warrant as of the date of issuance to be $507,000 which was recorded as a reduction to the carrying value of the Series C convertible preferred stock. The fair value was based on the contractual term of the warrant of seven years, risk-free interest rate of 3.39%, expected volatility of 98% and 0% expected dividend yield.

 

The change in the fair value of convertible preferred stock warrants resulted in a charge to other expense in the amount of $114,000 and $445,000 during the years ended December 31, 2008 and 2009. For the three months ended March 31, 2009 and 2010, the Company recorded a gain of $138,000 (unaudited) and $542,000 (unaudited), respectively as an offset to other expense to reflect the change in the fair value of the warrants. The Company determined the fair value of the warrants as of December 31, 2008 and 2009 and March 31, 2009 and 2010 using the Black-Scholes option pricing model with the following assumptions:

 

    December 31,   March 31,
    2008   2009   2009   2010
            (Unaudited)

Expected dividend yield

 

0%

 

0%

  0%   0%

Risk-free interest rate

 

1.6%-2.3%

 

1.7%-3.9%

 

1.2%-2.7%

  1.6%-3.8%

Contractual term (in years)

  4-9.5   3-9.8  

3.8-9.3

  2.8-9.5

Expected volatility

 

80%

 

98%-111%

 

90%-93%

 

98%-112%

 

Each of these warrants includes a cashless exercise provision which permits the holder of the warrant to elect to exercise the warrant without paying the cash exercise price, and receive a number of shares determined by multiplying (i) the number of shares for which the warrant is being exercised by (ii) the difference between the fair market value of the stock on the date of exercise and the warrant exercise price, and dividing such by (iii) the fair market value of the stock on the date of exercise. As of December 31, 2009 and March 31, 2010, these warrants were outstanding and exercisable.

 

11. Common Stock

 

The Articles of Incorporation authorize the Company to issue 33,000,000 and 38,000,000 (unaudited) shares of common stock as of December 31, 2009 and March 31, 2010, respectively. Holders of the Company’s common stock are entitled to dividends as and when declared by the Board of Directors, subject to the rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote.

 

12. Restricted stock

 

Pursuant to restricted stock agreements with the Company’s founders, the Company has the right, but not the obligation, to repurchase all or any portion of the unvested shares of common stock upon termination of employment at the original purchase price per share. The repurchase rights with respect to founders stock lapse over the vesting period, which ranges from 68 to 100 months. As of December 31, 2008 and 2009 and March 31, 2010, 267,711, 52,084 and 20,834 (unaudited) restricted shares of common stock held by the Company’s founders were subject to repurchase by the Company.

 

F-40


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

13. Stock Based Compensation

 

Employee Equity Plan

 

In 2005, the Company established its 2005 Stock Option Plan (the “Plan”) which provides for the granting of common stock options, RSUs, restricted stock and stock purchase rights awards to employees and consultants of the Company. The Plan allows for time-based or performance-based vesting for the awards. Options granted under the Plan may be either incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees and consultants.

 

Options under the Plan may be granted for periods of up to ten years. All options issued to date have had a ten year life. The exercise price of an ISO and NSO shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors. The exercise price of an ISO and NSO granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the underlying stock on the date of grant as determined by the Board of Directors. The Company’s options generally vest over four to five years.

 

In December 2009, the Company issued 10,000 shares of restricted stock to an employee with performance-based vesting conditions. The performance based vesting conditions require the achievement of certain operational performance criteria as a condition of vesting for such award within six months following the date of grant. As of December 31, 2009, the Company assessed the probability of achieving the performance conditions and determined it was not probable that the performance condition will be satisfied. No compensation cost was recorded during the year ended December 31, 2009 or the three months ended March 31, 2010 (unaudited).

 

No income tax benefit has been recognized relating to stock-based compensation expense and no tax benefits have been realized from exercised stock options.

 

F-41


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Stock Option Activity

 

The Company’s stock option, RSU and restricted stock grant activity and related information for the years ended December 31, 2007, 2008 and 2009 and the three months ended March 31, 2010 was as follows:

 

    Shares
Available
for Grant
    Number
of Stock

Options
Outstanding
    Weighted-
Average
Exercise
Price
  Weighted-
Average
Remaining
Contractual
Life (Years)
  Aggregate
Intrinsic
Value
                        (in thousands)

Outstanding—January 1, 2007

  386,800      247,200      $ 0.22   6.96   $ 0

Additional shares authorized

  3,662,700                

Options granted

  (2,792,060   2,792,060        1.65    

Options exercised

       (361,723     0.60    

Options cancelled

  48,627      (48,627     0.20    

Shares repurchased

  20,625             0.10    
                           

Outstanding—December 31, 2007

  1,326,692      2,628,910        1.69   8.81     5,891

Additional shares authorized

  1,390,000              

Options granted

  (1,289,549   1,289,549        3.93    

Restricted stock units granted

  (50,000             

Options exercised

       (172,059     3.42    

Options cancelled

  118,231      (118,231     2.37    

Shares repurchased

  1,498             1.16    
                           

Outstanding—December 31, 2008

  1,496,872      3,628,169        2.38   8.22     21,764

Additional shares authorized

                 

Options granted

  (1,109,553   1,109,553        4.31    

Restricted stock granted

  (10,000             

Options exercised

       (117,515     1.04    

Options cancelled

  173,313      (173,313     2.98    

Shares repurchased

  28,886             0.32    
                           

Outstanding—December 31, 2009

  579,518      4,446,894        2.87   8.19     28,661

Additional shares authorized (unaudited)

  1,026,272              

Options granted (unaudited)

  (1,415,310   1,415,310        10.15    

Restricted stock granted (unaudited)

  (126,272             

Options exercised (unaudited)

       (6,707     0.83    

Options cancelled (unaudited)

  36,042      (36,042     6.73    

Shares repurchased (unaudited)

  200             0.28    
                           

Outstanding—March 31, 2010 (unaudited)

  100,450      5,819,455      $ 4.62   8.38   $ 56,202
                           

Vested and expected to vest—March 31, 2010 (unaudited)

    5,572,615      $ 4.53   8.35   $ 54,317

Exercisable—March 31, 2010 (unaudited)

    2,159,243      $ 2.58   7.61   $ 25,260

 

The aggregate intrinsic value of options exercised under the Plan was $73,000, $26,000 and $308,000 for the years ended December 31, 2007, 2008 and 2009 and $71,000 for the three months ended March 31, 2010 (unaudited), determined as of the date of option exercise.

 

F-42


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

The following table summarizes information about stock options outstanding as of December 31, 2009:

 

     Options Outstanding    Options Exercisable

Exercise Price

     Number of Options      Weighted-Average
Remaining
Contractual Life
(Years)
     Number of Options  

$0.10

   36,700        5.96    35,574

$0.28

   1,180,400    7.10    706,686

$1.50

   273,660    7.57    186,633

$3.93

   1,846,591    8.11    760,537

$4.31

   1,109,543    9.69    208,353
            
   4,446,894    8.19    1,897,783
            

 

The following table summarizes information about stock options outstanding as of March 31, 2010 (unaudited):

 

     Options Outstanding    Options Exercisable

Exercise Price

     Number of Options      Weighted-Average
Remaining
Contractual Life
(Years)
     Number of Options  

$0.10

   34,700    5.74    34,700

$0.28

   1,174,700    6.83    765,956

$1.50

   273,660    7.33    195,597

$3.93

   1,841,096    7.89    844,811

$4.31

   1,094,714    9.40    254,639

$9.32

   1,168,835    9.76    52,957

$14.28

   231,750    9.96    10,583
            
   5,819,455    8.38    2,159,243
            

 

At December 31, 2008, 930,152 options were vested and exercisable under the plan with a weighted average exercise price of $1.27 per share.

 

Common Stock Subject to Repurchase

 

Historically, the Company allowed employees to exercise options prior to vesting. The Company has the right to repurchase at the original purchase price any unvested (but issued) common shares upon termination of service of an employee. The consideration received for an exercise of an option is considered to be a deposit of the exercise price and the related dollar amount is recorded as a liability. The shares and liability are reclassified into equity on a ratable basis as the award vests. The Company recorded a liability in accrued expenses of $262,000, $101,000 and $91,000 (unaudited) relating to 237,324, 69,954 and 56,027 (unaudited) options that were exercised and unvested as of December 31, 2008 and 2009 and March 31, 2010, respectively. These shares were subject to a repurchase right held by the Company and are included in issued and outstanding shares as of December 31, 2008 and 2009 and March 31, 2010, respectively.

 

F-43


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Stock-Based Compensation

 

Stock-based compensation expense related to options and restricted stock units granted to employees and nonemployees was allocated to research and development expense and sales, general and administrative expense as follows (in thousands):

 

     Years Ended December 31,    The Months Ended March 31,
     2007    2008    2009        2009            2010    
                    (Unaudited)

Research and development

   $ 117    $ 632    $ 773    $ 136    $ 453

Sales, general and administrative

     429      1,395      2,526      466      1,346
                                  

Total stock-based compensation expense

   $ 546    $ 2,027    $ 3,299    $ 602    $ 1,799
                                  

 

Employee Stock–Based Compensation

 

During the years ended December 31, 2007, 2008 and 2009, the Company granted 2,531,360, 1,289,549 and 1,089,053 stock options to employees with a weighted average grant date fair value of $1.65, $5.83 and $4.31 per share and during the three months ended March 31, 2010 the Company granted 1,390,310 options to employees with a weighted average grant date fair value of $10.15 (unaudited). As of December 31, 2009 and March 31, 2010, there was unrecognized compensation costs of $6.7 million and $15.6 million (unaudited) related to these stock options. The Company expects to recognize those costs over a weighted average period of 3.5 years as of March 31, 2010. Future option grants will increase the amount of compensation expense to be recorded in these periods.

 

Compensation expense was recorded for stock-based awards granted to employees based on the grant date estimated fair value (in thousands):

 

       Years Ended December 31,    Three Months Ended March 31,
       2007      2008      2009        2009              2010    
                          (Unaudited)

Research and development

     $ 38      $ 501      $ 765    $ 134      $ 435

Sales general and administrative

       268        849        1,822      322        843
                                          

Total stock-based compensation expense

     $ 306      $ 1,350      $ 2,587    $ 456      $ 1,278
                                          

 

The Company sells ethanol procured from third parties and relies on contracted third parties for the transportation and storage of products. Accordingly, the Company does not have any dedicated headcount included in cost of product sales. The six employees of Amyris Fuels are involved in sales, general and administrative functions and their entire compensation including stock compensation expense is recorded in sales, general and administrative expenses.

 

The Company estimated the fair value of employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following weighted-average assumptions:

 

       Years Ended December 31,   Three Months Ended March 31,
       2007   2008   2009   2009      2010
                   (Unaudited)

Expected dividend yield

     0%   0%   0%   *      0%

Risk-free interest rate

    

3.9%-4.7%

  3.2%   2.8%   *      2.8%

Expected term (in years)

     6.0   6.0   6.0   *      6.0

Expected volatility

     70%   70%   97%   *      98%

 

*   There were no stock option grants during the quarter ended March 31, 2009.

 

F-44


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Expected Dividend Yield —The Company has never paid dividends and does not expect to pay dividends.

 

Risk-Free Interest Rate —The risk-free interest rate is based on the United States Treasury yield curve in effect at the time of grant for zero coupon United States Treasury notes with maturities approximately equal to the option’s expected term.

 

Expected Term —Expected term represents the period that the Company’s stock-based awards are expected to be outstanding. The Company’s assumptions about the expected term have been based on that of companies that have similar industry, life cycle, revenue and market capitalization.

 

Expected Volatility —The expected volatility was based on the historical stock volatilities of several of the Company’s publicly listed comparable companies over a period equal to the expected terms of the options, as the Company does not have any trading history to use the volatility of its own common stock.

 

Fair Value of Common Stock —The fair value of the shares of common stock underlying the stock options has historically been determined by the Board of Directors. Because there has been no public market for the Company’s common stock, the Board of Directors has determined fair value of the common stock at the time of grant of the option by considering a number of objective and subjective factors including valuation of comparable companies, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock and general and industry specific economic outlook, amongst other factors. The fair value of the underlying common stock shall be determined by the Board of Directors until such time as the Company’s common stock is listed on an established stock exchange or national market system.

 

Information regarding the Company’s stock option grants during the year ended December 31, 2009 and the three months ended March 31, 2010, including the grant date; the number of stock options issued with each grant; the exercise price, which equals the grant date fair value of the underlying common stock for each grant of stock options, is summarized as follows:

 

Grant Date

   Number of Options
Granted
   Exercise Price and Fair
Value of Underlying
Common Stock

September 14, 2009

   965,153    $ 4.31

October 27, 2009

   144,400    $ 4.31

January 7, 2010

   1,178,810    $ 9.32

March 19, 2010

   236,500    $ 14.28

 

Forfeiture Rate —The Company estimates its forfeiture rate based on an analysis of its actual forfeitures and will continue to evaluate the adequacy of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover behavior, and other factors. The impact from a forfeiture rate adjustment will be recognized in full in the period of adjustment, and if the actual number of future forfeitures differs from that estimated by the Company, the Company may be required to record adjustments to stock-based compensation expense in future periods.

 

Each of the inputs discussed above is subjective and generally requires significant management and director judgment to determine.

 

Nonemployee Stock–Based Compensation

 

During the years ended December 31, 2007, 2008 and 2009, the Company granted options to purchase 260,700, 0 and 20,500 shares of common stock to nonemployees in exchange for services. During the three months ended March 31, 2010, the Company granted 25,000 options to purchase common stock to

 

F-45


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

nonemployees. Compensation expense of $240,000, $636,000 and $238,000 was recorded during the years ended December 31, 2007, 2008 and 2009 for stock-based awards granted to nonemployees. Compensation expense of $120,000 (unaudited) and $75,000 (unaudited) was recorded for the three months ended March 31, 2009 and 2010. The nonemployee options were valued using the Black-Scholes option pricing model with the following weighted-average assumptions:

 

       Years Ended December 31,   Three Months Ended March 31,
       2007   2008   2009           2009                   2010        
                   (Unaudited)

Expected dividend yield

     0%   0%   0%  

0%

 

0%

Risk-free interest rate

    

3.9%-4.8%

 

1.52%-4.1%

  1.8%-3.6%   1.8%-2.8%   3.7%

Contractual term (in years)

     9.7   7.0-9.2   6.0-10.0   6.3-9.0   7.4-10.0

Expected volatility

     70%  

70%-75%

 

90%-98%

 

90%

 

98%

 

During 2008, the Company entered into a related party transaction with a venture capital group to provide strategic advisory services to Amyris and its majority owned subsidiary Amyris Brasil. One of its directors is also a member of the Company’s Board of Directors. As compensation for the advisory services to be rendered, the Company granted 50,000 RSUs with a grant date fair value of $8.38 during the year ended December 31, 2008. No additional RSUs were granted during the year ended December 31, 2009. In the three months ended March 31, 2010, 126,272 RSUs were granted to the same related party. The RSUs vest quarterly and become fully vested in July 2010. Compensation expense of $41,000 and $466,000 was recorded for the years ended December 31, 2008 and 2009. Compensation expense of $26,000 (unaudited) and $446,000 (unaudited) was recorded for the three months ended March 31, 2009 and 2010, respectively.

 

Shares Reserved for Future Issuance

 

As of December 31, 2009 and March 31, 2010 the Company had reserved shares of common stock for issuance as follows:

 

     December 31, 2009    March 31, 2010
          (Unaudited)

Issuance of stock options

   5,026,412    5,919,905

Restricted stock units

   50,000    176,272

Conversion of convertible preferred stock*

   18,878,526    21,899,273

Issuance upon exercise of convertible preferred stock warrants

   146,447    195,604
         
   24,101,385    28,191,054
         

 

  *   The convertible preferred stock and convertible preferred stock warrants were computed on an as converted basis using the conversion ratios in effect as of March 31, 2010 for all periods presented. See Note 9 for conversion ratios.

 

14. Employee Benefit Plan

 

The Company established a 401(k) Plan to provide tax deferred salary deductions for all eligible employees. Participants may make voluntary contributions to the 401(k) Plan up to 90% of their eligible compensation, limited by certain Internal Revenue Service restrictions. The Company does not match employee contributions.

 

F-46


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

15. Related Party Transactions

 

The Company has entered into a license agreement with University of California, Berkeley. A co-founder and advisor to the Company is a professor at the University of California, Berkeley. The Company paid the advisor $15,000, $30,000, $34,000 and $15,000 during the years ended December 31, 2007, 2008 and 2009 and the three months ended March 31, 2010, respectively.

 

Crystalsev Comércio E Representação Ltda. (“Crystalsev”) was issued 40,193 shares of Series B convertible preferred stock by contributing $1.0 million during the Series B convertible preferred stock financing in March 2008 (see Note 16).

 

During 2008, the Company entered into an agreement with a venture capital group to provide strategic advisory services to Amyris and its majority owned subsidiary Amyris Brasil. One of its directors is also a member of the Company’s Board of Directors. (See Note 13).

 

16. Noncontrolling Interest

 

In February 2008, the Company formed a subsidiary Amyris Pesquisa e Desenvolvimento de Biocombustíveis, Ltda. In March 2008, the Company sold a 30% interest to Crystalsev and the subsidiary was renamed Amyris-Crystalsev Pesquisa e Desenvolvimento de Biocombustíveis Ltda. (“ACB”). The Company invested $3.8 million of cash for 70% interest in ACB and Crystalsev contributed $1.6 million of cash for the remaining 30% interest.

 

In April 2009, the Company re-purchased Crystalsev’s 30% interest in ACB for $2.3 million resulting in ACB once again becoming a wholly-owned subsidiary. The purchase of the noncontrolling interest was treated as an equity transaction and the fair value of the consideration paid of $2.3 million was recorded as a reduction of the carrying value of the noncontrolling interest and additional paid-in capital. In December 2009, ACB was renamed Amyris Brasil S.A.

 

On December 22, 2009, Amyris Brasil sold 1,111,111 shares of Amyris Brasil for a 4.8% interest in Amyris Brasil for BRL$10.0 million. The redeemable noncontrolling interest is reported in the mezzanine equity section of the consolidated balance sheet because the Company is subject to a contingent put option under which it may be required to repurchase an interest in Amyris Brasil from the noncontrolling interest holder. The Company has recognized a noncontrolling interest for December 22, 2009 to December 31, 2009 in the consolidated balance sheets and statements of operations. The Company has also recognized a receivable of $2.5 million for which payment was received in January 2010.

 

In March 2010, Amyris Brasil sold an additional 853,333 shares of its stock, an incremental 3.4% interest, for BRL $3.0 million (unaudited).

 

Under the terms of the agreements with these Amyris Brasil Investors, we have the right to require the investors to convert their shares of Amyris Brasil into shares of common stock at a 1:0.28 conversion ratio. We intend to exercise this right prior to the completion of this offering, and as a result will issue 550,044 shares of our common stock to these investors.

 

Under the terms of the agreements, the Company is required to make additional capital investments in Amyris Brasil worth at least BRL $50.0 million. The Company also entered into a contingent put option with the Investors in the event that Amyris Brasil receives a binding offer from one or more third parties willing to acquire control of Amyris Brasil through a change of control event that will entitle the Investors to sell their

 

F-47


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

shares to the Company. Under the terms of the put option, the Investors will have the right to receive from the Company its pro rate share of the total put option price. The put option price is defined as being the lower of (i) the amount invested by the Investors in Amyris Brasil plus 8% per year; and (ii) the total amount of proceeds actually received by the Company from a third party acquirer or from Amyris Brasil, in connection with a change of control event relating to the Company.

 

The following table provides a rollforward of the redeemable noncontrolling interest recorded as mezzanine equity:

 

Beginning balance as of December 31, 2008

   $   

Proceeds from redeemable noncontrolling interest

     5,626   

Net loss

     (120
        

Ending balance as of December 31, 2009

     5,506   

Proceeds from redeemable noncontrolling interest (unaudited)

     1,706   

Foreign currency translation adjustment (unaudited)

     65   

Net loss (unaudited)

     (183
        

Ending balance March 31, 2010 (unaudited)

   $ 7,094   
        

 

17. Restructuring

 

In June 2009, the Company initiated a restructuring plan to reduce its cost structure. The restructuring plan resulted in the consolidation of the Company’s headquarter facility located in Emeryville, California, which is under an operating lease. The Company ceased using a certain part of its headquarter facility in August 2009. The Company recorded approximately $5.4 million of restructuring charges associated with the facility lease costs after the operations ceased. In addition, as a result of the consolidation of the headquarter facility, the Company recorded approximately $3.1 million related to asset impairments and reversed $2.7 million related to deferred rent associated with the leased facility.

 

The following table summarizes the liability and utilization by cost type associated with the restructuring (in thousands):

 

     Exit Costs     Asset
Impairments
    Deferred Rent
Write-Off
    Total  

Accrued restructuring as of December 31, 2008

   $      $      $      $   

Additional accruals

     5,412        3,075        (2,719     5,768   

Cash payments

     (534                   (534

Accretion expense

     200                      200   

Non-cash settlements

            (3,075     2,719        (356

Accrued restructuring as of December 31, 2009

     5,078                      5,078   

Cash payments (unaudited)

     (320         (320

Accretion expense (unaudited)

     144            144   

Accrued restructuring as of March 31, 2010 (unaudited)

     4,902                      4,902   
                                

Less current portion (unaudited)

     (490         (490

Long-term portion as of March 31, 2010 (unaudited)

   $ 4,412      $      $      $ 4,412   
                                

 

The restructuring accrual for facility-related leases (net of estimated sublease proceeds) will be paid over the respective facility lease term through May 2018.

 

F-48


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

18. Reporting Segments

 

The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reporting segment and operating unit structure.

 

Revenues by geography are based on the billing address of the customer. The following tables set forth revenue and long-lived assets by geographic area (in thousands):

 

Revenues

 

     Years Ended December 31,    Three Months Ended
March 31,
     2007    2008    2009    2009    2010
                    (Unaudited)

United States

   $ 6,184    $ 13,892    $ 64,608    $ 2,091    $ 13,655
                                  

Total

   $ 6,184    $ 13,892    $ 64,608    $ 2,091    $ 13,655
                                  

 

Long-Lived Assets

 

     December 31,
2008
   December 31,
2009
   March 31,
2010
               (Unaudited)

United States

   $ 39,995    $ 34,868    $ 34,557

Brazil

     1,570      7,692      9,356
                    

Total

   $ 41,565    $ 42,560    $ 43,913
                    

 

19. Subsequent Events

 

The Company has evaluated subsequent events through April 16, 2010, the date on which the consolidated financial statements were issued for inclusion in the Company’s registration statement on Form S-1. In connection with this filing, such evaluation was performed through June 22, 2010.

 

In January 2010, the Company raised $3.7 million before issuance costs, by issuing 295,981 shares of Series C convertible preferred stock at $12.46 per share.

 

In March 2010, the Company raised $47.8 million before issuance costs, by issuing 2,724,766 shares of Series C-1 convertible preferred stock at $17.56 per share.

 

In March 2010, Amyris Brasil received an additional $1.7 million investment from an investor.

 

On April 13, 2010, the board of directors of the Company approved the filing of a registration statement with the Securities and Exchange Commission for an initial public offering of the Company’s common stock.

 

On April 14, 2010 we entered into a joint venture with Usina São Martinho, to produce Amyris renewable products. The joint venture, SMA Indústria Química S.A., was created to build the first facility in Brazil fully

 

F-49


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

dedicated to the production of Amyris renewable products. The new company will be located at the Usina São Martinho mill in Pradópolis, São Paulo state. The joint venture has a 20 year initial term.

 

Amyris plans to provide genetically engineered yeast to enable the joint venture to produce farnesene, a molecule which may be used as an ingredient in a wide range of consumer and industrial products, including detergents, cosmetics, perfumes and industrial lubricants.

 

The joint venture will be governed by a four member board of directors, of which the Company and São Martinho will each appoint two members. A three member executive committee, of which we appoint two members one of which will be the plant manager who is the most senior executive, will be responsible for managing construction and operation of the facility.

 

Under the joint venture agreements, Amyris will grant a royalty-free license to the JV. Amyris will fund the construction costs of the new facility, which is estimated to total between $80 million to $100 million, of which São Martinho will reimburse up to 61.8 million Brazilian reais (approximately $34 million (unaudited), based on a June 11, 2010 exchange rate) after we commence production. Post commercialization, Amyris will market and distribute the Amyris renewable products. São Martinho will sell feedstock and provide certain other services to the joint venture. The cost of the feedstock to the joint venture is a price that is based on the average return that Usina São Martinho could receive from the production of its current products, sugar and ethanol. We are required to purchase the output of the joint venture for the first four years at a price that guarantees the return of Usina São Martinho’s investment plus a fixed interest rate. After this four year period, the price is set to guarantee a break-even price to the joint venture plus an agreed upon return.

 

Amyris will have 50% ownership in the JV. We have identified the JV as a variable interest entity. We expect to be the Primary Beneficiary and consequently intend to consolidate the joint venture’s operations in our financial statements.

 

Reincorporation in Delaware

 

On June 10, 2010, the Company reincorporated in Delaware and, in connection therewith, increased its authorized number of shares of common and preferred stock to 61,862,355 and 23,862,355, respectively, and established the par value of each share of common and preferred stock to be $0.0001. In connection with the reincorporation, common stock and additional paid-in capital amounts in these financial statements have been adjusted to reflect the par value of common stock shares. All share information included in these financial statements has been adjusted to reflect this reincorporation.

 

Unaudited

 

In April 2010, the Company filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering.

 

In May 2010, Amyris Brasil received an additional $5.4 million investment from an investor.

 

In June 2010, the Company sold 7,101,548 shares of our Series D preferred stock at $18.75 per share for an aggregate purchase price of approximately $133.2 million to Total Gas & Power USA, SAS, or Total. The shares of Series D preferred stock are convertible into shares of the Company’s common stock on an one-for-one basis, provided that in the event the actual initial public offering price is lower than $         per share, the shares of Series D preferred stock will convert into a larger number of shares of common stock, and if the actual initial public offering price is greater than $18.75 per share per share, the Company would receive an additional payment (up to a maximum of approximately $14.3 million at an initial public offering price of $28.84 per share or above).

 

F-50


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

In June 2010, the Company entered into a term sheet with Cosan S.A. for the formation of a joint venture to develop and commercialize farnesene-based specialty chemicals for industrial and automotive applications. Subject to the joint venture meeting certain milestones, the rights granted by Amyris for these products would be exclusive to the joint venture.

 

In June 2010, the Company entered into a collaboration agreement with M&G Finanziaria S.R.L. Under the terms of the collaboration agreement each party bears its own costs incurred for the collaboration milestones. The agreement also establishes the terms under which M&G may purchase farnesene from the Company for use in M&G’s polyethylene terephthalate, or PET, resins to be incorporated into containers for food, beverages and other products.

 

In June 2010, the Company entered into a supply agreement with The Procter & Gamble Company that establishes terms under which P&G may purchase farnesene from the Company for use in P&G’s products. The terms of the agreement call for non-refundable development fees payable to the Company in addition to payments for purchase of farnesene. At this time, P&G does not have an obligation to purchase a specified quantity.

 

In June 2010, the Company entered into an agreement with Shell Western Supply and Trading Limited (“Shell), a subsidiary of Royal Dutch Shell plc, that contemplates the Company’s sale of certain minimum quantities of Company diesel fuel to Shell, commencing 18 months after the Company provides notice of election to sell under this agreement, and running for two years after the date specified in such notice, up to the end of March 2016 at the latest, with an option to renew for a further year. At this time, Shell does not have an obligation to purchase a specific quantity, or any, product under this agreement, and the Company is not obligated to sell specific quantities to Shell, but the parties will become subject to obligations to purchase and sell to the extent that formal notices and orders are submitted under the agreement in the future.

 

In June 2010, the Company entered into an agreement with Soliance for the development and commercialization of farnesene-based squalane for use as an ingredient in cosmetics products. The parties anticipate the formation of a joint venture for the production of these products, with Soliance to act as the distributor of such products. Initial production is expected to be completed at a Soliance facility in France, with production to commence as early as the second half of 2010, dependent upon the parties’ determination that production efficiency goals can be achieved at full scale production.

 

In June 2010, the Company entered into a technology license, development, research and collaboration agreement with Total Gas & Power USA Biotech, Inc., an affiliate of Total S.A. The agreement sets forth the terms for the research, development, production and commercialization of certain to be determined chemical and/or fuel products made through the use of the Company’s synthetic biology platform. The agreement establishes a multi-phased process through which projects are identified, screened, studied for feasibility, and ultimately selected as a project for development of an identified lead compound using an identified microbial strain. The agreement also contemplates that the Company and Total would work together on projects making microbial strains using pathways not currently under development by the Company. Subject to agreement between Total and Amyris on the initial projects and associated expenses, Total has agreed to pay up to the first $50.0 million in research and development costs for the selected projects; thereafter the parties will share such costs equally. The Company will dedicate the laboratory resources needed for collaboration projects. Total also plans to second employees at the Company to work on the projects. Once a development project has commenced, the parties are obligated to work together exclusively to develop the lead compound during the project development phase. After a development project is completed, the Company and Total expect to form one or more joint ventures to commercialize any products that are developed. Each party has certain rights to independently produce commercial quantities of these products under certain circumstances, subject to paying royalties to the other

 

F-51


Table of Contents

Amyris, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

party. In addition, the Company has retained rights to produce and commercialize products in the following markets: flavors and fragrances; cosmetics; pharmaceuticals; consumer packaged goods; food additives; and pesticides. Total has the right of first negotiation with respect to exclusive commercialization arrangements the Company would propose to enter into with certain third parties. In addition, Total has certain rights to require Amyris to work on non-collaboration projects. The collaboration agreement has an initial term of 12 years.

 

On June 4, 2010, our board of directors approved the 2010 Equity Incentive Plan, which will become effective upon the completion of the initial public offering of our common stock. A total of 4,200,000 shares of common stock were initially reserved for future issuance under the 2010 Equity Incentive Award Plan, and any shares of common stock reserved for future grant or issuance under our 2005 Stock Option/Stock Issuance Plan but which remain unissued at the time of the effectiveness of the registration statement in which these financial statements are included will be added to the shares to be reserved under our 2010 Equity Incentive Plan.

 

On June 4, 2010, our board of directors approved the 2010 Employee Stock Purchase Plan which will become effective upon the completion of the initial public offering of our common stock. A total of 168,627 shares of common stock were initially reserved for future issuance under the 2010 Employee Stock Purchase Plan.

 

F-52


Table of Contents

LOGO


Table of Contents

 

 

LOGO


Table of Contents

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS

 

ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION

 

The following table sets forth all expenses to be paid by the Registrant, other than estimated underwriting discounts and commissions, in connection with this offering. All amounts shown are estimates except for the SEC registration fee, the FINRA filing fee and The Nasdaq Global Market listing fee:

 

SEC registration fee

   $ 7,130

FINRA filing fee

     10,500

The Nasdaq Global Market listing fee

     25,000

Printing and engraving

     *

Legal fees and expenses

     *

Accounting fees and expenses

     *

Blue sky fees and expenses (including legal fees)

     *

Transfer agent and registrar fees

     *

Director and officer insurance

     *

Miscellaneous

     *
      

Total

   $ *
      

 

  *   To be completed by amendment.

 

ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS

 

Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s Board of Directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section 145 of the Delaware General Corporation Law are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act of 1933, as amended (the “Securities Act”).

 

As permitted by the Delaware General Corporation Law, the Registrant’s restated certificate of incorporation to be effective upon the completion of this offering contains provisions that eliminate the personal liability of its directors for monetary damages for any breach of fiduciary duties as a director, except liability for the following:

 

   

any breach of the director’s duty of loyalty to the Registrant or its stockholders;

 

   

acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

 

   

under Section 174 of the Delaware General Corporation Law (regarding unlawful dividends and stock purchases); or

 

   

any transaction from which the director derived an improper personal benefit.

 

As permitted by the Delaware General Corporation Law, the Registrant’s restated bylaws to be effective upon the completion of this offering, provide that:

 

   

the Registrant is required to indemnify its directors and executive officers to the fullest extent permitted by the Delaware General Corporation Law, subject to very limited exceptions;

 

   

the Registrant may indemnify its other employees and agents as set forth in the Delaware General Corporation Law;

 

II-1


Table of Contents
   

the Registrant is required to advance expenses, as incurred, to its directors and executive officers in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to very limited exceptions; and

 

   

the rights conferred in the bylaws are not exclusive.

 

Prior to the completion of this offering, the Registrant intends to enter into indemnification agreements with each of its current directors and executive officers to provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the Registrant’s restated certificate of incorporation and restated bylaws and to provide additional procedural protections. At present, there is no pending litigation or proceeding involving a director or executive officer of the Registrant regarding which indemnification is sought. Reference is also made to Section        of the underwriting agreement filed as Exhibit 1.1 to this registration statement, which provides for the indemnification of executive officers, directors and controlling persons of the Registrant against certain liabilities. The indemnification provisions in the Registrant’s restated certificate of incorporation, restated bylaws and the indemnification agreements entered into or to be entered into between the Registrant and each of its directors and executive officers may be sufficiently broad to permit indemnification of the Registrant’s directors and executive officers for liabilities arising under the Securities Act.

 

The Registrant currently carries liability insurance for its directors and officers.

 

Three of Registrant’s directors (Mr. Doerr, Dr. Duyk and Mr. Kaul) are also indemnified by their employers with regard to their service on the Registrant’s Board of Directors.

 

Reference is made to the following documents filed as exhibits to this Registration Statement regarding relevant indemnification provisions described above and elsewhere herein:

 

Exhibit Title

  

Exhibit

Number

 

Form of Underwriting Agreement

   1.01

Form of Restated Certificate of Incorporation of the Registrant, to be in effect upon the completion of this offering

   3.03   

Form of Restated Bylaws of the Registrant, to be in effect upon the completion of this offering

   3.04   

Amended and Restated Investors’ Rights Agreement, dated June 21, 2010, by and among the Registrant and certain security holders of the Registrant

   4.02   

Form of Indemnity Agreement

   10.01   

 

  *   To be filed by amendment

 

ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES

 

Since March 31, 2007, we have issued and sold the following securities:

 

  1.   As of March 31, 2010, we have issued 564,704 shares of our Common Stock to employees, directors, consultants and other service providers upon the exercise of options and stock purchase rights granted by us under our 2005 Stock Option/Stock Issuance Plan, with exercise prices ranging from $0.10 to $4.31 per share.

 

  2.   In April 2007 and May 2007, we sold an aggregate of 6,482,824 shares of our Series A preferred stock at $2.17 per share for an aggregate purchase price of approximately $14.1 million to 23 accredited investors.

 

  3.   In September 2007 and April 2008, we sold an aggregate of 1,667,817 shares of our Series B preferred stock at $24.88 per share for an aggregate purchase price of approximately $41.5 million to 11 accredited investors.

 

II-2


Table of Contents
  4.   In February 2008, April 2008, May 2008, July 2008, September 2008, November 2008, December 2008 and January 2009, we sold an aggregate of 2,615,721 shares of our Series B-1 preferred stock at $25.26 per share for an aggregate purchase price of approximately $66.1 million to 26 accredited investors.

 

  5.   From March 2008 through March 2009, we issued warrants to purchase an aggregate of 104,558 shares of our Series B-1 preferred stock at an exercise price of $25.26 per share to Advanced Equities Financial Corp.

 

  6.   In March 2008, we issued warrants to purchase 10,048 shares of our Series B preferred stock at an exercise price of $24.88 per share to TriplePoint Capital LLC. This warrant was cancelled before it was exercised, in exchange for the Series C preferred stock warrant issued to TriplePoint Capital LLC, referred to below.

 

  7.   In March 2008, we issued warrants to purchase 2,580 shares of our Series B preferred stock at an exercise price of $24.88 per share to Starfish, LLC.

 

  8.   In September 2008, we issued warrants to purchase 2,009 shares of our Series B-1 preferred stock at an exercise price of $25.26 per share to ES East Associates LLC.

 

  9.   In September 2008, we issued options to purchase up to 60,000 shares of our Common Stock at an exercise price of $3.93 per share to Lit Tele LLC, outside the terms of our 2005 Stock Option/Stock Issuance Plan.

 

  10.   In September 2008, September 2009, October 2009, November 2009, December 2009 and January 2010, we sold an aggregate of 4,902,665 shares of our Series C preferred stock at $12.46 per share for an aggregate purchase price of approximately $61.1 million to 34 accredited investors.

 

  11.   In September 2008, July 2009 and February 2010, we issued an aggregate of 176,272 restricted stock units to Lit Tele LLC, outside the terms of our 2005 Stock Option/Stock Issuance Plan.

 

  12.   In September 2009, we issued warrants to purchase an aggregate of 24,101 shares of our Series C preferred stock at an exercise price of $12.46 per share to TriplePoint Capital LLC.

 

  13.   In October 2009, we approved the issuance of 10,000 shares of restricted stock to a service provider under our 2005 Stock Option/Stock Issuance Plan at a price of $4.31 per share.

 

  14.   In December 2009, Amyris Brasil issued and sold 1,111,111 shares of Amyris Brasil to an investor in exchange for BR$10.0 million.

 

  15.   In January 2010, we issued warrants to purchase 49,157 shares of our Series C preferred stock at an exercise price of $12.46 per share to Advanced Equities Financial Corp.

 

  16.   In March 2010, we sold 2,724,766 shares of our Series C-1 preferred stock at $17.56 per share for an aggregate purchase price of approximately $47.8 million to Maxwell (Mauritius) Pte Ltd.

 

  17.   In March 2010, Amyris Brasil issued and sold 853,333 shares of Amyris Brasil to investors in exchange for BR$3.0 million.

 

  18.   In May 2010, Amyris Brasil issued and sold 1,111,111 shares of Amyris Brasil to an investor in exchange for BR$10.0 million.

 

  19.   In June 2010, we sold 7,101,548 shares of our Series D preferred stock at $18.75 per share, for an aggregate purchase price of approximately $133.2 million, to Total Gas & Power USA, SAS.

 

Unless otherwise stated, the sales of the above securities were deemed to be exempt from registration under the Securities Act in reliance upon Section 4(2) of the Securities Act or Regulation D or Regulation S promulgated thereunder, or Rule 701 promulgated under Section 3(b) of the Securities Act as transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us.

 

II-3


Table of Contents
ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a)  Exhibits.  The following exhibits are included herein or incorporated herein by reference:

 

Exhibit
Number

  

Description

  Previously Filed   Filed
Herewith
     Form   File No.   Filing Date   Exhibit  
  1.01*    Form of Underwriting Agreement          
  3.01    Restated Certificate of Incorporation           X
  3.02    Bylaws           X
  3.03    Form of Restated Certificate of Incorporation, to be effective upon the closing of this offering           X
  3.04    Form of Restated Bylaws, to be effective upon closing of this offering           X
  4.01*    Form of the Registrant’s common stock certificate          
  4.02    Amended and Restated Investors’ Rights Agreement dated June 21, 2010 among the Registrant and the Registrant’s securityholders listed therein           X
  4.03†    Investment Agreement by Fundo Mútuo de Investimento em Empresas Emergentes Inovadoras Stratus GC III, Amyris Biotechnologies, Inc., Amyris Brasil S.A. and, as Intervening Party, Stratus Investimendos Ltda. dated December 22, 2009           X
  4.04    Agreement by Fundo Mútuo de Investimento em Empresas Emergentes Inovadoras Stratus GC III, Amyris Biotechnologies, Inc., Amyris Brasil S.A. and Stratus Investimentos Ltda. dated March 3, 2010           X
  4.05†    Investment Agreement by Red Mountain Jet LLC, Amyris Biotechnologies, Inc., and Amyris Brasil S.A. dated May 26, 2010           X
  4.06    Amendment and Restatement to the Shareholders’ Agreement by Fundo Mútuo de Investimento em Empresas Emergentes Inovadoras Stratus GC III, Red Mountain Jet LLC, Amyris Biotechnologies, Inc., and, as Intervening Parties, Amyris Brasil S.A. and Stratus Investimentos Ltda. dated May 26, 2010           X
  4.07    Form of Warrant to Purchase Series B-1 Preferred Stock of the Registrant to Advanced Equities Financial Corp. and a schedule of issued Warrants to Purchase Series B-1 Preferred Stock of the Registrant to Advanced Equities Financial Corp.   S-1   333-166135   April 16, 2010   4.05  
  4.08    Warrant to Purchase Series C Preferred Stock dated January 7, 2010 issued by the Registrant to Advanced Equities Financial Corp.   S-1   333-166135   April 16, 2010   4.06  

 

II-4


Table of Contents

Exhibit
Number

  

Description

  Previously Filed   Filed
Herewith
     Form   File No.   Filing Date   Exhibit  
  4.09    Letter Agreement dated April 8, 2010 between the Registrant and Advanced Equities, Inc.   S-1   333-166135   April
16,
2010
  4.07  
  4.10    Stock Purchase Warrant dated September 23, 2008 issued by the Registrant to ES East Associates, LLC   S-1   333-166135   April
16,
2010
  4.08  
  4.11    Amendment No. 1 dated April 8, 2010 between ES East Associates, LLC and the Registrant to Stock Purchase Warrant dated September 23, 2008 issued by the Registrant to ES East Associates, LLC   S-1   333-166135   April
16,
2010
  4.09  
  4.12    Stock Purchase Warrant dated March 6, 2008 issued by the Registrant to Starfish, LLC   S-1   333-166135   April
16,
2010
  4.10  
  4.13    Amendment No. 1 dated April 8, 2010 between Starfish, LLC and the Registrant to Stock Purchase Warrant dated March 6, 2008 issued by the Registrant to Starfish, LLC   S-1   333-166135   April
16,
2010
  4.11  
  4.14    Amended and Restated Plain English Warrant Agreement dated March 14, 2008, as amended through September 18, 2009 between the Registrant and TriplePoint Capital LLC   S-1   333-166135   April
16,
2010
  4.12  
  4.15    Amendment No. 1 dated April 8, 2010 between the Registrant and TriplePoint Capital LLC to Amended and Restated Plain English Warrant Agreement originally dated March 14, 2008, as amended, on September 18, 2009 between the Registrant and TriplePoint Capital LLC   S-1   333-166135   April
16,
2010
  4.13  
  4.16    Plain English Warrant Agreement dated September 18, 2009 between the Registrant and TriplePoint Capital LLC   S-1   333-166135   April
16,
2010
  4.14  
  4.17    Amendment No. 1 dated April 8, 2010 between the Registrant and TriplePoint Capital LLC to Plain English Warrant Agreement dated September 18, 2009 between the Registrant and TriplePoint Capital LLC   S-1   333-166135   April
16,
2010
  4.15  
  4.18    Series D Preferred Stock Purchase Agreement dated June 21, 2010 between the Registrant and Total Gas & Power USA, SAS           X
  4.19†    Side Letter dated June 21, 2010 between the Registrant and Total Gas & Power USA, SAS           X
  5.01    Form of opinion of Fenwick & West LLP regarding the legality of the securities being registered   S-1   333-166135   May
25,
2010
  5.01  
10.01    Form of Indemnity Agreement between the Registrant and its directors and officers           X

 

II-5


Table of Contents

Exhibit
Number

  

Description

  Previously Filed   Filed
Herewith
     Form   File No.   Filing Date   Exhibit  
10.02†    Uncommitted Facility Letter dated November 25, 2008 between BNP Paribas and Amyris Fuels, Inc.   S-1   333-166135   May 25, 2010   10.02  
10.03†    Amendment to Uncommitted Facility Letter dated October 7, 2009 between BNP Paribas, Amyris Fuels, LLC, and the Registrant   S-1   333-166135   May 25, 2010   10.03  
10.04†    Amendment No. 2 to Uncommitted Facility Letter dated March 8, 2010 between BNP Paribas, Amyris Fuels, LLC, and the Registrant   S-1   333-166135   May 25, 2010   10.04  
10.05    Plain English Master Lease Agreement dated March 14, 2008 between the Registrant and TriplePoint Capital LLC   S-1   333-166135   April 16, 2010   10.04  
10.06    First Amendment to Plain English Master Lease Agreement dated September 18, 2009 between the Registrant and TriplePoint Capital LLC   S-1   333-166135   April 16, 2010   10.05  
10.07    Reimbursement and Security Agreement dated November 5, 2009 between the Registrant and Bank of the West   S-1   333-166135   April 16, 2010   10.06  
10.08    First Amendment to Reimbursement and Security Agreement dated December 3, 2009 between the Registrant and Bank of the West   S-1   333-166135   April 16, 2010   10.07  
10.09    Termination Letter dated April 28, 2010 between the Registrant and Bank of the West   S-1   333-166135   May 25, 2010   10.9  
10.10†    Pledge Agreement dated April 29, 2010 between the Registrant and Bank of the West   S-1   333-166135   May 25, 2010   10.10  
10.11    Registrant’s acceptance dated November 10, 2008 of offer by UBS Financial Services Inc. relating to auction rate securities   S-1   333-166135   April 16, 2010   10.08  
10.12    Assistance Agreement dated December 30, 2009, as modified by Assistance Agreement dated March 26, 2010, between the Registrant and U.S. Department of Energy, together with schedules and supplements thereto   S-1   333-166135   April 16, 2010   10.09  
10.13    Modification No. 2 to Assistance Agreement dated April 19, 2010 between the Registrant and U.S. Department of Energy   S-1   333-166135   May 25, 2010   10.13  
10.14    Amended and Restated Strategic Advisory Services Agreement dated July 31, 2009 between the Registrant and Lit Tele LLC   S-1   333-166135   April 16, 2010   10.10  
10.15    Amendment No. 1 dated February 11, 2010 to Amended and Restated Strategic Advisory Services Agreement between the Registrant and Lit Tele LLC   S-1   333-166135   April 16, 2010   10.11  

 

II-6


Table of Contents

Exhibit
Number

  

Description

  Previously Filed   Filed
Herewith
     Form   File No.   Filing Date   Exhibit  
10.16†    Joint Venture Agreement dated April 14, 2010 among Usina São Martinho S.A., Amyris Brasil S.A. and the Registrant   S-1   333-166135   May 25, 2010   10.16  
10.17†    Shareholders’ Agreement dated April 14, 2010 among SMA Indústria Química S.A., Usina São Martinho S.A. and Amyris Brasil S.A.   S-1   333-166135   May 25, 2010   10.17  
10.18    Lease dated August 22, 2007 between ES East Associates, LLC and Amyris Biotechnologies, Inc.   S-1   333-166135   April 16, 2010   10.17  
10.19    First Amendment to Lease dated March 10, 2008 between the Registrant and ES East Associates, LLC   S-1   333-166135   April 16, 2010   10.18  
10.20    Second Amendment to Lease dated April 25, 2008 between the Registrant and ES East Associates, LLC   S-1   333-166135   April 16, 2010   10.19  
10.21    Third Amendment to Lease dated July 31, 2008 between the Registrant and ES East Associates, LLC   S-1   333-166135   April 16, 2010   10.20  
10.22    Fourth Amendment to Lease dated November 14, 2009 between the Registrant and ES East Associates, LLC   S-1   333-166135   April 16, 2010   10.21  
10.23    Lease dated April 25, 2008 between the Registrant and EmeryStation Triangle, LLC   S-1   333-166135   April 16, 2010   10.22  
10.24    Letter amending Lease dated April 25, 2008 between the Registrant and EmeryStation Triangle, LLC   S-1   333-166135   April 16, 2010   10.23  
10.25    Second Amendment to Lease dated February 5, 2010 between the Registrant and EmeryStation Triangle, LLC   S-1   333-166135   April 16, 2010   10.24  
10.26    Pilot Plant Expansion Right Letter dated December 22, 2008 between the Registrant and EmeryStation Triangle, LLC   S-1   333-166135   April 16, 2010   10.25  
10.27    Private Instrument of Non-Residential Real Estate Lease Agreement between Lucio Tomasiello and Amyris Brasil S.A. dated March 31, 2008, as amended   S-1   333-166135   April 16, 2010   10.26  
10.28    Offer Letter dated September 27, 2006 between the Registrant and John Melo   S-1   333-166135   April 16, 2010   10.27  
10.29    Amendment dated December 18, 2008 to Offer Letter between the Registrant and John Melo   S-1   333-166135   April 16, 2010   10.28  
10.30    Offer Letter dated September 30, 2008 between the Registrant and Joel Cherry   S-1   333-166135   April 16, 2010   10.29  
10.31    Amendment dated December 19, 2008 to Offer Letter between the Registrant and Joel Cherry   S-1   333-166135   April 16, 2010   10.30  

 

II-7


Table of Contents

Exhibit
Number

  

Description

  Previously Filed   Filed
Herewith
     Form   File No.   Filing Date   Exhibit  
10.32    Offer Letter dated January 17, 2008 between the Registrant and Jeryl Hilleman   S-1   333-166135   April
16,
2010
  10.31  
10.33    Amendment dated December 18, 2008 to Offer Letter between the Registrant and Jeryl Hilleman   S-1   333-166135   April
16,
2010
  10.32  
10.34    Offer Letter dated October 22, 2007 between the Registrant and Jeff Lievense   S-1   333-166135   April
16,
2010
  10.33  
10.35    Amendment dated December 18, 2008 to Offer Letter between the Registrant and Jeff Lievense   S-1   333-166135   April
16,
2010
  10.34  
10.36    Offer Letter dated January 24, 2005 between the Registrant and Tamara Tompkins   S-1   333-166135   April
16,
2010
  10.35  
10.37    Amendment to Offer Letter dated January 15, 2009 between the Registrant and Tamara Tompkins   S-1   333-166135   April
16,
2010
  10.36  
10.38    2005 Stock Option/Stock Issuance Plan of the Registrant   S-1   333-166135   April
16,
2010
  10.37  
10.39    Form of Notice of Grant of Stock Option under the Registrant’s 2005 Stock Option/Stock Issuance Plan   S-1   333-166135   April
16,
2010
  10.38  
10.40    Form of Notice of Grant of Stock Option (non-Exempt) under the Registrant’s 2005 Stock Option/Stock Issuance Plan   S-1   333-166135   April
16,
2010
  10.39  
10.41    Form of Notice of Grant of Stock Option (non-US) under the Registrant’s 2005 Stock Option/Stock Issuance Plan   S-1   333-166135   April
16,
2010
  10.40  
10.42    Form of Stock Option Agreement under the Registrant’s 2005 Stock Option/Stock Issuance Plan   S-1   333-166135   April
16,
2010
  10.41  
10.43    Form of Stock Option Agreement (non-US) under the Registrant’s 2005 Stock Option/Stock Issuance Plan   S-1   333-166135   April
16,
2010
  10.42  
10.44    Form of Stock Purchase Agreement under the Registrant’s 2005 Stock Option/Stock Issuance Plan   S-1   333-166135   April
16,
2010
  10.43  
10.45    Form of Stock Purchase Agreement (non-US) under the Registrant’s 2005 Stock Option/Stock Issuance Plan   S-1   333-166135   April
16,
2010
  10.44  
10.46    2010 Equity Incentive Plan of the Registrant and forms of award agreements thereunder           X
10.47    2010 Employee Stock Purchase Plan of the Registrant and form of Subscription Agreement thereunder           X

 

II-8


Table of Contents

Exhibit
Number

  

Description

  Previously Filed   Filed
Herewith
     Form   File No.   Filing Date   Exhibit  
10.48*    Technology License, Development, Research and Collaboration Agreement dated June 21, 2010 between the Registrant and Total Gas & Power USA Biotech, Inc.          
21.01    List of subsidiaries of the Registrant   S-1   333-166135   April 16, 2010   21.01  
23.01    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm           X
23.02*    Consent of Fenwick & West LLP (included in Exhibit 5.01)          
24.01    Power of Attorney   S-1   333-166135   April 16, 2010   24.01  
24.02    Power of Attorney by Arthur Levinson, Ph.D.           X

 

  *   To be filed by amendment.
    Portions of this exhibit have been omitted pending a determination by the Securities and Exchange Commission as to whether these portions should be granted confidential treatment.

 

(b)  Financial Statement Schedules.  All financial statement schedules are omitted because they are not applicable or the information is included in the Registrant’s consolidated financial statements or related notes.

 

ITEM 17. UNDERTAKINGS

 

The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

The undersigned Registrant hereby undertakes that:

 

(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

 

(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

II-9


Table of Contents

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California, on this 22nd day of June, 2010.

 

AMYRIS, INC.

By:

 

/ S /    J OHN G. M ELO

  John G. Melo, President and Chief Executive Officer

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

  

Title

 

Date

/ S /    J OHN M ELO        

John Melo

  

Director, President and Chief Executive Officer

(Principal Executive Officer)

 

June 22, 2010

/ S /    J ERYL H ILLEMAN        

Jeryl Hilleman

  

Chief Financial Officer

(Principal Accounting and Financial Officer)

 

June 22, 2010

*

Ralph Alexander

   Director  

June 22, 2010

*

John Doerr

   Director  

June 22, 2010

*

Geoffrey Duyk, M.D., Ph.D.

   Director  

June 22, 2010

*

Samir Kaul

   Director  

June 22, 2010

*

Arthur Levinson, Ph.D.

   Director   June 22, 2010

*

Patrick Pichette

   Director  

June 22, 2010

*

Carole Piwnica

   Director  

June 22, 2010

*

Kinkead Reiling, Ph.D.

   Director  

June 22, 2010

*

Fernando Reinach, Ph.D.

   Director  

June 22, 2010

*By:

 

/ S /    J OHN M ELO        

 

John Melo

Attorney in Fact

 

II-10


Table of Contents

EXHIBIT  INDEX

 

Exhibit
Number

  

Description

  Previously Filed   Filed
Herewith
     Form   File No.   Filing Date   Exhibit  
  1.01*    Form of Underwriting Agreement          
  3.01    Restated Certificate of Incorporation of the Registrant           X
  3.02    Bylaws of the Registrant           X
  3.03    Form of Restated Certificate of Incorporation of the Registrant, to be effective upon the closing of this offering           X
  3.04    Form of Restated Bylaws of the Registrant, to be effective upon closing of this offering           X
  4.01*    Form of the Registrant’s common stock certificate          
  4.02    Amended and Restated Investors’ Rights Agreement dated June 21, 2010 among the Registrant and the Registrant’s securityholders listed therein           X
  4.03†    Investment Agreement by Fundo Mútuo de Investimento em Empresas Emergentes Inovadoras Stratus GC III, Amyris Biotechnologies, Inc., Amyris Brasil S.A. and, as Intervening Party, Stratus Investimendos Ltda. dated December 22, 2009           X
  4.04    Agreement by Fundo Mútuo de Investimento em Empresas Emergentes Inovadoras Stratus GC III, Amyris Biotechnologies, Inc., Amyris Brasil S.A. and Stratus Investimentos Ltda. dated March 3, 2010           X
  4.05†    Investment Agreement by Red Mountain Jet LLC, Amyris Biotechnologies, Inc., and Amyris Brasil S.A. dated May 26, 2010           X
  4.06    Amendment and Restatement to the Shareholders’ Agreement by Fundo Mútuo de Investimento em Empresas Emergentes Inovadoras Stratus GC III, Red Mountain Jet LLC, Amyris Biotechnologies, Inc., and, as Intervening Parties, Amyris Brasil S.A. and Stratus Investimentos Ltda. dated May 26, 2010           X
  4.07    Form of Warrant to Purchase Series B-1 Preferred Stock of the Registrant to Advanced Equities Financial Corp. and a schedule of issued Warrants to Purchase Series B-1 Preferred Stock of the Registrant to Advanced Equities Financial Corp.   S-1   333-166135   April 16, 2010   4.05  
  4.08    Warrant to Purchase Series C Preferred Stock dated January 7, 2010 issued by the Registrant to Advanced Equities Financial Corp.   S-1   333-166135   April 16, 2010   4.06  


Table of Contents

Exhibit
Number

  

Description

  Previously Filed   Filed
Herewith
     Form   File No.   Filing Date   Exhibit  
  4.09    Letter Agreement dated April 8, 2010 between the Registrant and Advanced Equities, Inc.   S-1   333-166135   April 16, 2010   4.07  
  4.10    Stock Purchase Warrant dated September 23, 2008 issued by the Registrant to ES East Associates, LLC   S-1   333-166135   April 16, 2010   4.08  
  4.11    Amendment No. 1 dated April 8, 2010 between ES East Associates, LLC and the Registrant to Stock Purchase Warrant dated September 23, 2008 issued by the Registrant to ES East Associates, LLC   S-1   333-166135   April 16, 2010   4.09  
  4.12    Stock Purchase Warrant dated March 6, 2008 issued by the Registrant to Starfish, LLC   S-1   333-166135   April 16, 2010   4.10  
  4.13    Amendment No. 1 dated April 8, 2010 between Starfish, LLC and the Registrant to Stock Purchase Warrant dated March 6, 2008 issued by the Registrant to Starfish, LLC   S-1   333-166135   April 16, 2010   4.11  
  4.14    Amended and Restated Plain English Warrant Agreement dated March 14, 2008, as amended through September 18, 2009 between the Registrant and TriplePoint Capital LLC   S-1   333-166135   April 16, 2010   4.12  
  4.15    Amendment No. 1 dated April 8, 2010 between the Registrant and TriplePoint Capital LLC to Amended and Restated Plain English Warrant Agreement originally dated March 14, 2008, as amended, on September 18, 2009 between the Registrant and TriplePoint Capital LLC   S-1   333-166135   April 16, 2010   4.13  
  4.16    Plain English Warrant Agreement dated September 18, 2009 between the Registrant and TriplePoint Capital LLC   S-1   333-166135   April 16, 2010   4.14  
  4.17    Amendment No. 1 dated April 8, 2010 between the Registrant and TriplePoint Capital LLC to Plain English Warrant Agreement dated September 18, 2009 between the Registrant and TriplePoint Capital LLC   S-1   333-166135   April 16, 2010   4.15  
  4.18    Series D Preferred Stock Purchase Agreement dated June 21, 2010 between the Registrant and Total Gas & Power USA, SAS           X
  4.19†    Side Letter dated June 21, 2010 between the Registrant and Total Gas & Power USA, SAS           X
  5.01    Form of opinion of Fenwick & West LLP regarding the legality of the securities being registered   S-1   333-166135   May 25, 2010   5.01  
10.01    Form of Indemnity Agreement between the Registrant and its directors and officers           X


Table of Contents

Exhibit
Number

  

Description

  Previously Filed   Filed
Herewith
     Form   File No.   Filing Date   Exhibit  
10.02†    Uncommitted Facility Letter dated November 25, 2008 between BNP Paribas and Amyris Fuels, Inc.   S-1   333-166135   May 25, 2010   10.02  
10.03†    Amendment to Uncommitted Facility Letter dated October 7, 2009 between BNP Paribas, Amyris Fuels, LLC, and the Registrant   S-1   333-166135   May 25, 2010   10.03  
10.04†    Amendment No. 2 to Uncommitted Facility Letter dated March 8, 2010 between BNP Paribas, Amyris Fuels, LLC, and the Registrant   S-1   333-166135   May 25, 2010   10.04  
10.05    Plain English Master Lease Agreement dated March 14, 2008 between the Registrant and TriplePoint Capital LLC   S-1   333-166135   April 16, 2010   10.04  
10.06    First Amendment to Plain English Master Lease Agreement dated September 18, 2009 between the Registrant and TriplePoint Capital LLC   S-1   333-166135   April 16, 2010   10.05  
10.07    Reimbursement and Security Agreement dated November 5, 2009 between the Registrant and Bank of the West   S-1   333-166135   April 16, 2010   10.06  
10.08    First Amendment to Reimbursement and Security Agreement dated December 3, 2009 between the Registrant and Bank of the West   S-1   333-166135   April 16, 2010   10.07  
10.09    Termination Letter dated April 28, 2010 between the Registrant and Bank of the West   S-1   333-166135   May 25, 2010   10.9  
10.10†    Pledge Agreement dated April 29, 2010 between the Registrant and Bank of the West   S-1   333-166135   May 25, 2010   10.10  
10.11    Registrant’s acceptance dated November 10, 2008 of offer by UBS Financial Services Inc. relating to auction rate securities   S-1   333-166135   April 16, 2010   10.08  
10.12    Assistance Agreement dated December 30, 2009, as modified by Assistance Agreement dated March 26, 2010, between the Registrant and U.S. Department of Energy, together with schedules and supplements thereto   S-1   333-166135   April 16, 2010   10.09  
10.13    Modification No. 2 to Assistance Agreement dated April 19, 2010 between the Registrant and U.S. Department of Energy   S-1   333-166135   May 25, 2010   10.13  
10.14    Amended and Restated Strategic Advisory Services Agreement dated July 31, 2009 between the Registrant and Lit Tele LLC   S-1   333-166135   April 16, 2010   10.10  
10.15    Amendment No. 1 dated February 11, 2010 to Amended and Restated Strategic Advisory Services Agreement between the Registrant and Lit Tele LLC   S-1   333-166135   April 16, 2010   10.11  


Table of Contents

Exhibit
Number

  

Description

  Previously Filed   Filed
Herewith
     Form   File No.   Filing Date   Exhibit  
10.16†    Joint Venture Agreement dated April 14, 2010 among Usina São Martinho S.A., Amyris Brasil S.A. and the Registrant   S-1   333-166135   May 25, 2010   10.16  
10.17†    Shareholders’ Agreement dated April 14, 2010 among SMA Indústria Química S.A., Usina São Martinho S.A. and Amyris Brasil S.A.   S-1   333-166135   May 25, 2010   10.17  
10.18    Lease dated August 22, 2007 between ES East Associates, LLC and Amyris Biotechnologies, Inc.   S-1   333-166135   April 16, 2010   10.17  
10.19    First Amendment to Lease dated March 10, 2008 between the Registrant and ES East Associates, LLC   S-1   333-166135   April 16, 2010   10.18  
10.20    Second Amendment to Lease dated April 25, 2008 between the Registrant and ES East Associates, LLC   S-1   333-166135   April 16, 2010   10.19  
10.21    Third Amendment to Lease dated July 31, 2008 between the Registrant and ES East Associates, LLC   S-1   333-166135   April 16, 2010   10.20  
10.22    Fourth Amendment to Lease dated November 14, 2009 between the Registrant and ES East Associates, LLC   S-1   333-166135   April 16, 2010   10.21  
10.23    Lease dated April 25, 2008 between the Registrant and EmeryStation Triangle, LLC   S-1   333-166135   April 16, 2010   10.22  
10.24    Letter amending Lease dated April 25, 2008 between the Registrant and EmeryStation Triangle, LLC   S-1   333-166135   April 16, 2010   10.23  
10.25    Second Amendment to Lease dated February 5, 2010 between the Registrant and EmeryStation Triangle, LLC   S-1   333-166135   April 16, 2010   10.24  
10.26    Pilot Plant Expansion Right Letter dated December 22, 2008 between the Registrant and EmeryStation Triangle, LLC   S-1   333-166135   April 16, 2010   10.25  
10.27    Private Instrument of Non-Residential Real Estate Lease Agreement between Lucio Tomasiello and Amyris Brasil S.A. dated March 31, 2008, as amended   S-1   333-166135   April 16, 2010   10.26  
10.28    Offer Letter dated September 27, 2006 between the Registrant and John Melo   S-1   333-166135   April 16, 2010   10.27  
10.29    Amendment dated December 18, 2008 to Offer Letter between the Registrant and John Melo   S-1   333-166135   April 16, 2010   10.28  
10.30    Offer Letter dated September 30, 2008 between the Registrant and Joel Cherry   S-1   333-166135   April 16, 2010   10.29  
10.31    Amendment dated December 19, 2008 to Offer Letter between the Registrant and Joel Cherry   S-1   333-166135   April 16, 2010   10.30  


Table of Contents

Exhibit
Number

  

Description

  Previously Filed   Filed
Herewith
     Form   File No.   Filing Date   Exhibit  
10.32    Offer Letter dated January 17, 2008 between the Registrant and Jeryl Hilleman   S-1   333-166135   April 16, 2010   10.31  
10.33    Amendment dated December 18, 2008 to Offer Letter between the Registrant and Jeryl Hilleman   S-1   333-166135   April 16, 2010   10.32  
10.34    Offer Letter dated October 22, 2007 between the Registrant and Jeff Lievense   S-1   333-166135   April 16, 2010   10.33  
10.35    Amendment dated December 18, 2008 to Offer Letter between the Registrant and Jeff Lievense   S-1   333-166135   April 16, 2010   10.34  
10.36    Offer Letter dated January 24, 2005 between the Registrant and Tamara Tompkins   S-1   333-166135   April 16, 2010   10.35  
10.37    Amendment to Offer Letter dated January 15, 2009 between the Registrant and Tamara Tompkins   S-1   333-166135   April 16, 2010   10.36  
10.38    2005 Stock Option/Stock Issuance Plan of the Registrant   S-1   333-166135   April 16, 2010   10.37  
10.39    Form of Notice of Grant of Stock Option under the Registrant’s 2005 Stock Option/Stock Issuance Plan   S-1   333-166135   April 16, 2010   10.38  
10.40    Form of Notice of Grant of Stock Option (non-Exempt) under the Registrant’s 2005 Stock Option/Stock Issuance Plan   S-1   333-166135   April 16, 2010   10.39  
10.41    Form of Notice of Grant of Stock Option (non-US) under the Registrant’s 2005 Stock Option/Stock Issuance Plan   S-1   333-166135   April 16, 2010   10.40  
10.42    Form of Stock Option Agreement under the Registrant’s 2005 Stock Option/Stock Issuance Plan   S-1   333-166135   April 16, 2010   10.41  
10.43    Form of Stock Option Agreement (non-US) under the Registrant’s 2005 Stock Option/Stock Issuance Plan   S-1   333-166135   April 16, 2010   10.42  
10.44    Form of Stock Purchase Agreement under the Registrant’s 2005 Stock Option/Stock Issuance Plan   S-1   333-166135   April 16, 2010   10.43  
10.45    Form of Stock Purchase Agreement (non-US) under the Registrant’s 2005 Stock Option/Stock Issuance Plan   S-1   333-166135   April 16, 2010   10.44  
10.46    2010 Equity Incentive Plan of the Registrant and forms of award agreements thereunder           X
10.47    2010 Employee Stock Purchase Plan of the Registrant and form of Subscription Agreement thereunder           X
10.48*    Technology License, Development, Research and Collaboration Agreement dated June 21, 2010 between the Registrant and Total Gas & Power USA Biotech, Inc.          


Table of Contents

Exhibit
Number

  

Description

  Previously Filed   Filed
Herewith
     Form   File No.   Filing Date   Exhibit  
21.01    List of subsidiaries of the Registrant   S-1   333-166135   April 16, 2010   21.01  
23.01    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm           X
23.02*    Consent of Fenwick & West LLP (included in Exhibit 5.01)          
24.01    Power of Attorney   S-1   333-166135   April 16, 2010   24.01  
24.02    Power of Attorney by Arthur Levinson, Ph.D.           X

 

  *   To be filed by amendment.
    Portions of this exhibit have been omitted pending a determination by the Securities and Exchange Commission as to whether these portions should be granted confidential treatment.

Exhibit 3.01

AMYRIS BIOTECHNOLOGIES, INC.

RESTATED CERTIFICATE OF INCORPORATION

(Pursuant to Sections 242 and 245 of the

General Corporation Law of the State of Delaware)

Amyris Biotechnologies, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “ General Corporation Law ”), does hereby certify as follows.

1.        The name of this corporation is Amyris Biotechnologies, Inc. and that this corporation was originally incorporated pursuant to the General Corporation Law on April 15, 2010 under the name Amyris Biotechnologies, Inc.

2.        The Board of Directors of this corporation duly adopted resolutions proposing to amend and restate the Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows.

RESOLVED, that the Certificate of Incorporation of this corporation be amended and restated in its entirety to read as set forth on Exhibit A attached hereto and incorporated herein by this reference.

3.         Exhibit A   referred to above is attached hereto as Exhibit A and is hereby incorporated herein by this reference. This Restated Certificate of Incorporation was approved by the holders of the requisite number of shares of this corporation in accordance with Section 228 of the General Corporation Law.

4.        This Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of this corporation’s Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law.

IN WITNESS WHEREOF , this Restated Certificate of Incorporation has been executed by a duly authorized officer of this corporation on this 18 th day of June, 2010.

 

By:   /s/ John G. Melo  
 

John G. Melo, President

 


EXHIBIT A

AMYRIS BIOTECHNOLOGIES, INC.

RESTATED CERTIFICATE OF INCORPORATION

ARTICLE I: NAME

The name of the corporation is Amyris, Inc. (the “ Company ”).

ARTICLE II: REGISTERED OFFICE

The address of the registered office of the Corporation in the State of Delaware is 3500 South Dupont Highway, in the City of Dover, County of Kent, Delaware 19901. The name of its registered agent at such address is Incorporation Services, Ltd.

ARTICLE III : PURPOSE

The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law.

ARTICLE IV : AUTHORIZED SHARES

The total number of shares of all classes of stock which the Corporation shall have authority to issue is (a) 70,000,000 shares of Common Stock, $0.0001 par value per share (“Common Stock”), and (b) 30,963,903 shares of Preferred Stock, $0.0001 par value per share (“Preferred Stock”). The Preferred Stock may be issued from time to time in one or more series, each of such series to consist of such number of shares and to have such terms, powers, preferences or rights, and the qualifications and limitations with respect thereto, as stated or expressed herein. As of the effective date of this Restated Certificate of Incorporation (this “Restated Certificate”), 9,475,000 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series A Preferred Stock”, 1,929,641 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series B Preferred Stock”, 4,700,000 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series B-1 Preferred Stock”, 4,976,000 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series C Preferred Stock”, 2,781,714 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series C-1 Preferred Stock”, and 7,101,548 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series D Preferred Stock”. The following is a statement of the designations and the powers, preferences or rights, and the qualifications, limitations or restrictions thereof, in respect of each class of capital stock of the Corporation.


A.

COMMON STOCK

1.         General .  The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the powers, preferences or rights of the holders of the Preferred Stock set forth herein.

2.         Voting .  The holders of the Common Stock are entitled to one vote for each share of Common Stock held at all meetings of stockholders (and written actions in lieu of meetings). Unless required by law, there shall be no cumulative voting. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of the Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law.

 

B.

PREFERRED STOCK

The following powers, preferences or rights, and restrictions, qualifications and limitations, shall apply to the Preferred Stock. Unless otherwise indicated, references to “Sections” in this Part B of this Article IV refer to sections of this Part B.

1.     Dividends.

  a.         Preferred Stock Dividends.   The holders of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock shall be entitled to receive non-cumulative dividends, on a pari passu basis, at the rate of 8% of the Series A Issue Price as defined in Section 2.a. (as adjusted for any stock dividends, combinations or splits with respect to such shares) per annum for the Series A Preferred Stock, at the rate of 8% of the Series B Issue Price as defined in Section 2.a (as adjusted for any stock dividends, combinations or splits with respect to such shares) per annum for the Series B Preferred Stock, at the rate of 8% of the Series B-1 Issue Price as defined in Section 2.a. (as adjusted for any stock dividends, combinations or splits with respect to such shares) per annum for the Series B-1 Preferred Stock, at the rate of 8% of the Series C Issue Price as defined in Section 2.a. (as adjusted for any stock dividends, combinations or splits with respect to such shares) per annum for the Series C Preferred Stock, at the rate of 8% of the Series C-1 Issue Price as defined in Section 2.a. (as adjusted for any stock dividends, combinations or splits with respect to such shares) per annum for the Series C-1 Preferred Stock, and at the rate of 8% of the Series D Issue Price as defined in Section 2.a. (as adjusted for any stock dividends, combinations or splits with respect to such shares) per annum for the Series D Preferred Stock, payable out of funds legally available therefor. Such dividends shall be payable only when, as, and if declared by the Board of Directors and shall be non-cumulative.

No dividends (other than those payable solely in the Common Stock of the Company) shall be paid or other distribution made on any Common Stock of the Company, or purchase, redemption or other acquisition of Common Stock for value during any fiscal year of the


Company until dividends, in the amount of 8% of the Series A Issue Price (as adjusted for any stock dividends, combinations or splits with respect to such shares) on the Series A Preferred Stock, 8% of the Series B Issue Price as defined in Section 2.a (as adjusted for any stock dividends, combinations or splits with respect to such shares) on the Series B Preferred Stock, 8% of the Series B-1 Issue Price as defined in Section 2.a (as adjusted for any stock dividends, combinations or splits with respect to such shares) on the Series B-1 Preferred Stock, 8% of the Series C Issue Price as defined in Section 2.a (as adjusted for any stock dividends, combinations or splits with respect to such shares) on the Series C Preferred Stock, 8% of the Series C-1 Issue Price as defined in Section 2.a (as adjusted for any stock dividends, combinations or splits with respect to such shares) on the Series C-1 Preferred Stock, and 8% of the Series D Issue Price as defined in Section 2.a (as adjusted for any stock dividends, combinations or splits with respect to such shares) on the Series D Preferred Stock shall have been paid or declared and set apart during that fiscal year, except for:

(i)        acquisitions of Common Stock by the Company pursuant to agreements which permit the Company to repurchase such shares at cost (or the lesser of cost or fair market value) upon termination of services to the Company;

(ii)        acquisitions of Common Stock in exercise of the Company’s right of first refusal to repurchase such shares; or

(iii)        distributions to holders of Common Stock in accordance with Section 2.

  b.         Common Stock Dividends.   In the event the Company shall declare a distribution or dividend on any Common Stock (other than dividends payable solely in Common Stock of the Company), then, in each such case, the holders of the Preferred Stock shall be entitled to a proportionate share of any such distribution as though the holders of the Preferred Stock were the holders of the number of shares of Common Stock of the Company into which their respective shares of Preferred Stock are convertible as of the record date fixed for the determination of the holders of Common Stock of the Company entitled to receive such distribution.

2.     Liquidation Preference.

  a.         Payments to Holders of Preferred Stock.   In the event of any liquidation, dissolution or winding up of the Company (a “ Liquidation ”), whether voluntary or involuntary, the holders of the Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock shall be entitled to receive, on a pari passu basis but prior and in preference to any distribution of any of the legally available assets or surplus funds of the Company to the holders of the Common Stock by reason of their ownership thereof, (i) in the case of Series A Preferred Stock, the amount of $2.174 per share, as adjusted for any stock dividends, combinations or splits with respect to such shares, (the “ Series A Issue Price ”), plus all declared but unpaid dividends, on each such share then held by them, (ii) in the case of Series B Preferred Stock, the amount of $24.88 per share, as adjusted for any stock dividends, combinations or splits with respect to such shares (the “ Series B Issue Price ”), plus all declared but unpaid dividends, on


each such share then held by them, (iii) in the case of Series B-1 Preferred Stock, the amount of $25.26 per share, as adjusted for any stock dividends, combinations or splits with respect to such shares (the “ Series B-1 Issue Price ”), plus all declared but unpaid dividends, on each such share then held by them, (iv) in the case of Series C Preferred Stock, the amount of $12.46 per share, as adjusted for any stock dividends, combinations or splits with respect to such shares (the “ Series C Issue Price ”), (v) in the case of Series C-1 Preferred Stock, the amount of $17.56 per share, as adjusted for any stock dividends, combinations or splits with respect to such shares (the “ Series C-1 Issue Price ”), and (vi) in the case of Series D Preferred Stock, the amount of $18.75 per share, as adjusted for any stock dividends, combinations or splits with respect to such shares (the “ Series D Issue Price ”). If upon the occurrence of such event, the assets and funds thus distributed among the holders of the Preferred Stock shall be insufficient to permit the payment to such holders of the full aforesaid preferential amount, then the entire assets and funds of the Company legally available for distribution shall be distributed ratably among the holders of the Preferred Stock in proportion to the preferential amount each such holder is otherwise entitled to receive.

  b.         Payments to Holders of Common Stock.   After payment to the holders of the Preferred Stock of the amounts set forth in Section 2.a above, the entire remaining assets and funds of the Company legally available for distribution, if any, shall be distributed ratably among the holders of the Common Stock pro rata based on the number of shares of Common Stock held by each.

  c.         Conversion for Payments.   Notwithstanding paragraphs (a) and (b) above, solely for purposes of determining the amount each holder of shares of Preferred Stock is entitled to receive with respect to a Liquidation, each series of Preferred Stock shall be treated as if all holders of such series had converted such holder’s shares of such series into shares of Common Stock immediately prior to the Liquidation if, as a result of an actual conversion of any series of Preferred Stock (including taking into account the operation of this paragraph (c) with respect to all series of Preferred Stock), holders of such series would receive (with respect to such series), in the aggregate, an amount greater than the amount that would be distributed to holders of such series if such holders had not converted such series of Preferred Stock into shares of Common Stock.

  d.         Deemed Liquidation.   For purposes of this Section 2, (i) any acquisition of the Company by means of merger or other form of corporate reorganization in which outstanding shares of the Company are exchanged for securities or other consideration issued, or caused to be issued, by the acquiring company or its subsidiary (other than a transaction effected solely to reincorporate the Company in another jurisdiction) and pursuant to which the holders of the outstanding voting securities of the Company immediately prior to such consolidation, merger or other transaction fail to hold equity securities representing a majority of the voting power of the Company or surviving entity immediately following such consolidation, merger or other transaction (an “ Acquisition ”) or (ii) a sale of all or substantially all of the assets of the Company (an “ Asset Sale ”), shall be treated as a Liquidation of the Company and shall entitle the holders of Preferred Stock to receive at the closing of such transaction in cash, securities or other property (valued as provided in Section 2.e below) the amounts as specified in Section 2.a above; provided that an Acquisition shall not include any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by the Company or any successor or indebtedness of the Company is cancelled or converted or a combination thereof.


  e.         Amount Deemed Paid or Distributed.   Whenever the distribution provided for in this Section 2 shall be payable in securities or property other than cash, the value of such distribution shall be the fair market value of such securities or other property. Any securities shall be valued as follows:

  (i)     If traded on a securities exchange, the value shall be deemed to be the average of the closing prices of the securities on such exchange or system over the thirty (30) day period ending three (3) days prior to the closing;

  (ii)     If actively traded over-the-counter, the value shall be deemed to be the average of the closing bid or sale prices (whichever is applicable) over the thirty (30) day period ending three (3) days prior to the closing; and

  (iii)     If there is no active market, the value shall be the fair market value thereof, as determined in good faith by the Board of Directors of the Company.

3.     Voting Rights.   Except as otherwise provided herein or as required by law, the Preferred Stock will be voted equally with the shares of the Common Stock and not as a separate class, at any annual or special meeting of stockholders of the Company, and may act by written consent in the same manner as the Common Stock, in either case upon the following basis: each holder of shares of the Preferred Stock shall be entitled to the number of votes equal to the respective number of shares of Common Stock into which such shares of Preferred Stock could be converted immediately after the close of business on the record date fixed for such meeting or the effective date of such written consent, and shall be entitled to notice of any stockholders’ meeting in accordance with the Bylaws of the Company. Fractional votes shall not, however, be permitted and any fractional voting rights resulting from the above formula (after aggregating all shares into which shares of Preferred Stock held by each holder could be converted) shall be rounded to the nearest whole number (with one-half being rounded upward).

4.     Conversion.   The holders of the Preferred Stock shall have conversion rights as follows:

  a.         Right to Convert.   Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time after the date of issuance of such share, at the office of the Company or any transfer agent for such stock, into fully paid and nonassessable shares of Common Stock. The number of shares of Common Stock to which a holder of Preferred Stock shall be entitled upon conversion shall be determined by dividing the Series A Issue Price, Series B Issue Price, Series B-1 Issue Price, Series C Issue Price, Series C-1 Issue Price or Series D Issue Price, as applicable, by the conversion price for such share in effect at the time that such certificate is surrendered for conversion, and then multiplying by the number of shares of Preferred Stock being converted. The conversion price per share (the “ Conversion Price ”) as of the Original Issue Date (as defined below) shall be (i) for shares of Series A Preferred Stock $2.174 per share, (ii) for shares of Series B Preferred Stock shall be $22.24 per share, (iii) for shares of Series B-1 Preferred Stock shall be $22.52 per share, (iv) for


shares of Series C Preferred Stock shall be $12.46 per share, (v) for shares of Series C-1 Preferred Stock, $17.56 per share, and (vi) for shares of Series D Preferred Stock, $18.75 per share, in each case each subject to adjustment as hereinafter provided.

b.         Automatic Conversion.

(i)     Each share of Series A Preferred Stock shall automatically be converted into shares of Common Stock at the then applicable Conversion Price upon the earlier to occur of (i) the date specified by written consent or agreement of stockholders holding at least a majority of the then outstanding shares of Series A Preferred Stock, voting together as a single class, or (ii) immediately upon the closing of the sale of the Company’s Common Stock in a firm commitment, underwritten public offering registered under the Securities Act of 1933, as amended (the “ Securities Act ”), which results in aggregate proceeds to the Company (before deduction for underwriters’ discounts and expenses relating to the issuance, including without limitation fees of the Company’s counsel) equal to at least $30,000,000 (a “ Qualified IPO ”). Upon such automatic conversion, any declared and unpaid dividends shall be paid in accordance with the provisions of Section 1.

(ii)     Each share of Series B Preferred Stock shall automatically be converted into shares of Common Stock at the then applicable Conversion Price upon the earlier to occur of (i) the date specified by written consent or agreement of (A) stockholders holding at least a majority of the then outstanding shares of Preferred Stock, voting together as a single class, and (B) stockholders holding at least a majority of the then outstanding shares of Series B Preferred Stock, voting together as a single class, or (ii) immediately upon the closing of a Qualified IPO. Upon such automatic conversion, any declared and unpaid dividends shall be paid in accordance with the provisions of Section 1.

(iii)     Each share of Series B-1 Preferred Stock shall automatically be converted into shares of Common Stock at the then applicable Conversion Price upon the earlier to occur of (i) the date specified by written consent or agreement of (A) stockholders holding at least a majority of the then outstanding shares of Preferred Stock, voting together as a single class, and (B) stockholders holding at least a majority of the then outstanding shares of Series B-1 Preferred Stock, voting together as a single class, or (ii) immediately upon the closing of a Qualified IPO. Upon such automatic conversion, any declared and unpaid dividends shall be paid in accordance with the provisions of Section 1.

(iv)     Each share of Series C Preferred Stock shall automatically be converted into shares of Common Stock at the then applicable Conversion Price upon the earlier to occur of (i) the date specified by written consent or agreement of (A) stockholders holding at least a majority of the then outstanding shares of Preferred Stock, voting together as a single class, and (B) stockholders holding at least a majority of the then outstanding shares of Series C Preferred Stock, voting together as a single class, or (ii) immediately upon the closing of a Qualified IPO. Upon such automatic conversion, any declared and unpaid dividends shall be paid in accordance with the provisions of Section 1.


(v)     Each share of Series C-1 Preferred Stock shall automatically be converted into shares of Common Stock at the then applicable Conversion Price upon the earlier to occur of (i) the date specified by written consent or agreement of (A) stockholders holding at least a majority of the then outstanding shares of Preferred Stock, voting together as a single class, and (B) stockholders holding at least a majority of the then outstanding shares of Series C-1 Preferred Stock, voting together as a single class, or (ii) immediately upon the closing of a Qualified IPO. Upon such automatic conversion, any declared and unpaid dividends shall be paid in accordance with the provisions of Section 1.

(vi)     Each share of Series D Preferred Stock shall automatically be converted into shares of Common Stock at the then applicable Conversion Price upon the earlier to occur of (A) the date specified by written consent or agreement of stockholders holding at least a majority of the then outstanding shares of Preferred Stock, voting together as a single class (provided that all other shares of Preferred Stock are converted into shares of Common Stock at the same time that the shares of Series D Preferred Stock are converted into shares of Common Stock), or (B) immediately upon the closing of a Qualified IPO. Upon such automatic conversion, any declared and unpaid dividends shall be paid in accordance with the provisions of Section 1. Notwithstanding the foregoing subclause (A), the consent of the holders of a majority of the Series D Preferred Stock shall also be required if the conversion of the shares of Series D Preferred Stock into shares of Common Stock is effected in connection with an Acquisition or Asset Sale in which the value of the consideration to be received (as determined in good faith by the Company’s Board of Directors) in respect of the share or shares of Common Stock issuable upon conversion of a share of Series D Preferred Stock is less than the product of one hundred fifty percent (150%) multiplied by the Series D Issue Price.

c.         Mechanics of Conversion .

(i)     Except in the case of an automatic conversion pursuant to Section 4.b., before any holder of Preferred Stock shall be entitled to convert the same into shares of Common Stock, such holder shall surrender the certificate or certificates therefor, duly endorsed, at the office of the Company or of any transfer agent for such stock, and shall give written notice to the Company at such office that such holder elects to convert the same and shall state therein the name or names in which such holder wishes the certificate or certificates for shares of Common Stock to be issued. The Company shall, as soon as practicable thereafter, issue and deliver at such office to such holder of Preferred Stock a certificate or certificates for the number of shares of Common Stock to which such holder shall be entitled as aforesaid and shall promptly pay (i) in cash or, to the extent sufficient funds are not then legally available therefor, in Common Stock (at the Common Stock’s fair market value determined by the Board as of the date of such conversion), any declared and unpaid dividends on the shares of Preferred Stock being converted and (ii) in cash (at the Common Stock’s fair market value determined by the Board as of the date of conversion) the value of any fractional share of Common Stock otherwise issuable to any holder of Preferred Stock. Such conversion shall be deemed to have been made immediately prior to the close of business on the date of surrender of the shares of Preferred Stock to be converted, and the person or persons entitled to receive the shares of Common Stock issuable upon such conversion shall be treated for all purposes as the record holder or holders of such shares of Common Stock on such date.


(ii)     If the conversion is in connection with an underwritten offering of securities pursuant to the Securities Act, the conversion may, at the option of any holder tendering shares of Preferred Stock for conversion, be conditioned upon the closing with the underwriters of the sale of securities pursuant to such offering, in which event the person(s) entitled to receive the Common Stock upon conversion of the Preferred Stock shall not be deemed to have converted such Preferred Stock until immediately prior to the closing of such sale of securities.

d.         Adjustments to Conversion Price for Certain Diluting Issues.

(i)     Special Definitions.   For purposes of this Section 4, the following definitions apply:

(1)     “ Options ” shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire either Common Stock or Convertible Securities (as defined below).

(2)     “ Original Issue Date ” shall mean the date on which the first share of Series D Preferred Stock is issued.

(3)     “ Convertible Securities ” shall mean any evidences of indebtedness, shares (other than Common Stock, Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock or Series D Preferred Stock) or other securities convertible into or exchangeable for Common Stock, including securities described in Section 4.d.(i)(4).

(4)     “ Additional Shares of Common Stock ” shall mean all shares of Common Stock issued (or, pursuant to Section 4.d(iii) deemed to be issued) by the Company after the Original Issue Date, other than shares of Common Stock issued or issuable after the Original Issue Date:

(A)     upon conversion of shares of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock or Series D Preferred Stock;

(B)     pursuant to or issuable upon exercise of options or warrants to purchase shares of Common stock, issued to employees, officers, directors or consultants of the Company or a subsidiary pursuant to stock option or stock purchase plans or other arrangements in each case on terms approved by at least 76% of the members of the Board of Directors of the Company;

(C)     pursuant to transactions involving research or development funding, technology licensing, joint ventures, strategic alliances, partnering arrangements, bank financings or lease arrangements pursuant to agreements in each case approved by at least 76% of the members of the Board of Directors of the Company;

(D)     pursuant to the acquisition of another corporation or entity by the corporation by way of merger, purchase of assets, stock for stock exchange or other reorganization or recapitalization in each case approved by at least 76% of the members of the Board of Directors of the Company;


(E)     in a Qualified IPO;

(F)     pursuant to a transaction described in Section 4.e or 4.f;

(G)     for which adjustment of the applicable Conversion Price is made pursuant to this Section 4;

(H)     pursuant to or issuable upon exercise of warrants, options or other rights to acquire securities of the Company outstanding as of the Original Issue Date and any securities issuable upon conversion thereof;

(I)     pursuant to or issuable upon conversion, exchange or cancellation of shares of Amyris Brasil S.A., a majority-owned subsidiary of the Company; or

(J)     upon the affirmative vote of at least a majority of the then outstanding shares of Preferred Stock, voting together as a single class on an as-if converted basis.

(ii)     No Adjustment of Conversion Price.   Any provision herein to the contrary notwithstanding, no adjustment in the applicable Conversion Price shall be made in respect of the issuance of Additional Shares of Common Stock unless the consideration per share (determined pursuant to Section 4.d(v) hereof) for an Additional Share of Common Stock issued or deemed to be issued by the Company is less than the applicable Conversion Price in effect immediately prior to such issue.

(iii)     Deemed Issue of Additional Shares of Common Stock.   In the event the Company at any time or from time to time after the Original Issue Date shall issue any Options or Convertible Securities or shall fix a record date for the determination of holders of any class of securities then entitled to receive any such Options or Convertible Securities, then the maximum number of shares (as set forth in the instrument relating thereto without regard to any provisions contained therein designed to protect against dilution) of Common Stock issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date, provided further that in any such case in which Additional Shares of Common Stock are deemed to be issued:

(1)     no further adjustments in the applicable Conversion Price shall be made upon the subsequent issue of Convertible Securities or shares of Common Stock upon the exercise of such Options or conversion or exchange of such Convertible Securities;

(2)     if such Options or Convertible Securities by their terms provide, with the passage of time or otherwise, for any increase in the consideration payable to the Company, or decrease in the number of shares of Common Stock issuable, upon the exercise, conversion or exchange thereof, the applicable Conversion Price computed upon the


original issue thereof (or upon the occurrence of a record date with respect thereto), and any subsequent adjustments based thereon, shall, upon any such increase or decrease becoming effective, be recomputed to reflect such increase or decrease insofar as it affects such Options or the rights of conversion or exchange under such Convertible Securities (provided, however, that no such adjustment of the Conversion Price shall affect Common Stock previously issued upon conversion of the Preferred Stock);

(3)     upon the expiration of any such options or rights, the termination of any such rights to convert or exchange or the expiration of any options or rights related to such convertible or exchangeable securities, the applicable Conversion Price to the extent in any way affected by or computed using such options, rights or securities or options or rights related to such securities, shall be recomputed to reflect the issuance of only the number of shares of Common Stock (and convertible or exchangeable securities which remain in effect) actually issued upon the exercise of such options or rights, upon the conversion or exchange of such securities or upon the exercise of the options or rights related to such securities;

(4)     no readjustment pursuant to clause (2) or (3) above shall have the effect of increasing the applicable Conversion Price to an amount which exceeds the lower of (a) the Conversion Price on the original adjustment date or (b) the Conversion Price that would have resulted from any issuance of Additional Shares of Common Stock between the original adjustment date and such readjustment date.

(iv)     Adjustment of Conversion Price Upon Issuance of Additional Shares of Common Stock. In the event the Company, at any time after the Original Issue Date shall issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to Section 4.d(iii)) without consideration or for a consideration per share less than the applicable Conversion Price in effect on the date of and immediately prior to such issue, then, and in such event, the applicable Conversion Price shall be reduced, concurrently with such issue, to a price (calculated to the nearest cent) determined by multiplying the Conversion Price by a fraction, the numerator of which shall be the number of shares of Common Stock deemed outstanding (as defined below) immediately prior to such issuance plus the number of shares of Common Stock which the aggregate consideration received by the Company for the total number of Additional Shares of Common Stock so issued would purchase at the Conversion Price in effect immediately prior to such issuance, and the denominator of which shall be the number of shares of Common Stock deemed outstanding (as defined below) immediately prior to such issuance plus the number of such Additional Shares of Common Stock so issued. For the purpose of the above calculation, the number of shares of Common Stock outstanding immediately prior to such issue shall be calculated on a fully diluted basis, as if all shares of Preferred Stock and all outstanding Convertible Securities had been fully converted into shares of Common Stock and any outstanding warrants, outstanding options or other rights outstanding for the purchase of shares of stock or convertible securities had been fully exercised (and the resulting securities fully converted into shares of Common Stock, if so convertible) as of such date. For the purposes of adjusting the applicable Conversion Price of a series of Preferred Stock, the grant, issue or sale of Additional Shares of Common consisting of the same class of security and warrants to purchase such security issued or issuable at the same price at two or more closings held within a six (6) month period shall be aggregated and shall be treated as one sale of Additional Shares of Common occurring on the earliest date on which such securities were granted, issued or sold.


(v)     Determination of Consideration.   For purposes of this Section 4.d, the consideration received by the Company for the issue of any Additional Shares of Common Stock shall be computed as follows:

(1)     Cash and Property.   Such consideration shall:

(A)     insofar as it consists of cash, be computed at the aggregate amount of cash received by the Company, excluding amounts paid or payable for accrued interest or declared but unpaid dividends;

(B)     insofar as it consists of property other than cash, be computed at the fair value thereof at the time of such issue, as determined in good faith by the Board of Directors; and

(C)     in the event Additional Shares of Common Stock are issued together with other shares or securities or other assets of the Company for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (A) and (B) above, as determined in good faith by the Board of Directors.

(2)     Options and Convertible Securities.   The consideration per share received by the Company for Additional Shares of Common Stock deemed to have been issued pursuant to Section 4.d(iii), relating to Options and Convertible Securities shall be determined by dividing

(A)     the total amount, if any, received or receivable by the Company as consideration for the issue of such Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein designed to protect against dilution) payable to the Company upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities by

(B)     the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard to any provision contained therein designed to protect against the dilution) issuable upon the exercise of such Options or conversion or exchange of such Convertible Securities.

e.         Adjustment of Conversion Price of Series D Preferred Stock Upon Qualified IPO .  In the event of a Qualified IPO that closes (i) on or before September 30, 2010, in which the initial public offering price for the Common Stock in such Qualified IPO (the “ IPO Price ”) is less than the product of (a) 1.16 multiplied by (b) the Series D Preferred Stock Conversion Price then in effect, the Series D Preferred Stock Conversion Price shall be reduced to the quotient obtained by dividing (w) the IPO Price by (x) 1.16; or (ii) after September 30, 2010, in which the IPO Price is less than the product of (c) 1.30 multiplied by (d) the Series D Preferred Stock Conversion Price then in effect, the Series D Preferred Stock Conversion Price shall be reduced to the quotient obtained by dividing (y) the IPO Price by (z) 1.30.


f.         Adjustments for Stock Dividends and for Combinations or Subdivisions of Common Stock. In the event that this Company at any time or from time to time after the Original Issue Date shall declare or pay, without consideration, any dividend on the Common Stock payable in Common Stock or in any right to acquire Common Stock for no consideration, or shall effect a subdivision of the outstanding shares of Common Stock into a greater number of shares of Common Stock (by stock split, reclassification or otherwise than by payment of a dividend in Common Stock or in any right to acquire Common Stock), or in the event the outstanding shares of Common Stock shall be combined or consolidated, by reclassification or otherwise, into a lesser number of shares of Common Stock, then the conversion price for any series of Preferred Stock in effect immediately prior to such event shall, concurrently with the effectiveness of such event, be proportionately decreased or increased, as appropriate. In the event that the Company shall declare or pay, without consideration, any dividend on the Common Stock payable in any right to acquire Common Stock for no consideration then the Company shall be deemed to have made a dividend payable in Common Stock in an amount of shares equal to the maximum number of shares issuable upon exercise of such rights to acquire Common Stock.

g.         Adjustments for Reclassification and Reorganization. If the Common Stock issuable upon conversion of any series of Preferred Stock shall be changed into the same or a different number of shares of any other class or classes of stock, whether by capital reorganization, reclassification or otherwise (other than a subdivision or combination of shares provided for in Section 4.e above or a merger or other reorganization referred to in Section 2.d above), the Conversion Price for any series of Preferred Stock then in effect shall, concurrently with the effectiveness of such reorganization or reclassification, be proportionately adjusted so that the Preferred Stock shall be convertible into, in lieu of the number of shares of Common Stock which the holders would otherwise have been entitled to receive, a number of shares of such other class or classes of stock equivalent to the number of shares of Common Stock that would have been subject to receipt by the holders upon conversion of the Preferred Stock immediately before that change, respectively.

h.         Certificates as to Adjustments. Upon the occurrence of each adjustment or readjustment of any conversion price pursuant to this Section 4, the Company at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and prepare and furnish to each holder of Preferred Stock a certificate executed by the Company’s President, Chief Financial Officer or a Vice President setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based. The Company shall, upon the written request at any time of any holder of Preferred Stock, furnish or cause to be furnished to such holder a like certificate setting forth (i) such adjustments and readjustments, (ii) the conversion price for such series of Preferred Stock at the time in effect, and (iii) the number of shares of Common Stock and the amount, if any, of other property which at the time would be received upon the conversion of the Preferred Stock.


i.         Notices of Record Date. In the event that the Company shall propose at any time (i) to declare any dividend or distribution upon its Common Stock, whether in cash, property, stock or other securities, whether or not a regular cash dividend and whether or not out of earnings or earned surplus, (ii) a Liquidation or any voluntary or involuntary dissolution or winding up of the Company, or (iii) to offer for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or other rights, then, in connection with each such event, unless otherwise waived by a majority of Preferred Stock, the Company shall send to the holders of Preferred Stock at least twenty (20) days’ prior written notice of the date on which a record shall be taken for such dividend, distribution, Liquidation, dissolution, winding up or subscription rights.

j.         Reservation of Stock Issuable Upon Conversion. The Company shall at all times reserve and keep available out of its authorized but unissued shares of Common Stock, solely for the purpose of effecting the conversion of the shares of the Preferred Stock, such number of its shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding shares of the Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Preferred Stock, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purpose, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to this Restated Certificate.

k.         Fractional Shares. No fractional share shall be issued upon the conversion of any share or shares of Preferred Stock. All shares of Common Stock (including fractions thereof) issuable upon conversion of more than one share of Preferred Stock by a holder thereof shall be aggregated for purposes of determining whether the conversion would result in the issuance of any fractional share. If, after the aforementioned aggregation, the conversion would result in the issuance of a fraction of a share of Common Stock, the Company shall, in lieu of issuing any fractional share, pay the holder otherwise entitled to such fraction a sum in cash equal to the fair market value of such fraction on the date of conversion (as determined in good faith by the Board of Directors).

l.         Notices. Any notice required by the provisions of this Section 4 shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after deposit in the United States mail, by registered or certified mail, postage prepaid and properly addressed to the party to be notified, or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All notices shall be addressed to each holder of record at the address of such holder appearing on the books of the Company.

5.     Board Representation.   In addition to the rights of the holders of Preferred Stock to vote on an as converted basis with holders of Common Stock pursuant to Section 3 above, with respect to election of directors:

a.        For so long as any shares of Series A Preferred Stock remain outstanding, the holders of Series A Preferred Stock, voting as a separate class, shall be entitled


to elect three (3) members of the Board of Directors (each a “ Series A Director ”) at each meeting or pursuant to each consent of the Company’s stockholders for the election of directors, and to remove from office such directors and to fill any vacancy caused by the resignation, death or removal of such directors. Notwithstanding the foregoing, the right of the holders of Series A Preferred Stock to elect the Series A Directors shall terminate upon the earliest to occur of the following: (i) an Acquisition; or (ii) an Asset Sale.

b. The holders of Series D Preferred Stock, voting as a separate class, shall be entitled to elect one (1) member of the Board of Directors (the “ Series D Director ”) at each meeting or pursuant to each consent of the Company’s stockholders for the election of directors, and to remove from office such directors and to fill any vacancy caused by the resignation, death or removal of such directors. Notwithstanding the foregoing, the right of the holders of Series D Preferred Stock to elect the Series D Director shall terminate upon the earliest to occur of the following: (i) such time as the Investor (as defined in that certain Series D Preferred Stock Purchase Agreement dated on or about the date of filing of this Restated Certificate by and between the Company and the Investor (the “ Purchase Agreement ”)), together with its Affiliates (as defined below), holds less than fifty percent (50%) of the shares of Series D Preferred Stock purchased by it pursuant to the Purchase Agreement; (ii) an Acquisition; or (iii) an Asset Sale. “ Affiliate ” means, with respect to a Person (as defined below), any Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such first Person. For purposes of this definition, “control” and, with correlative meanings, the terms “controlled by” and “under common control with” mean (x) the possession, directly or indirectly, of the power to direct the management or policies of a Person, whether through the ownership of voting securities, by contract relating to voting rights or corporate governance, or otherwise, or (y) the ownership, directly or indirectly, of more than 50% of the voting securities or other ownership interest of a Person. “ Person ” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.

c. The holders of Common Stock, voting as a separate class, shall be entitled to elect two (2) members of the Board of Directors (each a “ Common Director ”) at each meeting or pursuant to each consent of the Company’s stockholders for the election of directors, and to remove from office such directors and to fill any vacancy caused by the resignation, death or removal of such directors.

d.     The holders of Preferred Stock and the holders of Common Stock, voting together as a single class on an as-if converted basis, shall be entitled to elect any additional members of the Board of Directors (each an “ Independent Director ”), and to remove from office such directors and to fill any vacancy caused by the resignation, death or removal of such directors.

6.     Redemption.   The Preferred Stock shall not be redeemable.


7.     Restrictions and Limitations.   So long as at least 20% of the shares of the Preferred Stock sold by the Company (as adjusted for stock splits, dividends, combinations, recapitalizations and the like) remain outstanding, consent of the holders of at least the majority of the then outstanding shares of Preferred Stock shall be required for any action that (whether by amendment, merger, reorganization or otherwise):

a.     alters or changes the powers, preferences or rights of the Common Stock or the Preferred Stock,

b.     increases or decreases the authorized number of shares of Common or Preferred Stock,

c.     creates (whether by amendment, merger, reorganization or otherwise) any new class or series of shares having powers, preferences or rights senior to or on a parity with the Preferred Stock,

d.     results in the redemption of any shares of Preferred Stock or Common Stock (other than pursuant to equity incentive agreements with employees and other service providers giving the Company the right to repurchase shares upon the termination of employment or such other service relationship, at their original cost),

e.     results in a Liquidation or other corporate reorganization, including any reorganization or other transaction involving any parent or subsidiary of the Company,

f.     amends or waives any provision of the Company’s certificate of incorporation or bylaws,

g.     increases or decreases the authorized size of the Company’s Board of Directors, or

h.     results in the payment or declaration of any dividend on any shares of Common or Preferred Stock.

8.     Further Restrictions and Limitations . So long as at least 50% of the shares of the Series D Preferred Stock sold by the Company (as adjusted for stock splits, dividends, combinations, recapitalizations and the like with respect to such shares) remain outstanding, consent of the holders of at least the majority of the then outstanding shares of the Series D Preferred Stock shall be required for any action that (whether by amendment, merger, reorganization or otherwise):

a.     approves or permits the approval of a “drag-along” provision, or any provision that functions as a “drag-along” that would require the holders of Series D Preferred Stock to vote in favor of or otherwise support an Acquisition or Asset Sale,

b.     amends, alters or changes the powers, preferences or rights of the Series D Preferred Stock (provided that the creation (whether by amendment, merger, reorganization or otherwise) of any new class or series of shares having powers, preferences or rights on parity with the Series D Preferred Stock shall not constitute an amendment, alteration or change of the powers, preferences or rights of the Series D Preferred Stock),


c.     increases the number of authorized shares of Series D Preferred Stock,

d.     creates (whether by amendment, merger, reorganization or otherwise) any new class or series of shares having powers, preferences or rights senior to the Series D Preferred Stock, or

e.     results in the redemption of any shares of Preferred Stock or Common Stock (other than (i) pursuant to equity incentive agreements with employees and other service providers giving the Company the right to repurchase shares upon the termination of employment or such other service relationship, at their original cost, or (ii) repurchases or redemptions of shares from any founder or service provider upon terms approved by the Company’s Board of Directors),

f.     increases the authorized size of the Board of Directors to more than eleven (11) members,

9.     No Reissuance of Preferred Stock.   No share or shares of Preferred Stock acquired by the Company by reason of redemption, purchase, conversion, or otherwise shall be reissued; and, in addition, the certificate of incorporation shall be appropriately amended to effect the corresponding reduction in the Company’s authorized stock.

ARTICLE V : PREEMPTIVE RIGHTS .

No stockholder of the Corporation shall have a right to purchase shares of capital stock of the Corporation sold or issued by the Corporation except to the extent that such a right may from time to time be set forth in a written agreement between the Corporation and any stockholder.

ARTICLE VI : STOCK REPURCHASES .

In connection with repurchases by the Corporation of its Common Stock from Service Providers pursuant to agreements under which the Corporation has the option to repurchase such shares at cost upon the occurrence of certain events, such as the termination of employment, Sections 502 and 503 of the Corporations Code of the State of California shall not apply in all or in part with respect to such repurchases.

ARTICLE VII : BYLAW PROVISIONS .

A.        AMENDMENT OF BYLAWS. Subject to any additional vote required by the Restated Certificate or Bylaws, in furtherance and not in limitation of the powers conferred by statute, the Board is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation.

B.        NUMBER OF DIRECTORS. Subject to any additional vote required by the Restated Certificate, the number of directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation.


C.        BALLOT. Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.

D.        MEETINGS AND BOOKS. Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board or in the Bylaws of the Corporation.

ARTICLE VIII : DIRECTOR LIABILITY .

A.        LIMITATION.   To the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this Article VIII to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended. Any repeal or modification of the foregoing provisions of this Article VIII by the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of such director occurring prior to, such repeal or modification.

B.        INDEMNIFICATION .   To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the Corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section 145 of the General Corporation Law.

C.        MODIFICATION .   Any amendment, repeal or modification of the foregoing provisions of this Article VIII shall not adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification.

ARTICLE IX : CREDITOR AND STOCKHOLDER COMPROMISES

Whenever a compromise or arrangement is proposed between the Corporation and its creditors or any class of them and/or between the Corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of the Corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed for the Corporation under the provisions of §291 of Title 8 of the General Corporation Law or on the application of trustees in dissolution or of any receiver or receivers appointed for this Corporation under §279 of Title 8 of the General Corporation Law order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders of the Corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three-fourths in value of the creditors or class


of creditors, and/or of the stockholders or class of stockholders of the Corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of the Corporation as a consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders or class of stockholders, of the Corporation, as the case may be, and also on the Corporation.

*    *    *    *    *

Exhibit 3.02

 

 

 

 

 

AMYRIS BIOTECHNOLOGIES, INC.

a Delaware Corporation

BYLAWS

As Adopted April 15, 2010

 

 

 


BYLAWS

OF

AMYRIS BIOTECHNOLOGIES, INC.

(a Delaware corporation)

Table of Contents

 

         Page

ARTICLE I              STOCKHOLDERS

   1

Section 1.1:

  Annual Meetings    1

Section 1.2:

  Special Meetings    1

Section 1.3:

  Notice of Meetings    1

Section 1.4:

  Adjournments    1

Section 1.5:

  Quorum    2

Section 1.6:

  Organization.    2

Section 1.7:

  Voting; Proxies    2

Section 1.8:

  Fixing Date for Determination of Stockholders of Record    3

Section 1.9:

  List of Stockholders Entitled to Vote    3

Section 1.10:

  Action by Written Consent of Stockholders    3

Section 1.11:

  Inspectors of Elections    4

ARTICLE II            BOARD OF DIRECTORS

   6

Section 2.1:

  Number; Qualifications    6

Section 2.2:

  Election; Resignation; Removal; Vacancies    6

Section 2.3:

  Regular Meetings    6

Section 2.4:

  Special Meetings    6

Section 2.5:

  Remote Meetings Permitted    6

Section 2.6:

  Quorum; Vote Required for Action    7

Section 2.7:

  Organization    7

Section 2.8:

  Written Action by Directors    7

Section 2.9:

  Powers    7

Section 2.10:

  Compensation of Directors    7

ARTICLE III           COMMITTEES

   7

Section 3.1:

  Committees    7

 

i


TABLE OF CONTENTS

(continued)

 

         Page

Section 3.2:

  Committee Rules    8

ARTICLE IV           OFFICERS

   8

Section 4.1:

  Generally    8

Section 4.2:

  Chief Executive Officer    8

Section 4.3:

  Chairperson of the Board    9

Section 4.4:

  President    9

Section 4.5:

  Vice President    9

Section 4.6:

  Chief Financial Officer    9

Section 4.7:

  Treasurer    9

Section 4.8:

  Secretary    9

Section 4.9:

  Delegation of Authority    10

Section 4.10:

  Removal    10

ARTICLE V            STOCK

   10

Section 5.1:

  Certificates    10

Section 5.2:

  Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates    10

Section 5.3:

  Other Regulations    10

ARTICLE VI           INDEMNIFICATION

   10

Section 6.1:

  Indemnification of Officers and Directors    10

Section 6.2:

  Advance of Expenses    11

Section 6.3:

  Non-Exclusivity of Rights    11

Section 6.4:

  Indemnification Contracts    11

Section 6.5:

  Effect of Amendment    12

ARTICLE VII         NOTICES

   12

Section 7.1:

  Notice    12

Section 7.2:

  Waiver of Notice    13

ARTICLE VIII        INTERESTED DIRECTORS

   13

Section 8.1:

  Interested Directors; Quorum    13

ARTICLE IX           MISCELLANEOUS

   13

Section 9.1:

  Fiscal Year    13

 

ii


TABLE OF CONTENTS

(continued)

 

         Page

Section 9.2:

  Seal    13

Section 9.3:

  Form of Records    13

Section 9.4:

  Reliance Upon Books and Records    14

Section 9.5:

  Certificate of Incorporation Governs    14

Section 9.6:

  Severability    14

ARTICLE X            AMENDMENT

   14

Section 10.1:

  Amendments    14

 

iii


BYLAWS

OF

AMYRIS BIOTECHNOLOGIES, INC.

(a Delaware corporation)

April 15, 2010

ARTICLE I

STOCKHOLDERS

Section 1.1 :     Annual Meetings .  Unless directors are elected by written consent in lieu of an annual meeting as permitted by Section 211 of the Delaware General Corporation Law, an annual meeting of stockholders shall be held for the election of directors at such date and time as the Board of Directors shall each year fix. The meeting may be held either at a place, within or without the State of Delaware, or by means of remote communication as the Board of Directors in its sole discretion may determine. Any other proper business may be transacted at the annual meeting.

Section 1.2 :     Special Meetings .  Special meetings of stockholders for any purpose or purposes may be called at any time by the Board of Directors, the Chairperson of the Board of Directors, the Chief Executive Officer, the President, the holders of shares of the Corporation that are entitled to cast not less than ten percent (10%) of the total number of votes entitled to be cast by all stockholders at such meeting, or by a majority of the members of the Board of Directors. Special meetings may not be called by any other person or persons.

Section 1.3 :     Notice of Meetings .  Notice of all meetings of stockholders shall be given in writing or by electronic transmission in the manner provided by law (including, without limitation, as set forth in Section 7.1(b) of these Bylaws) stating the date, time and place, if any, of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Unless otherwise required by applicable law or the Certificate of Incorporation of the Corporation, such notice shall be given not less than ten (10) nor more than sixty (60) days before the date of the meeting to each stockholder of record entitled to vote at such meeting.

Section 1.4 :     Adjournments .  The chair of any meeting of stockholders shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seems to him or her to be in order. The chair shall have the power to adjourn the meeting to another time, date and place (if any). Any meeting of stockholders may adjourn from time to time, and notice need not be given of any such adjourned meeting if the time, date and place (if any) thereof are announced at the meeting at which the adjournment is taken; provided , however , that if the adjournment is for more than thirty (30) days, or if after the adjournment a new record date is fixed for the adjourned meeting, then a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at

 

1


the meeting. At the adjourned meeting the Corporation may transact any business that might have been transacted at the original meeting.

Section 1.5 :     Quorum .  At each meeting of stockholders the holders of a majority of the shares of stock entitled to vote at the meeting, present in person or represented by proxy, shall constitute a quorum for the transaction of business, except if otherwise required by applicable law. If a quorum shall fail to attend any meeting, the chairperson of the meeting or the holders of a majority of the shares entitled to vote who are present, in person or by proxy, at the meeting may adjourn the meeting. Shares of the Corporation’s stock belonging to the Corporation (or to another corporation, if a majority of the shares entitled to vote in the election of directors of such other corporation are held, directly or indirectly, by the Corporation), shall neither be entitled to vote nor be counted for quorum purposes; provided , however , that the foregoing shall not limit the right of the Corporation or any other corporation to vote any shares of the Corporation’s stock held by it in a fiduciary capacity and to count such shares for purposes of determining a quorum.

Section 1.6 :     Organization .  Meetings of stockholders shall be presided over by such person as the Board of Directors may designate, or, in the absence of such a person, the Chairperson of the Board of Directors, or, in the absence of such person, the President of the Corporation, or, in the absence of such person, such person as may be chosen by the holders of a majority of the shares entitled to vote who are present, in person or by proxy, at the meeting. Such person shall be chairperson of the meeting and, subject to Section 1.11 hereof, shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seems to him or her to be in order. The Secretary of the Corporation shall act as secretary of the meeting, but in such person’s absence the chairperson of the meeting may appoint any person to act as secretary of the meeting.

Section 1.7 :     Voting; Proxies .  Unless otherwise provided by law or the Certificate of Incorporation, and subject to the provisions of Section 1.8 of these Bylaws, each stockholder shall be entitled to one (1) vote for each share of stock held by such stockholder. Each stockholder entitled to vote at a meeting of stockholders, or to take corporate action by written consent without a meeting, may authorize another person or persons to act for such stockholder by proxy. Such a proxy may be prepared, transmitted and delivered in any manner permitted by applicable law. Voting at meetings of stockholders need not be by written ballot unless such is demanded at the meeting before voting begins by a stockholder or stockholders holding shares representing at least one percent (1%) of the votes entitled to vote at such meeting, or by such stockholder’s or stockholders’ proxy; provided , however , that an election of directors shall be by written ballot if demand is so made by any stockholder at the meeting before voting begins. If a vote is to be taken by written ballot, then each such ballot shall state the name of the stockholder or proxy voting and such other information as the chairperson of the meeting deems appropriate and, if authorized by the Board of Directors, the ballot may be submitted by electronic transmission in the manner provided by law. Directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors. Unless otherwise provided by applicable law, the Certificate of Incorporation or these Bylaws, every matter other than the election of directors shall be decided by the affirmative vote of the holders of a majority of the shares of stock entitled to vote thereon

 

2


that are present in person or represented by proxy at the meeting and are voted for or against the matter.

Section 1.8 :     Fixing Date for Determination of Stockholders of Record .  In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or to take corporate action by written consent without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors and which shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting, nor more than sixty (60) days prior to any other action. If no record date is fixed by the Board of Directors, then the record date shall be as provided by applicable law. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided , however , that the Board of Directors may fix a new record date for the adjourned meeting.

Section 1.9 :     List of Stockholders Entitled to Vote .  A complete list of stockholders entitled to vote at any meeting of stockholders, arranged in alphabetical order and showing the address of each stockholder and the number of shares registered in the name of each stockholder, shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10) days prior to the meeting, either on a reasonably accessible electronic network as permitted by law (provided that the information required to gain access to the list is provided with the notice of the meeting) or during ordinary business hours at the principal place of business of the Corporation. If the meeting is held at a place, the list shall also be produced and kept at the time and place of the meeting during the whole time thereof and may be inspected by any stockholder who is present at the meeting. If the meeting is held solely by means of remote communication, then the list shall be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access the list shall be provided with the notice of the meeting.

Section 1.10 :     Action by Written Consent of Stockholders .

(a)         Procedure .  Unless otherwise provided by the Certificate of Incorporation, any action required or permitted to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed in the manner permitted by law by the holders of outstanding stock having not less than the number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Written stockholder consents shall bear the date of signature of each stockholder who signs the consent in the manner permitted by law and shall be delivered to the Corporation as provided in subsection (b) below. No written consent shall be effective to take the action set forth therein unless, within sixty (60) days of the earliest dated consent delivered to the Corporation in the manner provided above, written consents signed by a sufficient number of

 

3


stockholders to take the action set forth therein are delivered to the Corporation in the manner provided above.

(b)        A telegram, cablegram or other electronic transmission consenting to an action to be taken and transmitted by a stockholder or proxyholder, or a person or persons authorized to act for a stockholder or proxyholder, shall be deemed to be written, signed and dated for the purposes of this section, provided that any such telegram, cablegram or other electronic transmission sets forth or is delivered with information from which the Corporation can determine (i) that the telegram, cablegram or other electronic transmission was transmitted by the stockholder or proxyholder or by a person or persons authorized to act for the stockholder or proxyholder and (ii) the date on which such stockholder or proxyholder or authorized person or persons transmitted such telegram, cablegram or electronic transmission. The date on which such telegram, cablegram or electronic transmission is transmitted shall be deemed to be the date on which such consent was signed. No consent given by telegram, cablegram or other electronic transmission shall be deemed to have been delivered until such consent is reproduced in paper form and until such paper form shall be delivered to the Corporation by delivery to its registered office in the State of Delaware, its principal place of business or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to a Corporation’s registered office shall be made by hand or by certified or registered mail, return receipt requested. Notwithstanding the foregoing limitations on delivery, consents given by telegram, cablegram or other electronic transmission may be otherwise delivered to the principal place of business of the Corporation or to an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded if, to the extent and in the manner provided by resolution of the Board of Directors of the Corporation.

(c)         Notice of Consent .  Prompt notice of the taking of corporate action by stockholders without a meeting by less than unanimous written consent of the stockholders shall be given to those stockholders who have not consented thereto in writing and who, if the action had been taken at a meeting, would have been entitled to notice of the meeting if the record date for such meeting had been the date that written consents signed by a sufficient number of holders to take the action were delivered to the Corporation as required by law. In the case of a Certificate Action (as defined below), if the Delaware General Corporation Law so requires, such notice shall be given prior to filing of the certificate in question. If the action which is consented to requires the filing of a certificate under the Delaware General Corporation Law (a “ Certificate Action ”), then if the Delaware General Corporation Law so requires, the certificate so filed shall state that written stockholder consent has been given in accordance with Section 228 of the Delaware General Corporation Law and that written notice of the taking of corporate action by stockholders without a meeting as described herein has been given as provided in such section.

Section 1.11 :     Inspectors of Elections .

(a)         Applicability .  Unless otherwise provided in the Corporation’s Certificate of Incorporation or required by the Delaware General Corporation Law, the following provisions of this Section 1.11 shall apply only if and when the Corporation has a class of voting stock that is: (i) listed on a national securities exchange; (ii) authorized for quotation on an automated

 

4


interdealer quotation system of a registered national securities association; or (iii) held of record by more than 2,000 stockholders; in all other cases, observance of the provisions of this Section 1.11 shall be optional, and at the discretion of the Corporation.

(b)         Appointment .  The Corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors of election to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting shall appoint one or more inspectors to act at the meeting.

(c)         Inspector’s Oath .  Each inspector of election, before entering upon the discharge of his duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of such inspector’s ability.

(d)         Duties of Inspectors .  At a meeting of stockholders, the inspectors of election shall (i) ascertain the number of shares outstanding and the voting power of each share, (ii) determine the shares represented at a meeting and the validity of proxies and ballots, (iii) count all votes and ballots, (iv) determine and retain for a reasonable period of time a record of the disposition of any challenges made to any determination by the inspectors, and (v) certify their determination of the number of shares represented at the meeting, and their count of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors.

(e)         Opening and Closing of Polls .  The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced by the inspectors at the meeting. No ballot, proxies or votes, nor any revocations thereof or changes thereto, shall be accepted by the inspectors after the closing of the polls unless the Court of Chancery upon application by a stockholder shall determine otherwise.

(f)         Determinations .  In determining the validity and counting of proxies and ballots, the inspectors shall be limited to an examination of the proxies, any envelopes submitted with those proxies, any information provided in connection with proxies in accordance with Section 212(c)(2) of the Delaware General Corporation Law, ballots and the regular books and records of the Corporation, except that the inspectors may consider other reliable information for the limited purpose of reconciling proxies and ballots submitted by or on behalf of banks, brokers, their nominees or similar persons which represent more votes than the holder of a proxy is authorized by the record owner to cast or more votes than the stockholder holds of record. If the inspectors consider other reliable information for the limited purpose permitted herein, the inspectors at the time they make their certification of their determinations pursuant to this Section 1.11 shall specify the precise information considered by them, including the person or persons from whom they obtained the information, when the information was obtained, the means by which the information was obtained and the basis for the inspectors’ belief that such information is accurate and reliable.

 

5


ARTICLE II

BOARD OF DIRECTORS

Section 2.1 :     Number; Qualifications .  The Board of Directors shall consist of one or more members. The initial number of directors shall be one (1), and thereafter shall be fixed from time to time by resolution of the Board of Directors. No decrease in the authorized number of directors constituting the Board of Directors shall shorten the term of any incumbent director. Directors need not be stockholders of the Corporation.

Section 2.2 :     Election; Resignation; Removal; Vacancies .  The Board of Directors shall initially consist of the person or persons elected by the incorporator or named in the Corporation’s initial Certificate of Incorporation. Each director shall hold office until such director’s successor is elected and qualified, or until such director’s earlier death, resignation or removal. Any director may resign at any time upon notice to the Corporation given in writing or by electronic transmission. Subject to the rights of any holders of Preferred Stock then outstanding: (i) any director or the entire Board of Directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors and (ii) any vacancy occurring in the Board of Directors for any cause, and any newly created directorship resulting from any increase in the authorized number of directors to be elected by all stockholders having the right to vote as a single class, may be filled by the stockholders, by a majority of the directors then in office, although less than a quorum, or by a sole remaining director.

Section 2.3 :     Regular Meetings .  Regular meetings of the Board of Directors may be held at such places, within or without the State of Delaware, and at such times as the Board of Directors may from time to time determine. Notice of regular meetings need not be given if the date, times and places thereof are fixed by resolution of the Board of Directors.

Section 2.4 :     Special Meetings .  Special meetings of the Board of Directors may be called by the Chairperson of the Board of Directors, the President or a majority of the members of the Board of Directors then in office and may be held at any time, date or place, within or without the State of Delaware, as the person or persons calling the meeting shall fix. Notice of the time, date and place of such meeting shall be given, orally, in writing or by electronic transmission (including electronic mail), by the person or persons calling the meeting to all directors at least four (4) days before the meeting if the notice is mailed, or at least twenty-four (24) hours before the meeting if such notice is given by telephone, hand delivery, telegram, telex, mailgram, facsimile, electronic mail or other means of electronic transmission. Unless otherwise indicated in the notice, any and all business may be transacted at a special meeting.

Section 2.5 :     Remote Meetings Permitted .  Members of the Board of Directors, or any committee of the Board, may participate in a meeting of the Board of Directors or such committee by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to conference telephone or other communications equipment shall constitute presence in person at such meeting.

 

6


Section 2.6 :     Quorum; Vote Required for Action .  At all meetings of the Board of Directors a majority of the total number of authorized directors shall constitute a quorum for the transaction of business. Except as otherwise provided herein or in the Certificate of Incorporation, or required by law, the vote of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors.

Section 2.7 :     Organization .  Meetings of the Board of Directors shall be presided over by the Chairperson of the Board of Directors, or in such person’s absence by the President, or in such person’s absence by a chairperson chosen at the meeting. The Secretary shall act as secretary of the meeting, but in such person’s absence the chairperson of the meeting may appoint any person to act as secretary of the meeting.

Section 2.8 :     Written Action by Directors .  Any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board of Directors or such committee, as the case may be, consent thereto in writing, or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee, respectively. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

Section 2.9:      Powers .  The Board of Directors may, except as otherwise required by law or the Certificate of Incorporation, exercise all such powers and do all such acts and things as may be exercised or done by the Corporation.

Section 2.10 :     Compensation of Directors .  Directors, as such, may receive, pursuant to a resolution of the Board of Directors, fees and other compensation for their services as directors, including without limitation their services as members of committees of the Board of Directors.

ARTICLE III

COMMITTEES

Section 3.1 :     Committees .  The Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting of such committee who are not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in place of any such absent or disqualified member. Any such committee, to the extent provided in a resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority in reference to the following matters: (i) approving or adopting, or recommending to the stockholders, any action or matter expressly required by the Delaware General Corporation Law

 

7


to be submitted to stockholders for approval or (ii) adopting, amending or repealing any bylaw of the Corporation.

Section 3.2 :     Committee Rules .  Unless the Board of Directors otherwise provides, each committee designated by the Board of Directors may make, alter and repeal rules for the conduct of its business. In the absence of such rules each committee shall conduct its business in the same manner as the Board of Directors conducts its business pursuant to Article II of these Bylaws.

ARTICLE IV

OFFICERS

Section 4.1 :     Generally .  The officers of the Corporation shall consist of a Chief Executive Officer and/or a President, one or more Vice Presidents, a Secretary, a Treasurer and such other officers, including a Chairperson of the Board of Directors and/or Chief Financial Officer, as may from time to time be appointed by the Board of Directors. All officers shall be elected by the Board of Directors; provided , however , that the Board of Directors may empower the Chief Executive Officer of the Corporation to appoint officers other than the Chairperson of the Board, the Chief Executive Officer, the President, the Chief Financial Officer or the Treasurer. Each officer shall hold office until such person’s successor is elected and qualified or until such person’s earlier resignation or removal. Any number of offices may be held by the same person. Any officer may resign at any time upon written notice to the Corporation. Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise may be filled by the Board of Directors.

Section 4.2 :     Chief Executive Officer .  Subject to the control of the Board of Directors and such supervisory powers, if any, as may be given by the Board of Directors, the powers and duties of the Chief Executive Officer of the Corporation are:

(a)        To act as the general manager and, subject to the control of the Board of Directors, to have general supervision, direction and control of the business and affairs of the Corporation;

(b)        To preside at all meetings of the stockholders;

(c)        To call meetings of the stockholders to be held at such times and, subject to the limitations prescribed by law or by these Bylaws, at such places as he or she shall deem proper; and

(d)        To affix the signature of the Corporation to all deeds, conveyances, mortgages, guarantees, leases, obligations, bonds, certificates and other papers and instruments in writing which have been authorized by the Board of Directors or which, in the judgment of the Chief Executive Officer, should be executed on behalf of the Corporation; to sign certificates for shares of stock of the Corporation; and, subject to the direction of the Board of Directors, to have general charge of the property of the Corporation and to supervise and control all officers, agents and employees of the Corporation.

 

8


The President shall be the Chief Executive Officer of the Corporation unless the Board of Directors shall designate another officer to be the Chief Executive Officer. If there is no President, and the Board of Directors has not designated any other officer to be the Chief Executive Officer, then the Chairperson of the Board of Directors shall be the Chief Executive Officer.

Section 4.3 :     Chairperson of the Board .  The Chairperson of the Board of Directors shall have the power to preside at all meetings of the Board of Directors and shall have such other powers and duties as provided in these Bylaws and as the Board of Directors may from time to time prescribe.

Section 4.4 :     President .  The President shall be the Chief Executive Officer of the Corporation unless the Board of Directors shall have designated another officer as the Chief Executive Officer of the Corporation. Subject to the provisions of these Bylaws and to the direction of the Board of Directors, and subject to the supervisory powers of the Chief Executive Officer (if the Chief Executive Officer is an officer other than the President), and subject to such supervisory powers and authority as may be given by the Board of Directors to the Chairperson of the Board of Directors, and/or to any other officer, the President shall have the responsibility for the general management the control of the business and affairs of the Corporation and the general supervision and direction of all of the officers, employees and agents of the Corporation (other than the Chief Executive Officer, if the Chief Executive Officer is an officer other than the President) and shall perform all duties and have all powers that are commonly incident to the office of President or that are delegated to the President by the Board of Directors.

Section 4.5 :     Vice President .  Each Vice President shall have all such powers and duties as are commonly incident to the office of Vice President, or that are delegated to him or her by the Board of Directors or the Chief Executive Officer. A Vice President may be designated by the Board to perform the duties and exercise the powers of the Chief Executive Officer in the event of the Chief Executive Officer’s absence or disability.

Section 4.6 :     Chief Financial Officer .  The Chief Financial Officer shall be the Treasurer of the Corporation unless the Board of Directors shall have designated another officer as the Treasurer of the Corporation. Subject to the direction of the Board of Directors and the Chief Executive Officer, the Chief Financial Officer shall perform all duties and have all powers that are commonly incident to the office of Chief Financial Officer.

Section 4.7 :     Treasurer .  The Treasurer shall have custody of all monies and securities of the Corporation. The Treasurer shall make such disbursements of the funds of the Corporation as are authorized and shall render from time to time an account of all such transactions. The Treasurer shall also perform such other duties and have such other powers as are commonly incident to the office of Treasurer, or as the Board of Directors or the Chief Executive Officer may from time to time prescribe.

Section 4.8 :     Secretary .  The Secretary shall issue or cause to be issued all authorized notices for, and shall keep, or cause to be kept, minutes of all meetings of the stockholders and the Board of Directors. The Secretary shall have charge of the corporate minute books and

 

9


similar records and shall perform such other duties and have such other powers as are commonly incident to the office of Secretary, or as the Board of Directors or the Chief Executive Officer may from time to time prescribe.

Section 4.9 :     Delegation of Authority .   The Board of Directors may from time to time delegate the powers or duties of any officer to any other officers or agents, notwithstanding any provision hereof.

Section 4.10 :     Removal .  Any officer of the Corporation shall serve at the pleasure of the Board of Directors and may be removed at any time, with or without cause, by the Board of Directors. Such removal shall be without prejudice to the contractual rights of such officer, if any, with the Corporation.

ARTICLE V

STOCK

Section 5.1 :     Certificates .  Every holder of stock shall be entitled to have a certificate signed by or in the name of the Corporation by the Chairperson or Vice-Chairperson of the Board of Directors, or the President or a Vice President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary, of the Corporation, certifying the number of shares owned by such stockholder in the Corporation. Any or all of the signatures on the certificate may be a facsimile.

Section 5.2 :     Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates .  The Corporation may issue a new certificate of stock in the place of any certificate previously issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner’s legal representative, to agree to indemnify the Corporation and/or to give the Corporation a bond sufficient to indemnify it, against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate.

Section 5.3 :     Other Regulations .  The issue, transfer, conversion and registration of stock certificates shall be governed by such other regulations as the Board of Directors may establish.

ARTICLE VI

INDEMNIFICATION

Section 6.1 :     Indemnification of Officers and Directors .  Each person who was or is made a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a “ Proceeding ”), by reason of the fact that such person (or a person of whom such person is the legal representative), is or was a director or officer of the Corporation or a Reincorporated Predecessor (as defined below) or is or was serving at the request of the Corporation or a Reincorporated Predecessor (as defined below) as a director or officer of another corporation, or of a partnership, joint venture, trust or

 

10


other enterprise, including service with respect to employee benefit plans, shall be indemnified and held harmless by the Corporation to the fullest extent permitted by the Delaware General Corporation Law, against all expenses, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes and penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such person in connection therewith, provided such person acted in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful. Such indemnification shall continue as to a person who has ceased to be a director or officer and shall inure to the benefit of such person’s heirs, executors and administrators. Notwithstanding the foregoing, the Corporation shall indemnify any such person seeking indemnity in connection with a Proceeding (or part thereof) initiated by such person only if such Proceeding (or part thereof) was authorized by the Board of Directors of the Corporation. As used herein, the term “ Reincorporated Predecessor ” means a corporation that is merged with and into the Corporation in a statutory merger where (a) the Corporation is the surviving corporation of such merger; (b) the primary purpose of such merger is to change the corporate domicile of the Reincorporated Predecessor to Delaware.

Section 6.2 :     Advance of Expenses .  The Corporation shall pay all expenses (including attorneys’ fees) incurred by such a director or officer in defending any such Proceeding as they are incurred in advance of its final disposition; provided , however , that if the Delaware General Corporation Law then so requires, the payment of such expenses incurred by such a director or officer in advance of the final disposition of such Proceeding shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it should be determined ultimately that such director or officer is not entitled to be indemnified under this Article VI or otherwise; and provided , further , that the Corporation shall not be required to advance any expenses to a person against whom the Corporation directly brings a claim, in a Proceeding, alleging that such person has breached such person’s duty of loyalty to the Corporation, committed an act or omission not in good faith or that involves intentional misconduct or a knowing violation of law, or derived an improper personal benefit from a transaction.

Section 6.3:      Non-Exclusivity of Rights .  The rights conferred on any person in this Article VI shall not be exclusive of any other right that such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, Bylaw, agreement, vote or consent of stockholders or disinterested directors, or otherwise. Additionally, nothing in this Article VI shall limit the ability of the Corporation, in its discretion, to indemnify or advance expenses to persons whom the Corporation is not obligated to indemnify or advance expenses pursuant to this Article VI.

Section 6.4 :     Indemnification Contracts .  The Board of Directors is authorized to cause the Corporation to enter into indemnification contracts with any director, officer, employee or agent of the Corporation, or any person serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including employee benefit plans, providing indemnification rights to such person. Such rights may be greater than those provided in this Article VI.

 

11


Section 6.5 :     Effect of Amendment .  Any amendment, repeal or modification of any provision of this Article VI shall be prospective only, and shall not adversely affect any right or protection conferred on a person pursuant to this Article VI and existing at the time of such amendment, repeal or modification.

ARTICLE VII

NOTICES

Section 7.1 :     Notice .

(a)        Except as otherwise specifically provided in these Bylaws (including, without limitation, Section 7.1(b) below) or required by law, all notices required to be given pursuant to these Bylaws shall be in writing and may in every instance be effectively given by hand delivery (including use of a delivery service), by depositing such notice in the mail, postage prepaid, or by sending such notice by prepaid telegram, telex, overnight express courier, mailgram or facsimile. Any such notice shall be addressed to the person to whom notice is to be given at such person’s address as it appears on the records of the Corporation. The notice shall be deemed given (i) in the case of hand delivery, when received by the person to whom notice is to be given or by any person accepting such notice on behalf of such person, (ii) in the case of delivery by mail, upon deposit in the mail, (iii) in the case of delivery by overnight express courier, when dispatched, and (iv) in the case of delivery via telegram, telex, mailgram or facsimile, when dispatched.

(b)        Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation under any provision of the Delaware General Corporation Law, the Certificate of Incorporation, or these Bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written notice to the Corporation. Any such consent shall be deemed revoked if (i) the Corporation is unable to deliver by electronic transmission two consecutive notices given by the Corporation in accordance with such consent and (ii) such inability becomes known to the Secretary or an Assistant Secretary of the Corporation or to the transfer agent, or other person responsible for the giving of notice; provided, however, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action. Notice given pursuant to this Section 7.1(b) shall be deemed given: (i) if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice; (ii) if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice; (iii) if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of (A) such posting and (B) the giving of such separate notice; and (iv) if by any other form of electronic transmission, when directed to the stockholder.

(c)        An affidavit of the Secretary or an Assistant Secretary or of the transfer agent or other agent of the Corporation that the notice has been given in writing or by a form of electronic transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein.

 

12


Section 7.2 :     Waiver of Notice .  Whenever notice is required to be given under any provision of these Bylaws, a written waiver of notice, signed by the person entitled to notice, or waiver by electronic transmission by such person, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders, directors or members of a committee of directors need be specified in any waiver of notice.

ARTICLE VIII

INTERESTED DIRECTORS

Section 8.1 :     Interested Directors; Quorum .  No contract or transaction between the Corporation and one or more of its directors or officers, or between the Corporation and any other corporation, partnership, association or other organization in which one or more of its directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board of Directors or committee thereof that authorizes the contract or transaction, or solely because his, her or their votes are counted for such purpose, if: (i) the material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the Board of Directors or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; (ii) the material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or (iii) the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board of Directors, a committee thereof, or the stockholders. Interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee which authorizes the contract or transaction.

ARTICLE IX

MISCELLANEOUS

Section 9.1 :     Fiscal Year .  The fiscal year of the Corporation shall be determined by resolution of the Board of Directors.

Section 9.2 :     Seal .  The Board of Directors may provide for a corporate seal, which shall have the name of the Corporation inscribed thereon and shall otherwise be in such form as may be approved from time to time by the Board of Directors.

Section 9.3 :     Form of Records .  Any records maintained by the Corporation in the regular course of its business, including its stock ledger, books of account and minute books,

 

13


may be kept on or by means of, or be in the form of, diskettes, computer hard drives, servers, or any other information storage device or method, provided that the records so kept can be converted into clearly legible paper form within a reasonable time. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant to any provision of the Delaware General Corporation Law.

Section 9.4 :     Reliance Upon Books and Records .  A member of the Board of Directors, or a member of any committee designated by the Board of Directors shall, in the performance of such person’s duties, be fully protected in relying in good faith upon records of the Corporation and upon such information, opinions, reports or statements presented to the Corporation by any of the Corporation’s officers or employees, or committees of the Board of Directors, or by any other person as to matters the member reasonably believes are within such other person’s professional or expert competence and who has been selected with reasonable care by or on behalf of the Corporation.

Section 9.5 :     Certificate of Incorporation Governs .  In the event of any conflict between the provisions of the Corporation’s Certificate of Incorporation and Bylaws, the provisions of the Certificate of Incorporation shall govern.

Section 9.6 :     Severability .  If any provision of these Bylaws shall be held to be invalid, illegal, unenforceable or in conflict with the provisions of the Corporation’s Certificate of Incorporation, then such provision shall nonetheless be enforced to the maximum extent possible consistent with such holding and the remaining provisions of these Bylaws (including without limitation, all portions of any section of these Bylaws containing any such provision held to be invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation, that are not themselves invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation) shall remain in full force and effect.

ARTICLE X

AMENDMENT

Section 10.1 :     Amendments .  Stockholders of the Corporation holding a majority of the Corporation’s outstanding voting stock then entitled to vote at an election of directors shall have the power to adopt, amend or repeal Bylaws. To the extent provided in the Corporation’s Certificate of Incorporation, the Board of Directors of the Corporation shall also have the power to adopt, amend or repeal Bylaws of the Corporation.

 

14


CERTIFICATION OF BYLAWS

OF

AMYRIS BIOTECHNOLOGIES, INC.

(a Delaware corporation)

KNOW ALL BY THESE PRESENTS:

I, Tamara Tompkins, certify that I am Secretary of Amyris Biotechnologies, Inc., a Delaware corporation (the “ Company ”), that I am duly authorized to make and deliver this certification, that the attached Bylaws are a true and correct copy of the Bylaws of the Company in effect as of the date of this certificate.

Dated: April 15, 2010

 

     LOGO
Tamara Tompkins, Secretary

Exhibit 3.03

AMYRIS, INC.

RESTATED CERTIFICATE OF INCORPORATION

Amyris, Inc., a Delaware corporation, hereby certifies as follows.

1.        The name of the corporation is Amyris, Inc. The date of filing its original Certificate of Incorporation with the Secretary of State was April 15, 2010. The corporation was originally incorporated under the name Amyris Biotechnologies, Inc.

2.        The Restated Certificate of Incorporation of the corporation attached hereto as Exhibit “1” , which is incorporated herein by this reference, and which restates, integrates and further amends the provisions of the Certificate of Incorporation of this corporation as previously amended or supplemented, has been duly adopted by the corporation’s Board of Directors and by the stockholders in accordance with Sections 242 and 245 of the Delaware General Corporation Law, with the approval of the corporation’s stockholders having been given by written consent without a meeting in accordance with Section 228 of the Delaware General Corporation Law.

IN WITNESS WHEREOF, this corporation has caused this Restated Certificate of Incorporation to be signed by its duly authorized officer and the foregoing facts stated herein are true and correct.

 

Dated:                                                  

   

Amyris, Inc.

   

By:                                                                   

   

Name:                                                              

   

Title:                                                                

 

1


EXHIBIT “1”

AMYRIS, INC.

RESTATED CERTIFICATE OF INCORPORATION

ARTICLE I: NAME

The name of the corporation is Amyris, Inc.

ARTICLE II: AGENT FOR SERVICE OF PROCESS

The address of the corporation’s registered office in the State of Delaware is 3500 South Dupont Highway, City of Dover, County of Kent, DE 19901. The name of the registered agent of the corporation at that address is: Incorporating Services, Ltd.

ARTICLE III: PURPOSE

The purpose of the corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.

ARTICLE IV: AUTHORIZED STOCK

1.          Total Authorized . The total number of shares of all classes of stock that the corporation has authority to issue is One-Hundred and Five Million (105,000,000) shares, consisting of two classes: One-Hundred Million (100,000,000) shares of Common Stock, $0.0001 par value per share, and Five Million (5,000,000) shares of Preferred Stock, $0.0001 par value per share.

2.          Designation of Additional Shares

2.1.        The Board of Directors is authorized, subject to any limitations prescribed by the law of the State of Delaware, to provide for the issuance of the shares of Preferred Stock in one or more series, and, by filing a Certificate of Designation pursuant to the applicable law of the State of Delaware, to establish from time to time the number of shares to be included in each such series, to fix the designation, powers, preferences and relative, participating, optional or other rights, if any, of the shares of each such series and any qualifications, limitations or restrictions thereof, and to increase (but not above the total number of authorized shares of the class) or decrease the number of shares of any such series (but not below the number of shares of such series then outstanding). The number of authorized shares of Preferred Stock may also be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of all the then-outstanding shares of capital stock of the corporation entitled to vote thereon, without a vote of the holders of the Preferred Stock, unless a vote of any such holders is required pursuant to the terms of any certificate or certificates establishing a series of Preferred Stock.

 

2


2.2        Except as otherwise expressly provided in any Certificate of Designation designating any series of Preferred Stock pursuant to the foregoing provisions of this Article IV, any new series of Preferred Stock may be designated, fixed and determined as provided herein by the Board of Directors without approval of the holders of Common Stock or the holders of Preferred Stock, or any series thereof, and any such new series may have powers, preferences and rights, including, without limitation, voting rights, dividend rights, liquidation rights, redemption rights and conversion rights, senior to, junior to or pari passu with the rights of the Common Stock, the Preferred Stock, or any future class or series of Preferred Stock or Common Stock.

2.3        Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the corporation for their vote; provided , however , that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (including any Certificate of Designation relating to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to this Certificate of Incorporation (including any Certificate of Designation relating to any series of Preferred Stock).

ARTICLE V: AMENDMENT OF BYLAWS

The Board of Directors of the corporation shall have the power to adopt, amend or repeal the Bylaws of the corporation. Any adoption, amendment or repeal of the Bylaws of the corporation by the Board of Directors shall require the approval of a majority of the Whole Board. For purposes of this Certificate of Incorporation, the term “ Whole Board ” shall mean the total number of authorized directors whether or not there exist any vacancies in previously authorized directorships. The stockholders shall also have power to adopt, amend or repeal the Bylaws of the corporation; provided , however , that in addition to any vote of the holders of any class or series of stock of the corporation required by law or by this Certificate of Incorporation (including any Preferred Stock issued pursuant to a Certificate of Designation), the affirmative vote of the holders of at least two-thirds (2/3) of the voting power of all of the then-outstanding shares of the capital stock of the corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to adopt, amend or repeal any provision of the Bylaws of the corporation.

ARTICLE VI: MATTERS RELATING TO THE BOARD OF DIRECTORS

1.         Director Powers . The conduct of the affairs of the corporation shall be managed by or under the direction of the Board of Directors. In addition to the powers and authority expressly conferred upon them by statute or by this Certificate of Incorporation or the Bylaws of the corporation, the directors are hereby empowered to exercise all such powers and do all such acts and things as may be exercised or done by the corporation.

2.         Number of Directors . Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the number of directors shall be fixed from time to time exclusively by resolution adopted by a majority of the Whole Board.

 

3


3.         Classified Board . Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the directors shall be divided, with respect to the time for which they severally hold office, into three classes designated as Class I, Class II and Class III, respectively (the “ Classified Board ”). The Board of Directors may assign members of the Board of Directors already in office to the Classified Board, which assignments shall become effective at the same time the Classified Board becomes effective. Directors shall be assigned to each class in accordance with a resolution or resolutions adopted by the Board of Directors, with the number of directors in each class to be divided as nearly equal as reasonably possible. The initial term of office of the Class I directors shall expire at the corporation’s first annual meeting of stockholders following the closing of the corporation’s initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of Common Stock to the public (the “ Initial Public Offering ”), the initial term of office of the Class II directors shall expire at the corporation’s second annual meeting of stockholders following the closing of the Initial Public Offering, and the initial term of office of the Class III directors shall expire at the corporation’s third annual meeting of stockholders following the closing of the Initial Public Offering. At each annual meeting of stockholders following the closing of the Initial Public Offering, directors elected to succeed those directors of the class whose terms then expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election. Each director shall hold office until his or her successor shall have been duly elected and qualified, or until such director’s earlier death, resignation or removal.

4.         Term and Removal . Each director shall hold office until such director’s successor is elected and qualified, or until such director’s earlier death, resignation or removal. Any director may resign at any time upon notice to the corporation given in writing or by any electronic transmission permitted in the corporation’s bylaws. Subject to the rights of the holders of any series of Preferred Stock, no director may be removed except for cause and only by the affirmative vote of the holders of at least two-thirds (2/3) of the voting power of the then-outstanding shares of capital stock of the corporation then entitled to vote at an election of directors voting together as a single class. No decrease in the authorized number of directors constituting the Board of Directors shall shorten the term of any incumbent director.

5.         Board Vacancies . Subject to the rights of the holders of any series of Preferred Stock, any vacancy occurring in the Board of Directors for any cause, and any newly created directorship resulting from any increase in the authorized number of directors, shall, unless (a) the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders or (b) as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for a term expiring at the annual meeting of stockholders at which the term of office of the class to which the director has been assigned expires or until such director’s successor shall have been duly elected and qualified. No decrease in the authorized number of directors shall shorten the term of any incumbent director.

6.         Vote by Ballot . Election of directors need not be by written ballot unless the Bylaws of the corporation shall so provide.

 

4


ARTICLE VII: DIRECTOR LIABILITY

1.         Limitation of Liability . To the fullest extent permitted by law, no director of the corporation shall be personally liable for monetary damages for breach of fiduciary duty as a director. Without limiting the effect of the preceding sentence, if the Delaware General Corporation Law is hereafter amended to authorize the further elimination or limitation of the liability of a director, then the liability of a director of the corporation shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended.

2.         Change in Rights . Neither any amendment nor repeal of this Article VII, nor the adoption of any provision of this Certificate of Incorporation inconsistent with this Article VII, shall eliminate, reduce or otherwise adversely affect any limitation on the personal liability of a director of the corporation existing at the time of such amendment, repeal or adoption of such an inconsistent provision.

ARTICLE VIII: MATTERS RELATING TO STOCKHOLDERS

1.         No Action by Written Consent of Stockholders . Subject to the rights of any series of Preferred Stock, no action shall be taken by the stockholders of the corporation except at a duly called annual or special meeting of stockholders and no action shall be taken by the stockholders by written consent.

2.         Special Meeting of Stockholders . Special meetings of the stockholders of the corporation may be called only by the board of directors acting pursuant to a resolution adopted by a majority of the Whole Board, the Chairman of the Board, the Chief Executive Officer or the President.

3.         Advance Notice of Stockholder Nominations and Business Transacted at Special Meetings . Advance notice of stockholder nominations for the election of directors of the corporation and of business to be brought by stockholders before any meeting of stockholders of the corporation shall be given in the manner provided in the Bylaws of the corporation. Business transacted at special meetings of stockholders shall be confined to the purpose or purposes stated in the notice of meeting.

ARTICLE IX: CREDITOR AND STOCKHOLDER COMPROMISES

Whenever a compromise or arrangement is proposed between the corporation and its creditors or any class of them and/or between the corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of the corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed for the corporation under the provisions of §291 of Title 8 of the Delaware General Corporation Law or on the application of trustees in dissolution or of any receiver or receivers appointed for this corporation under §279 of Title 8 of the Delaware General Corporation Law order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders of the corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three-fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of the corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of the corporation

 

5


as a consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders or class of stockholders, of the corporation, as the case may be, and also on the corporation.

ARTICLE X: AMENDMENT OF CERTIFICATE OF INCORPORATION

The corporation reserves the right to amend or repeal any provision contained in this Certificate of Incorporation in the manner prescribed by the laws of the State of Delaware and all rights conferred upon stockholders are granted subject to this reservation; provided , however , that, notwithstanding any other provision of this Certificate of Incorporation or any provision of law that might otherwise permit a lesser vote or no vote, but in addition to any vote of the holders of any class or series of the stock of this corporation required by law or by this Certificate of Incorporation, the affirmative vote of the holders of at least two-thirds (2/3) of the voting power of all of the then-outstanding shares of the capital stock of the corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend or repeal this Article X or Article V, Article VI, Article VII or Article VIII.

* * * * * * * * * * *

 

6

Exhibit 3.04

 

 

 

 

AMYRIS, INC.

a Delaware Corporation

 

RESTATED BYLAWS

As Adopted                              , 2010

 

 

 

 


AMYRIS, INC.

a Delaware Corporation

RESTATED BYLAWS

TABLE OF CONTENTS

 

            Page

Article I - STOCKHOLDERS

   1

Section 1.1:

    

Annual Meetings

   1

Section 1.2:

    

Special Meetings

   1

Section 1.3:

    

Notice of Meetings

   1

Section 1.4:

    

Adjournments

   1

Section 1.5:

    

Quorum

   2

Section 1.6:

    

Organization

   2

Section 1.7:

    

Voting; Proxies

   2

Section 1.8:

    

Fixing Date for Determination of Stockholders of Record

   2

Section 1.9:

    

List of Stockholders Entitled to Vote

   3

Section 1.10:

    

Action by Written Consent of Stockholders

   3

Section 1.11:

    

Inspectors of Elections

   4

Section 1.12:

    

Notice of Stockholder Business; Nominations

   5

Article II - BOARD OF DIRECTORS

   8

Section 2.1:

    

Number; Qualifications

   8

Section 2.2:

    

Election; Resignation; Removal; Vacancies

   8

Section 2.3:

    

Regular Meetings

   8

Section 2.4:

    

Special Meetings

   8

Section 2.5:

    

Remote Meetings Permitted

   9

Section 2.6:

    

Quorum; Vote Required for Action

   9

Section 2.7:

    

Organization

   9

Section 2.8:

    

Written Action by Directors

   9

Section 2.9:

    

Powers

   9

Section 2.10:

    

Compensation of Directors

   9

Article III - COMMITTEES

   9

Section 3.1:

    

Committees

   9

Section 3.2:

    

Committee Rules

   10

Article IV - OFFICERS

   10

Section 4.1:

    

Generally

   10

Section 4.2:

    

Chief Executive Officer

   10

Section 4.3:

    

Chairperson of the Board

   11

Section 4.4:

    

President

   11

Section 4.5:

    

Vice President

   11

 

- i -


            Page

Section 4.6:

    

Chief Financial Officer

   11

Section 4.7:

    

Treasurer

   11

Section 4.8:

    

Secretary

   12

Section 4.9:

    

Delegation of Authority

   12

Section 4.10:

    

Removal

   12

Article V - STOCK

   12

Section 5.l:

    

Certificates

   12

Section 5.2:

    

Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificate

   12

Section 5.3:

    

Other Regulations

   13

Article VI - INDEMNIFICATION

   13

Section 6.1:

    

Indemnification of Officers and Directors

   13

Section 6.2:

    

Advance of Expenses

   13

Section 6.3:

    

Non-Exclusivity of Rights

   14

Section 6.4:

    

Indemnification Contracts

   14

Section 6.5:

    

Right of Indemnitee to Bring Suit

   14

Section 6.6:

    

Nature of Rights

   15

Article VII - NOTICES

   15

Section 7.l:

    

Notice

   15

Section 7.2:

    

Waiver of Notice

   16

Article VIII - INTERESTED DIRECTORS

   16

Section 8.1:

    

Interested Directors

   16

Section 8.2:

    

Quorum

   16

Article IX – MISCELLANEOUS

   17

Section 9.1:

    

Fiscal Year

   17

Section 9.2:

    

Seal

   17

Section 9.3:

    

Form of Records

   17

Section 9.4:

    

Reliance Upon Books and Records

   17

Section 9.5:

    

Certificate of Incorporation Governs

   17

Section 9.6:

    

Severability

   17

Article X - AMENDMENT

   17

 

- ii -


AMYRIS, INC.

a Delaware Corporation

RESTATED BYLAWS

As Adopted                      , 2010

ARTICLE I: STOCKHOLDERS

Section 1.1 :     Annual Meetings .   An annual meeting of stockholders shall be held for the election of directors at such date and time as the Board of Directors of the Corporation (the “ Board ”) shall each year fix. The meeting may be held either at a place, within or without the State of Delaware as permitted by the Delaware General Corporation Law (the “ DGCL ”), or by means of remote communication as the Board in its sole discretion may determine. Any proper business may be transacted at the annual meeting.

Section 1.2 :     Special Meetings .   Special meetings of stockholders for any purpose or purposes may be called at any time by the Board acting pursuant to a resolution adopted by a majority of the “ Whole Board ,” which shall mean the total number of authorized directors, whether or not there exist any vacancies in previously authorized directorships, or by the Chairman of the Board, the Chief Executive Officer or the President. Special meetings may not be called by any other person or persons. The special meeting may be held either at a place, within or without the State of Delaware, or by means of remote communication as the Board in its sole discretion may determine.

Section 1.3 :     Notice of Meetings .   Notice of all meetings of stockholders shall be given in writing or by electronic transmission in the manner provided by law (including, without limitation, as set forth in Section 7.1.1 of these Bylaws) stating the date, time and place, if any, of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Unless otherwise required by applicable law or the Certificate of Incorporation of the Corporation (the “ Certificate of Incorporation ”), such notice shall be given not less than ten (10), nor more than sixty (60), days before the date of the meeting to each stockholder of record entitled to vote at such meeting.

Section 1.4 :     Adjournments .   The chairperson of the meeting shall have the power to adjourn the meeting to another time, date and place (if any). Any meeting of stockholders may adjourn from time to time, and notice need not be given of any such adjourned meeting if the time, date and place (if any) thereof and the means of remote communications (if any) by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken; provided , however , that if the adjournment is for more than thirty (30) days, or if a new record date is fixed for the adjourned meeting, then a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. At the adjourned meeting the Corporation may transact any business that might have been transacted at the original meeting. To the fullest extent permitted by law, the Board may postpone or reschedule any previously scheduled special or annual meeting of stockholders before it is to be held, in which case notice shall be provided

 

- 1 -


to the stockholders of the new date, time and place, if any, of the meeting as provided in Section 1.3 above.

Section 1.5 :     Quorum .   At each meeting of stockholders the holders of a majority of the voting power of the shares of stock entitled to vote at the meeting, present in person or represented by proxy, shall constitute a quorum for the transaction of business, unless otherwise required by applicable law. If a quorum shall fail to attend any meeting, the chairperson of the meeting or the holders of a majority of the shares entitled to vote who are present, in person or by proxy, at the meeting may adjourn the meeting. Shares of the Corporation’s stock belonging to the Corporation (or to another corporation, if a majority of the shares entitled to vote in the election of directors of such other corporation are held, directly or indirectly, by the Corporation), shall neither be entitled to vote nor be counted for quorum purposes; provided , however , that the foregoing shall not limit the right of the Corporation or any other corporation to vote any shares of the Corporation’s stock held by it in a fiduciary capacity and to count such shares for purposes of determining a quorum.

Section 1.6 :     Organization .   Meetings of stockholders shall be presided over by such person as the Board may designate, or, in the absence of such a person, the Chairperson of the Board, or, in the absence of such person, the President of the Corporation, or, in the absence of such person, such person as may be chosen by the holders of a majority of the voting power of the shares entitled to vote who are present, in person or by proxy, at the meeting. Such person shall be chairperson of the meeting and, subject to Section 1.11 hereof, shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seems to him or her to be in order. The Secretary of the Corporation shall act as secretary of the meeting, but in such person’s absence the chairperson of the meeting may appoint any person to act as secretary of the meeting.

Section 1.7 :     Voting; Proxies .   Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy. Such a proxy may be prepared, transmitted and delivered in any manner permitted by applicable law. Except as may be required in the Certificate of Incorporation, directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors. Unless otherwise provided by applicable law, the Certificate of Incorporation or these Bylaws, every matter other than the election of directors shall be decided by the affirmative vote of the holders of a majority of the voting power of the shares of stock entitled to vote on such matter that are present in person or represented by proxy at the meeting and are voted for or against the matter.

Section 1.8 :     Fixing Date for Determination of Stockholders of Record .   In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, unless otherwise required by law, the Board may fix, in advance, a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board and which shall not be more than sixty (60), nor less than ten (10), days before the date of such meeting, nor more than sixty (60) days prior to any other action. If no record date is fixed by the Board, then the record date shall be as provided

 

- 2 -


by applicable law. To the fullest extent permitted by law, a determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided , however , that the Board may fix a new record date for the adjourned meeting.

Section 1.9 :     List of Stockholders Entitled to Vote .   A complete list of stockholders entitled to vote at any meeting of stockholders, arranged in alphabetical order and showing the address of each stockholder and the number of shares registered in the name of each stockholder, shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10) days prior to the meeting, either on a reasonably accessible electronic network as permitted by law (provided that the information required to gain access to the list is provided with the notice of the meeting) or during ordinary business hours at the principal place of business of the Corporation. If the meeting is held at a location where stockholders may attend in person, the list shall also be produced and kept at the time and place of the meeting during the whole time thereof and may be inspected by any stockholder who is present at the meeting. If the meeting is held solely by means of remote communication, then the list shall be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access the list shall be provided with the notice of the meeting.

Section 1.10 :   Action by Written Consent of Stockholders .

1.10.1 Procedure .  Unless otherwise provided by the Certificate of Incorporation, any action required or permitted to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed in the manner permitted by law by the holders of outstanding stock having not less than the number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation by delivery to its registered office in the State of Delaware, to its principal place of business or to an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the agent of the Corporation’s registered office in the State of Delaware shall be by hand or by certified or registered mail, return receipt requested. Written stockholder consents shall bear the date of signature of each stockholder who signs the consent in the manner permitted by law and shall be delivered to the Corporation as provided in Section 1.10.2 below. No written consent shall be effective to take the action set forth therein unless, within sixty (60) days of the earliest dated consent delivered to the Corporation in the manner required by law, written consents signed by a sufficient number of stockholders to take the action set forth therein are delivered to the Corporation in the manner required by law.

1.10.2 Form of Consent A telegram, cablegram or other electronic transmission consenting to an action to be taken and transmitted by a stockholder or proxy holder, or a person or persons authorized to act for a stockholder or proxy holder, shall be deemed to be written, signed and dated for the purposes of this section, provided that any such telegram, cablegram or other electronic transmission sets forth or is delivered with information from which the Corporation can determine (a) that the telegram, cablegram or other electronic transmission was transmitted by the stockholder or proxy holder or by a person or persons authorized to act for the stockholder

 

- 3 -


or proxy holder and (b) the date on which such stockholder or proxy holder or authorized person or persons transmitted such telegram, cablegram or electronic transmission. The date on which such telegram, cablegram or electronic transmission is transmitted shall be deemed to be the date on which such consent was signed. No consent given by telegram, cablegram or other electronic transmission shall be deemed to have been delivered until such consent is reproduced in paper form and until such paper form shall be delivered to the Corporation by delivery to its registered office in the State of Delaware, its principal place of business or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to a Corporation’s registered office shall be made by hand or by certified or registered mail, return receipt requested. Notwithstanding the foregoing limitations on delivery, consents given by telegram, cablegram or other electronic transmission may be otherwise delivered to the principal place of business of the Corporation or to an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded if, to the extent and in the manner provided by resolution of the Board. Any copy, facsimile or other reliable reproduction of a consent in writing may be substituted or used in lieu of the original writing for any and all purposes for which the original writing could be used, provided that such copy, facsimile or other reproduction shall be a complete reproduction of the entire original writing.

1.10.3 Notice of Consent .  Prompt notice of the taking of corporate action by stockholders without a meeting by less than unanimous written consent of the stockholders shall be given to those stockholders who have not consented thereto in writing and, who, if the action had been taken at a meeting, would have been entitled to notice of the meeting, if the record date for such meeting had been the date that written consents signed by a sufficient number of holders to take the action were delivered to the Corporation as required by law. If the action which is consented to is such as would have required the filing of a certificate under the DGCL if such action had been voted on by stockholders at a meeting thereof, then if the DGCL so requires, the certificate so filed shall state, in lieu of any statement required by the DGCL concerning any vote of stockholders, that written stockholder consent has been given in accordance with Section 228 of the DGCL.

Section 1.11 :   Inspectors of Elections .

1.11.1 Applicability .  Unless otherwise required by the Certificate of Incorporation or by the DGCL, the following provisions of this Section 1.11 shall apply only if and when the Corporation has a class of voting stock that is: (a) listed on a national securities exchange; (b) authorized for quotation on an interdealer quotation system of a registered national securities association; or (c) held of record by more than two thousand (2,000) stockholders. In all other cases, observance of the provisions of this Section 1.11 shall be optional, and at the discretion of the Board.

1.11.2 Appointment .  The Corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors of election to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting shall appoint one or more inspectors to act at the meeting.

 

- 4 -


1.11.3 Inspector’s Oath .  Each inspector of election, before entering upon the discharge of his duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of such inspector’s ability.

1.11.4 Duties of Inspectors .  At a meeting of stockholders, the inspectors of election shall (a) ascertain the number of shares outstanding and the voting power of each share, (b) determine the shares represented at a meeting and the validity of proxies and ballots, (c) count all votes and ballots, (d) determine and retain for a reasonable period of time a record of the disposition of any challenges made to any determination by the inspectors, and (e) certify their determination of the number of shares represented at the meeting, and their count of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors.

1.11.5 Opening and Closing of Polls .  The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced by the chairperson of the meeting at the meeting. No ballot, proxies or votes, nor any revocations thereof or changes thereto, shall be accepted by the inspectors after the closing of the polls unless the Court of Chancery upon application by a stockholder shall determine otherwise.

1.11.6 Determinations .  In determining the validity and counting of proxies and ballots, the inspectors shall be limited to an examination of the proxies, any envelopes submitted with those proxies, any information provided in connection with proxies in accordance with any information provided pursuant to Section 211(a)(2)(B)(i) of the DGCL, or Sections 211(e) or 212(c)(2) of the DGCL, ballots and the regular books and records of the Corporation, except that the inspectors may consider other reliable information for the limited purpose of reconciling proxies and ballots submitted by or on behalf of banks, brokers, their nominees or similar persons which represent more votes than the holder of a proxy is authorized by the record owner to cast or more votes than the stockholder holds of record. If the inspectors consider other reliable information for the limited purpose permitted herein, the inspectors at the time they make their certification of their determinations pursuant to this Section 1.11 shall specify the precise information considered by them, including the person or persons from whom they obtained the information, when the information was obtained, the means by which the information was obtained and the basis for the inspectors’ belief that such information is accurate and reliable.

Section 1.12 :   Notice of Stockholder Business; Nominations .

1.12.1   Annual Meeting of Stockholders .

(a)        Nominations of persons for election to the Board and the proposal of business to be considered by the stockholders shall be made at an annual meeting of stockholders (i) pursuant to the Corporation’s notice of such meeting, (ii) by or at the direction of the Board or (iii) by any stockholder of the Corporation who was a stockholder of record at the time of giving of the notice provided for in this Section 1.12, who is entitled to vote at such meeting and who complies with the notice procedures set forth in this Section 1.12.

(b)        For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to Section 1.12.1(a):

 

- 5 -


(i)         the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation;

(ii)        such other business must otherwise be a proper matter for stockholder action;

(iii)        if the stockholder, or the beneficial owner on whose behalf any such proposal or nomination is made, has provided the Corporation with a Solicitation Notice, as that term is defined in this Section, such stockholder or beneficial owner must, in the case of a proposal, have delivered a proxy statement and form of proxy to holders of at least the percentage of the Corporation’s voting shares required under applicable law to carry any such proposal, or, in the case of a nomination or nominations, have delivered a proxy statement and form of proxy to holders of a percentage of the Corporation’s voting shares reasonably believed by such stockholder or beneficial holder to be sufficient to elect the nominee or nominees proposed to be nominated by such stockholder, and must, in either case, have included in such materials the Solicitation Notice; and

(iv)        if no Solicitation Notice relating thereto has been timely provided pursuant to this Section, the stockholder or beneficial owner proposing such business or nomination must not have solicited a number of proxies sufficient to have required the delivery of such a Solicitation Notice under this Section.

To be timely, a stockholder’s notice must be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the seventy-fifth (75th) day nor earlier than the close of business on the one hundred and fifth (105th) day prior to the first anniversary of the preceding year’s annual meeting (except in the case of the 2011 annual meeting, for which such notice shall be timely if delivered in the same time period as if such meeting were a special meeting governed by Section 1.12.2); provided , however , that in the event that the date of the annual meeting is more than thirty (30) days before or more than sixty (60) days after such anniversary date, notice by the stockholder to be timely must be so delivered (A) no earlier than the close of business on the one hundred and fifth (105th) day prior to currently proposed annual meeting and (B) no later than the close of business on the later of the seventy-fifth (75th) day prior to such annual meeting or the close of business on the tenth (10th) day following the day on which public announcement of the date of such meeting is first made by the Corporation. Such stockholder’s notice shall set forth:

(x)        as to each person whom the stockholder proposes to nominate for election or reelection as a director all information relating to such person that would be required to be disclosed in solicitations of proxies for election of directors, or would be otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), including such person’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected;

(y)        as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest

 

- 6 -


in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made;

(z)        as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made, (aa) the name and address of such stockholder, as they appear on the Corporation’s books, and of such beneficial owner, (bb) the class and number of shares of the Corporation that are owned beneficially and held of record by such stockholder and such beneficial owner, and (cc) whether either such stockholder or beneficial owner intends to deliver a proxy statement and form of proxy to holders of, in the case of a proposal, at least the percentage of the Corporation’s voting shares required under applicable law to carry the proposal or, in the case of a nomination or nominations, a sufficient number of holders of the Corporation’s voting shares to elect such nominee or nominees (an affirmative statement of such intent being a “ Solicitation Notice ”).

(c)        Notwithstanding anything in the second sentence of Section 1.12.1(b) to the contrary, in the event that the number of directors to be elected to the Board is increased and there is no Public Announcement by the Corporation naming all of the nominees for director or specifying the size of the increased Board at least seventy five (75) days prior to the first anniversary of the preceding year’s annual meeting (or, if the annual meeting is held more than thirty (30) days before or sixty (60) days after such anniversary date, at least seventy five (75) days prior to such annual meeting), a stockholder’s notice required by this Section 1.12 shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to the Secretary of the Corporation at the principal executive office of the Corporation no later than the close of business on the tenth (10th) day following the day on which such Public Announcement is first made by the Corporation.

1.12.2 Special Meetings of Stockholders .    Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation’s notice of such meeting. Nominations of persons for election to the Board may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation’s notice of such meeting (a) by or at the direction of the Board or (b) provided that the Board has determined that directors shall be elected at such meeting, by any stockholder of the Corporation who is a stockholder of record at the time of giving of notice of the special meeting, who shall be entitled to vote at the meeting and who complies with the notice procedures set forth in this Section 1.12. In the event the Corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board, any such stockholder may nominate a person or persons (as the case may be), for election to such position(s) as specified in the Corporation’s notice of meeting, if the stockholder’s notice required by Section 1.12.1(b) shall be delivered to the Secretary of the Corporation at the principal executive offices of the Corporation (i) no earlier than the one hundred fifth (105th) day prior to such special meeting and (ii) no later than the close of business on the later of the seventy fifth (75th) day prior to such special meeting or the tenth (10th) day following the day on which Public Announcement is first made of the date of the special meeting and of the nominees proposed by the Board to be elected at such meeting.

 

- 7 -


1.12.3 General .

(a)        Only such persons who are nominated in accordance with the procedures set forth in this Section 1.12 shall be eligible to serve as directors and only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Section 1.12. Except as otherwise provided by law or these Bylaws, the chairperson of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made or proposed, as the case may be, in accordance with the procedures set forth in this Section 1.12 and, if any proposed nomination or business is not in compliance herewith, to declare that such defective proposal or nomination shall be disregarded.

(b)        For purposes of this Section 1.12, the term “ Public Announcement ” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to section 13, 14 or 15(d) of the Exchange Act.

(c)      Notwithstanding the foregoing provisions of this Section 1.12, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth herein. Nothing in this Section 1.12 shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the Exchange Act.

ARTICLE II: BOARD OF DIRECTORS

Section 2.1 :     Number; Qualifications .   The Board shall consist of one or more members. The initial number of directors shall be eleven (11), and thereafter, unless otherwise required by law, shall be fixed from time to time as set forth in the Certificate of Incorporation. No decrease in the authorized number of directors constituting the Board shall shorten the term of any incumbent director. Directors need not be stockholders of the Corporation.

Section 2.2 :     Election; Resignation; Removal; Vacancies .     The directors shall be divided, with respect to the time for which they severally hold office, into classes as provided in the Certificate of Incorporation, and vacancies occurring in the Board and any newly created directorships resulting from any increase in the authorized number of directors shall be filled, as provided in the Certificate of Incorporation.

Section 2.3 :     Regular Meetings .   Regular meetings of the Board may be held at such places, within or without the State of Delaware, and at such times as the Board may from time to time determine. Notice of regular meetings need not be given if the date, times and places thereof are fixed by resolution of the Board.

Section 2.4 :     Special Meetings .   Special meetings of the Board may be called by the Chairperson of the Board, the President or a majority of the members of the Board then in office and may be held at any time, date or place, within or without the State of Delaware, as the person or persons calling the meeting shall fix. Notice of the time, date and place of such meeting shall be given, orally, in writing or by electronic transmission (including electronic mail), by the person or persons calling the meeting to all directors at least four (4) days before the meeting if the

 

- 8 -


notice is mailed, or at least twenty-four (24) hours before the meeting if such notice is given by telephone, hand delivery, telegram, telex, mailgram, facsimile, electronic mail or other means of electronic transmission. Unless otherwise indicated in the notice, any and all business may be transacted at a special meeting.

Section 2.5 :     Remote Meetings Permitted .   Members of the Board, or any committee of the Board, may participate in a meeting of the Board or such committee by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to conference telephone or other communications equipment shall constitute presence in person at such meeting.

Section 2.6 :     Quorum; Vote Required for Action .     At all meetings of the Board a majority of the Whole Board shall constitute a quorum for the transaction of business. If a quorum shall fail to attend any meeting, a majority of those present may adjourn the meeting to another place, date or time without further notice thereof. Except as otherwise provided herein or in the Certificate of Incorporation, or required by law, the vote of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board.

Section 2.7 :     Organization .   Meetings of the Board shall be presided over by the Chairperson of the Board, or in such person’s absence by the President, or in such person’s absence by a chairperson chosen at the meeting. The Secretary shall act as secretary of the meeting, but in such person’s absence the chairperson of the meeting may appoint any person to act as secretary of the meeting.

Section 2.8 :     Written Action by Directors .     Any action required or permitted to be taken at any meeting of the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or such committee, as the case may be, consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board or committee, respectively, in the minute books of the Corporation. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

Section 2.9:      Powers .   The Board may, except as otherwise required by law or the Certificate of Incorporation, exercise all such powers and manage and direct all such acts and things as may be exercised or done by the Corporation.

Section 2.10 :   Compensation of Directors .     Members of the Board, as such, may receive, pursuant to a resolution of the Board, fees and other compensation for their services as directors, including without limitation their services as members of committees of the Board.

ARTICLE III: COMMITTEES

Section 3.1 :     Committees .     The Board may designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting of such committee

 

- 9 -


who are not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in place of any such absent or disqualified member. Any such committee, to the extent provided in a resolution of the Board, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority in reference to the following matters: (a) approving, adopting, or recommending to the stockholders any action or matter (other than the election or removal of members of the Board) expressly required by the DGCL to be submitted to stockholders for approval or (b) adopting, amending or repealing any bylaw of the Corporation.

Section 3.2 :     Committee Rules .   Unless the Board otherwise provides, each committee designated by the Board may make, alter and repeal rules for the conduct of its business. In the absence of such rules each committee shall conduct its business in the same manner as the Board conducts its business pursuant to Article II of these Bylaws.

ARTICLE IV: OFFICERS

Section 4.1 :     Generally .   The officers of the Corporation shall consist of a Chief Executive Officer (who may be the Chairperson of the Board or the President), a Secretary and a Treasurer and may consist of such other officers, including a Chief Financial Officer, and one or more Vice Presidents, as may from time to time be appointed by the Board. All officers shall be elected by the Board; provided , however , that the Board may empower the Chief Executive Officer of the Corporation to appoint any officer other than the Chairperson of the Board, the Chief Executive Officer, the President, the Chief Financial Officer or the Treasurer. Each officer shall hold office until such person’s successor is appointed or until such person’s earlier resignation, death or removal. Any number of offices may be held by the same person. Any officer may resign at any time upon written notice to the Corporation. Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise may be filled by the Board.

Section 4.2 :     Chief Executive Officer .   Subject to the control of the Board and such supervisory powers, if any, as may be given by the Board, the powers and duties of the Chief Executive Officer of the Corporation are:

(a)        To act as the general manager and, subject to the control of the Board, to have general supervision, direction and control of the business and affairs of the Corporation;

(b)        Subject to Article I, Section 1.6, to preside at all meetings of the stockholders;

(c)        Subject to Article I, Section 1.2, to call special meetings of the stockholders to be held at such times and, subject to the limitations prescribed by law or by these Bylaws, at such places as he or she shall deem proper; and

(d)        To affix the signature of the Corporation to all deeds, conveyances, mortgages, guarantees, leases, obligations, bonds, certificates and other papers and instruments

 

- 10 -


in writing which have been authorized by the Board or which, in the judgment of the Chief Executive Officer, should be executed on behalf of the Corporation; to sign certificates for shares of stock of the Corporation; and, subject to the direction of the Board, to have general charge of the property of the Corporation and to supervise and control all officers, agents and employees of the Corporation.

The President shall be the Chief Executive Officer of the Corporation unless the Board shall designate another officer to be the Chief Executive Officer. If there is no President, and the Board has not designated any other officer to be the Chief Executive Officer, then the Chairperson of the Board shall be the Chief Executive Officer.

Section 4.3 :     Chairperson of the Board .   The Chairperson of the Board shall have the power to preside at all meetings of the Board and shall have such other powers and duties as provided in these Bylaws and as the Board may from time to time prescribe.

Section 4.4 :     President .   The Chief Executive Officer shall be the President of the Corporation unless the Board shall have designated one individual as the President and a different individual as the Chief Executive Officer of the Corporation. Subject to the provisions of these Bylaws and to the direction of the Board, and subject to the supervisory powers of the Chief Executive Officer (if the Chief Executive Officer is an officer other than the President), and subject to such supervisory powers and authority as may be given by the Board to the Chairperson of the Board, and/or to any other officer, the President shall have the responsibility for the general management and control of the business and affairs of the Corporation and the general supervision and direction of all of the officers, employees and agents of the Corporation (other than the Chief Executive Officer, if the Chief Executive Officer is an officer other than the President) and shall perform all duties and have all powers that are commonly incident to the office of President or that are delegated to the President by the Board.

Section 4.5 :     Vice President .   Each Vice President shall have all such powers and duties as are commonly incident to the office of Vice President, or that are delegated to him or her by the Board or the Chief Executive Officer. A Vice President may be designated by the Board to perform the duties and exercise the powers of the Chief Executive Officer in the event of the Chief Executive Officer’s absence or disability.

Section 4.6 :     Chief Financial Officer .   The Chief Financial Officer shall be the Treasurer of the Corporation unless the Board shall have designated another officer as the Treasurer of the Corporation. Subject to the direction of the Board and the Chief Executive Officer, the Chief Financial Officer shall perform all duties and have all powers that are commonly incident to the office of Chief Financial Officer.

Section 4.7 :     Treasurer .   The Treasurer shall have custody of all moneys and securities of the Corporation. The Treasurer shall make such disbursements of the funds of the Corporation as are authorized and shall render from time to time an account of all such transactions. The Treasurer shall also perform such other duties and have such other powers as are commonly incident to the office of Treasurer, or as the Board or the Chief Executive Officer may from time to time prescribe.

 

- 11 -


Section 4.8 :     Secretary .   The Secretary shall issue or cause to be issued all authorized notices for, and shall keep, or cause to be kept, minutes of all meetings of the stockholders and the Board. The Secretary shall have charge of the corporate minute books and similar records and shall perform such other duties and have such other powers as are commonly incident to the office of Secretary, or as the Board or the Chief Executive Officer may from time to time prescribe.

Section 4.9 :     Delegation of Authority .   The Board may from time to time delegate the powers or duties of any officer to any other officers or agents, notwithstanding any provision hereof.

Section 4.10 :     Removal .   Any officer of the Corporation shall serve at the pleasure of the Board and may be removed at any time, with or without cause, by the Board; provided that if the Board has empowered the Chief Executive Officer to appoint any Vice Presidents of the Corporation, then such Vice Presidents may be removed by the Chief Executive Officer. Such removal shall be without prejudice to the contractual rights of such officer, if any, with the Corporation.

ARTICLE V: STOCK

Section 5.1 :     Certificates .   The shares of capital stock of the Corporation shall be represented by certificates; provided , however , that the Board may provide by resolution or resolutions that some or all of any or all classes or series of its stock may be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation (or the transfer agent or registrar, as the case may be). Notwithstanding the adoption of such resolution by the Board, every holder of stock that is a certificated security shall be entitled to have a certificate signed by or in the name of the Corporation by the Chairperson or Vice-Chairperson of the Board, or the President or a Vice President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary, of the Corporation, certifying the number of shares owned by such stockholder in the Corporation. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were an officer, transfer agent or registrar at the date of issue. If any holder of uncertificated shares elects to receive a certificate, the Corporation (or the transfer agent or registrar, as the case may be) shall, to the extent permitted under applicable law and rules, regulations and listing requirements of any stock exchange or stock market on which the Corporation’s shares are listed or traded, cease to provide annual statements indicating such holder’s holdings of shares in the Corporation.

Section 5.2 :     Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates .   The Corporation may issue a new certificate of stock, or uncertificated shares, in the place of any certificate previously issued by it, alleged to have been lost, stolen or destroyed, , upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner’s legal representative, to agree to indemnify the Corporation and/or to give the Corporation a bond sufficient to indemnify it, against any claim that may be made against it

 

- 12 -


on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate.

Section 5.3 :     Other Regulations .   The issue, transfer, conversion and registration of stock certificates and uncertificated securities shall be governed by such other regulations as the Board may establish.

ARTICLE VI: INDEMNIFICATION

Section 6.1 :     Indemnification of Officers and Directors .   Each person who was or is made a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a “ Proceeding ”), by reason of the fact that such person (or a person of whom such person is the legal representative), is or was a member of the Board or officer of the Corporation or a Reincorporated Predecessor (as defined below) or is or was serving at the request of the Corporation or a Reincorporated Predecessor as a member of the board of directors, officer or trustee of another corporation, or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans (for purposes of this Article VI, an “ Indemnitee ”), shall be indemnified and held harmless by the Corporation to the fullest extent permitted by the DGCL as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), against all expenses, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes and penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such Indemnitee in connection therewith. Such indemnification shall continue as to an Indemnitee who has ceased to be a director or officer and shall inure to the benefit of such Indemnitees’ heirs, executors and administrators. Notwithstanding the foregoing, the Corporation shall indemnify any such Indemnitee seeking indemnity in connection with a Proceeding (or part thereof) initiated by such Indemnitee only if such Proceeding (or part thereof) was authorized by the Board or such indemnification is authorized by an agreement approved by the Board. As used herein, the term the “ Reincorporated Predecessor ” means a corporation that is merged with and into the Corporation in a statutory merger where (a) the Corporation is the surviving corporation of such merger; (b) the primary purpose of such merger is to change the corporate domicile of the Reincorporated Predecessor to Delaware.

Section 6.2 :     Advance of Expenses .   The Corporation shall pay all expenses (including attorneys’ fees) incurred by such an Indemnitee in defending any such Proceeding as they are incurred in advance of its final disposition; provided , however , that (a) if the DGCL then so requires, the payment of such expenses incurred by such an Indemnitee in advance of the final disposition of such Proceeding shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such Indemnitee, to repay all amounts so advanced if it should be determined ultimately by final judicial decision from which there is no appeal that such Indemnitee is not entitled to be indemnified under this Article VI or otherwise; and (b) the Corporation shall not be required to advance any expenses to a person against whom the Corporation directly brings a claim, in a Proceeding, alleging that such person has breached such person’s duty of loyalty to the Corporation, committed an act or omission not in good faith or that involves intentional

 

- 13 -


misconduct or a knowing violation of law, or derived an improper personal benefit from a transaction.

Section 6.3:      Non-Exclusivity of Rights .   The rights conferred on any person in this Article VI shall not be exclusive of any other right that such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, Bylaw, agreement, vote or consent of stockholders or disinterested directors, or otherwise. Additionally, nothing in this Article VI shall limit the ability of the Corporation, in its discretion, to indemnify or advance expenses to persons whom the Corporation is not obligated to indemnify or advance expenses pursuant to this Article VI.

Section 6.4 :     Indemnification Contracts .   The Board is authorized to cause the Corporation to enter into indemnification contracts with any director, officer, employee or agent of the Corporation, or any person serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including employee benefit plans, providing indemnification or advancement rights to such person. Such rights may be greater than those provided in this Article VI.

Section 6.5:      Right of Indemnitee to Bring Suit .     The following shall apply to the extent not in conflict with any indemnification contract provided for in Section 6.4 above.

6.5.1     Right to Bring Suit .    If a claim under Section 6.1 or 6.2 of this Article VI is not paid in full by the Corporation within sixty (60) days after a written claim has been received by the Corporation, except in the case of a claim for an advancement of expenses, in which case the applicable period shall be twenty (20) days, the Indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. If successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Indemnitee shall be entitled to be paid also the expense of prosecuting or defending such suit. In (a) any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the Indemnitee to enforce a right to an advancement of expenses) it shall be a defense that, and (b) in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that, the Indemnitee has not met any applicable standard for indemnification set forth in applicable law.

6.5.2     Effect of Determination .    Neither the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the applicable standard of conduct set forth in applicable law, nor an actual determination by the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) that the Indemnitee has not met such applicable standard of conduct, shall create a presumption that the Indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the Indemnitee, be a defense to such suit.

 

- 14 -


6.5.3     Burden of Proof .    In any suit brought by the Indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Article VI, or otherwise, shall be on the Corporation.

Section 6.6 :     Nature of Rights .   The rights conferred upon Indemnitees in this Article VI shall be contract rights and such rights shall continue as to an Indemnitee who has ceased to be a director, officer or trustee and shall inure to the benefit of the Indemnitee’s heirs, executors and administrators. Any amendment, repeal or modification of any provision of this Article VI that adversely affects any right of an Indemnitee or an Indemnitee’s successors shall be prospective only, and shall not adversely affect any right or protection conferred on a person pursuant to this Article VI and existing at the time of such amendment, repeal or modification.

ARTICLE VII: NOTICES

Section 7.1 :     Notice .

7.1.1     Form and Delivery .    Except as otherwise specifically required in these Bylaws (including, without limitation, Section 7.1.2 below) or by law, all notices required to be given pursuant to these Bylaws shall be in writing and may, (a) in every instance in connection with any delivery to a member of the Board, be effectively given by hand delivery (including use of a delivery service), by depositing such notice in the mail, postage prepaid, or by sending such notice by prepaid telegram, cablegram, overnight express courier, facsimile, electronic mail or other form of electronic transmission and (b) be effectively be delivered to a stockholder when given by hand delivery, by depositing such notice in the mail, postage prepaid or, if specifically consented to by the stockholder as described in Section 7.1.2 of this Article VII by sending such notice by telegram, cablegram, facsimile, electronic mail or other form of electronic transmission. Any such notice shall be addressed to the person to whom notice is to be given at such person’s address as it appears on the records of the Corporation. The notice shall be deemed given (a) in the case of hand delivery, when received by the person to whom notice is to be given or by any person accepting such notice on behalf of such person, (b) in the case of delivery by mail, upon deposit in the mail, (c) in the case of delivery by overnight express courier, when dispatched, and (d) in the case of delivery via telegram, cablegram, facsimile, electronic mail or other form of electronic transmission, when dispatched.

7.1.2     Electronic Transmission .    Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation under any provision of the DGCL, the Certificate of Incorporation, or these Bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given in accordance with Section 232 of the DGCL. Any such consent shall be revocable by the stockholder by written notice to the Corporation. Any such consent shall be deemed revoked if (a) the Corporation is unable to deliver by electronic transmission two consecutive notices given by the Corporation in accordance with such consent and (b) such inability becomes known to the Secretary or an Assistant Secretary of the Corporation or to the transfer agent, or other person responsible for the giving of notice; provided , however , the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action.

 

- 15 -


Notice given pursuant to this Section 7.1.2 shall be deemed given: (i) if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice; (ii) if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice; (iii) if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of such posting and the giving of such separate notice; and (iv) if by any other form of electronic transmission, when directed to the stockholder.

7.1.3     Affidavit of Giving Notice .  An affidavit of the Secretary or an Assistant Secretary or of the transfer agent or other agent of the Corporation that the notice has been given in writing or by a form of electronic transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein.

Section 7.2 :     Waiver of Notice .   Whenever notice is required to be given under any provision of the DGCL, the Certificate of Incorporation or these Bylaws, a written waiver of notice, signed by the person entitled to notice, or waiver by electronic transmission by such person, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders, directors or members of a committee of directors need be specified in any waiver of notice.

ARTICLE VIII: INTERESTED DIRECTORS

Section 8.1 :     Interested Directors .   No contract or transaction between the Corporation and one or more of its members of the Board or officers, or between the Corporation and any other corporation, partnership, association or other organization in which one or more of its directors or officers are members of the board of directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board or committee thereof that authorizes the contract or transaction, or solely because his, her or their votes are counted for such purpose, if: (a) the material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the Board or the committee, and the Board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; (b) the material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or (c) the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board, a committee thereof, or the stockholders.

Section 8.2 :     Quorum .   Interested directors may be counted in determining the presence of a quorum at a meeting of the Board or of a committee which authorizes the contract or transaction.

 

- 16 -


ARTICLE IX: MISCELLANEOUS

Section 9.1 :     Fiscal Year .     The fiscal year of the Corporation shall be determined by resolution of the Board.

Section 9.2 :     Seal .     The Board may provide for a corporate seal, which may have the name of the Corporation inscribed thereon and shall otherwise be in such form as may be approved from time to time by the Board.

Section 9.3 :      Form of Records .     Any records maintained by the Corporation in the regular course of its business, including its stock ledger, books of account and minute books, may be kept on or by means of, or be in the form of, diskettes, CDs, or any other information storage device or method, provided that the records so kept can be converted into clearly legible paper form within a reasonable time. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant to any provision of the DGCL.

Section 9.4 :     Reliance upon Books and Records .   A member of the Board, or a member of any committee designated by the Board shall, in the performance of such person’s duties, be fully protected in relying in good faith upon records of the Corporation and upon such information, opinions, reports or statements presented to the Corporation by any of the Corporation’s officers or employees, or committees of the Board, or by any other person as to matters the member reasonably believes are within such other person’s professional or expert competence and who has been selected with reasonable care by or on behalf of the Corporation.

Section 9.5 :     Certificate of Incorporation Governs .   In the event of any conflict between the provisions of the Certificate of Incorporation and Bylaws, the provisions of the Certificate of Incorporation shall govern.

Section 9.6 :     Severability .   If any provision of these Bylaws shall be held to be invalid, illegal, unenforceable or in conflict with the provisions of the Certificate of Incorporation, then such provision shall nonetheless be enforced to the maximum extent possible consistent with such holding and the remaining provisions of these Bylaws (including without limitation, all portions of any section of these Bylaws containing any such provision held to be invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation, that are not themselves invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation) shall remain in full force and effect.

ARTICLE X: AMENDMENT

Notwithstanding any other provision of these Bylaws, any amendment or repeal of these Bylaws shall require the approval of the Board or the stockholders of the Corporation as provided in the Certificate of Incorporation; provided that the affirmative vote of the holders of at two-thirds (2/3) of the voting power of all of the then-outstanding shares of the capital stock of the corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend Article II Section 2.1 of these Bylaws if the stockholders shall amend or repeal these Bylaws.

 

 

 

- 17 -


CERTIFICATION OF RESTATED BYLAWS

OF

AMYRIS, INC.

a Delaware Corporation

 

I,                                               , certify that I am Secretary of                                      , a Delaware corporation (the “ Corporation ”), that I am duly authorized to make and deliver this certification, that the attached Bylaws are a true and complete copy of the Restated Bylaws of the Corporation in effect as of the date of this certificate.

Dated:                                              

 

 

                                                             
, Secretary

Exhibit 4.02

AMYRIS, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “ Agreement ”) is made as of June 21, 2010, by and among Amyris, Inc., a Delaware corporation (the “ Company ”), and the holders of Series A Preferred Stock listed on Exhibit A attached hereto (the “ Series A Preferred Stock ”), the Series B Preferred Stock listed on Exhibit B attached hereto (the “ Series B Preferred Stock ”), the Series B-1 Preferred Stock listed on Exhibit C attached hereto (the “ Series B-1 Preferred Stock ”), the Series C Preferred Stock listed on Exhibit D attached hereto (the “ Series C Preferred Stock ”), the Series C-1 Preferred Stock listed on Exhibit E attached hereto (the “ Series C-1 Preferred Stock ”, the Series D Preferred Stock listed on Exhibit F attached hereto (the “ Series D Preferred Stock ”, and together with the Series A Preferred Stock, the Series B Preferred Stock, the Series B-1 Preferred Stock, the Series C Preferred Stock and the Series C-1 Preferred Stock, the “ Preferred Stock ”) (each, an “Investor” and collectively, the “ Investors ”) and the individuals listed on Exhibit G hereto (each, a “ Common Holder ” and, together, the “ Common Holders ”).

RECITALS

WHEREAS, the Company and certain of the Investors are parties to that certain Amended and Restated Investors’ Rights Agreement made and entered into as of March 12, 2010 (the “ Previous Agreement ”);

WHEREAS, the Investor listed on Exhibit F attached hereto and the Company have entered into a Series D Preferred Stock Purchase Agreement dated as of June 21, 2010 (the “ Series D Agreement ”), pursuant to which such Investor is purchasing from the Company shares of its Series D Preferred Stock;

WHEREAS, in order to induce the Company to enter into the Series D Agreement and to induce the Investor listed on Exhibit F attached hereto to purchase shares of Series D Preferred Stock pursuant to the Series D Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to register shares of Common Stock issuable to the Investors and certain other matters as set forth herein; and

WHEREAS, this Agreement has been signed and delivered by the Company and by the requisite holders as set forth in Section 3.7 of the Previous Agreement.

NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

1.         Registration Rights . The Company covenants and agrees as follows:

1.1       Definitions . For purposes of this Section 1:

(a)        The term “ Act ” means the Securities Act of 1933, as amended.

(b)        The term “ Form S-3 ” means such form under the Act as in effect


on the date hereof or any registration form under the Act subsequently adopted by the SEC that permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC.

(c)        The term “ Holder ” means any Investor having purchased more than 5% of the Preferred Stock sold by the Company and, except with respect to Sections 1.2, 1.12, 1.13 and Section 2 hereof, the Common Holders owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section 1.13 hereof.

(d)        The term “ 1934 Act ” shall mean the Securities Exchange Act of 1934, as amended.

(e)        The terms “ register ,” “ registered ” and “ registration ” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Act, and the declaration or ordering of effectiveness of such registration statement or document.

(f)        The term “ Registrable Securities ” means: (i) any Common Stock issued or issuable upon conversion of the Preferred Stock of the Company, (ii) other than with respect to Sections 1.2, 1.12, 1.13 and Section 2 hereof, any Common Stock of the Company held by the Common Holders, (iii) the Common Shares, as defined in that certain Stock Transfer Agreement, dated December 24, 2009, by and among the Company, certain holders of the Company’s Preferred Stock and certain holders of the Company’s Common Stock, and (iv) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange for, or in replacement of, the securities set forth in subsection (i), (ii) or (iii) hereof, excluding, however, any Registrable Securities which (A) have previously been registered or which have been sold to the public either pursuant to a registration statement or Rule 144, (B) which have been sold in a private transaction in which the transferor’s rights under this Agreement are not assigned, (C) held by a Holder (together with its affiliates) if, as reflected on the Company’s list of stockholders, such Holder (together with its affiliates) holds less than 1% of the Company’s outstanding Common Stock (treating all shares of Preferred Stock on an as converted basis) or (D) held by a Holder (together with its affiliates) if the Company has completed its IPO and all shares of Common Stock of the Company issuable or issued upon conversion of the shares held by and issuable to such Holder (and its affiliates) may be sold pursuant to Rule 144 during a ninety (90) day period.

(g)        The number of shares of “ Registrable Securities then outstanding ” shall mean the number of shares of Common Stock that are Registrable Securities and (i) are then issued and outstanding or (ii) are then issuable pursuant to the exercise or conversion of then outstanding and then exercisable options, warrants or convertible securities.

(h)        The term “ SEC ” shall mean the Securities and Exchange Commission.

1.2     Request for Registration .

(a)        If the Company shall receive at any time after the earlier of

 

2


(i) three (3) years after the date hereof and (ii) one-hundred eighty (180) days after the effective date of the first registration statement for an underwritten public offering of the Company’s Common Stock, a written request from the Holders of at least thirty percent (30%) of the Registrable Securities then outstanding that the Company use its commercially reasonable efforts to file a registration statement under the Act covering the registration of at least twenty percent (20%) of the Preferred Stock of the Company having an aggregate offering price to the public of not less than $5,000,000 (net of any underwriters’ discounts or commissions), then the Company shall:

(i)        within thirty (30) days of the receipt thereof, give written notice of such request to all Holders; and

(ii)        use its commercially reasonable efforts to effect, as soon as practicable, but no later than ninety (90) days except in connection with the Company’s first registered public offering of its Securities, the registration under the Act of all Registrable Securities that the Holders request to be registered, subject to the limitations of subsection 1.2(b).

(b)        If the Holders initiating the registration request hereunder (the “ Initiating Holders ”) intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to subsection 1.2(a) and the Company shall include such information in the written notice referred to in subsection 1.2(a). The underwriter will be selected by a majority in interest of the Initiating Holders and shall be reasonably acceptable to the Company. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in subsection 1.4(e)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting. Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be underwritten (including Registrable Securities), then the Initiating Holders shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the underwriting shall be allocated among all Holders thereof, including the Initiating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company owned by each Holder; provided , however , that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all securities other than Registrable Securities are first entirely excluded from the underwriting.

(c)        Notwithstanding the foregoing, if the Company shall furnish to Holders requesting a registration statement pursuant to this Section 1.2 a certificate signed by the President or Chief Executive Officer of the Company stating that, in the good-faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such registration statement to be filed, the Company shall have the right to defer taking action with respect to such filing for a period not to exceed ninety (90) days after receipt

 

3


of the request of the Initiating Holders, provided such right may not be exercised more than once in any twelve (12) month period.

(d)        In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section 1.2:

(i)        After the Company has effected two (2) registrations pursuant to this Section 1.2 and such registrations have been declared or ordered effective;

(ii)        During the period starting with the date ninety (90) days prior to the Company’s good-faith estimate of the date of filing of, and ending on a date one hundred eighty (180) days after the effective date of the first registration statement for an underwritten public offering of the Company’s Common Stock (the “ IPO ”); provided that the Company delivers notice to the Initiating Holders within thirty (30) days of any such registration request and the Company is actively employing in good faith all commercially reasonable efforts to cause such registration statement to become effective; or

(iii)        If the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 1.12 below.

1.3       Company Registration . If (but without any obligation to do so) the Company proposes to register for its own account, or the account of others, any of its capital stock or other securities under the Act in connection with the public offering of such securities solely for cash (other than a registration relating solely to the sale of securities to participants in a Company stock plan, a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered or an SEC Rule 145 transaction), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of each Holder given within thirty (30) days after mailing of such notice by the Company in accordance with Section 3.5, the Company shall, subject to the provisions of Section 1.8, use its commercially reasonable efforts to cause to be registered under the Act all of the Registrable Securities that each such Holder has requested to be registered. If a Holder decides not to include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth herein.

1.4       Obligations of the Company . Whenever required under this Section 1 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:

(a) Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of

 

4


the Registrable Securities registered thereunder, keep such registration statement effective for a period that is the shorter of one hundred twenty (120) days or until the distribution contemplated in the Registration Statement has been completed; provided , however , that (i) such 120-day period shall be extended for a period of time equal to the period the Holder refrains from selling any securities included in such registration at the request of an underwriter of Common Stock (or other securities) of the Company; and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, such 120-day period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Act, permits an offering on a continuous or delayed basis, and provided further that applicable rules under the Act governing the obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment that (x) includes any prospectus required by Section 10(a)(3) of the Act or (y) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the incorporation by reference of information required to be included in (x) and (y) above to be contained in periodic reports filed pursuant to Section 13 or 15(d) of the 1934 Act in the registration statement.

(b)        Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such registration statement.

(c)        Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them.

(d)        Use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, except as may be required by the Act.

(e)        In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement.

(f)        Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing. The Company will use its best efforts to amend or supplement such prospectus to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or

 

5


necessary to make the statements therein not misleading in light of the circumstances then existing.

(g)        Cause all such Registrable Securities registered hereunder to be listed on a national exchange or trading system and each securities exchange on which similar securities issued by the Company are then listed.

(h)        Provide a transfer agent and registrar for all Registrable Securities registered pursuant hereto and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration.

(i)        Furnish, at the request of any Holder requesting registration of Registrable Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities.

(j)        Furnish on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective a letter, dated as of such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering addressed to the underwriters.

1.5       Furnish Information . It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be reasonably required to effect the registration of such Holder’s Registrable Securities.

1.6       Expenses of Demand Registration . All expenses (other than underwriting discounts and commissions) incurred in connection with registrations, filings or qualifications pursuant to Section 1.2, including (without limitation) all registration, filing and qualification fees, printers’ and accounting fees, and fees and expenses of counsel to the Company and one (1) counsel to the Holders (such expenses of counsel to the Holders shall not exceed $25,000) shall be borne by the Company; provided , however , that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 1.2 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all participating Holders shall bear such expenses), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to Section 1.2 (in which event such right shall be forfeited by all

 

6


Holders); provided , further , however , that if at the time of such withdrawal, the Holders have learned of material adverse information or a material adverse change in the condition, business or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request based upon such information with reasonable promptness following disclosure by the Company of such material adverse information or material adverse change, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 1.2.

1.7       Expenses of Company Registration . The Company shall bear and pay all expenses incurred in connection with any registration, filing or qualification of Registrable Securities with respect to the registrations pursuant to Section 1.3 for each Holder (which right may be assigned as provided in Section 1.13), including (without limitation) all registration, filing and qualification fees, printers’ and accounting fees, and fees and expenses of counsel to the Company and one (1) counsel to the Holders (such expenses of counsel to the Holders shall not exceed $25,000), but excluding underwriting discounts and commissions relating to Registrable Securities.

1.8       Underwriting Requirements . If a registration statement for which the Company gives notice pursuant to Section 1.3 is for an underwritten offering, then the Company shall so advise the Holders of Registrable Securities. In such event, the right of any Holder’s Registrable Securities to be included in a registration pursuant to Section 1.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the managing underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Agreement, if the managing underwriter(s) determine(s) in good faith that marketing factors require a limitation of the number of shares to be underwritten, then the managing underwriter(s) may exclude shares (including Registrable Securities) from the registration and the underwriting, and the number of shares that may be included in the registration and the underwriting shall be allocated first , to the Company, second , to each of the Holders (other than any Holder who is also a Common Holder) requesting inclusion of their Registrable Securities in such registration statement on a pro rata basis based upon the total number of Registrable Securities then held by each such Holder, third , to each Holder who is also a Common Holder requesting inclusion of his Registrable Securities in such registration statement on a pro rata basis based upon the total number of Registrable Securities then held by each Holder who is also a Common Holder, and fourth , to any other securityholder; provided , however , that the right of the underwriters to exclude shares (including Registrable Securities) from the registration and underwriting as described above in this Section 1.8 shall be restricted so that: (i) the number of Registrable Securities then held by the Investors included in any such registration is not reduced below twenty-five percent (25%) of all the shares included in the registration, except for a registration relating to the Company’s initial public offering of its Common Stock, from which all Registrable Securities may be excluded and (ii) all shares held by securityholders that are not Registrable Securities shall first be excluded from such registration and underwriting before any Registrable Securities are so excluded, unless holders of two-thirds (2/3) of the Registrable Securities then outstanding approve the inclusion of such shares held by securityholders that are not Registrable Securities. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written

 

7


notice to the Company and the underwriter, delivered at least twenty (20) business days prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the registration. For any Holder that is a venture capital fund, partnership or corporation, the affiliated venture capital funds, partners, retired partners and stockholders of such Holder, or the estates and family members of any such partners, stockholders and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “Holder,” and any pro rata reduction with respect to such “Holder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “Holder,” as defined in this sentence.

1.9       Delay of Registration . No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1.

1.10     Indemnification . In the event any Registrable Securities are included in a registration statement under this Section 1:

(a)        To the extent permitted by law, the Company will indemnify and hold harmless each Holder, any underwriter (as defined in the Act) for such Holder, the partners, members, officers and directors of such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Act or the 1934 Act, against any losses, claims, damages or liabilities (joint or several) to which they may become subject under the Act, the 1934 Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively, a “ Violation ”) by the Company: (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated by reference therein, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Act, the 1934 Act, any state securities law or any rule or regulation promulgated under the Act, the 1934 Act or any state securities law; and the Company will pay to each such Holder, the partners, members, officers and directors of such Holder, underwriter or controlling person, as incurred, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided , however , that the indemnity agreement contained in this subsection 1.10(a) shall not apply (i) to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation that occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by any such Holder, the partners, members, officers and directors of such Holder, underwriter or controlling person, (ii) if such untrue statement (or alleged untrue statement) or omission (or alleged omission) was contained in a preliminary prospectus and corrected in a final or amended prospectus or supplement thereto, copies of which were delivered to such Holder on a timely basis, and such Holder failed to deliver a copy

 

8


of the final or amended prospectus at or prior to the confirmation for the sale of the Registrable Securities to the persons asserting any such loss, claim, damage, or liability in any case where such delivery is required by the Securities Act, or (iii) to the extent that the loss, claim, damage or liability as to which indemnification is sought is in connection with an offer or sale made by such Holder in breach of the terms of this Agreement.

(b)        To the extent permitted by law, each selling Holder will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Act, any underwriter, any other Holder selling securities in such registration statement and any partners, members, officers and directors of such Holder and any controlling person of any such underwriter or other Holder, against any losses, claims, damages or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Act, the 1934 Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay, as incurred, any legal or other expenses reasonably incurred by any person intended to be indemnified pursuant to this subsection 1.10(b), in connection with investigating or defending any such loss, claim, damage, liability or action; provided , however , that the indemnity agreement contained in this subsection 1.10(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided that in no event shall any indemnity under this subsection 1.10(b) exceed the net proceeds from the offering received by such Holder.

(c)        Promptly after receipt by an indemnified party under this Section 1.10 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.10, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided , however , that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to the indemnifying party’s ability to defend such action, shall relieve such indemnifying party of liability to the indemnified party under this Section 1.10 to the extent of such prejudice, but the omission to deliver written notice to the indemnifying party will not relieve the indemnifying party of any liability that it may have to any indemnified party otherwise than under this Section 1.10.

 

9


(d)        If the indemnification provided for in this Section 1.10 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided , however , that in no event shall any contribution by a Holder hereunder, when taken together with any indemnification by such Holder pursuant to Section 1.10(b), exceed the net proceeds from the offering received by such Holder.

(e)        Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control; provided , however , that to the extent the underwriting agreement does not address a matter addressed by this Agreement, the failure to address such matter shall not be deemed a conflict between the provisions of this Agreement and the underwriting agreement.

(f)        The obligations of the Company and Holders under this Section 1.10 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1, and otherwise.

1.11     Reports Under the 1934 Act . With a view to making available to the Holders the benefits of Rule 144 promulgated under the Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to use all commercially reasonable efforts to:

(a)        make and keep public information available, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the first registration statement filed by the Company for the offering of its securities to the general public;

(b)        take such action, including the voluntary registration of its Common Stock under Section 12 of the 1934 Act, as is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities;

(c)        file with the SEC in a timely manner all reports and other documents required of the Company under the Act and the 1934 Act; and

(d)        furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied

 

10


with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company), the Act and the 1934 Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents filed under the 1934 Act by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration or pursuant to such form.

1.12     Form S-3 Registration . If the Company shall receive from any Holder or Holders a written request or requests that the Company effect a registration on Form S-3 or any similar short-form registration statement and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will:

(a)        promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders; and

(b)        use its commercially reasonable efforts to effect, as soon as practicable, such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; provided , however , that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section 1.12: (i) if Form S-3 is not available for such offering by the Holders; (ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of any underwriters’ discounts or commissions) of less than two million dollars ($2,000,000); (iii) if the Company shall furnish to the Holders a certificate signed by the President or Chief Executive Officer of the Company stating that, in the good-faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such Form S-3 registration to be effected at such time, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a period not to exceed ninety (90) days after receipt of the request of the Holder or Holders under this Section 1.12 provided that such right may not be exercised more than once in any twelve (12) month period; (iv) if the Company has, within the twelve (12) month period preceding the date of such request, already effected one (1) registration on Form S-3 for the Holders pursuant to this Section 1.12; or (v) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance.

Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the Holders. All expenses incurred in connection with registrations requested pursuant to this Section 1.12, including (without limitation) all registration, filing, qualification, printers’ and accounting fees and the fees and expenses of

 

11


counsel to the Company and fees and expenses of counsel to the Holders, but excluding any underwriters’ discounts or commissions, associated with Registrable Securities, shall be borne pro rata by the participating Holders. Registrations effected pursuant to this Section 1.12 shall not be counted as demands for registration or registrations effected pursuant to Section 1.2 or Section 1.3.

The Company shall not be obligated to effect any registration pursuant to this Section 1.12 if the Company delivers to the Holders requesting registration under this Section 1.12 an opinion, in form and substance reasonably acceptable to such Holders, of counsel reasonably satisfactory to such Holders, that all Registrable Securities so requested to be registered may be sold or transferred pursuant to Rule 144 under the Act.

1.13     Assignment of Registration Rights . The rights to cause the Company to register Registrable Securities pursuant to this Section 1 may be assigned (but only with all related obligations) by a Holder to a transferee or assignee of such securities provided: (a) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; (b) such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement, including without limitation the provisions of Section 1.14 below; (c) the transfer involves a transfer of at least one percent (1%) of then outstanding shares of Registrable Securities (as adjusted for dividends, splits, recapitalizations and the like); provided , however , that transfers or assignments to partners, limited partners, retired partners, members, former members, stockholders, parents, children, spouses, trusts or affiliates of a Holder (and in addition to the foregoing, solely in the case of Total Gas & Power USA, SAS (“ Total G&P ”), transfers or assignments to any company affiliated or under common control with Total G&P) shall be without restriction as to the minimum number of shares to be transferred; and (d) such assignment shall be effective only if immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Act.

1.14     “Market Stand-Off” Agreement . Each Holder hereby agrees that, during the period of duration specified by the Company and an underwriter of common stock or other securities of the Company, following the effective date of a registration statement of the Company filed under the Act pertaining to the IPO, it shall not, to the extent requested by the Company or such underwriter, directly or indirectly sell, offer to sell, contract to sell (including, without limitation, any short sale), grant any option to purchase or otherwise transfer or dispose of (other than to donees who agree to be similarly bound) any securities of the Company held by it at any time during such period except common stock included in such registration; provided , however , that:

(a)        such agreement shall be applicable only to the first such registration statement of the Company pertaining to the IPO;

(b)        all executive officers, directors and holders of one percent (1%) or more of the outstanding common stock (on an as converted to common stock basis) of the Company enter into similar agreements or arrangements;

 

12


(c)        such agreement shall provide that any discretionary releases (other than discretionary financial hardship waivers not exceeding $25,000 for any holder) from the lock-up be allocated to holders of Registrable Securities on a pro rata basis; and

(d)        such market stand-off time period shall not exceed one hundred eighty (180) days; provided , however , that, if during the last 17 days of the restricted period the Company issues an earnings release or material news or a material event relating to the Company occurs, or prior to the expiration of the restricted period the Company announces that it will release earnings results during the 16-day period beginning on the last day of the restricted period, and if the Company’s securities are listed on the Nasdaq Stock Market and Rule 2711 of thereof applies, then the restrictions imposed by this Section 1.14 shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event.

In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the Registrable Securities of each Investor (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period.

Notwithstanding the foregoing, the obligations described in this Section 1.14 shall not apply to a registration relating solely to employee benefit plans on Form S-4 or Form S-8 or similar forms that may be promulgated in the future, or to a registration relating solely to an SEC Rule 145 transaction.

1.15     Termination of Registration Rights . No Holder shall be entitled to exercise any right provided for in this Section 1 after five (5) years following the consummation of the IPO.

2.         Covenants of the Company .

2.1      Delivery of Financial Statements . The Company shall deliver to each Investor, for so long as such Investor holds (together with its affiliates) at least 5% of the Registrable Securities, 39,589 shares of Series B-1 Preferred Stock or 2,000,000 shares of Series D Preferred Stock (each as adjusted for dividends, splits, recapitalizations and the like with respect to such shares) (each, a “ Significant Investor ”):

(a)        as soon as practicable, but in any event within forty-five (45) days after the end of each fiscal year of the Company, the Company’s annual operating plan, an income statement for such fiscal year, a balance sheet of the Company as of the end of such year, a statement of stockholder’s equity as of the end of such year and a statement of cash flows for such fiscal year, such year-end financial reports to be in reasonable detail, prepared in accordance with generally accepted accounting principles (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with generally accepted accounting principles), and such financial statements will be accompanied by a report and opinion thereon by independent public accountants selected by the Company’s Board of Directors within one hundred twenty (120) days after the end of each fiscal year;

 

13


(b)        as soon as practicable but in no event more than forty-five (45) days after the end of each of the first three quarters of each fiscal year of the Company, an unaudited income statement, balance sheet and statement of cash flows for and as of the end of each such quarter, such unaudited financial statements to be in reasonable detail; and

(c)        as soon as practicable after the end of each month, and in any event within thirty (30) days after the end of each month, an unaudited consolidated balance sheet of the Company as of the end of such monthly period, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such period, prepared in accordance with generally accepted accounting principles.

2.2 Inspection Rights . The Company will maintain true books and records of account in which full and correct entries will be made of all its business transactions pursuant to a system of accounting established and administered in accordance with generally accepted accounting principles consistently applied (except as noted therein, and will set aside on its books all such proper accruals and reserves as shall be required under generally accepted accounting principles consistently applied. The Company shall permit each Significant Investor, at such Significant Investor’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all upon reasonable notice and at such reasonable times as may be requested by such Significant Investor; provided , however , that the Company shall not be obligated under this Section 2.2 to provide information that it deems in good faith to be a trade secret or similar confidential or proprietary information if it believes in good faith that such disclosure would be detrimental to the Company; provided , however , that the determination of the Company to withhold information pursuant to the prior clause with respect to Total G&P shall require the consent of at least 76% of the members of the Board of Directors of the Company (except the director designated by Total G&P shall not be included as a member of the Board of Directors for any such purpose) that such disclosure would be detrimental to the Company. The rights set forth in this Section 2.2 shall be exercised solely in furtherance of the proper interests of such Significant Investor as an investor in the Company, and any Significant Investor exercising its rights of inspection hereunder agrees to maintain the confidentiality of all financial and other confidential information of the Company disclosed to it. At the request of the Company, each Significant Investor shall, as a condition of the exercise of its rights of inspection thereunder, execute a confidentiality agreement with the Company in form and substance satisfactory to the Company.

2.3     Option/Common Stock Vesting .

(a)        Unless otherwise unanimously approved by the Board of Directors or as otherwise contemplated herein, the Company hereby covenants that all stock, stock equivalents and options issued after the date hereof to employees, directors, consultants and other service providers of the Company shall vest in accordance with the following vesting schedule: twenty (20%) of the shares to vest at the expiration of one (1) year from (i) the date of the grant if the grantee is then in the service of the Company or (ii) the date service commences if the grantee is not then in service of the Company, and the remaining eighty percent (80%) of the shares to vest in a series of forty-eight (48) successive and equal monthly installments thereafter upon the completion by the employee, director, consultant or service provider of each month of service to the Company. Unless otherwise unanimously approved by the Board of

 

14


Directors, the Company’s repurchase option shall provide that upon termination of the service of the employee, director, consultant or other service provider, with or without cause, the Company or its assignee (to the extent permissible under applicable securities laws) retains the option to repurchase at cost any unvested shares held by such stockholder.

(b)        The shares of Common Stock held by Jay D. Keasling shall accelerate in full in the event there is a Change of Control of the Company (as defined in the applicable stock restriction agreement) followed by a termination of such person’s services to the Company without cause.

2.4       Right of First Offer . Subject to applicable securities laws and the terms and conditions specified in this Section 2.4, the Company hereby grants to each Significant Investor and to each Investor for so long as such Investor holds (together with its affiliates) at least 401,284 shares of Series C Preferred Stock and/or Series C-1 Preferred Stock (as adjusted for dividends, splits, recapitalizations and the like) (together with the Significant Investors, the “ First Offer Rights Holders ”) a right of first offer (the “ Right of First Offer ”) with respect to future sales by the Company of its Shares (as hereinafter defined). A First Offer Rights Holder shall be entitled to apportion the Right of First Offer hereby granted it among itself and its partners and affiliates in such proportions as it deems appropriate. Each time the Company proposes to offer any shares of, or securities convertible into or exchangeable or exercisable for any shares of, any class or series of its capital stock (“ Shares ”), the Company shall first make an offering of such Shares to each First Offer Rights Holder in accordance with the following provisions:

(a)        The Company shall deliver a notice by certified mail (“ Notice ”) to the First Offer Rights Holders stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such Shares.

(b)        Within ten (10) business days after giving of the Notice, each First Offer Rights Holder may elect to purchase or obtain, at the price and on the terms specified in the Notice, up to that portion of such Shares that equals the proportion that the number of shares of common stock issued and held, or issuable upon conversion of the Registrable Securities then held, by such First Offer Rights Holder bears to the total number of shares of common stock of the Company then outstanding (assuming full conversion and exercise of all then outstanding convertible and exercisable securities of the Company). The Company shall promptly, in writing, inform each First Offer Rights Holder that elects to purchase all the shares available to it (“ Fully Exercising Investor ”) of any other First Offer Rights Holder’s failure to do likewise. During the five (5) business day period commencing after such information is given, each Fully Exercising Investor shall be entitled to elect to purchase up to that portion of the Shares not subscribed for by the First Offer Rights Holders that is equal to the proportion that the number of shares of common stock issued and held, or issuable upon conversion of Registrable Securities then held, by such Fully Exercising Investor bears to the total number of shares of common stock issued and held, or issuable upon conversion of the Registrable Securities then held, by all Fully Exercising Investors who wish to purchase some of the unsubscribed shares (the “ Secondary Purchase Right ”).

 

15


(c)        If all Shares that First Offer Rights Holders are entitled to obtain pursuant to subsection 2.4(b) are not elected to be purchased as provided in subsection 2.4(b) hereof, the Company may, during the ninety (90) day period following the expiration of the period provided in subsection 2.4(b) hereof, offer the remaining unsubscribed portion of such Shares to any person or persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Notice. If the Company does not consummate the sale of the Shares within such period, or if such agreement is not consummated within forty-five (45) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the First Offer Rights Holders in accordance herewith.

(d)        The Right of First Offer in this Section 2.4 shall not be applicable to issuances of securities of the Company that are not “Additional Shares of Common Stock” (as defined in Article IV, Section B(4)(d)(i)(4) of the Company’s Restated Certificate of Incorporation, as such Restated Certificate of Incorporation may be amended from time to time (the “ Restated Certificate ”); provided that notwithstanding the foregoing clause, with respect solely to Total G&P, its Right of First Offer (but not its Secondary Purchase Right) shall be applicable to issuances of securities of the Company (i) that are pursuant to transactions involving research and development funding, technology licensing, joint ventures, strategic alliances and partnering arrangements as set forth in Article IV, Section B(4)(d)(i)(4)(C) of the Restated Certificate (for the sake of clarification, the Right of First Offer with respect to Total G&P set forth in this subclause (i) shall not be applicable to issuances of securities of the Company that are pursuant to transactions involving bank financings or lease arrangements as set forth in Article IV, Section B(4)(d)(i)(4)(C) of the Restated Certificate) or (ii) pursuant to Article IV, Section B(4)(d)(i)(4)(J) of the Restated Certificate (unless Total G&P consents to such issuance of securities of the Company pursuant to Article IV, Section B(4)(d)(i)(4)(J) of the Restated Certificate).

(e)        The Right of First Offer set forth in this Section 2.4 may not be assigned or transferred, except that (i) such right is assignable by each First Offer Rights Holder to any wholly owned subsidiary or parent of, or to any corporation or entity that is, within the meaning of the Act, controlling, controlled by or under common control with, any such First Offer Rights Holder and (ii) such right is assignable between and among any of the First Offer Rights Holders or between and among any such First Offer Rights Holder and any affiliated partnerships, venture capital funds or other entities of such First Offer Rights Holder.

2.5         Proprietary Information Agreements . The Company shall require each employee hired by the Company to execute a proprietary information and inventions agreement and each consultant or contractor engaged by the Company to execute a consulting agreement, each in a form as recommended by the Company’s legal counsel.

2.6         Assignment of Information and Inspection Rights . The information rights set forth in Section 2.1 and inspection rights in Section 2.2 may be assigned (but only with all related obligations) by a Significant Investor to a transferee or assignee of such securities that (a) is a subsidiary, parent, general partner, limited partner, retired partner, member or retired member or stockholder of a Significant Investor that is a corporation, partnership or limited liability company or an entity affiliated by common control (or other related entity) with such

 

16


Significant Investor or (b) is a Significant Investor’s family member or trust for the benefit of an individual Holder or (c) qualifies as a Significant Investor after such assignment or transfer.

2.7         Right of First Refusal . Any shares of Common Stock of the Company issued after the date hereof (other than shares of Common Stock issued upon conversion of Preferred Stock) shall be subject to a right of first refusal in favor of the Company upon transfer.

2.8         Assignment of Right of First Refusal . In the event the Company elects not to exercise any right of first refusal or right of first offer the Company may have on a proposed transfer of any of the Company’s outstanding capital stock pursuant to the Company’s charter documents, by contract or otherwise, the Company shall, to the extent it may do so, assign such right of first refusal or right of first offer to each Significant Investor. In the event of such assignment, each Significant Investor shall have a right to purchase its pro rata portion of the capital stock proposed to be transferred. Each Significant Investor’s pro rata portion shall be equal to the product obtained by multiplying (i) the aggregate number of shares proposed to be transferred by (ii) a fraction, the numerator of which is the number of shares of Registrable Securities held by such Significant Investor at the time of the proposed transfer and the denominator of which is the total number of Registrable Securities owned by all Significant Investors at the time of such proposed transfer.

2.9         Insurance . The Company shall continue to bind and maintain director & officer insurance with a carrier or carriers and on such terms and in such amount as is satisfactory to the Board, unless the Board determines that procuring such insurance would not be in the best interest of the Company and its stockholders.

2.10         Key Man Insurance . The Company will maintain a key-man life insurance policy on the life of John G. Melo with a carrier or carriers and on such terms and in such amount as is satisfactory to the Board, unless the Board determines that procuring such insurance would not be in the best interest of the Company and its stockholders.

2.11         Director Indemnification . The Company will use its best efforts to maintain indemnification agreements with directors that will indemnify board members to the broadest extent permitted by applicable law. In the event the Company merges with another entity and is not the surviving corporation, or transfers all of its assets, proper provisions shall be made so that successors of the Company assume the Company’s obligations with respect to the indemnification of directors.

2.12         Amended and Restated Right of First Refusal and Co-Sale Agreement . The Company shall use commercially reasonable efforts to cause all officers and holders of at least 5% of the Company’s Common Stock to become a party to the Amended and Restated Right of First Refusal and Co-Sale Agreement, dated as of the date hereof.

2.13         Amended and Restated Voting Agreement . The Company shall use commercially reasonable efforts to cause all officers and holders of at least 1% of the Company’s Common Stock to become a party to the Amended and Restated Voting Agreement, dated as of the date hereof.

2.14         Reservation of Common Stock . The Company will at all times reserve

 

17


and keep available, solely for issuance and delivery upon the conversion of the Preferred Stock, all Common Stock issuable from time to time upon such conversion.

2.15         Company Rights of First Refusal . As of the date hereof, there are not, and the Company shall not enter into (unless approved by at least 76% of the members of the Board of Directors of the Company), any rights of first refusal to repurchase shares of the Company’s Common Stock other than with service providers of the Company or its subsidiaries.

2.16         Termination of Covenants . The covenants set forth in Section 2 hereof shall terminate as to Investors and be of no further force or effect upon (i) the consummation of a firm commitment underwritten public offering of the Company’s securities pursuant to which all outstanding shares of Preferred Stock automatically convert into Common Stock, (ii) a Liquidation Event (as defined in the Restated Certificate of Incorporation) or (iii) with respect to Sections 2.1 and 2.2, when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or Section 15(d) of the 1934 Act, whichever event shall first occur.

3.         Miscellaneous .

3.1         Successors and Assigns . Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of Registrable Securities). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

3.2         Governing Law . This Agreement shall be governed by and construed under the laws of the State of California without regard for conflicts of laws principles.

3.3         Counterparts . This Agreement may be executed in two or more counterparts, including counterparts transmitted by facsimile, other electronic transmission or otherwise, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

3.4         Titles and Subtitles . The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

3.5         Notices . All notices required or permitted under this Agreement shall be given in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after deposit in the United States mail, by registered or certified mail, postage prepaid and properly addressed to the party to be notified as set forth on the signature page hereof, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties hereto, or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.

 

18


3.6         Attorneys’ Fees . If any dispute among the parties to this Agreement results in litigation, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including, without limitation, such reasonable fees and expenses of attorneys and accountants, that shall include, without limitation, all fees, costs and expenses of appeals.

3.7         Amendments and Waivers . Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding; provided , however , that any Registrable Securities that are held by the Common Holders shall only be taken into account for the purposes of the foregoing sentence in the event that an amendment or waiver of any term of this Agreement would materially and adversely affect the rights of the Common Holders hereunder; provided further , that any amendment of a provision relating to the termination, amendment or waiver of any rights of the Investors shall require a majority of the then-effected Investors. Notwithstanding the above, Sections 2.1, 2.2 and 2.4 may be amended and the observance of any terms in such sections may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority in interest of the First Offer Rights Holders based on the number of shares of Registrable Securities then held by the First Offer Rights Holders; provided , further , that for any amendment or waiver of any provision herein that would have a material, adverse and disproportionate effect on a series of Preferred Stock relative to any other series of Preferred Stock, consent of the holders of at least the majority of such series of Preferred Stock voting as a separate class shall be required. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Registrable Securities then outstanding, each future holder of all such Registrable Securities and the Company; provided , further , that the rights of Total G&P (or its permitted assignees pursuant to Section 2.4(c) above) as a First Offer Rights Holder pursuant to Section 2.4 (other than its Secondary Purchase Right) and this proviso shall not be amended or waived with respect to Total G&P without the written consent of Total G&P.

3.8         Severability . If any of the provisions of this Agreement should, for any reason, be held by a court or other tribunal of competent jurisdiction to be illegal, invalid or unenforceable in any respect, such provisions shall be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect.

3.9         Aggregation of Stock . All shares of Registrable Securities held or acquired by affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement.

3.10         Entire Agreement . This Agreement and the Exhibits hereto, along with the Series D Agreement and the other documents delivered pursuant thereto, constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof and no party shall be liable or bound to any other in any manner by any oral or written representations, warranties, covenants or agreements except as specifically set forth herein and therein. Each party expressly represents and warrants that it is not relying on any oral or written representations, warranties, covenants or agreements outside of this Agreement.

 

19


3.11         Delays or Omissions . It is agreed that no delay or omission to exercise any right, power, or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent, or approval of any kind or character on any party’s part of any breach, default or noncompliance under the Agreement or any waiver on such party’s part of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, by law, or otherwise afforded to any party, shall be cumulative and not alternative.

3.12         Additional Investors . Notwithstanding anything to the contrary contained herein, if the Company shall issue additional shares of its Preferred Stock, any purchaser of such shares of Preferred Stock shall become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and shall be deemed, as applicable, an “ Investor ” or a “ Holder , ” and a party hereunder.

3.13         Previous Agreement . The Previous Agreement is hereby amended and superseded in its entirety and restated herein. Such amendment and restatement is effective upon execution and delivery of this Agreement by the Company and by the requisite holders as set forth in Section 3.7 of the Previous Agreement. Upon such execution, all provisions of, rights granted and covenants made in the Previous Agreement are hereby waived, released and superseded in their entirety and shall have no further force or effect.

[Signature Pages Follow]

 

20


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

COMPANY:
AMYRIS, INC.
By:   /s/ John G. Melo
  John G. Melo
  Chief Executive Officer

 

Address:       5885 Hollis Street, Ste. 100
  Emeryville, CA 94608

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

COMMON HOLDERS:
/s/ Jack D. Newman
Jack D. Newman
Address:    
   
/s/ K. Kinkead Reiling
K. Kinkead Reiling
Address:    
   
 
Jay D. Keasling
Address:    
   
/s/ Neil Renninger
Neil Renninger
Address:    
   
/s/ Neil Renninger
Neil Renninger, as Trustee of the Neil Renninger 2010 Qualified Annuity Trust
Address:    
   

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

COMMON HOLDER:
/s/ John G. Melo
John G. Melo
Address:    
   

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

INVESTOR:
AEI CLEANTECH INVESTMENTS I, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  
AEI CLEANTECH INVESTMENTS II, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  
ADVANCED EQUITIES AMYRIS INVESTMENTS I, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

ADVANCED EQUITIES AMYRIS INVESTMENTS II, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  
ADVANCED EQUITIES AMYRIS INVESTMENTS III, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  
ADVANCED EQUITIES AMYRIS INVESTMENTS IV, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

INVESTORS:
DAG Ventures III-QP, L.P.
By:   DAG Ventures Management III, LLC, its General Partner
By:   /s/ R. Thomas Goodrich
  R. Thomas Goodrich, Managing Director
Address:     251 Lytton Ave., Suite 200
  Palo Alto, CA 94301
DAG Ventures III, L.P.
By:   DAG Ventures Management III, LLC, its General Partner
By:   /s/ R. Thomas Goodrich
  R. Thomas Goodrich, Managing Director
Address:     251 Lytton Ave., Suite 200
  Palo Alto, CA 94301
DAG Ventures GP Fund III, LLC
By:   DAG Ventures Management III, LLC, its Managing Member
By:   /s/ R. Thomas Goodrich
  R. Thomas Goodrich, Managing Director
Address:     251 Lytton Ave., Suite 200
  Palo Alto, CA 94301
DAG Ventures I-N, LLC
By:   DAG Ventures Management, LLC, its Managing Member
By:   /s/ R. Thomas Goodrich
  R. Thomas Goodrich, Managing Director
Address:     251 Lytton Ave., Suite 200
  Palo Alto, CA 94301

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

INVESTORS:
KHOSLA VENTURES II, L.P.
By:   Khosla Ventures Associates II, LLC, its general partner
By:   /s/ Samir Kaul
 
Name:   Samir Kaul
Title:   Partner
Address:   3000 Sand Hill Road, Bldg. 3, Ste. 170
  Menlo Park, CA 94025
KHOSLA VENTURES III, L.P.
By:   Khosla Ventures Associates III, LLC, its general partner
By:   /s/ Samir Kaul
 
Name:   Samir Kaul
Title:   Partner
Address:   3000 Sand Hill Road, Bldg. 3, Ste. 170
  Menlo Park, CA 94025
TPG BIOTECHNOLOGY PARTNERS II, L.P.
By:   TPG Biotechnology Genpar II, L.P.
By:   TPG Biotech Advisors II, LLC
By:   /s/ Jeffery D. Ekberg
 
Name:   Jeffery D. Ekberg
Title:   Vice President
Address:   301 Commerce Street, Suite 3300
  Fort Worth, Texas 76102
KPCB HOLDINGS, INC., AS NOMINEE
By:  

/s/ John Doerr

 
Name:   John Doerr
Title:   Partner
Address:   2750 Sand Hill Road
  Menlo Park, CA 94025

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

INVESTOR:
LIT TELE, LLC
By:   /s/ Paulo Henrique de Oliveira Santos
Name:   Paulo Henrique de Oliveira Santos
Title:   Manager
By:   /s/ Naldilei Zumpano
Name:   Naldilei Zumpano
Title:   Manager

 

A MENDED AND R ESTATED I NVESTORS ’ R IGHTS A GREEMENT

S IGNATURE P AGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

INVESTOR:
NAXYRIS S.A.
By:   /s/ Henri Reiter and /s/ Christoph Piel
Name:    
Title:    
Address:  

40 Boulevard Joseph II

L-1840 Luxembourg

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

INVESTOR:
TOTAL GAS & POWER USA, SAS
By:   /s/ Arnaud Chaperon
Name:   Arnaud Chaperon
Title:   Chairman
Address:  

2 Place Jean Millier, 92078 Paris,

La Defense, CEPEX, France

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the undersigned has duly executed this Amended and Restated Investors’ Rights Agreement as of the date set forth below.

 

Date:                             

    INVESTOR:
                                                                                                         
      [Please print exact name of Investor as it should appear on stock certificate.]
      By:                                                                                                
      Name:                                                                                           
      Title:                                                                                             
      [Please include title if Investor is an entity.]
       
      Address:                                                                                                          
                                                                                                               

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


EXHIBIT A

SCHEDULE OF SERIES A INVESTORS

 

S ERIES A I NVESTOR

   N UMBER OF
S HARES   OF  S ERIES
A S TOCK

Khosla Ventures II, L.P.

   3,449,861

KPCB Holdings, Inc., as nominee

   3,449,861

TPG Biotechnology Partners II, L.P.

   2,299,907

Total

   9,199,629


EXHIBIT B

SCHEDULE OF SERIES B INVESTORS

 

S ERIES B I NVESTOR

   N UMBER OF
S HARES   OF  S ERIES
B S TOCK

DAG Ventures III, L.P.

        44,883

DAG Ventures III-QP, L.P.

      477,134

DAG Ventures GP Fund III, LLC

             491

DAG Ventures I-N, LLC

      281,351

Khosla Ventures II, L.P.

      150,723

KPCB Holdings, Inc., as nominee

      150,723

TPG Biotechnology Partners II, L.P.

      401,929

ES East Associates, LLC

          9,859

BB Trust Dated 2/21/03 (Richard Rock, Trustee)

        70,338

Crystalsesv Comércio E Representação Ltda.

        40,193

Santelisa Vale Bioenergia S.A.

        40,193

Total

   1,667,817


EXHIBIT C

SCHEDULE OF SERIES B-1 INVESTORS

 

S ERIES B-1 I NVESTOR

   N UMBER OF
S HARES   OF  S ERIES
B-1 S TOCK

AEI 2008 CleanTech Investments I, LLC

      134,639

AEI 2008 CleanTech Investments II, LLC

      180,127

Advanced Equities Amyris Investments I, LLC

      226,465

Advanced Equities Amyris Investments II, LLC

      661,403

Advanced Equities Amyris Investments III, LLC

        32,258

Advanced Equities Amyris Investments IV, LLC

        66,240

Ameri Private Equity IV, LLC

        80,563

Aspire Business LTD

        98,970

Christopher Lenzo

      118,765

Counter Point Venture Fund II, LP

        19,800

Erasmus Louisiana Growth Fund II, LP

        39,589

Exccess Venture Fund I, LLC

        79,178

Gaenger Family Living Trust of 1995

             395

GB Sears Family Trust

          3,365

HS Partners Holdings III, LP

      158,353

Innovative Financial Private Equity Fund II, LLC

        45,527

Invest Biotech, LLC

        51,275

James A. Goddard

             989

Lit Tele, LLC

      395,883

Millenium Trust Company

        39,589

Northport Investments, LLC

        53,852

TCM2, LLC

        39,589

Technology Ventures, LLC

        39,588

The Barlow Family Trust

             989

Third Amended and Restated Robbins Trust of 1986

          4,159

Toronto Angel Group Amyris Holdings LP

        43,991

Total

   2,615,721


EXHIBIT D

SCHEDULE OF SERIES C INVESTORS

 

S ERIES C I NVESTOR

   N UMBER OF
S HARES   OF  S ERIES
C S TOCK

Khosla Ventures III, L.P.

   321,027

KPCB Holdings, Inc., as nominee

   321,027

TPG Biotechnology Partners II, L.P.

   321,027

Lit Tele, LLC

   802,568

DAG Ventures II, L.P.

   146,582

DAG Ventures III-QP, L.P.

     13,788

DAG Ventures GP Fund III, LLC

          144

DAG Ventures I-N, LLC

     60,193

Grober Business Corp.

   802,568

Naxyris SA (an affiliate of NAXOS Capital Partners)

   561,797

Advanced Equities Amyris Investments I, LLC

     22,685

Advanced Equities Amyris Investments II, LLC

     65,672

Advanced Equities Amyris Investments III, LLC

       2,184

Advanced Equities Amyris Investments IV, LLC

       3,249

AEI 2008 CleanTech Investments I, LLC

       5,003

AEI 2008 CleanTech Investments II, LLC

     14,483

Third Amended and Restated Robbins Trust of 1986 (Richard K. Robbins, Trustee)

       1,213

James A. Goddard

          288

Invest Biotech, LLC

       2,648

Kevin Kaster

       1,271

Millenium Trust Company LLP Cust FBO WNA Private Equity Fund B - Amyris LLC

       7,945

Northern Rivers Silicon Valley Access Fund LP

       8,025

Michael P. Waldbillig and Louise A. Waldbillig Trust, dated September 16, 2008

       1,324

Advanced Equities Amyris Investments I, LLC

     10,139

Advanced Equities Amyris Investments II, LLC

     30,724


EXHIBIT D

SCHEDULE OF SERIES C INVESTORS (cont.)

 

S ERIES C I NVESTOR

   N UMBER OF
S HARES   OF  S ERIES
C S TOCK

Advanced Equities Amyris Investments III, LLC

          312

Advanced Equities Amyris Investments IV, LLC

       3,593

AEI 2008 CleanTech Investments I, LLC

       2,644

AEI 2008 CleanTech Investments II, LLC

       3,818

Northport Investments LLC

       3,815

Innovative Financial Private Equity

     19,662

Orgone Capital IV, LLC

     61,810

HS Partners Holdings III, LP

     80,256

Phyllis Gardner

          264

Jeffrey and Andrea Tobias

       1,002

BCP Investment, L.P.

   128,410

Richard C. Blum Rollover IRA

   240,770

Magoo 1, LLC

       6,621

Advanced Equities Amyris Investments I, LLC

          394

Advanced Equities Amyris Investments II, LLC

       1,249

Advanced Equities Amyris Investments III, LLC

            96

Advanced Equities Amyris Investments IV, LLC

          104

AEI 2008 CleanTech Investments I, LLC

          491

AEI 2008 CleanTech Investments II, LLC

          812

Orgone Capital IV, LLC

     12,199

Excess Venture Fund I, LLC

       8,026

Westly Group

   381,219

Northport Investments

     21,207

Orgone Capital

     81,274

Innovative Financial Private Equity

     12,039

Advanced Equities Amyris Investments I, LLC

       1,989


EXHIBIT D

SCHEDULE OF SERIES C INVESTORS (cont.)

 

S ERIES C I NVESTOR

   N UMBER OF
S HARES   OF  S ERIES
C S TOCK

Advanced Equities Amyris Investments II, LLC

          5,034

Khosla Ventures III, L.P.

        98,661

KPCB Holdings, Inc., as nominee

        98,660

TPG Biotechnology Partners II, L.P.

        98,660

Total

   4,902,665


EXHIBIT E

SCHEDULE OF SERIES C-1 INVESTORS

 

S ERIES C-1 I NVESTOR

   N UMBER OF
S HARES   OF  S ERIES
C-1 S TOCK

Maxwell (Mauritius) Pte Ltd

   2,724,766

Total

   2,724,766


EXHIBIT F

SCHEDULE OF SERIES D INVESTORS

 

S ERIES D I NVESTOR

   N UMBER OF
S HARES   OF  S ERIES
D S TOCK

Total Gas & Power USA, SAS

   7,101,548

Total

   7,101,548


EXHIBIT G

SCHEDULE OF COMMON HOLDERS

 

N AME OF K EY E MPLOYEE

   N UMBER OF
S HARES   OF
C OMMON  S TOCK

Jack D. Newman

      900,000

K. Kinkead Reiling

      863,000

Jay D. Keasling

   1,000,000

Neil Renninger (including the Neil Renninger 2010 Qualified Annuity Trust)

      900,000

John G. Melo

   1,502,983 1

Total

   5,165,983

 

 

1 These are all outstanding options to purchase Common Stock.

Exhibit 4.03

Execution Version

CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS

DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR

CONFIDENTIAL TREATMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED

WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE

CONFIDENTIAL MATERIAL HAS BEEN FILED SEPARATELY WITH

THE SECURITIES AND EXCHANGE COMMISSION.

 

 

INVESTMENT AGREEMENT

BY

FUNDO MÚTUO DE INVESTIMENTO EM EMPRESAS EMERGENTES INOVADORAS STRATUS

GC III,

AMYRIS BIOTECHNOLOGIES, INC.,

AMYRIS BRASIL S.A.

AND, AS INTERVENING PARTY,

STRATUS INVESTIMENTOS LTDA.

DECEMBER 22, 2009

 

 


INVESTMENT AGREEMENT

This Investment Agreement (this “Agreement”) is executed on December 22, 2009 (the “Effective Date”), by the following parties (all of them, collectively, the “Parties” and individually, a “Party”):

(1)        FUNDO MÚTUO DE INVESTIMENTO EM EMPRESAS EMERGENTES INNOVADORAS STRATUS GC III (“STRATUS”) , a fund duly authorized by CVM according to Oficio n° 2607/06, dated November 23, 2006, registered with the CNPJ/MF under n° 08.083.268/0001-46, herein represented by Stratus Gestao de Carteiras Ltda. (“ SGC ”), a company incorporated and existing under the laws of Brazil, with head offices in the city of São Paulo, State of São Paulo, at Rua Funchal, 129, 13th floor, Suite B, Vila Olimpia, registered with the CNPJ/MF under n° 09.238.656/0001-11, authorized by CVM for the rendering of management of portfolio services, according to Ato Declaratório n° 9.808, dated April 28, 2008, herein represented in according with its regulations;

(2)        AMYRIS BIOTECHNOLOGIES, INC. , a company incorporated and existing under the laws of the State of California, United States of America, with head offices at 5980 Hollis Street, Suite 100, Emeryville, California 94608, herein represented by its undersigned representatives (“ABI”);

(3)        AMYRIS BRASIL S.A. , a company incorporated and existing under the laws of Brazil, with head offices in the city of Campinas, State of São Paulo, at Rua James Clerk Maxwell, n° 315, Techno Park, CEP 13069-380, registered with the CNPJ/MF under no 09.379.224/0001-20, herein represented by its undersigned representatives (“ AB ” or the “ Company ”); and, as intervening Party;

(4)        STRATUS INVESTIMENTOS LTDA. , Stratus’s administrator ( administradora ), a company incorporated and existing under the laws of Brazil, with head offices in the city of São Paulo, State of São Paulo, at Rua Funchal, 129, 13 th floor, Suite B, Vila Olimpia, registered with the CNPJ/MF under n° 02.263.285/0001-89, herein represented by its undersigned representatives (“ SIL ”).

WHEREAS:

(A)        ABI is a technology company focused on the research, development and commercialization of renewable fuel and renewable chemical products (the “ Amyris Renewable Products ”) through the use of a proprietary microbial production technology which converts simple sugars derived from various plant sources, including sugarcane, into specific compounds of interest (the “ Amyris Technology ”);

(B)        ABI established operations in Brazil by forming AB in March of 2008 for the purpose of (i) acquiring an ownership interest in certain sugar and ethanol assets in Brazil and converting a portion of the production capacity of such assets to the production of Amyris Renewable Products, and (ii) providing other Brazilian sugar and ethanol mills with access to the Amyris Technology for the production of Amyris Renewable Products;

(C)        To enable AB to carry out these activities, effective as of March 27, 2008, ABI entered into an intellectual property license with AB (the “ Technology License ”), the terms of which are attached hereto as Exhibit 1 , which provides AB with (i) the exclusive right to use the Amyris Technology to manufacture Amyris Renewable Products in Brazil and the exclusive right to grant manufacturing sublicenses to mills located in Brazil, (ii) the exclusive right to market and distribute Amyris Renewable Products in Brazil, and (iii) the non-exclusive right to market and distribute Amyris Renewable Products outside Brazil (collectively such rights, the “ ABI Technology Contribution ”);

(D)        ABI intends to make additional capital investments in AB worth at least US$ 30,000,000 (thirty million United States dollars) in the form of (i) a cash contribution of US$ 10,000,000 (ten million United


States dollars) (the “ ABI Cash Contribution ”), and (ii) an ownership interest in Usina Boa Vista S.A. (“ Usina Boa Vista ”) that corresponds to an investment in Usina Boa Vista equal to R$ [*] Brazilian Reais) (the “ ABI Mill Contribution ,” and together with the ABI Cash Contribution, the “ ABI Additional Contributions ”);

(E)        AB has entered into a binding agreement, attached hereto as Exhibit 2 , to access a sugar cane and ethanol mill located in Brazil, with a minimum cane crushing capacity of 1,000,000 (one million) tons per year which is capable of being converted to the production of Amyris Renewable Products;

(F)        AB has appointed a superintendent officer (“ Diretor Superintendente ”) and a financial officer (“ Diretor Financeiro ”) satisfactory to Stratus;

(G)        Stratus intends to make a capital contribution of R$ 10,000,000 (ten million Reais) into the Company and, jointly with qualified third party investors appointed by SGC or SIL (such qualified investors, jointly with Stratus, the “ Investors ”), has the right to make additional capital investments in AB in a way that the total capital contributed by the Investors is equal to the lesser of (i) US$ 32,500,000 (thirty-two million, five hundred thousand United States dollars), and (ii) that amount equal to twenty percent (20%) of the AB Post-Money Valuation (as defined below) (the “ Investors Cash Contribution ”), provided that such investments are made within 60 (sixty) days of the date hereof as required by section 3.3.7;

(H)        The Investors Cash Contribution shall be comprised of (i) R$ 10,000,000 (ten million Brazilian Reais) to be invested directly by Stratus, and (ii) any eventual balance from funds SGC or SIL raises from the qualified third party investors; and

(I)        ABI and the Investors intend for R$ 40,000,000 (forty million Brazilian Reais) of the proceeds raised through the ABI Cash Contribution and Investors Cash Contribution to be used for AB to fund a portion of the purchase price of Usina Boa Vista as promptly as possible after the Closing (as defined below).

Now, therefore, the Parties hereby decide to enter into this Agreement, which shall be governed by the following terms and conditions:

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


SECTION 1

DEFINITIONS AND INTERPRETATION

1.1        Definitions.

AB ” has the meaning set forth in the Preamble.

AB Post-Money Valuation ” means the sum of (i) the AB Pre-Money Valuation, (ii) the ABI Cash Contribution, (iii) the ABI Mill Contribution, and (iv) the Investors Cash Contribution.

AB Pre-Money Valuation ” means R$180,000,000 (one hundred and eighty million Brazilian Reais) which represents the value of the Company, agreed on by the Parties, after the ABI Technology Contribution and before the ABI Additional Contributions and the Investors Cash Contribution.

AB Share Price ” equals R$ 9.00 (nine Brazilian Reais).

ABI ” has the meaning set forth in the Preamble.

ABI Additional Contributions ” has the meaning set forth in item “D” of the preamble hereto.

ABI Cash Contribution ” has the meaning set forth in item “D” of the preamble hereto.

ABI Convertible Loans ” has the meaning set forth in section 3.1 hereto.

ABI Mill Contribution ” has the meaning set forth in item “D” of the preamble hereto.

ABI Technology Contribution ” has the meaning set forth in item “C” of the preamble hereto.

Affiliate ” means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries, Controls, or is Controlled by, or is under common Control with, such first Person.

Agreement ” has the meaning set forth in the Preamble and includes all exhibits and schedules hereto.

Amyris Renewable Products ” has the meaning set forth in item “A” of the preamble hereto.

Amyris Technology ” has the meaning set forth in item “A” of the preamble hereto.

Closing ” has the meaning set forth in section 3.3.1 hereto.

Company ” has the meaning set forth in the Preamble.

Control ” of a company means the power to direct the management and policies of such company and shall be presumed to exist upon ownership of securities entitling the holder thereof to exercise more than 50% (fifty percent) of the voting power in the election of directors and in the decision of any strategic matter of such company.


Definitive Documents ” means the Agreement, the Shareholders Agreement and the Minutes of Extraordinary General Meeting of Shareholders mentioned in section 3.2 hereof.

Effective Date ” has the meaning set forth in the preamble hereto.

Intellectual Property ” means all (i) trademarks, service marks, trade names, trade dress, domain names, copyrights and similar rights, including registrations and applications to register or renew the registration of any of the foregoing, (ii) letters patent, patent applications, inventions, processes, designs, formulae, trade secrets, know-how, confidential information, computer software, data and documentation, website content, and all similar intellectual property rights, (iii) tangible embodiments of any of the foregoing in any medium, (iv) Information Technology, and (v) licenses of any of the foregoing.

Investors ” has the meaning set forth in item “G” of the preamble hereto.

Investors Cash Contribution ” has the meaning set forth in item “G” of the preamble hereto.

Losses ” has the meaning set forth in section 7.2 hereto.

Usina Boa Vista Investment Amount ” has the meaning set forth in section 4.1 hereto.

Party ” or “ Parties ” has the meaning set forth in the Preamble.

Person ” means any individual, corporation, partnership, limited liability company, firm, joint venture, association, joint stock company, trust, unincorporated organization, governmental or regulatory body or subdivision thereof, or any other entity.

Rules of Arbitration ” has the meaning set forth in section 10.2 hereto.

Shareholders ” means the shareholders of AB, which shall correspond to ABI and the Investors.

Shareholders’ Agreement ” means the shareholders’ agreement to be entered into between ABI and the Investors simultaneously with this Agreement in the form attached hereto as Exhibit 3.

Shares ” shall mean (i) the shares of capital stock of AB held by ABI as of the Effective Date, (ii) the shares of capital stock of AB to be issued to ABI hereunder in consideration of the ABI Cash Contribution and ABI Mill Contribution, and (iii) the shares of capital stock of AB to be issued to the Investors hereunder in consideration of the Investor Cash Contribution.

SGC ” has the meaning set forth in the Preamble.

SIL ,” has the meaning set forth in the Preamble.

Stratus ” has the meaning set forth in the Preamble.

Technology License ” has the meaning set forth in item “C” of the Preamble hereto.

Total Contribution Amount ” means that amount equal to (i) the ABI Cash Contribution, plus (ii) the value of the ABI Mill Contribution, plus (iii) the Investors Cash Contribution.

Usina Boa Vista ” has the meaning set forth in item “D” of the preamble hereto.


1.2        Interpretation.

A reference in this Agreement to the singular includes a reference to the plural and vice versa. The term “including” shall be deemed to be followed by the phrase “but not limited to.” The words “hereof,” “herein,” “hereto,” “hereunder” and similar words refer to this Agreement as a whole. The headings of this Agreement are included for convenience purposes only and are to be ignored in the interpretation of this Agreement.

SECTION 2

PURPOSE OF THE COMPANY AND SCOPE OF THIS AGREEMENT

2.1        Purpose of the Company.

The Company’s purpose is to (i) acquire an ownership interest in certain sugar and ethanol assets in Brazil and convert a portion of the production capacity of such assets to the production of Amyris Renewable Products, and (ii) provide other Brazilian sugar and ethanol mills with access to the Amyris Technology for the production of Amyris Renewable Products.

2.2        Scope.

The scope of this Agreement is to establish the terms and conditions of the investments to be made in the Company by ABI and the Investors.

2.3        Shareholders’ Agreement.

Conditions relating to the transfer of the Company’s shares, voting rights, management and public offerings shall be set forth in the Shareholders’ Agreement which shall be executed simultaneously with this Agreement.

SECTION 3

INVESTMENTS IN THE COMPANY BY ABI AND THE INVESTORS

3.1          ABI Cash Contribution Made to Date.     Beginning 1 August 2009, ABI began to make the ABI Cash Contribution in the form of convertible loans pursuant to those certain Convertible Loan Agreements dated 7 August 2009, 6 October 2009, and 15 December 2009, which copies are attached hereto as Exhibit 4 hereto (the “ABI Convertible Loans”).

3.2          Subscription.     Upon the terms and subject to the conditions of this Agreement, on the date hereof, (a) ABI shall hold an Extraordinary General Meeting of Shareholders of AB and shall resolve on (i) a capital increase in the total amount of R$27,786,997.00 (twenty-seven million, seven hundred and eighty-six thousand, nine hundred and ninety-seven Reais), with the issuance of 3,087,444 (three million, eighty-seven thousand, four hundred and forty-four) new Shares, so that AB’s corporate capital will be modified from the current R$ 20,000,000 (twenty million Reais), divided in 20,000,000 (twenty million) Shares, to R.$47,786,997.00 (forty-seven million, seven hundred and eighty-six thousand, nine hundred and ninety-seven Reais), divided into 23,087,444 (twenty-three million, eighty-seven thousand, four hundred and forty-four) Shares, (ii) the establishment of an authorized corporate capital in the amount of R$ 130,000,000 (one hundred and thirty million Reais) for future capital increases, and (iii) the adoption of the By-laws to be agreed by the Parties; (b) ABI shall subscribe for 1,976,333 (one million, nine hundred and seventy-six thousand, three hundred and thirty-three) newly issued Shares, for the total subscription price of R$17,786,997.00 (seventeen million, seven hundred and eighty-six thousand, nine hundred and ninety-seven Reais) to be paid in through the capitalization of the ABI Convertible Loans, in


accordance with the terms of the ABI Convertible Loans, within 5 (five) business days as from the date hereof; and (c) Stratus shall subscribe for 1,111,111 (one million, one hundred and eleven thousand, one hundred and eleven) newly issued Shares, for the total subscription price of R$10,000,000 (ten million Reais) to be paid within 30 (thirty) days as from the date hereof; and (d) ABI shall waive its preemptive rights for the subscription of the newly issued shares to be subscribed by Stratus . Each Share shall be worth the AB Share Price.

3.2.1      Total Subscription Price Adjustment.     The Parties agree that the total number of shares to be subscribed by ABI, relating to the ABI Cash Contribution, and the total subscription price to be paid by ABI, described above, were calculated using the Reais/U.S. exchange rate published by the Brazilian Central Bank (PTAX/Venda) on December 21, 2009 . Should the exchange rate of the date on which ABI pays in its new Shares be different from the exchange rate of December 21, 2009, the total number of shares to be subscribed by ABI and the total subscription price to be paid by ABI shall be adjusted accordingly.

3.3        Closing.

3.3.1    Timing

The closing of issuance and subscription of the Shares as mentioned in Section 3.2 above shall take place on the date hereof, at the offices of Machado, Meyer, Sendacz e Opice Advogados, in the City of São Paulo, State of São Paulo, Brazil, or at any other time or place as shall be mutually agreed by the Parties (the “ Closing ”).

3.3.2    Closing

At the Closing:

(a)        ABI shall hold and take all of the actions described in the Extraordinary General Shareholders’ Meeting mentioned in section 3.2 above;

(b)        AB shall cause 1,111,111 (one million, one hundred and eleven thousand, one hundred and eleven) Shares to be issued to Stratus and 1,976,333 (one million, nine hundred and seventy-six thousand, three hundred and thirty-three) Shares to be issued to ABI as set forth in section 3.2 above;

(c)        AB shall cause 1,111,111 (one million, one hundred and eleven thousand, one hundred and eleven) Shares to be registered in the name of Stratus and 1,976,333 (one million, nine hundred and seventy-six thousand, three hundred and thirty-three) Shares to be registered in the name of ABI in the AB’s Share Register Book ( Livro de Registro de Acões Nominativas );

(d)        The Shareholders’ Agreement shall be executed by each of the Parties thereto; and

(e)        The Shareholders’ Agreement shall be filed at AB’s headquarters, for the purposes of article 118 of Law 6.404/76, and AB shall cause the following legend to be included, in Portuguese, in the relevant pages of AB’s Registered Share Register Book:

The shares held by [name of shareholder] are subject to the restrictions on transfer, voting arrangements, and other provisions set forth in a shareholders’ agreement dated December 22, 2009, copies of which are available for inspection at the headquarters of the company . No transfer of such shares will be made on the books of the company, and such transfer will be null


and void, unless accompanied by evidence of compliance with the terms of such agreement. Any transactions entered into by the company or any shareholder in violation of the shareholders’ agreement will be null and void.

3.3.3    Deliveries by Stratus

Subject to the terms and conditions set forth in this Agreement, on the date hereof, Stratus shall deliver the following to the other Parties (the delivery of which may be waived, in writing, by the other Parties):

(a)        all the Definitive Documents to which Stratus is a party duly executed by it;

(b)        evidence that Stratus has been authorized to execute each of the Definitive Document to which it is a party; and

(c)        all other documents, instruments, certificates and writings required to be delivered by Stratus pursuant to the Definitive Documents.

3.3.4    Deliveries by ABI

Subject to the terms and conditions hereof, on the date hereof, ABI shall deliver the following to the other Parties (the delivery of which may be waived, in writing, by the other Parties):

(a)        all the Definitive Documents to which ABI and/or AB is a party duly executed by ABI and/or AB, as the case may be;

(b)        evidence that ABI and AB have been authorized to execute each of the Definitive Documents to which they are parties;

(c)        all other documents, instruments, certificates and writings required to be delivered by ABI and/or AB pursuant to the Definitive Documents.

3.3.5    Closing Events

All of the transactions to occur at the Closing shall be deemed to have occurred simultaneously and neither Party shall have the obligation to consummate any of the transactions referred to in section 3.2 unless all of such actions shall have been consummated simultaneously. All of the transactions and actions listed in sections 3.3.2, 3.3.3 and 3.3.4 above shall be deemed to have taken place simultaneously and no action shall be deemed to have been made until all steps taken at the Closing have been completed in form and substance reasonably satisfactory to Stratus, ABI and AB, and their respective counsels.

3.3.6    Payment by Stratus

Stratus shall deliver to AB the price of the Shares subscribed by Stratus by wire transfers of immediately available funds, within 30 (thirty) days as from the date hereof, to the bank account No. [*], held by AB at agency no. [*] of Banco Itaú BBA S.A. Within said 30 (thirty) day period,

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


Stratus shall deliver to all other Parties evidence of the wire transfer of the price of the Shares subscribed by Stratus to the account previously designated by AB.

3.3.7    Additional Investments

Each of SGC and SIL has the right, for a period of up to 60 (sixty) days as of the Closing, to raise investments from additional Investors, in order to complete the Investors Cash Contribution. In the event the totality of the Investors Cash Contribution is not raised within said period, ABI may raise the eventual balance with any third party who shall then also be considered an Investor.

3.3.8    Election of Management

The Shareholders shall elect the board of directors of the Company within 30 (thirty) days as from the date hereof, in accordance with the Shareholders Agreement. The Shareholders shall then require the directors to elect a chief operational officer (“ Diretor de Operacõs ”) for the Company by March 31, 2010, and a chief executive officer (“ Diretor Presidente ”) by June 30, 2010.

3.4        ABI Mill Contribution.

ABI hereby agrees, unconditionally and irrevocably, to make the ABI Mill Contribution within 90 (ninety) days as of the date hereof. The Parties hereby agree to take all measures necessary to cause such ABI Mill Contribution, including, without limitation, the Extraordinary General Meeting of Shareholders of AB to resolve on the capital increase to be subscribed by ABI, at the AB Share Price, and to be paid in through such contribution. In the event, for any reason, ABI is not able to make the ABI Mill Contribution within said term, ABI shall have additional 60 (sixty) days to make a capital investment in AB in the amount of R$ 50,000,000 (fifty million Reais) through cash or any other consideration.

SECTION 4

USE OF PROCEEDS; AB EQUITY INTEREST IN USINA BOA VISTA

4.1        Use of Proceeds.

ABI and the Investors agree that R$ 40,000,000 (forty million Brazilian Reais) of the proceeds raised through the ABI Cash Contribution and Investors Cash Contribution shall be used to the purchase price of [*]% ([*] percent) of the shares of Usina Boa Vista within 90 (ninety) days as of the date hereof (the “ Usina Boa Vista Investment Amount ”).

4.2        AB Equity Interest in Usina Boa Vista.

ABI and the Investors intend for AB to become the owner of [*]% ([*] percent) of the outstanding equity in Usina Boa Vista as a result of the following contributions and transactions: (i) the ABI Mill Contribution, and (ii) payment by AB for the equity interest directly acquired by AB in Usina Boa Vista, through (a) the payment in cash of the Usina Boa Vista Investment Amount, and (b) AB entering into a promissory note in an aggregate amount of R$ [*] ([*] Brazilian Reais) for the balance of the Usina Boa Vista purchase price.

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


SECTION 5

REPRESENTATIONS AND WARRANTIES

5.1        General Representations and Warranties.

Each of the Parties represents and warrants that:

(i)        it has been duly incorporated, is validly existing and in good standing under the laws of its place of incorporation;

(ii)        it has full power and authority, and has taken all required corporate and other action necessary to execute and deliver this Agreement and to fulfill its obligations hereunder; the execution, delivery and performance of this Agreement shall not violate any applicable law of its places of incorporation;

(iii)       this Agreement constitutes a legal, valid and binding obligation, enforceable against it in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights generally or (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies;

(iv)       the execution, delivery and performance of this Agreement do not, and the consummation of the transactions contemplated hereby and compliance with the terms hereof will not conflict with, or result in any violation of or default under, or give rise to a right of termination, cancellation or acceleration of any obligation, of any contract, corporate or other documents executed by it; and

(v)        no order, consent, approval or authorization of, or registration, declaration or filing with any governmental authority is required to be obtained in connection with the execution, delivery and performance of this Agreement or the consummation of the transactions contemplated hereby.

5.2        Specific Representations and Warranties of AB.

In addition to the representations and warranties set forth in section 5.1 above, the Company hereby represents and warrants that:

(i)        AB has all requisite corporate power and authority to own and operate its properties and assets and carry out its business as now conducted and as presently proposed to be conducted after the ABI Technology Contribution and the ABI Cash Contribution;

(ii)       AB is not a party to any litigation, suit, action, investigation, proceeding, controversy or claim before any governmental authority that could materially and adversely affect the business;

(iii)      AB is not insolvent or unable to pay its debts and has not been held in default by lenders under any debt financing;

(iv)      AB has complied with all applicable laws and has not received any written notice nor has any claim alleging failure to comply with any applicable law and no expenditures are or will be required to comply with any law, except, in any case, in a manner that would not be materially adverse to its business and ability to perform under this Agreement;


(v)        as of the date hereof, the Technology License is in full force and effect and AB is not in violation or default of any term or provision set forth therein. AB has neither performed any act, the occurrence of which would result in AB’s loss of any right granted under the Technology License, nor failed to perform any act, the failure of which would result in AB’s loss of any right granted under the Technology License. To the best of AB’s knowledge and belief, after having carried out any investigation required by law, (i) AB owns or has been granted all necessary Intellectual Property rights to conduct it business as currently conducted, and (ii) use of the Amyris Technology by AB will not infringe the intellectual property rights of any third party. AB has not received any written communications alleging that AB has violated or, by conducting its business as proposed, would violate, infringe or misappropriate any of the Intellectual Property of any other person or entity; and

(vi)      AB has conducted a due diligence review of Usina Boa Vista and shall negotiate reasonable representations and warranties from São Martinho Group in connection with the purchase of the shares of Usina Boa Vista from the São Martinho Group.

SECTION 6

CONFIDENTIALITY

6.1        Confidentiality.

Each of the Parties hereby undertakes to maintain and to procure that its directors, officers, employees, advisers and contractors maintain in absolute confidentiality, any document or information deemed as confidential by the Parties, including documents, information related to this Agreement and its negotiation process. The provisions of this section shall not apply to any information:

(i)        generally available to the public other than through any disclosure by a Party to the other;

(ii)       independently received from a third party who is free from any obligations not to disclose it;

(iii)     in the possession of the recipient, on a non-confidential basis, prior to its receipt from the other Party (as demonstrated by contemporaneous records); and

(iv)      regarding which the recipient is bound by applicable laws or regulations to disclose, provided that such Party notify the other Party of such disclosure with a 24 (twenty-four) hour written notice after the requirement by the relevant authority.

SECTION 7

VALIDITY AND INDEMNITY

7.1        Validity.

All representations, warranties and obligations of the Parties set forth in this Agreement shall be valid as from the date hereof.

7.2        Indemnity.

Each Party shall indemnify and hold harmless the other Parties and their respective directors, officers, employees, Affiliates, controlling Persons, agents and representatives and their successors and assigns from and against any liability, demand, claim, action, assessment, expense, damage or loss (“ Losses ”)


arising from (i) the breach of any of its obligations hereunder, (ii) from the non¬compliance with any representation or warranty set forth herein. In addition to the foregoing, AB shall indemnify and hold harmless the other Parties and their respective directors, officers, employees, Affiliates, controlling Persons, agents and representatives and their successors and assigns from and against any Losses arising from any illegal act, fact or omission of AB and of any Person who may have served as manager of AB, acting in such capacity within the applicable corporate powers, occurred prior to the Closing.

The right to indemnification arising from the breach of either Party’s obligations hereunder or from the non-compliance with any representation or warranty set forth herein will not be affected by any investigation conducted or knowledge acquired at any time, whether before or after the Closing, with respect to the accuracy or inaccuracy of or compliance with, any such representation, warranty, covenant or obligation.

7.2.1    Payments

(a)        Immediately after having knowledge of any act or fact giving rise to an indemnification under this section 7.2, the applicable Party shall send to the other Parties hereto a notice to that effect with a description of such act or fact and a copy of any relevant document.

(b)        If, despite their best efforts, the Parties are not able reach a mutually acceptable settlement deemed reasonable by all Parties within fifteen (15) days from the receipt of such notice, the applicable indemnified party shall then have forty-eight hours, counted from the end of the negotiations mentioned herein, to send a notice to the indemnifying party, in which such indemnified party shall state whether it wishes to start an indemnification claim and, if so, it shall include reasonable details of the nature and basis for such indemnification claim and the total amount related thereto. Upon receipt of such response notice, the indemnifying party shall have seventy-two hours to either pay or contest the payment of the indemnification claimed by the applicable indemnified party.

(c)        If (A) the indemnifying party contests and does not make the claimed payment, or (B) the indemnified party contests the payment made by the indemnifying party of the indemnification claimed, then the indemnified party may start an arbitration procedure against the indemnifying party, in accordance with section 10.2 of this Agreement. The indemnifying party shall be required to pay any such indemnification within 48 (forty- eight) hours counted as of the date on which a final and non-appealable decision or arbitral award is rendered in favor of the indemnified party with respect to the claim started by the indemnified party against the indemnifying party or as of the date on which a settlement, agreement or compromise is made with respect thereto.

(d)        All payments to the applicable indemnified party shall be in immediately available funds and any indemnification payment must be grossed up to cover any and all taxes payable by the applicable indemnified party on account of such payment.

(e)        In the event the indemnifying party has knowledge of any act or fact giving rise to an indemnification under this section 7.2 and fails to deliver a notice in terms set forth herein to the applicable indemnified party, it shall further indemnify the applicable indemnified party for any additional Losses that such a delay may have caused.


7.2.2    Legal Action or Administrative Proceeding

(a)        In the event that any legal action or administrative proceeding that could give rise to an indemnification under this section 7.2 is filed against or made upon any indemnified party, such indemnified party shall notify the indemnifying party, in writing, as soon as reasonably practical, but in no event later than one third (1/3) of the legal term to present a defense for the respective legal action or administrative proceeding. Such notice shall contain, in reasonable detail, a description of the amounts being claimed and the basis thereto.

(b)        The indemnifying party may either decide to present a defense, counterclaim or pay the amount sought under the legal action or administrative proceeding (including to post a bond for such a defense, if so required), without prejudice to item “f” below.

(c)        The indemnifying party shall bear any and all costs incurred, including reasonable attorney’s fees and court fees, guarantees, as well as expenses incurred in relation to the defense of the legal action or administrative proceeding. In the event the indemnified party receives an order issued by any governmental authority requesting it to make a judicial deposit (or any similar payment) in connection with such legal or administrative proceeding, then such deposit amount shall be reimbursed by the indemnifying party within 48 (forty-eight) hours as of such payment by the indemnified party.

(d)        If the indemnifying party assumes the defense of any legal action or administrative proceeding in accordance with the terms of the preceding sentence, the indemnifying party shall not be entitled to agree to any settlement, agreement or compromise with respect thereto without the prior written consent of the applicable indemnified party, which consent shall not be unreasonably withheld. The applicable indemnified party shall not be required to agree to any settlement, agreement or compromise that (i) does not contain a full release with respect to the respective legal action or administrative proceeding, or (ii) provides for any injunctive or other non- monetary relief.

(e)        In the event that the indemnifying party does not present a defense, counterclaim or pay the amount sought under the legal action or administrative proceeding and notifies the applicable indemnified party within two thirds (2/3) of the period available for the presentation of the relevant defense, the applicable indemnified party shall have the right to assume the defense of the legal action or administrative proceeding. The indemnifying party shall promptly and immediately reimburse the applicable indemnified party for any and all expenses incurred in relation to said Legal Action, whether during an administrative or judicial proceeding, including, but not limited to attorneys’ expenses, court fees, administrative fees and penalties. If the applicable indemnified party assumes the defense of any legal action or administrative proceeding in accordance with the terms of the preceding sentence, such indemnified party shall be entitled to agree to any settlement, agreement or compromise with respect thereto without the prior written consent of the indemnifying party.

(f)        Notwithstanding the above, if the indemnifying party believes the legal action or administrative proceeding filed against or made upon any indemnified party should not give rise to an indemnification under this section 7.2, then the indemnified party may start an arbitration procedure against the indemnifying party, as set forth in section 7.2.1., item “c,” above. In that case, all costs and expenses incurred by the indemnified party in connection with such legal action or administrative proceeding shall be reimbursed by the indemnifying party after the date on which a final and non-appealable decision or arbitral award is rendered in favor of the indemnified party, also as set forth in section 7.2.1., item “c,” above.


SECTION 8

TERMINATION

This Agreement may not be terminated except by the written consent of all the Parties.

SECTION 9

GENERAL PROVISIONS

9.1        Entire Agreement.

This Agreement shall constitute the entire agreement between the Parties hereto and supersede and replace all other agreements and understandings, verbal or written, among the Parties with respect to the subject matter of this Agreement. No amendment or modification of any provision of this Agreement shall be effective unless it is done in writing and signed by each of the Parties.

9.2        Severability.

The invalidity of one or more provisions of this Agreement shall not affect the validity of this Agreement as a whole unless the invalid provision was of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without such invalid provision. The Parties shall negotiate in good faith to substitute any invalid provisions with other provisions that may substantially achieve their original intentions.

9.3        Waiver.

Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The failure of any Party at any time to enforce any provision of this Agreement shall not in any way affect its rights to require performance thereof, nor shall the waiver of any breach of any provision hereof be taken or held to be a waiver of any succeeding breach of any such provision or as a waiver or a novation ( novacão ) of the provision itself.

9.4        Assignment.

No Party may directly or indirectly transfer any of its rights and obligations under this Agreement to any third party, without the prior written consent of the other Parties, provided, however, that Stratus may transfer any of its rights and obligations under this Agreement to any of its Affiliates without the need of prior written consent of the other Parties.

9.5        Costs and Expenses.

Each Party shall bear all costs and expenses incurred by it in connection with the preparation, negotiation and delivery of this Agreement. However, in connection with the Closing, AB shall either pay directly or reimburse the Investors and ABI (the latter at ABI’s election) for reasonable transaction-related expenses, not to exceed R$ 250,000 (two hundred and fifty thousand Brazilian Reais) for each of ABI and the Investors. In the case of ABI, reasonable transaction related expenses shall be deemed to include any IOF or similar taxes associated with the ABI Cash Contribution and the ABI Mill Contribution.


9.6        Notices.

All notices, requests, claims and other communications hereunder shall be in writing and communicated to the receiving party either by hand, or sent by registered mail, electronic mail or facsimile and addressed as follows or to such other addresses as may from time to time be notified by any Party to the other Party:

If to ABI :

AMYRIS BIOTECHNOLOGIES, INC.

Address: 5885 Hollis Street, Suite 100, Emeryville, California 94608, USA

Telephone: +1 510 740-7416

Fax: +1 510 842 1460

E-mail: tompkinsgamyris.com

Attn: Tamara Tompkins - General Counsel

If to the Investors :

STRATUS GESTAO DE CARTEIRAS LTDA.

Address: Rua Funchal, 129, 13 th floor, São Paulo, SP, Brazil

Telephone: +55 11 2166-8800

Fax: +55 11 2166-8801

E-mail: acamoes@stratusbr.com

Attn: Alberto Camões

Copy to :

MACHADO, MEYER, SENDACZ E OPICE ADVOGADOS

Address: Avenida Brigadeiro Faria Lima, 3144, 11th floor

Telephone: +55 11 3150-7647

Fax: +55 11 3150-7071

E-mail: mau@mmso.com.br

Attn.: Mauro Cesar Leschziner

If to AB :

AMYRIS BRASIL S.A.

Address: Rua James Clerk Maxwell, 315, Campinas, SP, Brazil

Telephone: +55 19 3783-9450

Fax: +55 19 3283-0005

E-mail: collier@amyris.com

Attn: Roel Collier

9.6.1    Delivery of Notice.

Any notice served by hand shall be deemed to have been served upon delivery. Any notice served by prepaid registered mail shall be deemed to have been served upon evidenced receipt. Any notice served by e-mail or facsimile shall be deemed to have been served when sent, provided that evidence has been produced showing that the notice has been sent to the facsimile number/e-mail address, as indicated in this Agreement.

9.6.2    Change of Data.

In case of any change of data, if the new information is not notified by the relevant Party to the other Party, all notices sent to the previous addresses shall be deemed to have been duly served.


9.7        Language.

This Agreement shall be executed in the English and Portuguese languages, provided that the English version shall prevail, including in arbitration, and excluding when in proceedings before Brazilian courts, in which the Portuguese version shall prevail.

SECTION 10

GOVERNING LAW AND DISPUTE RESOLUTION

10.1        Governing Law.

This Agreement shall be governed by and construed in accordance with the laws of Brazil.

10.2        Dispute Resolution.

Any dispute, controversy or claim by and among the Parties to this Agreement, arising out of or relating to this Agreement, or the breach, termination or validity hereof, shall be settled by arbitration in accordance with the Rules of Arbitration of the Câmara de Comércio Brasil-Canadá (the “ Rules of Arbitration ”). The decision of the arbitrators shall be final and binding upon the Parties with no further appeal, recourse or review. Until such decision, the Parties agree to keep the arbitration procedure on a confidential basis, except to the extent necessary for any interim or conservatory measures permitted under the Rules of Arbitration.

10.2.1    Arbitration Place.

The place of arbitration shall be in the City of São Paulo, State of São Paulo, Brazil, where the arbitration award shall be rendered.

10.2.2    Arbitration Language.

The language of the arbitration shall be English.

10.2.3    Judicial Measures.

Without prejudice to this section 10.2 and without limiting any other powers the arbitrators may have, the Parties remain fully entitled to request judicial measures: (a) in order to obtain preliminary and urgent measures ( medidas cautelares ) prior to the formation of the arbitral tribunal, and such judicial recourse shall not be interpreted as a waiver of the arbitration as set forth in this section; and (b) to enforce any arbitral decision, including the final award. For that purpose, the Parties elect the courts of the city of São Paulo, State of São Paulo, Brazil, being waived any other no matter how privileged it may be. The Parties recognize that any provisional or urgent matter granted by judicial courts shall be, necessarily, reviewed by the arbitral tribunal, which shall decide on its ratification, revision or cancellation.

IN WITNESS hereof, this Agreement is executed in 4 (four) counterparts of the same form and content, in the City of São Paulo, State of São Paulo, Brazil, on December 22, 2009.

(Signature pages below)


(Signature pages of the Investment Agreement, entered into by Fundo Mútuo de Investimento em Empresas Emergentes Inovadoras Stratus GC Ill, Amyris Biotechnologies, Inc., Amyris Brasil S.A. and, as intervening party, Stratus Investimentos Ltda., dated December 22, 2009.)

LOGO


LIST OF EXHIBITS

 

1.

Technology License

 

2.

Copy of the Binding Agreement entered into by and among ABI and Usina Boa Vista

 

3.

Shareholders Agreement

 

4.

Copy of ABI Convertible Loans


EXHIBIT 1

LICENSE AGREEMENT BETWEEN ABI AND AB


LICENSE AGREEMENT

This LICENSE AGREEMENT (the “Agreement”), effective as of March 27, 2008 (the “ Effective Date ”), is made by and between AMYRIS BIOTECHNOLOGIES, INC. , a California corporation with a principal place of business at 5885 Hollis St., Ste. 100, Emeryville, CA 94608 (“ ABI ”), and. AMYRIS PESQUISA E DESENVOLVIMENTO DE BIOCOMBUSTIVEIS LTDA ., a company organized and existing as a “sociedade limitada” under the laws of Brazil with headquarters in the city of Campinas, state of São Paulo, at Rua James Clerk Maxwell, n° 315, Techno Park, CEP 13069-380, registered with the CNPJ/MF under n° 09.379.224/0001-20 (“ AB ”). ABI and AB are each a “ Party ” hereto, and collectively are the “ Parties .”

BACKGROUND

WHEREAS, ABI is a technology company which is focused on the research, development and commercialization of a variety of renewable fuel and chemical products;

WHEREAS, ABI has developed a proprietary microbial production technology which converts sugars derived from various plant sources, including sugar cane, into renewable fuel and chemical products;

WHEREAS, ABI formed AB as a wholly owned subsidiary with the intent of having AB hold certain rights to such technology in Brazil;

WHEREAS, AB intends to (a) acquire, own and manage sugar cane and ethanol mills in Brazil, and to convert such mills to the production of renewable fuel and chemical products using such technology; and (b) enter into commercial arrangements with other mills in. Brazil pursuant to which such mills would convert a portion of their assets to the production of renewable fuel and chemical products using such technology;

WHEREAS, ABI desires to license to AB the right to use certain ABI technology and the right to use certain ABI trade names and ABI trademarks (a) on an exclusive basis, to develop, make, have made, use, sell, distribute and market certain renewable fuel and chemical products in Brazil, with the right to grant limited sublicenses to such technology, trade names and trademarks to mills located in Brazil, and (b) on a nonexclusive basis, to sell, distribute and market certain renewable fuel and chemical products outside of Brazil, in each ease under the terms and conditions set forth herein, and AB desires to obtain such licenses; and

WHEREAS, in consideration of the licenses granted herein, AB desires to (a) license back to ABI the right to use any developments and improvements derived from or related to the ABI technology that are or become owned or controlled in whole or in part by AB outside of Brazil for any purpose on the terms and conditions set forth herein (subject only to AB’s nonexclusive license rights), and (b) permit ABI to assist patent prosecution and enforcement matters relating to such developments and improvements, under the terms and conditions set forth herein, and ABI desires to obtain such a license and such rights;

NOW, THEREFORE, on the terms and subject to the conditions set forth herein, the Parties hereby agree to enter into this Agreement upon the following terms and subject to the following conditions:


ARTICLE 1

DEFINITIONS

For purposes of this Agreement, the following definitions will apply:

1.1        “ ABI Base Technology ” means Patents, Production Strains and Know-How associated with such Patents and Production Strains, in each case that are (a) necessary for the development, manufacture, use, sale and distribution of Renewable Fuel Products and Renewable Chemical Products in Brazil and (b) Controlled by ABI as of the Effective Date of this Agreement. Patents and Production Strains within the ABI Base Technology are listed on Schedule 1 , attached hereto and incorporated herein by reference.

1.2        “ ABI Improvements ” means any Patents, Production Strains and Know-How associated with such Patents and Production Strains comprising Improvements that (a) are necessary for the development, manufacture, use, sale and distribution of Renewable Fuel Products and Renewable Chemical Products in Brazil and (b) become Controlled by ABI during the Term of this Agreement. Schedule 1 will be amended by the Parties from time to time to reflect the inclusion of Patents and Production Strains included within ABI Improvements.

1.3 “ ABI Technology ” means the ABI Base Technology and the ABI. Improvements.

1.4        “ AB Improvements ” means any Improvements and any other Patents, Production Strains or Know-How that are (a) Controlled by any AB Party as of the Effective Date or become Controlled at any time during the Term of this Agreement and for a period of five years after expiration of the Term of this Agreement, or (b) made, developed or created by or on behalf of any AB Party, or their employees or agents, solely or jointly with any Third Party, during the Term of this Agreement and for a period of five years after expiration of the Term of this Agreement in each case in connection with the exercise of its rights hereunder or otherwise through use of based upon, derived from or incorporating any ABI Technology. AB Improvements shall include, without limitation: (i) Improvements to the ABI Technology, (ii) Improvements to Joint Improvements, and (iii) Improvements to other AB Improvements.

1.5        “ AB Parties ” means AB, its successors and permitted assigns and its, or their permitted sublicensees.

1.6        “ Confidential Information ” has the meaning set forth in Section 5.1.

1.7        “ Control ” (including any variations such as “Controlled” or “Controlling”) means, in the context of. Patents, Production Strains, Know-How, Improvements and Licensed Marks, rights to such Patents, Production Strains, Know-How, Improvements and Licensed Marks sufficient to grant the applicable license or assignment under this Agreement without violating the terms of any arrangement with any Third Party.

1.8        “ Improvements ” means all enhancements, modifications and revisions, whether or not protectable under intellectual property laws, based upon, derived from or incorporating any ABI Technology or other applicable technology in which ABI holds any right, title or interest.

1.9        “ Joint Improvements ” means any Patents, Production Strains or Know-How that are made, developed or created jointly by or on behalf of ABI and by or on behalf of any AB Party, or their employees or agents, during the Term of this Agreement and for a period of five years after expiration of the Term of this Agreement.

 

1


1.10        “ Know-How ” means non patented information and tangible materials, including: (a) technical and non-technical data, specifications, formulae, compounds, formulations, assays, designs, results, information, conclusions, interpretations, inventions, developments, discoveries, ideas, improvements, and trade secrets; (b) methods, databases, tests, procedures, processes and techniques; (c) biological material, including strains, progeny, clones, vectors, recombinant DNA and samples; and (d) other know-how and technology.

1.11        “ Licenses ” has the meaning set forth in Section 2.1.

1.12        “ Licensed Marks ” means, collectively, (a) the trade name “Amyris”; (b) the logo set forth on Schedule 2 , attached hereto and incorporated herein by reference; (c) the additional trademarks listed on Schedule 3 , attached hereto and incorporated herein by reference; and (d) such future marks as determined by ABI in its sole discretion from time to time as appropriate for the development, manufacture, use, sale or distribution of Renewable Fuel Products and. Renewable Chemical Products in Brazil. Schedule 3 and Schedule 4 (Requirements of Licensed Marks Use), attached hereto and incorporated herein by reference, will be amended by the Parties from time to time to reflect the inclusion of such future marks and appropriate requirements for the use of such marks.

1.13        “ Patents ” means any patents and patent applications, together with all additions, divisions, continuations, continuations-in-part, substitutions, reissues, re-examinations, extensions, registrations, patent term extensions, supplemental protection certificates, renewals, and the like with respect to any of the foregoing.

1.14        “ Production Strain ” means recombinant yeast that: has been genetically engineered by or on behalf of ABI (which shall be deemed to include any Production Strains made by AB on behalf of ABI) to make a five carbon (C5), ten carbon (C10), or a fifteen carbon (C15) isoprenoid product during fermentation.

1.15 “ Term ” has the meaning set forth in Section 9.1,

1.16        “ Third Party ” means any person, corporation, joint venture or other entity, other than ABI or AB or their respective permitted successors and assigns.

1.17        “ Renewable Chemical Products ” means a compound made directly by a Production Strain for use, in industrial operations or in the commodity chemicals industry as a raw material which is then converted to a product of interest by formulation or by a chemical change in the compound. The term excludes use of a compound made directly by a Production Strain, including derivatives thereof, for use in pharmaceutical formulations, drugs and as ingredients in food.

1.18        “ Renewable Fuel Products ” means a combustible material that (a) is used to generate energy (heat or power), and (b) is derived from a product made by a Production Strain.

ARTICLE 2

TECHNOLOGY LICENSES

2.1         ABI Technology License Grant .

 

2


  (a)

Grant . Subject to the terms and conditions of this Agreement, ABI hereby grants to AB (i) an exclusive royalty-free right to the ABI Technology to develop, make, have made use, sell, distribute and market Renewable Fuel Products and Renewable Chemical Products in Brazil; and (ii) a non-exclusive royalty-free right to the ABI. Technology to sell, distribute and market. Renewable Fuel Products and Renewable Chemical Products outside of Brazil The foregoing grant is achieved by a grant of multiple licenses on a Patent-by-Patent and a Production Strain-by-Production Strain basis (collectively, the “Licenses”), whereas each such License includes the Know-How associated with the Patent or Production Strain covered by such License. The foregoing Licenses include the right to grant limited sublicenses in accordance with Section 2.2.

 

  (b)

Term . The term of each License will be determined on a License-by-License basis as follows: (i) each License to a Patent will expire upon the expiration of the term of the applicable Patent, unless earlier terminated as permitted herein; and (ii) each License to a Production Strain will expire upon the expiration of the applicable Patent, if any, covering such Production Strain or, if there is no Patent covering such Production Strain, then upon expiration of the last License to a Patent hereunder.

2.2         Sublicense Rights to ABI Technology . AB may grant limited sublicenses under the Licenses granted under Section 2.1 to sugar cane and ethanol mills in Brazil that are being converted either by AB in its capacity as a shareholder in such mills, or by the mill itself pursuant to a commercial agreement with AB, to the production of Renewable Fuel Products and Renewable Chemical Products in Brazil. Each sublicense will be in a form approved in advance by ABI, as determined by AST in its sole discretion and may be granted only under the following terms and conditions unless otherwise agreed to by ABI in writing in its sole and absolute discretion:

 

  (a)

Each such sublicense will only permit the sublicensee to develop, make and have made Renewable Fuel Products and Renewable Chemical Products in Brazil (or for that subset of uses and for such subset of Renewable Fuel Products and Renewable Chemical Products that are determined by AB in such sublicense.)

 

  (b)

Each such sublicense will not conflict with, and will be expressly subordinate to, the terms and conditions of this Agreement. In the event of a conflict, the terms of this Agreement shall prevail.

 

  (c)

Each such sublicense will prohibit the sublicensee from further sublicensing.

 

  (d)

AB will remain responsible to ABI under each sublicense for all the obligations of AB under this Agreement.

 

  (e)

Upon the expiration or earlier termination of this Agreement, at the option of ABI, all sublicenses granted hereunder will either continue with ABI succeeding AB as licensor, or automatically terminate, as determined by ABI in its sole discretion.

 

  (f)

Promptly following the execution of each sublicense, AB will provide ABI with an executed copy of such sublicense agreement.

 

3


For the avoidance of doubt, if AB desires to transfer any ABI Technology, including without limitation any Production Strain or any other tangible biological material received from ABI or derived from any materials received from ABI, to any Third Party to pursue development or scale-up work consistent with the license rights granted hereunder, such transfer must also be documented on the terms required for sublicenses set forth above.

2.3         AB License Grant Back to AB Improvements . AB hereby grants to ABI an exclusive fully paid-up, perpetual, irrevocable, royalty-free right and license, including the right to grant sublicenses in ABI’s sole and absolute discretion, to use the AB Improvements on an exclusive basis (subject only to AB’s nonexclusive license rights granted by ABI hereunder) to develop, make, have made, use, sell, have sold, distribute, have distributed and market Renewable Fuel Products and Renewable Chemical Products and for any other purpose whatsoever worldwide, excluding Brazil. AB will not grant rights to any Third Party to AB Improvements inconsistent with this Agreement.

2.4         AB License Grant Back to AB Interest in Joint Improvements . AB hereby grants to ABI an exclusive (even as to AB) fully paid-up, perpetual, irrevocable, royalty-free right and license, including the right to grant sublicenses ABI’s sole and absolute discretion, to use AB’s interest in the Joint Improvements (subject only to AB’s nonexclusive license rights granted by ABI hereunder) (a) worldwide, excluding Brazil, to develop, make, have made, us; sell, have sold, distribute, have distributed and market Renewable Fuel. Products and Renewable Chemical Products and for any other purpose whatsoever and (b) in Brazil, for any purpose other than developing, making, having made, using, selling, having sold, distributing, having distributed and marketing Renewable Fuel Products and Renewable Chemical Products. AB will not grant rights to any Third Party to AB’s interest in the Joint Improvements inconsistent with this Agreement. For the avoidance of doubt, the Parties hereby affirm that they (i) intend for the foregoing provisions to mean that AB shall grant back to ABI the rights AB otherwise have to use AB’s interest in the Joint Improvements for the purposes described in clauses (a) and (b; (ii) agreed to such rights after due diligence, careful deliberation and consultation with counsel; and (iii) agree that neither Party shall require the permission of the other Party to use the rights granted to such other Party in this Section 2.4 notwithstanding that the law of jurisdictions Other than the State of California, United States of America might otherwise grant such other Party pre-approval, prior consent or other similar blocking or permission rights.

2.5         No Other Rights . Except as expressly granted herein, no right, title or interest is granted by ABI to AB. In addition, any license granted by ABI under this Agreement is subject to applicable laws and regulations, including United States laws and regulations as shall from time to time govern the license and delivery of technology and products between the United States and other countries, including the United States Foreign Assets Control Regulations, Transaction Control Regulations and Export Control Regulations, as amended, and any successor legislation issued by the Department of Commerce, International Trade Administration, Office of Export Licensing, which laws and regulations may restrict ABI’s ability to grant the license or deliver the AIM Technology. In the event any such restrictions are found to apply, the Parties will work together in good faith to comply with requirements to lift or otherwise satisfy such restrictions. The costs of any activities in connection therewith will be borne by AB.

ARTICLE 3

TRADEMARK LICENSE GRANTS

3.1         Grant of Trademark License . Subject to the terms and conditions of this Agreement, ABI hereby grants to AB an exclusive license, without the right to sublicense, to use the Licensed Marks in

 

4


Brazil to practice the ABI Technology to develop, make, have made, use, sell, distribute and market Renewable Fuel Products and. Renewable Chemical Products in Brazil. The term of such license will expire, unless earlier terminated as permitted herein, upon the earlier of (a) fifteen (15) years from the Effective Date, and (b) the expiration of all of the Licenses granted in Section 2.1.

3.2         Acknowledgment of Rights . AB acknowledges that ABI is the owner of the Licensed Marks, and that all use of the Licensed Marks by AB inures to the benefit of ABI. AB further acknowledges that the Licensed Marks embody substantial goodwill and enjoy favorable public recognition, and that ABI’s rights therein constitute valuable assets of ABI.

3.3         Quality Control . In order to protect the goodwill and reputation associated with the Licensed Marks, AB agrees that AB will provide ABI with representative specimens of advertising and promotional materials showing. AB’s use of the Licensed Marks and will use the Licensed Marks in publicly disseminated materials in the manner set forth in the requirements of Requirements of Licensed Marks Use set forth on Schedule 4 attached hereto. Any deviation from the Requirements of Licensed Marks Use must be approved by ABI in writing.

3.4         Trademark Maintenance . During the Term of this Agreement, ABI at its own cost, will be responsible for maintaining and renewing registrations for the Licensed Marks. AB will cooperate with ABI in its efforts to protect the Licensed Marks in Brazil, including exerting its best efforts to exploit the Licensed Marks so as to maintain their validity in the territory of Brazil. ABI will timely notify AB of its decision not to maintain registration for any of the Licensed Marks in Brazil. If registration of AB as a registered user of the Licensed Marks is required, AB will bear all expenses, including government fees and attorney and trademark agent fees, relating to such registration.

3.5         Licensed Mark Infringement .

 

  (a)

Enforcement of Licensed Marks . If either Party becomes aware of any use by any Third Party of any name, mark or designation that infringes or is likely to infringe any of the Licensed Marks in Brazil, that Party will notify the other Party promptly in writing of the actual or threatened infringement. Whether to take action will be in ABI’s sole discretion. If requested by ABI, AB will join with ABI at ABI’s expense in such action as ABI in its reasonable discretion may deem advisable for the protection of its rights. In connection therewith, AB will cooperate to the extent reasonably required by ABI to stop such infringement or act, and, if so requested by ABI, will join with ABI as a party to any action brought by ABI for such purpose. ABI will have full control over any action taken, including, without limitation, the right to select counsel, to settle on any terms it deems advisable in its discretion, to appeal any adverse decision rendered in any court, to discontinue any action taken by it, and otherwise to make any decision in respect thereto as it in its discretion deems advisable. Any recovery as a result of such action shall belong solely to ABI.

 

  (b)

Infringement of Third Party Marks . If AB receives any written notice or claim that the use by AB of the Licensed Marks infringes the intellectual property rights of a Third Party, then AB will promptly so notify ABI in writing. ABI shall have the right, but not the obligation, to defend against any such claim. If requested by ABI, AB will join with ABI at ABI’s expense in such action as ABI in its reasonable discretion may deem advisable for the protection of its rights. In connection therewith, AB will cooperate to the extent reasonably required by ABI, and, if so requested by ABI, will join with AM as a party to any action

 

5


 

brought by ABI for such purpose. ABI will have full control over any action taken, including, without limitation, the right to select counsel, to settle on any terms it deems advisable in its discretion, to appeal any adverse decision rendered in any court, to discontinue any action taken by it, and otherwise to make any decision in respect thereto as it in its discretion deems advisable.

ARTICLE 4

DILIGENCE; REPORTING

4.1         Diligence . AB will use commercially reasonable efforts, consistent with prudent and reasonable business practices and judgment, to develop, make, and have made, directly or through its permitted sublicensees, and to use, sell, distribute and market Renewable Fuel Products and Renewable Chemical Products in Brazil. AB shall permit auditors or inspectors appointed by ABI to have access during ordinary business hours and as may be necessary to monitor compliance of AB with this Agreement.

4.2         AB Reporting . During the Term of this Agreement, AB will keep ABI informed as to the activities of AB and its sublicensees with respect to the development, manufacture, use, sale or distribution of Renewable Fuel Products and Renewable Chemical Products or otherwise involving the ABI Technology. In connection therewith, AB will deliver, to ABI, and will cause its sublicensees to deliver to ABI, no less frequently than quarterly, a written report summarizing in reasonable detail progress with respect to such activities, since the last such report, including without limitation any AB Improvements and Joint Improvements which have arisen during such time period.

4.3         ABI Reporting . During the Term of this Agreement, ABI will keep AB informed annually as to any ABI Technology or marks, trade names or trademarks that have become subject to any license under this Agreement.

ARTICLE 5

CONFIDENTIALITY

5.1         Confidential Information . The Parties understand and agree that in the performance of this Agreement each party may have access to proprietary or confidential data or information of the other Party, including, but not limited to, trade secrets, intellectual property, services and/or the business, finances, or affairs of either Party (“ Confidential Information ”). Confidential Information may be communicated orally, visually, in writing or in any other recorded or tangible form. All data and information shall be considered to be Confidential Information hereunder (i) if either Party has marked them as such, (ii) if either Party, orally (to be reduced to writing) or in writing, has advised the other Party of their confidential nature, or (iii) if, due to their character or nature, a reasonable person in a like position and under like circumstances would treat them as confidential.

5.2         Disclosure of Confidential Information . Each Party will maintain in confidence and not disclose to any third party any Confidential Information of the other Party. Each Party will use the Confidential Information of the other Party only for the purposes of this Agreement Each Party will ensure that access to Confidential Information will be provided to its employees and officers only on a need to know basis if such employees and/or officers must be familiar with the same in connection with the performance of their duties. Such employees and officers must be informed that the Confidential Information may be used only as permitted under this Agreement and must be obligated in writing to abide by such, Party’s obligations under this Agreement. The receiving party shall immediately notify the

 

6


disclosing party of any unauthorized disclosure or use of any Confidential Information by the disclosing party that comes to receiving party’s attention and shall take all action that the disclosing party reasonably requests to prevent any further unauthorized use or disclosure thereof. AB will cause each and every officer and employee and worker of AB who is likely to acquire knowledge of any Confidential Information of ABI to keep the confidentiality of such Confidential Information and agrees to prepare a written statement of undertaking agreeing that it will comply with the provisions of this Article 5.

5.3         Exceptions . The provisions of this Article 5 will not apply, or will cease to apply, to Confidential Information supplied by the disclosing party if the disclosing party demonstrates by written evidence that (i) was in the receiving party’s possession without restriction on use or disclosure prior to receipt from the disclosing party as shown by files existing at the time of disclosure, (ii) has come into the public domain other than through a breach of confidentiality by the receiving party, (iii) was developed independently by employees of the receiving party or by persons who have not had access to the disclosing party’s Confidential Information, (iv) was or is lawfully obtained, directly or indirectly, by the receiving party from a third party under no obligation of confidentiality, or (v) is required to be disclosed pursuant to any statutory or regulatory provision or court order; provided, however, that the receiving party provides notice thereof to the disclosing party, together with the statutory or regulatory provision, or court order, on which such disclosure is based, as soon as practicable prior to such disclosure so that the disclosing party has the opportunity to obtain a protective order or take other protective measures as it may deem necessary with respect to such information.

5.4         Survival . The obligations of the Parties under this Article 5 shall remain in effect for five (5) years from the date of termination or expiration of this Agreement.

ARTICLE 6

INTELLECTUAL PROPERTY; PATENT PROSECUTION AND MAINTENANCE

6.1         Ownership of Patents and Know-How .

(a)         ABI Technology . As between the Parties, ABI will own all right, title and interest in and to the ABI Base Technology and the ABI Improvements, subject only to the licenses set forth herein.

(b)         AB Improvements . As between the Parties, AB will own all right, title and interest in and to the AB Improvements, subject only to the licenses set forth herein and the rights conferred in Section 6.2.

(c)         Joint Improvements . The Parties will jointly own own all right, title and interest in and to the Joint Improvements, subject only to the licenses set forth herein and the rights conferred in Section 6.2.

6.2         Patent Strategy and Prosecution . ABI shall have the sole right to (i) determine the process for protecting the ABI Technology, the Joint Improvements and the AB Improvements worldwide, including whether or not to obtain patent protection and in what countries, and (ii) at its own expense, but without obligation, to prepare, file, prosecute and maintain throughout the world any and all Patents claiming or relating to the ABI Technology, the Joint Improvements and the AB Improvements. For the avoidance of doubt, the Parties hereby affirm that they intend for the foregoing provisions to apply and be upheld as an agreement reached between the Parties after due diligence, careful deliberation and consultation with counsel, notwithstanding that the law of jurisdictions other than the State of California, United States of America might otherwise not permit, uphold or otherwise enforce the granting of such rights.

 

7


6.3         Cooperation and Assistance . AB will provide to ABI and/or its designee, and AB will cause any and all relevant AB Parties to provide to ABI, as reasonably requested by ABI and at ABI’s expense (including reasonable attorney’s fees and other reasonable legal expenses), full cooperation and assistance (including the execution and delivery of any and all affidavits, declarations, oaths, exhibits, assignments, powers of attorney, or other documentation as may be reasonably required): (i) in order to allow ABI to apply for, register, obtain, maintain, defend, and enforce the Patents for which ABI has control under Section 6.2 and/or its rights therein; (ii) in connection with the prosecution or defense of any interference, opposition, re-examination, reissue, infringement, declaratory judgment, or other judicial or legal administrative proceedings that may arise in connection with such. Patents (including the validity and/or enforceability thereof) and/or any Production Strains, Know-How or other intellectual property owned by ABI (including testifying as to any facts, production of any documents, responses to any requests or demands relating to such Patents, Production Strains and/or Know-How); and/or (iii) in order to perfect the delivery, assignment, and conveyance to ABI, its successors, assigns, and nominees, of the entire right, title, and interest in and to all ABI Technology.

6.4         Enforcement of Patents . In the event either Party becomes aware of any activity that infringes or is likely to infringe the ABI Technology, the AB Improvements or the Joint Improvements, that Party will notify the other Party promptly in writing of the actual or threatened infringement. Whether to take action will be in ABI’s sole discretion whenever the infringement involves ABI’s rights. If requested by ABI, AB will join with AM at ABI’s expense in such action as ABI in its reasonable discretion may deem advisable for the protection of rights. In connection therewith, AB will cooperate to the extent reasonably required by ABI to stop such infringement or act, and, if so requested by ABI, will join with ABI as a party to any action brought by ABI for such purpose. ABI will have full control over any action taken, including, without limitation, the right to select counsel, to settle on any terms it deems advisable in its discretion, to appeal any adverse decision rendered in any court, to discontinue any action taken by it, and otherwise to make any decision in respect thereto as it in its discretion deems advisable. Any recovery as a result of such action shall belong solely to ABI.

6.5         Infringement of Third Party Rights . In the event either Party receives any written notice or claim that the use of the ABI Technology, the AB Improvements or the Joint Improvements infringes or is likely to infringe, the intellectual property rights of a Third Party, then that Party will notify the other Party promptly in writing. Whether to take action to defend against, any such claim will be in ABI’s sole discretion. If requested by ABI, AB will join with ABI at ABI’s expense in such action as ABI in its reasonable discretion may deem advisable for the protection of its rights. In connection therewith, AB will cooperate to the extent reasonably required by ABI, and, if so requested by ABI, will join with ABI as a party to any action brought by ABI for such purpose. ABI will have full control over any action taken, including, without limitation, the right to select counsel, to settle on any terms it deems advisable in its discretion, to appeal any adverse decision rendered in any court, to discontinue any action taken by it, and otherwise to make any decision in respect thereto as it in its discretion deems advisable, For the avoidance of doubt, the Parties hereby affirm that they intend for the foregoing provisions to apply and be upheld as an agreement reached between the Parties after due diligence, careful deliberation and consultation with counsel, notwithstanding that the law of jurisdictions other than the State of California, United States of America might otherwise not, permit, uphold or otherwise enforce the granting of such rights.

ARTICLE 7

REPRESENTATIONS AND WARRANTIES

ABI hereby represents and warrants to AB and AB hereby represents and warrants to ABI that as of the Effective Date:

 

8


(a)        They have the full right, power and authority to enter into this Agreement, this Agreement has been duly executed by such Party and constitutes a legal, valid and binding obligation of such Party, enforceable in accordance with its terms;

(b)        The execution, delivery and performance of this Agreement does not conflict with, or constitute a breach or default under any of its charter or organizational documents, any law, order or judgment or governmental rule or regulation applicable to it, or any material agreement, contract commitment or instrument to which it is a party; and

(c)        They shall comply in all material respects with all applicable laws, rules, regulations and other governmental requirements relating to or affecting its performance under this Agreement, and shall obtain and maintain all governmental permits, licenses and consents required in connection therewith.

ARTICLE 8

INDEMNIFICATION; INSURANCE

8.1         Indemnification . AB agrees to defend, indemnify and hold harmless ABI and its directors, officers, shareholders, employees, and agents (collectively, the “ABI Indemnitees”) from and against any and all suits, claims, actions, or demands (“Claims”), and any liabilities, damages, costs, expenses and/or losses incurred, including reasonable legal expenses and attorneys’ fees (collectively, “Losses”), suffered or sustained by any ABI Indemnitee, or to which an ABI Indemnitee becomes subject, arising out of or attributable to any of the following: (a) a breach by AB or a AB Party or its or their respective directors, officers, employees, agents, successors, assigns or sublicensees of a representation, warranty, covenant or agreement made or undertaken by AB under this Agreement; (b) the practice of any license granted by ABI to AB pursuant to this Agreement or any other use of the ABI Technology, the Joint Improvements, the Licensed Marks or Airs Confidential Information by AB or a AB Party or its or their respective directors, officers, employees, agents, successors, assigns or sublicensees; or (c) the negligence, recklessness or willful misconduct of AB or a AB Party or its or their respective directors, officers, employees, agents, successors, assigns or sublicensees. ABI and any ABI Indemnitee may, at its option and expense, be represented by counsel of its choice in any action or proceeding with respect to any such Claim or Loss. AB will not settle any Claim or Loss if such settlement: (i) does not fully and unconditionally release the ABI Indemnitees from all liability relating thereto; or (ii) adversely impacts the rights granted to any ABI Indemnitee under this Agreement, unless each affected ABI Indemnitee otherwise agrees in writing.

8.2         Insurance . At any time, promptly upon ABI’s request, AB will obtain and maintain, at its sole cost and expense, comprehensive general liability insurance providing reasonable coverage in. respect of AB’s activities under this Agreement and in its practice of the licenses granted hereunder. AB will provide ABI with written evidence of such insurance upon ABI’s request.

ARTICLE 9

TERM AND TERMINATION

9.1         Term . This Agreement will commence on the Effective Date and, unless earlier terminated as permitted herein, will continue until the expiration of all of the Licenses granted in Section 2.1 (the “ Term ”).

9.2         Termination by AB . AB may terminate this Agreement at any time upon sixty (60) days written notice to ABI.

 

9


9.3         Termination by ABI . The failure by AB to comply with any of the material obligations contained in this Agreement shall entitle ABI to give notice to have the default cured. If such default is not cured within sixty (60) days, or diligent steps are not taken to cure if by its nature such default could not be cured within sixty (60) days, ABI shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, and in addition to any other remedies that may be available to it, to terminate this Agreement. In addition, ABI may terminate this Agreement upon ABI’s written notice to AB in the event that (a) such termination is necessary to comply with any order, decree or request of the government of either Party hereto or of any court department or agency thereof; (b) normal conduct of the business of AB as a private enterprise ceases or is substantially altered as a consequence of any action taken by governmental, judicial, or any other authority; or (c) AB makes a general assignment for the benefit of creditors, is the, subject of proceedings in voluntary or involuntary bankruptcy instituted on behalf of or against AB, or has a receiver or trustee appointed for all or substantially all of its property.

9.4         Effect of Expiration and Termination . Upon the expiration or termination of this Agreement for any reason: (a) all licenses under this Agreement immediately terminate, except that, at the option of ABI, all sublicenses granted hereunder may continue as determined by ABI in its sole discretion; (b) AB and its sublicensees will cease using the ABI Technology for any and all purposes (except for uses under sublicenses continued as determined by ABI in its sole discretion); (c) within thirty (30) days of termination, AB will return or destroy, at its own expense, all tangible Know-How provided by, or owned by, ABI to ABI in accordance with written instructions from ABI; and (d) each. Party will return, at its own expense, to the other Party all Confidential Information of the other Party within thirty (30) days of termination.

9.5         Survival of Obligations . The termination or expiration of this Agreement shall not relieve the Parties of any obligations accruing prior to such termination, and any such termination shall be without prejudice to the rights of either Party against the other. The provisions of Sections 2.2, 2.3, 2.4, 2.5, 3.5, 8.1, 9.4 and 9.5 and Articles 5, 6, 7 and 10 shall survive any termination of this Agreement.

ARTICLE 10

MISCELLANEOUS

10.1         Governing Law; Venue . This Agreement shall be governed by, and construed in accordance with the laws of the State of California, United States of America, as if entered into by California residents and executed and wholly performed within the State of California. Any dispute as to the performance, enforcement, validity, or interpretation of this Agreement shall be brought only in a federal court of competent jurisdiction (or a state court if no federal court has jurisdiction) located in the Northern District of California, and the Parties hereby submit to the exclusive jurisdiction and venue of such courts. For the avoidance of doubt, the Parties hereby affirm that they intend for the laws of the State of California to apply to the interpretation and enforcement of this Agreement as a whole as well as each provision set forth herein, including, without limitation: all matters set forth in the Recitals, Article 2 and Article 6. The Parties’ decision to designate the laws of the State of California as the- governing law of this Agreement was reached after due diligence, careful deliberation and consultation with counsel and the Parties intend for this to be upheld and enforced notwithstanding that certain activities and obligations under this Agreement shall be performed outside the State of California and/or outside the United States of America.

10.2         Entire Agreement . This Agreement (including all Schedules attached hereto) contains the entire agreement between the Parties with respect to the subject matter hereof and supersedes any and all prior and contemporaneous, express and implied, agreements, understandings, and representations, either written or oral, which may have related to the subject matter hereof in any way.

 

10


10.3         Assignment . This Agreement may not be assigned or otherwise transferred, nor, except as otherwise expressly provided in this Agreement, may any right or obligation under this Agreement be assigned or otherwise transferred, by AB, including without limitation any assignment or transfer in connection with a change of control or otherwise by operation of law, without the consent of ABI. Any permitted assignee shall assume all obligations of AB under this Agreement. Any purported assignment by AB in violation of this Agreement shall be void. This Agreement shall be binding upon, and inure to the benefit of, each Party, its successors and permitted assigns.

10.4         Waiver; Amendment . Except as otherwise expressly provided in this Agreement, any term of this Agreement may be waived only by a written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of any Party at any time to require performance of any provision of this Agreement shall in no manner affect such Party’s rights at a later time to enforce the same. No alteration, amendment, change, or addition to this Agreement will] be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party.

10.5         Notices . Any notice or other communication required or permitted to be given under this Agreement must be in writing, in the English language, must specifically refer to this Agreement, and will be deemed given on the date delivered to the receiving Party if and when (a) delivered personally with a signed receipt of personal delivery; (b) sent by facsimile (receipt electronically verified and a copy promptly sent by personal delivery, registered or certified mail or courier as provided herein); (c) sent by internationally recognized courier providing evidence of receipt; or (d) sent by registered or certified mail, postage prepaid, return receipt requested. All such notices will be addressed to the Parties as follows (or such other address or facsimile number for a Party as may be specified by like notice):

 

For ABI:

  

Amyris Biotechnologies, Inc.

  

5885 Hollis St., Ste. 100

  

Emeryville, CA 94608

  

Fax: (510) 740-7416

  

Attn: General Counsel

For AB:

  

Amyris do Brasil Pesquisa e Desenvolvimento de

  

Biocombustiveis Ltda.

  

Rua James Clerk Maxwell, n° 315

  

Techno Park, Campinas, São Paulo, Brazil

  

Fax: 55 19 3283 0005

  

Attn: Roel Collier

10.6         No Strict Construction . This Agreement has been prepared jointly and will not be strictly construed against either Party.

10.7         Severability . If one or more provisions of this Agreement is held to be invalid, illegal or unenforceable, the Parties shall substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions which valid provisions are, in their economic effect, sufficiently similar to the invalid provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such provisions. In the event that such provisions cannot be agreed upon, the invalidity, illegality or unenforceability of one or more provisions of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without such invalid provisions.

 

11


10.8         Interpretation . The headings for each article and section in this Agreement have been inserted for convenience of reference only and are not intended to affect its meaning or interpretation. In this Agreement: (a) the word “including” (including any variations such as “includes”) shall be deemed to be followed by the phrase “without limitation” or like expression; (b) the singular shall include the plural and vice versa; and (c) masculine, feminine, and neuter pronouns and expressions shall be interchangeable.

10.9         Further Actions . Each Party agrees to execute, acknowledge, and deliver any further instruments, and to do all other acts, as may be necessary or appropriate to carry out the purposes and intent of this Agreement.

10.10       Independent Contractors . The relationship between the Parties created by this Agreement is one of independent contractors and shall not constitute or be deemed to constitute a partnership, joint venture, agency, or other fiduciary relationship. Neither Party shall have the authority to make any statements, representations, or commitments of any kind, or to take any action, that shall be binding on the other Party in whole or in part as a result of this Agreement, without the prior written consent of the other Party to do so.

10.11       No Warranty . BY GRANTING THE LICENSES SET FORTH HEREIN, ABI IS NOT MAKING ANY WARRANTY OF ANY KIND, AND EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS AND IMPLIED, WITH RESPECT TO THE ABI TECHNOLOGY OR THE LICENSED MARKS, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES AND/OR CONDITIONS OF MERCHANTABILITY, NONINFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE.

10.12       Limitation of Liability . IN NO EVENT SHALL ABI BE LIABLE TO AB HEREUNDER FOR INDIRECT, CONSEQUENTIAL, INCIDENTAL, PUNITIVE OR SPECIAL DAMAGES OR LOSSES, INCLUDING BUT NOT LIMITED TO LOST PROFITS, ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES, WHETHER SUCH DAMAGES ARE BASED UPON A BREACH OF EXPRESS OR IMPLIED WARRANTIES, BREACH OF CONTRACT, NEGLIGENCE, STRICT TORT, OR ANY OTHER LEGAL THEORY.

10.13       Non-Use of Names . Except as expressly permitted under this Agreement, AB may not use the name, trade name, trademark or other designation of ABI (including any contraction, abbreviation or simulation of any of the foregoing) or any of its directors, officers, employees and agents in any advertising, publicity, promotional activities, publication, press release, or other public announcement without the prior written consent of such person or entity in each case.

10.14         Language . This Agreement shall be executed in the English language.

[Remainder of this page intentionally left blank; signature page follows]

 

12


IN WITNESS WHEREOF, the Parties have duly executed this Agreement effective as of the day and year first above written.

LOGO

 

13


Schedule 1

Patents and Production Strains

 

  A.

Amyris owned Patents and Patent Applications

 

 

Amyris Ref. No.

 

 

Serial No.

 

 

Title

 

 

Status

 

AM-400 BR   PI0712160-1   Fuel Components, Fuel Compositions and Methods of Making and Using the Same  

Based on PCT Application No. PCT/US2007/012468; Published as WO 2007/139925

 

AM-500 BR   PI 0713105-4   Production of Isoprenoids  

Based on PCT Application No. PCT/US2007/069807; Published as WO 2007/140339

 

AM-700 BR   PI 0712508-9   Apparatus for Making a
Bio-Organic Compound
 

Based on PCT Application No. PCT/US2007/012467; Published as WO 2007/139924

 

AM-800 BR   PI0719659-8  

Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same

 

  Based on PCT Application No. PCT/US2007/021890; Published as WO 2008/045555
AM-900 BR   P10718978-8   Jet Fuel Compositions and Methods of Making and Using the Same  

Based on PCT Application No. PCT/US2007/024266; Published as WO 2008/140492

 

AM-1000 PCT  

PCT/US2008/008747

Filed: 07/17/2008

 

Fuel Compositions Comprising Tetramethylcyclohexane

 

   
AM-1200 PCT  

PCT/US2007/024270

Filed 11/20/2007

 

Jet Fuel Compositions and Methods for Making and Using the Same

 

  Published as WO 2008/133658 on 11/06/2008
AM-1400 PCT  

PCT/US2008/010886

Filed 09/19/2008

 

  Production of Isoprenoids    
AM-1800 PCT  

PCT/US2009/039769

Filed 04/08/2009

 

  Expression of Heterologous Sequences    
AM-1900 PCT  

PCT/US2009/042183

Filed 04/29/2009

 

Jet Fuel Compositions and Methods of Making and Using the Same

 

   
AM-2100 PCT  

PCT/US2009/004959

Filed 09/01/2009

 

  Farnesene Interpolymers    
AM-2200 PCT  

PCT/US2009/005158

Filed 09/16/2009

 

  Jet Fuel Compositions    


AM-2310 PCT  

PCT/US2009/005543

Filed 10/09/2009

 

Lubricant Compositions and Methods of Making and Using the Same

 

   
AM-2400 PCT   PCT/US2009/065048  

Compositions, and Methods for the Rapid Assembly of Polynucleotides

 

   
AM-3300 PCT  

PCT/US2009/004958

Filed 09/03/2009

 

Adhesive Compositions Comprising Polyfarnesene

 

   


  B.

Patents and Patent Applications Licensed from University of California

 

 

Amyris Ref. No.

 

 

Serial No.

 

 

Title

 

 

Status

 

UC-400 BR  

PI 0510115-8

Filed 05/20/05

  Method for Enhancing Production of Isoprenoid Compounds  

Based on PCT Application No. PCT/US05/17874; Published as WO 2006/085899

 

UC-500 BR  

PI0513837-0

Filed: 07/21/05

  Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds  

Based on PCT Application No. PCT/US05/026190; Published as WO 2006/014837

 

UC-700 BR  

PI0614990-1

Filed: 08/17/06

  Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds  

Based on PCT Application No. PCT/US/2006/32406; Published as WO 2007/024718

 

UC-1100 BR  

PI0716954-0

Filed 09/25/07

  Production of Isoprenoids and Precursors Thereof  

Based on PCT Application. No. PCT/US2007/020790; Published as WO 2008/039499

 

 

  C.

Production Strains

 

   

[*]

   

[*]

   

[*]

   

[*]

   

[*]

   

[*]

   

[*]

   

[*]

   

[*]

   

[*]

   

[*]

   

[*]

   

[*]

   

[*]

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


Schedule 2

Logo

LOGO


Schedule 3

Additional Trademarks

 

 

Mark

 

  

 

Country    

 

  

 

Application  
Number  

 

  

 

Filing Date    

 

  

 

Status

 

AMYRIS

(Class 4)

 

   BR    900766638    02/28/2008    Extension based on Registration No. IR948423 on 12/20/2007

AMYRIS

(Class 42)

 

   BR    900766654    02/28/2008    Extension based on Registration No. IR 948424 on 12/20/2007

DIAL-A-BLEND

(Class 4)

 

   BR    900766719    02/28/2008     

DIAL-A-BLEND

(Class 9)

 

   BR    900766735    02/28/2008     

NO COMPROMISE (class 4)

 

   BR    901470945    02/20/2009     


Schedule 4

Requirements for Use of Licensed Marks

 

1.

The Licensed Marks shall be used in all upper case letters, so as to distinguish them from the surrounding text.

 

2.

The first or most prominent reference to the Licensed Marks shall be marked with a ® or ™ symbol, as appropriate.

 

3.

The Licensed Marks shall not be used in possessive form.

 

4.

The Licensed Marks shall not be used in the plural form.

 

5.

The Licensed Marks can be used jointly with other marks.


EXHIBIT 2

COPY OF THE BINDING AGREEMENT ENTERED INTO BY AND AMONG ABI AND

USINA BOA VISTA


BINDING TERM SHEET

STRATEGIC AGREEMENT BETWEEN AMYRIS AND SÃO MARTINHO


1.     PARTIES:

  

Amyris Biotechnologies, Inc., a California corporation with a principal place of business located at 5885 Hollis Street, Suite 100, Emeryville, California 94608 (“ Amyris ”) on its behalf and on behalf of its wholly-owned subsidiary Amyris Pesquisa e Desenvolvimento de Blocombustíveis Ltda., a company organized and existing as a “sociedade limitada” under the laws of Brasil with headquarters in the city of Campinas, state of São Paulo, at Rua James Clerk Maxwell, n o 315, Techno Park, CEP 13069-380, registered with the CNPJ/MF under n o 09.379.224/0001-20 (hereinafter referred to as “ Amyris Brasil ” and, together with Amyris, as “ Amyris Entities ”); and

 

São Martinho S.A., a Brazilian corporation with principal place of business located at Fazenda São Martinho, Pradópolis, Estado de São Paulo, registered with the CNPJ/MF under n o 51.466.860/0001-56 (“ São Martinho ”).

 

2.     BACKGROUND:

  

Amyris is a technology company which is focused on the research, development and commercialization of a variety of renewable fuel and chemical products. Amyris has developed a proprietary microbial production technology (the “ Amyris Technology ”) which converts simple sugars derived from various plant sources, including sugar cane, into specific compounds of interest (the “ Amyris Renewable Product ”) including renewable performance chemical products (“ Amyris Renewable. Chemical. Products ”).

 

Amyris established operations in Brazil in March 2008 and now, through Amyris Brasil, is expanding those operations for the purpose of (i) acquiring an interest in certain sugar and ethanol assets in Brazil and converting a portion of the production capacity of such assets to the production of Amyris Renewable Products, and (ii) providing other Brazilian mills with access to the Amyris Technology.

 

São Martinho is engaged in the business of crushing sugar cane to produce sugar juice, molasses, sugar and ethanol. São Martinho, along with the other companies belonging to its economic group (“ Sao Martinho Group ”), is a leading sugar and ethanol manufacturer in Brazil.

 

The Amyris Entities and São Martinho engaged in good faith negotiations related to the terms and conditions of a possible partnership between the parties. The parties’ discussions have progressed to a point where they now wish to detail the elements of their partnership.

 

The parties therefore agree to execute this binding term sheet (“ Binding Term Sheet ”) setting forth the key elements and principle for their revised strategic relationship.

 


3.     DEFINITIONS AND INTERPRETATION

  

In this Binding Term Sheet, all capitalized terms, whether in singular or plural form or in masculine as well as in feminine and neuter genders of such terms, have the meanings ascribed to them herewith.

 

4.     ACQUISITION OF EQUITY INTEREST IN USINA BOA VISTA AND PURCHASE PRICE:

  

The Parties envision that they would engage in a joint venture relationship related to UBV (the “ UBV Transaction ”) that would have the following key elements and principles:

 

A.    Amyris will purchase a [*]% equity interest in UBV for a total purchase price of R$[*].

 

B.     Amyris will purchase its [*]% equity interest directly from São Martinho and/or from. Usina São Martinho S.A. by making the following payments:

 

(i)     A contribution to Sao Martinho of that number of shares of Series C-1 Preferred stock of Amyris equal to R$[*] (where the per share value of the Series C-1 Preferred Stock will be determined based upon a US$500 million pre-money valuation of Amyris) (the “ SM Series C-1 Holding ”). This contribution shall be made upon the closing of the UBV Transaction, i.e., simultaneously with the transfer of the UBV shares corresponding to [*]% of UBV equity from Sao Martinho and/or Usina São Martinho S.A. to Amyris (the “ Closing Date ”).

 

(ii)   A cash payment of R$[*] on the Closing Date.

 

(iii)  A note for the payment of the balance of R$[*] (plus CDI) (the “ Amyris Note ”) which shall be due and payable as described in Section 5 below.

 

C.     Immediately following the UBV equity investment by Amyris, the ownership structure of UBV shall be as follows:

 

•   São Martinho/Usina São Martinho S.A. – [*]%

•   Amyris – [*]%

 

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


5.     PAYMENT OF AMYRIS NOTE:

  

A.    As used herein, the following words shall have the ascribed meanings:

 

Amyris IPO ” shall mean the sale of Amyris’ common stock in an initial public offering.

 

Amyris IPO Price ” shall mean the per share price of the Amyris common stock on the effective date of the Amyris IPO.

 

Amyris Liquidity Event ” shall mean any “Liquidation,” as defined in Amyris’ Amended and Restated Articles of Incorporation.

 

Amyris Note, Reduction Amount ” shall mean up to [*]% of the SM Series C-1 Gain. For sake of clarification, if the amount corresponding to [*]% of the SM Series C-1 Gain is greater than the Amyris Note, then all the amounts exceeding the value of the Amyris Note shall belong exclusively to São Martinho.

 

SM Series C-1 Basis ” the aggregate purchase price paid by São Martinho for the SM Series C-1 Holding, i.e., R$ [*].

 

SM Series C-1 Gain .” shall mean: (i) in the event of an Amyris IPO, the positive difference (if any) between (x) the aggregate market price of the Amyris common stock into which the SM Series C-1 Holding would convert if converted at the Amyris IPO Price, and (y) the SM Series C-1 Basis, and (ii) in the event of any Amyris Liquidity Event, the difference between (x) the aggregate amount São Martinho is entitled to receive and actually receives under Amyris’ Amended and Restated Articles of Incorporation as its liquidation preference based on its SM Series C-1 Holding, and (y) the SM Series C-1 Basis.

 

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


    

B.     The Amyris Note shall be due and payable in full by [*], subject to reduction as described in Subsections C and D below. Amyris may pay part or all of the outstanding balance of the Amyris Note or any Subsequent Note (as defined below) in cash at any time until [*] without penalty.

 

C.     In the event that, prior to [*], there is the occurrence of either (i) an Amyris IPO in which São Martinho is offered the opportunity to sell its SM Series C-1 Holding, or (ii) an Amyris Liquidity Event which results São Martinho actually receiving proceeds, then (x) the Amyris Note shall automatically be reduced by the Amyris Note Reduction Amount (in the case of an Amyris IPO, whether or not São Martinho actually chooses to sell its SM Series C-1. Holding as part of the Amyris IPO), and (y) at Amyris option, Amyris shall either pay any remaining balance on the Amyris Note in cash or the parties shall simultaneously execute a new promissory note from Amyris Brasil to São Martinho for such remaining balance (“ Subsequent Note ”) which Subsequent Note shall be due and payable in cash by [*]. The parties recognize that it is in both parties interest that São Martinho is offered the right to sell its SM Series C-1 Holding at the Amyris IPO and Amyris hereby represents that to the best of its knowledge there is no reason for such right to be denied to Sao Martinho by the underwriter of the Amyris IPO and, as a consequence Amyris shall endeavor its best efforts to allow São Martinho to have this right.

 

D.    In the event that (i) Amyris undergoes an Amyris IPO prior to [*], (ii) São Martinho is not offered the opportunity to sell its SM Series C-1 Holding into the Amyris IPO, but (iii) São Martinho has the ability to freely sell its SM Series C-1 Holding after the expiration of applicable IPO lock-up periods, then the Amyris Note shall be automatically reduced by the Amyris Note Reduction Amount upon the earlier to occur of (x) the date on which São Martinho actually

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


    

does sell its SM Series C-1 Holding, and (y) the date on which Amyris pays off the Amyris Note, provided that Amyris informs Sao Martinho in writing of its decision to pay off the Amyris Note at least 48 (forty eight) hours in advance and that in the date of such payment São Martinho actually has the right and ability- i.e. liquidity - to sell its SM Series C-1 Holding on the very same date (whether or not Sao Martinho chooses to sell its SM Series C-1 Holding in such occasion). In the event the reduction pursuant to the foregoing clause (x) is not sufficient to pay off the Amyris Note in full, then at Amyris option, Amyris shall either pay any remaining balance on the Amyris Note in cash or the parties shall simultaneously execute a Subsequent Note which shall be due and payable in cash by [*].

 

E.     Effective the Closing Date, the percentage of Amyris’ UBV equity interest which corresponds to the value of the Amyris Note (the “ Residual Equity Interest ”) will be pledged in favor of São Martinho until the Amyris Note has been paid in full. In the event the Amyris Note is later decreased due to the occurrence of an Amyris IPO or Amyris Liquidity Event, in accordance with Subsection C or D above, the amount of the Residual Equity Interest pledged to São Martinho shall be correspondingly reduced. If the Amyris Note is not timely paid in full, Amyris shall return to Sao Martinho that portion of the Residual Equity Interest which corresponds to any remaining unpaid amount of the Amyris Note upon simple written, request by São Martinho.

 

F.     In the event that Amyris determines that it cannot pay the Amyris Note or any Subsequent Note in full, Amyris shall have the right to return to São Martinho that percentage of Amyris’ UBV equity interest which corresponds to the Residual Equity Interest.

 

G.    Except for restrictions on the sale of the SM Series C-1 Holding (including any common stock into which the SM Series C-1 Holding may convert) under Amyris’ Amended and Restated Investors’ Rights Agreement,

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


    

including the “Market Stand-Off” Agreement in Section 1.14 thereof, Amyris hereby represents and warrants to São Martinho that São Martinho will be able to freely sell or otherwise dispose of its SM Series C-1 Holding (or the common stock into which the SM Series C-l Holding may convert) after the IPO Effective Date.

 

6.     EXPANSION AND OPERATION OF USINA BOA VISTA:

  

A.    The crush capacity of UBV shall be expanded from its current capacity of 2.25 million tons to a total capacity of [*] million tons for the 2011/2012 crushing season. Up to R$[*] of the cost associated with this expansion shall be borne by UBV. Any costs in excess of R$[*] shall be born solely by São Martinho without affecting UBV’s capital structure or the parties’ respective equity interest in UBV. The Definitive Agreements (as defined below) shall provide that the São Martinho Group shall have control over the process of building this expansion, as well as all related decisions, including all capital expenditures and timelines. The Definitive Agreements shall further provide that commencing December 31, 2012, decisions related to additional expansions of crushing capacity (i.e., expansions beyond [*] million tons of crushing capacity) shall be under São Martinho’s control and may not be blocked by the Amyris Entities. In the event the Amyris Entities do not wish to make their pro-rata portion of any capital calls required to fund any such additional expansions, they shall be diluted accordingly, which dilution shall be the Amyris Entities’ sole liability and São Martinho’s sole remedy.

 

B.     In the event Amyris wishes to consolidate the UBV entity(ies) into Amyris financial statements, as part of the negotiations of the Definitive Agreements the parties shall structure a governance program to achieve that objective.

 

C.     Amyris, São Martinho and Usina São Martinho S.A. shall enter into a shareholders’ agreement which shall include the right of first refusal of both parties to acquire the other party’s interest in UBV, a Tag Along provision, among others.

 

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


    

D.    On the Closing Date, one of the Amyris Entities shall become a parent guarantor of UBV’s BNDES’s or other banks’ and/or governmental agencies (such as, Goias Fomento) existing and future loans in the percentage of [*]% of such loans (if a parent guarantor is required to any of the shareholders) and for that purpose it shall offer an acceptable collateral to the banks in a percentage corresponding to its then-total interest equity in UBV. São Martinho shall, on its turn, guarantee such loans in the percentage of its then-total interest equity on UBV. For sake of clarification, São Martinho guarantees already granted to banks will be replaced by guarantees by the Amyris Entities up to the percentage of [*]% of the amount of such guarantees.

 

7.     FIRST AMYRIS PLANT:

  

A.    A co-located manufacturing facility shall be built at UBV for the production of Amyris Renewable Chemical Products using the Amyris Technology for a total capacity of 2 million tons of cane juice equivalent (the “ First Amyris Plant ”), The First Amyris Plant shall commence first commercial production preferably in 2011 but no later than by the end of 2012 and shall achieve production at target capacity of 2.0 million tons of cane juice equivalent preferably in 2013 but no later than by the end of 2014. The Amyris Entities and São Martinho shall jointly agree on the volume of the first commercial production with a focus on reducing risk to successful operation of such first commercial production.

 

B.     Up to US$[*] (which amount shall be expressed in R$ in the Definitive Agreements based upon the average exchange rate over the ten day period ending the last business day before closing) of the cost incurred in building the First Amyris Plant will be borne by UBV. Such US$[*] amount may be adjusted by the parties in the event the crush capacity of the First Amyris Plant is less than 2.0 million tons as follows: At the end of the calendar year 2012, the parties shall review the plans and progress for the First Amyris Plant. In the event the

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


    

capacity for which the First Amyris Plant has been designed and built is less than 2.0 million tons, the parties shall make a pro-rata adjustment to UBV’s US$[*] obligation in accordance with pro-rata adjustment principles to be agreed to in the Definitive Agreements. Any costs in excess of such US$[*] (as such amount may be adjusted) for the First Amyris Plant shall be borne solely by the Amyris Entities without affecting UBV’s capital structure or the parties’ respective equity interest in UBV.

 

C.     The Amyris Entities shall control the process of building the Amyris Plant and all technical, engineering and similar decisions. The parties shall work together to duly obtain all appropriate licenses for the First Amyris Plant. Amyris acknowledges and agrees that such licenses may be a condition precedent to building and/or operating the First Amyris Plant. The parties shall endeavor to establish a corporate holding structure for the First Amyris Plant which provides maximum tax benefits for each party. This may include establishing a special purpose entity to hold the First Amyris Plant assets.

 

D.    The Amyris and São Martinho technical teams will work together for a term not to exceed 180 days from the signing of the Definitive Agreements to continue the commercial plant engineering and design work that the Amyris Entities have already undertaken with the goal of reducing risk of successful operation. Based on such work, Amyris and São Martinho technical teams will determine (i) the initial operation date of the First Amyris Plant, (ii) the initial production capacity of the First Amyris Plant, and (iii) the ramp in capacity of the First Amyris Plant to 2MM final capacity. Although Amyris will consider in good faith the input and recommendations from São Martinho’s technical team, the final recommendations on these matters shall be made by Amyris’ Senior Vice President of Process Development & Manufacturing. In the event São Martinho disagrees with such recommendations and the parties cannot resolve such disagreement pursuant to a

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


    

deadlock mechanism to be agreed in the Definitive Agreements, the Amyris Entities shall have no further obligation to São Martinho under Subsections G (i), (ii) and (iii) or H below.

 

E.     In advance of or during each crush season, the parties, in their capacities as Shareholders of UBV and in accordance with procedures agreed to in the UBV shareholder agreement, shall determine the quantity of Amyris Renewable Chemical Products to be produced by the First Amyris Plant for such crush season (“ Amyris Product Quantity ”),

 

F.     Amyris Brasil shall enter into the following agreements with the First Amyris Plant: (i) a royalty-free intellectual property license that provides the First Amyris Plant with the right to use the Amyris Technology for commercial production of an amount of Amyris Renewable Chemical Products made from up to 2.0 million tons of cane juice, (ii) for each crush year, an offtake agreement that obligates Amyris Brasil to “take or pay” for the Amyris Product Quantity for such year (where Amyris Brasil’s “pay” obligation shall mean an obligation to pay the margin the First Amyris Plant would earn for ethanol), and (iii) a commercial distribution agreement which provides Amyris Brasil with the exclusive right to market and distribute the Amyris Renewable Chemical Products produced by the First Amyris Plant (unless Amyris Brasil and its affiliates are legal prohibited from marketing and distributing such products, in which case the First Amyris Plant may sell the Amyris Renewable Chemical Products directly or through another distributor). The financial terms of the commercial distribution agreement shall take the form of a [*] (the First Amyris Plant/Amyris Brasil) profit share split on the margin benefit of the Amyris Renewable Chemical Products above ethanol (i.e. additional margin as compared to a standard ethanol production operation). See Exhibit A for example of the mechanism. For sake of clarification, the offtake agreements referred to in item (ii) above and the commercial distribution agreement

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


   

referred to in item (iii) above shall be consistent in a way to assure that despite of the take or pay obligation of Amyris Brasil to pay the margin the First Amyris Plant would earn for ethanol, the First Amyris Plant shall also be entitled to receive its percentage of the margin benefit of the Amyris Renewable Chemical Products above ethanol according to the financial terms agreed herein. Such license and commercial distribution agreements shall have an initial term of [*] and may be automatically renewed for up to [*] additional [*] terms (collectively, the “ Term ”).

 

G.    The parties agree that (i) UBV shall be the first milling company in Brazil to have a mill that produces Amyris Renewable Products, (ii) for the duration of the Term, anytime the First Amyris Plant has offtake agreements with Amyris Brasil for product produced by less than 2.0 million tons crushed sugarcane capacity, the First Amyris Plant shall have the right of first refusal to enter into any offtake agreement executed by an Amyris Entity with a mill in Brazil until the First Amyris Plant is back at full capacity of 2.0 million tons, (iii) in their capacities as shareholders of UBV they shall commit themselves to choose to manufacture Amyris Renewable Products at the First Amyris Plant which have the highest margin return potential, and (iv) if Amyris Renewable Products do not have a margin return greater than ethanol margin, then the First Amyris Plan shall not be obligated to manufacture Amyris Renewable Products but rather shall produce ethanol instead. For clarity, the right of first refusal referred to in the foregoing clause (ii) means the First Amyris Plant shall always be offered the offtake agreements for the production of the Amyris Renewable Products with the highest margin return potential.

 

H.    The Amyris Entities hereby agree, for as long as the Amyris Entities hold equity at UBV, without the prior written consent of São Martinho, not to enter into (either directly or indirectly, through any nominees or in any other way), and not to permit any of its Affiliates

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


   

        to enter into (either directly or indirectly, through any nominees or in any other way) a business relationship with another entity in Brazil in which Amyris or any of its Affiliates holds an equity interest (an “ Amyris Co-owned Company ”), if such relationship includes providing such Amyris Co-owned Company with the right to use Amyris Technology for the production of Amyris Renewable Chemical Products or Amyris Renewable Products then being manufactured by the First Amyris Plant on financial terms that are equal or more favorable than the financial terms then-applicable to the First Amyris Plant for the same Amyris Renewable Chemical Products or Amyris Renewable Products. For the avoidance of doubt, the parties agree that the foregoing sentence shall not be construed to prohibit an Amyris Entity from (i) entering into a business relationship with another entity in Brazil in which Amyris or any of its Affiliates holds an equity interest, or (ii) providing such entity with access to the Amyris Technology. For purpose of this Binding Term Sheet, Affiliates means with respect to any person, any other person that, directly or indirectly, through one or more intermediaries, controls or is controlled by or is under common control with such person.

 

8.     IRACEMA:

 

The parties shall also enter into agreements providing for the production of Amyris Bio-Isoprene or other Amyris Renewable Products at São Martinho’s Iracema mill during the crush season of 2013/2014 and in no event no later than 2014/2015 crush season (“ Iracema Deadline ”). The Iracema Deadline was established based on the assumption that the Amyris Entities will give timely notice (as “Timely Notice” will be defined in the Definitive Agreements) to São Martinho as provided in Subsection A below allowing São Martinho to take the appropriate steps to meet Iracema Deadline. However, if no Timely Notice is given by the Amyris Entities, then the Iracema Deadline shall be reviewed accordingly.

 

A.    The Amyris Entities shall have the following notice obligations to São Martinho: (i) the obligation to notify São Martinho when the development of the Amyris Technology for the production of Bio-Isoprene has achieved commercial viability and will be ready for deployment for commercial production (the “ Bio-Isoprene Notice ”), and (ii) provided the capacity of the First Amyris Plant has already been filled, the obligation to notify São Martinho when the Amyris


   

        Entities have an offtake agreement for another Amyris Renewable Product (“ Other Amyris Renewable Product Notice ”),

 

B.     São Martinho shall have the following rights of first refusal for Iracema mill:

 

(i)     Upon receipt of the Bio-Isoprene Notice, a one-time right of first refusal to choose to manufacture Bio-Isoprene at Iracema. If São Martinho exercises this right of first refusal, then Iracema shall be the first mill in Brasil to produce Amyris Bio-lsoprene and the provisions of Subsections D- I below shall apply in relation to the production of Bio Isoprene at Iracema. If São Martinho waives this right of first refusal (i.e., chooses not to manufacture Bio-Isoprene at Iracema) then the Amyris Entities shall be free to manufacture Bio-lsoprene at another mill in Brazil.

 

(ii)   Upon receipt of the Other Amyris Renewable Product Notice, a one-time right of first refusal to choose to manufacture such other Amyris Renewable Product (the “Other Amyris Renewable Product”) at Iracema. If São Martinho exercises this right of first refusal, then the provisions of Subsections D - I below shall apply in relation to the production of the Other Amyris Renewable Product at Iracema. If São Martinho waives this right of first refusal (i.e., chooses not to manufacture such Other Amyris Renewable Product at Iracema) then the Amyris Entities shall be free to manufacture such Other Amyris Renewable Product at another mill in Brazil. For sake of clarification, this right of first refusal is in addition to the right of first refusal to choose to manufacture Bio-Isoprene at Iracema and the only case in which it will not be applicable is if São Martinho exercises its right of first refusal in relation to Amyris Bio-Isoprene before it receives the Other Amyris Renewable Product Notice.

 

C.     Even if São Martinho has waived both rights of first refusal granted to it under Subsection B above, São Martinho shall still retain the right to produce Amyris Renewable Products at Iracema and in such case the provisions of Subsections D-I below shall apply accordingly.


   

D.    Amyris Brasil shall grant São Martinho a royalty-free intellectual property license that provides Iracema with the right to use the Amyris Technology for commercial production of Amyris Bio-Isoprene (if chosen pursuant to São Martinho’s right of first refusal described in Subsection B(i) above) or such other Amyris Renewable Product (whether or not chosen pursuant to São Martinho’s right of first refusal described in Subsection B(ii) above) to be determined by São Martinho up to an amount of Amyris Bio-Isoprene or other Amyris Renewable Product, as the case may be, made from up to 2.0 million tons of cane juice.

 

E.     Iracema shall enter into a commercial distribution agreement that provides the Amyris Entities with the exclusive right to market and distribute the Amyris Bio-Isoprene or other Amyris Renewable Products produced by Iracema (unless Amyris Brasil and its affiliates are legally prohibited from marketing and distributing such products, in which case Iracema may sell the Amyris Renewable Products directly or through another distributor).

 

F.     The parties agree that Iracema will have the right of first refusal to enter into any offtake agreement executed by an Amyris Entity with a mill in Brazil for the production of (i) Bio-Isoprene if São Martinho opts into Bio-Isoprene as provided in Subsection B (i) above, or (ii) another Amyris Renewable Product in the event São Martinho does not opt into Bio-Isoprene as provided in Subsection B (i) above until such time as Iracema has offtake agreements in place for 2.0 million tons of crushed sugarcane capacity for the production of Bio-Isoprene or Amyris Renewable Products, as the case may be. Once São Martinho passes one time on its right of first refusal hereunder however (whether with respect to Bio-Isoprene or another Amyris Renewable Product), such right shall terminate. The parties also agree that São Martinho shall lose this right of first refusal if the Iracema Deadline is not met due to exclusive fault of São Martinho, i.e., excluding delays that might be caused by third parties or by facts not directly attributable to São Martinho.


   

G.    The financial terms of the commercial distribution agreement ‘shall take the form of a [*] (Iracema/Amyris Brasil) profit share split on the margin benefit of the applicable Amyris Renewable Product above ethanol (i.e. additional gross/operational margin as compared to a standard ethanol production operation) for a term of [*]. See Exhibit B for examples of mechanism. Thereafter the financial terms for Iracema shall be MFN, where “MFN” means pricing that is no less favorable than the best pricing given by Amyris Brasil to other third party mills that direct the same amount of crushed sugarcane to the production of the same Amyris Renewable Product.

 

H.    The financial terms set forth in Section 8G above shall apply to that amount of Amyris Renewable Product produced from up to 2.0 million tons of crushed sugarcane. if São Martinho produces less Amyris Renewable Product within the term of [*] set forth in Section 8G above as a result of the lack of competitive offtake agreements presented by the Amyris Entities, then the financial terms referred to in Section 8G shall also apply to the quantities of the applicable Amyris Renewable Product(s) corresponding to the respective balance for subsequent periods of [*] each.

 

I.      Provided the Iracema Deadline is met (except if a delay is caused by reasons not directly attributable to São Martinho), then the Amyris Entities agree that during such initial [*] term, they shall not provide any other mill in Brazil with right to use Amyris Technology for the production of the Amyris Renewable Product then produced by Iracema on financial terms that are equal or more favorable than [*] (Mill/Amyris Brazil).

 

J.      Despite the fact that the parties envision, that the production of Amyris Renewable Products at Iracema mill shall start by the Iracema Deadline, São Martinho has no obligation to start the conversion of its plant or to build/convert/acquire a plant for the production of Amyris Renewable Products until it has competitive

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


   

        offtake agreements in place and until the Amyris Entities demonstrate to the satisfaction of São Martinho that the production of Amyris Renewable Product at Iracema will be technologically and commercially viable.

 

K.    São Martinho will invest all capital required to fund the conversion of Iracema mill or the construction of a plant at Iracema mill to produce Amyris Renewable Products and will be the sole owner of the Iracema assets acquired for such purposes. For sake of clarification, if São Martinho chooses not to invest all capital required to allow the conversion of Iracema mill or the construction of a plant at Iracema mill to produce Amyris Renewable Products and the achievement of the Iracema Deadline, then São Martinho’s sole liability and Amyris sole remedy shall be that São Martinho will lose the right referred to in subsection F and I above that are conditioned upon achievement of the Iracema Deadline.

 

9.     IMPROVED ETHANOL STRAINS

 

The Amyris Entities agree to collaborate with São Martinho to discover or develop improved ethanol strains on mutually agreeable terms and conditions to be further determined during the negotiation of the Definitive Agreements. In the event the Amyris Entities discover or develop improved São Martinho ethanol strains, São Martinho shall have the right to use such improved strains at mills it owns and operates without the payment of additional fees. The Amyris Entities agree to bear all the costs related to this development. For sake of clarification, the referred costs are those of development work done by the Amyris Entities only.

 

The Amyris Entities will also explore with São Martinho the possibility of allowing São Martinho to participate in any business the Amyris Entities develop focused on improvement of ethanol strains at other Brazilian mills.

 

10.   CONFIDENTIALITY:

 

A.    Except for the announcement to the market of the Transaction as per Section 10B below, the terms of this Binding Term Sheet shall be deemed confidential. Any information, document or other data of the Parties shall also be deemed confidential and shall be subject to the Acordo de Confidencialidade between Amyris Brasil, Amyris, Sao Martinho, Usina São Martinho S.A. and UBV dated 8 September, 2009.


   

B.     São Martinho shall make an announcement to the market of this transaction upon the signing of this Binding Term Sheet between the parties. The Amyris Entities hereby agree that they will not make any announcement before São Martinho’s announcement and that’ announcement shall be consistent with the one of Sao Martinho.

 

11.   TIMELINE & DEFINITIVE AGREEMENTS:

 

The parties intend to set forth in one or more definitive agreements (the “ Definitive Agreements ”) the detailed set of terms and conditions for the UBV Transaction and other elements of the Strategic Relationship described herein. The parties intend to negotiate in good faith and use their best efforts to enter into the Definitive Agreements and close the UBV Transaction no later than February 28, 2010.

 

Following is a more detailed timeline and description of the significant activities the parties envision undertaking between the date of this Binding Term Sheet and the closing:

 

•    Binding Term Sheet signed: December 2, 2009

 

•    First Draft of Definitive Agreements: December 7, 2009

 

•    Signing of Definitive Agreements: December 21, 2009

 

•    UBV Transaction closed: by February 28, 2010

 

This Binding Term Sheet will automatically terminate upon the earlier to occur of (i) the signing of the Definitive Agreements, or (ii) February 28, 2010, unless extended in writing by the parties.

 

The provisions of Section 10 (“Confidentiality’) shall survive the expiration or earlier termination of this Binding Term Sheet.

 

12.   BINDING

 

The parties acknowledge that the obligations set forth in this Binding Term Sheet are 1515binding but are still subject to the following conditions (i) the satisfactory completion by the Amyris Entities of their due diligence on UBV, (ii) validation of the Amyris Series C-1 pre-money valuation by a US-based third party valuation firm which specializes in providing such valuations for private, venture- backed technology companies like Amyris to be chosen by mutual agreement by both parties, (iii) approval of the Definitive Agreements by São Martinho’s


   

Board of Directors, and (iv) approval of the transaction by São Martinho’s Shareholders Meeting.

 

This Binding Term Sheet constitutes the entire agreement between the parties relating to the matters discussed herein, supersedes any other written or oral understandings and other communications between the parties, in relation to the themes herein contemplated and may be amended or modified only with the mutual written consent of the parties.

 

13.   APPLICABLE LAW AND ARBITRATION

 

This Binding Term Sheet shall be governed by the laws of Brasil without regard to the conflicts of laws provisions thereof. Any dispute arising out of or in connection with this Binding Term Sheet shall be resolved in accordance with the Arbitration Rules of the International Court of Arbitration of the International Chamber of Commerce by 3 (three) arbitrators. The seat of the arbitration shall be São Paulo, SP, Brasil, and the arbitration will be conducted in English.

In witness whereof, the parties have agreed to this Binding Term Sheet as of the later of the dates set forth below.


AMYRIS BIOTECHNOLOGIES, INC.

 

Signature: /s/ John G. Melo                 

 

By: John G. Molo

 

Title: Chief Executive Officer

 

Date 03/12/2009

 

Address:  5885 Hollis Street, Suite 100

                  Emeryville, CA 94608

 

Fax No. (510) 842-1460

 

SÃO MARTINHO S.A.

 

Signature: /s/ Fábio Venturelli

 

By: Fábio Venturelli

 

Title: Chief Executive Officer

 

Signature:     /s/ João Carvalho do Val                

 

By:João Carvalho do Val

 

Title: Chief Financial Officer

 

Date: 03/12/2009

 

Address:  61, Rua Geraldo Flausino Gomes

                  Street, conjunto 132, São Paulo, SP,

                  Brasil, ZIP Code 04575-060

                  Fax No.: (55-11) 2105414

(Signature Page of the Binding Term Sheet executed between Amyris Biotechnologies, Inc. and São Martinho S.A. as of December 2, 2009)


EXHIBIT A

[*]

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


EXHIBIT B

[*]

 

 

*  Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


EXHIBIT 3

SHAREHOLDERS’ AGREEMENT

(superseded)


EXHIBIT 4

COPY OF ABI CONVERTIBLE LOANS


INTERCOMPANY LOAN AGREEMENT

This Intercompany Loan Agreement (“Agreement”) is made and entered into as of August 7, 2009, by and between:

I.        AMYRIS BIOTECHNOLOGIES, INC. , a company organized and existing under the laws of the State of California, United States of America, with head offices at 5885 Hollis Street, Room 100, Emeryville, CA 94002, United States of America, enrolled with the National Registry of Legal Entities of Ministry of Finance (“CNPJ/MF”) n° 09.345.642/0001-05 (hereinafter referred to as “LENDER”), herein represented by its duly appointed officers.

II.        AMYRIS PESQUISA E DESENVOLVIMENTO DE BIOCOMBUSTÍVEIS LTDA. , a company duly organized under the laws of Brazil, enrolled with the National Registry of Legal Entities of the Ministry of Finance (“CNPJ/MF”) under No. 09.379.224/0001-20, with registered head offices in the city of Campinas, State of São Paulo, at Rua James Clerk Maxwell, 315, Federative Republic of Brazil (hereinafter referred to as “BORROWER”), herein represented by its duly appointed officers.

SECTION 1 - DISBURSEMENT

1.1.         LENDER shall lend to BORROWER the amount of USD 1,200,000.00 (one million two hundred thousand United States Dollars) (the “Disbursed Amount”), to be disbursed in one single installment immediately upon the execution of this Agreement (“Disbursement Date”).

SECTION 2 - REPAYMENT OF PRINCIPAL

2.1.         The principal amount due by the BORROWER under this Agreement shall be due and payable in one single installment, payable within 12 (twelve) months as of the Disbursement Date (the “Repayment Date”).

2.2.         At the LENDER’s option, the principal amount (plus any interest that may have accrued) may be converted into an equity Interest (“Equity Shares”) interest in the BORROWER under the following terms: (a) at such time as the BORROWER consummates its next equity financing transaction such that LENDER received that number of Equity Shares equal to the Disbursed Amount divided by the per share price of the Equity Shares. Additionally, the principal amount (plus any interest that may have accrued); and/or (b) if the LENDER sends a letter to the BORROWER acknowledging the intention to convert the credit into Equity Shares in the BORROWER.

SECTION 3 - INTEREST

3.1.         The principal amount due and payable by the BORROWER to the LENDER under this Agreement shall bear no interest.

SECTION 4 - PAYMENTS

4.1.         All payments due to LENDER shall be made by BORROWER for LENDER’s account, in United States Dollars, in immediately available funds.

4.2.         In the event a payment hereunder is due on a non-banking day in either the city of São Paulo or the city of Emeryville, it shall instead fall due on the next following banking day in both São Paulo and Emeryville.

 

1


4.3.         Repayments shall be made to the LENDER in accordance with instructions to be provided by the LENDER to the BORROWER specifically for this purpose.

SECTION 5 - TAXES

5.1.         The payment of principal hereunder or the payment of any other amount due or that becomes due by the BORROWER hereunder shall be made free and clear of any taxes, levies, deductions, charges and withholdings of any nature imposed by the Brazilian Government or any of its tax authorities (“Brazilian Taxes”). If Brazilian Taxes are required to be withheld or deducted from any such payment, the BORROWER shall pay immediately, for the account of the LENDER, such additional amount as may be necessary to ensure that the net amount actually received by the LENDER is equal to the amount which the LENDER would have received had no Brazilian Taxes been withheld or deducted from such payment.

SECTION 6 - EVENTS OF DEFAULT

6.1.         In the event (i) BORROWER shall file, or be subject of, a petition for bankruptcy or liquidation, or (ii) is generally unable to meet its obligation to its creditors when due, or (iii) fails to punctually pay any amount due hereunder (collectively, “Events of Default”), then anything hereinbefore to the contrary notwithstanding, the totality of the principal or any outstanding part of the principal under this Agreement shall become, at discretion of LENDER, immediately due and payable.

6.2.         Upon the occurrence of an Event of Default the LENDER shall have, in addition to any rights hereunder, all of the rights, powers and remedies provided at law or equity. The failure of LENDER to exercise any right or remedy available hereunder or at law or in equity shall not constitute a waiver of the right to exercise subsequently such option or such other right or remedy.

SECTION 7 - PREPAYMENT

7.1.         BORROWER may prepay this loan in whole or part at any time and from time to time without penalty of any kind.

SECTION 8 - APPLICABLE LAW AND JURISDICTION

8.1.         This Agreement shall be governed by and construed and interpreted in accordance with the laws of the Federative Republic of Brazil.

8.2.         The Courts of São Paulo, State of São Paulo, shall have jurisdiction to decide upon any dispute or conflict arising from the interpretation or performance of this Agreement.

SECTION 9 - AMENDMENTS

9.1.         No amendment or waiver of any provision hereof shall in any event be effective unless the same shall be in writing and signed by LENDER and BORROWER, and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

SECTION 10 - NO WAIVER

10.1.         No failure on the part of the LENDER to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right preclude any other or further exercise thereof or the exercise of any other right.

 

2


SECTION 11 - COUNTERPARTS

11.1.         This Agreement shall be executed by the parties in 2 (two) separate counterparts of equal tenor, each of which when so executed shall be deemed to be an original, and all of which shall together constitute one and the same agreement.

SECTION 12 - SEVERABILITY

12.1.         If any provision hereof is held to be contrary to, prohibited by, or deemed invalid under applicable laws or regulations, such provision shall be inapplicable and deemed omitted to the extent so contrary, prohibited or invalid, but the remainder hereof and thereof shall not be invalidated thereby and shall be given effect so far as possible.

SECTION 13 - SUCCESSORS AND ASSIGNS

13.1.         This Agreement shall be binding upon and inure to the benefit of the LENDER and the BORROWER and their respective successors or assigns.

 

3


IN WITNESS WHEREOF , the parties sign this Loan Agreement in the presence of the undersigned witnesses.

LOGO

 

4


INTERCOMPANY LOAN AGREEMENT

This Intercompany Loan Agreement (“Agreement”) is made and entered into as of October 6, 2009, by and between:

I.        AMYRIS BIOTECHNOLOGIES, INC. , a company organized and existing under the laws of the State of California, United States of America, with head offices at 5885 Hollis Street, Room 100, Emeryville, CA 94002, United States of America, enrolled with the National Registry of Legal Entities of Ministry of Finance (“CNPJ/MF”) n° 09.345.642/0001-05 (hereinafter referred to as “LENDER”), herein represented by its duly appointed officers.

II.        AMYRIS PESQUISA E DESENVOLVIMENTO DE BIOCOMBUSTÍVEIS LTDA. , a company duly organized under the laws of Brazil, enrolled with the National Registry of Legal Entities of the Ministry of Finance (“CNPJ/MF”) under No. 09.379.224/0001-20, with registered head offices in the city of Campinas, State of São Paulo, at Rua James Clerk Maxwell, 315, Federative Republic of Brazil (hereinafter referred to as “BORROWER”), herein represented by its duly appointed officers.

SECTION 1 - DISBURSEMENT

1.1.         LENDER shall lend to BORROWER the amount of USD 2,000,000.00 (two million United States Dollars) (the “Disbursed Amount”), to be disbursed in one single installment immediately upon the execution of this Agreement (“Disbursement Date”).

SECTION 2 - REPAYMENT OF PRINCIPAL

2.1.         The principal amount due by the BORROWER under this Agreement shall be due and payable in one single installment, payable within 12 (twelve) months as of the Disbursement Date (the “Repayment Date”).

2.2.         At the LENDER’s option, the principal amount (plus any interest that may have accrued) may be converted into an equity Interest (“Equity Shares”) interest in the BORROWER under the following terms: (a) at such time as the BORROWER consummates its next equity financing transaction such that LENDER received that number of Equity Shares equal to the Disbursed Amount divided by the per share price of the Equity Shares. Additionally, the principal amount (plus any interest that may have accrued); and/or (b) if the LENDER sends a letter to the BORROWER acknowledging the intention to convert the credit into Equity Shares in the BORROWER.

SECTION 3 - INTEREST

3.1.         The principal amount due and payable by the BORROWER to the LENDER under this Agreement shall bear no interest.

SECTION 4 - PAYMENTS

4.1.         All payments due to LENDER shall be made by BORROWER for LENDER’s account, in United States Dollars, in immediately available funds.

4.2.         In the event a payment hereunder is due on a non-banking day in either the city of São Paulo or the city of Emeryville, it shall instead fall due on the next following banking day in both São Paulo and Emeryville.

 

1


4.3.         Repayments shall be made to the LENDER in accordance with instructions to be provided by the LENDER to the BORROWER specifically for this purpose.

SECTION 5 - TAXES

5.1.         The payment of principal hereunder or the payment of any other amount due or that becomes due by the BORROWER hereunder shall be made free and clear of any taxes, levies, deductions, charges and withholdings of any nature imposed by the Brazilian Government or any of its tax authorities (“Brazilian Taxes”). If Brazilian Taxes are required to be withheld or deducted from any such payment, the BORROWER shall pay immediately, for the account of the LENDER, such additional amount as may be necessary to ensure that the net amount actually received by the LENDER is equal to the amount which the LENDER would have received had no Brazilian Taxes been withheld or deducted from such payment.

SECTION 6 - EVENTS OF DEFAULT

6.1.         In the event (i) BORROWER shall file, or be subject of, a petition for bankruptcy or liquidation, or (ii) is generally unable to meet its obligation to its creditors when due, or (iii) fails to punctually pay any amount due hereunder (collectively, “Events of Default”), then anything hereinbefore to the contrary notwithstanding, the totality of the principal or any outstanding part of the principal under this Agreement shall become, at discretion of LENDER, immediately due and payable.

6.2.         Upon the occurrence of an Event of Default the LENDER shall have, in addition to any rights hereunder, all of the rights, powers and remedies provided at law or equity. The failure of LENDER to exercise any right or remedy available hereunder or at law or in equity shall not constitute a waiver of the right to exercise subsequently such option or such other right or remedy.

SECTION 7 - PREPAYMENT

7.1.         BORROWER may prepay this loan in whole or part at any time and from time to time without penalty of any kind.

SECTION 8 - APPLICABLE LAW AND JURISDICTION

8.1.         This Agreement shall be governed by and construed and interpreted in accordance with the laws of the Federative Republic of Brazil.

8.2.         The Courts of São Paulo, State of São Paulo, shall have jurisdiction to decide upon any dispute or conflict arising from the interpretation or performance of this Agreement.

SECTION 9 - AMENDMENTS

9.1.         No amendment or waiver of any provision hereof shall in any event be effective unless the same shall be in writing and signed by LENDER and BORROWER, and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

SECTION 10 - NO WAIVER

10.1.         No failure on the part of the LENDER to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right preclude any other or further exercise thereof or the exercise of any other right.

 

2


SECTION 11 - COUNTERPARTS

11.1.         This Agreement shall be executed by the parties in 2 (two) separate counterparts of equal tenor, each of which when so executed shall be deemed to be an original, and all of which shall together constitute one and the same agreement.

SECTION 12 - SEVERABILITY

12.1.         If any provision hereof is held to be contrary to, prohibited by, or deemed invalid under applicable laws or regulations, such provision shall be inapplicable and deemed omitted to the extent so contrary, prohibited or invalid, but the remainder hereof and thereof shall not be invalidated thereby and shall be given effect so far as possible.

SECTION 13 - SUCCESSORS AND ASSIGNS

13.1.         This Agreement shall be binding upon and inure to the benefit of the LENDER and the BORROWER and their respective successors or assigns.

 

3


IN WITNESS WHEREOF , the parties sign this Loan Agreement in the presence of the undersigned witnesses.

LOGO

 

4


INTERCOMPANY LOAN AGREEMENT

This Intercompany Loan Agreement (“Agreement”) is made and entered into as of December 15, 2009, by and between:

I.        AMYRIS BIOTECHNOLOGIES, INC. , a company organized and existing under the laws of the State of California, United States of America, with head offices at 5885 Hollis Street, Room 100, Emeryville, CA 94002, United States of America, enrolled with the National Registry of Legal Entities of Ministry of Finance (“CNPJ/MF”) n° 09.345.642/0001-05 (hereinafter referred to as “LENDER”), herein represented by its duly appointed officers.

II.        AMYRIS PESQUISA E DESENVOLVIMENTO DE BIOCOMBUSTÍVEIS LTDA. , a company duly organized under the laws of Brazil, enrolled with the National Registry of Legal Entities of the Ministry of Finance (“CNPJ/MF”) under No. 09.379.224/0001-20, with registered head offices in the city of Campinas, State of São Paulo, at Rua James Clerk Maxwell, 315, Federative Republic of Brazil (hereinafter referred to as “BORROWER”), herein represented by its duly appointed officers.

SECTION 1 - DISBURSEMENT

1.1.         LENDER shall lend to BORROWER the amount of USD $6,800,000.00 (six million eight hundred United States Dollars) (the “Disbursed Amount”), to be disbursed in one single installment immediately upon the execution of this Agreement (“Disbursement Date”).

SECTION 2 - REPAYMENT OF PRINCIPAL

2.1.         The principal amount due by the BORROWER under this Agreement shall be due and payable in one single installment, payable within 12 (twelve) months as of the Disbursement Date (the “Repayment Date”).

2.2.         At the LENDER’s option, the principal amount (plus any interest that may have accrued) may be converted into an equity Interest (“Equity Shares”) interest in the BORROWER under the following terms: (a) at such time as the BORROWER consummates its next equity financing transaction such that LENDER received that number of Equity Shares equal to the Disbursed Amount divided by the per share price of the Equity Shares. Additionally, the principal amount (plus any interest that may have accrued); and/or (b) if the LENDER sends a letter to the BORROWER acknowledging the intention to convert the credit into Equity Shares in the BORROWER.

SECTION 3 - INTEREST

3.1.         The principal amount due and payable by the BORROWER to the LENDER under this Agreement shall bear no interest.

SECTION 4 - PAYMENTS

4.1.         All payments due to LENDER shall be made by BORROWER for LENDER’s account, in United States Dollars, in immediately available funds.

4.2.         In the event a payment hereunder is due on a non-banking day in either the city of São Paulo or the city of Emeryville, it shall instead fall due on the next following banking day in both São Paulo and Emeryville.

 

1


4.3.         Repayments shall be made to the LENDER in accordance with instructions to be provided by the LENDER to the BORROWER specifically for this purpose.

SECTION 5 - TAXES

5.1.         The payment of principal hereunder or the payment of any other amount due or that becomes due by the BORROWER hereunder shall be made free and clear of any taxes, levies, deductions, charges and withholdings of any nature imposed by the Brazilian Government or any of its tax authorities (“Brazilian Taxes”). If Brazilian Taxes are required to be withheld or deducted from any such payment, the BORROWER shall pay immediately, for the account of the LENDER, such additional amount as may be necessary to ensure that the net amount actually received by the LENDER is equal to the amount which the LENDER would have received had no Brazilian Taxes been withheld or deducted from such payment.

SECTION 6 - EVENTS OF DEFAULT

6.1.         In the event (i) BORROWER shall file, or be subject of, a petition for bankruptcy or liquidation, or (ii) is generally unable to meet its obligation to its creditors when due, or (iii) fails to punctually pay any amount due hereunder (collectively, “Events of Default”), then anything hereinbefore to the contrary notwithstanding, the totality of the principal or any outstanding part of the principal under this Agreement shall become, at discretion of LENDER, immediately due and payable.

6.2.         Upon the occurrence of an Event of Default the LENDER shall have, in addition to any rights hereunder, all of the rights, powers and remedies provided at law or equity. The failure of LENDER to exercise any right or remedy available hereunder or at law or in equity shall not constitute a waiver of the right to exercise subsequently such option or such other right or remedy.

SECTION 7 - PREPAYMENT

7.1.         BORROWER may prepay this loan in whole or part at any time and from time to time without penalty of any kind.

SECTION 8 - APPLICABLE LAW AND JURISDICTION

8.1.         This Agreement shall be governed by and construed and interpreted in accordance with the laws of the Federative Republic of Brazil.

8.2.         The Courts of São Paulo, State of São Paulo, shall have jurisdiction to decide upon any dispute or conflict arising from the interpretation or performance of this Agreement.

SECTION 9 - AMENDMENTS

9.1.         No amendment or waiver of any provision hereof shall in any event be effective unless the same shall be in writing and signed by LENDER and BORROWER, and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

SECTION 10 - NO WAIVER

10.1.         No failure on the part of the LENDER to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right preclude any other or further exercise thereof or the exercise of any other right.

 

2


SECTION 11 - COUNTERPARTS

11.1.         This Agreement shall be executed by the parties in 2 (two) separate counterparts of equal tenor, each of which when so executed shall be deemed to be an original, and all of which shall together constitute one and the same agreement.

SECTION 12 - SEVERABILITY

12.1.         If any provision hereof is held to be contrary to, prohibited by, or deemed invalid under applicable laws or regulations, such provision shall be inapplicable and deemed omitted to the extent so contrary, prohibited or invalid, but the remainder hereof and thereof shall not be invalidated thereby and shall be given effect so far as possible.

SECTION 13 - SUCCESSORS AND ASSIGNS

13.1.         This Agreement shall be binding upon and inure to the benefit of the LENDER and the BORROWER and their respective successors or assigns.

 

3


IN WITNESS WHEREOF , the parties sign this Loan Agreement in the presence of the undersigned witnesses.

LOGO

 

4

Exhibit 4.04

Execution Version

AGREEMENT

BY

FUNDO MUTUO DE INVESTIMENTO EM EMPRESAS EMERGENTES INOVADORAS STRATUS GC III.

AMYRIS BIOTECHNOLOGIES. INC.,

AMYRIS BRASIL S.A.

AND, AS INTERVENING PARTY,

STRATUS INVESTIMENTOS LTDA.

March  3 rd , 2010


A GREEMENT

This agreement (this “ Agreement ”) is executed on March 3 rd , 2010 (the “ Effective Date ”), by the following parties (all of them, collectively, the “ Parties ” and individually, a “ Party ”):

(1)     F UNDO M UTUO D E I NVESTIMENTO EM E MPRESAS E MERGENTES I NOVADORAS S TRATUS GC III (“ Stratus ”), a fund duly authorized by CVM according to Oficio n° 2607/06, dated November 23, 2006, registered with the CNPJ/MF under n°08.083.268/0001-46, herein represented by Stratus Gestão de Carteiras Ltda. (“ SGC ”), a company incorporated and existing under the laws of Brazil, with head offices in the city of São Paulo, State of São Paulo, at Rua Funchal, 129, 13 th floor, suite B, Vila Olímpia, registered with the CNPJ/MF under n° 09.238.656/0001-11, authorized by CVM for the rendering of management of portfolio services, according to Ato Declaratório n° 9.808, dated April 28, 2008 herein represented in according with its regulations;

(2)     A MYRIS B IOTECHNOLOGIES , I NC . , a company incorporated and existing under the laws of the State of California, United States of America, with head offices at 5980 Hollis Street, Suite 100, Emeryville, California 94608, herein represented by its undersigned representatives (“ ABI ”);

(3)     A MYRIS B RASIL S.A. , a company incorporated and existing under the laws of Brazil, with head offices in the city of Campinas, State of São Paulo, at Rua James Clerk Maxwell, n° 315, Techno Park, CEP 13069-380, registered with the CNPJ/MF under n° 09.379.224/0001-20, herein represented by its undersigned representatives (“ AB ” or the “ Company ”); and, as intervening party;

(4)     S TRATUS I NVESTIMENTOS L TDA . , Stratus’s administrator ( administradora ), a company incorporated and existing under the laws of Brazil, with head offices in the city of São Paulo, State of São Pualo, at Rua Funchal, 129, 13 th floor, suite B, Vila Olímpia, registered with the CNPJ/MF under n° 02.263.285/0001-89, herein represented by its undersigned representatives (“ SIL ”).

W HEREAS :

(A)     The Parties executed, on December 22, 2009, a certain Investment Agreement to regulate the investment, by Stratus, into the Company (the “ Investment Agreement ”);

(B)     In recognition of Stratus’ assistance in introducing AB to potential investors, AB and ABI have agreed to issue to Stratus and to certain of such potential investors, bonus de subscrição (subscription rights) on Shares of AB, under the terms and conditions of this Agreement;

Now, therefore, the Parties hereby decide to enter into this Agreement, which shall be governed by the following terms and conditions:


SECTION ONE

D EFINITIONS AND I NTERPRETATION

 

1.1 Definitions.

The terms defined under this Agreement shall have the meaning attributed to them under the Investment Agreement, except as otherwise expressly determined herein.

 

1.2 Interpretation.

A reference in this Agreement to the singular includes a reference to the plural and vice-versa. The term “including” shall be deemed to be followed by the phrase “but not limited to”. The words “hereof”, “herein”, “hereto”, “hereunder” and similar words refer to this Agreement as a whole. The headings of this Agreement are included for convenience purposes only and are to be ignored in the interpretation of this Agreement.

SECTION TWO

I SSUANCE OF B ONUS DE S UBSCRIÇÃO

2.1      Upon the earlier of (i) the completion (subscription and payment) of an additional investment of no less than R$5,000,000 (five million Reais) by Stratus and by certain investors, who will make their investment by means of a portfolio managed by Stratus (Stratus, along with such investors, the “ Eligible Investors ”), into AB; or (ii) March 16, 2010, AB will grant the Eligible Investors a bonus de subscrição for up to 600,000 (six hundred thousand) Shares of AB.

2.1.1      The final number of Shares to be acquired by the Eligible Investors upon exercise of its rights under the bonus de subscrição will be calculated as follows: (A) (i) the total amount invested (subscribed and paid-in) by the Eligible Investors into the capital of AB, divided by (ii) 15,000,000 (fifteen million), times (B) 600,000 (six hundred thousand). The bonus de subscrição is exercisable only through March 30, 2010, for a price for the issued Shares equal to R$1.00 (one Real).

2.2      ABI hereby irrevocably agrees to take all necessary measures to cause the Company to issue to the Eligible Investors, by no later than March 16, 2010, bonus de subscrição that will give them the right to subscribe and pay-in for additional Shares of AB, pursuant to the provisions above.

2.3      The failure by any of AB or ABI to take all necessary, required or desirable measures to implement the issuance of the bonus de subscrição (and the issuance of Shares of AB to the Eligible Investors, upon exercise of the bonus de subscrição ) shall be considered as an event of default by AB and ABI, indemnifiable under the Investment Agreement.


SECTION THREE

M ISCELLANEOUS

3.1      The provisions of the Investment Agreement and the Shareholders’ Agreement shall apply to this Agreement, mutatis mutandis , to the extent applicable, including but not limited to indemnification, choice of law and dispute resolution (arbitration) provisions.

3.2      For the avoidance of doubt, any Shares acquired by the Eligible Investors pursuant to the exercise of the bonus de subscrição will be deemed as bound to the Shareholders’ Agreement. References to “Shares” in both the Investment Agreement and the Shareholders’ Agreement shall cover any and all Shares acquired by the Eligible Investors, pursuant to the exercise of the bonus de subscrição hereby provided for.

3.3      This Agreement shall be executed in the Portuguese and English languages, provided that the English language shall prevail, including in arbitration and excluding when in proceedings before Brazilian courts, in which the Portuguese version shall prevail.

I N WITNESS hereof, this Agreement is executed in 4 (four) counterparts of the same form and content, in the City of São Paulo, State of São Paulo, Brazil, on March 3 rd , 2010.

(Signature page below)


(Signature page of the Agreement, entered into by Fundo Mútuo de Investimento em Empresas Emergentes Inovadoras Stratus GC III, Amyris Biotechnologies, Inc., Amyris Brasil S.A., and, as intervening party, Stratus Investmentos Ltda., dated March 3 rd , 2010.)

P ARTIES :

/s/  [illegible]                                                 /s/  [illegible]

 

F UNDO M ÚTUO DE I NVESTIMENTO EM E MPRESAS E MERGENTES I NOVADORAS S TRATUS GC III BY ITS M ANAGER S TRATUS G EST Ã O DE C ARTEIRAS L TDA .

/s/  [illegible]

 

A MYRIS B IOTECHNOLOGIES , I NC .

/s/  [illegible]                                                 /s/  [illegible]

 

A MYRIS B RASIL S.A.

/s/  [illegible]                                                 /s/  [illegible]

 

S TRATUS I NVESTIMENTOS L TDA .

W ITNESSES :

 

1.   /s/ Maria Virginia N. do A Mesquita            

  

2.   /s/ Ana Paula S. de Souza                        

Name:  Maria Virginia N. do A Mesquita

  

Name:  Ana Paula S. de Souza

Exhibit 4.05

CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS

DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR

CONFIDENTIAL TREATMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED

WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE

CONFIDENTIAL MATERIAL HAS BEEN FILED SEPARATELY WITH

THE SECURITIES AND EXCHANGE COMMISSION.

 

 

I NVESTMENT A GREEMENT

B Y

R ED M OUNTAIN J ET LLC,

A MYRIS B IOTECHNOLOGIES , I NC .,

A ND

A MYRIS B RASIL S.A.

 

 

M AY  26, 2010

 

 

 

 


I NVESTMENT A GREEMENT

This Investment Agreement (this “ Agreement ”) is executed on May 26, 2010 (the “ Effective Date ”), by the following parties (all of them, collectively, the “ Parties ” and individually, a “ Party ”):

(1)        R ED M OUNTAIN J ET LLC company incorporated and existing under the laws of State of Delaware, with head offices at 16192 Coastal Highway, Lewes, Delaware 19958, United States of America, herein represented by its undersigned representatives (“ Red Mountain ”)

(2)        A MYRIS B IOTECHNOLOGIES , I NC . , a company incorporated and existing under the laws of the State of California, United States of America, with head offices at 5980 Hollis Street, Suite 100, Emeryville, California 94608, Estados Unidos da America herein represented by its undersigned representatives (“ ABI ”); and

(3)        A MYRIS B RASIL S.A. , a company incorporated and existing under the laws of Brazil, with head offices in the city of Campinas, State of Sao Paulo, at Rua James Clerk Maxwell, n° 315, Techno Park, CEP 13069-380, registered with the CNPJ/MF under n° 09.379.224/0001-20, herein represented by its undersigned representatives (“ AB ” or the “ Company ”).

W HEREAS :

(A)        ABI is a technology company focused on the research, development and commercialization of renewable fuel and renewable chemical products (the “ Amyris Renewable Products ”) through the use of a proprietary microbial production technology which converts simple sugars derived from various plant sources, including sugarcane, into specific compounds of interest (the “ Amyris Technology ”);

(B)        ABI established operations in Brazil by forming AB in March of 2008 for the purpose of (i) acquiring an ownership interest in or by any other means partnering with certain sugar and ethanol producers in Brazil and converting a portion of the production capacity of their assets to the production of Amyris Renewable Products, and (ii) providing other Brazilian sugar and ethanol mills with access to the Amyris Technology for the production of Amyris Renewable Products;

(C)        To enable AB to carry out these activities, effective as of March 27, 2008, ABI entered into an intellectual property license with AB (the “ Technology License ”), the terms of which are attached hereto as Exhibit 1 , which provides AB with (i) the exclusive right to use the Amyris Technology to manufacture Amyris Renewable Products in Brazil and the exclusive right to grant manufacturing sublicenses to mills located in Brazil, (ii) the exclusive right to market and distribute Amyris Renewable Products in Brazil, and (iii) the non-exclusive right to market and distribute Amyris Renewable Products outside Brazil;

(D)        On December 22, 2009, Fundo Mútuo de Investimento em Empresas Emergentes Inovadoras Stratus GC III and Stratus Investimentos Ltda. (both referred to, individually or collectively, as “ Stratus ”), ABI and AB entered into an Investment Agreement and a Shareholders’ Agreement under which Stratus has made, to date, an equity investment in AB equal to R$ 10,000,000 (ten million Brazilian Reais) (the “ Stratus Cash Contribution ”);

(E)        To date, ABI has made cash contributions to AB in the amount of US$ 10,000,000.00 (ten million United States dollars) (the “ ABI Cash Contributions ”);


(F)        Red Mountain intends to make a capital contribution of R$ 10,000,000.00 (ten million Reais) into the Company (“ Red Mountain Cash Contribution ” and, together with the Stratus Cash Contribution, the “ Investors Cash Contribution ”);

Now, therefore, the Parties hereby decide to enter into this Agreement, which shall be governed by the following terms and conditions:

SECTION ONE

DEFINITIONS AND INTERPRETATION

1.1        Definitions.

AB ” has the meaning set forth in the Preamble.

AB Share Price ” equals R$ 9.00 (nine Brazilian Reais).

ABI ” has the meaning set forth in the Preamble.

ABI Cash Contributions ” has the meaning set forth in item “E” of the preamble hereto.

Affiliate ” means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries, Controls, or is Controlled by, or is under common Control with, such first Person.

Agreement ” has the meaning set forth in the Preamble and includes all exhibits and schedules hereto.

Amyris Renewable Products ” has the meaning set forth in item “A” of the preamble hereto.

Amyris Technology ” has the meaning set forth in item “A” of the preamble hereto.

Closing ” has the meaning set forth in section 3.2.1 hereto.

Company ” has the meaning set forth in the Preamble.

Control ” of a company means the power to direct the management and policies of such company and shall be presumed to exist upon ownership of securities entitling the holder thereof to exercise more than 50% (fifty percent) of the voting power in the election of directors and in the decision of any strategic matter of such company.

Definitive Documents ” means the Agreement, the Shareholders Agreement and the Minutes of Board of Directors Meeting mentioned in section 3.1 hereof.

Effective Date ” has the meaning set forth in the preamble hereto.

Intellectual Property ” means all (i) trademarks, service marks, trade names, trade dress, domain names, copyrights and similar rights, including registrations and applications to register or renew the registration of any of the foregoing, (ii) letters patent, patent applications, inventions, processes, designs, formulae, trade secrets, know-how, confidential information, computer software, data and documentation, website content, and all similar intellectual property rights, (iii) tangible embodiments of any of the foregoing in any medium, (iv) Information Technology, and (v) licenses of any of the foregoing.

Investors ” shall mean, on the date hereof, Stratus and Red Mountain.


Investors Cash Contribution ” has the meaning set forth in item “F” of the preamble hereto.

Losses ” has the meaning set forth in section 7.2 hereto.

Party ” or “ Parties ” has the meaning set forth in the Preamble.

Person ” means any individual, corporation, partnership, limited liability company, firm, joint venture, association, joint stock company, trust, unincorporated organization, governmental or regulatory body or subdivision thereof, or any other entity.

Rules of Arbitration ” has the meaning set forth in section 10.2 hereto.

Shareholders ” means the shareholders of AB, which shall correspond to ABI and the Investors.

Shareholders’ Agreement ” means the shareholders’ agreement of AB dated December 22, 2009, which shall be amended on the date hereof as to include Red Mountain.

Shares ” shall mean the shares of capital stock of AB.

Red Mountain ” has the meaning set forth in the Preamble.

Red Mountain Cash Contribution ” has the meaning set forth in item “F” of the preamble hereto.

Stratus ” has the meaning set forth in item “D” of the preamble hereto.

Stratus Cash Contribution ” has the meaning set forth in item “D” of the preamble hereto.

Technology License ” has the meaning set forth in item “C” of the Preamble hereto.

Total Contribution Amount ” means that amount equal to (i) the ABI Cash Contribution, plus (ii) the Investors Cash Contribution.

1.2        Interpretation.

A reference in this Agreement to the singular includes a reference to the plural and vice versa. The term “including” shall be deemed to be followed by the phrase “but not limited to”. The words “hereof’, “herein”, “hereto”, “hereunder” and similar words refer to this Agreement as a whole. The headings of this Agreement are included for convenience purposes only and are to be ignored in the interpretation of this Agreement.

SECTION TWO

PURPOSE OF THE COMPANY AND SCOPE OF THIS AGREEMENT

2.1        Purpose of the Company.

The Company’s purpose is to (i) acquire an ownership interest in certain or by any other means partnering with certain sugar and ethanol producers in Brazil and converting a portion of the production capacity of their assets to the production of Amyris Renewable Products, and (ii) provide other Brazilian sugar and ethanol mills with access to the Amyris Technology for the production of Amyris Renewable Products.


2.2        Scope.

The scope of this Agreement is to establish the terms and conditions of the investments to be made in the Company by Red Mountain.

2.3        Shareholders’ Agreement.

Conditions relating to the transfer of the Company’s shares, voting rights, management and public offerings are set forth in the Shareholders’ Agreement.

SECTION THREE

INVESTMENTS IN THE COMPANY BY RED MOUNTAIN

3.1          Subscription.   Upon the terms and subject to the conditions of this Agreement: (a) on May 25th, 2010, AB’s board members shall hold a Board of Directors Meeting of AB and shall resolve on a capital increase in the total amount of R$ 10,000,000.00 (ten million Brazilian Reais), with the issuance of 1,111,111 (one million, one hundred and eleven thousand, one hundred and eleven) new Shares; (b) on the date hereof, Red Mountain shall subscribe for all of those newly issued Shares, for the total subscription price of R$ 10,000,000.00 (ten million Brazilian Reais) to be paid within 5 (five) days as from the date hereof; and (c) on the date hereof, AB’s current Shareholders shall waive its preemptive rights for the subscription of the newly issued Shares to be subscribed by Red Mountain. Each Share shall be worth the AB Share Price.

3.2        Closing.

3.2.1     Timing.

The closing of issuance and subscription of the Shares as mentioned in Section 3.1 above takes place on the date hereof, at the offices of Machado, Meyer, Sendacz e Opice Advogados, in the City of São Paulo, State of São Paulo, Brazil (the “ Closing ”).

3.2.2     Closing.

At the Closing:

 

  (a)

AB shall hold a Board of Directors Meeting and take all of the actions mentioned in section 3.1 above, being the relevant minutes executed by all of the members of the Board of Directors;

 

  (b)

AB shall cause 1,111,111 Shares to be issued to Red Mountain, have a subscription bulletin of the newly-issued shares duly prepared and executed by Red Mountain, and have those shares registered in the name of Red Mountain in the AB’s Share Register Book ( Livro de Registro de Ações Nominativas ); and

 

  (c)

The Shareholders’ Agreement shall be amended as to include Red Mountain.

3.2.3     Deliveries by Red Mountain.

Subject to the terms and conditions set forth in this Agreement, on the date hereof, Red Mountain shall deliver the following to AB (the delivery of which may be waived, in writing, by AB):

 

  (a)

all the Definitive Documents to which Red Mountain is a party and a subscription bulletin duly executed by it;


  (b)

evidence that Red Mountain has been authorized to execute each of the Definitive Document to which it is a party; and

 

  (c)

all other documents, instruments, certificates and writings required to be delivered by Red Mountain pursuant to the Definitive Documents.

3.2.4     Deliveries by AB.

Subject to the terms and conditions hereof, on the date hereof, AB shall deliver the following to Red Mountain (the delivery of which may be waived, in writing, by Red Mountain):

 

  (a)

all the Definitive Documents to which AB is a party duly executed by AB and by the members of its Board of Directors, as the case may be;

 

  (b)

evidence that AB has been authorized to execute each of the Definitive Documents to which they are parties;

 

  (c)

all other documents, instruments, certificates and writings required to be delivered by AB pursuant to the Definitive Documents.

3.2.5     Closing Events.

All of the transactions to occur at the Closing shall be deemed to have occurred simultaneously and neither Party shall have the obligation to consummate any of the transactions referred to in section 3.1 unless all of such actions shall have been consummated simultaneously. All of the transactions and actions listed in sections 3.2.2, 3.2.3 and 3.2.4 above shall be deemed to have taken place simultaneously and no action shall be deemed to have been made until all steps taken at the Closing have been completed in form and substance reasonably satisfactory to Red Mountain and AB, and their respective counsels.

3.2.6     Payment by Red Mountain.

Red Mountain shall deliver to AB the price of the Shares subscribed by Red Mountain by wire transfers of immediately available funds, within 5 (five) days as from the date hereof, to the bank account No. [*], held by AB at agency no. [*] of Banco Itaú BBA S.A. Within said period, Red Mountain shall deliver to all other Parties evidence of the wire transfer of the price of the Shares subscribed by Red Mountain to the referred AB account.

SECTION FOUR

USE OF PROCEEDS

4.1        Use of Proceeds.

The Parties agree that the proceeds raised through the ABI Cash Contribution and the Investors Cash Contribution shall be put towards the funding of projects for production of Amyris Renewable Products in Brazil.

 

*

Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


SECTION FIVE

REPRESENTATIONS AND WARRANTIES

5.1        General Representations and Warranties.

Each of the Parties represents and warrants that:

 

(i)

it has been duly incorporated, is validly existing and in good standing under the laws of its place of incorporation;

 

(ii)

it has full power and authority, and has taken all required corporate and other action necessary to execute and deliver this Agreement and to fulfill its obligations hereunder; the execution, delivery and performance of this Agreement shall not violate any applicable law of its places of incorporation;

 

(iii)

this Agreement constitutes a legal, valid and binding obligation, enforceable against it in accordance with its terms, except (A) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights generally or (B) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies;

 

(iv)

the execution, delivery and performance of this Agreement do not, and the consummation of the transactions contemplated hereby and compliance with the terms hereof will not conflict with, or result in any violation of or default under, or give rise to a right of termination, cancellation or acceleration of any obligation, of any contract, corporate or other documents executed by it; and

 

(v)

no order, consent, approval or authorization of, or registration, declaration or filing with any governmental authority is required to be obtained in connection with the execution, delivery and performance of this Agreement or the consummation of the transactions contemplated hereby.

5.2        Specific Representations and Warranties of AB.

In addition to the representations and warranties set forth in section 5.1 above, the Company hereby represents and warrants that:

 

(i)

AB has all requisite corporate power and authority to own and operate its properties and assets and carry out its business as now conducted;

 

(ii)

AB is not a party to any litigation, suit, action, investigation, proceeding, controversy or claim before any governmental authority that could materially and adversely affect the business;

 

(iii)

AB is not insolvent or unable to pay its debts and has not been held in default by lenders under any debt financing;

 

(iv)

AB has complied with all applicable laws and has not received any written notice nor has any claim alleging failure to comply with any applicable law and no expenditures are or will be required to comply with any law, except, in any case, in a manner that would not be materially adverse to its business and ability to perform under this Agreement; and

 

(v)

as of the date hereof, the Technology License is in full force and effect and AB is not in violation or default of any term or provision set forth therein. AB has neither performed any act, the occurrence of which would result in AB’s loss of any right granted under the Technology License, nor failed to perform any act, the failure of which would result in AB’s loss of any right granted under the Technology License. To the best of AB’s knowledge and belief, after having


 

carried out any investigation required by law, (A) AB owns or has been granted all necessary Intellectual Property rights to conduct it business as currently conducted, and (B) use of the Amyris Technology by AB will not infringe the intellectual property rights of any third party. AB has not received any written communications alleging that AB has violated or, by conducting its business as proposed, would violate, infringe or misappropriate any of the Intellectual Property of any other person or entity.

SECTION SIX

CONFIDENTIALITY.

6.1        Confidentiality.

Each of the Parties hereby undertakes to maintain and to procure that its directors, officers, employees, advisers and contractors maintain in absolute confidentiality, any document or information deemed as confidential by the Parties, including documents, information related to this Agreement and its negotiation process. The provisions of this section shall not apply to any information:

 

(i)

generally available to the public other than through any disclosure by a Party to the other;

 

(ii)

independently received from a third party who is free from any obligations not to disclose it;

 

(iii)

in the possession of the recipient, on a non-confidential basis, prior to its receipt from the other Party (as demonstrated by contemporaneous records);

 

(iv)

regarding which the recipient is bound by applicable laws or regulations to disclose, provided that such Party notify the other Party of such disclosure with a 24 (twenty-four) hour written notice after the requirement by the relevant authority; and

 

(v)

in the case of ABI or AB, information which is provided to actual or prospective investors, underwriters, or acquirers of ABI or AB and/or their affiliates.

SECTION SEVEN

VALIDITY AND INDEMNITY

7.1        Validity.

All representations, warranties and obligations of the Parties set forth in this Agreement shall be valid as from the date hereof and will remain in full force and effect for the respective statute of limitation.

7.2        Indemnity.

Each Party shall indemnify and hold harmless the other Parties and their respective directors, officers, employees, Affiliates, controlling Persons, agents and representatives and their successors and assigns from and against any liability, demand, claim, action, assessment, expense, damage or loss (“ Losses ”) arising from (i) the breach of any of its obligations hereunder and (ii) from the non-compliance with any representation or warranty set forth herein. In addition to the foregoing, AB shall indemnify and hold harmless the other Parties and their respective directors, officers, employees, Affiliates, controlling Persons, agents and representatives and their successors and assigns from and against any Losses arising


from any illegal act, fact or omission of AB and of any Person who may have served as manager of AB, acting in such capacity within the applicable corporate powers, occurred prior to the Closing.

The right to indemnification arising from the breach of either Party’s obligation hereunder or from the non-compliance with any representation and warranty set forth herein will not be affected by any investigation conducted or knowledge acquired at any time, whether before or after the Closing, with respect to the accuracy or inaccuracy of or compliance with, any such representation, warranty, covenant or obligation.

7.2.1     Payments .

 

  (a)

Immediately after having knowledge of any act or fact giving rise to an indemnification under this section 7.2, the applicable Party shall send to the other Parties hereto a notice to that effect with a description of such act or fact and a copy of any relevant document.

 

  (b)

If, despite their best efforts, the Parties are not able to reach a mutually acceptable settlement deemed reasonable by all Parties within fifteen (15) days from the receipt of such notice, the applicable indemnified party shall then have forty-eight (48) hours, counted from the end of the negotiations mentioned herein, to send a notice to the indemnifying party, in which such indemnified party shall state whether it wishes to start an indemnification claim and, if so, it shall include reasonable details of the nature and basis for such indemnification claim and the total amount related thereto. Upon receipt of such response notice, the indemnifying party shall have seventy-two hours to either pay or contest the payment of the indemnification claimed by the applicable indemnified party.

 

  (c)

If (A) the indemnifying party contests and does not make the claimed payment, or (B) the indemnified party contests the payment made by the indemnifying party of the indemnification claimed, then the indemnified party may start an arbitration procedure against the indemnifying party, in accordance with section 10.2 of this Agreement. The indemnifying party shall be required to pay any such indemnification within 48 (forty-eight) hours counted as of the date on which a final and non-appealable decision or arbitral award is rendered in favor of the indemnified party with respect to the claim started by the indemnified party against the indemnifying party or as of the date on which a settlement, agreement or compromise is made with respect thereto.

 

  (d)

All payments to the applicable indemnified party shall be in immediately available funds and any indemnification payment must be grossed up to cover any and all taxes payable by the applicable indemnified party on account of such payment.

 

  (e)

In the event the indemnifying party has knowledge of any act or fact giving rise to an indemnification under this section 7.2 and fails to deliver a notice in terms set forth herein to the applicable indemnified party, it shall further indemnify the applicable indemnified party for any additional Losses that such a delay may have caused.

7.2.2     Legal Action or Administrative Proceeding

 

  (a)

In the event that any legal action or administrative proceeding that could give rise to an indemnification under this section 7.2 is filed against or made upon any indemnified party, such indemnified party shall notify the indemnifying party, in writing, as soon as reasonably practical, but in no event later than one third (1/3) of the legal term to present


 

a defense for the respective legal action or administrative proceeding. Such notice shall contain, in reasonable detail, a description of the amounts being claimed and the basis thereto.

 

  (b)

The indemnifying party may either decide to present a defense, counterclaim or pay the amount sought under the legal action or administrative proceeding (including to post a bond for such a defense, if so required), without prejudice to item “f’ below.

 

  (c)

The indemnifying party shall bear any and all costs incurred, including reasonable attorney’s fees and court fees, guarantees, as well as expenses incurred in relation to the defense of the legal action or administrative proceeding. In the event the indemnified party receives an order issued by any governmental authority requesting it to make a judicial deposit (or any similar payment) in connection with such legal or administrative proceeding, then such deposit amount shall be reimbursed by the indemnifying party within 48 (forty-eight) hours as of such payment by the indemnified party.

 

  (d)

If the indemnifying party assumes the defense of any legal action or administrative proceeding in accordance with the terms of the preceding sentence, the indemnifying party shall not be entitled to agree to any settlement, agreement or compromise with respect thereto without the prior written consent of the applicable indemnified party, which consent shall not be unreasonably withheld. The applicable indemnified party shall not be required to agree to any settlement, agreement or compromise that (i) does not contain a full release with respect to the respective legal action or administrative proceeding, or (ii) provides for any injunctive or other non-monetary relief.

 

  (e)

In the event that the indemnifying party does not present a defense, counterclaim or pay the amount sought under the legal action or administrative proceeding and notifies the applicable indemnified party within two thirds (2/3) of the period available for the presentation of the relevant defense, the applicable indemnified party shall have the right to assume the defense of the legal action or administrative proceeding. The indemnifying party shall promptly and immediately reimburse the applicable indemnified party for any and all expenses incurred in relation to said Legal Action, whether during an administrative or judicial proceeding, including, but not limited to attorneys’ expenses, court fees, administrative fees and penalties. If the applicable indemnified party assumes the defense of any legal action or administrative proceeding in accordance with the terms of the preceding sentence, such indemnified party shall be entitled to agree to any settlement, agreement or compromise with respect thereto without the prior written consent of the indemnifying party.

 

  (f)

Notwithstanding the above, if the indemnifying party believes the legal action or administrative proceeding filed against or made upon any indemnified party should not give rise to an indemnification under this section 7.2, then the indemnified party may start an arbitration procedure against the indemnifying party, as set forth in section 7.2.1., item “c”, above. In that case, all costs and expenses incurred by the indemnified party in connection with such legal action or administrative proceeding shall be reimbursed by the indemnifying party after the date on which a final and non-appealable decision or arbitral award is rendered in favor of the indemnified party, also as set forth in section 7.2.1., item “c”, above.


SECTION EIGHT

TERMINATION

This Agreement may not be terminated except by the written consent of all the Parties.

SECTION NINE

GENERAL PROVISIONS

9.1        Entire Agreement.

This Agreement shall constitute the entire agreement between the Parties hereto and supersede and replace all other agreements and understandings, verbal or written, among the Parties with respect to the subject matter of this Agreement. No amendment or modification of any provision of this Agreement shall be effective unless it is done in writing and signed by each of the Parties.

9.2        Severability.

The invalidity of one or more provisions of this Agreement shall not affect the validity of this Agreement as a whole unless the invalid provision was of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without such invalid provision. The Parties shall negotiate in good faith to substitute any invalid provisions with other provisions that may substantially achieve their original intentions.

9.3        Waiver.

Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The failure of any Party at any time to enforce any provision of this Agreement shall not in any way affect its rights to require performance thereof, nor shall the waiver of any breach of any provision hereof be taken or held to be a waiver of any succeeding breach of any such provision or as a waiver or a novation ( novação ) of the provision itself.

9.4        Assignment.

No Party may directly or indirectly transfer any of its rights and obligations under this Agreement to any third party, without the prior written consent of the other Parties.

9.5        Costs and Expenses.

Each Party shall bear all costs and expenses incurred by it in connection with the preparation, negotiation and delivery of this Agreement.


9.6        Notices.

All notices, requests, claims and other communications hereunder shall be in writing and communicated to the receiving party either by hand, or sent by registered mail, electronic mail or facsimile and addressed as follows or to such other addresses as may from time to time be notified by any Party to the other Party:

If to ABI :

AMYRIS BIOTECHNOLOGIES, INC.

Address: 5885 Hollis Street, Suite 100, Emeryville, California 94608, USA

Telephone: +1 510 740-7416

Fax: +1 510 842 1460

E-mail: tompkins@amyris.com

Attn: Tamara Tompkins - General Counsel

If to Red Mountain :

PEDRO PAULO FALLEIROS DOS SANTOS DINIZ

Address: Rua Jerônimo da Veiga, 384, 3rd floor

Telephone: +55 11 3705-5161

Fax: + 55 11 3702-5112

E-mail: pedro@ppdholding.com

If to AB :

AMYRIS BRASIL S.A.

Address: Rua James Clerk Maxwell, 315, Campinas, SP, Brazil

Telephone: +55 19 3783-9450

Fax: +55 19 3283-0005

E-mail: collier@amyris.com

Attn: Roel Collier

9.6.1     Delivery of Notice.

Any notice served by hand shall be deemed to have been served upon delivery. Any notice served by prepaid registered mail shall be deemed to have been served upon evidenced receipt. Any notice served by e-mail or facsimile shall be deemed to have been served when sent, provided that evidence has been produced showing that the notice has been sent to the facsimile number/e-mail address, as indicated in this Agreement.

9.6.2     Change of Data.

In case of any change of data, if the new information is not notified by the relevant Party to the other Party, all notices sent to the previous addresses shall be deemed to have been duly served.

9.7        Language.

This Agreement shall be executed in the English and Portuguese languages, provided that the English version shall prevail, including in arbitration, and excluding when in proceedings before Brazilian courts, in which the Portuguese version shall prevail.


SECTION TEN

GOVERNING LAW AND DISPUTE RESOLUTION

10.1        Governing Law.

This Agreement shall be governed by and construed in accordance with the laws of Brazil.

10.2        Dispute Resolution.

Any dispute, controversy or claim by and among the Parties to this Agreement, arising out of or relating to this Agreement, or the breach, termination or validity hereof, shall be settled by arbitration in accordance with the Rules of Arbitration of the Câmara de Comércio Brasil-Canadá (the “ Rules of Arbitration ”). The decision of the arbitrators shall be final and binding upon the Parties with no further appeal, recourse or review. Until such decision, the Parties agree to keep the arbitration procedure on a confidential basis, except to the extent necessary for any interim or conservatory measures permitted under the Rules of Arbitration.

10.2.1     Arbitration Place.

The place of arbitration shall be in the City of São Paulo, State of São Paulo, Brazil, where the arbitration award shall be rendered.

10.2.2     Arbitration Language.

The language of the arbitration shall be English.

10.2.3     Judicial Measures.

Without prejudice to this section 10.2 and without limiting any other powers the arbitrators may have, the Parties remain fully entitled to request judicial measures: (a) in order to obtain preliminary and urgent measures ( medidas cautelares ) prior to the formation of the arbitral tribunal, and such judicial recourse shall not be interpreted as a waiver of the arbitration as set forth in this section; and (b) to enforce any arbitral decision, including the final award. For that purpose, the Parties elect the courts of the city of São Paulo, State of São Paulo, Brazil, being waived any other no matter how privileged it may be. The Parties recognize that any provisional or urgent matter granted by judicial courts shall be, necessarily, reviewed by the arbitral tribunal, which shall decide on its ratification, revision or cancellation.

IN WITNESS hereof, this Agreement is executed in 3 (three) counterparts of the same form and content, in the City of São Paulo, State of São Paulo, Brazil, on May 26, 2010.

PARTIES:

 

/s/ [illegible]

RED MOUNTAIN JET LLC
/s/ [illegible]
AMYRIS BIOTECHNOLGOIES, INC.


/s/ [illegible]
AMYRIS BRASIL S.A.

WITNESSES:

 

1. /s/ Luana Komatsu

   

2. /s/ Gabriel Aldallah Mundinn

Name: /s/ Luana Yo Ko Vieira Komatsu

   

Name: /s/ Gabriel Aldallah Mundinn


LIST OF EXHIBITS

 

1.

Technology License

 

2.

Shareholders Agreement


EXHIBIT 1

LICENSE AGREEMENT BETWEEN ABI AND AB


LICENSE AGREEMENT

This LICENSE AGREEMENT (the “ Agreement ”), effective as of March 27, 2008 (the “ Effective Date ”), is made by and between AMYRIS BIOTECHNOLOGIES, INC. , a California corporation with a principal place of business at 5885 Hollis St., Ste. 100, Emeryville, CA 94608 (“ ABI ”), and AMYRIS PESQUISA E DESENVOLVIMENTO DE BIOCOMBUSTIVEIS LTDA. , a company organized and existing as a “sociedade limitada” under the laws of Brazil with headquarters in the city of Campinas, state of São Paulo, at Rua James Clerk Maxwell, n° 315, Techno Park, CEP 13069-380, registered with the CNPJ/MF under n° 09.379.224/0001-20 (“ AB ”). ABI and AB are each a “ Party ” hereto, and collectively are the “ Parties .”

BACKGROUND

WHEREAS, ABI is a technology company which is focused on the research, development and commercialization of a variety of renewable fuel and chemical products;

WHEREAS, ABI has developed a proprietary microbial production technology which converts sugars derived from various plant sources, including sugar cane, into renewable fuel and chemical products;

WHEREAS, ABI formed AB as a wholly owned subsidiary with the intent of having AB hold certain rights to such technology in Brazil;

WHEREAS, AB intends to (a) acquire, own and manage sugar cane and ethanol mills in Brazil, and to convert such mills to the production of renewable fuel and chemical products using such technology; and (b) enter into commercial arrangements with other mills hi Brazil pursuant to which such mills would convert a portion of their assets to the production of renewable fuel and chemical products using such technology;

WHEREAS, ABI desires to license to AB, the right to use certain ABI technology and the right to use certain ABI trade names and ABI trademarks (a) on an exclusive basis, to develop, make, have made, use, sell, distribute and market certain renewable fuel and chemical products in Brazil, with the right to grant limited sublicenses to such technology, trade names and trademarks to mills located in Brazil, and (b) on a nonexclusive basis, to sell, distribute and market certain renewable fuel and chemical products outside of Brazil, in each case under the terms and conditions set forth herein, and AB desires to obtain such licenses; and

WHEREAS, in consideration of the licenses granted herein, AB desires to (a) license back to ABI the right to use any developments and improvements derived from or related to the ABI technology that. are or become owned or controlled in whole or in part by AB outside of Brazil for any purpose on the terms and conditions set forth herein (subject only to AB’s nonexclusive license rights), and (b) permit ABI to assist patent prosecution and enforcement matters relating to such developments and improvements, under the terms and conditions set forth herein, and ABI desires to obtain such a license and such rights:

NOW, THEREFORE, on the terms and subject to the conditions set forth herein, the Parties hereby agree to enter into this Agreement upon the following terms and subject to the following conditions:


ARTICLE 1

DEFINITIONS

For purposes of this Agreement, the following definitions will apply:

1.1        “ ABI Base Technology ” means Patents, Production Strains and Know-How associated with such Patents and Production Strains, in each case that are (a) necessary for the development, manufacture, rise, sale and distribution of Renewable Fuel Products and Renewable Chemical Products Brazil and (b) Controlled by ABI as of the Effective Date of this Agreement. Patents and Production Strains within the ABI Base Technology are listed on Schedule 1 attached hereto and incorporated herein by reference.

1.2        “ ABI Improvements ” means any Patents, Production Strains and Know-How associated with such Patents and Production Strains comprising Improvements that (a) are necessary for the development, manufacture, use, sale and distribution of Renewable Fuel Products and Renewable Chemical Products in Brazil and (b) become Controlled by ABI during the Term of this Agreement. Schedule I will be amended by the Parties from rime to time to reflect the inclusion of Patents and Production Strains included within ABI Improvements.

1.3        “ ABI Technology ” means the ABI Base Technology and the ABI Improvements.

1.4         “AR Improvements ” means any Improvements and any other Patents, Production Strains or Know-How that are (a) Controlled by any AR Party as of the Effective Date or become Controlled at any time during the Term of this Agreement and for a period of five years after expiration of the Term of this Agreement, or (b) made, developed or created by or on behalf of any AB Party, or their employees or agents, solely or jointly with any Third Party, during the Term of this Agreement and for a period of five years after expiration of the Term of this Agreement in each case in connection with the exercise of its rights hereunder or otherwise through use of based upon, derived from or incorporating any ABI Technology. AB Improvements shall include, without limitation: (i) Improvements to the ABI Technology, (ii) Improvements to Joint Improvements, and (iii) Improvements to other AB Improvements,

1.5         “AB Parties ” means AB, its successors and permitted assigns and its or their permitted sublicensees.

1.6          “Confidential Information ” has the meaning set forth in Section 5.1.

1.7         “Control ” (including any variations such as “Controlled” or “Controlling”) means, in the context of Patents, Production Strains, Know-How, Improvements and Licensed Marks, rights to such Patents, Production Strains, Know-How, improvements and Licensed Marks sufficient to grant the applicable license or assignment under this Agreement without violating the terms of any arrangement with any Third Party.

1.8         “Improvements ” means all enhancements, modifications and revisions, whether or not protectable under intellectual property laws, based upon, derived from or incorporating any ABI Technology or other applicable technology in which ABI holds any right, title or interest.

1.9         “Joint Improvements ” means any Patents, Production Strains or Know-How that are made, developed or created-jointly by or out behalf of ABI and by or on behalf or any AB Party, or their employees or agents, during the Term of this Agreement and for a period of five years after expiration of the Term of this Agreement.


1.10         “Know-How ” means non patented information and tangible materials, including: (a) technical and non-technical data, specifications, formulae, compounds, formulations, assays, designs, results, information, conclusions, interpretations, inventions, developments, discoveries, ideas, improvements, and trade secrets; (b) methods, databases, tests, procedures, processes and techniques; (c) biological material, including strains, progeny, clones, vectors, recombinant DNA and samples; and (d) other know-how and technology.

1.11         “Licenses ” has the meaning set forth in Section 2,1.

1.12        “ Licensed Marks ” means, collectively, (a) the trade name “Amyris”; (b) the logo set forth on Schedule 2, attached hereto and incorporated herein by reference; (c) the additional trademarks listed on Schedule 3, attached hereto and incorporated herein by reference; and (d) such future marks as determined by ABI in its sole discretion from time to time ns appropriate for the development, manufacture, use, sale or distribution of Renewable Fuel Products and Renewable Chemical Products in Brazil. Schedule 3 and Schedule 4 (Requirements of Licensed Marks Use), attached hereto and incorporated herein by reference will be amended by the Parties from time to time to reflect the inclusion of such future marks and appropriate requirements for lie use of such marks.

1.13        “ Patents ” means any patents and patent applications, together with all additions, divisions, continuations, continuations-in-part, substitutions, reissues, re-examinations, extensions, registrations, patent term extensions, supplemental protection certificates, renewals, and the like with respect to any of the foregoing.

1.14         “Production Strain ” means recombinant yeast that has been genetically engineered by or on behalf of ABI (which shall be deemed to include any Production Strains made by AB on behalf of ABI1) to make a five carbon (CS), ten carbon (C10), or a fifteen carbon (C15) isoprenoid product during fermentation.

1.15         “Term ” has the meaning set forth in Section 9.1.

1.16         “Third Party ” means any person, corporation, joint venture or other entity, other than ABI or AB or their respective permitted successors and assigns.

1.17         “Renewable Chemical Products ” means a compound made directly by a Production Strain for use in industrial operations or in the commodity chemicals industry as a raw material which is then converted to a product of interest by formulation or by a chemical change in the compound. The term excludes use of a compound made directly by a Production Strain, including derivatives thereof, for use in pharmaceutical formulations, drugs and as ingredients in food.

1.18         “Renewable Fuel Products ” means a combustible material that (a) is used to generate energy (heat or power), and (b) is derived from a product made by a Production Strain ,


ARTICLE 2

TECHNOLOGY LICENSES

2.1         ABI Technology License Grant .

 

  (a)

Grant . Subject to the terms and conditions of this Agreement, ABI hereby grants to AB (i) an exclusive royalty-free right to the ABI Technology to develop, make, have made, use, sell, distribute and market Renewable Fuel Products and Renewable Chemical Products in Brazil; and (ii) a non-exclusive royalty-free right to the ABI Technology to sell, distribute and market Renewable Fuel Products and Renewable Chemical Products outside of Brazil. The foregoing grant is achieved by a grant of multiple licenses on a Patent-by-Patent and a Production Strain-by-Production Strain basis (collectively, the “ Licenses ”), whereas each such License includes the Know-How associated with the Patent or Production Strain covered by such License. The foregoing Licenses include the right to grant limited sublicenses accordance with Section 2.2.

 

  (b)

Term . The term of each License will be determined un a License-by-License basis as follows: (i) each License to a Patent will expire upon the expiration of the term of the applicable Patent, unless earlier terminated as permitted herein; and (ii) each License to a Production Strain will expire upon the expiration of the applicable Patent, if any, covering such Production Strain or, if there is no Patent covering such Production Strain, then upon expiration of the last License to a Patent hereunder.

2.2         Sublicense Rights to ABI Technology .  AB may grant limited sublicenses under the Licenses granted under Section 2.1 to sugar cane and ethanol mills in Brazil that are being Converted either by AB in its capacity as a shareholder in such mills, or by the mill itself pursuant to a commercial agreement with AB, to the production of Renewable Fuel Products and Renewable Chemical Products in Brazil. Each sublicense will be in a form approved in advance by ABI, as determined by ABI in its sole discretion and may be granted only under the following terms and conditions unless otherwise agreed to by ABI in writing in its sole and absolute discretion:

 

  (a)

Each such sublicense will only permit the sublicensee to develop, make and have made Renewable Fuel Products and Renewable Chemical Products in Brazil (or for that subset of uses and for such subset of Renewable Fuel Products and Renewable Chemical Products that ore determined by AB in such sublicense.)

 

  (b)

Each such sublicense will not conflict with, and will be expressly subordinate to, the terms and conditions of this Agreement. In the event of a conflict, the terms of this Agreement shall prevail.

 

  (c)

Each such sublicense will prohibit the sublicensee from further sublicensing.

 

  (d)

AB will remain responsible to ABI under each sublicense for all the obligations of AB under this Agreement.

 

  (e)

Upon the expiration or earlier termination of this Agreement, at the option of ABI, all sublicenses granted hereunder will either continue with ABI succeeding AB as licensor, or automatically terminate, as determined by ABI in its sole discretion.


  (f)

Promptly following the execution of each sublicense, AB will provide ABI with an executed copy of such sublicense agreement.

For the avoidance of doubt, if AB desires to transfer any ABI Technology, including without limitation any Production Strain or any other tangible biological material received from ABI or derived from any materials received front ABI, to any Third Party to pursue development or scale-up work consistent with the license rights granted hereunder, such transfer must also be documented on the terms required for sublicenses set forth above.

2.3         AB License Grant Back to AB Improvements .  AB hereby grants to ABI an exclusive fully paid-up, perpetual, irrevocable, royalty-free right and license, including the right to grant sublicenses in ABI’s sole and absolute discretion, to use the AB Improvements on an exclusive basis (subject only to AB’s nonexclusive license rights granted by ABI hereunder) to develop, make, have made, use, sell, have sold, distribute, have distributed and market Renewable Fuel Products and Renewable Chemical Products and any other purpose whatsoever worldwide, excluding Brazil. AB will not grant rights to any Third Party to AB Improvements inconsistent with this Agreement.

2.4         AB License Grant Back to AB Interest in Joint Improvements .  AB hereby grants to ABI an exclusive (even as to AB) fully paid-up, perpetual, irrevocable, royalty-free right and license, including the right to grant sublicenses in ABI’s sole and absolute discretion, to use AB’s interest in the Joint Improvements (subject only to AB’s nonexclusive license rights granted by ABI hereunder) (a) worldwide, excluding Brazil, to develop, make, have made, use, sell, have sold, distribute, have distributed and market Renewable Fuel Products and Renewable Chemical Products and for any other purpose, whatsoever and (b) in Brazil, for any purpose other than developing, making, having made, using, selling, having sold, distributing, having distributed and marketing Renewable Fuel Products and Renewable Chemical Products. AB will not grant rights to any Third Party to AB’s interest in the Joint Improvements inconsistent with this Agreement. For the avoidance of doubt, the Parties hereby affirm that they (i) intend for the foregoing provisions to mean that AB shall grant back to ABI the rights AB otherwise have to use AB’s interest in the Joint Improvements for the purposes described in clauses (a) and (b; (ii) agreed to such rights after due diligence, careful deliberation and consultation with counsel; and (iii) agree that neither Party shall require the permission of the other Party to use the rights granted to such other Party in this Section 2.4 notwithstanding that the law of jurisdictions other than the State of California, United States of America might otherwise grant such other Party pre-approval, prior consent or other similar blocking or permission rights.

2.5         No Other Rights .  Except as expressly granted herein, no right, title or interest is granted by ABI to AB. In addition, any license granted by ABI under this Agreement is subject to applicable laws and regulations, including United States laws and regulations as shall front time to time govern the license and delivery of technology and products between the United States and other countries, including the United States Foreign Assets Control Regulations, Transaction Control Regulations and Export Control Regulations, as amended, and any successor legislation issued by the Department of Commerce, International Trade Administration, Office of Export Licensing, which laws and regulations may restrict ABI’s ability to grant the lice-use or deliver the ABI Technology. In the event any such restrictions are found to apply, the Parties will work together in good faith to comply with requirements to lift or otherwise satisfy such restrictions. The costs of any activities in connection therewith will be borne by AB.


ARTICLE 3

TRADEMARK LICENSE GRANTS

3.1         Grant of Trademark License .  Subject to the terms and conditions of this Agreement, ABI hereby grants to AB an exclusive license, without the right to sublicense, to use the Licensed Marks in Brazil to practice the ABI Technology to develop, make, have made, use, sell, distribute and market Renewable Fuel Products and Renewable Chemical Products in Brazil. The term of such license will expire, unless earlier terminated as permitted herein, upon the earlier of (a) fifteen (15) years from the Effective Date, and (b) the expiration of all of the Licenses granted in Section 2.1,

3.2         Acknowledgment of Rights .  ABI acknowledges that ABI is the owner of the Licensed Marks, and that all use of the Licensed Marks by AB inures to the benefit of ABI. AB further acknowledges that the Licensed Marks embody substantial goodwill and enjoy favorable public recognition, and that ABI’s rights therein constitute valuable assets of ABI.

3.3         Quality Control .  In order to protect the goodwill and reputation associated with the Licensed Marks, AB agrees that AB will provide ABI with representative specimens of advertising and promotional materials showing AB’s use of the Licensed Marks and will use the Licensed Marks in publicly disseminated materials in the manner set forth in the requirements of Requirements of Licensed Marks Use set forth on Schedule 4 attached hereto. Any deviation from the Requirements of Licensed Marks Use must be approved by ABI in writing.

3.4         Trademark Maintenance .  During the Term of this Agreement, ABI, at its own cost, will be responsible for maintaining and renewing registrations for the Licensed Marks. AB will cooperate with ABI in its efforts to protect the Licensed Marks in Brazil, including exerting its best efforts to exploit the Licensed Marks so as to maintain their validity in the territory of Brazil. ABI will timely notify AB of its decision not to maintain registration for any of the Licensed Marks in Brazil. If registration of AB as a registered user of the Licensed Marks is required, AB will bear all expenses, including government fees and attorney and trademark agent lees, relating to such registration.

3.5         Licensed Mark Infringement .

 

  (a)

Enforcement of Licensed Marks .  If either Party becomes aware of any use by any Third Party of any name, mark or designation that infringes or is likely to infringe any of the Licensed Marks in Brazil, that Party will notify the other Party promptly in writing of the actual or threatened infringement. Whether to take action will be in ABI’s sole discretion. If requested by ABI, AB will join with ABI at ABE’s expense in such action as ABI in its reasonable discretion nay deem advisable for the protection of its rights. In connection therewith, AB will cooperate to the extent reasonably required by ABI to stop such infringement or act, and, if so requested by ABI, will join with AB as a party to any action brought by ABI for such purpose. ABI will have full control over any action taken, including, without limitation, the right to select counsel, to settle on any terms it deems advisable in its discretion, to appeal any adverse decision rendered in any court, to discontinue any action taken by it, and otherwise to make any decision in respect thereto as it in its discretion deems advisable. Any recovery as a result of such action shall belong solely to ABI.

 

  (b)

Infringement of Third Party Marks .  If AB receives any written notice or claim that the use by AB of the Licensed Marks infringes the intellectual property rights of a Third Party, then AB will promptly so notify ABI in writing. ABI shall have the right, but not


 

the obligation, to defend against any such claim. If requested by ABI, AB will join with ABE at ABI’s expense in such action as ABI in its reasonable discretion may deem advisable for the protection of its rights. In connection therewith, AB will cooperate to the extent reasonably required by ABI, and, if so requested by ABI, will join with ABI as a party to any action brought by ABI for such purpose. ABI will have full control over any action taken, including; without limitation, the right to select counsel, to settle on any terms it deems advisable in its discretion, to appeal any adverse decision rendered in any court, to discontinue any action taken by it, and otherwise to make any decision in respect thereto as it in its discretion deems advisable,

ARTICLE 4

DILIGENCE; REPORTING

4.1         Diligence .  AB will use commercially reasonable efforts, consistent with prudent and reasonable business practices and judgment, to develop, make, and have made, directly or through its permitted sublicensees, and to use, sell, distribute and market Renewable Fuel Products and Renewable Chemical Products in Brazil. AB shall permit auditors or inspectors appointed by ABI to have access during ordinary business hours and as may be necessary, to monitor compliance of AB with this Agreement.

4.2         AB Reporting .  During the Term of this Agreement, AB will keep ABI informed as to the activities of AB and its sublicensees with respect to the development, manufacture, use, sale or distribution of Renewable Fuel Products and Renewable Chemical Products or otherwise involving the ABI Technology. In connection therewith, AB will deliver to ABI, and will cause its sublicensees to deliver to ABI, no less frequently than quarterly, a written report summarizing in reasonable detail progress with respect to such activities since the last such report, including without limitation any AB Improvements and Joint Improvements which have arisen during such time period.

4.3         ABI Reporting .  During the Term of this Agreement, ABI will keep AB informed annually as to any ABI Technology or marks, trade names or trademarks that have become subject to any license under this Agreement.

ARTICLE 5

CONFIDENTIALITY

5.1         Confidential Information .  The Parties understand and agree that in the performance of this Agreement each party may have access to proprietary or confidential data or information of the other Party, including, but not limited to, trade secrets, intellectual property, services and/or the business, finances, or affairs of either Party (“ Confidential Information ”). Confidential Information may be communicated orally, visually, in writing or in ally other recorded or tangible form. All data and information shall be considered to be Confidential Information hereunder (i) if either Party has marked them as such, (ii) if either Party, orally (to be reduced to writing) or in writing, has advised the other Party of their confidential nature, or (iii) if, due to their-character or nature, a reasonable person in a like position and under like circumstances would treat them as confidential.

5.2          Disclosure of Confidential Information .  Each Party will maintain in confidence and not disclose to any third party any Confidential Information of the other Party. Each Party will use the Confidential Information of the other Party only for the purposes of this Agreement. Each Party will ensure that access to Confidential Information will be provided to its employees and officers only on a need to know basis if such employees and/or officers must be familiar with the same in connection with the performance of


their duties. Such employees and officers must be informed that the Confidential Information may be used only as permitted under this Agreement and must be obligated in writing to abide by such Party’s obligations under this Agreement. The receiving party shall immediately notify the disclosing party of any unauthorized disclosure or use of any Confidential Information by the disclosing party that comes to receiving party’s attention and shall take all action that the disclosing party reasonably requests to prevent any timber unauthorized use or disclosure thereof. AB will cause each and every officer and employee and worker of AB who is likely to acquire knowledge of any Confidential Information of ABI to keep the confidentiality of such Confidential Information and agrees to prepare a written statement of undertaking agreeing that it will comply with the provisions of this Article 5.

5.3         Exceptions .  The provisions of this Article 5 will not apply, or will cease to apply, to Confidential Information supplied by the disclosing party if disclosing party demonstrates by written evidence that (i) was in the receiving party’s possession without restriction on use or disclosure prior to receipt from the disclosing Party as shown by files existing at the time of disclosure, (ii) has come into the public domain other than through a breach of confidentiality by the receiving party, (iii) was developed independently by employees of the receiving party or by persons who have not had access to the disclosing party’s Confidential Information; (iv) was or is lawfully obtained, directly or indirectly, by the receiving party from a third party under no obligation of confidentiality, or (v) is required to be disclosed pursuant to any statutory or regulatory provision or court order; provided, however, that the receiving party provides notice thereof to the disclosing party, together with the statutory or regulatory provision, or court order, on which such disclosure is based, as soon as practicable prior to such disclosure so that the disclosing party has the opportunity to obtain a protective order or take other protective measures as it may deem necessary with respect to such information.

5.4         Survival .  The obligations of the Parties under this Article 5 shall remain in effect for five (5) years from the dale of termination or expiration of this Agreement.

ARTICLE 6

INTELLECTUAL PROPERTY; PATENT PROSECUTION AND MAINTENANCE

6.1         Ownership of Patents and Know-How .

 

  (a)

ABI Technology .  As between the Parties, ABI will own all right, title and interest in and to the ABI Base Technology and the ABI Improvements, subject only to the licenses set forth herein.

 

  (b)

AB Improvements .  As between the Parties, AB will own all right, title and interest in and to the AB Improvements, subject only to the licenses set forth herein and the rights conferred in Section 6.2.

 

  (c)

Joint Improvements .  The Parties will jointly own own all right, title and interest in and to the Joint Improvements, subject only to the licenses set forth herein and the rights conferred in Section 6.2.

6.2         Patent Strategy and Prosecution . ABI shall have the sole right to (i) determine the process for protecting The ABI Technology, the Joint Improvements and the AB Improvements worldwide, including whether or not to obtain patent protection and in what countries, and (ii) at its own expense, but without obligation, to prepare, file, prosecute and maintain throughout the world any and all Patents claiming or relating to the ABI Technology, the Joint Improvements and the AB Improvements. For the avoidance of doubt, the Parties hereby affirm that they intend for the foregoing provisions to apply and be upheld as an


agreement reached between the Parties after due diligence, careful deliberation and consultation with counsel, notwithstanding that the law of jurisdictions other than the State of California, United States of America might otherwise not permit, uphold or otherwise enforce the granting of such rights.

6.3         Cooperation and Assistance .  AB will provide to ABI and/or its designee. and AB will cause any and all relevant AB Parties to provide to ABI, as reasonably requested by ABI and at ABI’s expense (including reasonable attorney’s fees and other reasonable legal expenses), full cooperation and assistance (including the execution and delivery of any and all affidavits, declarations, oaths, exhibits, assignments, powers of attorney, or other documentation as may be reasonably required): (i) in order to allow ABI to apply for, register, obtain, maintain, defend, and enforce the Patents for which ABI has control under Section 6.2 and/or its rights therein: (ii) in connection with the prosecution or defense of any interference, opposition, re-examination. reissue, infringement, declaratory judgment, or other judicial or legal administrative proceedings that may arise in connection with such Patents (including the validity and/or enforceability thereof) and/or any Production Strains, Know-How or other intellectual property owned by ABI (including testifying as to any facts, production of any documents, responses to any requests or demands relating to such Patents, Production Strains and/or Know-How); and/or (iii) in order to perfect the delivery, assignment, and conveyance to ABI, its successors, assigns, and nominees, of the entire right, title, and interest in and to all ABE Technology.

6.4         Enforcement of Patents .  In the event either Party becomes aware of any activity that infringes or is likely to infringe the ABI Technology, the AB Improvements or the Joint Improvements, that Party will notify the other Party promptly in writing of the actual or threatened infringement. Whether to take action will be in ABI’s sole discretion whenever the infringement involves ABI’s rights. If requested by ABI, AB will join with ABI at ABI’s expense in such action as ABI in its reasonable discretion may deem advisable for the protection of its rights. In connection therewith, AB will cooperate to the extent reasonably required by ABI to stop such infringement or act, and, if so requested by ABI, will join with ABI as a party to any action brought by ABI for such purpose. ABI will have full control over any action taken, including, without limitation, the right to select counsel, to settle on any terms it deems advisable in its discretion, to appeal any adverse decision rendered in any court, to discontinue any action taken by it, and otherwise to make any decision in respect thereto as it in its discretion deems advisable. Any recovery as a result of such action shall belong solely to ABI.

6.5         Infringement of Third Party Rights .  In the event either Party receives any written notice or claim that the use of the ABI Technology, the AB Improvements or the Joint Improvements infringes or is likely to infringe the intellectual property rights of a Third Party, then that Party will notify the other Party promptly in writing. Whether to take action to defend against any such claim will be in ABI’s sole discretion. If requested by ABI, AB will join with ABI at ABI’s expense in such action as ABI in its reasonable discretion may deem advisable for the protection of its rights. In connection therewith, AB will cooperate to the extent reasonably required by ABI. and, if so requested by ABI, will join with ABI as a party to any action brought by ABI for such purpose. ABI will have full control over any action taken, including, without limitation, the right to select counsel, to settle on any terms it deems advisable in its discretion, to appeal any adverse decision rendered in any court, no discontinue any action taken by it, and otherwise to make any decision in respect thereto as it in its discretion deems advisable. For the avoidance of doubt, the Parties hereby affirm that they intend for the foregoing provisions to apply and be upheld as an agreement reached between the Parties after due diligence, careful deliberation and consultation with counsel, notwithstanding that the law of jurisdictions other than the State of California, United States of America might otherwise not permit, uphold or otherwise enforce the granting of such rights.


ARTICLE 7

REPRESENTATIONS AND WARRANTIES

ABI hereby represents and warrants to AB and AB hereby represents and warrants to ABI that as of the Effective Date:

 

  (a)

They have the full right, power and authority to enter into this Agreement, this Agreement has been duly executed by such Party and constitutes a legal, valid and binding obligation of such Party, enforceable in accordance with its terms;

 

  (b)

The execution, delivery and performance of this Agreement does not conflict with, or constitute a breach or default under any of its charter or organizational documents, any law, order or judgment or governmental rule or regulation applicable to it, or any material agreement, contract commitment or instrument to which it is a party; and

 

  (c)

They shall comply in all material respects with all applicable laws, rules, regulations and other governmental requirements relating to or affecting its performance under this Agreement, and shall obtain and maintain all governmental permits, licenses and consents required in connection therewith.

ARTICLE 8

INDEMNIFICATION; INSURANCE

8.1         Indemnification .  AB agrees to defend, indemnify and hold harmless ABI and its directors, officers, shareholders, employees, and agents (collectively, the “ ABI Indemnitees ”) from and against any and all suits, claims, actions, or demands (“ Claims ”), and any liabilities, damages, costs, expenses and/or losses incurred, including reasonable legal expenses and attorneys’ lees (collectively, “ Losses ”), suffered or sustained by any ABI Indemnitee, or to which an ABI Indemnitee becomes subject, arising out of or attributable to any of the following: (a) a breach by AB or a AB Party or its or their respective directors, officers, employees, agents, successors, assigns or sublicensees of a representation, warranty, covenant or agreement made or undertaken by AB under this Agreement; (b) the practice of any license granted by ABI to AB pursuant to this Agreement or any other use of the ABI Technology, the Joint Improvements, the Licensed Marks or ABI’s Confidential Information by AB or a AB Party or its or their respective director’s, officers, employees, agents, successors, assigns or sublicensees; or (c) the negligence, recklessness or willful misconduct of AB or a AB Party or its or their respective directors, officers, employees, agents, successors, assigns or sublicensees. ABI and any ABI indemnitee may, at its option and expense, be represented by counsel of its choice in any action or proceeding with respect to any such Claim or Loss. ABI will not settle any Claim or Loss if such settlement: (i) does not fully and unconditionally release the ABI Indemnitees from all liability relating thereto; or (ii) adversely impacts the rights granted to any ABI Indemnitee under this Agreement, unless each affected ABI Indemnitee otherwise agrees in writing.

8.2         Insurance .  At any time, promptly upon ABI’s request, AB will obtain and maintain, at its sole cost and expense, comprehensive general liability insurance providing reasonable coverage in respect of AB’s activities under this Agreement and in its practice of the licenses granted hereunder. AB will provide ABI with written evidence of such insurance upon ABI’s request.


ARTICLE 9

TERM AND TERMINATION

9.1         Term .  This Agreement will commence on the Effective Date and, unless earlier terminated as permitted herein, will continue until the expiration of all of the Licenses granted in Section 2.1 (the “ Term ”).

9.2         Termination by AB .  AB may terminate this Agreement at any time upon sixty (60) days written notice to ABI.

9.3         Termination by ABI .  The failure by AB comply with any of the material obligations contained in this Agreement shall entitle ABI to give notice to have the default cured. If such default is not cured within sixty (60) days, or diligent steps are not taken to cure if by its nature such default could not be cured within sixty (60) days, ABI shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, and in addition to any other remedies that may be available to it, to terminate this Agreement. In addition, ABI may terminate this Agreement upon ABI’s written notice to AB in the event that (a) such termination is necessary to comply with any order, decree or request of the government of either Party hereto or of any court department or agency thereof; (b) normal conduct of the business of AB as a private enterprise ceases or is substantially altered as a consequence of any action taken by governmental, judicial, or any other authority: or (c) AB makes a general assignment for the benefit of creditors, is the subject of proceedings in voluntary or involuntary bankruptcy instituted on behalf of or against AB, or has a receiver or trustee appointed for all or substantially all of its property.

9.4         Effect of Expiration and Termination .  Upon the expiration or termination of this Agreement for any reason: (a) all licenses under this Agreement immediately terminate, except that, at the option of ABI, all sublicenses granted hereunder may continue as determined by ABI in its sole discretion; (b) AB and its sublicensees will cease using the ABI Technology for any and all purposes (except for uses under sublicenses continued as determined by ABI in its sole discretion); (c) within thirty (30) days of termination, AB will return or destroy, at its own expense, all tangible Know-How provided by, or owned by, ABI to ABI in accordance with written instructions from ABI; and (d) each Party will return, at its own expense, to the other Party all Confidential information of the other Party within thirty (30) days of termination.

9.5         Survival of Obligations .  The termination or expiration of this Agreement shall not relieve the Parties of any obligations accruing prior to such termination, and any such termination shall be without prejudice to the rights of either Party against the other. The provisions of Sections 2.2, 2.3, 2.4, 2.5, 3.5, 8.1, 9.4 and 9.5 and Articles 5, 6, 7 and 10 shall survive any termination of this Agreement.

ARTICLE 10

MISCELLANEOUS

10.1         Governing Law; Venue .  This Agreement shall be governed by, and construed in accordance with the laws of the State of California, United States of America, as if entered into by California residents and executed and wholly performed within the State of California. Any dispute as to the performance, enforcement, validity, or interpretation of this Agreement shall be brought only in a federal court of competent jurisdiction (or a state court if no federal court has jurisdiction) located in the Northern District of California, and the Parties hereby submit to the exclusive jurisdiction and venue of such courts. For the avoidance of doubt, the Parties hereby affirm that they intend for the laws of the Slate of California to apply to the interpretation and enforcement of this Agreement as a whole as well as each provision set


forth herein, including, without limitation; all matters set forth in the Recitals, Article 2 and Article 6. The Parties’ decision to designate the laws of the State of California as the governing law of this Agreement was reached after due diligence, careful deliberation and consultation with counsel and the Parties intend for this to be upheld and enforced notwithstanding that certain activities and obligations under this Agreement shall be performed outside the State of California and/or outside the United Stales of America.

10.2         Entire Agreement .  This Agreement (including all Schedules attached hereto) contains the entire agreement between the Parties with respect to the subject matter hereof and supersedes any and all prior and contemporaneous, express and implied, agreements, understandings, and representations, either written or oral, which may have related to the subject matter hereof in any way.

10.3         Assignment .  This Agreement may not be assigned or otherwise transferred, nor, except as otherwise expressly provided in this Agreement, may any right or obligation tinder’ this Agreement be assigned or otherwise transferred, by AB, including without limitation any assignment or transfer in connection with a change of control or otherwise by operation of law, without the consent of ABI. Any permitted assignee shall assume all obligations of AB under this Agreement. Any purported assignment by AB in violation of this Agreement shall be void. This Agreement shall he binding upon, and inure to the benefit of, each Party, its successors and permitted assigns.

10.4         Waiver; Amendment .  Except as otherwise expressly provided in this Agreement, any term of this Agreement may be waived only by a written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of any Party at any time to require performance of any provision of this Agreement shall in no manner affect such Party’s rights at a later time to enforce the same. No alteration, amendment, change, or addition to this Agreement will be binding upon the Patties unless reduced to writing and signed by an authorized officer of each Party.

10.5         Notices .  Any notice or other communication required or permitted to be given under this Agreement must be in writing, in the English language, must specifically refer to this Agreement, and will be deemed given on the date delivered to the receiving Party if and when (a) delivered personally with a signed receipt of personal delivery; (b) sent by facsimile (receipt electronically verified and a copy promptly sent by personal delivery, registered or certified mail or courier as provided herein); (c) sent by internationally recognized courier providing evidence of receipt; or (d) sent by registered or certified mail, postage prepaid, return receipt requested. All such notices will be addressed to the Parties as follows (or such other address or facsimile number for a Party as may be specified by like notice):

 

  For ABI:

Amyris Biotechnologies, Inc.

      

5885 Hollis St,, Ste, 100

      

Emeryville, CA 94608

      

Fax: (510) 740-7416

      

Attn: General Counsel

 
  For AB:

Amyris do Brasil Pesquisa e Desenvolvimento de

      

Biocombustiveis Ltda.

      

Rua James Clerk Maxwell, n o 315

      

Techno Park, Campinas

      

Sâo Paulo, Brazil

      

Fax: 55 19 3283 0005

      

Attn: Roel Collier


10.6         No Strict Construction .  This Agreement has been prepared jointly and will not be strictly construed against either Party.

10.7         Severability .  If one or more provisions of this Agreement is held to be invalid, illegal or unenforceable, the Parties shall substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions which valid provisions are, in their economic effect, sufficiently similar to the invalid provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such provisions. In the event that such provisions cannot be agreed upon, the invalidity, illegality or unenforceability of one or more provisions of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without such invalid provisions.

10.8         Interpretation .  The headings for each article and section in this Agreement have been inserted for convenience of reference only and are not intended to affect its meaning or interpretation. In this Agreement: (a) the word “including” (including any variations such as “includes”) shall be deemed to be followed by the phrase “without limitation” or like expression; (b) the singular shall include the plural and vice versa; and (c) masculine, feminine, and neuter pronouns and expressions shall be interchangeable.

10.9         Further Actions .  Each Party agrees to execute, acknowledge, and deliver any further instruments, and to do all other acts, as may be necessary or appropriate to carry out the purposes and intent of this Agreement.

10.10       Independent Contractors .  The relationship between the Parties created by this Agreement is one of independent contractors and shall not constitute or be deemed to constitute a partnership, joint venture, agency, or other fiduciary relationship. Neither Party shall have the authority to make any statements, representations, or commitments of any kind, or to take any action, that shall be binding on the other Party in whole or in part as a result of this Agreement, without the prior written consent of the other Party to do so.

10.11       No Warranty .  BY GRANTING THE LICENSES SET FORTH HEREIN, ABI IS NOT MAKING ANY WARRANTY OF ANY KIND, AND EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS AND IMPLIED, WITH RESPECT TO ABI TECHNOLOGY OR THE LICENSED MARKS, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES AND/OR CONDITIONS OF MERCHANTABILITY, NONINFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE.

10.12       Limitation of Liability .  IN NO EVENT SHALL ABI BE LIABLE To AB HEREUNDER FOR INDIRECT, CONSEQUENTIAL, INCIDENTAL, PUNITIVE OR SPECIAL DAMAGES OR LOSSES, INCLUDING BUT NOT LIMITED TO LOST PROFITS, ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE: POSSIBILITY OF SUCH DAMAGES, WHETHER SUCH DAMAGES ARE BASED UPON A BREACH OF EXPRESS OR IMPLIED WARRANTIES, BREACH OF CONTRACT, NEGLIGENCE, STRICT TORT, OR ANY OTHER LEGAL THEORY.

10.13       Non-Use of Names .  Except as expressly permitted under this Agreement, AB may not use the name, trade name, trademark or other designation of ABI (including any contraction, abbreviation or simulation of any of the foregoing) or any of its directors, officers, employees and agents in any advertising, publicity, promotional activities, publication, press release, or other public announcement without the prior written consent of such person or entity in each case.


10.14       Language .  This Agreement shall be executed in the English Language.

[Remainder of this page intentionally left blank; signature page follows]


IN WITNESS WHEREOF, the Parties have duly executed this Agreement effective as of the day and year first above written.

LOGO


Schedule 1

Patents and Production Strains

A.   Amyris owned Patents and Patent Applications

 

Amyris Ref. No.

 

 

Serial No.

 

 

Title

 

 

Status

 

AM-400 BR

 

 

P10712160-1

 

 

Fuel Components, Fuel Compositions and Methods of Making and Using the Same

 

 

Based on PCT Application No. PCT/US2007/012468; Published as WO 2007/139925

 

AM-500 BR

 

P10713105-4

  Production of Isoprenoids  

Based on PCT Application No. PCT/US2007/069807; Published as WO 2007/140339

 

AM-700 BR

 

P10712508-9

  Apparatus for Making a Bio-Organic Compound  

Based on PCT Application No. PCT/US2007/012467; Published as WO 2007/139924

 

AM-800 BR

 

P10719659-8

 

Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same

 

  Based on PCT Application No. PCT/US2007/021890; Published as WO 2008/045555

AM-900 BR

 

P10718978-8

  Jet Fuel Compositions and Methods of Making and Using the Same  

Based on PCT Application No. PCT/US2007/024266; Published as WO 2008/140492

 

AM-1000 PCT

 

PCT/US2008/008747

Filed 07/17/2008

 

Fuel Compositions Comprising Tetramethylcyclohexane

 

   

AM-1200 PCT

 

PCT/US2007/024270

Filed 11/20/2007

 

Jet Fuel Compositions and Methods of Making and Using the Same

 

  Published as WO 2008/133658 on 11/06/2008

AM-1400 PCT

 

PCT/US2008/010886

Filed 09/19/2008

 

  Production of Isoprenoids    

AM-1800 PCT

 

PCT/US2009/039769

Filed 04/08/2009

 

  Expression of Heterologous Sequences    

AM-1900 PCT

 

PCT/US2009/042183

Filed 04/29/2009

 

 

Jet Fuel Compositions and Methods of Making and Using the Same

 

   

AM-2100 PCT

 

PCT/US2009/004959

Filed 09/01/2009

 

  Farnesene Interpolymers    

AM-2200 PCT

 

PCT/US2009/005158

Filed 09/16/2009

 

  Jet Fuel Compositions    

AM-2310 PCT

 

PCT/US2009/005543

Filed 10/09/2009

 

Lubricant Compositions and Methods of Making and Using the Same

 

   

AM-2400 PCT

 

PCT/US2009/065048

 

Compositions and Methods for the Rapid Assembly of Polynucleotides

 

   

AM-3300 PCT

 

PCT/US2009/004958

Filed 09/03/2009

 

Adhesive Compositions Comprising Polyfarnesene

 

   


B.   Patents and Patent Applications Licensed from University of California

 

Amyris Ref. No.

 

 

Serial No.

 

 

Title

 

 

Status

 

UC-400 BR

 

P10510115-8

Filed 05/20/05

  Method for Enhancing Production of Isoprenoid Compounds  

Based on PCT Application No. PCT/US05/17874; Published as WO 2006/085899

 

UC-500 BR

 

P10513837-0

Filed: 07/21/05

  Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds  

Based on PCT Application No. PCT/US05/026190; Published as WO 2006/014837

 

UC-700 BR

 

P10614990-1

Filed: 08/17/06

  Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds  

Based on PCT Application No. PCT/US/2006/32406; Published as WO 2007/024718

 

UC-1100 BR

 

P10716954-0

Filed 09/25/07

  Production of Isoprenoids and Precursors Thereof  

Based on PCT Application No. PCT/US/2007/020790; Published as WO 2008/039499

 

C.   Production Strains

 

  o

[*]

  o

[*]

  o

[*]

  o

[*]

  o

[*]

  o

[*]

  o

[*]

  o

[*]

  o

[*]

  o

[*]

  o

[*]

  o

[*]

  o

[*]

  o

[*]

  o

[*]

 

*

Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


Schedule 2

Logo

LOGO


Schedule 3

Additional Trademarks

 

Mark    Country   

Application
Number

 

   Filing Date    Status

AMYRIS

(Class 4)

 

  

BR

  

900766638

  

02/28/2008

   Extension based on Registration No. 1R948423 on 12/20/2007

AMYRIS

(Class 42)

 

  

BR

  

900766654

  

02/28/2008

   Extension based on Registration No. 1R 948424 on 12/20/2007

DIAL-A-BLEND

(Class 4)

 

  

BR

  

900766719

  

02/28/2008

    

DIAL-A-BLEND

(Class 9)

 

  

BR

  

900766735

  

02/28/2008

    

NO COMPROMISE

(class 4)

 

  

BR

  

901470945

  

02/20/2009

    


Schedule 4

Requirements for Use of Licensed Marks

 

1.

The Licensed Marks shall be used in all upper ease letters, so as to distinguish them from the surrounding text.

 

2.

The first or most prominent reference to the Licensed Marks shall be marked with a ® or ™ symbol, as appropriate.

 

3.

The Licensed Marks shall not be used in possessive form.

 

4.

The Licensed Marks shall not be used in the plural form.

 

5.

The Licensed Marks can be used jointly with other marks.


EXHIBIT 2

SHAREHOLDERS AGREEMENT

[See Exhibit 4.06 to the Registration Statement on Form S-1 filed by Amyris, Inc. with the Securities and

Exchange Commission, File No. 333-166135]

Exhibit 4.06

Execution Version

AMENDMENT AND RESTATEMENT TO THE SHAREHOLDERS’ AGREEMENT

BY

FUNDO MÚTUO DE INVESTIMENTOS EM EMPRESAS EMERGENTES INOVADORAS

STRATUS GC III,

RED MOUNTAIN JET LLC,

AMYRIS BIOTECHNOLOGIES, INC.,

AND, AS INTERVENING PARTIES,

AMYRIS BRASIL S.A.

AND

STRATUS INVESTIMENTOS LTDA.

MAY 26, 2010


Execution Version

 

AMENDMENT AND RESTATEMENT TO THE SHAREHOLDERS’ AGREEMENT

This amendment and restatement to the Shareholders’ Agreement (this “ Amendment ”) is executed on May 26, 2010, by the following parties (all of them, collectively, the “ Parties ”, and individually, a “ Party ”):

 

(1) FUNDO MÚTUO DE INVESTIMENTO EM EMPRESAS EMERGENTES INOVADORAS STRATUS GC III (“ Stratus ”), a fund duly authorized by CVM according to Oficio n° 2607/06, dated November 23, 2006, registered with the CNPJ/MF under n° 08.083.268/0001-46, herein represented by Stratus Gestão de Carteiras Ltda. (“ SGC ”), a company incorporated and existing under the laws of Brazil, with head offices in the city of São Paulo, State of São Paulo, at Rua Funchal, 129, 13 th floor, suite B, Vila Olímpia, registered with the CNPJ/MF under n° 09.238.656/0001-11, authorized by CVM for the rendering of management of portfolio services, according to Ato Declaratório n° 9.808, dated April 28, 2008, herein represented in accordance with its regulations;

 

(2) RED MOUNTAIN JET LLC , a company incorporated and existing under the laws of State of Delaware, with head offices at 16192 Coastal Highway, Lewes, Delaware 19958, United States of America, herein represented by its undersigned representatives (“ Red Mountain ”)

 

(3) AMYRIS BIOTECHNOLOGIES, INC. , a company incorporated and existing under the laws of the State of California, United States of America, with head offices at 5980 Hollis Street, Suite 100, Emeryville, California 94608, herein represented by its undersigned representatives (“ ABI ”);

And, as intervening parties,

 

(4) AMYRIS BRASIL S.A. , a company incorporated and existing under the laws of Brazil, with head offices in the city of Campinas, state of São Paulo, at Rua James Clerk Maxwell, n° 315, Techno Park, CEP 13069-380, registered with the CNPJ/MF under n° 09.379.224/0001-20, herein represented by its undersigned representatives (“ AB ” or the “ Company ”); and

 

(5) STRATUS INVESTIMENTOS LTDA. , Stratus’s administrator ( administradora ), a company incorporated and existing under the laws of Brazil, with head offices in the city of São Paulo, State of São Paulo, at Rua Funchal, 129, 13 th floor, suite B, Vila Olímpia, registered with the CNPJ/MF under n° 02.263.285/0001-89, herein represented by its undersigned representatives (“ SIL ”).

WHEREAS , on December 22, 2009, Stratus, ABI, AB and SIL entered into a Shareholders’ Agreement, in order to govern the relationship between Stratus and ABI, as shareholder of the Company (the “ Agreement ”),

WHEREAS Red Mountain has also made capital contributions into the Company, thus becoming one of its shareholders and subject to the rules set forth in the Agreement,

 

1


Execution Version

 

WHEREAS , besides including Red Mountain as a party of the Agreement, the Parties intend to further agree on a conversion right for the Investors (as defined in this Amendment), to convert their shares of AB into shares of ABI, under certain circumstances,

WHEREAS the Parties intend to alter certain other terms of the Agreement,

Now, therefore, the Parties hereby decide to amend the Agreement, as set forth below.

1.        Parties. Red Mountain shall be deemed as a Party to the Agreement and, thus any reference to the Parties contained in the Agreement shall hereinafter include Red Mountain.

2.        Definitions. The Parties agree to amend Section 1.1 of the Agreement, in order to exclude and modify certain definitions contained therein and to insert new definitions, as follows:

2.1.      The Parties agree to modify the following definitions of Section 1.1 of the Agreement, which shall hereinafter be read as follows:

AB Post-Money Valuation ” means the sum of (i) the AB Pre-Money Valuation, (ii) the ABI Cash Contribution, and (iii) the Investors Cash Contribution.

AB Pre-Money Valuation ” means R$180,000,000 (one hundred and eighty million Brazilian Reais) which represents the value of the Company, agreed on by the Parties, after the ABI Technology Contribution and before the ABI Cash Contribution and the Investors Cash Contribution.

Closing ” means the date on which Stratus has made its capital contribution to the Company.

Conditions for Distribution ” means the following conditions necessary to allow AB to distribute capital (dividends or interest on capital (juros sobre capital próprio) to the Shareholders: (a) all legal requirements for distribution of capital under Brazilian laws, including the existence of net profits or distributable capital reserves, are complied with; and (b) the Company has cash immediately available for the distribution.

Investors ” jointly, Stratus, Red Mountain and all the qualified third party investors appointed by ABI, SGC or SIL, which are on this date or become a direct or indirect shareholder of the Company, who shall invest the Investors Cash Contribution.

Share ” means a common share issued by the Company and held by the Shareholders as well as any other shares issued by the Company which the shareholders may subscribe, receive or otherwise acquire in the future during the term of this Agreement.

Shareholders ” means the shareholders of AB, which are subject to the terms and conditions of this Agreement.

Total Contribution Amount ” means that amount equal to (i) the ABI Cash Contribution, plus (ii) the Investors Cash Contribution.


Execution Version

 

2.2.      The Parties agree to insert the following definitions in Section 1.1 of the Agreement:

ABI Conversion Notice ” shall have the meaning set forth in the section 7.3 hereto.

Red Mountain ” shall have the meaning set forth in the Preamble.

2.3.      The Parties agree to exclude the following definitions from Section 1.1 of the Agreement and accordingly agree to exclude all references to such definitions contained throughout the Agreement: ABI Additional Contributions ”, “ ABI Mill Contribution ”, “ Investment Agreement ”, “ Usina Boa Vista ”.

2.4.      The Parties decide to rename the definitions “ Investor Offer Notice ” and “ Investor Offered Shares ”, so that they shall now read “ Investors Offer Notice ” and “ Investors Offered Shares ”. The meaning of both of these renamed definitions shall remain the same.

3.        Additional language to Section 2.2.   The Parties agree to add additional language to Section 2.2 of the Agreement, which shall from now on the read as follows:

“2.2    Scope of this Agreement.

The scope of this Agreement is to establish the terms and conditions that shall rule the relationship of the Shareholders of the Company, including: (i) management and corporate governance of the Company, (ii) voting rights, (iii) conditions applicable to the Transfer of Shares, and (iv) a possible IPO of the Company.

2.2.1    Capital ownership

For future reference regarding the capital ownership of the Company, parties should refer to the copy of the Company’s share registry book as of this date, which is attached to this Agreement as Exhibit I.”

4.        Observer Seat at the Board of Directors and Related Provisions. The Parties agree that as long as Red Mountain is a Shareholder of the Company, it shall be entitled to 1 (one) non-voting observer at the Company’s Board of Directors. Therefore, Section 4.3 of the Agreement shall be amended accordingly and shall hereinafter be read as follows:

“4.3    Election of the Board of Directors.

The Board of Directors shall consist of 5 (five) directors appointed as follows: (i) ABI shall be entitled to appoint 3 (three) directors; (ii) the Investors shall be entitled to appoint 1 (one) director as long as the amount of Investors’ cash contribution into the Company corresponds to at least 10% (ten per cent) of the sum of the Total Contribution Amount and all future contributions made into the Company, provided that all Investors shall vote as block to elect such director; and (iii) 1 (one) independent director; with substantial experience in the Brazilian sugar and ethanol sector, shall be unanimously appointed by the other directors. The Shareholders’ undertake to approve the election of the directors appointed in accordance with the conditions established in this section, for a term of office of 2 (two) years, being re-election permitted.


Execution Version

 

4.3.1 Resignation of the Director Appointed by the Investors.

Whenever the amount of the Investors’ cash contribution into the Company falls below 10% (ten per cent) of the sum of the Total Contribution Amount and all future contributions made into the Company, the Board of Directors may require the resignation of the director appointed by it, in which case the Board of Directors will consist of 4 (four) directors after the resignation.

4.3.2 Observer Seat at the Board of Directors.

4.3.2.1 Stratus.

Whenever Stratus is not able to elect a member of the Board of Directors, it shall be entitled to 1 (one) non-voting observer at the Board of Directors.

4.3.2.2 Red Mountain.

As long as Red Mountain is a Shareholder of the Company, it shall be entitled to 1 (one) non-voting observer at the Board of Directors.”

5.        Board of Officers. The Parties agree that the Company’s Board of Directors shall no longer be required to appoint a chief operational officer ( Diretor de Operações ). Therefore, Section 4.5 of the Agreement shall be amended accordingly and henceforth read as follows:

“4.5    Board of Officers

The initial Board of Officers shall consist of either one Chief Executive Officer (“ CEO ”) or one officer superintendent (Diretor Superintendente), one Financial Officer (Diretor Financeiro) and such additional senior management as may be necessary. The Board of Officers shall be responsible for routine management of the activities of the Company. The members of the Board of Officers shall perform their duties in accordance with applicable laws, the by-laws of the Company, and any internal guidelines of the Company (including instructions given by the Board of Directors). The Board of Directors may alter the composition of the Board of Officers from time to time by majority vote.”

6.        Additional language to Section Five. The Parties agree to add additional wording to Sections 5.3, 5.4, 5.5, 5.6 and 5.8 which shall, henceforth, read as follows:

“5.3    Right of First Refusal for Acquisition of the Investors’ Shares.

If any Investor wishes, directly or indirectly, to Transfer some or all of its Shares (the “ Investor Offered Shares ”), it must offer such Investor Offered Shares to ABI in accordance with the following provisions:

 

(a)

The Investor shall deliver a notice (“ ABI Offer Notice ”) to ABI stating (i) its bona fide intention to offer such Investor Offered Shares, (ii) the number of such Investor Offered Shares to be offered, (iii) the price and terms, if any, upon which it proposes to offer such Investor Offered Shares, and (iv) when applicable, the identity of any third party who has offered to buy such Investor Offered Shares and a copy of the offer received from such


Execution Version

 

 

third party, as long as ABI accepts in writing to be subject to the confidentiality requirements established by the Investor and the third party.

 

(b) The Investor’s offer shall remain effective for acceptance by ABI for a period of 30 (thirty) days, as of the date of receipt of the Offer Notice, unless earlier waived by ABI (the “ ABI Acceptance Period ”). During the ABI Acceptance Period, ABI shall have the right to accept all, but not less than all of the Investor Offered Shares, by giving written notice to the Investor who wishes to sell its Shares. The failure by ABI to reply to the ABI Offer Notice within the ABI Acceptance Period shall be deemed as the non-exercise of its right of first refusal.

 

(c) If ABI does not exercise its right of first refusal, the Investor shall have the right, exercisable not later than 90 (ninety) days following the expiration of the ABI Acceptance Period, to consummate the Transfer of the Investor Offered Shares to a third party on the same terms and conditions of the offer presented to ABI in the ABI Offer Notice. If the Investor does not consummate such Transfer within such 90 (ninety) day period, the Investor Offered Shares shall again be subject to the terms, conditions and restrictions set forth in this section 5.3.

5.4    Right of First Refusal for Acquisition of ABI’s Shares.

If ABI wishes, directly or indirectly, to Transfer some or all of its Shares (the “ ABI Offered Shares ”), it must offer such ABI Offered Shares to the Investors in accordance with the following provisions:

 

(a) ABI shall deliver a notice (“ Investors Offer Notice ”) to the Investors stating (i) its bona fide intention to offer such ABI Offered Shares, (ii) the number of such ABI Offered Shares to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such ABI Offered Shares and (iv) when applicable, the identity of any third party who has offered to buy such ABI Offered Shares and a copy of the offer received from such third party, as long as the Investors accept in writing to be subject to the confidentiality requirements established by ABI and the third party.

 

(b) ABI’s offer shall remain effective for acceptance by the Investors for a period of 30 (thirty) days, as of the date of receipt of the Investors Offer Notice, unless earlier waived by the Investors and subject to the additional term provided for in section 5.4(d), if applicable, (the “ Investors Acceptance Period ”). During the Investors Acceptance Period, the Investors shall have the right to accept all, but not less than all of the ABI Offered Shares, by giving written notice to ABI. The failure by the Investors to reply to the Investors Offer Notice within the Investors Acceptance Period shall be deemed as the non-exercise of the right of first refusal by the Investors.

 

(c)

If the Investors do not exercise their right of first refusal, ABI shall have the right, exercisable not later than ninety (90) days following the expiration of the Investors Acceptance Period, to consummate the Transfer of the ABI Offered Shares to a third party on the same terms and conditions of the offer presented to the Investors in the Investors Offer Notice. If ABI does not consummate such Transfer within the mentioned


Execution Version

 

 

ninety (90) day period, the ABI Offered Shares shall again be subject to the terms, conditions and restrictions set forth in this section 5.4.

 

(d) Each Investor shall have the right to accept to acquire a number of the ABI Offered Shares proportional to their equity participation in the Company. If one or more Investors accept to acquire their pro rata share of the ABI Offered Shares (the “ Accepting Investors ”), but one or more Investors refuse to acquire such Shares, then the Accepting Investors shall have the right to acquire the refused part of the ABI Offered Shares, also on a pro rata basis, according to their equity participation in the Company. The Accepting Investors shall have additional 15 (fifteen) days to accept to acquire all remaining ABI Offered Shares. The failure by the Accepting Investors to accept all, but not less than all remaining ABI Offered Shares within such additional period shall be deemed as the non-exercise of all Investors’ right of first refusal under this section 5.4.

5.5     Tag Along Rights.

If, subject to the provisions of sections 5.3 or 5.4 above, ABI decides to Transfer the Control of the Company to a third party, other than to an Affiliate and in a way that ABI ceases to hold the direct or indirect Control of the Company, in one transaction or in a series of transactions (whether related or not), by contract or otherwise, each of the Investors shall have the right to sell all of its Shares to the same third party, together with the Shares Transferred by ABI, at the same terms, conditions, price and form of payment (“ Tag Along Right ”), according to the following procedure:

 

(a) ABI shall present to the Investors a notice, which shall include the identity of the acquiring third party, the proposed sale price per Share and any other terms and conditions of the intended Transfer, including a copy of the offer received by ABI, when applicable (“ Tag Along Notice ”).

 

(b) Each of the Investors shall have the right to exercise its Tag Along Right during a period of 30 (thirty) days, as of the date of receipt of the Tag Along Notice, by giving written notice to the transferring Shareholder, being the failure of doing so interpreted as non- exercise of such right.

5.6     Drag Along Rights.

If, subject to the provisions of section 5.4 above and section 5.8 below, ABI decides to Transfer all of its Shares to any third party, ABI may compel all the Investors to sell all of their Shares to the same third party, together with the Shares Transferred by ABI, at the same terms, conditions, price and form of payment. ABI shall provide the identity of any third party who has offered to buy its Shares and a copy of the offer received from such third party, as long as the Investors accept in writing to be subject to the confidentiality requirements established by ABI and the third party.

For ABI to be able to exercise the Drag Along Rights provided for in this section, the price to be paid to each of the Investors for the Shares to be transferred upon such exercise may not be lower than their pro rata share of the Put Option Price provided for on section 5.8, The Change


Execution Version

 

of Put Option Price provided for on section 5.8.1 shall also be applicable in case of exercise of Drag Along Rights under this section.

 

  

5.8     Change of Control of AB.

If the Company undergoes a Change of Control Event in which the Investors’ pro rata share of the Acquisition Price is lower than the Minimum Investors’ Return, each Investor will have a put option against ABI. Such put option will be exercisable within 10 (ten) days, as of the receipt by the Investors of a notice sent by ABI informing that it has received a binding offer from one or more third parties willing to acquire the control of AB through a Change of Control Event (the “ Third Party Acquirer ”), and will entitle the Investors to sell all their Shares to ABI, for a total amount equal to the Put Option Price. Each of the Investors shall have the right to receive from ABI its pro rata share of the total Put Option Price, in accordance with its respective equity participation in AB determined as of the date the put option is exercised. The Put Option Price shall be paid by ABI to each Investor within 5 (five) business days of receipt by ABI of the effective payment, made by the Third Party Acquirer or by AB, of the sale proceeds arising from said Change of Control Event.

5.8.1  Change of Put Option Price.

In the event AB is valued at the Minimum Future AB Pre-Money Valuation in connection with a Change of Control Event or an IPO of AB, the price of the put option held by the Investors, in the situation described in this section 5.8, shall be the lower of (i) the amount invested by the Investors in AB in Brazilian Reais; and (ii) the total amount of proceeds actually received by ABI from a third party acquirer or from AB, in connection with a Change of Control Event relating to the Company.

7.        Minor adjustments to Section 6.   The Parties agree to amend Sections 6.1 and 6.3, which shall henceforth read as follows:

“6.1    Approval of the IPO.

The Shareholders hereby commit to vote in a Shareholders’ Meeting in order to approve an IPO of the Company, after 4 (four) years of the Closing, as long as market conditions are favourable for an IPO, as determined by an internationally recognized investment bank to be selected by the Board of Directors.

(…)

6.3     Secondary Offers by the Shareholders.

In the event the investment bank coordinating the IPO recommends that the IPO may include the offer of shares held by the shareholders (secondary offering), each of the Investors shall have the right to participate of such secondary offering, through the public offer of their Shares jointly with the Company’s primary offer at the time of the IPO, pro rata to their then stock ownership.”


Execution Version

 

8.        Additional wording on Section 7.   The Parties agree to amend Sections 7.1(i) 7.2 and 7.3, of the Agreement, which shall henceforth read as follows:

“7.1    ABI Change of Control Event.

 

  

 

(i) Each of the Investors shall have the right to convert all, and not less than all of its Shares in AB to shares of ABI common stock at the Conversion Ratio by providing written notice to ABI of its desire to carry out the conversion within ten (10) business days of receipt of a written notice by ABI, explaining the general terms of the transaction underlying the Change of Control Event, the identification of the potential acquirer(s), the expected closing date and the consideration to be provided for the acquisition of Control in AB (“ ABI Change of Control Notice ”);

7.2     ABI IPO.

Subject to the restrictions on the transfer of AB’s Shares set forth in Section Five above, in the event of an ABI IPO, each of the Investors shall have the following rights:

(…)

7.3.     ABI’s Call for Conversion.

ABI shall have the right to require the Investors to exchange some or all of their Shares in AB for restricted shares of ABI common stock, at the Conversion Ratio, in the event ABI is valued at least U.S. $ 500,000,000 (five hundred million United States dollars) in connection with an ABI IPO or an ABI Change of Control Event. In that case, ABI shall provide written notice to the Investors of its desire to carry out the conversion no later than ten (10) days prior to the closing of the transaction in connection with which the conversion is being required (the “ABI Conversion Notice”). The conversion will be effective immediately prior to the closing of the relevant transaction. The Investors shall (i) enter into the applicable agreement for effecting the conversion (in reasonable form provided by ABI), (ii) in the event the triggering transaction is an ABI IPO, enter into any lock-up agreement and/or plan of sale documents required by the underwriters, and (iii) enter into and deliver such other documents as are necessary to cause the relevant transaction to be completed. The Investors further agree to provide such information as may be requested by ABI to ensure compliance with all applicable laws, including securities laws. Each Party agrees to take such further actions as are necessary to cause the conversion of shares to be consummated.

7.3.1     Each Party agrees to use reasonable efforts to cause the conversion of shares to be consummated in such a way that would maximize benefits for each of the Parties.

7.3.2     In the event the conversion required under this section 7.3, cannot be carried out due to regulatory restrictions applicable to ABI or one of the Investors, the parties shall use reasonable efforts to agree on a mechanism, within 30 (thirty) days of receipt of the


Execution Version

 

ABI Conversion Notice, by which the Investors would (i) cease to be shareholders of AB; and reach the same economic results as if they had converted their Shares into shares of ABI as provided herein. In any case, no regulatory restriction applicable to the Investors, nor the failure of any of the Investors to comply with any obligation provided for in the Agreement, especially those provided for in this Section 7.3 shall prevent ABI from exercising the right set forth in this section.

9.        Conversion Right. The Parties agree to include in the Agreement a new Section Eight and to accordingly renumber the other subsequent Sections. The new Section shall read as follows:

“SECTION EIGHT

RIGHT TO CONVERT INTO ABI STOCK

8.1.     Right to Convert into ABI stock

 

(i) In case, by December 31, 2012, any of the Investors who remain as Shareholders of AB, having not converted their shares in AB to shares of ABI common stock pursuant to Section 7.1 in connection with a Change of Control of ABI, or pursuant to Section 7.2 or Section 7.3 in connection with an ABI IPO, such Investor will have the right to convert its Shares of AB into shares of ABI common stock, at the Conversion Ratio, subject to compliance by ABI and the Investors with all applicable laws (including securities laws).

 

(ii) The Investors will have fifteen (15) days from the abovementioned date to provide ABI with notice of their intention to convert their Shares of AB into shares of ABI common stock. ABI shall endeavor to use reasonable efforts to carry out the exchange of shares within ninety (90) days after the deadline provided for in this paragraph has elapsed.

8.2      The Parties agree that the right of the Investors to convert their Shares of AB into shares of ABI common stock, provided for in section 8.1 above, is fully conditioned and inherent to the fact that they are (i) shareholders of AB and (ii) part of this Agreement, so that this right, as well as any other rights or obligations arising out of this Agreement may not be transferred to any third party without the Parties’ prior consent. Any assignment of rights in disregard with this provision shall be rendered null and void.

10.     Notices to Red Mountain. The Parties agree to amend the Section 11.6 of the Agreement to add that, if to Red Mountain, the notices to be sent pursuant to the Agreement shall be sent to the following address:

“If to Red Mountain:

PEDRO PAULO FALLEIROS DOS SANTOS DINIZ

Address: Rua Jerônimo da Veiga, 384, 3 rd floor

Telephone: +55 11 3702-5161

Fax: +55 11 3702-5112

E-mail: pedro@ppdholding.com”


Execution Version

 

Copy to:

KLA- Koury Lopes Advogados

Address: Avenida Brigadeiro Faria Lima, 1355, 18th floor

Telephone: +55 11 3799-8118

Fax: +55 11 3799-8200

E-mail: mcortez@klalaw.com.br

Attn.: Mariana Machado Cortez

11.     Consolidation. For the avoidance of doubt, the Parties decide to consolidate a final version of the Agreement, which shall from now on be read as follows:

“SHAREHOLDERS’ AGREEMENT

This Shareholders’ Agreement, as amended from time to time (this “ Agreement ”), is executed by the following parties (all of them, collectively, the “ Parties ” and individually, a “ Party ”):

 

(1) FUNDO MÚTUO DE INVESTIMENTO EM EMPRESAS EMERGENTES INOVADORAS STRATUS GC III (“ Stratus ”), a fund duly authorized by CVM according to Oficio n° 2607/06, dated November 23, 2006, registered with the CNPJ/MF under n° 08.083.268/0001-46, herein represented by Stratus Gestão de Carteiras Ltda. (“ SGC ”), a company incorporated and existing under the laws of Brazil, with head offices in the city of São Paulo, state of São Paulo, at Rua Funchal, 129, 13 t h floor, suite B, Vila Olímpia, registered with the CNPJ/MF under n° 09.238.656/0001-11, authorized by CVM for the rendering of management of portfolio services, according to Ato Declaratório n° 9.808, dated April 28, 2008, herein represented in according with its regulations;

 

(2) RED MOUNTAIN JET LLC , a company incorporated and existing under the laws of State of Delaware, with head offices at 16192 Coastal Highway, Lewes, Delaware 19958, United States of America, herein represented by its undersigned representatives (“ Red Mountain ”)

 

(3) AMYRIS BIOTECHNOLOGIES, INC. , a company incorporated and existing under the laws of the State of California, United States of America, with head offices at 5980 Hollis Street, Suite 100, Emeryville, California 94608, herein represented by its undersigned representatives (“ ABI ”);

And, as intervening parties,

 

(4) AMYRIS BRASIL S.A. , a company incorporated and existing under the laws of Brazil, with head offices in the city of Campinas, state of São Paulo, at Rua James Clerk Maxwell, n° 315, Techno Park, CEP 13069-380, registered with the CNPJ/MF under n° 09.379.224/0001-20, herein represented by its undersigned representatives (“ AB ” or the “ Company ”); and

 

(5) STRATUS INVESTIMENTOS LTDA. , Stratus’s administrator ( administradora ), a company incorporated and existing under the laws of Brazil, with head offices in the city of São Paulo, at Rua Funchal, 129, 13 th floor, suite B, Vila Olímpia, registered with the CNPJ/MF under n° 02.263.285/0001-89, herein represented by its undersigned representatives (“ SIL ”).


Execution Version

 

WHEREAS ABI and the Investors (as defined below) have made capital contributions into the Company and intend to establish the rules that shall govern their relationship as shareholders of the Company,

WHEREAS ABI and the Investors (as defined below) have made capital contributions into the Company and intend to establish the rules that shall govern their relationship as shareholders of the Company,

Now, therefore, the Parties hereby decide to enter into this Agreement, which shall be governed by the following terms and conditions:

SECTION ONE

DEFINITIONS AND INTERPRETATION

1.1     Definitions:

AB ” has the meaning set forth in the Preamble.

AB Competitor ” means any person or entity that has current or prospective business activities or interests that, in ABI’s reasonable judgment, are competitive with the business of the Company.

AB Post-Money Valuation ” means the sum of (i) the AB Pre-Money Valuation, (ii) the ABI Cash Contribution, and (iii) the Investors Cash Contribution.

AB Pre-Money Valuation ” means R$180,000,000 (one hundred and eighty million Brazilian Reais) which represents the value of the Company, agreed on by the Parties, after the ABI Technology Contribution and before the ABI Cash Contribution and the Investors Cash Contribution.

ABI ” has the meaning set forth in the Preamble.

ABI Acceptance Period ” has the meaning set forth in section 5.3(b) hereto.

ABI BDRs ” means Brazilian Depositary Receipts tracking to ABI stock that is issued and publicly traded in the United States.

ABI Cash Contribution ” means a cash contribution of US$ 10,000,000 (ten million United States dollars) to be made by ABI in AB.

ABI Change of Control Notice ” has the meaning set forth in section 7.1(i) hereto.

ABI Conversion Notice ” shall have the meaning set forth in the section 7.3 hereto.

ABI IPO ” means an initial public offering of the shares issued by ABI, at a value determined through a book-building process by internationally recognized investment banks to be selected by the ABI’s management, either relating to shares newly issued by ABI for the offering (primary offering) or shares held by ABI’s shareholders and publicly offered by such shareholders (secondary offering), or a combination of both.


Execution Version

 

ABI Offer Notice ” has the meaning set forth in section 5.3(a) hereto.

ABI Offered Shares ” has the meaning set forth in section 5.4 hereto.

Accepting Investors ” has the meaning set forth in section 5.4(d) hereto.

Acquisition Price ” means the purchase price to be paid by the acquirer/buyer to the seller in connection with a Change of Control Event.

Affiliate ” of a certain Person (the “first Person”) means a Person that directly or indirectly through one or more intermediaries, Controls, or is Controlled by, or is under common Control with, the first Person.

Agreement ” has the meaning set forth in the Preamble.

Amyris Renewable Products ” means renewable chemical and fuel products to be manufactured by AB through the use of Amyris Technology under the terms and conditions set forth in the Technology License.

Amyris Technology ” means ABI’s proprietary microbial production technology which converts simple sugars derived from various plant sources, including sugarcane, into specific compounds of interest, with respect to which certain exclusive and non-exclusive rights were transferred by ABI to AB by means of the Technology License.

Block Sale ” means any individual sale or sequence of sales within a one (1)-year time frame, under which at least twenty percent (20%) of the Company’s shares are sold to one single entity or to a group of different entities subject to common Control.

Board of Directors ” means the board of directors (“ Conselho de Administração ”) of the Company.

Board of Officers ” means the board of officers (“ Diretoria ”) of the Company.

Bovespa ” means the São Paulo stock exchange ( Bolsa de Valores, Mercadorias e Futuros - BM&FBovespa ).

Bovespa Mais ” means a certain listing segment of Bovespa.

Brazilian Civil Procedure Code ” means law No. 5,869, enacted on January 11, 1973, as amended from time to time.

Brazilian Corporation Law ” means law No. 6,404, enacted on December 15, 1976, as amended from time to time.

Business Plan and Budget ” means a written two-(2)-year business, operational and strategic plan governing the operation of the Company, including strategic plans for capital requirements


Execution Version

 

and capital expenditures for each of the two (2) years; a capital budget for each of the two (2) years; and an operating budget for the relevant year.

Change of Control Event ” means, with respect to an entity, (i) a merger, reorganization, consolidation or other transaction (or series of related transactions of such nature) pursuant to which more than fifty percent (50%) of the voting power of all outstanding equity securities of the entity is transferred by the holders of such entity’s outstanding shares (excluding a reincorporation to effect a change in domicile), (ii) a sale of all or substantially all of the assets of the entity, or (iii) any other transaction or series of related transactions, in which the entity’s shareholders immediately prior to such transaction or transactions own immediately after such transaction less than fifty (50%) of the voting equity securities of the surviving corporation or its parent.

Company ” has the meaning set forth in the Preamble.

Conditions for Distribution ” means the following conditions necessary to allow AB to distribute capital (dividends or interest on capital ( juros sobre capital próprio ) to the Shareholders: (a) all legal requirements for distribution of capital under Brazilian laws, including the existence of net profits or distributable capital reserves, are complied with; and (b) the Company has cash immediately available for the distribution.

Control ” of an entity means the power to direct the management and policies of such entity and shall be presumed to exist upon ownership of securities entitling the holder thereof to exercise more than 50% (fifty per cent) of the voting power in the election of directors and in the decision of any strategic matter of such entity.

Conversion Ratio ” shall mean 0.28 (twenty-eight hundredths) shares of ABI per each 1 share of AB.

Closing ” means the date on which Stratus has made its capital contribution to the Company.

Encumbrance ” means any claim, charge, mortgage, lien, option, power of sale, usufruct, right of pre-emption, right of first refusal or other third party rights or security interest of any kind or an agreement, arrangement or obligation to create any of the foregoing.

Investors ” means, jointly, Stratus, Red Mountain and all the qualified third party investors appointed by ABI, SGC or SIL, which are on this date or become a direct or indirect shareholder of the Company, who shall invest the Investors Cash Contribution.

Investors Acceptance Period ” has the meaning set forth in section 5.4(b) hereto.

Investors Cash Contribution ” means the capital investments in AB that the Investors are entitled to make in an amount up to the lesser of (i) US$ 32,500,000 (thirty-two million, five hundred thousand United States dollars), and (ii) that amount equal to twenty percent (20%) of the AB Post-Money Valuation (as defined above).

Investor Offer Notice ” has the meaning set forth in section 5.4(a) hereto.


Execution Version

 

Investor Offered Shares ” has the meaning set forth in section 5.3 hereto.

IPO ” means the initial public offering of Shares of the Company, at a value determined through a book-building process by internationally recognized investment banks to be selected by the Company, either relating to Shares newly issued by the Company for the offering (primary offering) or Shares held by the Shareholders and publicly offered by such Shareholders (secondary offering), or a combination of both, after which the Company shall be listed at Bovespa.

Minimum Future AB Pre-Money Valuation ” means an amount representing the value of the Company, according to which the Investors’ equity participation in AB would value more than the Minimum Investors’ Return in Brazilian Reais.

Minimum Investors’ Return ” means the amount invested by the Investors in AB in Brazilian Reais, plus 8% (eight per cent) per year.

Off-Exchange Sale ” means any sale of the Company’s shares, after the Company is publicly listed and traded in Brazil, that is not within Bovespa.

Parties ” has the meaning set forth in the Preamble.

Person ” means any individual, corporation, partnership, limited liability company, firm, joint venture, association, joint stock company, trust, unincorporated organization, governmental or regulatory body or subdivision thereof, or any other entity.

Put Option Price ” means the lower of (i) the Minimum Investors’ Return; and (ii) the total amount of proceeds actually received by ABI from a third party acquirer or from AB, in connection with a Change of Control Event relating to the Company.

Red Mountain ” has the meaning set forth in the Preamble.

Related Party ” means, with respect to any Person, (i) its Affiliates, (ii) a spouse, parent, grandparent, descendant or sibling of such Person, (iii) any other Person owning twenty percent (20%) or more of the issued and outstanding equity securities of such Person, and (iv) any other Person Controlled by the Affiliates of such Person.

Related Party Transaction ” means any transaction between the Company, on the one hand, and any Related Party, on the other hand, or entered into by the Company for the benefit of a Related Party.

Rules of Arbitration ” has the meaning set forth in section 12.2 hereto.

Shareholders ” means the shareholders of AB, which are subject to the terms and conditions of this Agreement.

Shareholders’ Meeting ” means a shareholders’ meeting of the Company, either annual (ordinary) or extraordinary.


Execution Version

 

Share ” means a common share issued by the Company and held by the Shareholders as well as any other shares issued by the Company which the Shareholders may subscribe, receive or otherwise acquire in the future during the term of this Agreement.

SGC ” has the meaning set forth in the Preamble.

SIL ” has the meaning set forth in the Preamble.

Stratus ” has the meaning set forth in the Preamble.

Tag Along Notice ” has the meaning set forth in section 5.5(a) hereto.

Tag Along Right ” has the meaning set forth in section 5.5 hereto.

Technology License ” means that certain Technology License Agreement between ABI and the Company effective as of March 27, 2008.

Third Party Acquirer ” has the meaning set forth in section 5.8 hereto.

Total Contribution Amount ” means that amount equal to (i) the ABI Cash Contribution, plus (ii) the Investors Cash Contribution.

Transfer ” (including the terms “Transfer”, “Transferring” and “Transferred”) means (i) any direct or indirect transfer, sale, assignment (including assignment of pre-emptive rights), exchange, donation or other disposition of any kind, voluntary or involuntary, contingent or non-contingent, including any transfer, sale, assignment, exchange, donation or other disposition of any kind that results from the foreclosure of any pledge, mortgage, grant of security interest or Encumbrance, or in connection with any merger, consolidation, spin-off, reorganization, amalgamation, issuance of equity securities or other transactions having a similar effect, (ii) entering into any agreement for the direct or indirect transfer of the voting rights attached to any Shares; and (iii) any agreement (whether or not subject to conditions) to do or create or grant any of the foregoing.

1.2     Interpretation.

A reference in this Agreement to the singular includes a reference to the plural and vice versa. The term “including” shall be deemed to be followed by the phrase “but not limited to”. The words “hereof’, “herein”, “hereto”, “hereunder” and similar words refer to this Agreement as a whole. The headings of this Agreement are included for convenience purposes only and are to be ignored in the interpretation of this Agreement.

SECTION TWO

PURPOSE OF THE COMPANY AND SCOPE OF THIS AGREEMENT

2.1     Purpose of the Company.

The Company’s purpose is to (i) acquire an ownership interest in certain sugar and ethanol assets in Brazil and convert a portion of the production capacity of such assets to the production of


Execution Version

 

Amyris Renewable Products, and (ii) provide other Brazilian sugar and ethanol mills with access to the Amyris Technology for the production of Amyris Renewable Products.

2.2       Scope of this Agreement.

The scope of this Agreement is to establish the terms and conditions that shall rule the relationship of the Shareholders of the Company, including: (i) management and corporate governance of the Company, (ii) voting rights, (iii) conditions applicable to the Transfer of Shares, and (iv) a possible IPO of the Company.

2.2.1    Capital ownership

For future reference regarding the capital ownership of the Company, parties should refer to the copy of the Company’s share registry book as of this date, which is attached to this Agreement as Exhibit I.

SECTION THREE

SHAREHOLDERS’ MEETING

3.1       Shareholders Meetings.

Annual Shareholders’ Meetings shall take place in the head offices of the Company, within four (4) months following the end of each fiscal year, and extraordinary Shareholders’ Meetings may take place whenever called by any member of the Board of Directors or in accordance with article 123 of the Brazilian Corporation Law.

3.2       Shares Representation.

Each Share shall represent 1 (one) vote at any Shareholders’ Meeting and the Shareholders agree not to adopt multiple vote provisions under article 141 of the Brazilian Corporation Law. Except as may be otherwise expressly stated herein, in the Company’s by-laws, in the Brazilian Corporation Law or in any other applicable laws, resolutions passed at any Shareholders’ Meeting shall require the approval of the Shareholders holding a simple majority of the Shares authorized and entitled to vote.

3.3       Matters Subject to the Shareholders’ Meeting.

Subject to section 3.4 below, the following matters shall be decided by the Shareholders in a Shareholders’ Meeting, without prejudice to other matters attributed to the Shareholders’ Meeting by the Brazilian Corporation Law:

 

(i) amendment to the by-laws of the Company;

 

(ii) any capital increase and the issuance of new shares by the Company, whenever such capital increase is greater than the authorized capital ( capital autorizado ) set forth in the Company’s by-laws and the price per share is equal to or greater than the price paid by Stratus on December 22 nd , 2009, as well as issuance of other securities;


Execution Version

 

(iii) any capital reduction of the Company;

 

(iv) election of the members of the Board of Directors of the Company, with due regard to the provisions set forth in section 4.1 below;

 

(v) approval of bonus, stock option or similar plans or schemes for the employees and managers of the Company, and any amendment of the foregoing, with due regard to section 4.7 below;

 

(vi) approval of any dividend policy and any amendments to the foregoing;

 

(vii) specific approval of the distribution of dividends in a given year by the Company, in accordance with the applicable dividend policy; and

 

(viii) decision to carry out the IPO, with due regard to the provisions set forth in section 6.1 below.

3.4     Supermajority Approvals.

The following matters shall be decided in a Shareholders’ Meeting by Shareholders holding at least 85% (eighty-five per cent) of the total corporate capital of the Company:

 

(i) dissolution or liquidation of the Company;

 

(ii) merger, transformation, amalgamation or spin-off of the Company;

 

(iii) request for bankruptcy, as well as for judicial or non-judicial recovery ( recuperação judicial ou extrajudicial ); and

 

(iv) any capital increase and the issuance of new shares by the Company, whenever such capital increase is greater than the authorized capital ( capital autorizado ) set forth in the Company’s by-laws and the price per share is lower than the price paid by Stratus on December 22 nd , 2009.

3.5.    Authorized Capital.

The Shareholders agree that they shall not amend the bylaws of the Company to exclude or reduce the amount of the Company’s authorized corporate capital established on December 22 nd , 2009.

SECTION FOUR

MANAGEMENT

4.1     Management.

The management of the Company shall be carried out by the Board of Directors and the Board of Officers in accordance with the provisions set forth in this Section Four.


Execution Version

 

4.2      Board of Directors.

The Board of Directors shall be responsible for the supervision of the management of the Company, for strategic and policy decisions, and other tasks and matters allotted to the Board of Directors by the laws of Brazil, this Agreement and the by-laws of the Company.

4.3      Election of the Board of Directors.

The Board of Directors shall consist of 5 (five) directors appointed as follows: (i) ABI shall be entitled to appoint 3 (three) directors; (ii) the Investors shall be entitled to appoint 1 (one) director as long as the amount of Investors’ cash contribution into the Company corresponds to at least 10% (ten per cent) of the sum of the Total Contribution Amount and all future contributions made into the Company, provided that all Investors shall vote as block to elect such director; and (iii) 1 (one) independent director, with substantial experience in the Brazilian sugar and ethanol sector, shall be unanimously appointed by the other directors. The Shareholders’ undertake to approve the election of the directors appointed in accordance with the conditions established in this section, for a term of office of 2 (two) years, being re-election permitted.

4.3.1     Resignation of the Director Appointed by the Investors.

Whenever the amount of the Investors’ cash contribution into the Company falls below 10% (ten per cent) of the sum of the Total Contribution Amount and all future contributions made into the Company, the Board of Directors may require the resignation of the director appointed by it, in which case the Board of Directors will consist of 4 (four) directors after the resignation.

4.3.2     Observer Seat at the Board of Directors.

4.3.2.1 Stratus.

Whenever Stratus is not able to elect a member of the Board of Directors, it shall be entitled to 1 (one) non-voting observer at the Board of Directors.

4.3.2.2 Red Mountain.

As long as Red Mountain is a Shareholder of the Company, it shall be entitled to 1 (one) non-voting observer at the Board of Directors.

4.4      Matters Subject to the Board of Directors.

The matters below shall be subject to the approval of the simple majority of the members of the Board of Directors:

 

(i) any capital increase and the issuance of new shares by the Company, whenever such capital increase is lower than or equal to the authorized capital ( capital autorizado ) set forth in the Company’s by-laws and the price per share is equal to or greater than the price paid by Stratus on December 22 nd , 2009;


Execution Version

 

(ii) the sale or disposal of any assets of the Company in an amount of over R$ 250,000 (two hundred and fifty thousand Brazilian Reais);

 

(iii) the assumption of any obligations by the Company in an amount of over R$ 1,000,000 (one million Brazilian Reais), except for any obligation that requires the unanimous consent of the Board of Directors pursuant to section 4.4.1 below;

 

(iv) approval of the Company’s Business Plan and Budget;

 

(v) creation of Encumbrances over the Company’s assets that are not provided for in the annual budget;

 

(vi) appointment and replacement of the officers of the Company, with due regard to section 4.6 below;

 

(vii) approval of the policies of the Company (finance and investments, people and organization, insurance, legal affairs etc.);

 

(viii) approval of material commercial and operational decisions related to the use of the Amyris Technology;

 

(ix) any Related Party Transaction; and

 

(x) approval of any contract entered into by AB related to the use of the Amyris Technology or the manufacture, marketing, sale or distribution of Amyris Renewable Products, and/or any other products or services made through the use of Amyris Technology or otherwise in connection with the rights granted under the Technology License.

4.4.1     Matters Subject to the Unanimous Approval of the Board of Directors.

The matters below shall be subject to the approval of all of the members of the Board of Directors:

 

  (i) any capital increase and the issuance of new shares by the Company, whenever such capital increase is lower than or equal to the authorized capital ( capital autorizado ) set forth in the Company’s by-laws and the price per share is lower than the price paid by Stratus on December 22 nd , 2009;

 

  (ii) the contracting of loans or the entering into other financial obligations by the Company in an amount that exceeds, individually or in the aggregate in any period of 12 (twelve) months, 100% of the Company’s paid in equity;

 

  (iii) any sale or Transfer of assets by the Company in an amount that exceeds, individually or in the aggregate in any period of 12 (twelve) months, 15% (fifteen percent) of the Company’s paid in equity;


Execution Version

 

  (iv) replacement of the auditors of the Company for auditors that are not within the “Big Four” accounting firms (namely PricewaterhouseCoopers, KPMG, Deloitte and Ernst & Young and their respective successors in title); and

 

  (v) termination of the Technology License.

4.5      Board of Officers.

The initial Board of Officers shall consist of either one Chief Executive Officer (“ CEO ”) or one officer superintendent ( Diretor Superintendente ), one Financial Officer ( Diretor Financeiro ) and such additional senior management as may be necessary. The Board of Officers shall be responsible for routine management of the activities of the Company. The members of the Board of Officers shall perform their duties in accordance with applicable laws, the by-laws of the Company, and any internal guidelines of the Company (including instructions given by the Board of Directors). The Board of Directors may alter the composition of the Board of Officers from time to time by majority vote.

4.6      Election of the Board of Officers.

The CEO and the Financial Officer must be approved by the unanimous vote of the Board of Directors, while the other members of the Board of Officers must be approved by the majority of the Board of Directors.

4.7      Management Incentive Program.

The Shareholders’ Meeting shall approve an equity incentive plan of up to 5% of the fully diluted equity of the Company, if there is any dilution, to be set forth in the Company’s by-laws, consisting of options to purchase Shares of the Company to be issued through a capital increase within the Company’s authorized capital ( capital autorizado ) or other type of incentive plans as proposed by the Board of Directors. In the event Shares are issued and acquired by the Company’s managers under an incentive plan, such Shares shall be subject to the conversion rights and obligations set forth in Section Seven hereof.

4.8      D&O Insurance.

The Shareholders shall cause the Company to contract D&O insurance for all of the members of the Board of Directors and of the Board of Officers, in accordance with market terms.

SECTION FIVE

TRANSFER OF SHARES

5.1      General Restriction and Lock-Up Periods.

 

(a)

Except for Transfer of Shares by Shareholders to any of its Affiliates, no Shareholder may Transfer any Shares issued by the Company, except in accordance with the provisions of this Section Five. Any attempt by a Shareholder to Transfer any of its Shares without compliance with this Agreement shall be null and void ab initio, and the Company shall not give any effect to such attempted Transfer in its books and records.


Execution Version

 

 

The transferee of any Shares Transferred by a Shareholder in violation of this Agreement shall not be entitled to (i) any right, title and interest in or to such Shares, (ii) any rights to vote such Shares, or (iii) any distributions in respect thereof.

 

(b) Transfer at any time of Shares of the Investors to funds, vehicles or investment accounts managed by SGC or SIL shall be allowed at any time, as long as there is no change of the final beneficiary of such Investors.

 

(c) Conversion of Shares of the Investors into shares of ABI pursuant to Section Seven shall be allowed at any time.

 

(d) For the avoidance of doubt, a Change of Control Event of ABI shall not be considered a Transfer of AB’s Shares.

 

(e) From December 22 nd , 2009 and until 18 (eighteen) months after the Closing, no Shareholder shall be permitted to Transfer its Shares to any third party. Additionally, until June 30, 2013, the Investors shall not be permitted to Transfer their Shares to an AB Competitor, unless the Company becomes publicly listed and traded in Brazil during that period, in which case such restriction shall not apply with respect to any Off-Exchange Sales that are not Block Sales.

5.2      Preemptive Rights.

The Shareholders will have preemptive rights to purchase any equity or convertible debt security issued and offered by the Company from time to time so as to maintain their pro rata ownership in the Company, in accordance with article 171 of the Brazilian Corporation Law, except for cases of issuance of shares by the Company under a management stock option plan, being certain that the Shareholders may transfer such rights to Affiliates or vehicles under common control, subject to the transfer restrictions set forth in this Agreement.

5.3      Right of First Refusal for Acquisition of the Investors’ Shares.

If any Investor wishes, directly or indirectly, to Transfer some or all of its Shares (the “ Investor Offered Shares ”), it must offer such Investor Offered Shares to ABI in accordance with the following provisions:

 

(a) The Investor shall deliver a notice (“ ABI Offer Notice ”) to ABI stating (i) its bona fide intention to offer such Investor Offered Shares, (ii) the number of such Investor Offered Shares to be offered, (iii) the price and terms, if any, upon which it proposes to offer such Investor Offered Shares, and (iv) when applicable, the identity of any third party who has offered to buy such Investor Offered Shares and a copy of the offer received from such third party, as long as ABI accepts in writing to be subject to the confidentiality requirements established by the Investor and the third party.

 

(b)

The Investor’s offer shall remain effective for acceptance by ABI for a period of 30 (thirty) days, as of the date of receipt of the Offer Notice, unless earlier waived by AIM (the “ ABI Acceptance Period ”). During the ABI Acceptance Period, ABI shall have the right to accept all, but not less than all of the Investor Offered Shares, by giving written


Execution Version

 

 

notice to the Investor who wishes to sell its Shares. The failure by ABI to reply to the ABI Offer Notice within the ABI Acceptance Period shall be deemed as the non-exercise of its right of first refusal.

 

(c) If ABI does not exercise its right of first refusal, the Investor shall have the right, exercisable not later than 90 (ninety) days following the expiration of the ABI Acceptance Period, to consummate the Transfer of the Investor Offered Shares to a third party on the same terms and conditions of the offer presented to ABI in the ABI Offer Notice. If the Investor does not consummate such Transfer within such 90 (ninety) day period, the Investor Offered Shares shall again be subject to the terms, conditions and restrictions set forth in this section 5.3.

5.4      Right of First Refusal for Acquisition of ABI’s Shares.

If ABI wishes, directly or indirectly, to Transfer some or all of its Shares (the “ ABI Offered Shares ”), it must offer such ABI Offered Shares to the Investors in accordance with the following provisions:

 

(a) ABI shall deliver a notice (“ Investors Offer Notice ”) to the Investors stating (i) its bona fide intention to offer such ABI Offered Shares, (ii) the number of such ABI Offered Shares to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such ABI Offered Shares and (iv) when applicable, the identity of any third party who has offered to buy such ABI Offered Shares and a copy of the offer received from such third party, as long as the Investors accept in writing to be subject to the confidentiality requirements established by ABI and the third party.

 

(b) ABI’s offer shall remain effective for acceptance by the Investors for a period of 30 (thirty) days, as of the date of receipt of the Investors Offer Notice, unless earlier waived by the Investors and subject to the additional term provided for in section 5.4(d), if applicable, (the “ Investors Acceptance Period ”). During the Investors Acceptance Period, the Investors shall have the right to accept all, but not less than all of the ABI Offered Shares, by giving written notice to ABI. The failure by the Investors to reply to the Investors Offer Notice within the Investors Acceptance Period shall be deemed as the non-exercise of the right of first refusal by the Investors.

 

(c) If the Investors do not exercise their right of first refusal, ABI shall have the right, exercisable not later than ninety (90) days following the expiration of the Investors Acceptance Period, to consummate the Transfer of the ABI Offered Shares to a third party on the same terms and conditions of the offer presented to the Investors in the Investors Offer Notice. If ABI does not consummate such Transfer within the mentioned ninety (90) day period, the ABI Offered Shares shall again be subject to the terms, conditions and restrictions set forth in this section 5.4.

 

(d)

Each Investor shall have the right to accept to acquire a number of the ABI Offered Shares proportional to their equity participation in the Company. If one or more Investors accept to acquire their pro rata share of the ABI Offered Shares (the “ Accepting Investors ”), but one or more Investors refuse to acquire such Shares, then the Accepting


Execution Version

 

 

Investors shall have the right to acquire the refused part of the ABI Offered Shares, also on a pro rata basis, according to their equity participation in the Company. The Accepting Investors shall have additional 15 (fifteen) days to accept to acquire all remaining ABI Offered Shares. The failure by the Accepting Investors to accept all, but not less than all remaining ABI Offered Shares within such additional period shall be deemed as the non-exercise of all Investors’ right of first refusal under this section 5.4.

5.5      Tag Along Rights.

If, subject to the provisions of sections 5.3 or 5.4 above, ABI decides to Transfer the Control of the Company to a third party, other than to an Affiliate and in a way that ABI ceases to hold the direct or indirect Control of the Company, in one transaction or in a series of transactions (whether related or not), by contract or otherwise, each of the Investors shall have the right to sell all of its Shares to the same third party, together with the Shares Transferred by ABI, at the same terms, conditions, price and form of payment (“ Tag Along Right ”), according to the following procedure:

 

(a) ABI shall present to the Investors a notice, which shall include the identity of the acquiring third party, the proposed sale price per Share and any other terms and conditions of the intended Transfer, including a copy of the offer received by ABI, when applicable (“ Tag Along Notice ”).

 

(b) Each of the Investors shall have the right to exercise its Tag Along Right during a period of 30 (thirty) days, as of the date of receipt of the Tag Along Notice, by giving written notice to the transferring Shareholder, being the failure of doing so interpreted as non-exercise of such right.

5.6      Drag Along Rights.

If, subject to the provisions of section 5.4 above and section 5.8 below, ABI decides to Transfer all of its Shares to any third party, ABI may compel all the Investors to sell all of their Shares to the same third party, together with the Shares Transferred by ABI, at the same terms, conditions, price and form of payment. ABI shall provide the identity of any third party who has offered to buy its Shares and a copy of the offer received from such third party, as long as the Investors accept in writing to be subject to the confidentiality requirements established by ABI and the third party.

For ABI to be able to exercise the Drag Along Rights provided for in this section, the price to be paid to each of the Investors for the Shares to be transferred upon such exercise may not be lower than their pro rata share of the Put Option Price provided for on section 5.8, The Change of Put Option Price provided for on section 5.8.1 shall also be applicable in case of exercise of Drag Along Rights under this section.

5.7      Adhesion to this Agreement.

No Transfer of Shares shall be allowed if the potential transferee refuses to adhere fully to this Agreement.


Execution Version

 

5.8      Change of Control of AB.

If the Company undergoes a Change of Control Event in which the Investors’ pro rata share of the Acquisition Price is lower than the Minimum Investors’ Return, each Investor will have a put option against ABI. Such put option will be exercisable within 10 (ten) days, as of the receipt by the Investors of a notice sent by ABI informing that it has received a binding offer from one or more third parties willing to acquire the control of AB through a Change of Control Event (the “ Third Party Acquirer ”), and will entitle the Investors to sell all their Shares to ABI, for a total amount equal to the Put Option Price. Each of the Investors shall have the right to receive from ABI its pro rata share of the total Put Option Price, in accordance with its respective equity participation in AB determined as of the date the put option is exercised. The Put Option Price shall be paid by ABI to each Investor within 5 (five) business days of receipt by ABI of the effective payment, made by the Third Party Acquirer or by AB, of the sale proceeds arising from said Change of Control Event.

5.8.1    Change of Put Option Price.

In the event AB is valued at the Minimum Future AB Pre-Money Valuation in connection with a Change of Control Event or an IPO of AB, the price of the put option held by the Investors, in the situation described in this section 5.8, shall be the lower of (i) the amount invested by the Investors in AB in Brazilian Reais; and (ii) the total amount of proceeds actually received by ABI from a third party acquirer or from AB, in connection with a Change of Control Event relating to the Company.

SECTION SIX

INITIAL PUBLIC OFFERING OF AB

6.1      Approval of the IPO.

The Shareholders hereby commit to vote in a Shareholders’ Meeting in order to approve an IPO of the Company, after 4 (four) years of the Closing, as long as market conditions are favourable for an IPO, as determined by an internationally recognized investment bank to be selected by the Board of Directors.

6.2      Lock-Up after the IPO.

The Shareholders undertake to comply with written any recommendations of the investment bank coordinating the IPO relating to restrictions on Transfer of shares during a certain period following the IPO, such recommendations aimed at maximizing the shares’ price at the IPO, provided, however, that following such period, the Investors shall be immediately released from the lock-up established under section 5.1 above.

6.3      Secondary Offers by the Shareholders.

In the event the investment bank coordinating the IPO recommends that the IPO may include the offer of shares held by the shareholders (secondary offering), each of the Investors shall have the right to participate of such secondary offering, through the public offer of their Shares jointly with the Company’s primary offer at the time of the IPO, pro rata to their then stock ownership.


Execution Version

 

SECTION SEVEN

EFFECTS OF ABI CHANGE OF CONTROL EVENT AND ABI IPO

7.1      ABI Change of Control Event.

Subject to the restrictions on the transfer of the Shares set forth in Section Five above, if ABI undergoes a Change of Control Event, the following provisions shall apply:

 

(i) Each of the Investors shall have the right to convert all, and not less than all of its Shares in AB to shares of ABI common stock at the Conversion Ratio by providing written notice to ABI of its desire to carry out the conversion within ten (10) business days of receipt of a written notice by ABI, explaining the general terms of the transaction underlying the Change of Control Event, the identification of the potential acquirer(s), the expected closing date and the consideration to be provided for the acquisition of Control in AB (“ ABI Change of Control Notice ”);

 

(ii) In the case described in item “i” above, the Investors shall become shareholders of ABI after the conversion and before the Change of Control Event and will be able to sell their equity interest in ABI under the same conditions granted to other common stock holders of ABI within the Change of Control Event.

7.2      ABI IPO.

Subject to the restrictions on the transfer of AB’s Shares set forth in Section Five above, in the event of an ABI IPO, each of the Investors shall have the following rights:

 

(i) The right to exchange some or all of its Shares in AB for restricted shares of ABI common stock at the Conversion Ratio, by providing written notice to ABI of its desire to carry out the conversion, such notice to be delivered within ten (10) business days of receipt of a written notice informing the Investors about the ABI IPO which will be issued by ABI promptly after the relevant underwriter is chosen and a registration statement is filed with the United States Securities Exchange Commission, being certain that any such notice by the Investors shall be binding upon them after delivery, and that once the conversion is completed the Investors shall be subject to the lock-up requirements and any plan of sale requirements imposed by the underwriters of ABI. Notwithstanding the foregoing, the Investors acknowledge and agree that the shares of ABI to be received pursuant to this section 7.2(i) shall not be registered as secondary shares in the ABI IPO unless and to the extent determined by ABI in consultation with the relevant underwriter and as allowed by all applicable laws. In the event that the finance liquidation of the IPO does not occur for any reason within 12 (twelve) months as of the delivery of the notice mentioned above by the Investors to ABI, the Investors shall have the right to cancel the exchange of the applicable Shares for registered shares of ABI and to receive back its Shares issued by AB, at ABI’s expense, and the Parties hereby agree to take all measures necessary or required in order to implement the foregoing; and

 

(ii) Notwithstanding the foregoing, in the event the Parties and ABI’s Board of Directors agree to convert ABI’s investment in AB into BDRs, the Investors shall have the right to convert their AB Shares into ABI BDRs at the Conversion Ratio after the completion of an ABI IPO.


Execution Version

 

7.3.      ABI’s Call for Conversion.

ABI shall have the right to require the Investors to exchange some or all of their Shares in AB for restricted shares of ABI common stock, at the Conversion Ratio, in the event ABI is valued at least U.S.$ 500,000,000 (five hundred million United States dollars) in connection with an ABI IPO or an ABI Change of Control Event. In that case, ABI shall provide written notice to the Investors of its desire to carry out the conversion no later than ten (10) days prior to the closing of the transaction in connection with which the conversion is being required (the “ABI Conversion Notice”). The conversion will be effective immediately prior to the closing of the relevant transaction. The Investors shall (i) enter into the applicable agreement for effecting the conversion (in reasonable form provided by ABI), (ii) in the event the triggering transaction is an ABI IPO, enter into any lock-up agreement and/or plan of sale documents required by the underwriters, and (iii) enter into and deliver such other documents as are necessary to cause the relevant transaction to be completed. The Investors further agree to provide such information as may be requested by ABI to ensure compliance with all applicable laws, including securities laws. Each Party agrees to take such further actions as are necessary to cause the conversion of shares to be consummated.

 

  7.3.1 Each Party agrees to use reasonable efforts to cause the conversion of shares to be consummated in such a way that would maximize benefits for each of the Parties.

 

  7.3.2 In the event the conversion required under this section 7.3, cannot be carried out due to regulatory restrictions applicable to ABI or one of the Investors, the parties shall use reasonable efforts to agree on a mechanism, within 30 (thirty) days of receipt of the ABI Conversion Notice, by which the Investors would (i) cease to be shareholders of AB; and reach the same economic results as if they had converted their Shares into shares of ABI as provided herein. In any case, no regulatory restriction applicable to the Investors, nor the failure of any of the Investors to comply with any obligation provided for in the Agreement, especially those provided for in this Section 7.3 shall prevent ABI from exercising the right set forth in this section.

SECTION EIGHT

RIGHT TO CONVERT INTO ABI STOCK

8.1.      Right to Convert into ABI stock

 

(i) In case, by December 31, 2012, any of the Investors who remain as Shareholders of AB, having not converted their shares in AB to shares of ABI common stock pursuant to Section 7.1 in connection with a Change of Control of ABI, or pursuant to Section 7.2 or Section 7.3 in connection with an ABI IPO, such Investor will have the right to convert its Shares of AB into shares of ABI common stock, at the Conversion Ratio, subject to compliance by ABI and the Investors with all applicable laws (including securities laws).


Execution Version

 

(ii) The Investors will have fifteen (15) days from the abovementioned date to provide ABI with notice of their intention to convert their Shares of AB into shares of ABI common stock. ABI shall endeavor to use reasonable efforts to carry out the exchange of shares within ninety (90) days after the deadline provided for in this paragraph has elapsed.

8.2       The Parties agree that the right of the Investors to convert their Shares of into shares of ABI common stock, provided for in section 8.1 above, is fully conditioned and inherent to the fact that they are (i) shareholders of AB and (ii) part of this Agreement, so that this right, as well as any other rights or obligations arising out of this Agreement may not be transferred to any third party without the Parties’ prior consent. Any assignment of rights in disregard with this provision shall be rendered null and void.

SECTION NINE

INFORMATION RIGHTS

9.1.     Information Rights.

The following information rights shall apply to AB and to the Investors.

 

(i) The right to receive AB’s annual unaudited financial statements before March 15th of the subsequent year and audited financials as soon as they are available;

 

(ii) Forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, the right to request and receive financial and operational reports relating to a certain month;

 

(iii) At each Party’s own expense, upon reasonable advanced notice and during normal business hours: (A) the right to inspect AB’s facilities; (B) the right to inspect AB’s books and records; and (C) reasonable access rights to members of AB’s management team.

SECTION TEN

CORPORATE GOVERNANCE STANDARDS

10.1     Corporate Governance Standards.

The Company and its management shall follow the best practices of corporate governance, following the requirement of Bovespa Mais, including in relation to transparency and reporting, and shall adopt the following practices:

 

(i) During the first year following December 22nd, 2009, the Company shall hold at least ten meetings of the Board of Directors per year;

 

(ii) After the period mentioned in “i” above, if approved by an unanimous vote of the Board of Directors, the Company shall hold at least quarterly meetings of the Board of Directors per year;


Execution Version

 

(iii) The agenda with matters to be discussed in meetings of the Board of Directors shall be distributed to its member with 8 (eight) days in advance;

 

(iv) The meetings of the Board of Directors may be carried out through videoconference or teleconference;

 

(v) Monthly the management of the Company shall inform the Shareholders about revenues, cash and debt position on a monthly basis.

SECTION ELEVEN

SPECIFIC PERFORMANCE

11.1    Specific Performance.

The Shareholders agree that the obligations imposed on them in this Agreement are special, unique and of an extraordinary character, and that, in the event of breach by any Shareholder, damages would not be an adequate remedy and, therefore, each of the other Shareholders shall be entitled to specific performance and injunctive relief, in addition to any other remedy to which it may be entitled, by law or in equity; and the Shareholders further agree to waive any requirement for the securing or posting of any bond in connection with the obtaining of any such injunctive or other equitable relief. The Shareholders agree that all of the obligations undertaken by them hereunder are subject to, and shall enjoy the benefit of specific performance in accordance with Articles 461, 466-A and 466-B of the Brazilian Civil Procedure Code.

SECTION TWELVE

GENERAL PROVISIONS

12.1    Entire Agreement.

This Agreement shall constitute the entire agreement between the Parties hereto and supersede and replace all other agreements and understandings, verbal or written, among the Parties with respect to the subject matter of this Agreement. No amendment or modification of any provision of this Agreement shall be effective unless it is done in writing and signed by each of the Parties.

12.2    Severability.

The invalidity of one or more provisions of this Agreement shall not affect the validity of this Agreement as a whole unless the invalid provision was of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without such invalid provision. The Parties shall negotiate in good faith to substitute any invalid provisions with other provisions that may substantially achieve their original intentions.

12.3    Waiver.

Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The


Execution Version

 

failure of any Party at any time to enforce any provision of this Agreement shall not in any way affect its rights to require performance thereof, nor shall the waiver of any breach of any provision hereof be taken or held to be a waiver of any succeeding breach of any such provision or as a waiver or a novation ( novação ) of the provision itself.

12.4    Assignment.

No Party may directly or indirectly transfer any of its rights and obligations under this Agreement to any third party, without the prior written consent of the other Party, except that (i) any person may acquire the Shares in compliance with the provisions of Section Five hereto, and then adhere to this Agreement, and (ii) that Stratus may transfer any of its rights and obligations under this Agreement to any of its Affiliates without the need of prior written consent of the other Parties.

12.5    Costs and Expenses.

Each Party shall bear all costs and expenses incurred by it in connection with the preparation, negotiation and delivery of this Agreement. However, AB shall either pay directly or reimburse the Investors and ABI (the latter at ABI’s own election) for reasonable transaction-related expenses, not to exceed R$ 250,000 (two hundred and fifty thousand Brazilian Reais) for each of ABI and the Investors. In the case of ABI, reasonable transaction related expenses shall be deemed to include any IOF or similar taxes associated with the ABI Cash Contribution.

12.6    Notices.

All notices, requests, claims and other communications hereunder shall be in writing and communicated to the receiving party either by hand, or sent by registered mail, electronic mail or facsimile and addressed as follows or to such other addresses as may from time to time be notified by any Party to the other Party:

If to ABI :

AMYRIS BIOTECHNOLOGIES, INC.

Address: 5885 Hollis Street, Suite 100, Emeryville, California 94608, USA

Telephone: +1 510 740-7416

Fax: +1 510 842 1460

E-mail: tompkins@amyris.com

Attn: Tamara Tompkins - General Counsel

If to Stratus :

FUNDO MÚTUO DE INVESTIMENTO EM EMPRESAS EMERGENTES INOVADORAS

STRATUS GC III

Address: Rua Funchal, 129, 13 th floor, São Paulo, SP, Brazil

Telephone: +55 11 2166-8800

Fax: +55 11 2166-8801

E-mail: acamoes@stratusbr.com

Attn: Alberto Camões


Execution Version

 

Copy to :

MACHADO, MEYER, SENDACZ E OPICE ADVOGADOS

Address: Avenida Brigadeiro Faria Lima, 3144, 11 th floor

Telephone: +55 11 3150-7647

Fax: +55 11 3150-7071

E-mail: mau@mmso.com.br

Attn.: Mauro Cesar Leschziner

If to AB :

AMYRIS BRASIL S.A.

Address: Rua James Clerk Maxwell, 315, Campinas, SP, Brazil

Telephone: +55 19 3783-9450

Fax: +55 19 3283-0005

E-mail: collier@amyris.com

Attn: Roel Collier

If to Red Mountain :

PEDRO PAULO FALLEIROS DOS SANTOS DINIZ

Address: Rua Jerônimo da Veiga, 384, 3 rd floor

Telephone: +55 11 3705-5161

Fax: + 55 11 3702-5112

E-mail: pedro@ppdholding.com

Copy to :

KLA- KOURY LOPES ADVOGADOS

Address: Avenida Brigadeiro Faria Lima, 1355, 18 th floor

Telephone: +55 11 3799-8118

Fax: +55 11 3799-8200

E-mail: mcortez@klalaw.com.br

Attn.: Mariana Machado Cortez

12.6.1  Delivery of Notice.

Any notice served by hand shall be deemed to have been served upon delivery. Any notice served by prepaid registered mail shall be deemed to have been served upon evidenced receipt. Any notice served by e-mail or facsimile shall be deemed to have been served when sent, provided that evidence has been produced showing that the notice has been sent to the facsimile number/e-mail address, as indicated in this Agreement.

12.6.2  Change of Data.

In case of any change of data, if the new information is not notified by the relevant Party to the other Party, all notices sent to the previous addresses shall be deemed to have been duly served.


Execution Version

 

12.7    Language.

This Agreement shall be executed in the English and Portuguese languages, provided that the English version shall prevail, including in arbitration, and excluding when in proceedings before Brazilian courts, in which the Portuguese version shall prevail.

SECTION THIRTEEN

GOVERNING LAW AND DISPUTE RESOLUTION

13.1    Governing Law.

This Agreement shall be governed by and construed in accordance with the laws of Brazil.

13.2    Dispute Resolution.

Any dispute, controversy or claim by and among the Parties to this Agreement, arising out of or relating to this Agreement, or the breach, termination or validity hereof, shall be settled by arbitration in accordance with the Rules of Arbitration of the Câmara de Comércio Brasil-Canadá (the “ Rules of Arbitration ”). The decision of the arbitrators shall be final and binding upon the Parties with no further appeal, recourse or review. Until such decision, the Parties agree to keep the arbitration procedure on a confidential basis, except to the extent necessary for any interim or conservatory measures permitted under the Rules of Arbitration.

13.2.1  Arbitration Place.

The place of arbitration shall be in the City of São Paulo, State of São Paulo, Brazil, where the arbitration award shall be rendered.

13.2.2  Arbitration Language.

The language of the arbitration shall be English.

13.2.3  Judicial Measures.

Without prejudice to this section 13.2 and without limiting any other powers the arbitrators may have, the Parties remain fully entitled to request judicial measures: (a) in order to obtain preliminary and urgent measures ( medidas cautelares ) prior to the formation of the arbitral tribunal, and such judicial recourse shall not be interpreted as a waiver of the arbitration as set forth in this section; and (b) to enforce any arbitral decision, including the final award. For that purpose, the Parties elect the courts of the city of São Paulo, State of São Paulo, Brazil, being waived any other no matter how privileged it may be. The Parties recognize that any provisional or urgent matter granted by judicial courts shall be, necessarily, reviewed by the arbitral tribunal, which shall decide on its ratification, revision or cancellation.”

12.      Language. This Amendment shall be executed in the English and Portuguese languages, provided that the English version shall prevail, including in arbitration, and excluding when in proceedings before Brazilian courts, in which the Portuguese version shall prevail.


Execution Version

 

In witness whereof, this Amendment is executed in 5 (five) counterparts of the same form and content, in the City of São Paulo, State of São Paulo, Brazil, on May 26, 2010.

PARTIES:

 

    /s/ [illegible]
R ED M OUNTAIN J ET LLC
    /s/ [illegible]
F UNDO M ÚTUO DE I NVESTIMENTO EM E MPRESAS E MERGENTES I NOVADORAS S TRATUS GC III BY ITS MANAGER S TRATUS GESTÃO DE CARTIEIRAS LTDA .
    /s/ [illegible]
A MYRIS B IOTECHNOLOGIES , I NC .
    /s/ [illegible]
A MYRIS B RASIL S.A.
    /s/ [illegible]
S TRATUS I NVESTIMENTOS L TDA .

WITNESSES:

 

1.       /s/ Luana Komatsu       2.        /s/ Gabriel Aldallah Mundim

Name: Luana YoKo Vieira Komatsu

     

Name: Gabriel Aldallah Mundim

Exhibit 4.18

 

 

AMYRIS, INC.

SERIES D PREFERRED STOCK PURCHASE AGREEMENT


AMYRIS, INC.

SERIES D PREFERRED STOCK PURCHASE AGREEMENT

THIS SERIES D PREFERRED STOCK PURCHASE AGREEMENT (this “ Agreement ”) is made as of June 21, 2010, by and among Amyris, Inc., a Delaware corporation (the “ Company ”), and the investor listed on Schedule A hereto, which investor is herein referred to as the “ Investor ”.

THE PARTIES HEREBY AGREE AS FOLLOWS:

1.       Purchase and Sale of Stock .

1.1     Sale and Issuance of Series D Preferred Stock .

(a)     The Company shall adopt and file with the Secretary of State of Delaware on or before the Closing (as defined below) the Restated Certificate of Incorporation in the form attached hereto as Exhibit A (the “ Restated Certificate ”). The Company has authorized (i) the sale and issuance to the Investor of the Series D Preferred Stock and (ii) the issuance of such shares of Common Stock to be issued upon conversion of the Series D Preferred Stock. The Series D Preferred Stock and the Common Stock to be issued upon conversion of the Series D Preferred Stock have the powers, preferences and rights set forth in the Restated Certificate.

(b)     Subject to the terms and conditions of this Agreement, the Investor agrees to purchase at the Closing, and the Company agrees to sell and issue to the Investor at the Closing, that number of shares of the Company’s Series D Preferred Stock (the “ Series D Preferred Stock ”) set forth opposite such Investor’s name on Schedule A hereto at a purchase price per share of $18.75.

1.2     Closing .     The purchase and sale of the Series D Preferred Stock (the “ Closing ”) shall take place via the electronic exchange of documents and signatures on the date hereof, or at such other time and place as the Company and the Investor may mutually agree. At the Closing, the Company shall deliver to the Investor a certificate representing the Series D Preferred Stock that such Investor is purchasing against delivery to the Company by such Investor of a wire transfer evidenced by a Swift message and/or cancellation of indebtedness, or any combination thereof, in the amount of the purchase price therefor payable to the Company. The Investor shall become a party to this Agreement, the Amended and Restated Investors’ Rights Agreement, attached hereto as Exhibit B (the “ Investors’ Rights Agreement ”), the Amended and Restated Right of First Refusal and Co-Sale Agreement, attached hereto as Exhibit C (the “ Co-Sale Agreement ”), the Amended and Restated Voting Agreement, attached hereto as Exhibit D (the “ Voting Agreement ”), and the Side Letter attached hereto as Exhibit F (the “Side Letter”)(collectively, the “ Transaction Documents ”) and shall have the rights and obligations thereunder.


1.3     IPO Valuation Adjustment Payment .

(a)       Payment . Concurrent with the closing of the IPO (as defined below) and provided that such IPO closing occurs on or before September 30, 2010, the Investor shall pay the IPO Valuation Adjustment (as defined below) to the Company, if such amount is a positive number.

(b)       Definitions .

(i)     “ Adjusted Pre-Series D Fully Diluted Capitalization ” means 34,672,921 shares of Common Stock, which equates to the sum of (A) the total number of shares of the Company’s Common Stock outstanding immediately following the Closing, plus (B) the total number of shares of the Company’s Common Stock into which all then outstanding shares of the Company’s Preferred Stock, but excluding the shares of Series D Preferred Stock issued to the Investor at the Closing, are then convertible, plus (C) the total number of shares of the Company’s Common Stock for which all outstanding options to purchase Common Stock may be exercised (treating all options as exercisable, whether or not then-vested or exercisable) and the total number of authorized but unissued shares of Common Stock available for issuance pursuant to the Option Plan (as defined in Section 2.2(d) below) (or any other equity incentive plan), plus (D) the total number of shares of the Company’s Common Stock that may be issued upon exercise or exercise and conversion of outstanding securities not already described above (including, for the avoidance of doubt, all shares of Common Stock directly or indirectly issuable on account of securities of Amyris Brasil S.A. then outstanding).

(ii)     “ IPO ” means the initial public offering of the Company’s Common Stock registered pursuant to the Act.

(iii)     “ IPO Price ” means the initial price per share to the public in the IPO.

(iv)     “ IPO Valuation ” means the lesser of (A) the product of (I) the IPO Price multiplied by (II) the Adjusted Pre-Series D Fully Diluted Capitalization, and (B) $1,000,000,000.

(v)     “ IPO Valuation Adjustment ” shall be equal to:

[((80% x $650,000,000) + (20% x IPO Valuation)) / 83%] x 17% - $133,130,000.00

(c)       IPO Certificate . At the closing of the IPO, provided that such IPO occurs on or before September 30, 2010, the Company shall deliver to the Investor a certificate certifying that as of such date the prospectus contained in the Registration Statement (as defined below) did not contain an untrue statement of a material fact or, to the Company’s knowledge, omit to state a material fact necessary in order to make the statements contained therein not misleading.

1.4    The Company will use the proceeds from the sale of the Series D Preferred Stock for the establishment of production facilities, research and development

 

2


expenditures and working capital or other corporate purposes as determined by management and/or the Company’s Board of Directors.

2.       Representations and Warranties of the Company . The Company hereby represents and warrants to the Investor as of the date hereof that, except as set forth in the Disclosure Schedule in the form provided to special counsel to the Investor, which exceptions shall be deemed to be representations and warranties as if made hereunder:

2.1     Organization, Good Standing and Qualification .

(a)     The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted and as presently proposed to be conducted, to own and operate its assets and to enter into the Transaction Documents, issue and sell the Series D Preferred Stock and the Common Stock to be issued upon conversion of the Series D Preferred Stock and to carry out the provisions of the Transaction Documents and the Restated Certificate. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a material adverse effect on its business, properties, assets, liabilities, operations, prospects or financial condition.

(b)     Each of the Company’s subsidiaries set forth in Section 2.1 of the Disclosure Schedule (collectively, the “ Subsidiaries ”) is duly organized, validly existing and, if applicable, in good standing under the laws of its jurisdiction of organization and has all requisite corporate power and authority to carry on its business as now conducted and as presently proposed to be conducted, and to own and operate its assets. Each such subsidiary is duly qualified to transact business and, if applicable, is in good standing in each jurisdiction in which the failure to so qualify would have a material adverse effect on its business, properties, assets, liabilities, operations, prospects or financial condition.

2.2     Capitalization and Voting Rights . The authorized capital of the Company will consist immediately prior to the Closing (unless otherwise noted) of:

(a)      Preferred Stock . 30,963,903 shares of Preferred Stock (the “ Preferred Stock ”) of which 9,475,000 shares have been designated Series A Preferred Stock, all of which are issued and outstanding, 1,929,641 shares have been designated Series B Preferred Stock, 1,667,817 of which are issued and outstanding, 4,700,000 shares have been designated Series B-1 Preferred Stock, 2,615,721 of which are issued and outstanding, 4,976,000 shares have been designated Series C Preferred Stock, 4,902,665 of which are issued and outstanding, 2,781,714 shares have been designated Series C-1 Preferred Stock, 2,724,766 of which are issued and outstanding, 7,101,548 shares have been designated Series D Preferred Stock, none of which are issued and outstanding and all of which may be sold pursuant to this Agreement. The powers, preferences and rights of the Series D Preferred Stock, Series C-1 Preferred Stock, Series C Preferred Stock, Series B-1 Preferred Stock, Series B Preferred Stock and Series A Preferred Stock will be as stated in the Restated Certificate. Each outstanding series of Preferred Stock is convertible into Common Stock on a one-for-one basis as of the date hereof, and the consummation of the transactions contemplated hereunder will not result in any anti-dilution adjustment or similar adjustment to the outstanding shares of Preferred Stock.

 

3


(b)       Common Stock . 70,000,000 shares of common stock (“ Common Stock ”), of which 5,128,045 shares are issued and outstanding.

(c)       Valid Issuance . The outstanding shares of Common Stock and Preferred Stock are (i) all duly and validly authorized and issued, fully paid and nonassessable, and were issued in accordance with the registration or qualification provisions of the Securities Act of 1933, as amended (the “ Act ”), and any relevant state securities laws, or pursuant to valid exemptions therefrom and (ii) the outstanding shares of Common Stock are subject to a right of first refusal in favor of the Company on transfer. All outstanding shares of Common Stock and Preferred Stock and all shares of Common Stock and Preferred Stock issuable upon the exercise or conversion of outstanding options, warrants or other exercisable or convertible securities are subject to a market standoff or “lockup” agreement of not less than 180 days following the Company’s initial public offering.

(d)       Stock Options / Rights to Acquire Stock .

(i)     Except for (A) the conversion privileges of the Series D Preferred Stock to be issued under this Agreement, the Series C-1 Preferred Stock, the Series C Preferred Stock, the Series B-1 Preferred Stock, the Series B Preferred Stock and the Series A Preferred Stock, (B) outstanding options and restricted stock under the Company’s 2005 Stock Option/Stock Issuance Plan (the “ Option Plan ”) to purchase 6,227,980 shares (the “ Outstanding Pool ”) of Common Stock of the Company, and (C) the rights provided in that certain Investors’ Rights Agreement, as the same may be amended from time to time, there are no options, warrants, rights (including but not limited to conversion or preemptive rights and rights of first refusal) or proxy or stockholder rights or agreements of any kind for the purchase or acquisition or other rights to receive from the Company any shares of its capital stock. In addition, there are no options, warrants, rights (including but not limited to conversion or preemptive rights and rights of first refusal) or proxy or stockholder rights or agreements of any kind for the purchase or acquisition or other rights to receive from any of the Subsidiaries any shares of its capital stock. In addition to the aforementioned options, the Company has reserved an additional 124,592 shares (the “ Available Pool ”) of its Common Stock for purchase upon exercise of options to be granted in the future under the Option Plan. The Company has reserved a total of 7,342,700 shares of Common Stock for issuance under the Option Plan, including the Outstanding Pool and the Available Pool. The Company has not made any representations regarding equity incentives to any officer, employee, director or consultant that are inconsistent with the share amounts and terms set forth in the Company’s board minutes. The Company is not a party or subject to any agreement or understanding, and to the Company’s knowledge, there is no agreement or understanding between any persons and/or entities that affects or relates to the voting or giving of written consents with respect to any security or by a director of the Company, other than the Voting Agreement, as the same may be amended from time to time.

(ii)     All options granted and Common Stock issued prior to July 18, 2006 vest as follows: twenty-five percent (25%) of the shares vest one (1) year following the vesting commencement date, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the next three (3) years. All options granted and Common Stock issued on or after July 18, 2006 vest as follows: twenty percent (20%) of the shares vest one (1) year following the vesting commencement date, with the remaining eighty percent (80%) vesting

 

4


in equal monthly installments over the next four (4) years. No stock plan, stock purchase, stock option or other agreement or understanding between the Company and any holder of any equity securities or rights to purchase equity securities provides for acceleration or other changes in the vesting provisions or severance or bonus payments or other terms of such agreement or understanding as the result of (A) termination of employment or consulting services (whether actual or constructive); (B) any merger, consolidated sale of stock or assets, change in control or any other transaction(s) by the Company; or (C) the occurrence of any other similar event or combination of similar events. All options granted and Common Stock issued were issued in accordance with the registration or qualification provisions of the Act, and any relevant state securities laws, or pursuant to valid exemptions therefrom.

(e)      Section 2.2(e) of the Disclosure Schedule sets forth the capitalization of the Company and each of its Subsidiaries immediately following the Initial Closing, including the number of shares of the following: (i) issued and outstanding Common Stock, (ii) issued stock options, (iii) stock options not yet issued but reserved for issuance; (iv) each series of Preferred Stock; and (v) warrants or stock purchase rights, and any other rights to purchase or receive shares of the Company, including but not limited to by conversion of shares of any of its Subsidiaries (if any).

(f)      409A . The Company believes in good faith that any “nonqualified deferred compensation plan” (as such term is defined under Section 409A(d)(1) of the Code and the guidance thereunder) under which the Company makes, is obligated to make or promises to make, payments (each, a “ 409A Plan ”) complies in all material respects, in both form and operation, with the requirements of Section 409A of the Code and the guidance thereunder. To the knowledge of the Company, no payment to be made under any 409A Plan is, or will be, subject to the penalties of Section 409A(a)(1) of the Code.

2.3     Subsidiaries .   Except for the Subsidiaries, the Company has never owned or controlled, and does not presently own or control, directly or indirectly, any interest in any other corporation, partnership, association, or other business entity. The Company is not a participant in any joint venture, partnership, limited liability company or similar arrangement. Since its inception, the Company has not consolidated or merged with, acquired all or substantially all of the assets of, or acquired the stock of or any interest in any corporation, partnership, limited liability company or other business entity. Each of the Subsidiaries is wholly-owned by the Company.

2.4     Authorization .   All corporate action on the part of the Company and its officers, directors and stockholders necessary for the authorization, execution and delivery of the Transaction Documents and the Restated Certificate, the performance of all obligations of the Company hereunder and thereunder and the authorization, issuance (and reservation for issuance), sale and delivery of the Series D Preferred Stock being sold hereunder and the Common Stock issuable upon conversion of the Series D Preferred Stock has been taken or will be taken prior to the Closing, and the Transaction Documents, and all the other agreements required to be executed and delivered by the Company in connection therewith, constitute valid and legally binding obligations of the Company, enforceable against the Company in accordance with their terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights

 

5


generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) to the extent the indemnification provisions contained in the Investors’ Rights Agreement may be limited by applicable federal or state securities laws.

2.5     Valid Issuance of Preferred and Common Stock . The Series D Preferred Stock that is being purchased by the Investor, when issued, sold and delivered in accordance with the terms hereof for the consideration expressed herein, will be duly and validly issued, fully paid and nonassessable, will be free of restrictions on transfer (other than restrictions on transfer contained in the Transaction Documents and under applicable federal and state laws), and will be issued in compliance with all applicable federal and state securities laws. The Common Stock issuable upon conversion of the Series D Preferred Stock purchased under this Agreement has been duly and validly reserved for issuance and, upon issuance in accordance with the terms of the Restated Certificate, shall be duly and validly issued, fully paid and nonassessable and will be free of restrictions on transfer (other than restrictions on transfer contained in the Transaction Documents and under applicable federal and state laws). The powers, preferences and rights of the Series D Preferred Stock are as set forth in the Restated Certificate. The sale of the Series D Preferred Stock and the subsequent conversion of the Series D Preferred Stock into Common Stock are not and will not be subject to any preemptive rights or rights of first refusal that have not been properly waived or complied with.

2.6     Governmental Consents . No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority on the part of the Company is required in connection with the consummation of the transactions contemplated by this Agreement, except for filings pursuant to state securities laws (all of which have been made by the Company, other than those that are required to be made after the Closing and that will be duly made within the time period required by such laws).

2.7     Litigation . There is no action, suit, proceeding or investigation pending or, to the Company’s knowledge, currently threatened against the Company or the Subsidiaries, or to the Company’s knowledge, currently threatened in writing against the Company, any of its Subsidiaries or any officer, director or key employee of the Company or any of the Subsidiaries arising out of their employment or Board of Directors relationship with the Company or any of the Subsidiaries, or that questions the validity of the Transaction Agreements or the right of the Company to enter into them, or to consummate the transactions contemplated by the Transaction Agreements. The foregoing includes, without limitation, actions, suits, proceedings or investigations pending or threatened (or any reasonable basis therefor known to the Company) involving the prior employment of any of the employees, consultants or officers of the Company or the Subsidiaries, their use in connection with the Company’s business of any information or techniques allegedly proprietary to any of their former employers, or their obligations under any agreements with prior employers. Neither the Company nor the Subsidiaries is a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. There is no action, suit, proceeding or investigation by the Company or the Subsidiaries currently pending or that the Company or the Subsidiaries intends to initiate.

2.8     Proprietary Information and Inventions Agreements . Each current and former employee or consultant of the Company and the Subsidiaries has executed an employee

 

6


proprietary information and inventions agreement, consultant proprietary information nondisclosure agreement, consulting services agreement or confidential information and invention assignment agreement, in the forms provided to special counsel to the Investor (each a “ PIIA ”). The Company does not believe it is or will be necessary to utilize any inventions, trade secrets or proprietary information of any of its or the Subsidiaries’ employees or consultants made prior to their employment by or engagement with the Company or the Subsidiaries, except for inventions, trade secrets or proprietary information that have been assigned to the Company or the Subsidiaries.

2.9      Title to Property and Assets . The Company and/or the Subsidiaries have good and marketable title to all of its properties and assets free and clear of all mortgages, pledges, leases, liens and encumbrances, except (i) liens for current taxes and assessments not yet due and (ii) possible minor liens and encumbrances that arise in the ordinary course of business and do not, in any case, individually or in the aggregate, materially detract from the value of the property subject thereto or materially impair the operations of the Company or the Subsidiaries or materially impair the Company’s or the Subsidiaries’ ownership or use of such properties or assets. With respect to the property and assets they lease, the Company and the Subsidiaries are in compliance with such leases in all material respects and, to the Company’s knowledge, hold a valid leasehold interest free of all liens, claims or encumbrances, subject to clauses (i) and (ii). The Company’s properties and assets, and those of the Subsidiaries, are in good condition and repair in all material respects (ordinary wear and tear excepted).

2.10      Employees . Schedule 2.10 of the Disclosure Schedule describes how many full-time employees and part-time employees the Company and each of the Subsidiaries employs. The Company and the Subsidiaries have complied with all applicable laws related to employment. Neither the Company nor the Subsidiaries is a party to or bound by any currently effective employment contract, employee benefit plan (as defined in the Employee Retirement Income Security Act of 1974, as amended), deferred compensation agreement, severance agreement, bonus plan, incentive plan, profit sharing plan, retirement agreement or other employee compensation agreement or arrangement with any collective bargaining agent. No employees of the Company or the Subsidiaries are represented by any labor union or covered by any collective bargaining agreement. There is no pending or, to the Company’s knowledge, threatened labor dispute involving the Company or the Subsidiaries and any employee or group of its employees. To the Company’s knowledge, no officer, key employee or group of employees intend to terminate his, her or their employment with the Company or the Subsidiaries nor does the Company or the Subsidiaries have a present intent to terminate the employment of any officer, key employee or group of employees. No employee of the Company or the Subsidiaries has been granted the right to continued employment by the Company or the Subsidiaries or to any material compensation following termination of employment with the Company or the Subsidiaries. To the Company’s knowledge, no employee of the Company or the Subsidiaries, nor any consultant with whom the Company or the Subsidiaries has contracted, is in violation of any term of any employment contract, proprietary information agreement or any other agreement relating to the right of any such individual to be employed by, or to contract with, the Company or the Subsidiaries; and, to the Company’s knowledge, the continued employment by the Company or the Subsidiaries of its present employees, and the performance of the Company’s contracts with its independent contractors, will not result in any such violation. Neither the Company nor the Subsidiaries has received any notice alleging that any such

 

7


violation has occurred. Each former employee of the Company or the Subsidiaries whose employment was terminated by the Company or the Subsidiaries has entered into an agreement with the Company or the Subsidiaries providing for the full release of any claims against the Company or the Subsidiaries or any related party arising out of such employment. The Company is not delinquent in payments to any of its employees, consultants, or independent contractors for any wages, salaries, commissions, bonuses, or other direct compensation for any service performed for it to the date hereof or amounts required to be reimbursed to such employees, consultants, or independent contractors. The Company has complied in all material respects with all applicable state and federal equal employment opportunity laws and with other laws related to employment, including those related to wages, hours, worker classification, and collective bargaining. The Company has withheld and paid to the appropriate governmental entity or is holding for payment not yet due to such governmental entity all amounts required to be withheld from employees of the Company and is not liable for any arrears of wages, taxes, penalties, or other sums for failure to comply with any of the foregoing.

2.11      Authorization of Agreements, Etc . The execution, delivery and performance of this Agreement and the Transaction Documents and the consummation of the transactions contemplated hereby will not result in (i) the violation of any provision of the Restated Certificate or the Bylaws of the Company or any of the Subsidiaries or, (ii) to the Company’s knowledge, any violation of any provision of law or any order of any court or other agency of government, or (iii) any violation of any provision of any material indenture, agreement or other instrument to which the Company or the Subsidiaries is bound, or be in conflict with or constitute, with or without the passage of time and giving of notice, either a default under any such material indenture, agreement or other instrument or result in the creation of any lien, charge or encumbrance upon any assets of the Company or the Subsidiaries or the suspension, revocation, impairment, forfeiture or nonrenewal of any permit, license, authorization or approval applicable to the Company or the Subsidiaries, their business operations, or any of their assets or properties.

2.12      Intellectual Property .

(i)       The Company and/or the Subsidiaries owns or possesses all legal rights to patents, patent applications, trademark rights, service marks, service mark rights, trade names, trade name rights, licenses, domain names, trade secrets, copyrights, information and processes and similar proprietary rights (collectively, the “ Intellectual Property ”) necessary for their business as now conducted and as proposed to be conducted. The Company and the Subsidiaries have taken all steps reasonably necessary to preserve their legal rights in all their Intellectual Property, except those for which disclosure is required for legitimate business or legal reasons. Section 2.12 of the Disclosure Schedule lists all registered Company and Subsidiary Intellectual Property.

(ii)       There are no outstanding options, licenses or agreements claims, encumbrances or shared ownership interests of any kind relating to the Company’s or the Subsidiaries’ Intellectual Property, nor is the Company or the Subsidiaries bound by or a party to any options, licenses or agreements of any kind with respect to the Intellectual Property of any other person or entity, except for standard end-user, object code, internal-use software license and support and/or maintenance agreements entered into in the ordinary course of business.

 

8


(iii)       Neither the Company nor the Subsidiaries has received any communications alleging that either the Company or any of the Subsidiaries has violated or, by conducting its business as proposed, would violate, infringe or misappropriate any of the Intellectual Property of any other person or entity.

(iv)       To the Company’s knowledge, none of the employees of the Company or the Subsidiaries are obligated under any contract (including, without limitation, licenses, covenants or commitments of any nature or contracts entered into with prior employers), or subject to any judgment, decree or order of any court or administrative agency, that would interfere with the use of his or her best efforts to promote the interests of the Company or the Subsidiaries or would conflict with the business as proposed of the Company or the Subsidiaries.

(v)       Neither the execution nor delivery of the Transaction Documents will conflict with or result in a breach of the terms, conditions or provisions of, or constitute a default under any contract, covenant or instrument under which any of the employees of the Company or the Subsidiaries is now obligated and of which the Company is aware, and neither the Company nor the Subsidiaries will need to use any inventions that any of its employees, or persons it currently intends to employ, have made prior to their employment with the Company or the Subsidiaries, except for inventions that have been assigned or licensed to the Company or the Subsidiaries as of the date hereof.

2.13      Agreements; Action.

   (a)     Except for agreements explicitly contemplated hereby and by the other Transaction Documents, there are no agreements, or proposed transactions between the Company or the Subsidiaries and any of their officers, directors, employees, affiliates or, to the Company’s knowledge, any affiliate thereof.

   (b)     There are no agreements, contracts, instruments, judgments, orders, writs or decrees to which the Company or the Subsidiaries is a party or by which the Company or the Subsidiaries is bound that may involve (i) obligations of or payments to the Company or the Subsidiaries, respectively, in excess of $500,000, (ii) any license of any Intellectual Property to or from the Company or the Subsidiaries (other than the license to the Company of standard, generally commercially available, “off-the-shelf” third-party products), (iii) indemnification by the Company or the Subsidiaries with respect to infringements of proprietary rights, or (iv) provisions restricting the development, manufacture or distribution of the products or services of the Company or the Subsidiaries.

   (c)     The Company has not (i) accrued, declared or paid any dividends or authorized or made any distribution upon or with respect to any class or series of its capital stock, (ii) incurred any liabilities or guaranteed any indebtedness for money borrowed individually in excess of $500,000 or, in the case of indebtedness and/or liabilities individually less than $500,000, in excess of $1,000,000 in the aggregate, (iii) made any loans or advances to any person, other than ordinary reasonable advances for travel expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than the sale of its inventory in the ordinary course of business.

 

9


(d)     For the purposes of subsections (b) and (c) above, all indebtedness, liabilities, agreements and contracts involving the same person or entity shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such subsections.

(e)     Neither the Company nor the Subsidiaries is in violation or default of any term (including without limitation any diligence obligation) or of any provision of any of the agreements set forth in Schedule 2.13 of the Disclosure Schedule (the “ Material Agreements ”). The execution, delivery, and performance of and compliance with this Agreement, and the Transaction Documents, and the issuance and sale of the Series D Preferred Stock pursuant hereto and of the Common Stock issuable upon conversion of the Series D Preferred Stock pursuant to the Restated Certificate, will not, with or without the passage of time or giving of notice, result in any such violation, or be in conflict with or constitute a default under any such term or provision, or result in the creation of any mortgage, pledge, lien, encumbrance or charge upon any of the properties or assets of the Company or the Subsidiaries or the suspension, revocation, impairment, forfeiture or nonrenewal of any Material Agreement, permit, license, authorization or approval applicable to the Company or the Subsidiaries, its business or operations or any of its assets or properties. The Company has avoided every condition, and has neither performed any act, the occurrence of which would result in the loss of any right granted to the Company or the Subsidiaries under any Material Agreement, nor failed to perform any act, the failure of which would result in the loss of any right granted to the Company or the Subsidiaries under any Material Agreement.

2.14     Permits .   The Company and the Subsidiaries have all franchises, permits, licenses and any similar authority necessary for the conduct of their business as it is now being conducted, the lack of which could materially and adversely affect the business or assets of the Company or the Subsidiaries, and the Company believes it can obtain or the Subsidiaries can obtain, without undue burden or expense, any similar authority for the conduct of their business as planned to be conducted.

2.15     Compliance with Other Instruments, Etc .   The Company and the Subsidiaries are not in violation of any provision of the Company’s Restated Certificate of Incorporation or Bylaws, or in breach of any term or provision of any agreement, indenture, contract, lease, instrument or contract to which the Company or the Subsidiaries is a party that is required to be listed on Schedule 2.13 of the Disclosure Schedule (a) such violation could reasonably be expected to have a material adverse effect upon the financial condition, operating results, assets or business of the Company or the Subsidiaries, or (b) such agreement, indenture, contract, lease, instrument or contract is required to be listed on Schedule 2.13 of the Disclosure Schedule, and are not in violation of any writ, order, statute, rule or regulation applicable to the Company or the Subsidiaries where such violation could reasonably be expected to have a material adverse effect upon the financial condition, operating results, assets or business of the Company or the Subsidiaries.

2.16     Offering .   Assuming the accuracy of the Investor’s representations and warranties in Section 3 hereof, the offer, sale and issuance of the Series D Preferred Stock to be issued in conformity with the terms of this Agreement and the issuance of the Common Stock to be issued upon conversion of such shares, constitute transactions exempt from the registration requirements of Section 5 of the Act and from the qualification requirements of the California

 

10


Corporate Securities Law of 1968, as amended (the “ Registration Requirements ”), and will be exempt from the Registration Requirements at the closing of any public offering of the Company’s securities, including but not limited to any offering pursuant to the Registration Statement on Form S-1 filed by the Company with the Securities and Exchange Commission (the “ SEC ”) on April 16, 2010 (as subsequently amended) (the “ Registration Statement ”).

2.17     Financial Statements . The Company has delivered to the Investor the Company’s and the Subsidiaries’ audited financial statements for the fiscal year ended December 31, 2009 and the Company’s and the Subsidiaries” unaudited financial statements (including balance sheet, income statement and statement of cash flows) as of March 31, 2010 and for the three (3) month period ending March 31, 2010 (the “ Financial Statements ”), and except as set forth in Section 2.17 of the Disclosure Schedule, such Financial Statements are accurate and complete in all material respects, are consistent with the books and records of the Company and the Subsidiaries and have been prepared in accordance with U.S. generally accepted accounting principles (“ GAAP ”), except that the unaudited Financial Statements may not contain all footnotes required by GAAP. The Financial Statements fairly present the financial condition and operating results of the Company and the Subsidiaries as of the dates, and for the periods, indicated therein, subject to normal year-end audit adjustments, which are not expected to be material, either individually or in the aggregate. Except as set forth in the Financial Statements, neither the Company nor the Subsidiaries has any (i) liabilities other than liabilities and obligations that have arisen in the ordinary course of business, (ii) obligations under contracts and commitments incurred in the ordinary course of business that would not be required to be reflected in financial statements prepared in accordance with GAAP and (iii) other liabilities and obligations expressly disclosed in the Disclosure Schedule, none of which either individually or in the aggregate are materially adverse. The Company maintains a standard system of accounting established and administered in accordance with GAAP.

2.18     Changes . Except as set forth in Section 2.18 of the Disclosure Schedule, since March 31, 2010, there has not been:

  (a)     any change in the assets, liabilities, financial condition, prospects or operations of the Company or the Subsidiaries from that reflected in the Financial Statements, other than changes in the ordinary course of business, none of which individually or in the aggregate has had or is reasonably expected to have a material adverse effect on such assets, liabilities, financial condition, prospects or operations of the Company or the Subsidiaries;

  (b)     any damage, destruction or loss, whether or not covered by insurance, materially adversely affecting the business, properties, operations, financial condition, or, to the Company’s actual knowledge, prospects of the Company or the Subsidiaries;

  (c)     any waiver or compromise by the Company or the Subsidiaries of a valuable right or of a material debt owed to the Company or the Subsidiaries, respectively;

  (d)     any satisfaction or discharge of any material lien, claim, or encumbrance or payment of any obligation by the Company or the Subsidiaries, except in the ordinary course of business;

 

11


  (e)     any sale, assignment, exclusive license or transfer of Intellectual Property or other assets;

  (f)     any resignation or termination of employment of any key officer of the Company or the Subsidiaries, and the Company is not aware of any impending resignation or termination of employment of any such key officer;

  (g)     receipt of notice that there has been a loss of, or material order cancellation by, any major customer of the Company or the Subsidiaries;

  (h)     any mortgage, pledge, transfer of a security interest in, or lien, created by the Company or the Subsidiaries, with respect to any of its material properties or assets, except liens for taxes not yet due or payable;

  (i)     any declaration, setting aside, or payment or other distribution in respect of any of the Company’s capital stock, or any direct or indirect redemption, purchase, or other acquisition of any of such stock by the Company or the Subsidiaries;

  (j)     any change in any material agreement to which the Company or the Subsidiaries is a party or by which the Company or the Subsidiaries is bound that materially and adversely affects the business, assets, liabilities, financial condition, operations or prospects of the Company or the Subsidiaries;

  (k)     any other event or condition of any character that, either individually or cumulatively, has materially and adversely affected the business, assets, liabilities, financial condition, prospects or operations of the Company or the Subsidiaries;

  (l)     any material change in any compensation arrangement or agreement with any employee, officer, director or stockholder of the Company or the Subsidiaries; or

  (m)     any agreement or commitment by the Company or the Subsidiaries to do any of the things described in this Section 2.18.

2.19     Taxes . Except as set forth in Section 2.19 of the Disclosure Schedule, the Company is and always has been a subchapter C corporation. The Company and the Subsidiaries have filed all Tax (as hereinafter defined) returns and reports as required by foreign, federal, state and local law and these returns and reports are true and correct in all material respects. There are no foreign, federal, state, county or local Taxes due and payable by the Company which have not been timely paid. Neither the Company nor the Subsidiaries has been advised (a) that any of its tax returns, federal, state, county, local, foreign or other, have been or are being audited as of the date hereof, or (b) of any deficiency in assessment or proposed judgment to its federal, state or other Taxes. The Company has no knowledge of any liability of any Tax to be imposed upon its properties or assets as of the date of this Agreement that is not adequately provided for. “ Tax ” or “ Taxes ” means any foreign, federal, state or local income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall, profits, environmental, customs, capital stock, franchise, employees’ income withholding, foreign or domestic withholding, social security, unemployment, disability, real

 

12


property, personal property, sales, use, transfer, value added, alternative or add-on minimum or other similar tax, governmental fee, governmental assessment or governmental charge of any kind whatsoever, including any interest, penalties or additions to Taxes or additional amounts with respect to the foregoing.

2.20     Regulatory Matters .

  (a)     The Company and each of its Subsidiaries operates in material compliance with all applicable laws, rules, regulations, codes, permits, approvals and authorizations applicable to them and their businesses and facilities.

  (b)     As to each of the manufacturing processes, intermediate products and research or commercial products of the Company and each of its Subsidiaries, including, without limitation, products or compounds currently under research and/or development by the Company, subject to the jurisdiction of the United States Environmental Protection Agency (“ EPA ”) under the Toxic Substances Control Act and regulations thereunder (“ TSCA ”) or the Food and Drug Administration (“ FDA ”) under the Federal Food, Drug and Cosmetic Act and the regulations thereunder (“ FDCA ”) (each such product, a “ Life Science Product ”), such Life Science Product is being researched, developed, manufactured, tested, distributed and/or marketed in compliance in all material respects with all applicable requirements under the FDCA and TSCA and similar laws and regulations applicable to such Life Science Product, including those relating to investigational use, premarket approval, good manufacturing practices, labeling, advertising, record keeping, filing of reports and security. The Company has not received any notice or other communication from the FDA, EPA or any other Federal, state or foreign governmental entity (i) contesting the premarket approval of, the uses of or the labeling and promotion of any Life Science Product or (ii) otherwise alleging any violation by the Company of any law, regulation or other legal provision applicable to a Life Science Product.

  (c)     Neither the Company, nor any officer, employee or agent of the Company has made an untrue statement of a material fact or fraudulent statement to the FDA or other Federal, state or foreign governmental entity performing similar functions or failed to disclose a material fact required to be disclosed to the FDA or such other Federal, state or foreign governmental entity.

2.21     Obligations to Related Parties . There are no obligations of the Company or the Subsidiaries to officers, directors, stockholders, or employees of the Company or the Subsidiaries other than (a) for payment of salary for services rendered, (b) reimbursement for reasonable expenses incurred on behalf of the Company or the Subsidiaries and (c) for other standard employee benefits made generally available to all employees (including stock option agreements outstanding under any stock option plan approved by the Board of Directors of the Company). None of the officers, directors or, to the best of the Company’s knowledge, key employees or stockholders of the Company or the Subsidiaries or any members of their immediate families, is indebted to the Company or the Subsidiaries or has any direct or indirect ownership interest in any firm or corporation with which the Company is affiliated or with which the Company or the Subsidiaries has a business relationship, or any firm or corporation that competes with the Company or the Subsidiaries, other than (i) passive investments in publicly traded companies (representing less than 1% of such company) that may compete with the

 

13


Company or the Subsidiaries and (ii) investments by venture capital funds with which directors of the Company or the Subsidiaries may be affiliated and service as a board member of a company in connection therewith due to a person’s affiliation with a venture capital fund or similar institutional investor in such company. No officer, director or stockholder, or any member of their immediate families, is, directly or, to the best of the Company’s knowledge, indirectly, interested in any material contract with the Company or the Subsidiaries (other than such contracts as relate to any such person’s ownership of capital stock or other securities of the Company or the Subsidiaries).

2.22    Obligations of Management .     Each officer and key employee of the Company or the Subsidiaries is currently devoting substantially all of his or her business time to the conduct of the business of the Company or the Subsidiaries, respectively. The Company is not aware that any officer or key employee of the Company or the Subsidiaries is planning to work less than full time at the Company or the Subsidiaries, respectively, in the future. No officer or key employee is currently working or, to the Company’s knowledge, plans to work for a competitive enterprise, whether or not such officer or key employee is or will be compensated by such enterprise. To the Company’s knowledge, no officer or person currently nominated to become an officer of the Company or the Subsidiaries is or has been subject to any judgment or order of, the subject of any pending civil or administrative action by the Securities and Exchange Commission or any self-regulatory organization.

2.23    Minute Books .     The minute books of the Company made available to the Investor or its counsel contain a complete summary of all meetings of directors and stockholders since the time of incorporation and a copy of all actions by written consent of directors and stockholders since the time of incorporation.

2.24    Registration Rights .     Except as provided in the Investors’ Rights Agreement, the Company is not under any obligation to register under the Act any of its currently outstanding securities or any securities issuable upon exercise or conversion of its currently outstanding securities nor is the Company obligated to register or qualify any such securities under any state securities or blue sky laws.

2.25    Real Property Holding Corporation .     Neither the Company nor the Subsidiaries is now nor has ever been a real property holding corporation within the meaning of Code Section 897(c)(2) and any regulations promulgated thereunder. The Company has filed with the Internal Revenue Service all statements, if any, with its United States income tax returns which are required under such regulations.

2.26    Full Disclosure .     The Company has provided the Investor with all information reasonably requested by the Investor in writing in connection with its decision to purchase the Series D Preferred Stock. Neither this Agreement, the exhibits hereto, the Transaction Documents, nor any other document delivered by the Company to the Investor or its attorneys or agents in connection herewith or therewith at the Closing or with the transactions contemplated hereby or thereby, contains any untrue statement of a material fact, nor to the Company’s knowledge, omits to state a material fact necessary in order to make the statements contained herein or therein not misleading.

 

14


2.27     83(b) Elections . To the Company’s knowledge, all elections and notices under Section 83(b) of the Code have been or will be timely filed by all individuals who have acquired unvested shares of the Company’s Common Stock.

3.       Representations, Warranties and Covenants of the Investor . The Investor hereby represents and warrants to the Company that as to itself (provided that such representations and warranties do not lessen or obviate the representations and warranties of the Company set forth in this Agreement):

3.1      Authorization .   The Investor has full power and authority to enter into the Transaction Documents, and each Transaction Document constitutes its valid and legally binding obligation, enforceable against the Investor in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights generally, (b) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (c) to the extent the indemnification provisions contained in the Investors’ Rights Agreement may be limited by applicable federal or state securities laws.

3.2      Purchase Entirely for Own Account .   The Series D Preferred Stock to be purchased by the Investor and the Common Stock issuable upon conversion thereof (collectively, the “ Securities ”) will be acquired for investment for the Investor’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same.

3.3      Disclosure of Information .   The Investor represents that it has had an opportunity to ask questions and receive answers from the Company regarding the Company and the terms and conditions of the offering of the Series D Preferred Stock.

3.4      Investment Experience .   The Investor is an investor in securities of companies in the development stage and acknowledges that it is able to fend for itself, can bear the economic risk of its investment and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Series D Preferred Stock. If other than an individual, Investor also represents it has not been organized specifically for the purpose of acquiring the Series D Preferred Stock.

3.5      Accredited Investor .   The Investor is an “accredited investor” within the meaning of SEC Rule 501 of Regulation D, as presently in effect and understands the meaning of that term.

3.6      Restricted Securities .   The Investor understands that the shares of Series D Preferred Stock it is purchasing are characterized as “restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the Act, only in certain limited circumstances. In this connection, the Investor represents that it is familiar with SEC Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Act.

 

15


3.7     Further Limitations on Disposition .   Without in any way limiting the representations set forth above, the Investor further agrees not to make any disposition of all or any portion of the Series D Preferred Stock (or the Common Stock issuable upon the conversion thereof) unless and until the transferee has agreed in writing for the benefit of the Company to be bound by the terms and conditions of this Agreement and the Investors’ Rights Agreement, and:

 (a)      There is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or

 (b)      (x) The Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with the terms of the proposed disposition, and (y) if requested by the Company, the Investor shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company that such disposition will not require registration of such shares under the Act. It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule 144 except in unusual circumstances. Notwithstanding the foregoing, no such registration statement or opinion of counsel shall be necessary for a transfer of shares by the Investor:

  (i)     to a fund, partnership, limited liability company or other entity that is affiliated with the Investor;

  (ii)     to a partner or member (or retired partner or member) of the Investor, or to the estate of any such partner or member (or retired partner or member);

  (iii)     to the Investor’s spouse, siblings, lineal descendants or ancestors by gift, will or intestate succession; or

  (iv)     in compliance with Rule 144 (or any successor provision) of the Act so long as the Company is furnished with satisfactory evidence of compliance with such rule;

3.8    provided, however, that, in the case of subsections (i), (ii) and (iii) above, the transferee agrees in writing to be subject to the terms hereof to the same extent as if such transferee were an original Investor hereunder. The Investor shall cause any proposed purchaser, assignee, transferee or pledgee of any shares of Series D Preferred Stock or the underlying Common Stock held by the Investor to take and hold such securities subject to the provisions and upon the conditions of this Agreement.

3.9     Legends .     It is understood that the certificates evidencing the Series D Preferred Stock (and the Common Stock issuable upon conversion thereof) may bear one or all of the following legends:

 (a)     “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE

 

16


COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144 OF SUCH ACT.”

  (b)     Any legend required by any applicable state securities laws.

3.10     Prior Relationship .   The Investor became interested in the Company and the purchase of the Series D Preferred Stock through its substantive relationship with the Company, which existed prior to the Company’s filing of a Registration Statement on Form S-1.

3.11     Qualified Institutional Buyer .   Such Investor is a “qualified institutional buyer” within the meaning of Rule 144A of the Act, as presently in effect.

3.12     No General Solicitation .   Neither the Investor, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including through a broker or finder (a) engaged in, or became interested in the transactions contemplated by this Agreement as a result of, any general solicitation, or (b) published any advertisement in connection with the offer and sale of the Series D Preferred Stock.

3.13     Foreign Investor .   If the Investor is not a United States person (as defined by Section 7701(a)(30) of the Code), the Investor hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Series D Preferred Stock or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the purchase of the Series D Preferred Stock, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Series D Preferred Stock. The Investor’s subscription and payment for and continued beneficial ownership of the Series D Preferred Stock will not violate any applicable securities or other laws of the Investor’s jurisdiction.

4.       Conditions of The Investor’s Obligations at Closing .   The obligations of the Investor in the Closing under Section 1.1(b) of this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions:

4.1     Representations and Warranties .   The representations and warranties of the Company contained in Section 2 shall be true and correct in all respects on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the date of the Closing.

4.2     Performance .   The Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied by it on or before the Closing.

4.3     Compliance Certificate .   The Chief Executive Officer of the Company shall deliver to the Investor at the Closing a certificate certifying that the conditions specified in Sections 4.1, 4.2, 4.4, 4.5, and 4.13 have been fulfilled.

4.4     Qualifications .   All authorizations, approvals or permits, if any, of any

 

17


governmental authority or regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Series D Preferred Stock pursuant to this Agreement shall be duly obtained and effective as of the Closing.

4.5     Restated Certificate of Incorporation .   The Restated Certificate in the form attached as Exhibit A hereto shall have been filed with and accepted by the Secretary of State of the State of Delaware.

4.6     Amended and Restated Investors’ Rights Agreement .   The Company shall have entered into an Investors’ Rights Agreement in the form attached as Exhibit B hereto with the Investor and sufficient other parties named therein to amend and restate the predecessor agreement thereto.

4.7     Amended and Restated Right of First Refusal and Co-Sale Agreement .   The Company shall have entered into a Right of First Refusal and Co-Sale Agreement in the form attached as Exhibit C hereto with the Investor and sufficient other parties named therein to amend and restate the predecessor agreement thereto.

4.8     Amended and Restated Voting Agreement .   The Company shall have entered into a Voting Agreement in the form attached as Exhibit D hereto with the Investor and sufficient other parties named therein to amend and restate the predecessor agreement thereto.

4.9     Opinion of Company Counsel .   The Investor shall have received from Fenwick & West LLP, counsel to the Company, an opinion dated as of the Closing, in the form attached hereto as Exhibit E .

4.10     Secretary’s Certificate .   The Investor shall have received from the Secretary of the Company a certificate having attached thereto: (i) the Restated Certificate as in effect at the time of the Closing, (ii) the Company’s Bylaws as in effect at the time of the Closing, (iii) resolutions approved by the Board of Directors authorizing the transactions contemplated hereby, (iv) resolutions approved by the Company’s stockholders authorizing the filing of the Restated Certificate, and (v) good standing certificates with respect to the Company from the Secretary of State of the State of Delaware, dated a recent date before the Closing.

4.11     Blue Sky .   The Company shall have obtained all necessary Blue Sky law permits and qualifications, or have the availability of exemptions therefrom, required by any state for the offer and sale of the Series D Preferred Stock hereunder.

4.12     Proceedings and Documents .   All corporate and other proceedings in connection with the transactions contemplated at the Closing and all documents incident thereto shall be reasonably satisfactory in form and substance to Investor’s special counsel, and Investor and its special counsel shall have received all such counterpart originals or certified or other copies of such documents as they may reasonably request.

4.13     Reservation of Conversion Shares .   The Common Stock issuable upon conversion of the Series D Preferred Stock shall have been duly authorized and reserved for issuance upon such conversion.

 

18


4.14    Side Letter .   The Company shall have entered into the Side Letter Agreement in the form attached as Exhibit F hereto with the Investor.

5.       Conditions of the Company’s Obligations at Closing .   The obligations of the Company to the Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions by such Investor:

5.1     Representations and Warranties .   The representations and warranties of the Investor contained in Section 3 shall be true and correct in all respects on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the Closing.

5.2     Payment of Purchase Price .   The Investor shall have delivered the purchase price specified in Section 1.1(b).

5.3     Qualifications .   All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Series D Preferred Stock pursuant to this Agreement shall be duly obtained and effective as of the Closing.

5.4     Amended and Restated Investors’ Rights Agreement .   The Investor shall have entered into an Investors’ Rights Agreement in the form attached as Exhibit B hereto with the Company and sufficient other parties named therein to amend and restate the predecessor agreement thereto.

5.5     Amended and Restated Right of First Refusal and Co-Sale Agreement .   The Investor shall have entered into a Right of First Refusal and Co-Sale Agreement in the form attached as Exhibit C hereto with the Company and sufficient other parties named therein to amend and restate the predecessor agreement thereto.

5.6     Amended and Restated Voting Agreement .   The Investor shall have entered into a Voting Agreement in the form attached as Exhibit D hereto with the Company and sufficient other parties named therein to amend and restate the predecessor agreement thereto.

5.7     Side Letter .   The Investor shall have entered into the Side Letter in the form attached as Exhibit F hereto with the Company.

5.8    The Investor shall have entered into a Lock-Up Agreement in the form attached as Exhibit G hereto.

6.       Miscellaneous .

6.1     Corporate Securities Laws .   THE SALE OF THE SECURITIES THAT ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM QUALIFICATION

 

19


BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.

6.2     Survivability .   The warranties, representations, agreements and covenants of the Company and the Investor contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing.

6.3     Successors and Assigns .   Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of Series D Preferred Stock sold hereunder or any Common Stock issued upon conversion thereof). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

6.4     Governing Law .   This Agreement shall be governed by and construed under the laws of the State of Delaware without regard for conflict of laws principles.

6.5     Counterparts .   This Agreement may be executed in two or more counterparts, including counterparts transmitted by facsimile, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

6.6     Titles and Subtitles .   The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

6.7     Notices .   All notices required or permitted under this Agreement shall be given in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after deposit in the United States mail, by registered or certified mail, postage prepaid and properly addressed to the party to be notified as set forth on the signature page hereof, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties hereto, or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.

6.8     Finder’s Fee .   Each party represents that it neither is nor will be obligated for any finder’s or broker’s fee or commission in connection with this transaction. The Investor agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finder’s fee (and the costs and expenses of defending against such liability or asserted liability) for which the Investor or any of its officers, partners, employees, or representatives is responsible. The Company agrees to indemnify and hold harmless the Investor from any liability for any commission or compensation in the nature of a finder’s fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible.

 

20


6.9     Amendments and Waivers .    Except as otherwise set forth in this Agreement, this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the holders of at least a majority of the shares of Common Stock issued or issuable upon conversion of the Series D Preferred Stock issued pursuant to this Agreement. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any securities purchased under this Agreement at the time outstanding (including securities into which such securities are convertible), each future holder of all such securities, and the Company.

6.10     Severability .    If any of the provisions of this Agreement should, for any reason, be held by a court or other tribunal of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provisions shall be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect.

6.11     Attorneys’ Fees .    If any dispute among the parties to this Agreement results in litigation, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including, without limitation, such reasonable fees and expenses of attorneys and accountants, that shall include, without limitation, all fees, costs and expenses of appeals.

6.12     Entire Agreement .    This Agreement, the exhibits and schedules hereto and the documents referred to herein constitute the entire agreement among the parties, and no party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically set forth herein or therein.

6.13     Delays or Omissions .    It is agreed that no delay or omission to exercise any right, power or remedy accruing to any party, upon any breach, default or noncompliance by another party under the Transaction Documents or the Restated Certificate, shall impair any such right, power or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of or in any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent or approval of any kind or character on any party’s part of any breach, default or noncompliance under the Transaction Documents or under the Restated Certificate or any waiver on such party’s part of any provisions or conditions of the Transaction Documents or the Restated Certificate must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under the Transaction Documents, the Restated Certificate, by law, or otherwise afforded to any party, shall be cumulative and not alternative.

6.14     Fees and Expenses .    The Company shall pay, in connection with the preparation, execution and delivery of this Agreement and the issuance of the Series D Preferred Stock, the fees and out-of-pocket expenses of the Investor, with respect thereto, such fees and expenses not to exceed Twenty-Four Thousand Twenty-Five Dollars ($24,025).

6.15     DGCL 203 .    On or before the earliest to occur of (a) July 15, 2010, and (b) the closing of the IPO, the Company shall amend its Restated Certificate to (i) expressly elect

 

21


not to be governed by Section 203 of the Delaware General Corporation Law (“ Section 203 ”), and (ii) provide for limitations on the Company’s stockholders (other than the Investor and its affiliates) substantially similar to those set forth in Section 203.

 

[Signature Pages Follow]

 

22


IN WITNESS WHEREOF, the parties have executed this Series D Preferred Stock Purchase Agreement as of the date first above written.

 

AMYRIS, INC.

By:

 

/s/John G. Melo

 

John G. Melo

 

Chief Executive Officer

Address:

  5885 Hollis Street, Ste. 100
  Emeryville, CA 94608

 

SERIES D PREFERRED STOCK PURCHASE AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Series D Preferred Stock Purchase Agreement as of the date first above written.

 

INVESTOR:
TOTAL GAS & POWER USA, SAS
By:   /s/Arnaud Chaperon
Name:   Arnaud Chaperon
Title:   Chairman
Address: 2 Place Jean Millier, 92078 Paris, La Defense, CEDEX, FRANCE

 

S ERIES D P REFERRED S TOCK P URCHASE A GREEMENT

S IGNATURE P AGE


SCHEDULE A

SCHEDULE OF INVESTORS

 

INVESTOR    NUMBER    
OF SHARES     
   PURCHASE    
PRICE    

Total Gas & Power USA, SAS

   7,101,548    $133,154,025.00

TOTAL    

   7,101,548    $133,154,025.00


EXHIBIT A

RESTATED CERTIFICATE OF INCORPORATION

(filed as Exhibit 3.01 to the Registration Statement filed by the Company, File No. 333-166135)


EXHIBIT B

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

(filed as Exhibit 4.02 to the Registration Statement filed by the Company, File No. 333-166135)


EXHIBIT C

 

AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT


AMYRIS, INC.

AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT

THIS AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (the “ Agreement ”) is made and entered into as of June 21, 2010, by and among Amyris, Inc., a Delaware corporation (the “ Company ”), each of the persons and entities listed on Exhibit A , Exhibit B , Exhibit C , Exhibit D , Exhibit E and Exhibit F hereto (the “ Investors ”), and each of the persons listed on Exhibit G hereto (each referred to herein as a “ Key Employee ” and collectively as the “ Key Employees ”).

RECITALS

WHEREAS, the Company, certain of the Investors, and the Key Employees entered into that certain Amended and Restated Right of First Refusal and Co-Sale Agreement (the “ Previous Agreement ”) as of March 19, 2010, in connection with the sale and issuance of shares of Series C-1 Preferred Stock of the Company pursuant to that certain Series C-1 Preferred Stock Purchase Agreement dated as of March 12, 2010;

WHEREAS, the Key Employees are the beneficial owners of the Key Employee Stock (as defined herein);

WHEREAS, the Investor listed on Exhibit F attached hereto is purchasing shares of the Company’s Series D Preferred Stock (together with the Company’s Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock and Series C-1 Preferred Stock, the “ Preferred Stock ”) pursuant to that certain Series D Preferred Stock Purchase Agreement (the “ Purchase Agreement ”) dated as of June 21, 2010 (the “ Financing ”);

WHEREAS, the obligations in the Purchase Agreement are conditioned upon the execution and delivery of this Agreement;

WHEREAS, in connection with the consummation of the Financing, the parties desire to enter into this Agreement in order to grant first refusal and co-sale rights to the Company and to the Investors; and

WHEREAS, this Agreement has been signed and delivered by the Company and by the requisite Investors and Key Holders as set forth in Section 6.3 of the Previous Agreement.

NOW, THEREFORE, in consideration of these premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree hereto as follows:

 

1.

DEFINITIONS .

1.1     “ Key Employee Stock ” shall mean shares of the Company’s Common Stock now owned or subsequently acquired by the Key Employees by gift, purchase, dividend, option exercise or any other means whether or not such securities are only registered in a Key


Employee’s name or beneficially or legally owned by such Key Employee, including any interest of a spouse in any of the Key Employee Stock, whether that interest is asserted pursuant to marital property laws or otherwise, provided , however , that “ Key Employee Stock ” shall not include shares of the Company’s Common Stock issued or issuable upon conversion of any shares of the Company’s preferred stock now owned or subsequently owned or acquired by a Key Employee. The number of shares of Key Employee Stock owned by the Key Employees as of the date hereof are set forth on Exhibit E , which Exhibit may be amended from time to time by the Company to reflect changes in the number of shares owned by the Key Employees, but the failure to so amend shall have no effect on such Key Employee Stock being subject to this Agreement.

1.2    “ Investor Stock ” shall mean the shares of the Company’s Common Stock now owned or subsequently acquired by the Investors whether or not such securities are only registered in an Investor’s name or beneficially or otherwise legally owned by such Investor.

1.3    “ Common Stock ” shall mean shares of the Company’s common stock and shares of common stock issued or issuable upon conversion of the Company’s outstanding preferred stock or exercise of any option, warrant or other security or right of any kind convertible into or exchangeable for common stock.

1.4    For purposes of this Agreement, the term “ Transfer ” shall include any sale, assignment, encumbrance, hypothecation, pledge, conveyance in trust, gift, transfer by request, devise or descent, or other transfer or disposition of any kind, including, but not limited to, transfers to receivers, levying creditors, trustees or receivers in bankruptcy proceedings or general assignees for the benefit of creditors, whether voluntary or by operation of law, directly or indirectly, of any of the Key Employee Stock.

 

2.

TRANSFERS BY A KEY EMPLOYEE .

2.1     Notice of Transfer . If a Key Employee proposes to Transfer any shares of Key Employee Stock then the Key Employee shall promptly give written notice (the “ Notice ”) to the Company and Investors at least thirty (30) days prior to the closing of such Transfer. The Notice shall describe in reasonable detail the proposed Transfer including, without limitation, the number of shares of Key Employee Stock to be transferred, the nature of such Transfer, the consideration to be paid, and the name and address of each prospective purchaser or transferee. In the event that the Transfer is being made pursuant to the provisions of Section 3.1, the Notice shall state under which clause of Section 3.1 the Transfer is being made.

2.2     Company Right of First Refusal .

(a)    For a period of twenty (20) days following receipt of any Notice described in Section 2.1, the Company shall have the right to purchase all or a portion of the Key Employee Stock subject to such Notice on the same terms and conditions as set forth therein (the “ Company Right of First Refusal ”). The Company’s purchase right shall be exercised by written notice signed by an officer of the Company (the “ Purchase Notice ”) and delivered to the Key Employee within such twenty (20) day period. The Company shall effect the purchase of the Key Employee Stock, including payment of the purchase price, not more than five (5) business


days after delivery of the Purchase Notice, and at such time the Key Employee shall deliver to the Company the certificate(s) representing the Key Employee Stock to be purchased by the Company, each certificate to be properly endorsed for transfer. The Key Employee Stock so purchased shall thereupon, be cancelled and cease to be issued and outstanding shares of the Company’s Common Stock.

(b)   In the event that the Company does not elect to purchase all of the Key Employee Stock available pursuant to its rights under Section 2.2 within the period set forth therein, the Key Employee shall promptly give written notice (the “ Second Notice ”) to each of the Investors, which shall set forth the number of shares of Key Employee Stock not purchased by the Company. Each Investor shall then have the right, exercisable upon written notice to the Key Employee (the “ Investor Notice ”) within ten (10) days after the receipt of the Second Notice, to purchase its pro rata share of the Key Employee Stock subject to the Second Notice and on the same terms and conditions as set forth therein. Except as set forth in Section 2.2(d), the Investors who so exercise their rights (the “ Participating Investors ”) shall effect the purchase of the Key Employee Stock, including payment of the purchase price, not more than five (5) days after delivery of the Investor Notice, and at such time the Key Employee shall deliver to the Participating Investors the certificate(s) representing the Key Employee Stock to be purchased by the Participating Investors, each certificate to be properly endorsed for transfer.

(c)   Each Investor’s pro rata share shall be equal to the product obtained by multiplying (i) the aggregate number of shares of Key Employee Stock covered by the Second Notice and (ii) a fraction, the numerator of which is the number of shares of Common Stock issued or issuable upon the conversion or exercise of Preferred Stock or other rights to acquire shares of Common Stock held by the Participating Investor at the time of the Notice, and the denominator of which is the total number of shares of Common Stock issued or issuable upon the conversion or exercise of Preferred Stock or other rights to acquire shares of Common Stock at the time of the Notice held by all Investors.

(d)   In the event that not all of the Investors elect to purchase their pro rata share of the Key Employee Stock available pursuant to their rights under Section 2.2(b) within the time period set forth therein, then the Key Employee shall promptly give written notice to each of the Participating Investors (the “ Overallotment Notice ”), which shall set forth the number of shares of Key Employee Stock not purchased by the other Investors, and shall offer such Participating Investors the right to acquire such unsubscribed shares. Each Participating Investor shall have five (5) days after receipt of the Overallotment Notice to deliver a written notice to the Key Employee (the “ Participating Investors Overallotment Notice ”) indicating the number of unsubscribed shares that such Participating Investor desires to purchase, and each such Participating Investor shall be entitled to purchase such number of unsubscribed shares on the same terms and conditions as set forth in the Second Notice. In the event that the Participating Investors desire, in the aggregate, to purchase in excess of the total number of available unsubscribed shares, then the number of unsubscribed shares that each Participating Investor may purchase shall be reduced on a pro rata basis. For purposes of this Section 2.2(d) the denominator described in clause (ii) of subsection 2.2(c) above shall be the total number of shares of Common Stock issued or issuable upon the conversion or exercise of Preferred Stock or other rights to acquire shares of Common Stock held by all the Participating Investors at the time of the Notice. The Participating Investors shall then effect the purchase of the Key


Employee Stock, including payment of the purchase price, not more than five (5) days after delivery of the Participating Investors Overallotment Notice, and at such time, the Key Employee shall deliver to the Investors the certificates representing the Key Employee Stock to be purchased by the Participating Investors, each certificate to be properly endorsed for transfer.

2.3      Right of Co-Sale .

(a)   In the event the Company or its assignee(s) fail to exercise its right to purchase all of the Key Employee Stock subject to Section 2.2 hereof, following the exercise or expiration of the rights of purchase set forth in Section 2.2, then the Key Employee shall deliver to the Company and each Investor written notice (the “ Co-Sale Notice ”) that each Investor shall have the right, exercisable upon written notice to such Key Employee with a copy to the Company within fifteen (15) days after receipt of the Co-Sale Notice, to participate in such Transfer of Key Employee Stock on the same terms and conditions. Such notice shall indicate the number of shares of Investor Stock up to that number of shares determined under Section 2.3(b) such Investor wishes to sell under his or her right to participate. To the extent one or more of the Investors exercise such right of participation in accordance with the terms and conditions set forth below, the number of shares of Key Employee Stock that such Key Employee may sell in the transaction shall be correspondingly reduced.

(b)   Each Investor may sell all or any part of that number of shares equal to the product obtained by multiplying (i) the aggregate number of shares of Key Employee Stock covered by the Co-Sale Notice and not purchased by the Company or its assignees pursuant to Section 2.2 by (ii) a fraction, the numerator of which is the number of shares of Common Stock owned by such Investor at the time of the Co-Sale Notice and the denominator of which is the total number of shares of Common Stock, in the aggregate, owned by such Key Employee (excluding shares purchased by the Company and/or its assignee(s) pursuant to Section 2.2) and the Investors at the time of the Co-Sale Notice. If not all of the Investors elect to sell their share of Common Stock proposed to be transferred within said fifteen (15) day period, then the Key Employee shall promptly notify in writing the Investors who do so elect and shall offer such Investors the additional right to participate in the sale of such additional shares of Key Employee Stock proposed to be transferred on the same percentage basis as set forth above in this Section 2.3(b). The Investors shall have five (5) days after receipt of such notice to notify the Key Employee in writing, with a copy to the Company, of its election to sell all or a portion of the unsubscribed shares.

(c)   Each Investor that elects to participate in the Transfer pursuant to this Section 2 (a “ Co-Sale Participant ”) shall effect its participation in the Transfer by promptly delivering to such Key Employee for transfer to the prospective purchaser one or more certificates, properly endorsed for transfer, which represent:

(i)     the type and number of shares of Common Stock which such Co-Sale Participant elects to sell; or

(ii)     that number of shares of Preferred Stock which is at such time convertible into the number of shares of Common Stock which such Co-Sale Participant elects to sell; provided , however , that if the prospective purchaser objects to the delivery of Preferred


Stock in lieu of Common Stock, such Co-Sale Participant shall convert such Preferred Stock into Common Stock and deliver Common Stock as provided in Section 2.3(c)(i) above. The Company agrees to make any such conversion concurrent with and contingent upon the actual transfer of such shares to the purchaser.

(d)   The stock certificate or certificates that the Co-Sale Participant delivers to such Key Employee pursuant to Section 2.3(c) shall be transferred to the prospective purchaser in consummation of the sale of the Common Stock pursuant to the terms and conditions specified in the Co-Sale Notice, and the Key Employee shall concurrently therewith remit to such Co-Sale Participant that portion of the sale proceeds to which such Co-Sale Participant is entitled by reason of its participation in such sale. To the extent that any prospective purchaser or purchasers prohibit such assignment or otherwise refuse to purchase shares or other securities from a Co-Sale Participant exercising its rights of co-sale hereunder, such Key Employee shall not sell to such prospective purchaser or purchasers any Key Employee Stock unless and until, simultaneously with such sale, such Key Employee shall purchase such shares or other securities from such Co-Sale Participant on the same terms and conditions specified in the Co-Sale Notice.

(e)   The exercise or non-exercise of the rights of any Investor hereunder to participate in one or more Transfers of Key Employee Stock made by any Key Employee shall not adversely affect his right to participate in subsequent Transfers of Key Employee Stock subject to this Section 2.

(f)   To the extent that the Investors do not elect to participate in the sale of the Key Employee Stock subject to the Co-Sale Notice, such Key Employee may, not later than sixty (60) days following delivery to the Company of the Co-Sale Notice, enter into an agreement providing for the closing of the Transfer of such Key Employee Stock covered by the Co-Sale Notice within thirty (30) days of such agreement on terms and conditions not materially more favorable to the transferor than those described in the Co-Sale Notice. Any proposed Transfer on terms and conditions materially more favorable than those described in the Co-Sale Notice, as well as any subsequent proposed Transfer of any of the Key Employee Stock by a Key Employee, shall again be subject to the first refusal and co-sale rights of the Company and/or Investors and shall require compliance by a Key Employee with the procedures described in this Section 2.

 

3.

EXEMPT TRANSFERS .

3.1     Notwithstanding the foregoing, the first refusal and co-sale rights of the Company and/or the Investors set forth in Section 2 above shall not apply to any transfer without consideration to (i) the Key Employee’s spouse, children, parents or siblings (collectively, “ Family Members ”), (ii) any trust or for estate planning purposes solely for the benefit of such Key Employee and/or Family Member(s) and of which such Key Employee and/or any such Family Member(s) is the trustee or are the trustees, and (iii) any partnership, corporation or limited liability company that is wholly owned and controlled by such Key Employee and/or any such Family Member(s), provided that (A) the Key Employee shall inform the Investors of such transfer prior to effecting it and (B) the transferee shall enter into a written agreement to be bound by and comply with all provisions of this Agreement, as if it were an original Key Employee hereunder, including without limitation Section 2. Such transferred Key Employee


Stock shall remain “Key Employee Stock” hereunder, and such transferee shall be treated as the “ Key Employee ” for purposes of this Agreement.

3.2     Notwithstanding the foregoing, the provisions of Section 2 shall not apply to the sale of any Key Employee Stock to the public pursuant to a registration statement filed with, and declared effective by, the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “ Securities Act ”).

3.3     This Agreement is subject to, and shall in no manner limit the right which the Company may have to repurchase securities from the Key Employee pursuant to (i) a stock restriction agreement or other agreement between the Company and the Key Employee and (ii) any right of first refusal set forth in any agreement between the Company and the Key Employees regarding the repurchase of Common Stock of the Company.

 

4.

PROHIBITED TRANSFERS .

4.1      Put Option .

(a)   In the event that a Key Employee should sell any Key Employee Stock in contravention of the co-sale rights of each Investor under Section 2.3 of this Agreement (a “ Prohibited Transfer ”), each Investor, in addition to such other remedies as may be available at law, in equity or hereunder, shall have the put option provided below, and such Key Employee shall be bound by the applicable provisions of such option.

(b)   In the event of a Prohibited Transfer, each Investor shall have the right to sell to such Key Employee the type and number of shares of Common Stock equal to the number of shares each Investor would have been entitled to transfer to the purchaser under Section 2.3 hereof had the Prohibited Transfer been effected pursuant to and in compliance with the terms hereof. Such sale shall be made on the following terms and conditions:

(i)     The price per share at which the shares are to be sold to the Key Employee shall be equal to the price per share paid by the purchaser to such Key Employee in such Prohibited Transfer. The Key Employee shall also reimburse each Investor for any and all fees and expenses, including legal fees and expenses, incurred in connection with the exercise or the attempted exercise of the Investor’s rights under Section 2.3.

(ii)     Within ninety (90) days after the date on which an Investor receives notice of the Prohibited Transfer, such Investor shall, if exercising the option created hereby, deliver to the Key Employee the certificate or certificates representing the shares to be sold, each certificate to be properly endorsed for transfer.

(iii)     Such Key Employee shall, upon receipt of the certificate or certificates for the shares to be sold by an Investor, pursuant to this Section 4.1, pay the aggregate purchase price therefor and the amount of reimbursable fees and expenses, as specified in Section 4.1(b)(i), in cash or by other means acceptable to the Investor.

4.2      Voidability of Transfer .   Notwithstanding the foregoing, any purported Transfer by a Key Employee of Key Employee Stock in violation of Section 2 and/or Section 3 hereof


shall be voidable at the option of the holders of a majority of the Investor Stock if the Investors do not elect to exercise the call or put option set forth in this Section 4, and the Company agrees it will not effect such a transfer nor will it treat any alleged transferee as the holder of such shares without the written consent of the holders of a majority of the Investor Stock.

 

5.

LEGEND .

5.1     Each certificate representing shares of Key Employee Stock now or hereafter owned by the Key Employee or issued to any person in connection with a Transfer pursuant to Section 3.1 hereof shall be endorsed with the following legend:

 

“THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT BY AND AMONG THE STOCKHOLDER, THE COMPANY AND CERTAIN HOLDERS OF STOCK OF THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY.”

5.2     The Key Employees agree that the Company may instruct its transfer agent to impose transfer restrictions on the shares represented by certificates bearing the legend referred to in Section 5.1 above to enforce the provisions of this Agreement and the Company agrees to promptly do so. The legend shall be removed at the request of any Key Employee following termination of this Agreement.

 

6.

MISCELLANEOUS .

6.1      Conditions to Exercise of Rights .   Exercise of the Investors’ rights under this Agreement shall be subject to and conditioned upon, and the Key Employees and the Company shall use their best efforts to assist each Investor in, compliance with applicable laws.

6.2      Governing Law .   This Agreement shall be governed by and construed under the laws of the State of California in all respects as applied to agreements among California residents entered into and performed entirely within California. The parties agree that any action brought by either party under or in relation to this Agreement, including without limitation to interpret or enforce any provision of this Agreement, shall be brought in, and each party agrees to and does hereby submit to the jurisdiction and venue of, any state or federal court located in the County of Santa Clara, California.

6.3      Amendment .   Any provision of this Agreement may be amended or modified and/or the observance thereof may be waived or this Agreement terminated, only with the written consent of (i) the Company, (ii) as to the Investors, persons holding a majority in interest of the Common Stock issued or issuable upon (a) the conversion or exercise of Preferred Stock, (b) the exercise of up to 166,367 warrants to purchase shares of Preferred Stock (on an as-converted to Common Stock basis) issued to entities associated with Advanced Equities Financing Corp. and its assignees, pursuant to Section 6.4 hereof, and (c) the settlement of up to 176,272 restricted stock units and exercise of up to 60,000 options to purchase shares of


Common Stock issued to Lit Tele LLC and its assignees, pursuant to Section 6.4 hereof, and (iii) as to the Key Employees, a majority in interest of the Key Employee Stock held by Key Employees then providing services to the Company as officers, employees or consultants; provided , that no consent of any Key Employee shall be necessary for any amendment and/or restatement which merely includes additional holders of Preferred Stock or other preferred stock of the Company as “Investors” as parties hereto or other employees of the Company as “Key Employees” and parties hereto and does not materially increase such Key Employees’ obligations hereunder other than the increase in the number of shares determined by Section 2.3 hereof as a result of the addition of such additional holder; provided , further , that for any amendment or waiver of any provision herein that would have a material, adverse and disproportionate effect on a series of Preferred Stock relative to any other series of Preferred Stock, consent of the holders of at least a majority of such series of Preferred Stock voting as a separate class. Any amendment or waiver effected in accordance with clauses (i), (ii), and (iii) of this Section 6.3 shall be binding upon each Investor, its successors and assigns, the Company and each of the Key Employees.

6.4      Successors and Assigns .   The provisions hereof shall inure to the benefit of, and be binding upon, the parties hereto and their respective successors, assigns, heirs, executors and administrators and other legal representatives.

6.5       Term .  This Agreement shall continue in full force and effect from the date hereof through the earliest of the date of the closing of Liquidation or Qualified IPO, each as defined in the Company’s Amended and Restated Articles of Incorporation, as amended from time to time, on which date it shall terminate in its entirety.

6.6       Ownership .  The Key Employees represent and warrant that each is the sole legal and beneficial owner of those shares of Key Employee Stock he or she currently holds subject to the Agreement and that no other person has any interest (other than a community property interest) in such shares.

6.7       Notices .  All notices required or permitted under this Agreement shall be given in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after deposit in the United States mail, by registered or certified mail, postage prepaid and properly addressed to the party to be notified as set forth on the signature page hereof, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties hereto, or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.

6.8       Severability .  In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein.


6.9      Aggregation of Stock . All shares of Preferred Stock held or acquired by affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement.

6.10      Attorneys’ Fees . In the event that any suit or action is instituted under or in relation to this Agreement, including without limitation to enforce any provision in this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals.

6.11      Entire Agreement . This Agreement and the Exhibits hereto, along with the Purchase Agreement and the other documents delivered pursuant thereto, constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof and no party shall be liable or bound to any other in any manner by any oral or written representations, warranties, covenants or agreements except as specifically set forth herein and therein. Each party expressly represents and warrants that it is not relying on any oral or written representations, warranties, covenants or agreements outside of this Agreement.

6.12      Counterparts . This Agreement may be executed in two or more counterparts, including counterparts transmitted by facsimile, other electronic transmission or otherwise, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

6.13      Previous Agreement . The Previous Agreement is hereby amended and superseded in its entirety and restated herein. Such amendment and restatement is effective upon execution and delivery of this Agreement by the Company and by the requisite holders as set forth in Section 6.3 of the Previous Agreement. Upon such execution, all provisions of, rights granted and covenants made in the Previous Agreement are hereby waived, released and superseded in their entirety and shall have no further force or effect.

[SIGNATURE PAGES FOLLOW]


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Right of First Refusal and Co-Sale Agreement as of the date first above written.

 

COMPANY:
AMYRIS, INC.

By:

 

/s/ John G. Melo

 

John G. Melo

  Chief Executive Officer

 

Address:  

 

5885 Hollis Street, Ste. 100

 

Emeryville, CA 94608

 

S IGNATURE P AGE TO A MYRIS , I NC .

A MENDED AND R ESTATED R IGHT OF F IRST R EFUSAL & C O -S ALE A GREEMENT


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Right of First Refusal and Co-Sale Agreement as of the date first above written.

 

 

KEY EMPLOYEES:

/s/ Jack D. Newman

Jack D. Newman

 

Address:  

   
   

 

/s/ Kinkhead Reiling

K. Kinkead Reiling

 

Address:      
   

 

   
Jay D. Keasling

 

Address:      
   

 

/s/ Neil Renninger

Neil Renninger

 

Address:      
   

 

/s/ John G. Melo

John G. Melo

 

Address:      
   

 

S IGNATURE P AGE TO A MYRIS , I NC .

A MENDED AND R ESTATED R IGHT OF F IRST R EFUSAL & C O -S ALE A GREEMENT


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Right of First Refusal and Co-Sale Agreement as of the date first above written.

 

INVESTOR:
AEI CLEANTECH INVESTMENTS I, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  
AEI CLEANTECH INVESTMENTS II, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  
ADVANCED EQUITIES AMYRIS INVESTMENTS I, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  

 

S IGNATURE P AGE TO A MYRIS , I NC .

A MENDED AND R ESTATED R IGHT OF F IRST R EFUSAL & C O -S ALE A GREEMENT


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Right of First Refusal and Co-Sale Agreement as of the date first above written.

 

ADVANCED EQUITIES AMYRIS INVESTMENTS II, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  
ADVANCED EQUITIES AMYRIS INVESTMENTS III, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  
ADVANCED EQUITIES AMYRIS INVESTMENTS IV, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  

 

S IGNATURE P AGE TO A MYRIS , I NC .

A MENDED AND R ESTATED R IGHT OF F IRST R EFUSAL & C O -S ALE A GREEMENT


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Right of First Refusal and Co-Sale Agreement as of the date first above written.

 

INVESTORS:
DAG Ventures III-QP, L.P.

By:

 

DAG Ventures Management III, LLC, its General Partner

By:

 

/s/ R. Thomas Goodrich

  R. Thomas Goodrich, Managing Director

 

Address:

 

251 Lytton Ave., Suite 200

Palo Alto, CA 94301

 

DAG Ventures III, L.P.

By:

 

DAG Ventures Management III, LLC, its General Partner

By:

 

/s/ R. Thomas Goodrich

  R. Thomas Goodrich, Managing Director

 

Address:

 

251 Lytton Ave., Suite 200

Palo Alto, CA 94301

 

DAG Ventures GP Fund III, LLC

By:

 

DAG Ventures Management III, LLC, its Managing Member

By:

 

/s/ R. Thomas Goodrich

  R. Thomas Goodrich, Managing Director

 

Address:

 

251 Lytton Ave., Suite 200

Palo Alto, CA 94301

 

DAG Ventures I-N, LLC

By:

 

DAG Ventures Management, LLC, its Managing Member

By:

 

/s/ R. Thomas Goodrich

  R. Thomas Goodrich, Managing Director

 

Address:

 

251 Lytton Ave., Suite 200

Palo Alto, CA 94301

 

S IGNATURE P AGE TO A MYRIS , I NC .

A MENDED AND R ESTATED R IGHT OF F IRST R EFUSAL & C O -S ALE A GREEMENT


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Right of First Refusal and Co-Sale Agreement as of the date first above written.

 

INVESTORS:
KHOSLA VENTURES II, L.P.

By:

 

Khosla Ventures Associates II, LLC, its general partner

By:   /s/ Samir Kaul
Name: Samir Kaul
Title: Partner

Address: 3000 Sand Hill Road, Bldg. 3, Ste. 170

                Menlo Park, CA 94025

KHOSLA VENTURES III, L.P.
By:   Khosla Ventures Associates III, LLC, its general partner
By:   /s/ Samir Kaul
Name: Samir Kaul
Title: Partner

Address: 3000 Sand Hill Road, Bldg. 3, Ste. 170

                Menlo Park, CA 94025

TPG BIOTECHNOLOGY PARTNERS II, L.P.

 

By:

 

TPG Biotechnology Genpar II, L.P.

By:   TPG Biotech Advisors II, LLC
By:   /s/ Jeffery D. Ekberg
Name: Jeffery D. Ekberg
Title: Vice President
Address: 301 Commerce Street, Suite 3300

                Fort Worth, Texas 76102

KPCB HOLDINGS, INC., AS NOMINEE
By:   /s/ John Doerr
Name: John Doerr
Title: Partner
Address: 2750 Sand Hill Road
                Menlo Park, CA 94025

S IGNATURE P AGE TO A MYRIS , I NC .

A MENDED AND R ESTATED R IGHT OF F IRST R EFUSAL & C O -S ALE A GREEMENT


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Right of First Refusal and Co-Sale Agreement as of the date first above written.

 

INVESTOR:
LIT TELE, LLC
By:   /s/ Paulo Henrique de Oliveira Santos
Name:   Paulo Henrique de Oliveira Santos
Title:   Manager
By:   /s/ Naldilei Zumpano
Name:   Naldilei Zumpano
Title:   Manager

 

S IGNATURE P AGE TO A MYRIS , I NC .

A MENDED AND R ESTATED R IGHT OF F IRST R EFUSAL & C O -S ALE A GREEMENT


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Right of First Refusal and Co-Sale Agreement as of the date first above written.

 

INVESTOR:
NAXYRIS S.A.
By:   /s/ Henri Reiter & /s/ Christoph Piel
Name: Henri Reiter & Christoph Piel
Title:________________________________
Address: 40 Boulevard Joseph II, L-1840
LUXEMBOURG

 

S IGNATURE P AGE TO A MYRIS , I NC .

A MENDED AND R ESTATED R IGHT OF F IRST R EFUSAL & C O -S ALE A GREEMENT


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Right of First Refusal and Co-Sale Agreement as of the date first above written.

 

INVESTOR:
TOTAL GAS & POWER USA, SAS
By:   /s/ Arnaud Chaperon
 Name: Arnaud Chaperon
 Title: Chairman
 Address: 2 Place Jean Millier,
 92078 Paris, La Defense, CEDEX, FRANCE

 

S IGNATURE P AGE TO A MYRIS , I NC .

A MENDED AND R ESTATED R IGHT OF F IRST R EFUSAL & C O -S ALE A GREEMENT


IN WITNESS WHEREOF, the undersigned has duly executed this Amended and Restated Right of First Refusal and Co-Sale Agreement as of the date set forth below.

 

Date:____________

    INVESTOR:
     

______________________________________________

     

[Please print exact name of Investor as it should

appear on stock certificate.]

     

By:___________________________________________

      Name:__________________________________________
      Title:___________________________________________
     

[Please include title if Investor is an entity.]

      Address:         __________________________________
                             __________________________________

S IGNATURE P AGE TO A MYRIS , I NC .

A MENDED AND R ESTATED R IGHT OF F IRST R EFUSAL & C O -S ALE A GREEMENT


EXHIBIT A

SCHEDULE OF SERIES A INVESTORS

 

S ERIES A I NVESTOR

   N UMBER   OF
S HARES   OF  S ERIES
A S TOCK

Khosla Ventures II, L.P.

   3,449,861

KPCB Holdings, Inc., as nominee

   3,449,861

TPG Biotechnology Partners II, L.P.

   2,299,907

Total

   9,199,629


EXHIBIT B

SCHEDULE OF SERIES B INVESTORS

 

S ERIES B I NVESTOR

   N UMBER   OF
S HARES   OF  S ERIES
B S TOCK

DAG Ventures III, L.P.

   44,883        

DAG Ventures III-QP, L.P.

   477,134        

DAG Ventures GP Fund III, LLC

   491        

DAG Ventures I-N, LLC

   281,351        

Khosla Ventures II, L.P.

   150,723        

KPCB Holdings, Inc., as nominee

   150,723        

TPG Biotechnology Partners II, L.P.

   401,929        

ES East Associates, LLC

   9,859        

BB Trust Dated 2/21/03 (Richard Rock, Trustee)

   70,338        

Crystalsesv Comércio E Representação Ltda.

   40,193        

Santelisa Vale Bioenergia S.A.

   40,193        

Total

   1,667,817        


EXHIBIT C

SCHEDULE OF SERIES B-1 INVESTORS

 

S ERIES B-1 I NVESTOR

   N UMBER   OF
S HARES   OF  S ERIES
B-1 S TOCK

AEI 2008 CleanTech Investments I, LLC

   134,639        

AEI 2008 CleanTech Investments II, LLC

   180,127        

Advanced Equities Amyris Investments I, LLC

   226,465        

Advanced Equities Amyris Investments II, LLC

   661,403        

Advanced Equities Amyris Investments III, LLC

   32,258        

Advanced Equities Amyris Investments IV, LLC

   66,240        

Ameri Private Equity IV, LLC

   80,563        

Aspire Business LTD

   98,970        

Christopher Lenzo

   118,765        

Counter Point Venture Fund II, LP

   19,800        

Erasmus Louisiana Growth Fund II, LP

   39,589        

Exccess Venture Fund I, LLC

   79,178        

Gaenger Family Living Trust of 1995

   395        

GB Sears Family Trust

   3,365        

HS Partners Holdings III, LP

   158,353        

Innovative Financial Private Equity Fund II, LLC

   45,527        

Invest Biotech, LLC

   51,275        

James A. Goddard

   989        

Lit Tele, LLC

   395,883        

Millenium Trust Company

   39,589        

Northport Investments, LLC

   53,852        

TCM2, LLC

   39,589        

Technology Ventures, LLC

   39,588        

The Barlow Family Trust

   989        

Third Amended and Restated Robbins Trust of 1986

   4,159        

Toronto Angel Group Amyris Holdings LP

   43,991        

Total

   2,615,721        


EXHIBIT D

SCHEDULE OF SERIES C INVESTORS

 

S ERIES C I NVESTOR

   N UMBER   OF
S HARES   OF   S ERIES
C S TOCK

Khosla Ventures III, L.P.

   321,027

KPCB Holdings, Inc., as nominee

   321,027

TPG Biotechnology Partners II, L.P.

   321,027

Lit Tele, LLC

   802,568

DAG Ventures II, L.P.

   146,582

DAG Ventures III-QP, L.P.

   13,788

DAG Ventures GP Fund III, LLC

   144

DAG Ventures I-N, LLC

   60,193

Grober Business Corp.

   802,568

Naxyris SA (an affiliate of NAXOS Capital Partners)

   561,797

Advanced Equities Amyris Investments I, LLC

   22,685

Advanced Equities Amyris Investments II, LLC

   65,672

Advanced Equities Amyris Investments III, LLC

   2,184

Advanced Equities Amyris Investments IV, LLC

   3,249

AEI 2008 CleanTech Investments I, LLC

   5,003

AEI 2008 CleanTech Investments II, LLC

   14,483

Third Amended and Restated Robbins Trust of 1986

(Richard K. Robbins, Trustee)

   1,213

James A. Goddard

   288

Invest Biotech, LLC

   2,648

Kevin Kaster

   1,271

Millenium Trust Company LLP Cust FBO WNA Private Equity Fund B - Amyris LLC

   7,945

Northern Rivers Silicon Valley Access Fund LP

   8,025

Michael P. Waldbillig and Louise A. Waldbillig Trust, dated September 16, 2008

   1,324

Advanced Equities Amyris Investments I, LLC

   10,139

Advanced Equities Amyris Investments II, LLC

   30,724


EXHIBIT D

SCHEDULE OF SERIES C INVESTORS (cont.)

 

S ERIES C I NVESTOR    N UMBER   OF
S HARES   OF   S ERIES
C S TOCK

Advanced Equities Amyris Investments III, LLC

   312

Advanced Equities Amyris Investments IV, LLC

   3,593

AEI 2008 CleanTech Investments I, LLC

   2,644

AEI 2008 CleanTech Investments II, LLC

   3,818

Northport Investments LLC

   3,815

Innovative Financial Private Equity

   19,662

Orgone Capital IV, LLC

   61,810

HS Partners Holdings III, LP

   80,256

Phyllis Gardner

   264

Jeffrey and Andrea Tobias

   1,002

BCP Investment, L.P.

   128,410

Richard C. Blum Rollover IRA

   240,770

Magoo 1, LLC

   6,621

Advanced Equities Amyris Investments I, LLC

   394

Advanced Equities Amyris Investments II, LLC

   1,249

Advanced Equities Amyris Investments III, LLC

   96

Advanced Equities Amyris Investments IV, LLC

   104

AEI 2008 CleanTech Investments I, LLC

   491

AEI 2008 CleanTech Investments II, LLC

   812

Orgone Capital IV, LLC

   12,199

Excess Venture Fund I, LLC

   8,026

Westly Group

   381,219

Northport Investments

   21,207

Orgone Capital

   81,274

Innovative Financial Private Equity

   12,039

Advanced Equities Amyris Investments I, LLC

   1,989


EXHIBIT D

SCHEDULE OF SERIES C INVESTORS (cont.)

 

S ERIES C I NVESTOR    N UMBER   OF
S HARES   OF   S ERIES
C S TOCK

Advanced Equities Amyris Investments II, LLC

   5,034

Khosla Ventures III, L.P.

   98,661

KPCB Holdings, Inc., as nominee

   98,660

TPG Biotechnology Partners II, L.P.

   98,660

Total

   4,902,665


EXHIBIT E

SCHEDULE OF SERIES C-1 INVESTORS

 

S ERIES C-1 I NVESTOR

   N UMBER   OF
S HARES   OF  S ERIES
C-1 S TOCK

Maxwell (Mauritius) Pte Ltd

   2,724,766

Total

   2,724,766


EXHIBIT F

SCHEDULE OF SERIES D INVESTORS

 

S ERIES D I NVESTOR

   N UMBER   OF
S HARES   OF  S ERIES
D S TOCK

Total Gas & Power USA, SAS

   7,101,548

Total

   7,101,548


EXHIBIT G

LIST OF KEY EMPLOYEES

 

N AME OF K EY E MPLOYEE

   N UMBER   OF
S HARES   OF
C OMMON  S TOCK

Jack D. Newman

   900,000

K. Kinkead Reiling

   863,000

Jay D. Keasling

   1,000,000

Neil Renninger (including the Neil Renninger 2010 Qualified Annuity Trust)

   900,000

John G. Melo

   1,502,983 1

Total

   5,165,983

 

 

 

 

1 These are all outstanding options to purchase Common Stock.


EXHIBIT D

AMENDED AND RESTATED VOTING AGREEMENT


AMYRIS, INC.

AMENDED AND RESTATED VOTING AGREEMENT

THIS AMENDED AND RESTATED VOTING AGREEMENT (the “ Agreement ”) by and among Amyris, Inc., a Delaware corporation (the “ Company ”), the holders of the Company’s Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock (collectively, the “ Preferred Stock ”) listed on Schedule A hereto (each of which is herein referred to as an “ Investor ”) and the holders of common stock of the Company (“ Common Stock ”) set forth on Schedule B hereto (the “ Common Holders ”) is dated as of June 21, 2010.

WHEREAS, the Company and certain of the Investors entered into that certain Amended and Restated Voting Agreement dated March 12, 2010 (the “ Previous Agreement ”), in connection with the sale and issuance of shares of Series C-1 Preferred Stock of the Company pursuant to that certain Series C-1 Preferred Stock Purchase Agreement dated as of March 12, 2010;

WHEREAS, the Series D Investor listed on Schedule A hereto is purchasing shares of the Company’s Series D Preferred Stock (the “ Series D Preferred Stock ”) pursuant to that certain Series D Preferred Stock Purchase Agreement dated as of June 21, 2010 (the “ Purchase Agreement ”);

WHEREAS, in order to induce the Series D Investor listed on Schedule A hereto to consummate its purchase of the Series D Preferred Stock, the parties have agreed to enter into this Agreement;

WHEREAS, the parties have agreed that (i) the holders of a majority in interest of the shares of Common Stock, voting separately as a single class, shall be entitled to elect two (2) directors to the Company’s Board of Directors; (ii) the holders of a majority in interest of the shares of Series A Preferred Stock, voting separately as a single class on an as converted to Common Stock basis, shall be entitled to elect three (3) directors to the Company’s Board of Directors; (iii) in certain circumstances, the holders of a majority in interest of the shares of Series D Preferred Stock, voting separately as a single class on an as converted to Common Stock basis, shall be entitled to elect one (1) director to the Company’s Board of Directors; and (iv) the Common Directors and Series A Directors shall unanimously select five (5) directors to the Company’s Board of Directors; and

WHEREAS, this Agreement has been signed and delivered by the Company and by the requisite holders as set forth in Section 13(d) of the Previous Agreement.

NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:

1.      Agreement to Vote .

        (a)    The Investors agree to vote all of their respectively held shares of capital stock of the Company at a regular or special meeting of stockholders (or by written


consent) now held or hereafter acquired by them, or over which such Investors have voting control (whether by proxy or otherwise), in accordance with the provisions of this Agreement.

        (b)    The Common Holders agree to vote all of their respectively held shares of capital stock of the Company (including any option shares) at a regular or special meeting of stockholders (or by written consent) now held or hereafter acquired by them, or over which such Investors have voting control (whether by proxy or otherwise), in accordance with the provisions of this Agreement.

2.      Board Size .    Each of the Common Holders and the Investors agree to vote all of their respectively held shares of capital stock of the Company at a regular or special meeting of stockholders (or by written consent) now held or hereafter acquired by them to ensure that the size of the Company’s Board of Directors shall be set and remain at eleven (11) directors or such other number of directors as may be unanimously approved by the Board of Directors.

3.      Election of Directors .

        (a)      Election of the Common Directors . At each election of or action by written consent to elect directors in which the holders of Common Stock, voting as a separate class, are entitled to elect directors of the Company, each of the Common Holders and the Investors shall vote all of their respectively held shares of capital stock to elect two (2) members of the Company’s Board of Directors (the “ Common Directors ”), each of whom shall be nominated by the holders of a majority of the Common Stock of the Company held subject to this Agreement, (i) one (1) of whom shall be nominated by the holders of a majority of the then outstanding shares of Common Stock who shall initially be Kinkead Reiling and (ii) one (1) of which shall be the Company’s Chief Executive Officer (the “ CEO Director ”) who initially shall be John G. Melo, provided that at such time as Kinkead Reiling shall cease to be a director, the Company shall take such action as required to cause him to become a non-voting observer (subject to customary exclusions and confidentiality restrictions) until such time as the Board may determine otherwise.

        (b)      Election of the Series A Directors .

        (i)    At each election of or action by written consent to elect directors in which the holders of Series A Preferred Stock, voting as a separate class, are entitled to elect directors of the Company, each of the Common Holders and the Investors shall vote all of their respectively held shares of Series A Preferred Stock to elect one (1) member of the Company’s Board of Directors, whom shall be nominated by Khosla Ventures II, L.P. who shall initially be Samir Kaul (a “ Series A Director ”).

        (ii)    At each election of or action by written consent to elect directors in which the holders of Series A Preferred Stock, voting as a separate class, are entitled to elect directors of the Company, each of the Common Holders and the Investors shall vote all of their respectively held shares of Series A Preferred Stock to elect one (1) member of the Company’s Board of Directors, whom shall be nominated by TPG Biotechnology Partners II, L.P. who shall initially be Geoff Duyk (a “ Series A Director ”).


        (iii)    At each election of or action by written consent to elect directors in which the holders of Series A Preferred Stock, voting as a separate class, are entitled to elect directors of the Company, each of the Common Holders and the Investors shall vote all of their respectively held shares of Series A Preferred Stock to elect one (1) member of the Company’s Board of Directors, whom shall be nominated by KPCB Holdings, Inc. who shall initially be John Doerr (a “ Series A Director ” and collectively with the other Series A Directors, the “ Series A Directors ”).

        (c)     Election of the Series D Director . At each election of or action by written consent to elect directors in which the holders of Series D Preferred Stock, voting as a separate class, are entitled to elect a director of the Company, each of the Common Holders and the Investors shall vote all of their respectively held shares of Series D Preferred Stock to elect one (1) member of the Company’s Board of Directors, whom shall be nominated by Total Gas & Power USA, SAS (“ Total G&P ”), which seat shall initially be vacant (the “ Series D Director ”). In order to effect the election of the Series D Director, Total G&P shall execute the form of Stockholder Consent attached hereto as Exhibit A . Notwithstanding the foregoing, the right of the holders of Series D Preferred Stock to elect the Series D Director shall terminate upon the earliest to occur of the following: (i) such time as Total G&P (together with its Affiliates (as defined below)) holds less than 3,550,774 shares of Series D Preferred Stock purchased by it pursuant to the Purchase Agreement (as adjusted for stock splits, dividends, combinations, recapitalizations and the like with respect to such shares); (ii) an Acquisition (as defined in the Company’s Restated Certificate of Incorporation, as amended from time to time); or (iii) an Asset Sale (as defined in the Company’s Restated Certificate of Incorporation, as amended from time to time). “ Affiliate ” means, with respect to a Person (as defined below), any Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such first Person. For purposes of this definition, “control” and, with correlative meanings, the terms “controlled by” and “under common control with” mean (a) the possession, directly or indirectly, of the power to direct the management or policies of a Person, whether through the ownership of voting securities, by contract relating to voting rights or corporate governance, or otherwise, or (b) the ownership, directly or indirectly, of more than 50% of the voting securities or other ownership interest of a Person. “ Person ” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.

        (d)     Election of the Independent Directors . At each election of directors in which the holders of Common Stock and holders of Preferred Stock, voting together as a single class on an as-converted to Common Stock basis, are entitled to elect directors of the Company, each of the Common Holders and the Investors shall vote all of their respectively held shares of capital stock to elect four members of the Company’s Board of Directors, who shall be individuals with relevant industry experience nominated unanimously by the Common Directors and the Series A Directors, who shall initially be Ralph Alexander, Fernando Reinach, Carole Piwnica, Patrick Pichette and Arthur Levinson (together, the “ Independent Directors ”).

        (e)     Removal of the Common Directors . On all matters relating to the removal of a Common Director, each of the Common Holders and the Investors shall vote at a

 


regular or special meeting of stockholders (or by written consent) all of their respectively held shares of capital stock to ensure that any Common Director selected for removal as a Common Director by the holders of a majority in interest of all of the shares of Common Stock shall be so removed. Any vacancy created by such removal shall be filled pursuant to paragraph 3(a) hereof.

        (f)     Removal of the Series A Directors .

    (i)    On all matters relating to the removal of a Series A Director designated by Khosla Ventures II, L.P. pursuant to Section 3(b)(i) hereof, each of the Common Holders and the Investors shall vote at a regular or special meeting of stockholders (or by written consent) all of its shares of capital stock to ensure that any Series A Director selected for removal as a Series A Director by Khosla Ventures II, L.P. shall be so removed. Any vacancy created by such removal shall be filled pursuant to paragraph 3(b)(i) hereof.

    (ii)    On all matters relating to the removal of a Series A Director designated by TPG Biotechnology Partners II, L.P. pursuant to Section 3(b)(ii) hereof, each of the Common Holders and the Investors shall vote at a regular or special meeting of stockholders (or by written consent) all of its shares of capital stock to ensure that any Series A Director selected for removal as a Series A Director by TPG Biotechnology Partners II, L.P. shall be so removed. Any vacancy created by such removal shall be filled pursuant to paragraph 3(b)(ii) hereof.

    (iii)    On all matters relating to the removal of a Series A Director designated by KPCB Holdings, Inc. pursuant to Section 3(b)(iii) hereof, each of the Common Holders and the Investors shall vote at a regular or special meeting of stockholders (or by written consent) all of its shares of capital stock to ensure that any Series A Director selected for removal as a Series A Director by KPCB Holdings, Inc. shall be so removed. Any vacancy created by such removal shall be filled pursuant to paragraph 3(b)(iii) hereof.

        (g)     Removal of the Series D Director . On all matters relating to the removal of a Series D Director designated by Total G&P pursuant to Section 3(c) hereof, each of the Common Holders and the Investors shall vote at a regular or special meeting of stockholders (or by written consent) all of its shares of capital stock to ensure that any Series D Director selected for removal as a Series D Director by Total G&P shall be so removed. Any vacancy created by such removal shall be filled pursuant to paragraph 3(c) hereof.

        (h)     Removal of the Independent Directors . On all matters relating to the removal of the Independent Director, each of the Common Holders and the Investors shall vote at a regular or special meeting of stockholders (or by written consent) all of its respectively held shares of capital stock to ensure that any Independent Directors selected for removal as an Independent Director by the vote of each and all of the Common Directors and the Series A Directors, shall be so removed. Any vacancy created by such removal shall be filled pursuant to paragraph 3(d) hereof.

        (i)     No Obligation to Convert . The provisions of this Section 3 notwithstanding, nothing in this Section 3 shall be deemed or interpreted to oblige any Investor

 


to convert shares of Preferred Stock into shares of Common Stock or other securities in order to comply with the voting requirements and obligations outlined in this Section 3.

(j)      Observer Rights .   For so long as Maxwell (Mauritius) Lte Ltd (“ Temasek ”) holds (together with its affiliates) at least one-half of the shares of Series C-1 Preferred Stock held by Temasek as of the date of this Agreement (as adjusted for stock splits, dividends, combinations, recapitalizations and the like), Temasek shall have the right to designate one non-voting board observer who will be entitled to attend all meetings of the Board of Directors of the Company, participate in all deliberations of the Board of Directors of the Company and receive copies of all materials provided to the Board of Directors of the Company, and if requested, copies of all materials provided to the Board of Directors of the Company’s subsidiaries, provided that such observer shall have no voting rights with respect to actions taken or elected not to be taken by the Board of Directors of the Company, and provided further that such board observer must enter into a confidentiality agreement in favor of the Company and its subsidiaries in a form reasonably acceptable to the Company prior to attending his or her first meeting of the Board of Directors of the Company; provided further that the Company may withhold any information and exclude such observer from any meeting or portion thereof if access to such information or attendance at such meeting (i) could adversely affect the attorney-client privilege between the Company and its counsel, (ii) could result in disclosure of trade secrets or a conflict of interest, (iii) would contravene a Company non-disclosure obligation to a third party, or (iv) if such observer is or is affiliated with a competitor of the Company; provided further that the Company shall provide Temasek with prior notice of, including the Company’s reason for, such an exclusion from a meeting.

4. Drag-Along .

(a)      Voting .   If a Merger Transaction (as defined herein and referred to as a “ Voting Transaction ”), is approved by a majority of the Board of Directors, including a majority of the Board of Directors elected by the holders of the Preferred Stock, and a majority of the outstanding shares of Preferred Stock; then each Common Holder and each Investor (but in all cases excluding Total G&P and any of its Affiliates that hold shares of the Company’s capital stock or transferees of shares initially issued to Total G&P or any of its affiliates) hereby agrees with respect to all securities of the Company which it owns or otherwise exercises voting or dispositive authority to:

(i)     Be present, in person or by proxy, as a holder of shares of voting securities, at all meetings and be counted for the purposes of determining the presence of a quorum at all meetings in the event any approval of a Voting Transaction is to be brought to a vote at a stockholder meeting;

(ii)     Vote (in person, by proxy or by action by written consent, as applicable) the capital stock then held by them (or as to which they then have voting power) on an as converted to Common Stock basis, in favor of such Voting Transaction and in opposition of any and all other proposals that could reasonably be expected to delay or impair the ability of the Company to consummate such Voting Transaction;


(iii)   Refrain from exercising any dissenters’ rights or rights of appraisal under applicable law at any time in connection with such Voting Transaction (if applicable);

(iv)   Execute and deliver all related documentation and take such other action in support of the Voting Transaction as shall reasonably be requested by the Company; and

(v)   Sell the number of shares of capital stock held by such Common Holder or Investor, as applicable, in a Merger Transaction or Asset Sale.

(b)       Definitions .

(i)   “ Merger Transaction ” shall mean an Acquisition or Asset Sale as defined in the Restated Certificate of Incorporation of the Company, as amended from time to time.

(c)       No Agreement to Convert . The foregoing notwithstanding, nothing in this Section 4 shall require Investors holding shares of Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock or Series D Preferred Stock to convert, or consent to the conversion of, such shares of Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock or Series D Preferred Stock into Common Stock in connection with or in anticipation of a Merger Transaction absent the affirmative election of holders of a majority of the Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock or Series D Preferred Stock , as applicable, then outstanding.

5.    Covenants of the Company and the Investors .

(a)      The Company agrees to use its best efforts to ensure that the rights granted hereunder are effective and that the parties hereto enjoy the benefits thereof. Such actions include, without limitation, the use of the Company’s best efforts to cause the nomination and election of the directors as provided above. The Company will not, by any voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all of the provisions of this Agreement and in the taking of all such actions as may be necessary, appropriate or reasonably requested by the holders of a majority of the outstanding voting securities held by the parties hereto, assuming conversion of all outstanding preferred securities in order to protect the rights of the parties hereunder against impairment.

(b)      The Company and the Investors agree that they shall not enter into any agreement, amend any existing agreement or otherwise adopt a provision that would require Total G&P to vote or otherwise take any action related to a Voting Transaction.

6.    No Liability for Election of Recommended Directors .   None of the Company, the Common Holders or the Investors, nor any officer, director, stockholder, partner, employee or agent of such party, if any, makes any representation or warranty as to the fitness or competence of the nominee of any party hereunder to serve on the Company’s Board of


Directors by virtue of such party’s execution of this Agreement or by the act of such party in voting for such nominee pursuant to this Agreement.

7.    Specific Enforcement .   It is agreed and understood that monetary damages would not adequately compensate an injured party for the breach of this Agreement by any party, that this Agreement shall be specifically enforceable, and that any breach or threatened breach of this Agreement shall be the proper subject of a temporary or permanent injunction or restraining order without a requirement of posting bond. Further, each party hereto waives any claim or defense that there is an adequate remedy at law for such breach or threatened breach. Should the provisions of this Agreement be construed to constitute the granting of proxies, such proxies shall be deemed coupled with an interest and irrevocable for the term of this Agreement.

8.    No Liability of Stockholders .   No Investor shall, by reason of his or its ability to designate and cause the election of any member of the Board of Directors hereunder, or otherwise, be subject to any liability or obligation whatsoever with respect to the management and affairs of the Company or otherwise be or become responsible for any debts, liabilities or obligations of the Company. Neither any Investor nor any controlling person, officer, director, partner, agent or employee of any Investor (each an “ Investor Agent ”) shall be liable to any other Investor or Investor Agent in connection with the rights and obligations of such Investor arising under this Agreement.

9.    Successors in Interest .

(a)         The provisions of this Agreement shall be binding upon the successors in interest to any securities of the Company held by any party to this Agreement and their successors and assigns. The Company shall not permit the transfer of any of the securities on its books or issue new certificates representing any such securities unless and until the person(s) to whom such shares are to be transferred shall have executed a written agreement, substantially in the form of this Agreement, pursuant to which such person becomes a party to this Agreement and agrees to be bound by all the provisions hereof as if such person was a party hereunder.

(b)         Each certificate representing each of the securities shall bear a legend reading as follows:

 

“THE SHARES EVIDENCED HEREBY ARE SUBJECT TO THE TERMS OF A VOTING AGREEMENT (A COPY OF WHICH MAY BE OBTAINED WITHOUT CHARGE FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF THE VOTING AGREEMENT.”

10. Execution by the Company . The Company, by its execution in the space provided below, agrees that it will cause the certificates evidencing the shares of capital stock subject to this Agreement to bear the legend required by paragraph 9 hereof and will not permit such legend to be removed, and it shall supply, free of charge, a copy of this Agreement to any


holder of a certificate evidencing shares of capital stock of the Company upon written request from such holder to the Company at its principal office. If at any time or from time to time any Common Holder or Investor holds any certificate representing shares of the Company’s capital stock not bearing the legend required by paragraph 9, such Common Holder or Investor agrees to deliver such certificate to the Company promptly to have such legend placed on such certificate. The parties hereto do hereby agree that the failure to cause the certificates evidencing the shares of capital stock subject to this Agreement to bear the legend required by paragraph 9 hereof and/or failure of the Company to supply, free of charge, a copy of this Agreement as provided under this paragraph 10 shall not affect the validity or enforcement of this Agreement.

11.       Term .   This Agreement shall be effective as of the date hereof and shall continue in effect until and shall terminate upon the earliest to occur of (i) the consummation of the first underwritten public offering of the Company’s Common Stock pursuant to a registration statement under the Securities Act of 1933, as amended, pursuant to which all outstanding shares of Preferred Stock convert into Common Stock, (ii) the consummation of a Merger Transaction (as such term is defined in the this Agreement, as amended from time to time), or (iii) termination of this Agreement in accordance with Section 13(d) hereof.

12.       Grant of Proxy .   Upon the failure of any stockholder to vote their shares, as applicable, in accordance with the terms of this Agreement, such stockholder hereby grants to a stockholder designated by the Board, who or which is a party to this Agreement, a proxy coupled with an interest in all shares owned by such stockholder, with the power to act alone and with full power of substitution, which proxy shall be irrevocable until this Agreement terminates pursuant to its terms or this Section 12 is amended to remove such grant of proxy in accordance with Section 13 hereof, to vote all such shares in the manner provided in Section 1 hereof and to execute all appropriate instruments consistent with this Agreement on behalf of such stockholder. The proxy and power, so long as any party hereto is an individual, will survive death, incompetency and disability of such party or any other individual holder of the shares of capital stock and, so long as any party hereto is an entity, will survive the merger or reorganization of such party.

13.       Miscellaneous

(a)          Captions .     The captions, headings and arrangements used in this Agreement are for convenience only and do not in any way limit or amplify the terms and provisions hereof.

(b)          Manner of Voting .     The voting of shares pursuant to this Agreement may be effected in person, by proxy, by written consent, or in any other manner permitted by applicable law.

(c)          Stock Splits, Stock Dividends, etc .     In the event of any issuance of shares of the Company’s voting securities hereafter to any of the parties hereto (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization, or the like), such shares shall become subject to this Agreement and shall be endorsed with the legend set forth in paragraph 9(b).


(d)          Amendments, and Waivers and Termination .   Any term hereof may be amended (either generally or in a particular instance and either retroactively or prospectively), or provisions of this Agreement waived or the Agreement terminated only with the written consent of (a) the Company; (b) the holders of at least a majority of the shares of Common Stock held by the Common Holders then providing services to the Company as officers or employees; and (c) the holders of at least a majority of the shares of Preferred Stock outstanding (or Common Stock issued upon the conversion thereof), provided , however , that notwithstanding the foregoing, Sections 3(b)(i), 3(f)(i) and 4 shall not be amended or waived without the written consent of Khosla Ventures II, L.P., Sections 3(b)(ii), 3(f)(ii) and 4 shall not be amended or waived without the written consent of TPG Biotechnology Partners II, L.P., Sections 3(b)(iii), 3(f)(iii) and 4 shall not be amended or waived without the written consent of KPCB Holdings, Inc., Sections 3(c), 3(g), 4 and 5(b) shall not be amended or waived without the written consent of Total G&P, and Section 3(j) shall not be amended or waived without the written consent of Temasek; provided , further , that for any amendment or waiver of any provision herein that would have a material, adverse and disproportionate effect on a series of Preferred Stock relative to any other series of Preferred Stock, consent of the holders of at least the majority of such series of Preferred Stock voting as a separate class shall be required. Any amendment or waiver so effected shall be binding upon the Company, the Common Holders, the Investors and all of their respective successors and assigns whether or not such party, assignee or other stockholder entered into or approved such amendment or waiver.

(e)          Ownership .   Each Common Holder represents and warrants to the Investors and the Company that (a) such Common Holder now owns the shares of capital stock listed on Schedule B hereto, free and clear of liens or encumbrances, and has not, prior to or on the date of this Agreement, executed or delivered any proxy or entered into any other voting agreement or similar arrangement other than one which has expired or terminated prior to the date hereof, and (b) such Common Holder has full power and capacity to execute, deliver and perform this Agreement, which has been duly executed and delivered by, and evidences the valid and binding obligation of, such Common Holder enforceable in accordance with its terms.

(f)          Enforceability/Severability .   The parties hereto agree that each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable law. If any provision of this Agreement shall nevertheless be held to be prohibited by or invalid under applicable law, (a) such provision shall be invalid only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement, and (b) the parties shall, to the extent permissible by applicable law, amend this Agreement so as to make effective and enforceable the intent of this Agreement.

(g)          Governing Law .   This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware.

(h)          Counterparts .   This Agreement may be executed in counterparts, including counterparts transmitted by facsimile, other electronic media or otherwise, each of


which shall be deemed an original, but all of which together shall constitute one and the same instrument.

(i)          Successors and Assigns .   The provisions hereof shall inure to the benefit of, and be binding upon, the successors and assigns of the parties hereto.

(j)          Additional Investors .   Notwithstanding anything to the contrary contained herein, if the Company shall issue additional shares of its Series D Preferred Stock pursuant to the Purchase Agreement, any purchaser of such shares of Preferred Stock shall become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and shall be deemed an “Investor” and a party hereunder.

(k)          Additional Common Holders .   The Company shall use its reasonable best efforts to have all officers and holders of at least one percent (1%) of the Company’s Common Stock (including holders of Common Stock issued or issuable upon conversion of Preferred Stock) become a party to this Agreement by executing the Joinder Agreement attached as Exhibit E to the Purchase Agreement.

(l)          Attorney’s Fees .   If any dispute among the parties to this Agreement results in litigation, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including, without limitation, such reasonable fees and expenses of attorneys and accountants, that shall include, without limitation, all fees, costs and expenses of appeals.

(m)          Notices .   All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after deposit in the United States mail, by registered or certified mail, postage prepaid and properly addressed to the party to be notified as set forth on the signature page hereof or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties hereto, or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.

(n)          Entire Agreement .   This Agreement and the Exhibits hereto, along with the Purchase Agreement and the other documents delivered pursuant thereto, constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof and no party shall be liable or bound to any other in any manner by any oral or written representations, warranties, covenants or agreements except as specifically set forth herein and therein. Each party expressly represents and warrants that it is not relying on any oral or written representations, warranties, covenants or agreements outside of this Agreement.

(o)          Delays or Omissions .   It is agreed that no delay or omission to exercise any right, power or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement shall impair any such right, power or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or


any acquiescence therein, or of or in any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent or approval of any kind or character on any party’s part of any breach, default or noncompliance under this Agreement or any waiver on such party’s part of any provisions or conditions of the Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement by law, or otherwise afforded to any party, shall be cumulative and not alternative.

(p)          Waiver .   No waivers of any breach of this Agreement extended by any party hereto to any other party shall be construed as a waiver of any rights or remedies of any other party hereto or with respect to any subsequent breach.

(q)          Previous Agreement .   The Previous Agreement is hereby amended and superseded in its entirety and restated herein. Such amendment and restatement is effective upon execution and delivery of this Agreement by the Company and by the requisite holders as set forth in Section 13(d) of the Previous Agreement. Upon such execution, all provisions of, rights granted and covenants made in the Previous Agreement are hereby waived, released and superseded in their entirety and shall have no further force or effect.

[Signature Pages Follow]


IN WITNESS WHEREOF, the parties hereto have executed this Amended and Restated Voting Agreement as of the day and year herein above first written.

 

COMPANY:
AMYRIS, INC.
By:   /s/John G. Melo
  John G. Melo
  Chief Executive Officer

 

Address:     5885 Hollis Street, Ste. 100
  Emeryville, CA 94608

 

A MENDED AND R ESTATED V OTING A GREEMENT

S IGNATURE P AGE


IN WITNESS WHEREOF, the parties hereto have executed this Amended and Restated Voting Agreement as of the day and year herein above first written.

 

COMMON HOLDERS:
/s/ Jack D. Newman
Jack D. Newman

 

Address:      
   
/s/ K. Kinkhead Reiling
K. Kinkead Reiling

 

Address:      
   

 

   
Jay D. Keasling

 

Address:      
   

 

/s/ Neil Renninger
Neil Renninger

 

/s/ Neil Renninger
Neil Renninger as Trustee of the Neil
Renninger 2010 Qualified Annuity Trust

 

Address:      
   

 

A MENDED AND R ESTATED V OTING A GREEMENT

S IGNATURE P AGE


IN WITNESS WHEREOF, the parties hereto have executed this Amended and Restated Voting Agreement as of the day and year herein above first written.

 

COMMON HOLDER:
/s/ John G. Melo
John G. Melo

 

Address:      
   

 

A MENDED AND R ESTATED V OTING A GREEMENT

S IGNATURE P AGE


IN WITNESS WHEREOF, the parties hereto have executed this Amended and Restated Voting Agreement as of the day and year herein above first written.

 

COMMON HOLDER:
KHOSLA VENTURES II, L.P.
By: Khosla Ventures Associates II, LLC, its general partner
By:   /s/ Samir Kaul
  Samir Kaul, Partner

 

A MENDED AND R ESTATED V OTING A GREEMENT

S IGNATURE P AGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Voting Agreement as of the date first above written.

 

INVESTOR:
AEI CLEANTECH INVESTMENTS I, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  
AEI CLEANTECH INVESTMENTS II, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  
ADVANCED EQUITIES AMYRIS INVESTMENTS I, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  

 

A MENDED AND R ESTATED V OTING A GREEMENT

S IGNATURE P AGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Voting Agreement as of the date first above written.

 

ADVANCED EQUITIES AMYRIS INVESTMENTS II, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  
ADVANCED EQUITIES AMYRIS INVESTMENTS III, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  
ADVANCED EQUITIES AMYRIS INVESTMENTS IV, LLC
By:  
Its:  
By:   /s/ Keith Daubenspeck
Name:   Keith Daubenspeck
Title:  

 

A MENDED AND R ESTATED V OTING A GREEMENT

S IGNATURE P AGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Voting Agreement as of the date first above written.

 

INVESTORS:
DAG Ventures III-QP, L.P.
By:   DAG Ventures Management III, LLC, its General Partner
By:   /s/ R. Thomas Goodrich
  R. Thomas Goodrich, Managing Director
Address:   251 Lytton Ave., Suite 200
  Palo Alto, CA 94301
DAG Ventures III, L.P.
By:   DAG Ventures Management III, LLC, its General Partner
By:   /s/ R. Thomas Goodrich
  R. Thomas Goodrich, Managing Director
Address:   251 Lytton Ave., Suite 200
  Palo Alto, CA 94301
DAG Ventures GP Fund III, LLC
By:   DAG Ventures Management III, LLC, its Managing Member
By:   /s/ R. Thomas Goodrich
  R. Thomas Goodrich, Managing Director
Address:   251 Lytton Ave., Suite 200
  Palo Alto, CA 94301
DAG Ventures I-N, LLC
By:   DAG Ventures Management, LLC, its Managing Member
By:   /s/ R. Thomas Goodrich
  R. Thomas Goodrich, Managing Director
Address:   251 Lytton Ave., Suite 200
  Palo Alto, CA 94301

 

A MENDED AND R ESTATED V OTING A GREEMENT

S IGNATURE P AGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Voting Agreement as of the date first above written.

 

INVESTORS:
KHOSLA VENTURES II, L.P.
By:   Khosla Ventures Associates II, LLC, its general partner
By:   /s/ Samir Kaul
Name: Samir Kaul
Title: Partner
Address:   3000 Sand Hill Road, Bldg. 3, Ste. 170 Menlo Park, CA 94025
KHOSLA VENTURES III, L.P.
By:   Khosla Ventures Associates III, LLC, its general partner
By:   /s/ Samir Kaul
Name: Samir Kaul
Title: Partner
Address:   3000 Sand Hill Road, Bldg. 3, Ste. 170
Menlo Park, CA 94025
TPG BIOTECHNOLOGY PARTNERS II, L.P.
By:  

TPG Biotechnology Genpar II, L.P.

By:  

TPG Biotech Advisors II, LLC.

By:   /s/ Jeffery D. Ekberg
Name: Jeffery D. Ekberg
Title: Vice President
Address:   301 Commerce Street, Suite 3300
Fort Worth, Texas 76102
KPCB HOLDINGS, INC., AS NOMINEE
By:   /s/ John Doerr
Name: John Doerr
Title: Partner
Address:   2750 Sand Hill Road
Menlo Park, CA 94025

 

A MENDED AND R ESTATED V OTING A GREEMENT

S IGNATURE P AGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Voting Agreement as of the date first above written.

 

INVESTOR:
LIT TELE, LLC
By:   /s/ Paulo Henrique de Oliveira Santos
Name:   Paulo Henrique de Oliveira Santos
Title:   Manager
By:   /s/ Naldilei Zumpano
Name:   Naldilei Zumpano
Title:   Manager

 

A MENDED AND R ESTATED V OTING A GREEMENT

S IGNATURE P AGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Voting Agreement as of the date first above written.

 

INVESTOR:
NAXYRIS S.A.
By:   /s/ Henri Reiter & /s/ Christoph Piel
Name:  

Henri Reiter & Christoph Piel

Title:    
Address: 40, Boulevard Joseph II
L-1840 LUXEMBOURG

 

A MENDED AND R ESTATED V OTING A GREEMENT

S IGNATURE P AGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Voting Agreement as of the date first above written.

 

INVESTOR:

TOTAL GAS & POWER USA, SAS

By:

 

/s/ Arnaud Chaperon

Name:

 

Arnaud Chaperon

Title:

 

Chairman

Address:

 

2 Place Jean Millier

92078 Paris, La Defense, CEDEX, FRANCE

 

A MENDED AND R ESTATED V OTING A GREEMENT

S IGNATURE P AGE


SCHEDULE A

SCHEDULE OF INVESTORS

 

S ERIES A I NVESTOR

   N UMBER   OF
S HARES   OF  S ERIES
A S TOCK

Khosla Ventures II, L.P.

   3,449,861

KPCB Holdings, Inc., as nominee

   3,449,861

TPG Biotechnology Partners II, L.P.

   2,299,907

Total

   9,199,629

S ERIES B I NVESTOR

   N UMBER OF
S HARES OF S ERIES
B S TOCK

DAG Ventures III, L.P.

   44,883

DAG Ventures III-QP, L.P.

   477,134

DAG Ventures GP Fund III, LLC

   491

DAG Ventures I-N, LLC

   281,351

Khosla Ventures II, L.P.

   150,723

KPCB Holdings, Inc., as nominee

   150,723

TPG Biotechnology Partners II, L.P.

   401,929

ES East Associates, LLC

   9,859

BB Trust Dated 2/21/03 (Richard Rock, Trustee)

   70,338

Crystalsesv Comércio E Representação Ltda.

   40,193

Santelisa Vale Bioenergia S.A.

   40,193

Total

   1,667,817


SCHEDULE A

SCHEDULE OF INVESTORS (cont.)

 

S ERIES B-1 I NVESTOR

   N UMBER   OF
S HARES   OF  S ERIES
B-1 S TOCK

AEI 2008 CleanTech Investments I, LLC

   134,639

AEI 2008 CleanTech Investments II, LLC

   180,127

Advanced Equities Amyris Investments I, LLC

   226,465

Advanced Equities Amyris Investments II, LLC

   661,403

Advanced Equities Amyris Investments III, LLC

   32,258

Advanced Equities Amyris Investments IV, LLC

   66,240

Ameri Private Equity IV, LLC

   80,563

Aspire Business LTD

   98,970

Christopher Lenzo

   118,765

Counter Point Venture Fund II, LP

   19,800

Erasmus Louisiana Growth Fund II, LP

   39,589

Exccess Venture Fund I, LLC

   79,178

Gaenger Family Living Trust of 1995

   395

GB Sears Family Trust

   3,365

HS Partners Holdings III, LP

   158,353

Innovative Financial Private Equity Fund II, LLC

   45,527

Invest Biotech, LLC

   51,275

James A. Goddard

   989

Lit Tele, LLC

   395,883

Millenium Trust Company

   39,589

Northport Investments, LLC

   53,852

TCM2, LLC

   39,589

Technology Ventures, LLC

   39,588

The Barlow Family Trust

   989

Third Amended and Restated Robbins Trust of 1986

   4,159

Toronto Angel Group Amyris Holdings LP

   43,991

Total

   2,615,721


SCHEDULE A

SCHEDULE OF INVESTORS (cont.)

 

S ERIES C I NVESTOR

   N UMBER   OF
S HARES   OF   S ERIES
C S TOCK

Khosla Ventures III, L.P.

   321,027

KPCB Holdings, Inc., as nominee

   321,027

TPG Biotechnology Partners II, L.P.

   321,027

Lit Tele, LLC

   802,568

DAG Ventures II, L.P.

   146,582

DAG Ventures III-QP, L.P.

   13,788

DAG Ventures GP Fund III, LLC

   144

DAG Ventures I-N, LLC

   60,193

Grober Business Corp.

   802,568

Naxyris SA (an affiliate of NAXOS Capital Partners)

   561,797

Advanced Equities Amyris Investments I, LLC

   22,685

Advanced Equities Amyris Investments II, LLC

   65,672

Advanced Equities Amyris Investments III, LLC

   2,184

Advanced Equities Amyris Investments IV, LLC

   3,249

AEI 2008 CleanTech Investments I, LLC

   5,003

AEI 2008 CleanTech Investments II, LLC

   14,483

Third Amended and Restated Robbins Trust of 1986 (Richard K. Robbins, Trustee)

   1,213

James A. Goddard

   288

Invest Biotech, LLC

   2,648

Kevin Kaster

   1,271

Millenium Trust Company LLP Cust FBO WNA Private Equity Fund B - Amyris LLC

   7,945

Northern Rivers Silicon Valley Access Fund LP

   8,025

Michael P. Waldbillig and Louise A. Waldbillig Trust, dated September 16, 2008

   1,324

Advanced Equities Amyris Investments I, LLC

   10,139

Advanced Equities Amyris Investments II, LLC

   30,724


SCHEDULE A

SCHEDULE OF INVESTORS (cont.)

 

S ERIES C I NVESTOR

   N UMBER   OF
S HARES   OF   S ERIES
C S TOCK

Advanced Equities Amyris Investments III, LLC

   312

Advanced Equities Amyris Investments IV, LLC

   3,593

AEI 2008 CleanTech Investments I, LLC

   2,644

AEI 2008 CleanTech Investments II, LLC

   3,818

Northport Investments LLC

   3,815

Innovative Financial Private Equity

   19,662

Orgone Capital IV, LLC

   61,810

HS Partners Holdings III, LP

   80,256

Phyllis Gardner

   264

Jeffrey and Andrea Tobias

   1,002

BCP Investment, L.P.

   128,410

Richard C. Blum Rollover IRA

   240,770

Magoo 1, LLC

   6,621

Advanced Equities Amyris Investments I, LLC

   394

Advanced Equities Amyris Investments II, LLC

   1,249

Advanced Equities Amyris Investments III, LLC

   96

Advanced Equities Amyris Investments IV, LLC

   104

AEI 2008 CleanTech Investments I, LLC

   491

AEI 2008 CleanTech Investments II, LLC

   812

Orgone Capital IV, LLC

   12,199

Excess Venture Fund I, LLC

   8,026

Westly Group

   381,219

Northport Investments

   21,207

Orgone Capital

   81,274

Innovative Financial Private Equity

   12,039

Advanced Equities Amyris Investments I, LLC

   1,989


SCHEDULE A

SCHEDULE OF INVESTORS (cont.)

 

S ERIES C I NVESTOR

   N UMBER   OF
S HARES   OF   S ERIES
C S TOCK

Advanced Equities Amyris Investments II, LLC

   5,034

Khosla Ventures III, L.P.

   98,661

KPCB Holdings, Inc., as nominee

   98,660

TPG Biotechnology Partners II, L.P.

   98,660
Total    4,902,665

S ERIES C-1 I NVESTOR

   N UMBER OF
S HARES OF S ERIES
C-1 S TOCK

Maxwell (Mauritius) Pte Ltd

   2,724,766

Total

   2,724,766

S ERIES D I NVESTOR

   N UMBER OF
S HARES OF S ERIES
D S TOCK

Total Gas & Power USA, SAS

   7,101,548

Total

   7,101,548


SCHEDULE B

SCHEDULE OF COMMON HOLDERS

 

N AME OF K EY E MPLOYEE

   N UMBER   OF
S HARES   OF
C OMMON  S TOCK

Jack D. Newman

   900,000

K. Kinkead Reiling

   863,000

Jay D. Keasling

   1,000,000

Neil Renninger (including the Neil Renninger 2010 Qualified Annuity Trust)

   900,000

John G. Melo

   1,502,983 1

Total

   5,165,983

These are all outstanding options to purchase Common Stock.


EXHIBIT A

STOCKHOLDER CONSENT


ACTION BY WRITTEN CONSENT

OF THE

STOCKHOLDER OF

AMYRIS, INC.

(a Delaware corporation)

                              , 20     

Pursuant to Section 228(a) of the Delaware General Corporation Law (the “ DGCL ”) and the Bylaws of the Corporation, the undersigned stockholder of Amyris, Inc., a Delaware corporation (the “ Corporation ”), does hereby consent to and approve the adoption of the following resolutions, by written consent without a meeting, effective as of the date first set forth above (unless otherwise noted in the resolutions):

 

1.

Election of Director .

WHEREAS, the number of directors of the Corporation is currently set at [insert number of director positions] directors with one (1) vacancy, which vacancy, pursuant to the Corporation’s Restated Certificate of Incorporation, is to be filled by a director elected by the holders of the Corporation’s Series D Preferred Stock, voting as a separate class (the “ Series D Director ”).

WHEREAS, pursuant to Section 3(c) of that certain Amended and Restated Voting Agreement dated as of June 21, 2010 by and among the Corporation and certain of its stockholders, the stockholder parties thereunder have agreed to vote their shares from time to time to elect as the Series D Director an individual nominated by Total Gas & Power USA, SAS.

WHEREAS, the undersigned stockholder of the Corporation, constituting a majority of the outstanding shares of the Corporation’s Series D Preferred Stock, voting as a separate class, desires to elect [insert name] to the Board as the Series D Director.

NOW, THEREFORE, BE IT RESOLVED, that [insert name] is hereby elected to the Board as the Series D Director, to serve until [insert name]’s successor has been elected or appointed and duly qualified or until [his/her] earlier death, resignation or removal.

 

2.

Omnibus Resolution .


RESOLVED, that the officers of the Corporation, and each of them with full authority to act without the others, are hereby authorized to do all things necessary or desirable, in their sole discretion, to carry out the intent of the foregoing resolutions.

[R EMAINDER OF P AGE I NTENTIONALLY L EFT B LANK ]


IN WITNESS WHEREOF, the undersigned stockholder of the Corporation hereby adopts all of the foregoing resolutions as of the date first above written.

 

STOCKHOLDER :

 

TOTAL GAS & POWER USA, SAS

 
Name:    
Title:    
Date:    

A CTION BY W RITTEN C ONSENT OF THE S TOCKHOLDER

S IGNATURE P AGE


EXHIBIT E

LEGAL OPINION OF FENWICK & WEST LLP


H ORACE L. N ASH

  

E MAIL HNASH @ FENWICK . COM

D IRECT D IAL (650) 335-7934

June 21, 2010

Total Gas & Power USA, SAS

2 place Jean Millier – La Defense 6

92076 Paris La Defense Cedex, France

Ladies and Gentlemen:

We have acted as counsel for Amyris, Inc., a Delaware corporation (the “ Company ”), in connection with the sale by the Company to you (“ you ” or “ Purchaser ”) of 7,101,548 shares of the Company’s Series D Preferred Stock (the “ Shares ”) pursuant to the Series D Preferred Stock Purchase Agreement, dated as of June 21, 2010 (the “ Purchase Agreement ”), between the Company and Purchaser, and the execution and delivery by the Company of the Amended and Restated Investors’ Rights Agreement (the “ Rights Agreement ”), the Amended and Restated Right of First Refusal and Co-Sale Agreement (the “ Co-Sale Agreement ”) and the Amended and Restated Voting Agreement (the “ Voting Agreement ”), each dated June 21, 2010. This opinion is given to you pursuant to Section 4.9 of the Purchase Agreement in connection with the Closing of the sale of the Shares. The Purchase Agreement, the Rights Agreement, the Co-Sale Agreement and the Voting Agreement are referred to herein collectively as the “ Transaction Documents .” Unless defined herein, capitalized terms have the meaning given them in the Purchase Agreement.

In rendering this opinion, we have examined such matters of law as we considered necessary for the purpose of rendering this opinion. As to matters of fact material to the opinions expressed herein, we have relied upon the representations and warranties as to factual matters contained in, and made by the Company pursuant to, the Purchase Agreement and upon certificates and statements of government officials and of officers of the Company, including but not limited to a certificate of the Company (the “ Opinion Certificate ”). In addition, we have examined originals or copies of documents, corporate records and other writings that we consider relevant for the purposes of this opinion. In such examination, we have assumed that the signatures on documents and instruments examined by us are authentic, that each is what it purports to be, and that all documents and instruments submitted to us as copies or facsimiles conform with the originals, which facts we have not independently verified.

In making our examination of documents and rendering our opinions, we have further assumed that, except for the Company with respect to the Transaction Documents, (a) each party to such documents had the entity power and entity authority to enter into and perform all of such


To Total Gas & Power USA, SAS

on the date hereof

Page 2

 

party’s obligations thereunder, (b) each party to such documents has duly authorized, executed and delivered such documents and (c) each of such documents is enforceable against and binding upon the parties thereto. We have also assumed that (i) the representations and warranties of Purchaser set forth in the Transaction Documents are accurate and complete, (ii) there is no fact or circumstance relating to you or your business that might prevent you from enforcing any of your rights provided for in the Transaction Documents and (iii) there are no extrinsic agreements or understandings among the parties to the Transaction Documents, that would modify or interpret the terms of the Transaction Documents or the respective rights or obligations of the parties thereto.

Notwithstanding the examination described above, the expressions “ to our knowledge, ” “ known to us, ” “ our actual knowledge ” or words of similar import when used in this opinion letter, refer to the current actual knowledge of attorneys within the firm who have rendered legal services to the Company in connection with the Transaction Documents and means that, while such attorneys have not been informed by the Company that a matter stated is factually incorrect, we have made no independent factual investigation with respect to such matter. No inference as to our knowledge of any matters bearing on the accuracy of any such statement should be drawn from the fact of our representation of the Company or the rendering of the opinions set forth below.

Where statements in this opinion concerning the Company, or an effect on the Company, are qualified by the term “ material ” or “ materially ,” those statements involve judgments and opinions as to the materiality or lack of materiality of any matter to the Company’s business, assets, results of operations or financial condition that are entirely those of the Company and its officers.

We express no opinion as to matters governed by any laws other than the laws of the State of California, the Delaware General Corporation Law (the “ DGCL ”) and the federal law of the United States of America, including the rules and regulations promulgated by governmental authorities thereunder (collectively, “ Applicable Laws ”). We express no opinion as to whether the laws of any particular jurisdiction apply, or to the extent that the laws of any jurisdiction other than those identified above are applicable to the Transaction Documents or the transactions contemplated thereby.

In rendering the opinion set forth in paragraph (1) (Qualification to Do Business) below as to the valid existence and good standing of the Company under the laws of the State of Delaware, and as to its qualification to do business as a foreign corporation in good standing under the laws of the State of California, we have relied exclusively on certificates of public officials.

In rendering the opinion set forth in paragraph (2) (Authority and Power to Do Business) below concerning the Company’s corporate power and corporate authority to conduct its business


To Total Gas & Power USA, SAS

on the date hereof

Page 3

 

as it is presently conducted, as to the types of businesses the Company presently conducts, we have relied exclusively upon representations made to us in the Opinion Certificate.

With respect to the opinion rendered in paragraph (3) (Capitalization) below relating to the Company’s authorized, issued and outstanding capital stock and the confirmation as to Preemptive and Other Rights that follows our opinions, please note that we have not maintained any of the Company’s stock records. Such records have been maintained by the Company and its former counsel, either directly or through eProsper, a third party service, until we began representing the Company during October 2008 and we have not had any knowledge of the procedures used by the Company and its former counsel for issuing and transferring the Company’s securities. Accordingly, in rendering the opinion set forth in paragraph (3) and in the Preemptive and Other Rights Confirmation, we have relied without further investigation on (a) the Company’s Restated Certificate of Incorporation certified by the Delaware Secretary of State on June 18, 2010 (the “ Restated Certificate ”), (b) the bylaws of the Company certified by the Secretary of the Company on June 21, 2010 (the “ Bylaws ”), (c) minute books relating to meetings and written actions of the incorporator(s), Board of Directors and stockholders of the Company, (d) stock ledger, certificate books, stock holder list, list of options, list of warrants and lists of stock purchase rights that have been maintained by the Company and its former counsel or eProsper prior to our representation and that are now maintained by us and eProsper in the course of our representation based upon information received by us from the Company, and (e) statements in the Opinion Certificate relating to the equity capitalization of the Company (collectively, the “ Capitalization Records ”). We do not have the information necessary to verify the accuracy and completeness of the information on the number and type of securities outstanding, other than by reviewing the Capitalization Records. Accordingly, our opinion on, and confirmation of, the number and type of issued and outstanding securities means that, based upon the examination referred to above, the Capitalization Records are consistent with the information as to the number and type of outstanding stock, options, warrants, conversion privileges or other rights that is set forth in paragraph (3) and in such confirmation.

In connection with our opinion set forth in paragraph (3) (Capitalization) and in the Preemptive and Other Rights Confirmation that follows our opinions, we have relied without independent verification on the Opinion Certificate, to the effect that the Company has received the consideration approved by its Board of Directors for all of the issued shares of capital stock of the Company.

We note that the parties to the Purchase Agreement and the Voting Agreement (together, the “ Delaware Agreements ”) have designated the laws of the State of Delaware as the laws governing the Delaware Agreements. We are not licensed to practice law in the State of Delaware. As a result, notwithstanding the designation therein of the laws of the State of Delaware, our opinion in paragraph (5) (Enforceability) below as to the validity, binding effect and enforceability of the Delaware Agreements is premised upon the results that would be obtained if a California court were to apply the internal laws of the State of California to


To Total Gas & Power USA, SAS

on the date hereof

Page 4

 

contracts made between California residents present in California when the Delaware Agreements are entered into (without regard to laws regarding choice of law or conflict of laws).

In rendering the opinion in paragraph (7) (No Violations) below relating to violations of Applicable Laws, and paragraph (8) (No Consents) below relating to consents, approvals, authorizations and filings under, or pursuant to, Applicable Laws, such opinions are limited to Applicable Laws that in our experience are typically applicable to transactions of the nature provided for in the Transaction Documents. Moreover, we render no opinion in such paragraphs, or in paragraph (5) (Enforceability), regarding the Company’s compliance with applicable securities laws, including but not limited to laws regarding the registration or qualification of the offer and sale of securities, or the registration by the Company under any such securities laws, and no such opinion should be inferred from the language of those paragraphs. Any opinion rendered in connection with applicable securities laws is rendered solely and expressly in paragraph (9) (Securities Law Compliance) below.

In rendering the opinion expressed in paragraph (9) (Securities Law Compliance) below, we have assumed the accuracy of, and have relied upon, the Company’s representations to us that the Company has made no offer to sell the Shares by means of any general solicitation or publication of any advertisement therefor. We have relied upon the Company’s representation that it had a pre-existing substantive business relationship with you prior to the filing of the Form S-1 Registration Statement filed by the Company with the Securities and Exchange Commission on April 16, 2010, as amended (together the “ Registration Statement ”) and that the filing of the Registration Statement did not cause you to seek to purchase the Shares. Furthermore, we have assumed the accuracy of, and have relied upon, your representation that you are a “qualified institutional buyer” within the meaning of Rule 144A of the Securities Act of 1933, as amended. In addition, we are rendering no opinion as to whether the Company’s press release titled “Amyris Secures Funding to Advance Scale Up, First Commercial Plan” dated October 1, 2009 constituted a general solicitation or publication of any advertisement in connection with the Company’s issuance and sale of any of its securities, nor the effect such press release had on any offerings of its securities. We have assumed for the purposes of this opinion that such press release did not constitute a general solicitation nor publication of any advertisement within the meaning of the securities laws referred to in paragraph (9)

This opinion is qualified by, and we render no opinion with respect to, or as to the effect of, the following:

(a)     bankruptcy, insolvency, reorganization, moratorium and other similar laws relating to or affecting the relief of debtors or the rights and remedies of creditors generally, including without limitation the effect of statutory or other law regarding fraudulent conveyances, preferential transfers and equitable subordination;

(b)     general principles of equity, including but not limited to judicial decisions holding that certain provisions are unenforceable when their enforcement would violate


To Total Gas & Power USA, SAS

on the date hereof

Page 5

 

the implied covenant of good faith and fair dealing, or would be commercially unreasonable or involve undue delay, whether or not such principles or decisions have been codified by statute;

(c)     Section 1670.5 of the California Civil Code or any other California or United States federal law or provision of the DGCL or equitable principle which provides that a court may refuse to enforce, or may limit the application of, a contract or any clause thereof that the court finds to have been unconscionable at the time it was made, unconscionable in performance or contrary to public policy;

(d)     any provision purporting to (i) exclude conflict of law principles under any law or (ii) select certain courts as the venue, or establish a particular jurisdiction as the forum, for the adjudication of any controversy;

(e)     judicial decisions, that may permit the introduction of extrinsic evidence to modify the terms or the interpretation of any agreement;

(f)     the tax or accounting consequences of any transaction contemplated in connection with the sale of the Shares under applicable tax laws and regulations and under applicable accounting rules, regulations, releases, statements, interpretations or technical bulletins;

(g)     applicable antifraud statutes, rules or regulations of United States federal or applicable state laws concerning the issuance or sale of securities, including, without limitation, (i) the accuracy and completeness of the information provided by the Company to Purchaser in connection with the offer and sale of the Shares, and (ii) the accuracy or fairness of the past, present or future fair market value of any securities;

(h)     the effect any breach of the fiduciary duties of the members of the Company’s Board of Directors, officers or principal stockholders would have on the enforceability authorization and performance of any agreement;

(i)     whether or not any agreement, and the transactions provided for therein, were fair and reasonable to the Company at the time of their authorization by the Company’s Board of Directors and stockholders within the meaning of Section 144 of the DGCL;

(j)     any United States federal or other antitrust laws, statutes, rules or regulations , including without limitation the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or other laws relating to collusive or unfair trade practices or designed to promote competition in any jurisdiction;

(k)     any provision purporting to (i) waive rights to trial by jury, service of process or objections to the laying of venue or forum in connection with any litigation


To Total Gas & Power USA, SAS

on the date hereof

Page 6

 

arising out of or pertaining to the agreement in which such provision appears, (ii) change or waive the rules of evidence, make determinations conclusive or fix the method or quantum of proof (iii) limit the effect of waivers by trade practice or course of conduct or (iv) waive the statute of limitations;

(l)     any choice-of-law clause, to the extent the provision to be governed by that law could be determined by the court (i) to be contrary to a public or fundamental policy of a state or country whose law would apply in the absence of a choice-of-law clause, and (ii) to involve an issue in which such state or country, or California State, has a materially greater interest in the determination of the particular issue than does the state whose law is chosen;

(m)     indemnification and contribution provisions to the extent enforcement of such provisions are contrary to public policy or indemnify a party against liability for future conduct or the party’s own fraud or wrongful, reckless or negligent acts or omissions;

(n)     any provisions imposing obligations to vote the Company’s capital stock in a certain manner, or any drag-along provision, including without limitation those provisions set forth in the Voting Agreement, due to (i) the application of equitable principles in connection with any remedy sought to enforce such provisions, irrespective of whether the remedies sought are legal or equitable in nature, (ii) the application of general legal principles requiring that waivers of rights be knowing and intelligent, and with knowledge of consequences of the waiver, and (iii) conflict with the provisions of the DGCL requiring that votes be counted as cast, rather than in accordance with such voting or drag-along terms and conditions, and the extent to which a corporation can take action to enforce such terms and conditions; and

(o)     any provision concerning the obligation of the Company (or its underwriters or agents) to sell shares of stock to certain persons or entities in connection with a public offering, including but not limited to the provisions of the right of first offer set forth in Section 2.4 of the Investors’ Rights Agreement entitling Purchaser to acquire certain shares in a public offering other than a firm commitment underwritten public offering of the Company’s securities pursuant to which all outstanding shares of Preferred Stock automatically convert into Common Stock.

In connection with an opinion rendered herein that is dependent upon the validity of the Company’s certificate of incorporation, we render no opinion as to whether or not all shares of any one class of the Company’s capital stock has the same voting, conversion and redemption rights and other rights, preferences, privileges and restrictions, unless the class is divided into series, nor, if divided into series, that each such series has the same voting, conversion and redemption rights and other rights, preferences, privileges and restrictions.

In accordance with Section 95 of the American Law Institute’s Restatement (Third) of the


To Total Gas & Power USA, SAS

on the date hereof

Page 7

 

Law Governing Lawyers (2000), this opinion letter is to be interpreted in accordance with customary practices of lawyers rendering opinions to third parties in transactions of the type provided for in the Transaction Documents.

Based upon and subject to the foregoing, and except as set forth in the Purchase Agreement or the Disclosure Schedule thereto, as of immediately prior to the Closing we are of the following opinion.

(1)     The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware. The Company is qualified to do business as a foreign corporation in good standing under the laws of the State of California.

(2)     The Company has all corporate power and corporate authority required (a) to conduct its business as, to our knowledge, it is presently conducted, and (b) to execute, deliver and perform its obligations under the Transaction Documents.

(3)     As of immediately prior to the Closing, the authorized capital stock of the Company consists of 70,000,000 shares of Common Stock, par value $0.0001 per share, 5,128,045 of which are issued and outstanding, and 30,963,903 shares of Preferred Stock, par value $0.0001 per share, 9,475,000 shares of which have been designated Series A Preferred Stock, all of which are issued and outstanding, 1,929,641 shares of which have been designated Series B Preferred Stock, 1,667,817 shares of which are issued and outstanding, 4,700,000 shares of which have been designated Series B-1 Preferred Stock, 2,615,721 of which are issued and outstanding, 4,976,000 of which have been designated Series C Preferred Stock, 4,902,665 of which are issued and outstanding, 2,781,714 of which have been designated Series C-1 Preferred Stock, 2,724,766 of which are issued and outstanding, and 7,101,548 of which have been designated Series D Preferred Stock, none of which are issued and outstanding.

(4)     All corporate action has been taken on the part of the Company’s Board of Directors and stockholders (a) that is necessary for the execution and delivery of the Transaction Documents by the Company and (b) that must be taken as of the date hereof to authorize the sale and issuance of the Shares and performance by the Company of its obligations under the Transaction Documents.

(5)     Each of the Transaction Documents has been duly executed by the Company and has been delivered by the Company to Purchaser. Each of the Transaction Documents constitutes a valid and binding obligation of the Company, enforceable by you against the Company in accordance with its terms.

(6)     The Shares to be issued on the date hereof, when issued in compliance with the provisions of the Purchase Agreement, will be duly authorized, validly issued, fully paid and nonassessable. Assuming the Common Stock issuable upon conversion of such Shares is issued


To Total Gas & Power USA, SAS

on the date hereof

Page 8

 

as of the date hereof in accordance with the Restated Certificate, such Common Stock will be duly authorized, validly issued, fully paid and nonassessable.

(7)     The execution, delivery and performance of the Transaction Documents do not, as of the Closing, result in (a) a violation of the Restated Certificate or Bylaws, (b) a material violation of any judgment or order of any court or governmental entity that is specifically identified on the Disclosure Schedule, if any, or (c) a material violation of any Applicable Law.

(8)     Other than those that previously may have been obtained or made, no consent, approval or authorization of, or filing with, any governmental authority pursuant to any Applicable Law is required on the part of the Company in connection with the Company’s (a) valid execution and delivery of the Transaction Documents and (b) performance of the Transaction Documents as of the date hereof.

(9)     Based in part upon the representations made by you in the Purchase Agreement, and subject to the filings of such securities law notices as may be required to be filed subsequent to the Closing, the offer, sale and issuance of the Shares to be issued to you in conformity with the terms of the Purchase Agreement and the issuance of the Common Stock to you, if any, to be issued upon conversion thereof for no additional consideration and pursuant to the Restated Certificate, constitute transactions exempt from the registration requirements of Section 5 of the Securities Act of 1933, as amended, and exempt from the qualification requirements of Section 25110 of the California Corporate Securities Law of 1968, as amended.

In addition to the foregoing opinions, based upon the foregoing and other than as set forth in the Purchase Agreement or the Disclosure Schedule thereto, we supplementally confirm the following to you as of immediately prior to the Closing.

Litigation Confirmation. To our knowledge, there is no action, suit, proceeding or investigation by or before any court or governmental body that is pending or threatened in writing against the Company and that questions the validity of the Transaction Documents or the right of the Company to enter into the Transaction Documents. Please note that we have not conducted a docket search in any jurisdiction with respect to litigation that may be pending against the Company or any of its affiliates, officers or directors, nor, other than to request the Opinion Certificate from the Company, have we undertaken any further inquiry whatsoever in connection with the existence any such action, suit, proceeding or investigation.

Preemptive and other Rights Confirmation. To our knowledge, there are no presently outstanding preemptive rights, options, warrants, conversion privileges or rights to purchase from the Company any of the authorized but unissued capital stock of the Company other than (a) the conversion privileges of the Company’s Preferred Stock, (b) rights to purchase the Shares pursuant to the Purchase Agreement, (c) any options to purchase the Common Stock of the Company that may have been granted under the 2005 Stock Issuance/Stock Option Plan (the “ Plan ”), pursuant to which 7,342,700 shares of the Company’s Common Stock may be


To Total Gas & Power USA, SAS

on the date hereof

Page 9

 

issued in the aggregate to recipients of awards thereunder, (d) options to purchase 60,000 shares of Common Stock issued outside of the Plan, (e) 176,272 restricted stock units issued outside of the Plan, (f) the rights of first offer provided in Section 2.4 of the Investors’ Rights Agreement dated March 19, 2010, among the Company and certain of its stockholders, (g) pursuant to or issuable upon conversion, exchange or cancellation of shares of the Company’s subsidiary, Amyris Brasil, S.A., for Company restricted Common Stock upon the Company’s IPO as provided in Sections 7.2 and 7.3 of the Amendment and Restatement to the Shareholders’ Agreement dated May 26, 2010, among the Company, Fundo Mútuo de Investimento em Empresas Emergentes Inovadoras Stratus GC III, Red Mountain Jet LLC and, as intervening parties, Amyris Brasil, S.A., and Stratus Investimentos Ltda., (h) warrants to purchase 2,580 shares of the Company’s Series B Preferred Stock, (i) warrants to purchase 106,567 shares of the Company’s Series B-1 Preferred Stock, and (j) warrants to purchase 73,258 shares of the Company’s Series C Preferred Stock.

This opinion is rendered as of the date first written above solely for your benefit in connection with the sale and issuance of the Shares pursuant to the Purchase Agreement and may not be relied on by, nor may any copy be delivered to, any other person or entity without our prior written consent. Our opinion is expressly limited to the matters set forth above and we render no opinion, whether by implication or otherwise, as to any other matters. We assume no obligation to inform you of any fact, circumstance, event or change in the law or the facts that may hereafter be brought to our attention that may alter, affect or modify the opinions expressed herein.

[Remainder of page left blank]


To Total Gas & Power USA, SAS

on the date hereof

Page 10

 

Very truly yours,
FENWICK & WEST LLP
By:   /s/ Horace L. Nash
  Horace L. Nash, a Partner


EXHIBIT F

SIDE LETTER AGREEMENT

(filed as Exhibit 4.19 to the Registration Statement filed by the Company, File No. 333-166135)


EXHIBIT G

LOCK-UP AGREEMENT


June _, 2010

Morgan Stanley & Co. Incorporated

Goldman, Sachs & Co.

JP Morgan Securities Inc.

c/o Morgan Stanley & Co. Incorporated

    1585 Broadway

    New York, NY 10036

Dear Sirs and Mesdames:

The undersigned understands that Morgan Stanley & Co. Incorporated (“ Morgan Stanley ”) and Goldman, Sachs & Co. (“ Goldman, Sachs ” and together with Morgan Stanley, the “ Representatives ”) propose to enter into an Underwriting Agreement (the “ Underwriting Agreement ”) with Amyris Biotechnologies, Inc., a California corporation (together with any successor thereto, the “ Company ”), providing for the public offering (the “ Public Offering ”) by the several underwriters, including the Representatives (the “ Underwriters ”), of shares (the “ Shares ”) of the Common Stock, no par value per share, of the Company (the “ Common Stock ”).

To induce the Underwriters that may participate in the Public Offering to continue their efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent of the Representatives on behalf of the Underwriters, it will not, during the period commencing on the date hereof and ending 180 days after the date of the final prospectus relating to the Public Offering (the “ Prospectus ”) (such period, the “ Lock-Up Period ”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”)), by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Common Stock or (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise, or (3) publicly announce the intent to do any of the foregoing. The foregoing sentence shall not apply to:

(a) transactions relating to shares of Common Stock or other securities acquired in open market transactions after the completion of the Public Offering, provided that no filing under the Exchange Act (other than a filing on a Form 5, Schedule 13D or Schedule 13G (or 13D/A or 13G/A) made after the expiration of the Lock-Up Period), shall be required or shall be voluntarily made in connection with subsequent sales of Common Stock or other securities acquired in such open market transactions;

(b) transfers of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock as a bona fide gift;


(c) distributions of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock to limited partners, members or stockholders of the undersigned;

(d) transfers of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock by will or intestate succession or to any trust or partnership for the direct or indirect benefit of such person or any member of the immediate family of the undersigned;

(e) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act, provided that the undersigned shall not engage in any transaction under such trading plan until the termination of the Lock-Up Period;

(f) the exercise of options, warrants or rights to acquire shares of Common Stock or any security convertible into Common Stock, in each case outstanding on the date hereof, in accordance with their terms, provided that the acquired Common Stock is subject to the same terms of the Lock-Up Period;

(g) transfers of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock to the Company, pursuant to agreements under which the Company has the option to repurchase such shares or a right of first refusal with respect to transfers of such shares, provided that such transfers after the date of the Prospectus shall be for less than market value of the Common Stock at the time of transfer;

(h) the sale of shares of Common Stock to the Underwriters; and

(i) in the case of a non-natural person, transfers of shares of Common Stock to any wholly-owned subsidiary of the undersigned (including any corporation, partnership, limited liability company or other entity that is directly or indirectly owned by the undersigned) or to the parent corporation of the undersigned or any wholly owned subsidiary of such parent corporation;

provided that in the case of any transfer or distribution pursuant to clauses (b), (c), (d) and (i), (1) each donee, distributee or transferee shall sign and deliver a lock-up letter substantially in the form of this letter, (2) no filing under the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock, shall be required or shall be voluntarily made during the Lock-Up Period, (3) such transfer or distribution shall not be a disposition for value and (4) each party (transferor, transferee, donor or donee) shall not be required by law (including without limitation the disclosure requirements of the Exchange Act) to make, and shall agree to not voluntarily make, any public announcement of the transfer or disposition (other than a filing on a Form 5, Schedule 13D or Schedule 13G (or 13D/A or 13G/A) made after the expiration of the Lock-Up Period). In addition, the undersigned agrees that, without the prior written consent of the Representatives on behalf of the Underwriters, it will not, during the Lock-Up Period, make any demand for or exercise any right with respect to, the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock. The undersigned also agrees and consents to the entry of stop transfer instructions with the


Company’s transfer agent and registrar against the transfer of the undersigned’s shares of Common Stock except in compliance with the foregoing restrictions.

If:

(1) during the last 17 days of the Lock-Up Period the Company issues an earnings release or material news or a material event relating to the Company occurs; or

(2) prior to the expiration of the Lock-Up Period, the Company announces that it will release earnings results during the 16-day period beginning on the last day of the Lock-Up Period;

the restrictions imposed by this agreement shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event.

The undersigned shall not engage in any transaction that may be restricted by this agreement during the 34-day period beginning on the last day of the initial Lock-Up Period unless the undersigned requests and receives prior written confirmation from the Company or the Representatives that the restrictions imposed by this agreement have expired.

The undersigned understands that the Company and the Underwriters are relying upon this agreement in proceeding toward consummation of the Public Offering. The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors and assigns. This Lock-Up Agreement shall automatically terminate upon the earliest to occur, if any, of (a) the date the Company advises the Representatives, in writing, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering, (b) the date of the termination of the Underwriting Agreement if prior to the closing of the Public Offering or (c) December 31, 2010 if, and only if, the Public Offering of the Shares has not been completed by such date.


Whether or not the Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters.

 

Very truly yours,
By:    
Name:  
Its:  
Address:

Exhibit 4.19

CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS

DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR

CONFIDENTIAL TREATMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED

WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE

CONFIDENTIAL MATERIAL HAS BEEN FILED SEPARATELY WITH

THE SECURITIES AND EXCHANGE COMMISSION.

AMYRIS, INC.

5885 Hollis Street, Suite 100

Emeryville, CA 94608

June 21, 2010

TOTAL GAS & POWER USA, SAS

2, place Jean Millier – La Defense 6

92076 Paris La Defense Cedex – France

 

 

Re:

Letter Agreement Regarding Certain Agreements between Amyris, Inc. (the “ Company ”) and Total Gas & Power USA, SAS (“ Total G&P ”)

Dear Sir or Madam:

Reference is hereby made to that certain Series D Preferred Stock Purchase Agreement, dated as of June 21, 2010 (the “ Series D Agreement ”), by and among the Company and Total G&P (as the Investor).

This Letter Agreement (this “ Side Letter Agreement ”) is made by and between the Company and Total G&P in connection with the Series D Agreement. The Company and Total G&P agree to the following:

1.         Certain Definitions .  For purposes of this Side Letter Agreement, the following terms shall have the following respective meanings:

 

 

(a)

Acquisition ” has the meaning set forth in Section 4 below.

 

 

(b)

Acquisition Proposal ” means any agreement, explicit offer or explicit proposal for, or any written indication of interest in, an Acquisition.

 

 

(c)

Affiliate ” means, with respect to a Person, any Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such first Person. For purposes of this definition, “control” and, with correlative meanings, the terms “controlled by” and “under common control with” mean (i) the possession, directly or indirectly, of the power to direct the management or policies of a Person, whether through the ownership of voting securities, by contract relating to voting rights or corporate governance, or otherwise, or (ii) the ownership,

 

1


 

directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interest of a Person.

 

 

(d)

Board ” means the Company’s Board of Directors.

 

 

(e)

Person ” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.

 

 

(f)

Third Party ” means any Person other than the Company, Total G&P and Total G&P’s Affiliates.

2.         Board of Directors: Total Designee Post-IPO .

(a)        Effective following the closing of the Company’s initial public offering of its Common Stock registered pursuant to the Securities Act of 1933 (the “ IPO ”) and until such time as the earlier to occur of the following: (i) Total G&P (together with its Affiliates) holds less than 3,550,774 shares of Series D Preferred Stock purchased by it pursuant to the Series D Agreement (with such number to be subject to proportionate adjustment in the event of stock splits, combinations, dividends, recapitalizations, and the like with respect to the Company’s Common Stock occurring after the date hereof) (or any security issued or issuable on conversion thereof) or (ii) an Acquisition, the Company shall use its reasonable efforts, to the extent consistent with the fiduciary duties of the Board, to cause one designee of Total G&P (the “ Total Designee ”) to be appointed to the Board at a meeting of the Board or nominated or re-nominated for election at each annual meeting at which such designee is up for election or re-election, as the case may be.

(b)        In connection with the IPO, the Company shall (i) adopt a classified Board providing for three (3) classes of directors to be elected in successive years and (ii) cause the Total Designee to serve in a seat subject to the latest date of re-election. This Section 2(b) shall terminate at such time as Section 2(a) terminates.

(c)        The Company shall not take any action that precludes the appointment of the Total Designee to serve in the seat subject to the latest date of re-election as set forth in Section 2(b)(ii) above. This Section 2(c) shall terminate at such time as Section 2(a) terminates.

(d)        Until such time as the earlier to occur of the following: (i) Total G&P (together with its Affiliates) holds less than 3,550,774 shares of Series D Preferred Stock purchased by it pursuant to the Series D Agreement (with such number to be subject to proportionate adjustment in the event of stock splits, combinations, dividends, recapitalizations, and the like with respect to the Company’s Common Stock occurring after the date hereof) (or any security issued or issuable on conversion thereof) or (ii) an Acquisition, the Company will permit one representative of Total G&P (the “ Observer ”)

 

2


to attend all meetings of the Board and all committees thereof (whether in person, telephonic or other) in a non-voting, observer capacity and shall provide to Total G&P notice of such meeting and a copy of all materials provided to such members. The Company may, in its sole discretion, invite one or more additional representatives of Total G&P to attend meetings of the Board as additional Observers; provided that the terms set forth in this Side Letter Agreement shall apply to the attendance of any such additional Observers. Total G&P hereby agrees that its Observer(s) will hold in confidence and trust as a fiduciary to the Company and not misuse or disclose any information (including within Total G&P) provided to him or her in connection with the Observer rights set forth in this Side Letter Agreement, in each case to the same extent and in the same manner as is required of Total G&P’s representative on the Board, including without limitation pursuant to any requirements set forth in policies and procedures of the Company that apply to all members of the Board. A majority of the Board shall have the right to exclude the Observer(s) from portions of meetings of the Board or omit to provide the Observer(s) with certain information if such members of the Board believe that attendance at such meeting or portion thereof or access to such information (i) could, based on the advice of Company counsel, adversely affect the Company’s attorney-client privilege, (ii) would contravene a Company non-disclosure obligation to a third party or (iii) could result in a conflict of interest; provided that the Observer(s) shall not be permitted to attend any executive session of the Board unless the Total Designee is not in attendance at such executive session of the Board.

(e)        The Company acknowledges that Total G&P will likely have, from time to time, information that is not Amyris Information (as defined below) but that may be of interest to the Company (“ Total Information ”) regarding a wide variety of matters including, by way of example only, (a) Total G&P’s (or its Affiliates’) technologies, plans and services, and plans and strategies relating thereto, (b) current and future investments Total G&P (or its Affiliates) has made, may make, may consider or may become aware of with respect to other companies and other technologies, products and services, including, without limitation, technologies, products and services that may be competitive with the Company’s, and (c) developments with respect to the technologies, products and services, and plans and strategies relating thereto, of other companies, including, without limitation, companies that may be competitive with the Company. The Company recognizes that a portion of such Total Information may be of interest to the Company. Such Total Information may or may not be known by Total G&P’s representative serving on the Board and/or the Observer(s). The Company, as a material part of the consideration for this Side Letter Agreement, agrees that Total G&P, Total G&P’s representative serving on the Board and/or the Observer(s) shall have no duty to disclose any Total Information to the Company or permit the Company to participate in any projects or investments based on any Total Information, or to otherwise take advantage of any opportunity that may be of interest to the Company if it were aware of such Total Information, and hereby waives, to the extent permitted by law, any claim based on the corporate opportunity doctrine or otherwise that could limit Total G&P’s ability to pursue opportunities based on such Total Information or that would require Total G&P, Total G&P’s representative serving on the Board and/or the Observer(s) to disclose any such Total Information to the Company or offer any opportunity relating thereto to the Company.

 

3


(f)        Total G&P acknowledges that the Company will, from time to time, disclose to Total G&P’s representative serving on the Board and/or to the Observer(s) information relating to the business of the Company (“ Amyris Information ”) regarding a wide variety of matters including, by way of example only, (a) the Company’s (or its Affiliates’) technologies, plans and services, and plans and strategies relating thereto, (b) current and future investments the Company (or its Affiliates) has made, may make, may consider or may become aware of with respect to other companies and other technologies, products and services, including, without limitation, technologies, products and services that may be competitive with Total G&P’s, and (c) developments with respect to the technologies, products and services, and plans and strategies relating thereto, of other companies, including, without limitation, companies that may be competitive with Total G&P. Amyris Information does not include information that: (i) was in the public domain at the time of the disclosure or after the disclosure, other than through the act or negligence of Total G&P or its Affiliates, Board representative or Observer(s), (ii) was already rightfully in the possession of Total G&P or its Affiliates at the time of the disclosure, (iii) is lawfully received from a third party without breach of an obligation to the Company, (iv) was independently developed by Total G&P or its Affiliates without access to any Amyris Information, as proven by contemporaneous written evidence, or (v) is disclosed to third parties generally by the Company without confidentiality restrictions. Total G&P recognizes that a portion of the Amyris Information may be of interest to Total G&P. Total G&P, as a material part of the consideration for this Side Letter Agreement, agrees that neither it nor its Affiliates shall have the right to receive or use such Amyris Information nor shall Total G&P and/or its Affiliates be permitted to participate in, or profit from, any projects or investments based on any Amyris Information, or otherwise take advantage of any opportunity that may be of interest to Total G&P and/or its Affiliates as a result of, or based upon, such Amyris Information. Total G&P hereby waives, and agrees not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that the corporate opportunity doctrine does not apply to such Amyris Information with respect to the Observer(s); for the sake of clarification, the Company is not waiving any claim that the corporate opportunity doctrine applies to such Amyris Information with respect to Total G&P’s representative serving on the Board.

3.         Participation in Sale Process .    The following provisions shall remain in effect until terminated in accordance with Section 3(c) below:

(a)         Notice of Acquisition Proposal .  In the event that the Company receives an unsolicited Acquisition Proposal from a Third Party (a “ Third Party Offer ”), or the Board, acting in good faith, authorizes the officers of the Company to initiate or pursue an Acquisition Proposal (a “ Solicitation Decision ”), within one (1) business day after receipt of such Third Party Offer by the Company or such Solicitation Decision, as the case may be, the Company shall provide Total G&P with written notice (the “ Notice ”) of such Third Party Offer or Solicitation Decision, as the case may be. In the event of a Third Party Offer, the Notice shall also include the following information regarding the Acquisition Proposal: (i) whether the Company believes the offering party to be a strategic or financial buyer; (ii) whether the offering party is a public or private company and, if the offering party is a public company, whether it has a market capitalization in

 

4


excess of $1,000,000,000; and (iii) whether the offering party is on the list of entities (or, to the Company’s knowledge, is affiliated with one of such entities) listed on Exhibit A attached hereto. After delivering the Notice to Total G&P, and subject to a mutually acceptable nondisclosure agreement, the Company shall, if requested by Total G&P, provide Total G&P prompt access to, and copies of, all due diligence documents containing non-public information of the Company that are supplied by the Company to any Third Party that makes an Acquisition Proposal.

(b)         Negotiation Period .

 

 

(i)

(A) In the case of a Solicitation Decision, for a period of fifteen (15) business days after delivery of the Notice, or (B) in the case of a Third Party Offer, for a period of five (5) business days after delivery of the Notice, Total G&P shall have the exclusive right to negotiate with the Company to reach mutually agreeable terms for an Acquisition of the Company by Total G&P (such 15- or 5-business day period, the “ Exclusive Negotiation Period ”). During the Exclusive Negotiation Period, the Company shall (X) not enter into any agreement (including, without limitation, any no shop agreement, binding term sheet or merger agreement) other than a confidentiality agreement no less favorable to the Company than those binding Total with respect to an Acquisition of the Company by any Person, other than by Total G&P or its Affiliates, (Y) not engage in any negotiations or discussions with any Person, other than with Total G&P or its Affiliates, in each case, with respect to a potential Acquisition and (Z) continue to provide Total G&P with due diligence materials as set forth in Section 3(a) above. In the event that Total G&P presents the Company with an Acquisition Proposal during the Exclusive Negotiation Period, such Acquisition Proposal shall be considered by the Board in the exercise of its fiduciary duties.

 

 

(ii)

Upon the expiration of the Exclusive Negotiation Period, the Company shall, if requested by Total G&P, continue to negotiate with Total G&P for an additional period of ten (10) business days following the expiration of the Exclusive Negotiation Period (the “ Restricted Negotiation Period ”) to reach mutually agreeable terms for the Acquisition of the Company by Total G&P. During the Restricted Negotiation Period, the Company shall (X) not enter into any agreement (including, without limitation, any no shop agreement, binding term sheet or merger agreement) other than a confidentiality agreement no less favorable to the Company than those binding Total with respect to an Acquisition of the Company by any Person, other than by Total G&P or its Affiliates, and (Y) continue to provide Total G&P with due diligence materials as set forth in Section 3(a) above; provided that during the Restricted Negotiation Period the Company shall be entitled to also engage in any negotiations and discussions with any Person. After the Restricted Negotiation Period, the

 

5


 

Company shall not be obligated to provide any due diligence information to Total G&P. In the event that Total G&P presents the Company with an Acquisition Proposal during the Restricted Negotiation Period, such Acquisition Proposal shall be considered by the Board in the exercise of its fiduciary duties.

 

 

(iii)

The Exclusive Negotiation Period or Restricted Negotiation Period will terminate prior to the expiration of the applicable period if Total G&P notifies the Company in writing that it has determined that it does not desire or intend to negotiate an Acquisition involving the Company.

 

 

(iv)

In the event of a Third Party Offer or a Solicitation Decision, if the Company has complied in all material respects with the foregoing requirements of this Section 3, the Company will have no further obligations under this Section 3 until the date that is 135 days following the Restricted Negotiation Period relating thereto. If the Company has materially complied with the foregoing provisions of this Section 3 and enters into a definitive agreement during such 135-day period, it may thereafter consummate an Acquisition pursuant to such definitive agreement without any further obligations under this Section 3. If the Company does not enter into a definitive agreement with a Third Party to consummate an Acquisition within such 135-day period or if the Company enters into a definitive agreement within the 135-day period but such agreement terminates prior to the Acquisition being consummated, the Company must again comply with the foregoing provisions of this Section 3 after the expiration of the 135-day period or the termination of such definitive agreement, if applicable.

(c)         Termination .  This Section 3 shall terminate and be of no further force or effect upon the earlier of (i) such time as Total G&P (together with its Affiliates) holds securities representing less than 10% of the voting securities of the Company or (ii) provided that the Company has complied with all of the procedures and requirements of this Section 3 for any Acquisition Proposal, the date of the completion of the transactions contemplated by such Acquisition Proposal.

4.         Standstill Agreement .

(a)         Initial Standstill Period .  During the period of time commencing on the date hereof (the “ Effective Date ”) and continuing until the second anniversary of the Effective Date (the “Second Anniversary ”) (with such period being referred to as the “ Initial Standstill Period ”), without the prior consent of the Board (as evidence by a duly adopted resolution), Total G&P shall not, and shall cause its Affiliates not to acquire, or offer or seek or agree to acquire, directly or indirectly, by purchase or otherwise (collectively, “ Acquire ”), ownership (beneficial or otherwise) of any additional securities or assets of the Company or any of its subsidiaries (or any direct or indirect rights or

 

6


options to acquire such ownership, or otherwise act in concert with respect to any such securities, rights or options with any Person) in excess of the greater of (i) the number of shares of Series D Preferred Stock purchased by Total G&P pursuant to the Series D Agreement (as adjusted for stock splits, dividends, combinations, recapitalizations and the like with respect to the Company’s Common Stock occurring after the date hereof) (the “ Series D Purchase ”), and (ii) twenty percent (20%) of the Company’s then outstanding capital stock (assuming the conversion of all outstanding shares of the Company’s Preferred Stock into the Company’s Common Stock) (together, the “ Initial Standstill Threshold ”), provided that so long as Total G&P is not otherwise in breach of this Section 4 and notwithstanding the Initial Standstill Threshold, if, during the Initial Standstill Period, any Third Party Acquires more of the Company’s then outstanding capital stock (assuming conversion of all outstanding shares of the Company’s Preferred Stock into the Company’s Common Stock) then owned (beneficially or otherwise) by Total G&P and its Affiliates in the aggregate, Total G&P (and/or its Affiliates) may Acquire an additional number of shares of Common Stock of the Company such that Total G&P and its Affiliates own (beneficially or otherwise) in the aggregate no greater than one more share of Common Stock of the Company than is then owned (beneficially or otherwise) by such Third Party (assuming the conversion to Common Stock of all of such Third Party’s capital stock) (it being understood that Total G&P and its Affiliates shall not Acquire any additional securities or assets of the Company or any of its subsidiaries thereafter, except pursuant to the terms of this Section 4); provided , however , that for purposes of clarity, in no event shall Total G&P be required to dispose of any securities of the Company that it may rightfully Acquire if, subsequent to such transaction, the number of shares of outstanding capital stock of the Company shall subsequently decrease, nor shall the voting rights of any securities that it holds be impaired or reduced.

(b)         Second Standstill Period .  During the period of time commencing on the Second Anniversary and continuing until the third anniversary of the Effective Date (the “ Third Anniversary ”) (with such period being referred to as the “ Second Standstill Period ”), without the prior consent of the Board (as evidence by a duly adopted resolution), Total G&P shall not, and shall cause its Affiliates not to Acquire, ownership (beneficial or otherwise) of any additional securities or assets of the Company or any of its subsidiaries (or any direct or indirect rights or options to acquire such ownership, or otherwise act in concert with respect to any such securities, rights or options with any Person) in excess of the greater of (i) the Series D Purchase, and (ii) thirty percent (30%) of the Company’s then outstanding capital stock (assuming the conversion of all outstanding shares of the Company’s Preferred Stock into the Company’s Common Stock) (the “ Second Standstill Threshold ”), provided that so long as Total G&P is not otherwise in breach of this Section 4 and notwithstanding the Second Standstill Threshold, if, during the Second Standstill Period, any Third Party Acquires more of the Company’s then outstanding capital stock (assuming conversion of all outstanding shares of the Company’s Preferred Stock into the Company’s Common Stock) then owned (beneficially or otherwise) by Total G&P and its Affiliates in the aggregate, Total G&P (and/or its Affiliates) may Acquire an additional number of shares of Common Stock of the Company such that Total G&P and its Affiliates own (beneficially or otherwise) in the aggregate no greater than one more share of Common Stock of the Company than is

 

7


then owned (beneficially or otherwise) by such Third Party (assuming the conversion to Common Stock of all of such Third Party’s capital stock) (it being understood that Total G&P and its Affiliates shall not Acquire any additional securities or assets of the Company or any of its subsidiaries thereafter, except pursuant to the terms of this Section 4); provided , however , that for purposes of clarity, in no event shall Total G&P be required to dispose of any securities of the Company that it may rightfully Acquire if, subsequent to such transaction, the number of shares of outstanding capital stock of the Company shall subsequently decrease, nor shall the voting rights of any securities that it holds be impaired or reduced.

(c)         Other Prohibited Actions .      In addition to Sections 4(a) and 4(b), during the period of time commencing on the Effective Date and continuing until the Third Anniversary, without the prior consent of the Board (as evidence by a duly adopted resolution), Total G&P shall not, and shall cause its Affiliates not to

 

 

(i)

make, or participate in, directly or indirectly, any “solicitation” of “proxies” to vote (as such terms are used in the Regulation 14A promulgated under the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”)), become a “participant” in any “election contest” (as such terms are defined in Rule 14a-11 promulgated under the Exchange Act) or initiate, propose or otherwise solicit stockholders of the Company or its subsidiaries for the approval of any stockholder proposals;

 

 

(ii)

make, or participate in, directly or indirectly, in any tender offer, exchange offer, merger, business combination, recapitalization, restructuring, liquidation, dissolution or extraordinary transaction involving the Company or any of its subsidiaries or their securities or assets, provided that nothing in this Section 4 shall be construed to limit Total G&P’s (or its Affiliates’) ability to exercise rights that are exercisable by the holders of the class of securities held by Total G&P or its Affiliates with respect to a given transaction;

 

 

(iii)

form, join, participate in, or encourage the formation of, a group (within the meaning of Section 13(d)(3) of the Exchange Act) with respect to any voting securities of the Company or any of its subsidiaries;

 

 

(iv)

deposit any securities of the Company or any of its subsidiaries into a voting trust, or subject any securities of the Company or any of its subsidiaries to any agreement or arrangement with respect to the voting of such securities other than the Amended and Restated Voting Agreement, dated as of even date herewith, by and among the Company, Investor and certain other security holders of the Company;

 

 

(v)

make any public announcement with respect to, or submit a proposal for, or offer (with or without conditions) of any extraordinary

 

8


 

transaction involving the Company or any of its subsidiaries or any of their securities or assets;

 

 

(vi)

seek, or encourage or support any effort, to influence or control the management, board of directors, business, or policies of the Company or any of its subsidiaries, provided that this subclause (g) shall not apply to any actions taken by a representative of Total G&P on the Board in his or her capacity as a director or actions taken by Total G&P or any entity affiliated with Total G&P or in common control with Total G&P in accordance with agreements between it and the Company or any subsidiary of the Company;

 

 

(vii)

encourage or assist any other Person to undertake any of the foregoing actions; or

 

 

(vii)

take any action that could reasonably be expected to require the Company or any of its subsidiaries to make a public announcement regarding the possibility of any of the events described in this Section 4.

(d)       Exceptions .     Notwithstanding Sections 4(a), 4(b) and 4(c), this Section 4 shall be of no further effect and shall not bind Total G&P or its Affiliates in any manner from and after such time, if any, as (i) the Company is in breach of the “Participation in Sale Process” as described in Section 3 above, provided that Total G&P shall have provided the Company with prior written notice of such breach and given the Company at least five (5) business days to cure such breach, (ii) the Company fails to present to the Board a written request of Total G&P for a waiver of the standstill agreement within three (3) business days of the Company’s receipt of such written request, provided that this subclause (ii) shall only apply to the first four (4) requests made in any given twelve-month period, or (iii) the Company shall make a public announcement that it has, or the Company has in fact, entered into a letter of intent or definitive agreement with a Third Party Acquirer providing for any of the following transactions (each, an “ Acquisition ”) with a Third Party (a “ Third Party Acquirer ”):

(w) until the closing of the Company’s IPO, or a transaction or series of related transactions that would constitute a “Liquidation” pursuant to the Company’s Restated Certificate of Incorporation, as amended from time to time (the “ Restated Certificate ”), including but not limited to a restructuring, recapitalization or a reorganization;

(x) a merger or consolidation of the Company with the Third Party Acquirer which results in the holders of the voting securities of the Company outstanding immediately prior thereto (other than the Third Party Acquirer, its Affiliates and “associates” (as such term is used in the Exchange Act)) ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity (or, if applicable, its parent company) immediately after such merger or consolidation;

 

9


(y) the sale or exclusive license to the Third Party Acquirer of all or substantially all of the assets of the Company; or

(z) the Third Party Acquirer, together with any of the Third Party Acquirer’s Affiliates or “associates” (as such term is used in the Exchange Act), becoming the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of the Company or by contract or otherwise having the right to control the board of directors of the Company or the ability to cause the direction of management of the Company.

Nothing in this Section 4 shall preclude either party from initiating discussions with the other party regarding a possible negotiated transaction on a non-public basis or any discussion in the ordinary course of business in connection with their existing relationships. In connection with the immediately preceding sentence, the Company’s management shall promptly present to the Board any such solicitation or request from Total G&P.

5.         Stop-Transfer Instructions .    Total G&P agrees that, in order to ensure that Total G&P does not acquire any securities of the Company in contravention of the standstill restrictions imposed by Section 4 of this Side Letter Agreement, the Company may issue appropriate “stop-transfer” instructions to its transfer agent, if any, and if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. The Company will not be required (a) to transfer on its books any securities that have been acquired in violation of the standstill restrictions imposed by Section 4 of this Side Letter Agreement or (b) to treat Total G&P (and/or its Affiliates) as owner of such securities, or to accord Total G&P (and/or its Affiliates) the right to vote or receive dividends.

6.         Specific Performance .  Each party to this Side Letter Agreement acknowledges and agrees that any breach by either of them of this Side Letter Agreement shall cause the other party irreparable harm which may not be adequately compensable by money damages. Accordingly, in the event of a breach or threatened breach by a party of any provision of this Side Letter Agreement, including, without limitation, Section 3 of this Side Letter Agreement, each party shall be entitled to seek the remedies of specific performance, injunction or other preliminary or equitable relief, without having to prove irreparable harm or actual damages, and the Company shall not raise any defenses to specific performance (including but not limited to any argument that money damages are adequate), and that no bond need be posted. The foregoing right shall be in addition to such other rights or remedies as may be available to any party for such breach or threatened breach, including but not limited to the recovery of money damages.

7.         Costs of Enforcement .  If any party to this Side Letter Agreement seeks to enforce its rights under this Side Letter Agreement by legal proceedings, the non-prevailing party shall pay all costs and expenses incurred by the prevailing party, including, without limitation, all reasonable attorneys’ fees.

8.         Amendment and Waiver .      No amendment, modification, termination or cancellation of this Side Letter Agreement shall be effective unless it is in writing signed by the Company and Total G&P. No waiver of any of the provisions of this Side Letter Agreement

 

10


shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.

9.         Entire Agreement .    This Side Letter Agreement and the documents referenced herein set forth the entire understanding between the parties hereto and supersedes and merges all previous written and oral negotiations, commitments, understandings and agreements relating to the subject matter hereof between the Company and Total G&P.

10.         Assignment .    This Side Letter Agreement may not be transferred or assigned (whether by operation of law or otherwise) by either party without the prior written consent of the other party.

11.         Severability .    In case any one or more of the provisions contained in this Side Letter Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision of this Side Letter Agreement, and such invalid, illegal or unenforceable provision shall be reformed and construed so that it will be valid, legal and enforceable to the maximum extent permitted by law.

12.         Notices .    All notices and other communications hereunder shall be in writing and shall be deemed given when delivered personally or by commercial messenger or courier service to the parties at the following addresses (or at such other address for a party as shall be specified by like notice):

 

 

(a)

if to the Company, to:

 

 

  

Amyris, Inc.

 

  

5885 Hollis Street, Suite 100

 

  

Emeryville, CA 94608

 

  

Attention: Tamara Tompkins, General Counsel

 

 

  

with a copy (which shall not constitute notice) to:

 

 

  

Fenwick & West LLP

 

  

801 California Street

 

  

Mountain View, CA 94041

 

  

Attention: Gordon Davidson and Sayre Stevick

 

 

(b)

if to Total G&P, to:

 

 

  

2, place Jean Millier – La Defense 6

 

  

92076 Paris La Defense Cedex – France

 

  

Attention: Stephen Douglas

 

 

  

with a copy (which shall not constitute notice) to:

 

 

  

Orrick, Herrington & Sutcliffe LLP

 

  

1000 Marsh Road

 

  

Menlo Park, CA 94025

 

11


 

  

Attention: Greg Heibel

13.       Miscellaneous .    This Side Letter Agreement shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. The parties (a) irrevocably and unconditionally submit to the jurisdiction of the federal or state courts located in the State of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Side Letter Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Side Letter Agreement except in the federal or state courts located in the State of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Side Letter Agreement or the subject matter hereof may not be enforced in or by such court. This Side Letter Agreement may be executed in one or more counterparts, which shall together constitute one agreement.

14.       Additional Covenants .

(a)        To the Company’s knowledge, Total G&P has not exerted control over, or directly or indirectly induced the Company’s actions with respect to, the IPO or the contents of the Form S-1 Registration Statement filed by the Company with the Securities and Exchange Commission on April 16, 2010, as amended (the “ S-1 ”), nor has Total G&P engaged in any other conduct with respect to the IPO or the S-1 that would result in Total G&P being considered a “controlling person” within the meaning of Section 15 or Section 20 of the Securities Exchange Act of 1934.

(b)        The Company shall not amend its current Investment Policy (attached hereto as Exhibit B ) without the prior approval of the Company’s Audit Committee of the Board (the “ Audit Committee ”); provided, however, that prior to the Audit Committee’s approval of any changes to such Investment Policy, the Company shall notify, and the Audit Committee shall consult with, a representative of Total G&P to be designated in writing by Total G&P.

(c)        After the date hereof, the Company shall not issue any additional shares of its Series B Preferred Stock without the consent of (i) the holders of a majority of the then outstanding shares of Preferred Stock, voting together as a single class on an as-converted basis and (ii) the holders of a majority of the then outstanding shares of Series D Preferred Stock.

Please indicate your agreement to the terms of this Side Letter Agreement by executing the acknowledgement and agreement below and returning a copy to the attention of Tamara Tompkins, our General Counsel.

[Remainder of page left blank]

 

12


 

Very truly yours,

 
 

AMYRIS, INC.

 
 

/s/ John G. Melo

 
 

Name: John G. Melo

 
 

Title: President and Chief Executive Officer

 

 

 

Acknowledged and Agreed as Aforesaid,

as of the date first written above.

 

TOTAL GAS & POWER USA, SAS

By:

 

/s/ Arnaud Chaperon

Name:

 

Arnaud Chaperon

Title:

 

Chairman

 

 

 

SIGNATURE PAGE TO SIDE LETTER


Exhibit A

Specified Parties

[*]

 

 

 

 

 

* Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


Exhibit B

Investment Policy


Amyris Biotechnologies, Inc.

Investment Policy Guidelines

Date Last Reviewed: March 6, 2008

 

1.

PURPOSE

To establish guidelines for the investment of Amyris Biotechnologies’s surplus cash balances. Surplus cash balances are balances in corporate accounts not immediately required for working capital, capital investment, debt repayment, or other outstanding near-term financial obligations.

 

2.

OBJECTIVES

The objectives of the policy are, in order of priority:

 

 

2.1

Preservation of capital.

 

 

2.2

Fulfillment of liquidity needs.

 

 

2.3

Diversify investments to minimize risk and inappropriate concentrations of investments in any one entity.

 

 

2.3

Maximization of investment performance

 

 

2.4

Fiduciary control of cash and investments.

 

3.

ELIGIBLE INVESTMENTS

All investments must be U.S. dollar-denominated.

Borrowing for investment purposes is prohibited.

Investment in securities with underlying leverage risk or esoteric structures is prohibited.

Investment in derivative securities, other than floating-rate debt obligations, is prohibited.

 

 

3.1

U.S. Treasury bills, notes, and bonds

3.1.1      Includes putable, callable, and floating-rate obligations

 

 

3.2

U.S. agency debt obligations

3.2.1      Includes obligations issued by government-sponsored enterprises


 

3.3

Corporate debt obligations

3.3.1      Issue or issuer rated one of the following:

 3.3.1.1 A or better by Moody’s and/or Standard & Poor’s

 3.3.1.2 P-1 by Moody’s and/or A-1 or better by Standard & Poor’s

3.3.2      Includes eurodollar and yankee debt obligations

 

 

3.4

Bank debt obligations

3.4.1      Issue or issuer rated one of the following:

 3.4.1.1 A or better by Moody’s and/or Standard & Poor’s

 3.4.1.2 P-1 by Moody’s and/or A-1 or better by Standard & Poor’s

3.4.2      Includes eurodollar and yankee debt obligations

 

 

3.5

Taxable and tax-exempt municipal debt obligations

3.5.1      Issue or issuer rated one of the following:

 3.5.1.1  A or better by Moody’s and/or Standard & Poor’s

 3.5.1.2  MIG1 or VMIG1 by Moody’s and/or SP-1 or better by Standard & Poor’s

 3.5.1.3  P-1 by Moody’s and/or A-1 or better by Standard & Poor’s

 

3.5.2

Tax-exempt municipal debt obligations are eligible only when Amyris Biotechnologies is a tax-paying entity

 

 

3.6

Money market funds

3.6.1      SEC-registered

3.6.2      Maintain a net asset value of $1.00/share

3.6.3      Consist of a minimum of $1 billion in assets

 

 

3.7

Repurchase agreements

3.7.1      Collateralized at a minimum of 102% with one of the following:

 3.7.1.1  U.S. Treasury bills, notes, or bonds

 3.7.1.2  U.S. agency debt obligations

Collateral may not have maturities in excess of 24 months

 

4.

CONCENTRATION LIMITS

4.1 There is no limit to the percentage of Amyris Biotechnologies’ portfolio that may be maintained in U.S. Treasury debt obligations, U.S. agency debt obligations, or SEC-registered money market funds.

4.2 With the exception of those investments listed in Section 4.1, no one issuer or group of issuers from the same holding company shall exceed fifteen (15) percent of the book value of Amyris Biotechnologies’ portfolio at the time of purchase.

 

5.

MATURITY LIMITS

 

 

5.1

The maximum maturity of individual securities in Amyris Biotechnologies’ portfolio shall not exceed twenty-four (24) months.

 

 

5.2

The weighted-average days to maturity of Amyris Biotechnologies’ portfolio shall not exceed twelve (12) months.


 

5.3

For securities that have put, reset, or expected average maturity dates, the put, reset, or expected average maturity dates will be used, instead of the final maturity dates, for maturity limit purposes.

 

 

5.4

For securities that have call dates, the final maturity dates will be used for maturity limit purposes, unless callable securities are purchased at significant premiums, in which cases Capital Advisors Group may determine at its discretion to use call dates, instead of final maturity dates, for the purpose of calculating the weighted-average days to maturity of Amyris Biotechnologies’ portfolio.

 

 

5.5

The liquidity requirements stated in Section 6. will always take priority over the maturity limits stated in Sections 5.1, 5.2, and 5.3.

 

 

5.6

The Chief Financial Officer of Amyris Biotechnologies’ is provided discretion under this Policy to designate up to fifty percent (50%) of the market value of the portfolio of securities as “held to maturity” rather than “available-for-sale” if he or she believe this is a more appropriate classification, at the time Amyris Biotechnologies acquires the specific securities.

 

6.

LIQUIDITY REQUIREMENT

 

 

6.1

A minimum of two times the amount of expected monthly cash outflow must be liquid each business day.

 

 

6.1.1

Liquidity may be reduced below the amount of two times expected monthly cash outflow upon written notice by the individual(s) appointed by Amyris Biotechnologies’ Board of Directors to oversee fiduciary control.

 

6.1.2

For purposes of determining liquidity, book value shall be used.

 

 

6.2

The sale of securities prior to maturity is permitted only for managing liquidity and/or credit deterioration and must be pre-approved by the individual(s) appointed by Amyris Biotechnologies’ Board of Directors to oversee fiduciary control.

 

7.

INVESTMENT PERFORMANCE

 

 

7.1

Capital Advisors Group, Inc. shall issue a quarterly investment performance analysis using time-weighted measures.

 

 

7.2

Capital Advisors Group, Inc. shall meet regularly with the individual(s) appointed by Amyris Biotechnologies’ Board of Directors to oversee fiduciary control.

 

8.

CREDIT QUALITY

 

 

8.1

Trends for a given company or industry must be reviewed periodically by Capital Advisors Group, Inc. and adjustments in percentage positions made accordingly.


 

8.2

Should any investment held in Amyris Biotechnologies’ portfolio fall short of prescribed guidelines, Capital Advisors Group, Inc. shall immediately notify the individual(s) appointed by Amyris Biotechnologies’ Board of Directors to oversee fiduciary control.

 

 

8.3

In determining investment eligibility, Capital Advisors Group, Inc. shall rely on securities rating information obtained from Bloomberg, L.P.

 

9.

MARKETABILITY

 

 

9.1

All securities must be purchased through investment banking and brokerage firms of high quality and reputation, with a history of making markets for the securities in which Amyris Biotechnologies invests.

 

 

9.2

In the unlikely event that securities must be sold before their maturity, all securities must be easily remarketed. To accomplish this, securities must be conventional products with strong name recognition.

 

10.

TRADING GUIDELINES

 

 

10.1

Normal investing practice is to reinvest the funds on the day a security matures in order to minimize lost interest.

 

 

10.2

A daily transaction log shall be maintained by Capital Advisors Group, Inc. and shall be available for Amyris Biotechnologies’s review at any time.

 

 

10.3

All trading firms must generate a hard copy document for each transaction that shall be mailed to Capital Advisors Group, Inc. on behalf of Amyris Biotechnologies.

 

 

10.4

Quarterly summaries of Amyris Biotechnologies’ investment holdings and cash usage shall be maintained by Capital Advisors Group, Inc. and shall be available for Amyris Biotechnologies’ review at any time.

 

11.

  CUSTODY

 

 

11.1

Assets must be held in a segregated bank custody account with separate fiduciary documents executed by the bank. Assets shall not be held by any investment manager or securities dealer.

 

 

11.2

The Bank operating the segregated bank custody account with separate fiduciary documents must be SAS70 Type II certified for the previous 12 months and must be intending to maintain current certification status at all times.

 

12.

FIDUCIARY DISCRETION


 

12.1

Capital Advisors Group, Inc. shall have full discretion to invest Amyris Biotechnologies’ portfolio subject to strict adherence to these guidelines.

 

 

12.2

Capital Advisers Group, Inc. shall act with the highest level of care, prudence, and diligence in carrying out the investment objectives set forth herein.

 

13.

AMENDMENTS TO INVESTMENT POLICY GUIDELINES

 

 

13.1

Capital Advisors Group, Inc. shall review these guidelines periodically with the individual(s) appointed by Amyris Biotechnologies’ Board of Directors to oversee fiduciary control.

 

 

13.2

Amendments to these guidelines may be made upon notification to Capital Advisors Group, Inc. by the individual(s) appointed by Amyris Biotechnologies’ Board of Directors to oversee fiduciary control, provided that such amendments are consistent with the investment objectives set forth in Section 2 of this document.

 

 

 

 

Date                          

  

BY                                                                                                   

    

                Chief Financial Officer

Exhibit 10.01

INDEMNITY AGREEMENT

This Indemnity Agreement, dated as of                              , 2010 is made by and between Amyris Biotechnologies, Inc., a Delaware corporation (the “ Company ”), and                                  , a director, officer or key employee of the Company or one of the Company’s subsidiaries or other service provider who satisfies the definition of Indemnifiable Person set forth below (“ Indemnitee ”).

RECITALS

A.    The Company is aware that competent and experienced persons are increasingly reluctant to serve as representatives of corporations unless they are protected by comprehensive liability insurance and indemnification, due to increased exposure to litigation costs and risks resulting from their service to such corporations, and due to the fact that the exposure frequently bears no relationship to the compensation of such representatives;

B.    The members of the Board of Directors of the Company (the “ Board ”) have concluded that to retain and attract talented and experienced individuals to serve as representatives of the Company and its Subsidiaries and Affiliates and to encourage such individuals to take the business risks necessary for the success of the Company and its Subsidiaries and Affiliates, it is necessary for the Company to contractually indemnify certain of its representatives and the representatives of its Subsidiaries and Affiliates, and to assume for itself maximum liability for Expenses and Other Liabilities in connection with claims against such representatives in connection with their service to the Company and its Subsidiaries and Affiliates;

C.    Section 145 of the Delaware General Corporation Law (“ Section 145 ”), empowers the Company to indemnify by agreement its officers, directors, employees and agents, and persons who serve, at the request of the Company, as directors, officers, employees or agents of other corporations, partnerships, joint ventures, trusts or other enterprises, and expressly provides that the indemnification provided thereby is not exclusive; and

D.    The Company desires and has requested Indemnitee to serve or continue to serve as a representative of the Company and/or the Subsidiaries or Affiliates of the Company free from undue concern about inappropriate claims for damages arising out of or related to such services to the Company and/or the Subsidiaries or Affiliates of the Company.


AGREEMENT

NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows:

 

  1. Definitions .

(a)      Affiliate .  For purposes of this Agreement, “Affiliate” of the Company means any corporation, partnership, limited liability company, joint venture, trust or other enterprise in respect of which Indemnitee is or was or will be serving as a director, officer, trustee, manager, member, partner, employee, agent, attorney, consultant, member of the entity’s governing body (whether constituted as a board of directors, board of managers, general partner or otherwise), fiduciary, or in any other similar capacity at the request, election or direction of the Company, and including, but not limited to, any employee benefit plan of the Company or a Subsidiary or Affiliate of the Company.

(b)      Change in Control .  For purposes of this Agreement, “Change in Control” means (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), other than a Subsidiary or a trustee or other fiduciary holding securities under an employee benefit plan of the Company or Subsidiary, is or becomes the “Beneficial Owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing 20% or more of the total voting power represented by the Company’s then outstanding capital stock, or (ii) during any period of two consecutive years, individuals who at the beginning of such period constitute the Board and any new director whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof, or (iii) the stockholders of the Company approve a merger or consolidation of the Company with any other corporation, other than a merger or consolidation that would result in the outstanding capital stock of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into capital stock of the surviving entity) at least 80% of the total voting power represented by the capital stock of the Company or such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the Company approve a plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company (in one transaction or a series of transactions) of all or substantially all of the Company’s assets.

(c)      Expenses .  For purposes of this Agreement, “Expenses” means all direct and indirect costs of any type or nature whatsoever (including, without limitation, all attorneys’ fees and related disbursements, and other out-of-pocket costs), paid or incurred by Indemnitee in connection with either the investigation, defense or appeal of, or being a witness in a Proceeding (as defined below), or establishing or enforcing a right to indemnification under this Agreement, Section 145 or otherwise; provided, however, that Expenses shall not include any judgments, fines, ERISA excise taxes or penalties or amounts paid in settlement of a Proceeding.

(d)      Indemnifiable Event .  For purposes of this Agreement, “Indemnifiable Event” means any event or occurrence related to Indemnitee’s service for the Company or any Subsidiary or Affiliate as an Indemnifiable Person (as defined below), or by reason of anything done or not done, or any act or omission, by Indemnitee in any such capacity.

(e)      Indemnifiable Person .  For the purposes of this Agreement, “Indemnifiable Person” means any person who is or was a director, officer, employee, attorney, trustee, manager, member, partner, consultant, member of an entity’s governing body (whether constituted as a board of

 

2


directors, board of managers, general partner or otherwise) or other agent or fiduciary of the Company or a Subsidiary or Affiliate of the Company.

(f)      Independent Counsel .  For purposes of this Agreement, “Independent Counsel” means legal counsel that has not performed services for the Company or Indemnitee in the five years preceding the time in question and that would not, under applicable standards of professional conduct, have a conflict of interest in representing either the Company or Indemnitee.

(g)      Other Liabilities .  For purposes of this Agreement, “Other Liabilities” means any and all liabilities of any type whatsoever (including, but not limited to, judgments, fines, penalties, ERISA (or other benefit plan related) excise taxes or penalties, and amounts paid in settlement and all interest, taxes, assessments and other charges paid or payable in connection with or in respect of any such judgments, fines, ERISA (or other benefit plan related) excise taxes or penalties, or amounts paid in settlement).

(h)      Proceeding .  For the purposes of this Agreement, “Proceeding” means any threatened, pending, or completed action, suit or other proceeding, whether civil, criminal, administrative, investigative, legislative or any other type whatsoever, preliminary, informal or formal, including any arbitration or other alternative dispute resolution and including any appeal of any of the foregoing.

(i)      Subsidiary .  For purposes of this Agreement, “Subsidiary” means any entity of which more than 50% of the outstanding voting securities is owned directly or indirectly by the Company.

2.      Agreement to Serve .  The Indemnitee agrees to serve and/or continue to serve as an Indemnifiable Person in the capacity or capacities in which Indemnitee currently serves the Company as an Indemnifiable Person, and any additional capacity in which Indemnitee may agree to serve, until such time as Indemnitee’s service in a particular capacity shall end according to the terms of an agreement, the Company’s Certificate of Incorporation or Bylaws, governing law, or otherwise. Nothing contained in this Agreement is intended to create any right to continued employment or other form of service for the Company or a Subsidiary or Affiliate of the Company by Indemnitee.

 

  3. Mandatory Indemnification .

(a)      Agreement to Indemnify .  In the event Indemnitee is a person who was or is a party to or witness in or is threatened to be made a party to or witness in any Proceeding by reason of an Indemnifiable Event, the Company shall indemnify Indemnitee from and against any and all Expenses and Other Liabilities incurred by Indemnitee in connection with (including in preparation for) such Proceeding to the fullest extent not prohibited by the provisions of the Company’s Bylaws and the Delaware General Corporation Law (“ GCL ”), as the same may be amended from time to time (but only to the extent that such amendment permits the Company to provide broader indemnification rights than the Bylaws or the GCL permitted prior to the adoption of such amendment).

 

3


(b)      Exception for Amounts Covered by Insurance and Other Sources .  Notwithstanding the foregoing, the Company shall not be obligated to indemnify Indemnitee for Expenses or Other Liabilities of any type whatsoever (including, but not limited to judgments, fines, penalties, ERISA excise taxes or penalties and amounts paid in settlement) to the extent such have been paid directly to Indemnitee (or paid directly to a third party on Indemnitee’s behalf) by any directors and officers, or other type, of insurance maintained by the Company.

(c)      Company Obligations Primary .  The Company hereby acknowledges that Indemnitee may have rights to indemnification for Expenses and Other Liabilities provided by a third party (“ Other Indemnitor ”). The Company agrees with Indemnitee that the Company is the indemnitor of first resort of Indemnitee with respect to matters for which indemnification is provided under this Agreement and that the Company will be obligated to make all payments due to or for the benefit of Indemnitee under this Agreement without regard to any rights that Indemnitee may have against the Other Indemnitor. The Company hereby waives any equitable rights to contribution or indemnification from the Other Indemnitor in respect of any amounts paid to Indemnitee hereunder. The Company further agrees that no reimbursement of Other Liabilities or payment of Expenses by the Other Indemnitor to or for the benefit of Indemnitee shall affect the obligations of the Company hereunder, and that the Company shall be obligated to repay the Other Indemnitor for all amounts so paid or reimbursed to the extent that the Company has an obligation to indemnify Indemnitee for such Expenses or Other Liabilities hereunder.

4.      Partial Indemnification .  If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of any Expenses or Other Liabilities but not entitled, however, to indemnification for the total amount of such Expenses or Other Liabilities, the Company shall nevertheless indemnify Indemnitee for such total amount except as to the portion thereof for which indemnification is prohibited by the provisions of the Company’s Bylaws or the GCL. In any review or Proceeding to determine the extent of indemnification, the Company shall bear the burden to establish, by clear and convincing evidence, the lack of a successful resolution of a particular claim, issue or matter and which amounts sought in indemnity are allocable to claims, issues or matters which were not successfully resolved.

5.      Liability Insurance .  So long as Indemnitee shall continue to serve the Company or a Subsidiary or Affiliate of the Company as an Indemnifiable Person and thereafter so long as Indemnitee shall be subject to any possible claim or threatened, pending or completed Proceeding as a result of an Indemnifiable Event, the Company shall use reasonable efforts to maintain in full force and effect for the benefit of Indemnitee as an insured (i) liability insurance issued by one or more reputable insurers and having the policy amount and deductible deemed appropriate by the Board and providing in all respects coverage at least comparable to and in the same amount as that provided to the Chairman of the Board or the Chief Executive Officer of the Company and (ii) any replacement or substitute policies issued by one or more reputable insurers providing in all respects coverage at least comparable to and in the same amount as that being provided to the Chairman of the Board or the Chief Executive Officer of the Company. The purchase, establishment and maintenance of any such insurance or other arrangements shall not in any way limit or affect the rights and obligations of the Company or of Indemnitee under this Agreement except as expressly provided herein, and the execution and delivery of this Agreement by the Company and Indemnitee shall not in any way limit or affect the rights and obligations of the Company or the other party or parties thereto under any such insurance or other arrangement.

6.      Mandatory Advancement of Expenses .

(a)      Advancement .  If requested by Indemnitee, the Company shall advance prior to the final disposition of the Proceeding all Expenses reasonably incurred by Indemnitee in connection

 

4


with (including in preparation for) a Proceeding related to an Indemnifiable Event. Indemnitee hereby undertakes to repay such amounts advanced if, and only if and to the extent that, it shall ultimately be determined that Indemnitee is not entitled to be indemnified by the Company under the provisions of this Agreement, the Company’s Bylaws or the GCL. The advances to be made hereunder shall be paid by the Company to Indemnitee or directly to a third party designated by Indemnitee within thirty (30) days following delivery of a written request therefor by Indemnitee to the Company. Indemnitee’s undertaking to repay any Expenses advanced to Indemnitee hereunder shall be unsecured and shall not be subject to the accrual or payment of any interest thereon.

(b)      Exception .  Notwithstanding the provisions of Section 6(a), the Company shall not be obligated to make any further advance of Expenses to Indemnitee if any one of the following determines in good faith that the facts known to them at the time such determination is made demonstrate clearly and convincingly that Indemnitee acted in bad faith: (i) those members of the Board consisting of directors who were not parties to the Proceeding for which a claim is made under this Agreement (“ Independent Directors ”), even though less than a quorum, (ii) by a committee of Independent Directors designated by a majority vote of Independent Directors, even though less than a quorum, (iii) Independent Counsel, by written legal opinion, or (iv) a panel of arbitrators (one of whom is selected by the Company, another of whom is selected by Indemnitee and the last of whom is selected by the first two arbitrators so selected). The Company shall have the option to submit the question of whether Indemnitee has acted in bad faith to one of the four alternative decision makers set forth in the preceding sentence and to select the decision maker, but following a favorable determination to Indemnitee rendered by the first decision maker selected, the Company may not submit the matter to another of the named decision makers. If the Company elects to submit the matter to Independent Counsel, such counsel shall be selected by Indemnitee and approved by the Independent Directors or a committee of Independent Directors (which approval may not be unreasonably withheld). Any decision maker so selected shall render a decision within thirty (30) days of such decision maker’s selection (which shall include in the case of Independent Counsel or a panel of arbitrators, when the person or persons acting as such counsel or such panel has or have been selected as provided above).

If a decision is made by the decision maker that Indemnitee acted in bad faith, Indemnitee shall have the right to apply to the Delaware Court of Chancery for the purpose of determining whether Indemnitee has acted in bad faith.

7.      Notice and Other Indemnification Procedures .

(a)      Notification .  Promptly after receipt by Indemnitee of notice of the commencement of or the threat of commencement of any Proceeding, Indemnitee shall, if Indemnitee believes that indemnification or advancement of Expenses with respect thereto may be sought from the Company under this Agreement, notify the Company of the commencement or threat of commencement thereof. However, a failure so to notify the Company promptly following Indemnitee’s receipt of such notice shall not relieve the Company from any liability that it may have to Indemnitee except to the extent that the Company is materially prejudiced in its defense of such Proceeding as a result of such failure.

(b)      Insurance and Other Matters .  If, at the time of the receipt of a notice of the commencement of a Proceeding pursuant to Section 7(a) above, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such Proceeding to the issuers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all reasonable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such insurance policies.

 

5


(c)      Assumption of Defense .  In the event the Company shall be obligated to advance the Expenses for any Proceeding against Indemnitee, the Company, if deemed appropriate by the Company, shall be entitled to assume the defense of such Proceeding as provided herein. Such defense by the Company may include the representation of two or more parties by one attorney or law firm as permitted under the ethical rules and legal requirements related to joint representations. Following delivery of written notice to Indemnitee of the Company’s election to assume the defense of such Proceeding, the approval by Indemnitee (which approval shall not be unreasonably withheld) of counsel designated by the Company and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any fees and expenses of counsel subsequently incurred by Indemnitee with respect to the same Proceeding. If (A) the employment of counsel by Indemnitee has been previously authorized by the Company, (B) Indemnitee shall have notified the Board in writing that Indemnitee has reasonably concluded that there is likely to be a conflict of interest between the Company and Indemnitee in the conduct of any such defense, or (C) the Company fails to employ counsel to assume the defense of such Proceeding, the fees and expenses of Indemnitee’s counsel shall be subject to indemnification and/or advancement pursuant to the terms of this Agreement. Nothing herein shall prevent Indemnitee from employing counsel for any such Proceeding at Indemnitee’s expense.

(d)      Settlement .  The Company shall not be liable to indemnify Indemnitee under this Agreement or otherwise for any amounts paid in settlement of any Proceeding effected without the Company’s written consent; provided, however, that if a Change in Control has occurred, the Company shall be liable for indemnification of Indemnitee for amounts paid in settlement if the Independent Counsel has approved the settlement. Neither the Company nor any Subsidiary or Affiliate of the Company shall enter into a settlement of any Proceeding that might result in the imposition of any Expense, Other Liability, penalty, limitation or detriment on Indemnitee, whether indemnifiable under this Agreement or otherwise, without Indemnitee’s written consent. Neither the Company nor Indemnitee shall unreasonably withhold consent from any settlement of any Proceeding.

8.      Determination of Right to Indemnification .

(a)      Success on the Merits or Otherwise .  To the extent that Indemnitee has been successful on the merits or otherwise in defense of any Proceeding referred to in Section 3(a) above or in the defense of any claim, issue or matter described therein, the Company shall indemnify Indemnitee against Expenses actually and reasonably incurred in connection therewith.

(b)      Indemnification in Other Situations .  In the event that Section 8(a) is inapplicable, the Company shall also indemnify Indemnitee if he or she has not failed to meet the applicable standard of conduct for indemnification.

(c)      Forum .  Indemnitee shall be entitled to select the forum in which determination of whether or not Indemnitee has met the applicable standard of conduct shall be decided, and such election will be made from among the following:

(1)     Those members of the Board who are Independent Directors even though less than a quorum;

(2)     A committee of Independent Directors designated by a majority vote of Independent Directors, even though less than a quorum; or

 

6


(3)     Independent Counsel selected by Indemnitee and approved by the Board, which approval may not be unreasonably withheld, which counsel shall make such determination in a written opinion.

If Indemnitee is an officer or a director of the Company at the time that Indemnitee is selecting the forum, then Indemnitee shall not select Independent Counsel as such forum unless there are no Independent Directors or unless the Independent Directors agree to the selection of independent counsel as the forum.

The selected forum shall be referred to herein as the “Reviewing Party”. Notwithstanding the foregoing, following any Change in Control, the Reviewing Party shall be Independent Counsel selected in the manner provided in (3) above.

(d)     As soon as practicable, and in no event later than thirty (30) days after receipt by the Company of written notice of Indemnitee’s choice of forum pursuant to Section 8(c) above, the Company and Indemnitee shall each submit to the Reviewing Party such information as they believe is appropriate for the Reviewing Party to consider. The Reviewing Party shall arrive at its decision within a reasonable period of time following the receipt of all such information from the Company and Indemnitee, but in no event later than thirty (30) days following the receipt of all such information, provided that the time by which the Reviewing Party must reach a decision may be extended by mutual agreement of the Company and Indemnitee. All Expenses associated with the process set forth in this Section 8(d), including but not limited to the Expenses of the Reviewing Party, shall be paid by the Company.

(e)      Delaware Court of Chancery .  Notwithstanding a final determination by any Reviewing Party that Indemnitee is not entitled to indemnification with respect to a specific Proceeding, Indemnitee shall have the right to apply to the Court of Chancery, for the purpose of enforcing Indemnitee’s right to indemnification pursuant to this Agreement.

(f)      Expenses .  The Company shall indemnify Indemnitee against all Expenses incurred by Indemnitee in connection with any hearing or Proceeding under this Section 8 or under Section 6(b) involving Indemnitee and against all Expenses and Other Liabilities incurred by Indemnitee in connection with any other Proceeding between the Company and Indemnitee involving the interpretation or enforcement of the rights of Indemnitee under this Agreement unless a court of competent jurisdiction finds that each of the material claims of Indemnitee in any such Proceeding was frivolous or made in bad faith.

(g)      Determination of “Good Faith” .  For purposes of any determination of whether Indemnitee acted in “ good faith ” or acted in “ bad faith ,” Indemnitee shall be deemed to have acted in good faith or not acted in bad faith if in taking or failing to take the action in question Indemnitee relied on the records or books of account of the Company or a Subsidiary or Affiliate of the Company, including financial statements, or on information, opinions, reports or statements provided to Indemnitee by the officers or other employees of the Company or a Subsidiary or Affiliate of the Company in the course of their duties, or on the advice of legal counsel for the Company or a Subsidiary or Affiliate of the Company, or on information or records given or reports made to the Company or a Subsidiary or Affiliate of the Company by an independent certified public accountant or by an appraiser or other expert selected by the Company or a Subsidiary or Affiliate of the Company, or by any other person (including legal counsel, accountants and financial advisors) as to matters Indemnitee reasonably believes are within such other person’s professional or expert competence and who has been selected with reasonable care by or on behalf of the Company. In connection with any determination as to whether Indemnitee is entitled to be indemnified hereunder, or to advancement of expenses, the

 

7


Reviewing Party, decision maker pursuant to Section 6(b) or court shall presume that Indemnitee has satisfied the applicable standard of conduct and is entitled to indemnification or advancement of Expenses, as the case may be, and the burden of proof shall be on the Company to establish, by clear and convincing evidence, that Indemnitee is not so entitled. The provisions of this Section 8(g) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement. In addition, the knowledge and/or actions, or failures to act, of any other person serving the Company or a Subsidiary or Affiliate of the Company as an Indemnifiable Person shall not be imputed to Indemnitee for purposes of determining the right to indemnification hereunder

 

  9. Exceptions .  Any other provision herein to the contrary notwithstanding,

(a)      Claims Initiated by Indemnitee .  The Company shall not be obligated pursuant to the terms of this Agreement to indemnify or advance Expenses to Indemnitee with respect to Proceedings or claims initiated or brought voluntarily by Indemnitee and not by way of defense, except (1) with respect to Proceedings brought to establish or enforce a right to indemnification under this Agreement, any other statute or law, as permitted under Section 145, or otherwise, (2) where the Board has consented to the initiation of such Proceeding, or (3) with respect to Proceedings brought to discharge Indemnitee’s fiduciary responsibilities, whether under ERISA or otherwise, but such indemnification or advancement of Expenses may be provided by the Company in specific cases if the Board finds it to be appropriate; or

(b)      Section 16(b) Actions .  The Company shall not be obligated pursuant to the terms of this Agreement to indemnify Indemnitee on account of any suit in which judgment is rendered against Indemnitee for an accounting of profits made from the purchase or sale by Indemnitee of securities of the Company pursuant to the provisions of Section 16(b) of the Securities Exchange Act of l934 and amendments thereto or similar provisions of any federal, state or local statutory law; or

(c)      Unlawful Indemnification .  The Company shall not be obligated pursuant to the terms of this Agreement to indemnify Indemnitee for Other Liabilities if such indemnification is prohibited by law.

10.      Non-exclusivity .  The provisions for indemnification and advancement of Expenses set forth in this Agreement shall not be deemed exclusive of any other rights which Indemnitee may have under any provision of law, the Company’s Certificate of Incorporation or Bylaws, the vote of the Company’s stockholders or disinterested directors, other agreements, or otherwise, both as to acts or omissions in his or her official capacity and to acts or omissions in another capacity while serving the Company or a Subsidiary or Affiliate of the Company as an Indemnifiable Person and Indemnitee’s rights hereunder shall continue after Indemnitee has ceased serving the Company or a Subsidiary or Affiliate of the Company as an Indemnifiable Person and shall inure to the benefit of the heirs, executors and administrators of Indemnitee.

11.      Severability .  If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever, (i) the validity, legality and enforceability of the remaining provisions of the Agreement (including, without limitation, all portions of any paragraphs of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby, and (ii) to the fullest extent possible, the provisions of this Agreement (including, without limitation, all portions of any paragraphs of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.

 

8


12.      Modification and Waiver .  No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not similar) and except as expressly provided herein, no such waiver shall constitute a continuing waiver.

13.      Successors and Assigns .  The terms of this Agreement shall bind, and shall inure to the benefit of, the successors and assigns of the parties hereto.

14.      Notice .  All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed duly given (i) if delivered by hand and a receipt is provided by the party to whom such communication is delivered, (ii) if mailed by certified or registered mail with postage prepaid, return receipt requested, on the signing by the recipient of an acknowledgement of receipt form accompanying delivery through the U.S. mail, (iii) personal service by a process server, or (iv) delivery to the recipient’s address by overnight delivery (e.g., FedEx, UPS or DHL) or other commercial delivery service. Addresses for notice to either party are as shown on the signature page of this Agreement, or as subsequently modified by written notice complying with the provisions of this Section 14. Delivery of communications to the Company with respect to this Agreement shall be sent to the attention of the Company’s General Counsel.

15.      No Presumptions .  For purposes of this Agreement, the termination of any Proceeding, by judgment, order, settlement (whether with or without court approval) or conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that Indemnitee did not meet any particular standard of conduct or have any particular belief or that a court has determined that indemnification is not permitted by applicable law or otherwise. In addition, neither the failure of the Company or a Reviewing Party or one of the decision makers described in Section 6(b) to have made a determination as to whether Indemnitee has met any particular standard of conduct or had any particular belief, nor an actual determination by the Company including a determination pursuant to Section 6(b), or a Reviewing Party that Indemnitee has not met such standard of conduct or did not have such belief, prior to the commencement of Proceedings by Indemnitee to secure a judicial determination by exercising Indemnitee’s rights under Section 6(b) or 8(e) of this Agreement shall be a defense to Indemnitee’s claim or create a presumption that Indemnitee has failed to meet any particular standard of conduct or did not have any particular belief or is not entitled to indemnification under applicable law or otherwise.

16.      Survival of Rights .  The rights conferred on Indemnitee by this Agreement shall continue after Indemnitee has ceased to serve the Company or a Subsidiary or Affiliate of the Company as an Indemnifiable Person and shall inure to the benefit of Indemnitee’s heirs, executors and administrators.

17.      Subrogation .  Except as otherwise expressly provided in this Agreement, in the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to enable the Company effectively to bring suit to enforce such rights.

18.      Specific Performance, Etc.   The parties recognize that if any provision of this Agreement is violated by the Company, Indemnitee may be without an adequate remedy at law. Accordingly, in the event of any such violation, Indemnitee shall be entitled, if Indemnitee so elects, to institute Proceedings, either in law or at equity, to obtain damages, to enforce specific performance, to enjoin such violation, or to obtain any relief or any combination of the foregoing as Indemnitee may elect to pursue.

 

9


19.      Counterparts .  This Agreement may be executed in counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

20.      Headings .  The headings of the sections and paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction or interpretation thereof.

21.      Governing Law .  This Agreement shall be governed exclusively by and construed according to the laws of the State of Delaware, as applied to contracts between Delaware residents entered into and to be performed entirely with Delaware.

22.      Consent to Jurisdiction .  The Company and Indemnitee each hereby irrevocably consent to the jurisdiction of the courts of the State of Delaware for all purposes in connection with any Proceeding which arises out of or relates to this Agreement.

[Signature Page Next.]

 

10


The parties hereto have entered into this Indemnity Agreement effective as of the date first above written.

 

By:    
Its:    

INDEMNITEE:

   
Address:    
   

 

11

Exhibit 10.46

AMYRIS BIOTECHNOLOGIES, INC.

2010 EQUITY INCENTIVE PLAN

1.         PURPOSE . The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents and Subsidiaries that exist now or in the future, by offering them an opportunity to participate in the Company’s future performance through the grant of Awards. Capitalized terms not defined elsewhere in the text are defined in Section 27.

2.          SHARES SUBJECT TO THE PLAN .

2.1       Number of Shares Available .    Subject to Sections 2.6 and 21 and any other applicable provisions hereof, the total number of Shares reserved and available for grant and issuance pursuant to this Plan as of the date of adoption of the Plan by the Board, is 4,200,000 Shares plus (i) any reserved shares not issued or subject to outstanding grants under the Company’s 2005 Stock Option Plan (the “ Prior Plan ”) on the Effective Date (as defined below), (ii) shares that are subject to stock options granted under the Prior Plan that cease to be subject to such stock options after the Effective Date and (iii) shares issued under the Prior Plan before or after the Effective Date pursuant to the exercise of stock options that are, after the Effective Date, forfeited and (iv) shares issued under the Prior Plan that are repurchased by the Company at the original issue price.

2.2       Lapsed, Returned Awards .    Shares subject to Awards, and Shares issued under the Plan under any Award, will again be available for grant and issuance in connection with subsequent Awards under this Plan to the extent such Shares: (a) are subject to issuance upon exercise of an Option or SAR granted under this Plan but which cease to be subject to the Option or SAR for any reason other than exercise of the Option or SAR; (b) are subject to Awards granted under this Plan that are forfeited or are repurchased by the Company at the original issue price; (c) are subject to Awards granted under this Plan that otherwise terminate without such Shares being issued; or (d) are surrendered pursuant to an Exchange Program. To the extent an Award under the Plan is paid out in cash rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance under the Plan. Shares used to pay the exercise price of an Award or to satisfy the tax withholding obligations related to an Award will become available for future grant or sale under the Plan. For the avoidance of doubt, Shares that otherwise become available for grant and issuance because of the provisions of this Section 2.2 shall not include Shares subject to Awards that initially became available because of the substitution clause in Section 21.2 hereof.

2.3       Minimum Share Reserve .    At all times the Company shall reserve and keep available a sufficient number of Shares as shall be required to satisfy the requirements of all outstanding Awards granted under this Plan.

2.4       Automatic Share Reserve Increase .    The number of Shares available for grant and issuance under the Plan shall be increased on January 1 of each of the calendar years that commence following the Effective Date by the lesser of five (5%) percent of the number of Shares issued and outstanding on each December 31 immediately prior to the date of increase or (ii) such number of Shares determined by the Board or the Committee.


2.5       Limitations .    No more than thirty (30,000,000) million Shares shall be issued pursuant to the exercise of ISOs.

2.6       Adjustment of Shares .    If the number of outstanding Shares is changed by a stock dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in the capital structure of the Company, without consideration, then (a) the number of Shares reserved for issuance and future grant under the Plan set forth in Section 2.1 and 2.4 (b) the Exercise Prices of and number of Shares subject to outstanding Options and SARs, (c) the number of Shares subject to other outstanding Awards, (d) the maximum number of shares that may be issued as ISOs set forth in Section 2.5 and (e) the maximum number of Shares that may be issued to an individual or to a new Employee in any one calendar year set forth in Section 3, shall be proportionately adjusted, subject to any required action by the Board or the stockholders of the Company and in compliance with applicable securities laws; provided that fractions of a Share will not be issued.

3.          ELIGIBILITY .    ISOs may be granted only to Employees. All other Awards may be granted to Employees, Consultants, Directors and Non-Employee Directors of the Company or any Parent or Subsidiary of the Company; provided such Consultants, Directors and Non-Employee Directors render bona fide services not in connection with the offer and sale of securities in a capital-raising transaction. No Participant will be eligible to receive more than one (1,000,000) million Shares in any calendar year under this Plan pursuant to the grant of Awards except that new Employees of the Company or a Parent or Subsidiary of the Company (including new Employees who are also officers and directors of the Company or any Parent or Subsidiary of the Company) are eligible to receive up to a maximum of two (2,000,000) million Shares in the calendar year in which they commence their employment.

4.          ADMINISTRATION .

4.1       Committee Composition; Authority .    This Plan will be administered by the Committee or by the Board acting as the Committee. Subject to the general purposes, terms and conditions of this Plan, and to the direction of the Board, the Committee will have full power to implement and carry out this Plan, except, however, the Board shall establish the terms for the grant of an Award to Non-Employee Directors. The Committee will have the authority to:

(a)        construe and interpret this Plan, any Award Agreement and any other agreement or document executed pursuant to this Plan;

(b)        prescribe, amend and rescind rules and regulations relating to this Plan or any Award;

(c)        select persons to receive Awards;

(d)        determine the form and terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Committee will determine;

(e)        determine the number of Shares or other consideration subject to Awards;

(f)        determine the Fair Market Value in good faith, if necessary;


(g)        determine whether Awards will be granted singly, in combination with, in tandem with, in replacement of, or as alternatives to, other Awards under this Plan or any other incentive or compensation plan of the Company or any Parent or Subsidiary of the Company;

(h)        grant waivers of Plan or Award conditions;

(i)        determine the vesting, exercisability and payment of Awards;

(j)        correct any defect, supply any omission or reconcile any inconsistency in this Plan, any Award or any Award Agreement;

(k)        determine whether an Award has been earned;

(l)        determine the terms and conditions of any, and to institute any Exchange Program;

(m)        reduce or waive any criteria with respect to Performance Factors;

(n)        adjust Performance Factors to take into account changes in law and accounting or tax rules as the Committee deems necessary or appropriate to reflect the impact of extraordinary or unusual items, events or circumstances to avoid windfalls or hardships provided that such adjustments are consistent with the regulations promulgated under Section 162(m) of the Code with respect to persons whose compensation is subject to Section 162(m) of the Code; and

(o)        make all other determinations necessary or advisable for the administration of this Plan.

4.2       Committee Interpretation and Discretion .    Any determination made by the Committee with respect to any Award shall be made in its sole discretion at the time of grant of the Award or, unless in contravention of any express term of the Plan or Award, at any later time, and such determination shall be final and binding on the Company and all persons having an interest in any Award under the Plan. Any dispute regarding the interpretation of the Plan or any Award Agreement shall be submitted by the Participant or Company to the Committee for review. The resolution of such a dispute by the Committee shall be final and binding on the Company and the Participant. The Committee may delegate to one or more executive officers the authority to review and resolve disputes with respect to Awards held by Participants who are not Insiders, and such resolution shall be final and binding on the Company and the Participant.

4.3       Section 162(m) of the Code and Section 16 of the Exchange Act .    When necessary or desirable for an Award to qualify as “performance-based compensation” under Section 162(m) of the Code the Committee shall include at least two persons who are “outside directors” (as defined under Section 162(m) of the Code) and at least two (or a majority if more than two then serve on the Committee) such “outside directors” shall approve the grant of such Award and timely determine (as applicable) the Performance Period and any Performance Factors upon which vesting or settlement of any portion of such Award is to be subject. When required by Section 162(m) of the Code, prior to settlement of any such Award at least two (or a majority if more than two then serve on the Committee) such “outside directors” then serving on the Committee shall determine and certify in writing the extent to which such Performance Factors have been timely achieved and the extent to which the Shares subject to such Award have thereby been earned. Awards granted to Participants who are subject to Section 16 of the Exchange Act must be approved by two or more “non-employee directors” (as defined in the regulations promulgated under Section 16 of the Exchange Act). With respect to Participants whose


compensation is subject to Section 162(m) of the Code, and provided that such adjustments are consistent with the regulations promulgated under Section 162(m) of the Code, the Committee may adjust the performance goals to account for changes in law and accounting and to make such adjustments as the Committee deems necessary or appropriate to reflect the impact of extraordinary or unusual items, events or circumstances to avoid windfalls or hardships, including without limitation (i) restructurings, discontinued operations, extraordinary items, and other unusual or non-recurring charges, (ii) an event either not directly related to the operations of the Company or not within the reasonable control of the Company’s management, or (iii) a change in accounting standards required by generally accepted accounting principles.

4.4       Documentation .    The Award Agreement for a given Award, the Plan and any other documents may be delivered to, and accepted by, a Participant or any other person in any manner (including electronic distribution or posting) that meets applicable legal requirements.

5.          OPTIONS .    The Committee may grant Options to Participants and will determine whether such Options will be Incentive Stock Options within the meaning of the Code (“ ISOs ”) or Nonqualified Stock Options (“ NQSOs ”), the number of Shares subject to the Option, the Exercise Price of the Option, the period during which the Option may be exercised, and all other terms and conditions of the Option, subject to the following:

5.1       Option Grant .    Each Option granted under this Plan will identify the Option as an ISO or an NQSO. An Option may be, but need not be, awarded upon satisfaction of such Performance Factors during any Performance Period as are set out in advance in the Participant’s individual Award Agreement. If the Option is being earned upon the satisfaction of Performance Factors, then the Committee will: (x) determine the nature, length and starting date of any Performance Period for each Option; and (y) select from among the Performance Factors to be used to measure the performance, if any. Performance Periods may overlap and Participants may participate simultaneously with respect to Options that are subject to different performance goals and other criteria.

5.2       Date of Grant .    The date of grant of an Option will be the date on which the Committee makes the determination to grant such Option, or a specified future date. The Award Agreement and a copy of this Plan will be delivered to the Participant within a reasonable time after the granting of the Option.

5.3       Exercise Period .    Options may be exercisable within the times or upon the conditions as set forth in the Award Agreement governing such Option; provided , however , that no Option will be exercisable after the expiration of ten (10) years from the date the Option is granted; and provided further that no ISO granted to a person who, at the time the ISO is granted, directly or by attribution owns more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or of any Parent or Subsidiary of the Company (“ Ten Percent Stockholder ”) will be exercisable after the expiration of five (5) years from the date the ISO is granted. The Committee also may provide for Options to become exercisable at one time or from time to time, periodically or otherwise, in such number of Shares or percentage of Shares as the Committee determines.

5.4       Exercise Price .    The Exercise Price of an Option will be determined by the Committee when the Option is granted; provided that: (i) the Exercise Price of an ISO will be not less than one hundred percent (100%) of the Fair Market Value of the Shares on the date of grant and (ii) the Exercise Price of any ISO granted to a Ten Percent Stockholder will not be less than one hundred ten percent (110%) of the Fair Market Value of the Shares on the date of grant. Payment for the Shares purchased may be made in accordance with Section 11. Payment for the Shares purchased may be made in accordance with Section 11 and the Award Agreement and in accordance with any procedures


established by the Company. The Exercise Price of a NQSO may not be less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.

5.5       Method of Exercise .    Any Option granted hereunder will be exercisable according to the terms of the Plan and at such times and under such conditions as determined by the Committee and set forth in the Award Agreement. An Option may not be exercised for a fraction of a Share. An Option will be deemed exercised when the Company receives: (i) notice of exercise (in such form as the Committee may specify from time to time) from the person entitled to exercise the Option, and (ii) full payment for the Shares with respect to which the Option is exercised (together with applicable withholding taxes). Full payment may consist of any consideration and method of payment authorized by the Committee and permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option will be issued in the name of the Participant. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares, notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 2.6 of the Plan. Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under the Option, by the number of Shares as to which the Option is exercised.

5.6       Termination .    The exercise of an Option will be subject to the following (except as may be otherwise provided in an Award Agreement):

(a)        If the Participant is Terminated for any reason except for Cause or the Participant’s death or Disability, then the Participant may exercise such Participant’s Options only to the extent that such Options would have been exercisable by the Participant on the Termination Date no later than three (3) months after the Termination Date (or such shorter time period or longer time period not exceeding five (5) years as may be determined by the Committee, with any exercise beyond three (3) months after the Termination Date deemed to be the exercise of an NQSO), but in any event no later than the expiration date of the Options.

(b)        If the Participant is Terminated because of the Participant’s death (or the Participant dies within three (3) months after a Termination other than for Cause or because of the Participant’s Disability), then the Participant’s Options may be exercised only to the extent that such Options would have been exercisable by the Participant on the Termination Date and must be exercised by the Participant’s legal representative, or authorized assignee, no later than twelve (12) months after the Termination Date (or such shorter time period not less than six (6) months or longer time period not exceeding five (5) years as may be determined by the Committee, but in any event no later than the expiration date of the Options.

(c)        If the Participant is Terminated because of the Participant’s Disability, then the Participant’s Options may be exercised only to the extent that such Options would have been exercisable by the Participant on the Termination Date and must be exercised by the Participant (or the Participant’s legal representative or authorized assignee) no later than twelve (12) months after the Termination Date (with any exercise beyond (a) three (3) months after the Termination Date when the Termination is for a Disability that is not a “permanent and total disability” as defined in Section 22(e)(3) of the Code, or (b) twelve (12) months after the Termination Date when the Termination is for a Disability that is a “permanent and total disability” as defined in Section 22(e)(3) of the Code, deemed to be exercise of an NQSO), but in any event no later than the expiration date of the Options.


(d)        If the Participant is terminated for Cause, then Participant’s Options shall expire on such Participant’s Termination Date, or at such later time and on such conditions as are determined by the Committee, but in any no event later than the expiration date of the Options.

5.7       Limitations on Exercise .    The Committee may specify a minimum number of Shares that may be purchased on any exercise of an Option, provided that such minimum number will not prevent any Participant from exercising the Option for the full number of Shares for which it is then exercisable.

5.8       Limitations on ISOs .    With respect to Awards granted as ISOs, to the extent that the aggregate Fair Market Value of the Shares with respect to which such ISOs are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds one hundred thousand dollars ($100,000), such Options will be treated as NQSOs. For purposes of this Section 5.8, ISOs will be taken into account in the order in which they were granted. The Fair Market Value of the Shares will be determined as of the time the Option with respect to such Shares is granted. In the event that the Code or the regulations promulgated thereunder are amended after the Effective Date to provide for a different limit on the Fair Market Value of Shares permitted to be subject to ISOs, such different limit will be automatically incorporated herein and will apply to any Options granted after the effective date of such amendment.

5.9       Modification, Extension or Renewal .    The Committee may modify, extend or renew outstanding Options and authorize the grant of new Options in substitution therefor, provided that any such action may not, without the written consent of a Participant, impair any of such Participant’s rights under any Option previously granted. Any outstanding ISO that is modified, extended, renewed or otherwise altered will be treated in accordance with Section 424(h) of the Code. Subject to Section 18 of this Plan, by written notice to affected Participants, the Committee may reduce the Exercise Price of outstanding Options without the consent of such Participants; provided , however , that the Exercise Price may not be reduced below the Fair Market Value on the date the action is taken to reduce the Exercise Price.

6.         RESTRICTED STOCK AWARDS .

6.1       Awards of Restricted Stock .    A Restricted Stock Award is an offer by the Company to sell to a Participant Shares that are subject to restrictions (“ Restricted Stock ”). The Committee will determine to whom an offer will be made, the number of Shares the Participant may purchase, the Purchase Price, the restrictions under which the Shares will be subject and all other terms and conditions of the Restricted Stock Award, subject to the Plan.

6.2       Restricted Stock Purchase Agreement .    All purchases under a Restricted Stock Award will be evidenced by an Award Agreement. Except as may otherwise be provided in an Award Agreement, a Participant accepts a Restricted Stock Award by signing and delivering to the Company an Award Agreement with full payment of the Purchase Price, within thirty (30) days from the date the Award Agreement was delivered to the Participant. If the Participant does not accept such Award within thirty (30) days, then the offer of such Restricted Stock Award will terminate, unless the Committee determines otherwise.

6.3       Purchase Price .    The Purchase Price for a Restricted Stock Award will be determined by the Committee and may be less than Fair Market Value on the date the Restricted Stock Award is granted. Payment of the Purchase Price must be made in accordance with Section 11 of the Plan, and the Award Agreement. Payment of the Purchase Price must be made in accordance with


Section 11 of the Plan, and the Award Agreement and in accordance with any procedures established by the Company.

6.4       Terms of Restricted Stock Awards .    Restricted Stock Awards will be subject to such restrictions as the Committee may impose or are required by law. These restrictions may be based on completion of a specified number of years of service with the Company or upon completion of Performance Factors, if any, during any Performance Period as set out in advance in the Participant’s Award Agreement. Prior to the grant of a Restricted Stock Award, the Committee shall: (a) determine the nature, length and starting date of any Performance Period for the Restricted Stock Award; (b) select from among the Performance Factors to be used to measure performance goals, if any; and (c) determine the number of Shares that may be awarded to the Participant. Performance Periods may overlap and a Participant may participate simultaneously with respect to Restricted Stock Awards that are subject to different Performance Periods and having different performance goals and other criteria.

6.5       Termination of Participant .  Except as may be set forth in the Participant’s Award Agreement, vesting ceases on such Participant’s Termination Date (unless determined otherwise by the Committee).

7.         STOCK BONUS AWARDS .

7.1       Awards of Stock Bonuses .    A Stock Bonus Award is an award to an eligible person of Shares for services to be rendered or for past services already rendered to the Company or any Parent or Subsidiary. All Stock Bonus Awards shall be made pursuant to an Award Agreement. No payment from the Participant will be required for Shares awarded pursuant to a Stock Bonus Award.

7.2       Terms of Stock Bonus Awards .    The Committee will determine the number of Shares to be awarded to the Participant under a Stock Bonus Award and any restrictions thereon. These restrictions may be based upon completion of a specified number of years of service with the Company or upon satisfaction of performance goals based on Performance Factors during any Performance Period as set out in advance in the Participant’s Stock Bonus Agreement. Prior to the grant of any Stock Bonus Award the Committee shall: (a) determine the nature, length and starting date of any Performance Period for the Stock Bonus Award; (b) select from among the Performance Factors to be used to measure performance goals; and (c) determine the number of Shares that may be awarded to the Participant. Performance Periods may overlap and a Participant may participate simultaneously with respect to Stock Bonus Awards that are subject to different Performance Periods and different performance goals and other criteria.

7.3       Form of Payment to Participant .    Payment may be made in the form of cash, whole Shares, or a combination thereof, based on the Fair Market Value of the Shares earned under a Stock Bonus Award on the date of payment, as determined in the sole discretion of the Committee.

7.4       Termination of Participation .    Except as may be set forth in the Participant’s Award Agreement, vesting ceases on such Participant’s Termination Date (unless determined otherwise by the Committee).

8.         STOCK APPRECIATION RIGHTS .

8.1       Awards of SARs .    A Stock Appreciation Right (“ SAR ”) is an award to a Participant that may be settled in cash, or Shares (which may consist of Restricted Stock), having a value equal to (a) the difference between the Fair Market Value on the date of exercise over the Exercise Price multiplied by (b) the number of Shares with respect to which the SAR is being settled (subject to any


maximum number of Shares that may be issuable as specified in an Award Agreement). All SARs shall be made pursuant to an Award Agreement.

8.2       Terms of SARs .    The Committee will determine the terms of each SAR including, without limitation: (a) the number of Shares subject to the SAR; (b) the Exercise Price and the time or times during which the SAR may be settled; (c) the consideration to be distributed on settlement of the SAR; and (d) the effect of the Participant’s Termination on each SAR. The Exercise Price of the SAR will be determined by the Committee when the SAR is granted, and may not be less than Fair Market Value. A SAR may be awarded upon satisfaction of Performance Factors, if any, during any Performance Period as are set out in advance in the Participant’s individual Award Agreement. If the SAR is being earned upon the satisfaction of Performance Factors, then the Committee will: (x) determine the nature, length and starting date of any Performance Period for each SAR; and (y) select from among the Performance Factors to be used to measure the performance, if any. Performance Periods may overlap and Participants may participate simultaneously with respect to SARs that are subject to different Performance Factors and other criteria.

8.3       Exercise Period and Expiration Date .    A SAR will be exercisable within the times or upon the occurrence of events determined by the Committee and set forth in the Award Agreement governing such SAR. The SAR Agreement shall set forth the expiration date; provided that no SAR will be exercisable after the expiration of ten (10) years from the date the SAR is granted. The Committee may also provide for SARs to become exercisable at one time or from time to time, periodically or otherwise (including, without limitation, upon the attainment during a Performance Period of performance goals based on Performance Factors), in such number of Shares or percentage of the Shares subject to the SAR as the Committee determines. Except as may be set forth in the Participant’s Award Agreement, vesting ceases on such Participant’s Termination Date (unless determined otherwise by the Committee). Notwithstanding the foregoing, the rules of Section 5.6 also will apply to SARs.

8.4       Form of Settlement .    Upon exercise of a SAR, a Participant will be entitled to receive payment from the Company in an amount determined by multiplying (i) the difference between the Fair Market Value of a Share on the date of exercise over the Exercise Price; times (ii) the number of Shares with respect to which the SAR is exercised. At the discretion of the Committee, the payment from the Company for the SAR exercise may be in cash, in Shares of equivalent value, or in some combination thereof. The portion of a SAR being settled may be paid currently or on a deferred basis with such interest or dividend equivalent, if any, as the Committee determines, provided that the terms of the SAR and any deferral satisfy the requirements of Section 409A of the Code.

8.5       Termination of Participation .    Except as may be set forth in the Participant’s Award Agreement, vesting ceases on such Participant’s Termination Date (unless determined otherwise by the Committee).

9.         RESTRICTED STOCK UNITS .

9.1       Awards of Restricted Stock Units .    A Restricted Stock Unit (“ RSU ”) is an award to a Participant covering a number of Shares that may be settled in cash, or by issuance of those Shares (which may consist of Restricted Stock). All RSUs shall be made pursuant to an Award Agreement.

9.2       Terms of RSUs .    The Committee will determine the terms of an RSU including, without limitation: (a) the number of Shares subject to the RSU; (b) the time or times during which the RSU may be settled; and (c) the consideration to be distributed on settlement, and the effect of the Participant’s Termination on each RSU. An RSU may be awarded upon satisfaction of such performance goals based on Performance Factors during any Performance Period as are set out in advance in the


Participant’s Award Agreement. If the RSU is being earned upon satisfaction of Performance Factors, then the Committee will: (x) determine the nature, length and starting date of any Performance Period for the RSU; (y) select from among the Performance Factors to be used to measure the performance, if any; and (z) determine the number of Shares deemed subject to the RSU. Performance Periods may overlap and participants may participate simultaneously with respect to RSUs that are subject to different Performance Periods and different performance goals and other criteria.

9.3       Form and Timing of Settlement .    Payment of earned RSUs shall be made as soon as practicable after the date(s) determined by the Committee and set forth in the Award Agreement. The Committee, in its sole discretion, may settle earned RSUs in cash, Shares, or a combination of both. The Committee may also permit a Participant to defer payment under a RSU to a date or dates after the RSU is earned provided that the terms of the RSU and any deferral satisfy the requirements of Section 409A of the Code.

9.4       Termination of Participant .    Except as may be set forth in the Participant’s Award Agreement, vesting ceases on such Participant’s Termination Date (unless determined otherwise by the Committee).

10.         PERFORMANCE AWARDS .

10.1       Performance Awards .    A Performance Award is an award to a Participant of a cash bonus or a Performance Share bonus. Grants of Performance Awards shall be made pursuant to an Award Agreement.

10.2       Terms of Performance Awards .    The Committee will determine, and each Award Agreement shall set forth, the terms of each award of Performance Award including, without limitation: (a) the amount of any cash bonus; (b) the number of Shares deemed subject to Performance Share bonus; (c) the Performance Factors and Performance Period that shall determine the time and extent to which each Performance shall be settled; (d) the consideration to be distributed on settlement, and the effect of the Participant’s Termination on each Performance Award. In establishing Performance Factors and the Performance Period the Committee will: (x) determine the nature, length and starting date of any Performance Period and; (y) select from among the Performance Factors to be used. Prior to settlement, the Committee shall determine the extent to which Performance Awards have been earned. Performance Periods may overlap and Participants may participate simultaneously with respect to Performance Awards that are subject to different Performance Periods and different performance goals and other criteria.

10.3       Value, Earning and Timing of Performance Shares .    Any Performance Share bonus will have an initial value equal to the Fair Market Value of a Share on the date of grant. After the applicable Performance Period has ended, the holder of Performance Share bonus will be entitled to receive a payout of the number of Shares earned by the Participant over the Performance Period, to be determined as a function of the extent to which the corresponding Performance Factors or other vesting provisions have been achieved. The Committee, in its sole discretion, may pay earned Performance Share bonus in the form of cash, in Shares (which have an aggregate Fair Market Value equal to the value of the earned Performance Shares at the close of the applicable (Performance Period) or in a combination thereof. Performance Share bonuses may also be settled in Restricted Stock.

10.4       Termination of Participant .    Except as may be set forth in the Participant’s Award Agreement, vesting ceases on such Participant’s Termination Date (unless determined otherwise by the Committee).


11.         PAYMENT FOR SHARE PURCHASES .

Payment from a Participant for Shares purchased pursuant to this Plan may be made in cash or by check or, where expressly approved for the Participant by the Committee and where permitted by law (and to the extent not otherwise set forth in the applicable Award Agreement):

(a)        by cancellation of indebtedness of the Company to the Participant;

(b)        by surrender of shares of the Company held by the Participant that have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which said Award will be exercised or settled;

(c)        by waiver of compensation due or accrued to the Participant for services rendered or to be rendered to the Company or a Parent or Subsidiary of the Company;

(d)        by consideration received by the Company pursuant to a broker-assisted or other form of cashless exercise program implemented by the Company in connection with the Plan;

(e)        by any combination of the foregoing; or

(f)        by any other method of payment as is permitted by applicable law.

12.         GRANTS TO NON-EMPLOYEE DIRECTORS .

12.1       Types of Awards .    Non-Employee Directors are eligible to receive any type of Award offered under this Plan except ISOs. Awards pursuant to this Section 12 may be automatically made pursuant to policy adopted by the Board, or made from time to time as determined in the discretion of the Board.

12.2       Eligibility .    Awards pursuant to this Section 12 shall be granted only to Non-Employee Directors. A Non-Employee Director who is elected or re-elected as a member of the Board will be eligible to receive an Award under this Section 12.

12.3       Vesting, Exercisability and Settlement .    Except as set forth in Section 21, Awards shall vest, become exercisable and be settled as determined by the Board. With respect to Options and SARs, the exercise price granted to Non-Employee Directors shall not be less than the Fair Market Value of the Shares at the time that such Option or SAR is granted.

13.         WITHHOLDING TAXES .

13.1       Withholding Generally .    Whenever Shares are to be issued in satisfaction of Awards granted under this Plan, the Company may require the Participant to remit to the Company an amount sufficient to satisfy applicable federal, state, local and international withholding tax requirements prior to the delivery of Shares pursuant to exercise or settlement of any Award. Whenever payments in satisfaction of Awards granted under this Plan are to be made in cash, such payment will be net of an amount sufficient to satisfy applicable federal, state, local and international withholding tax requirements.

13.2       Stock Withholding .    The Committee, in its sole discretion and pursuant to such procedures as it may specify from time to time, may require or permit a Participant to satisfy such tax withholding obligation, in whole or in part by (without limitation) (i) paying cash, (ii) electing to have the Company withhold otherwise deliverable cash or Shares having a Fair Market Value equal to the


minimum statutory amount required to be withheld, or (iii) delivering to the Company already-owned Shares having a Fair Market Value equal to the minimum amount required to be withheld. The Fair Market Value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be withheld.

14.         TRANSFERABILITY .

14.1       Transfer Generally .    Unless determined otherwise by the Committee, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution. If the Committee makes an Award transferable, including, without limitation, by instrument to an inter vivos or testamentary trust in which the Awards are to be passed to beneficiaries upon the death of the trustor (settlor) or by gift to a Permitted Transferee, such Award will contain such additional terms and conditions as the Administrator deems appropriate.

14.2       Award Transfer Program .    Notwithstanding any contrary provision of the Plan, the Committee shall have all discretion and authority to determine and implement the terms and conditions of any Award Transfer Program instituted pursuant to this Section 14(b) and shall have the authority to amend the terms of any Award participating, or otherwise eligible to participate in, the Award Transfer Program, including (but not limited to) the authority to (i) amend (including to extend) the expiration date, post-termination exercise period and/or forfeiture conditions of any such Award, (ii) amend or remove any provisions of the Award relating to the Award holder’s continued service to the Company, (iii) amend the permissible payment methods with respect to the exercise or purchase of any such Award, (iv) amend the adjustments to be implemented in the event of changes in the capitalization and other similar events with respect to such Award, and (v) make such other changes to the terms of such Award as the Committee deems necessary or appropriate in its sole discretion.

15.         PRIVILEGES OF STOCK OWNERSHIP; RESTRICTIONS ON SHARES .

15.1       Voting and Dividends .    No Participant will have any of the rights of a stockholder with respect to any Shares until the Shares are issued to the Participant. After Shares are issued to the Participant, the Participant will be a stockholder and have all the rights of a stockholder with respect to such Shares, including the right to vote and receive all dividends or other distributions made or paid with respect to such Shares; provided , that if such Shares are Restricted Stock, then any new, additional or different securities the Participant may become entitled to receive with respect to such Shares by virtue of a stock dividend, stock split or any other change in the corporate or capital structure of the Company will be subject to the same restrictions as the Restricted Stock; provided , further , that the Participant will have no right to retain such stock dividends or stock distributions with respect to Shares that are repurchased at the Participant’s Purchase Price or Exercise Price, as the case may be, pursuant to Section 15.2.

15.2       Restrictions on Shares .    At the discretion of the Committee, the Company may reserve to itself and/or its assignee(s) a right to repurchase (a “ Right of Repurchase ”) a portion of any or all Unvested Shares held by a Participant following such Participant’s Termination at any time within ninety (90) days after the later of the Participant’s Termination Date and the date the Participant purchases Shares under this Plan, for cash and/or cancellation of purchase money indebtedness, at the Participant’s Purchase Price or Exercise Price, as the case may be.

16.          CERTIFICATES .    All certificates for Shares or other securities delivered under this Plan will be subject to such stock transfer orders, legends and other restrictions as the Committee may deem necessary or advisable, including restrictions under any applicable federal, state or foreign


securities law, or any rules, regulations and other requirements of the SEC or any stock exchange or automated quotation system upon which the Shares may be listed or quoted.

17.          ESCROW; PLEDGE OF SHARES .    To enforce any restrictions on a Participant’s Shares, the Committee may require the Participant to deposit all certificates representing Shares, together with stock powers or other instruments of transfer approved by the Committee, appropriately endorsed in blank, with the Company or an agent designated by the Company to hold in escrow until such restrictions have lapsed or terminated, and the Committee may cause a legend or legends referencing such restrictions to be placed on the certificates. Any Participant who is permitted to execute a promissory note as partial or full consideration for the purchase of Shares under this Plan will be required to pledge and deposit with the Company all or part of the Shares so purchased as collateral to secure the payment of the Participant’s obligation to the Company under the promissory note; provided , however , that the Committee may require or accept other or additional forms of collateral to secure the payment of such obligation and, in any event, the Company will have full recourse against the Participant under the promissory note notwithstanding any pledge of the Participant’s Shares or other collateral. In connection with any pledge of the Shares, the Participant will be required to execute and deliver a written pledge agreement in such form as the Committee will from time to time approve. The Shares purchased with the promissory note may be released from the pledge on a pro rata basis as the promissory note is paid.

18.          REPRICING; EXCHANGE AND BUYOUT OF AWARDS .    Without prior stockholder approval the Committee may (i) reprice Options or SARS (and where such repricing is a reduction in the Exercise Price of outstanding Options or SARS, the consent of the affected Participants is not required provided written notice is provided to them), and (ii) with the consent of the respective Participants (unless not required pursuant to Section 5.9 of the Plan), pay cash or issue new Awards in exchange for the surrender and cancellation of any, or all, outstanding Awards.

19.          SECURITIES LAW AND OTHER REGULATORY COMPLIANCE .    An Award will not be effective unless such Award is in compliance with all applicable federal and state securities laws, rules and regulations of any governmental body, and the requirements of any stock exchange or automated quotation system upon which the Shares may then be listed or quoted, as they are in effect on the date of grant of the Award and also on the date of exercise or other issuance. Notwithstanding any other provision in this Plan, the Company will have no obligation to issue or deliver certificates for Shares under this Plan prior to: (a) obtaining any approvals from governmental agencies that the Company determines are necessary or advisable; and/or (b) completion of any registration or other qualification of such Shares under any state or federal law or ruling of any governmental body that the Company determines to be necessary or advisable. The Company will be under no obligation to register the Shares with the SEC or to effect compliance with the registration, qualification or listing requirements of any state securities laws, stock exchange or automated quotation system, and the Company will have no liability for any inability or failure to do so.

20.          NO OBLIGATION TO EMPLOY .    Nothing in this Plan or any Award granted under this Plan will confer or be deemed to confer on any Participant any right to continue in the employ of, or to continue any other relationship with, the Company or any Parent or Subsidiary of the Company or limit in any way the right of the Company or any Parent or Subsidiary of the Company to terminate Participant’s employment or other relationship at any time.

21.         CORPORATE TRANSACTIONS .

21.1       Assumption or Replacement of Awards by Successor .    In the event of a Corporate Transaction any or all outstanding Awards may be assumed or replaced by the successor corporation, which assumption or replacement shall be binding on all Participants. In the alternative, the


successor corporation may substitute equivalent Awards or provide substantially similar consideration to Participants as was provided to stockholders (after taking into account the existing provisions of the Awards). The successor corporation may also issue, in place of outstanding Shares of the Company held by the Participant, substantially similar shares or other property subject to repurchase restrictions no less favorable to the Participant. In the event such successor or acquiring corporation (if any) refuses to assume, convert, replace or substitute Awards, as provided above, pursuant to a Corporate Transaction, then notwithstanding any other provision in this Plan to the contrary, such Awards shall have their vesting accelerate as to all shares subject to such Award (and any applicable right of repurchase fully lapse) immediately prior to the Corporate Transaction. In addition, in the event such successor or acquiring corporation (if any) refuses to assume, convert, replace or substitute Awards, as provided above, pursuant to a Corporate Transaction, the Committee will notify the Participant in writing or electronically that such Award will be exercisable for a period of time determined by the Committee in its sole discretion, and such Award will terminate upon the expiration of such period. Awards need not be treated similarly in a Corporate Transaction.

21.2       Assumption of Awards by the Company .    The Company, from time to time, also may substitute or assume outstanding awards granted by another company, whether in connection with an acquisition of such other company or otherwise, by either; (a) granting an Award under this Plan in substitution of such other company’s award; or (b) assuming such award as if it had been granted under this Plan if the terms of such assumed award could be applied to an Award granted under this Plan. Such substitution or assumption will be permissible if the holder of the substituted or assumed award would have been eligible to be granted an Award under this Plan if the other company had applied the rules of this Plan to such grant. In the event the Company assumes an award granted by another company, the terms and conditions of such award will remain unchanged ( except that the Purchase Price or the Exercise Price, as the case may be, and the number and nature of Shares issuable upon exercise or settlement of any such Award will be adjusted appropriately pursuant to Section 424(a) of the Code). In the event the Company elects to grant a new Option in substitution rather than assuming an existing option, such new Option may be granted with a similarly adjusted Exercise Price. Substitute Awards shall not reduce the number of Shares authorized for grant under the Plan or authorized for grant to a Participant in any calendar year.

21.3       Non-Employee Directors’ Awards .    Notwithstanding any provision to the contrary herein, in the event of a Corporate Transaction, the vesting of all Awards granted to Non-Employee Directors shall accelerate and such Awards shall become exercisable (as applicable) in full prior to the consummation of such event at such times and on such conditions as the Committee determines.

22.          ADOPTION AND STOCKHOLDER APPROVAL .    This Plan shall be submitted for the approval of the Company’s stockholders, consistent with applicable laws, within twelve (12) months before or after the date this Plan is adopted by the Board.

23.          TERM OF PLAN/GOVERNING LAW .    Unless earlier terminated as provided herein, this Plan will become effective on the Effective Date and will terminate ten (10) years from the date this Plan is adopted by the Board. This Plan and all Awards granted hereunder shall be governed by and construed in accordance with the laws of the State of Delaware.

24.          AMENDMENT OR TERMINATION OF PLAN .    The Board may at any time terminate or amend this Plan in any respect, including, without limitation, amendment of any form of Award Agreement or instrument to be executed pursuant to this Plan; provided , however , that the Board will not, without the approval of the stockholders of the Company, amend this Plan in any manner that


requires such stockholder approval; provided further , that a Participant’s Award shall be governed by the version of this Plan then in effect at the time such Award was granted.

25.          NONEXCLUSIVITY OF THE PLAN .    Neither the adoption of this Plan by the Board, the submission of this Plan to the stockholders of the Company for approval, nor any provision of this Plan will be construed as creating any limitations on the power of the Board to adopt such additional compensation arrangements as it may deem desirable, including, without limitation, the granting of stock awards and bonuses otherwise than under this Plan, and such arrangements may be either generally applicable or applicable only in specific cases.

26.          INSIDER TRADING POLICY .    Each Participant who receives an Award shall comply with any policy adopted by the Company from time to time covering transactions in the Company’s securities by Employees, officers and/or directors of the Company.

27.          DEFINITIONS . As used in this Plan, and except as elsewhere defined herein, the following terms will have the following meanings:

Award ” means any award under the Plan, including any Option, Restricted Stock, Stock Bonus, Stock Appreciation Right, Restricted Stock Unit or award of Performance Shares.

Award Agreement ” means, with respect to each Award, the written or electronic agreement between the Company and the Participant setting forth the terms and conditions of the Award, which shall be in substantially a form (which need not be the same for each Participant) that the Committee has from time to time approved, and will comply with and be subject to the terms and conditions of this Plan.

Award Transfer Program ” means any program instituted by the Committee which would permit Participants the opportunity to transfer any outstanding Awards to a financial institution or other person or entity approved by the Committee.

Board ” means the Board of Directors of the Company.

Cause ” means (a) the commission of an act of theft, embezzlement, fraud, dishonesty, (b) a breach of fiduciary duty to the Company or a Parent or Subsidiary, or (c) a failure to materially perform the customary duties of Employee’s employment.

Code ” means the United States Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.

Committee ” means the Compensation Committee of the Board or those persons to whom administration of the Plan, or part of the Plan, has been delegated as permitted by law.

Common Stock ” means the common stock of the Company.

Company ” means AMYRIS BIOTECHNOLOGIES, INC., or any successor corporation.

Consultant ” means any person, including an advisor or independent contractor, engaged by the Company or a Parent or Subsidiary to render services to such entity.

Corporate Transaction ” means the occurrence of any of the following events: (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company


representing fifty percent (50%) or more of the total voting power represented by the Company’s then-outstanding voting securities; (ii) the consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets; (iii) the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation or (iv) any other transaction which qualifies as a “corporate transaction” under Section 424(a) of the Code wherein the stockholders of the Company give up all of their equity interest in the Company (except for the acquisition, sale or transfer of all or substantially all of the outstanding shares of the Company).

Director ” means a member of the Board.

Disability ” means in the case of incentive stock options, total and permanent disability as defined in Section 22(e)(3) of the Code and in the case of other Awards, that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months.

Effective Date ” means the date of the underwritten initial public offering of the Company’s Common Stock pursuant to a registration statement that is declared effective by the SEC.

Employee ” means any person, including Officers and Directors, employed by the Company or any Parent or Subsidiary of the Company. Neither service as a Director nor payment of a director’s fee by the Company will be sufficient to constitute “employment” by the Company.

Exchange Act ” means the United States Securities Exchange Act of 1934, as amended.

Exchange Program ” means a program pursuant to which outstanding Awards are surrendered, cancelled or exchanged for cash, the same type of Award or a different Award (or combination thereof).

Exercise Price ” means, with respect to an Option, the price at which a holder may purchase the Shares issuable upon exercise of an Option and with respect to a SAR, the price at which the SAR is granted to the holder thereof.

Fair Market Value ” means, as of any date, the value of a share of the Company’s Common Stock determined as follows:

(a)        if such Common Stock is publicly traded and is then listed on a national securities exchange, its closing price on the date of determination on the principal national securities exchange on which the Common Stock is listed or admitted to trading as reported in The Wall Street Journal ;

(b)        if such Common Stock is publicly traded but is neither listed nor admitted to trading on a national securities exchange, the average of the closing bid and asked prices on the date of determination as reported in The Wall Street Journal ;

(c)        in the case of an Option or SAR grant made on the Effective Date, the price per share at which shares of the Company’s Common Stock are initially offered for sale to the


public by the Company’s underwriters in the initial public offering of the Company’s Common Stock pursuant to a registration statement filed with the SEC under the Securities Act; or

(d)        if none of the foregoing is applicable, by the Board or the Committee in good faith.

Insider ” means an officer or director of the Company or any other person whose transactions in the Company’s Common Stock are subject to Section 16 of the Exchange Act.

Non-Employee Director ” means a Director who is not an Employee of the Company or any Parent or Subsidiary.

Option ” means an award of an option to purchase Shares pursuant to Section 5.

Parent ” means any corporation (other than the Company) in an unbroken chain of corporations ending with the Company if each of such corporations other than the Company owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

Participant ” means a person who holds an Award under this Plan.

“Performance Award” means cash or stock granted pursuant to Section 10 or Section 12 of the Plan.

“Performance Factors” means any of the factors selected by the Committee and specified in an Award Agreement, from among the following objective measures, either individually, alternatively or in any combination, applied to the Company as a whole or any business unit or Subsidiary, either individually, alternatively, or in any combination, on a GAAP or non-GAAP basis, and measured, to the extent applicable on an absolute basis or relative to a pre-established target, to determine whether the performance goals established by the Committee with respect to applicable Awards have been satisfied:

(a)        Profit Before Tax;

(b)        Billings;

(c)        Revenue;

(d)        Net revenue;

(e)        Earnings (which may include earnings before interest and taxes, earnings before taxes, and net earnings);

(f)        Operating income;

(g)        Operating margin;

(h)        Operating profit;

(i)        Controllable operating profit, or net operating profit;


(j)        Net Profit;

(k)        Gross margin;

(l)        Operating expenses or operating expenses as a percentage of revenue;

(m)        Net income;

(n)        Earnings per share;

(o)        Total stockholder return;

(p)        Market share;

(q)        Return on assets or net assets;

(r)        The Company’s stock price;

(s)        Growth in stockholder value relative to a pre-determined index;

(t)        Return on equity;

(u)        Return on invested capital;

(v)        Cash Flow (including free cash flow or operating cash flows)

(w)        Cash conversion cycle;

(x)        Economic value added; and

(y)        Individual confidential business objectives;

(z)        Contract awards or backlog;

(aa)        Overhead or other expense reduction;

(bb)        Credit rating;

(cc)        Strategic plan development and implementation;

(dd)        Succession plan development and implementation;

(ee)        Improvement in workforce diversity;

(ff)        Customer indicators;

(gg)        New product invention or innovation;

(hh)        Attainment of research and development milestones;


(ii)        Improvements in productivity;

(jj)        Attainment of objective operating goals and employee metrics.

The Committee may, in recognition of unusual or non-recurring items such as acquisition-related activities or changes in applicable accounting rules, provide for one or more equitable adjustments (based on objective standards) to the Performance Factors to preserve the Committee’s original intent regarding the Performance Factors at the time of the initial award grant. It is within the sole discretion of the Committee to make or not make any such equitable adjustments.

Performance Period ” means the period of service determined by the Committee, not to exceed five (5) years, during which years of service or performance is to be measured for the Award.

Performance Share ” means a performance share bonus granted as a Performance Award.

Permitted Transferee ” means any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law (including adoptive relationships) of the Employee, any person sharing the Employee’s household (other than a tenant or employee), a trust in which these persons (or the Employee) have more than 50% of the beneficial interest, a foundation in which these persons (or the Employee) control the management of assets, and any other entity in which these persons (or the Employee) own more than 50% of the voting interests

Plan ” means this Amyris Biotechnologies, Inc. 2010 Equity Incentive Plan.

Purchase Price ” means the price to be paid for Shares acquired under the Plan, other than Shares acquired upon exercise of an Option or SAR.

Restricted Stock Award ” means an award of Shares pursuant to Section 6 or Section 12 of the Plan, or issued pursuant to the early exercise of an Option.

Restricted Stock Unit ” means an Award granted pursuant to Section 9 or Section 12 of the Plan.

SEC ” means the United States Securities and Exchange Commission.

Securities Act ” means the United States Securities Act of 1933, as amended.

Shares ” means shares of the Company’s Common Stock and the common stock of any successor security.

Stock Appreciation Right ” means an Award granted pursuant to Section 8 or Section 12 of the Plan.

Stock Bonus ” means an Award granted pursuant to Section 7 or Section 12 of the Plan.

Subsidiary ” means any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.


Termination ” or “ Terminated ” means, for purposes of this Plan with respect to a Participant, that the Participant has for any reason ceased to provide services as an employee, officer, director, consultant, independent contractor or advisor to the Company or a Parent or Subsidiary of the Company. An employee will not be deemed to have ceased to provide services in the case of (i) sick leave, (ii) military leave, or (iii) any other leave of absence approved by the Committee; provided , that such leave is for a period of not more than 90 days, unless reemployment upon the expiration of such leave is guaranteed by contract or statute or unless provided otherwise pursuant to formal policy adopted from time to time by the Company and issued and promulgated to employees in writing. In the case of any employee on an approved leave of absence, the Committee may make such provisions respecting suspension of vesting of the Award while on leave from the employ of the Company or a Parent or Subsidiary of the Company as it may deem appropriate, except that in no event may an Award be exercised after the expiration of the term set forth in the applicable Award Agreement. The Committee will have sole discretion to determine whether a Participant has ceased to provide services and the effective date on which the Participant ceased to provide services (the “ Termination Date ”).

Unvested Shares ” means Shares that have not yet vested or are subject to a right of repurchase in favor of the Company (or any successor thereto).


AMYRIS BIOTECHNOLOGIES, INC.

2010 EQUITY INCENTIVE PLAN

NOTICE OF STOCK OPTION GRANT

Unless otherwise defined herein, the terms defined in the 2010 Amyris Biotechnologies, Inc. (the “Company”) Equity Incentive Plan (the “ Plan ”) shall have the same meanings in this Notice of Stock Option Grant (the “ Notice ”).

 

 

 

Name:   

 

Address:   

 

You (the “ Participant ”) have been granted an option to purchase shares of Common Stock of the Company under the Plan subject to the terms and conditions of the Plan, this Notice and the Stock Option Award Agreement (the “ Option Agreement ”).

 

Grant Number:

 

 

  

Date of Grant:

 

 

  

Vesting Commencement Date:

 

 

  

Exercise Price per Share:

 

 

  

Total Number of Shares:

 

 

  

Type of Option:

 

         Non-Qualified Stock Option (                  shares)

 

         Incentive Stock Option (                  shares)

Expiration Date:

 

 

  

Post-Termination Exercise Period:

 

Termination for Cause = None

  
 

Voluntary Termination = 3 Months

  
 

Termination without Cause = 3 Months

  
 

Disability = 12 Months

  
 

Death = 12 Months

  

Vesting Schedule:

 

Subject to the limitations set forth in this Notice, the Plan and the Option Agreement, the Option will vest and may be exercised, in whole or in part, in accordance with the following schedule: [ INSERT VESTING SCHEDULE ]

You understand that your employment or consulting relationship or service with the Company is for an unspecified duration, can be terminated at any time (i.e., is “at-will”), and that nothing in this Notice, the Option Agreement or the Plan changes the at-will nature of that relationship. You acknowledge that the vesting of the Options pursuant to this Notice is earned only by continuing service as an Employee, Director or Consultant of the Company. You also understand that this Notice is subject to the terms and conditions of both the Option Agreement and the Plan, both of which are incorporated herein by reference. You have read both the Option Agreement and the Plan.

 

PARTICIPANT:       AMYRIS BIOTECHNOLOGIES, INC.  
Signature:                                                                                  By:                                                                                                       
Print Name:                                                                              Its:                                                                                                       
Date:                                                                                             Date:                                                                                                       


AMYRIS BIOTECHNOLOGIES, INC.

2010 EQUITY INCENTIVE PLAN

STOCK OPTION AWARD AGREEMENT

Unless otherwise defined in this Stock Option Award Agreement (the “ Agreement ”), any capitalized terms used herein shall have the meaning ascribed to them in the Amyris Biotechnologies, Inc. (the “ Company ”) 2010 Equity Incentive Plan (the “ Plan ”).

Participant has been granted an option to purchase Shares (the “ Option ”), subject to the terms and conditions of the Plan, the Notice of Stock Option Grant (the “ Notice ”) and this Agreement.

1.          Vesting Rights .   Subject to the applicable provisions of the Plan and this Agreement, this Option may be exercised, in whole or in part, in accordance with the schedule set forth in the Notice.

2.         Termination Period .

(a)         General Rule .  Except as provided below, and subject to the Plan, this Option may be exercised for 3 months after termination of Participant’s employment with the Company. In no event shall this Option be exercised later than the Expiration Date set forth in the Notice.

(b)         Death; Disability .  Unless provided otherwise in the Notice, upon the termination of Participant’s service to the Company by reason of his or her Disability or death, or if a Participant dies within three months of the Termination Date, this Option may be exercised for twelve months, provided that in no event shall this Option be exercised later than the Expiration Date set forth in the Notice.

(c)         Cause .   Upon the termination of Participant’s employment by the Company for Cause, the Option shall expire on such date of Participant’s Termination Date. For purposes of this Agreement, “Cause” shall be defined in the Plan.

3.         Grant of Option .  The Participant named in the Notice has been granted an Option for the number of Shares set forth in the Notice at the exercise price per Share set forth in the Notice (the “ Exercise Price ”). In the event of a conflict between the terms and conditions of the Plan and the terms and conditions of this Agreement, the terms and conditions of the Plan shall prevail. If designated in the Notice as an Incentive Stock Option (“ ISO ”), this Option is intended to qualify as an Incentive Stock Option under Section 422 of the Code. However, if this Option is intended to be an ISO, to the extent that it exceeds the $100,000 rule of Code Section 422(d) it shall be treated as a Nonqualified Stock Option (“ NSO ”).

4.         Exercise of Option .

(a)         Right to Exercise .  This Option is exercisable during its term in accordance with the Vesting Schedule set forth in the Notice and the applicable provisions of the Plan and this Agreement. In the event of Participant’s death, Disability, Termination for Cause or other Termination, the exercisability of the Option is governed by the applicable provisions of the Plan, the Notice and this Agreement.

(b)         Method of Exercise .  This Option is exercisable by delivery of an exercise notice (the “ Exercise Notice ”), which shall state the election to exercise the Option, the number of Shares in respect of which the Option is being exercised (the “ Exercised Shares ”), and such other representations and agreements as may be required by the Company pursuant to the provisions of the Plan. The Exercise Notice shall be delivered in person, by mail, via electronic mail or facsimile or by other authorized method to the Secretary of the Company or other person designated by the Company. The Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to all Exercised Shares. This


Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by such aggregate Exercise Price.

(c)        No Shares shall be issued pursuant to the exercise of this Option unless such issuance and exercise complies with all relevant provisions of law and the requirements of any stock exchange or quotation service upon which the Shares are then listed. Assuming such compliance, for income tax purposes the Exercised Shares shall be considered transferred to the Participant on the date the Option is exercised with respect to such Exercised Shares.

5.         Method of Payment .  Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the election of the Participant:

(a)        cash;

(b)        check;

(c)        a “broker-assisted” or “same-day sale” (as described in Section 11(d) of the Plan); or

(d)        other method authorized by the Company.

6.         Non-Transferability of Option .  This Option may not be transferred in any manner other than by will or by the laws of descent or distribution or court order and may be exercised during the lifetime of Participant only by the Participant unless otherwise permitted by the Committee on a case-by-case basis. The terms of the Plan and this Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of the Participant.

7.     Term of Option .   This Option shall in any event expire on the expiration date set forth in the Notice, which date is 10 years after the Date of Grant (five years after the Date of Grant if this option is designated as an ISO in the Notice of Stock Option Grant and Section 5.3 of the Plan applies).

8.     U.S. Tax Consequences .  For Participants subject to U.S. income tax, some of the federal tax consequences relating to this Option, as of the date of this Option, are set forth below. All other Participants should consult a tax advisor for tax consequences relating to this Option in their respective jurisdiction. THIS SUMMARY IS NECESSARILY INCOMPLETE, AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE. THE PARTICIPANT SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THIS OPTION OR DISPOSING OF THE SHARES.

(a)         Exercising the Option .

(i)         Nonqualified Stock Option .  The Participant may incur federal ordinary income tax liability upon exercise of a NSO. The Participant will be treated as having received compensation income (taxable at ordinary income tax rates) equal to the excess, if any, of the Fair Market Value of the Exercised Shares on the date of exercise over their aggregate Exercise Price. If the Participant is an Employee or a former Employee, the Company will be required to withhold from his or her compensation an amount equal to the minimum amount the Company is required to withhold for income and employment taxes or collect from Participant and pay to the applicable taxing authorities an amount in cash equal to a percentage of this compensation income at the time of exercise, and may refuse to honor the exercise and refuse to deliver Shares if such withholding amounts are not delivered at the time of exercise.

(ii)         Incentive Stock Option .  If this Option qualifies as an ISO, the Participant will have no regular federal income tax liability upon its exercise, although the excess, if any, of the aggregate Fair Market Value of the Exercised Shares on the date of exercise over their aggregate


Exercise Price will be treated as an adjustment to alternative minimum taxable income for federal tax purposes and may subject the Participant to alternative minimum tax in the year of exercise.

(b)         Disposition of Shares .

(i)         NSO .  If the Participant holds NSO Shares for at least one year, any gain realized on disposition of the Shares will be treated as long-term capital gain for federal income tax purposes.

(ii)         ISO .  If the Participant holds ISO Shares for at least one year after exercise and two years after the grant date, any gain realized on disposition of the Shares will be treated as long-term capital gain for federal income tax purposes. If the Participant disposes of ISO Shares within one year after exercise or two years after the grant date, any gain realized on such disposition will be treated as compensation income (taxable at ordinary income rates) to the extent of the excess, if any, of the lesser of (A) the difference between the Fair Market Value of the Shares acquired on the date of exercise and the aggregate Exercise Price, or (B) the difference between the sale price of such Shares and the aggregate Exercise Price.

(c)         Notice of Disqualifying Disposition of ISO Shares .  If the Participant sells or otherwise disposes of any of the Shares acquired pursuant to an ISO on or before the later of (i) two years after the grant date, or (ii) one year after the exercise date, the Participant shall immediately notify the Company in writing of such disposition. The Participant agrees that he or she may be subject to income tax withholding by the Company on the compensation income recognized from such early disposition of ISO Shares by payment in cash or out of the current earnings paid to the Participant.

9.         Acknowledgement .  The Company and Participant agree that the Option is granted under and governed by the Notice, this Agreement and by the provisions of the Plan (incorporated herein by reference). Participant: (i) acknowledges receipt of a copy of the Plan and the Plan prospectus, (ii) represents that Participant has carefully read and is familiar with their provisions, and (iii) hereby accepts the Option subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice.

10.         Entire Agreement; Enforcement of Rights .  This Agreement, the Plan and the Notice constitute the entire agreement and understanding of the parties relating to the subject matter herein and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning the purchase of the Shares hereunder are superseded. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing and signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.

11.         Compliance with Laws and Regulations .  The issuance of Shares will be subject to and conditioned upon compliance by the Company and Participant with all applicable state and federal laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company’s Common Stock may be listed or quoted at the time of such issuance or transfer.

12.         Governing Law; Severability .  If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law.


13.         No Rights as Employee, Director or Consultant .  Nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company, or a Parent or Subsidiary of the Company, to terminate Participant’s service, for any reason, with or without cause.

By Participant’s signature and the signature of the Company’s representative on the Notice, Participant and the Company agree that this Option is granted under and governed by the terms and conditions of the Plan, the Notice and this Agreement. Participant has reviewed the Plan, the Notice and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing the Notice, and fully understands all provisions of the Plan, the Notice and this Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan, the Notice and the Agreement. Participant further agrees to notify the Company upon any change in the residence address indicated on the Notice.


AMYRIS BIOTECHNOLOGIES, INC.

2010 EQUITY INCENTIVE PLAN

NOTICE OF RESTRICTED STOCK UNIT AWARD

GRANT NUMBER:                 

Unless otherwise defined herein, the terms defined in the Amyris Biotechnologies, Inc. (the “Company” ) 2010 Equity Incentive Plan (the “Plan” ) shall have the same meanings in this Notice of Restricted Stock Unit Award (the “Notice” ).

 

Name:

      

Address:

      

You (“ Participant ”) have been granted an award of Restricted Stock Units (“ RSUs ”) under the Plan subject to the terms and conditions of the Plan, this Notice and the attached Award Agreement (Restricted Stock Units) (hereinafter “ RSU Agreement ”).

 

Number of RSUs:

      

Date of Grant:

      

Vesting Commencement Date:

      

Expiration Date:

     The date on which settlement of all RSUs granted hereunder occurs, with earlier expiration upon the Termination Date

Vesting Schedule:

     Subject to the limitations set forth in this Notice, the Plan and the RSU Agreement, the RSUs will vest in accordance with the following schedule: [INSERT VESTING SCHEDULE]

You understand that your employment or consulting relationship or service with the Company is for an unspecified duration, can be terminated at any time (i.e., is “at-will”), and that nothing in this Notice, the RSU Agreement or the Plan changes the at-will nature of that relationship. You acknowledge that the vesting of the RSUs pursuant to this Notice is earned only by continuing service as an Employee, Director or Consultant of the Company. You also understand that this Notice is subject to the terms and conditions of both the RSU Agreement and the Plan, both of which are incorporated herein by reference. You have read both the RSU Agreement and the Plan.

 

PARTICIPANT

   AMYRIS BIOTECHNOLOGIES, INC.

Signature:

       By:     

Print Name:

       Its:     


AMYRIS BIOTECHNOLOGIES, INC.

AWARD AGREEMENT (RESTRICTED STOCK UNITS) TO THE

AMYRIS BIOTECHNOLOGIES, INC. 2010 EQUITY INCENTIVE PLAN

Unless otherwise defined herein, the terms defined in the Amyris Biotechnologies, Inc. (the “ Company ”) 2010 Equity Incentive Plan (the “ Plan ”) shall have the same defined meanings in this Award Agreement (Restricted Stock Units) (the “ Agreement ”).

Participant has been granted Restricted Stock Units (“ RSUs ”) subject to the terms, restrictions and conditions of the Plan, the Notice of Restricted Stock Unit Award (the “ Notice ”) and this Agreement.

1.      Settlement .   Settlement of RSUs shall be made within 30 days following the applicable date of vesting under the vesting schedule set forth in the Notice. Settlement of RSUs shall be in Shares.

2.      No Stockholder Rights .   Unless and until such time as Shares are issued in settlement of vested RSUs, Participant shall have no ownership of the Shares allocated to the RSUs and shall have no right dividends or to vote such Shares.

3.     Dividend Equivalents .   Dividends, if any (whether in cash or Shares), shall not be credited to Participant.

4.      No Transfer .   The RSUs and any interest therein shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of.

5.      Termination .   If Participant’s service Terminates for any reason, all unvested RSUs shall be forfeited to the Company forthwith, and all rights of Participant to such RSUs shall immediately terminate. In case of any dispute as to whether Termination has occurred, the Committee shall have sole discretion to determine whether such Termination has occurred and the effective date of such Termination.

6.      U.S. Tax Consequences .   Participant acknowledges that there will be tax consequences upon settlement of the RSUs or disposition of the Shares, if any, received in connection therewith, and Participant should consult a tax adviser regarding Participant’s tax obligations prior to such settlement or disposition. Upon vesting of the RSU, Participant will include in income the fair market value of the Shares subject to the RSU. The included amount will be treated as ordinary income by Participant and will be subject to withholding by the Company when required by applicable law. Upon disposition of the Shares, any subsequent increase or decrease in value will be treated as short-term or long-term capital gain or loss, depending on whether the Shares are held for more than one year from the date of settlement. Further, an RSU may be considered a deferral of compensation that may be subject to Section 409A of the Code. Section 409A of the Code imposes special rules to the timing of making and effecting certain amendments of this RSU with respect to distribution of any deferred compensation. You should consult your personal tax advisor for more information on the actual and potential tax consequences of this RSU.

7.      Acknowledgement .   The Company and Participant agree that the RSUs are granted under and governed by the Notice, this Agreement and the provisions of the Plan. Participant: (i) acknowledges receipt of a copy of the Plan and the Plan prospectus, (ii) represents that Participant has carefully read and is familiar with their provisions, and (iii) hereby accepts the RSUs subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice.

8.      Entire Agreement; Enforcement of Rights .   This Agreement, the Plan and the Notice constitute the entire agreement and understanding of the parties relating to the subject matter herein and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning the purchase of the Shares hereunder are superseded. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing and signed by the


parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.

9.      Compliance with Laws and Regulations .   The issuance of Shares will be subject to and conditioned upon compliance by the Company and Participant with all applicable state and federal laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company’s Common Stock may be listed or quoted at the time of such issuance or transfer.

10.      Governing Law; Severability .   If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law.

11.      No Rights as Employee, Director or Consultant .   Nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company, or a Parent or Subsidiary of the Company, to terminate Participant s service, for any reason, with or without cause.

By Participant’s signature and the signature of the Company’s representative on the Notice, Participant and the Company agree that this RSU is granted under and governed by the terms and conditions of the Plan, the Notice and this Agreement. Participant has reviewed the Plan, the Notice and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement, and fully understands all provisions of the Plan, the Notice and this Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan, the Notice and this Agreement. Participant further agrees to notify the Company upon any change in Participant’s residence address.


AMYRIS BIOTECHNOLOGIES, INC.

2010 EQUITY INCENTIVE PLAN

NOTICE OF STOCK APPRECIATION RIGHT AWARD

GRANT NUMBER:                 

Unless otherwise defined herein, the terms defined in the 2010 Amyris Biotechnologies, Inc. (the “ Company ”) Equity Incentive Plan (the “ Plan ”) shall have the same meanings in this Notice of Stock Appreciation Right Award (the “ Notice ”).

Name:                                                                                                                        

Address:                                                                                                                    

You (the “ Participant ”) have been granted an award of Stock Appreciation Rights (“ SARs ”) of the Company under the Plan subject to the terms and conditions of the Plan, this Notice and the Stock Appreciation Right Award Agreement (the “ SAR Agreement ”).

 

Grant Number:

  

                                                                                                                                             

  

Date of Grant:

  

                                                                                                                                             

  

Vesting Commencement Date:

  

                                                                                                                                             

  

Fair Market Value on Date of Grant:

  

                                                                                                                                             

  

Total Number of Shares:

  

                                                                                                                                             

  

Expiration Date:

  

                                                                                                                                             

  

Post-Termination Exercise Period:

  

            Termination for Cause = None

  
  

            Voluntary Termination = 3 Months

  
  

            Termination without Cause = 3 Months

  
  

            Disability = 12 Months

  
  

            Death = 12 Months

  

Vesting Schedule:

  

Subject to the limitations set forth in this Notice, the Plan and the Stock Appreciation Right Agreement, the SAR will vest and may be exercised, in whole or in part, in accordance with the following schedule: [INSERT VESTING SCHEDULE]

  

 


You understand that your employment or consulting relationship or service with the Company is for an unspecified duration, can be terminated at any time (i.e., is “at-will”), and that nothing in this Notice, the SAR Agreement or the Plan changes the at-will nature of that relationship. You acknowledge that the vesting of the SARs pursuant to this Notice is earned only by continuing service as an Employee, Director or Consultant of the Company. You also understand that this Notice is subject to the terms and conditions of both the SAR Agreement and the Plan, both of which are incorporated herein by reference. You have read both the SAR Agreement and the Plan.

 

PARTICIPANT:     AMYRIS BIOTECHNOLOGIES, INC.
Signature:         By:    
Print Name:         Its:    
Date:         Date:    
       


AMYRIS BIOTECHNOLOGIES, INC.

2010 EQUITY INCENTIVE PLAN

STOCK APPRECIATION RIGHT AWARD AGREEMENT

Unless otherwise defined in this Stock Appreciation Right Award Agreement (the “ Agreement ”), any capitalized terms used herein shall have the meaning ascribed to them in the Amyris Biotechnologies, Inc. (the “ Company ”) 2010 Equity Incentive Plan (the “ Plan ”).

Participant has been granted Stock Appreciation Rights (“ SARs ”), subject to the terms and conditions of the Plan, the Notice of Stock Appreciation Right Award (the “ Notice ”) and this Agreement.

1.         Vesting Rights .   Subject to the applicable provisions of the Plan and this Agreement, this SAR may be exercised, in whole or in part, in accordance with the schedule set forth in the Notice.

2.         Termination Period .

(a)         General Rule .  Except as provided below, and subject to the Plan, this SAR may be exercised for 3 months after termination of Participant’s employment with the Company. In no event shall this SAR be exercised later than the Expiration Date set forth in the Notice.

(b)         Death; Disability .  Unless provided otherwise in the Notice, upon the termination of Participant’s service to the Company by reason of his or her Disability or death, or if a Participant dies within three months of the Termination Date, this SAR may be exercised for twelve months, provided that in no event shall this SAR be exercised later than the Expiration Date set forth in the Notice.

(c)         Cause .  Upon the termination of Participant’s employment by the Company for Cause, the SAR shall expire on such date of Participant’s Termination Date. For purposes of this Agreement, “Cause” shall be defined in the Plan.

3.         Grant of SAR .  The Participant named in the Notice has been granted a SAR for the number of Shares set forth in the Notice at the fair market value set forth in the Notice. In the event of a conflict between the terms and conditions of the Plan and the terms and conditions of this Agreement, the terms and conditions of the Plan shall prevail.

4.         Exercise of SAR .

(a)         Right to Exercise .  This SAR is exercisable during its term in accordance with the Vesting Schedule set forth in the Notice and the applicable provisions of the Plan and this Agreement. In the event of Participant’s death, Disability, Termination for Cause or other Termination, the exercisability of the SAR is governed by the applicable provisions of the Plan, the Notice and this Agreement.

(b)         Method of Exercise .  This SAR is exercisable by delivery of an exercise notice (the “ Exercise Notice ”), which shall state the election to exercise the SAR, the number of SARS to be exercised (the “ Exercised SARs ”), and such other representations and agreements as may be required by the Company pursuant to the provisions of the Plan. The Exercise Notice shall be delivered in person, by mail, via electronic mail or facsimile or by other authorized method to the Secretary of the Company or other person designated by the Company. This SAR shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice.

(c)        No Shares shall be issued pursuant to the exercise of this SAR unless such issuance and exercise complies with all relevant provisions of law and the requirements of any stock exchange or quotation


service upon which the Shares are then listed. Assuming such compliance, for income tax purposes the Exercised Shares shall be considered transferred to the Participant on the date the SAR is exercised with respect to such Exercised Shares.

5.         Non-Transferability of SAR .  This SAR may not be transferred in any manner other than by will or by the laws of descent or distribution or court order and may be exercised during the lifetime of Participant only by the Participant unless otherwise permitted by the Committee on a case-by-case basis. The terms of the Plan and this Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of the Participant.

6.         Term of SAR .  This SAR shall in any event expire on the expiration date set forth in the Notice, which date is 10 years after the Date of Grant.

7.         U.S. Tax Consequences .  For Participants subject to U.S. income tax, some of the federal tax consequences relating to this SAR, as of the date of this SAR, are set forth below. All other Participants should consult a tax advisor for tax consequences relating to this SAR in their respective jurisdiction. THIS SUMMARY IS NECESSARILY INCOMPLETE, AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE. THE PARTICIPANT SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THIS SAR. The Participant will incur federal ordinary income tax liability upon exercise of the SAR. The Participant will be treated as having received compensation income (taxable at ordinary income tax rates) equal to the excess, if any, of the Fair Market Value of the Exercised Shares on the date of exercise over their Fair Market Value on the date of grant. If the Participant is an Employee or a former Employee, the Company will be required to withhold from his or her compensation an amount equal to the minimum amount the Company is required to withhold for income and employment taxes or collect from Participant and pay to the applicable taxing authorities an amount in cash equal to a percentage of this compensation income at the time of exercise, and may refuse to honor the exercise and refuse to deliver Shares if such withholding amounts are not delivered at the time of exercise. If the Participant holds the Shares received upon exercise of the SAR for at least one year, any gain realized on disposition of the Shares will be treated as long-term capital gain for federal income tax purposes.

9.         Acknowledgement .  The Company and Participant agree that the SAR is granted under and governed by the Notice, this Agreement and by the provisions of the Plan (incorporated herein by reference). Participant: (i) acknowledges receipt of a copy of the Plan and the Plan prospectus, (ii) represents that Participant has carefully read and is familiar with their provisions, and (iii) hereby accepts the SAR subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice.

10.         Entire Agreement; Enforcement of Rights .  This Agreement, the Plan and the Notice constitute the entire agreement and understanding of the parties relating to the subject matter herein and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning the purchase of the Shares hereunder are superseded. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing and signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.

11.         Compliance with Laws and Regulations .  The issuance of Shares will be subject to and conditioned upon compliance by the Company and Participant with all applicable state and federal laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company’s Common Stock may be listed or quoted at the time of such issuance or transfer.

12.         Governing Law; Severability .  If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement shall be interpreted as if


such provision were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law.

13.         No Rights as Employee, Director or Consultant .  Nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company, or a Parent or Subsidiary of the Company, to terminate Participant’s service, for any reason, with or without cause.

By Participant’s signature and the signature of the Company’s representative on the Notice, Participant and the Company agree that this SAR is granted under and governed by the terms and conditions of the Plan, the Notice and this Agreement. Participant has reviewed the Plan, the Notice and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing the Notice, and fully understands all provisions of the Plan, the Notice and this Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan, the Notice and the Agreement. Participant further agrees to notify the Company upon any change in the residence address indicated on the Notice.


AMYRIS BIOTECHNOLOGIES, INC.

2010 EQUITY INCENTIVE PLAN

NOTICE OF STOCK BONUS AWARD

GRANT NUMBER:                 

Unless otherwise defined herein, the terms defined in the Amyris Biotechnologies, Inc. (the “ Company ”) 2010 Equity Incentive Plan (the “ Plan ”) shall have the same meanings in this Notice of Stock Bonus Award (the “ Notice ”).

 

Name:

       

Address:

       

You ( “Participant” ) have been granted an award of Shares under the Plan subject to the terms and conditions of the Plan, this Notice, and the attached Stock Bonus Award Agreement (the “Stock Bonus Agreement” ) to the Plan.

 

Number of Shares:

       

Date of Grant:

       

Vesting Commencement Date:

       

Expiration Date:

      The date on which all the Shares granted hereunder become vested, with earlier expiration upon the Termination Date

Vesting Schedule:

      Subject to the limitations set forth in this Notice, the Plan and the Stock Bonus Agreement, the Shares will vest in accordance with the following schedule: [INSERT VESTING SCHEDULE]

You understand that your employment or consulting relationship or service with the Company is for an unspecified duration, can be terminated at any time (i.e., is “at-will”), and that nothing in this Notice, the Stock Bonus Agreement or the Plan changes the at-will nature of that relationship. You acknowledge that the vesting of the Shares pursuant to this Notice is earned only by continuing service as an Employee, Director or Consultant of the Company. You also understand that this Notice is subject to the terms and conditions of both the Stock Bonus Agreement and the Plan, both of which are incorporated herein by reference. You have read both the Stock Bonus Agreement and the Plan.

 

PARTICIPANT

   AMYRIS BIOTECHNOLOGIES, INC.
Signature:       

By:

    

Print Name:

       Its:     


AMYRIS BIOTECHNOLOGIES, INC.

STOCK BONUS AWARD AGREEMENT

AMYRIS BIOTECHNOLOGIES, INC. 2010 EQUITY INCENTIVE PLAN

Unless otherwise defined herein, the terms defined in the Amyris Biotechnologies, Inc. (the “ Company ”) 2010 Equity Incentive Plan (the “ Plan ”) shall have the same defined meanings in this Stock Bonus Agreement (the “ Agreement ”).

Participant has been granted a Stock Bonus Award (“ Stock Bonus Award ”) subject to the terms, restrictions and conditions of the Plan, the Notice of Stock Bonus Award (the “ Notice ”) and this Agreement.

1.      Issuance .   Stock Bonus Awards shall be issued in Shares, and the Company’s transfer agent shall record ownership of such Shares in Participant’s name as soon as reasonably practicable.

2.      Stockholder Rights .   Participant shall have no right to dividends or to vote Shares until Participant is recorded as the holder of such Shares on the stock records of the Company and its transfer agent.

3.      No-Transfer .   Unvested Shares, and unvested Stock Bonus Awards, and any interest in either shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of by Participant or any person whose interest derives from Participant’s interest. “ Unvested Shares ” are Shares that have not yet vested pursuant to the terms of the vesting schedule set forth in the Notice.

4.      Termination .   Upon Participant’s Termination for any reason, all Unvested Shares shall immediately be forfeited to the Company, and all rights of Participant to such Unvested Shares shall immediately terminate as of Participant’s Termination Date. In case of any dispute as to whether Termination has occurred, the Committee shall have sole discretion to determine whether such Termination has occurred and the effective date of such Termination.

5.      U.S. Tax Consequences .   Upon vesting of Shares, Participant will include in taxable income the difference between the fair market value of the vesting Shares, as determined on the date of their vesting, and the price paid for the Shares. This will be treated as ordinary income by Participant and will be subject to withholding by the Company when required by applicable law. Before any Shares subject to this Agreement are issued the Company shall withhold a number of Shares with a fair market value (determined on the date the Shares are issued) equal to the minimum amount the Company is required to withhold for income and employment taxes. Upon disposition of the Shares, any subsequent increase or decrease in value will be treated as short-term or long-term capital gain or loss, depending on whether the Shares are held for more than one year from the date of settlement.

6.      Acknowledgement .   The Company and Participant agree that the Stock Bonus Award is granted under and governed by the Notice, this Agreement and by the provisions of the Plan (incorporated herein by reference). Participant: (i) acknowledges receipt of a copy of the Plan and the Plan prospectus, (ii) represents that Participant has carefully read and is familiar with their provisions, and (iii) hereby accepts the Stock Bonus Award subject to all of the terms and conditions set forth herein and those set forth in the Plan, this Agreement and the Notice.

7.      Entire Agreement; Enforcement of Rights .   This Agreement, the Plan and the Notice constitute the entire agreement and understanding of the parties relating to the subject matter herein and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning the purchase of the Shares hereunder are superseded. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing and signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.


8.      Compliance with Laws and Regulations .   The issuance of Shares will be subject to and conditioned upon compliance by the Company and Participant with all applicable state and federal laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company’s Common Stock may be listed or quoted at the time of such issuance or transfer.

9.      Governing Law; Severability .   If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law.

10.     No Rights as Employee, Director or Consultant .   Nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company, or a Parent or Subsidiary of the Company, to terminate Purchaser s service, for any reason, with or without cause.

By Participant’s signature and the signature of the Company’s representative on the Notice, Participant and the Company agree that this Stock Bonus Award is granted under and governed by the terms and conditions of the Plan, the Notice and this Agreement. Participant has reviewed the Plan, the Notice and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement, and fully understands all provisions of the Plan, the Notice and this Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan, the Notice and this Agreement. Participant further agrees to notify the Company upon any change in Participant’s residence address.


AMYRIS BIOTECHNOLOGIES, INC.

2010 EQUITY INCENTIVE PLAN

NOTICE OF PERFORMANCE SHARES AWARD

GRANT NUMBER:                 

Unless otherwise defined herein, the terms defined in the Amyris Biotechnologies, Inc. (the “ Company ”) 2010 Equity Incentive Plan (the “ Plan ”) shall have the same meanings in this Notice of Performance Shares Award (the “ Notice ”).

 

Name:

       

Address:

       

You (“ Participant ”) have been granted an award of Performance Shares under the Plan subject to the terms and conditions of the Plan, this Notice and the attached Performance Shares Award Agreement (hereinafter “ Performance Shares Agreement ”).

 

Number of Shares:

       

Date of Grant:

       

Vesting Commencement Date:

       

Expiration Date:

      The date on which all the Shares granted hereunder become vested, with earlier expiration upon the Termination Date

Vesting Schedule:

      Subject to the limitations set forth in this Notice, the Plan and the Performance Shares Agreement, the Shares will vest in accordance with the following schedule: [INSERT VESTING SCHEDULE]

You understand that your employment or consulting relationship or service with the Company is for an unspecified duration, can be terminated at any time (i.e., is “at-will”), and that nothing in this Notice, the Performance Shares Agreement or the Plan changes the at-will nature of that relationship. You acknowledge that the vesting pursuant to this Notice is earned only upon the applicable certification of attainment of the requisite Performance Factors enumerated above while still in service as an Employee, Director or Consultant of the Company. You also understand that this Notice is subject to the terms and conditions of both the Performance Shares Award Agreement and the Plan, both of which are incorporated herein by reference. Participant has read both the Performance Shares Agreement and the Plan.

 

PARTICIPANT

   AMYRIS BIOTECHNOLOGIES, INC.

Print Name:

       Its:     

Signature:

       By:     


AMYRIS BIOTECHNOLOGIES, INC.

PERFORMANCE SHARES AGREEMENT TO THE

AMYRIS BIOTECHNOLOGIES, INC. 2010 EQUITY INCENTIVE PLAN

Unless otherwise defined herein, the terms defined in the Amyris Biotechnologies, Inc. (the “ Company ”) 2010 Equity Incentive Plan (the “ Plan ”) shall have the same defined meanings in this Performance Shares Agreement (the “ Agreement ”).

Participant has been granted a Performance Shares Award (“ Performance Shares Award ”) subject to the terms, restrictions and conditions of the Plan, the Notice of Performance Shares Award (“ Notice ”) and this Agreement.

1.        Settlement .   Performance Shares shall be settled in Shares and the Company’s transfer agent shall record ownership of such Shares in Participant’s name as soon as reasonably practicable after achievement of the Performance Factors enumerated in the Notice.

2.        Stockholder Rights .   Participant shall have no right to dividends or to vote Shares until Participant is recorded as the holder of such Shares on the stock records of the Company and its transfer agent.

3.        No-Transfer .   Participant’s interest in this Performance Shares Award shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of.

4.        Termination .   Upon Participant’s Termination for any reason, all of Participant’s rights under the Plan, this Agreement and the Notice in respect of this Award shall immediately terminate. In case of any dispute as to whether Termination has occurred, the Committee shall have sole discretion to determine whether such Termination has occurred and the effective date of such Termination.

5.        U.S. Tax Consequences .   Participant acknowledges that there will be tax consequences upon issuance of the Shares, and Participant should consult a tax adviser regarding Participant’s tax obligations prior to such settlement or disposition. Upon vesting of the Shares, Participant will include in income the fair market value of the Shares. The included amount will be treated as ordinary income by Participant and will be subject to withholding by the Company when required by applicable law. Before any Shares subject to this Agreement are issued the Company shall withhold a number of Shares with a fair market value (determined on the date the Shares are issued) equal to the minimum amount the Company is required to withhold for income and employment taxes. Upon disposition of the Shares, any subsequent increase or decrease in value will be treated as short-term or long-term capital gain or loss, depending on whether the Shares are held for more than one year from the date of issuance.

6.        Acknowledgement .   The Company and Participant agree that the Performance Shares Award is granted under and governed by the Notice, this Agreement and by the provisions of the Plan (incorporated herein by reference). Participant: (i) acknowledges receipt of a copy of the Plan and the Plan prospectus, (ii) represents that Participant has carefully read and is familiar with their provisions, and (iii) hereby accepts the Performance Shares Award subject to all of the terms and conditions set forth herein and those set forth in the Plan, this Agreement and the Notice.

7.        Entire Agreement; Enforcement of Rights .   This Agreement, the Plan and the Notice constitute the entire agreement and understanding of the parties relating to the subject matter herein and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning the purchase of the Shares hereunder are superseded. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing and signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.


8.        Compliance with Laws and Regulations .   The issuance of Shares will be subject to and conditioned upon compliance by the Company and Participant with all applicable state and federal laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company’s Common Stock may be listed or quoted at the time of such issuance or transfer.

9.        Governing Law; Severability .   If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law.

10.       No Rights as Employee, Director or Consultant .   Nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company, or a Parent or Subsidiary of the Company, to terminate Purchaser s service, for any reason, with or without cause.

By Participant’s signature and the signature of the Company’s representative on the Notice, Participant and the Company agree that this Performance Shares Award is granted under and governed by the terms and conditions of the Plan, the Notice and this Agreement. Participant has reviewed the Plan, the Notice and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement, and fully understands all provisions of the Plan, the Notice and this Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan, the Notice and this Agreement. Participant further agrees to notify the Company upon any change in Participant’s residence address.


AMYRIS BIOTECHNOLOGIES, INC.

2010 EQUITY INCENTIVE PLAN

NOTICE OF RESTRICTED STOCK AWARD

GRANT NUMBER:                 

Unless otherwise defined herein, the terms defined in the Company’s 2010 Equity Incentive Plan (the “ Plan ”) shall have the same meanings in this Notice of Restricted Stock Award (the “ Notice ”).

Name:                                                                                                                        

Address:                                                                                                                    

You (“ Participant ”) have been granted an award of Restricted Shares of Common Stock of Amyris Biotechnologies, Inc. (the “ Company ”) under the Plan subject to the terms and conditions of the Plan, this Notice and the attached Restricted Stock Agreement (the “ Restricted Stock Purchase Agreement ”).

 

Total Number of Restricted Shares Awarded:

  

                                                                                                                                        

  

Fair Market Value per Restricted Share:

   $                                                                                                                                         

Total Fair Market Value of Award:

   $                                                                                                                                         

Purchase Price per Restricted Share:

   $                                                                                                                                         

Total Purchase Price for all Restricted Shares:    

   $                                                                                                                                         

Date of Grant:

                                                                                                                                              

Vesting Commencement Date:

                                                                                                                                              

Vesting Schedule:

  

Subject to the limitations set forth in this Notice, the Plan and the Restricted Stock Purchase Agreement, the Restricted Shares will vest and the right of repurchase shall lapse, in whole or in part, in accordance with the following schedule: [INSERT VESTING SCHEDULE]

  

You understand that your employment or consulting relationship with the Company is for an unspecified duration, can be terminated at any time (i.e., is “at-will”), and that nothing in this Notice, the Restricted Stock Agreement or the Plan changes the at-will nature of that relationship. You acknowledge that the vesting of the Restricted Shares pursuant to this Notice is earned only by continuing service as an Employee, Director or Consultant of the Company. You also understand that this Notice is subject to the terms and conditions of both the Restricted Stock Agreement and the Plan, both of which are incorporated herein by reference. You have read both the Restricted Stock Agreement and the Plan. If the Restricted Stock Purchase Agreement is not executed by you within thirty (30) days of the Date of Grant above, then this grant shall be void.

 

AMYRIS BIOTECHNOLOGIES, INC.     RECIPIENT:  
By:                                                                                                                 Signature                                                                                      
Its:                                                                                                                 Please Print Name                                                                    


AMYRIS BIOTECHNOLOGIES, INC.

2010 EQUITY INCENTIVE PLAN

RESTRICTED STOCK AGREEMENT

THIS RESTRICTED STOCK AGREEMENT (this “ Agreement ”) is made as of                                  , 20          by and between Amyris Biotechnologies, Inc., a Delaware corporation (the “ Company ”), and ___________________________________ (“ Participant ”) pursuant to the Company’s 2010 Equity Incentive Plan (the “ Plan ”). Unless otherwise defined herein, the terms defined in the Plan shall have the same meanings in this Agreement.

1.      Sale of Stock .  Subject to the terms and conditions of this Agreement, on the Purchase Date (as defined below) the Company will issue and sell to Participant, and Participant agrees to purchase from the Company the number of Shares shown on the Notice of Restricted Stock Award (the “ Notice ”) at a purchase price of $                              per Share. The per Share purchase price of the Shares shall be not less than the par value of the Shares as of the date of the offer of such Shares to the Participant. The term “Shares” refers to the purchased Shares and all securities received in replacement of or in connection with the Shares pursuant to stock dividends or splits, all securities received in replacement of the Shares in a recapitalization, merger, reorganization, exchange or the like, and all new, substituted or additional securities or other properties to which Participant is entitled by reason of Participant’s ownership of the Shares.

2.      Time and Place of Purchase .  The purchase and sale of the Shares under this Agreement shall occur at the principal office of the Company simultaneously with the execution of this Agreement by the parties, or on such other date as the Company and Participant shall agree (the “ Purchase Date ”). On the Purchase Date, the Company will issue in Participant’s name a stock certificate representing the Shares to be purchased by Participant against payment of the purchase price therefor by Participant by (a) check made payable to the Company, (b) cancellation of indebtedness of the Company to Participant, (c) Participant’s personal services that the Committee has determined have already been rendered to the Company and have a value not less than aggregate par value of the Shares to be issued Participant, or (d) a combination of the foregoing.

3.      Restrictions on Resale .  By signing this Agreement, Participant agrees not to sell any Shares acquired pursuant to the Plan and this Agreement at a time when applicable laws, regulations or Company or underwriter trading policies prohibit exercise or sale. This restriction will apply as long as Participant is providing service to the Company or a Subsidiary of the Company.

3.1      Repurchase Right on Termination Other Than for Cause .  For the purposes of this Agreement, a “ Repurchase Event ” shall mean an occurrence of one of the following:

(i)     termination of Participant’s service, whether voluntary or involuntary and with or without cause;

(ii)     resignation, retirement or death of Participant; or

(iii)     any attempted transfer by Participant of the Shares, or any interest therein, in violation of this Agreement.

Upon the occurrence of a Repurchase Event, the Company shall have the right (but not an obligation) to purchase the Shares of Participant at a price equal to the Purchase Price per Share (the “ Repurchase Right ”). The Repurchase Right shall lapse in accordance with the vesting schedule set forth in the


Notice. For purposes of this Agreement, “ Unvested Shares ” means Stock pursuant to which the Company’s Repurchase Right has not lapsed.

3.2      Exercise of Repurchase Right .  Unless the Company provides written notice to Participant within 90 days from the date of termination of Participant’s service to the Company that the Company does not intend to exercise its Repurchase Right with respect to some or all of the Unvested Shares, the Repurchase Right shall be deemed automatically exercised by the Company as of the 90th day following such termination, provided that the Company may notify Participant that it is exercising its Repurchase Right as of a date prior to such 90th day. Unless Participant is otherwise notified by the Company pursuant to the preceding sentence that the Company does not intend to exercise its Repurchase Right as to some or all of the Unvested Shares, execution of this Agreement by Participant constitutes written notice to Participant of the Company’s intention to exercise its Repurchase Right with respect to all Unvested Shares to which such Repurchase Right applies at the time of Termination of Participant. The Company, at its choice, may satisfy its payment obligation to Participant with respect to exercise of the Repurchase Right by either (A) delivering a check to Participant in the amount of the purchase price for the Unvested Shares being repurchased, or (B) in the event Participant is indebted to the Company, canceling an amount of such indebtedness equal to the purchase price for the Unvested Shares being repurchased, or (C) by a combination of (A) and (B) so that the combined payment and cancellation of indebtedness equals such purchase price. In the event of any deemed automatic exercise of the Repurchase Right by canceling an amount of such indebtedness equal to the purchase price for the Unvested Shares being repurchased, such cancellation of indebtedness shall be deemed automatically to occur as of the 90th day following termination of Participant’s employment or consulting relationship unless the Company otherwise satisfies its payment obligations. As a result of any repurchase of Unvested Shares pursuant to the Repurchase Right, the Company shall become the legal and beneficial owner of the Unvested Shares being repurchased and shall have all rights and interest therein or related thereto, and the Company shall have the right to transfer to its own name the number of Unvested Shares being repurchased by the Company, without further action by Participant.

3.3      Acceptance of Restrictions .  Acceptance of the Shares shall constitute Participant’s agreement to such restrictions and the legending of his or her certificates with respect thereto. Notwithstanding such restrictions, however, so long as Participant is the holder of the Shares, or any portion thereof, he or she shall be entitled to receive all dividends declared on and to vote the Shares and to all other rights of a stockholder with respect thereto.

3.4      Non-Transferability of Unvested Shares .  In addition to any other limitation on transfer created by applicable securities laws or any other agreement between the Company and Participant, Participant may not transfer any Unvested Shares, or any interest therein, unless consented to in writing by a duly authorized representative of the Company. Any purported transfer is void and of no effect, and no purported transferee thereof will be recognized as a holder of the Unvested Shares for any purpose whatsoever. Should such a transfer purport to occur, the Company may refuse to carry out the transfer on its books, set aside the transfer, or exercise any other legal or equitable remedy. In the event the Company consents to a transfer of Unvested Shares, all transferees of Shares or any interest therein will receive and hold such Shares or interest subject to the provisions of this Agreement, including, insofar as applicable, the Repurchase Right. In the event of any purchase by the Company hereunder where the Shares or interest are held by a transferee, the transferee shall be obligated, if requested by the Company, to transfer the Shares or interest to the Participant for consideration equal to the amount to be paid by the Company hereunder. In the event the Repurchase Right is deemed exercised by the Company, the Company may deem any transferee to have transferred the Shares or interest to Participant prior to their purchase by the Company, and payment of the purchase price by the Company to such transferee shall be deemed to satisfy Participant’s obligation to pay such transferee for such Shares or interest, and also to satisfy the Company’s obligation to pay Participant for such Shares or interest.


3.5      Assignment .  The Repurchase Right may be assigned by the Company in whole or in part to any persons or organization.

4.      Restrictive Legends and Stop Transfer Orders .

4.1      Legends .  The certificate or certificates representing the Shares shall bear the following legend (as well as any legends required by applicable state and federal corporate and securities laws):

THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.

4.2          Stop-Transfer Notices .  Participant agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records.

4.3      Refusal to Transfer .  The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (ii) to treat as the owner or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred.

5.      No Rights as Employee, Director or Consultant .  Nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company, or a Parent or Subsidiary of the Company, to terminate Participant s service, for any reason, with or without cause.

6.      Miscellaneous .

6.1      Acknowledgement .  The Company and Participant agree that the Restricted Shares are granted under and governed by the Notice, this Agreement and by the provisions of the Plan (incorporated herein by reference). Participant: (i) acknowledges receipt of a copy of the Plan and the Plan prospectus, (ii) represents that Participant has carefully read and is familiar with their provisions, and (iii) hereby accepts the Restricted Shares subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice.

6.2      Entire Agreement; Enforcement of Rights .  This Agreement, the Plan and the Notice constitute the entire agreement and understanding of the parties relating to the subject matter herein and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning the purchase of the Shares hereunder are superseded. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing and signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.

6.3      Compliance with Laws and Regulations .  The issuance of Shares will be subject to and conditioned upon compliance by the Company and Participant with all applicable state and federal laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company’s Common Stock may be listed or quoted at the time of such issuance or transfer.


6.4      Governing Law; Severability .  If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law.

6.5      Construction .  This Agreement is the result of negotiations between and has been reviewed by each of the parties hereto and their respective counsel, if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be construed in favor of or against any one of the parties hereto.

6.6      Notices .  Any notice to be given under the terms of the Plan shall be addressed to the Company in care of its principal office, and any notice to be given to the Participant shall be addressed to such Participant at the address maintained by the Company for such person or at such other address as the Participant may specify in writing to the Company.

6.7      Counterparts .  This Agreement may be executed in two or more counterparts, each of which shall he deemed an original and all of which together shall constitute one instrument.

6.8      U.S. Tax Consequences .  Upon vesting of Shares, Participant will include in taxable income the difference between the fair market value of the vesting Shares, as determined on the date of their vesting, and the price paid for the Shares. This will be treated as ordinary income by Participant and will be subject to withholding by the Company when required by applicable law. In the absence of an Election (defined below), the Company shall withhold a number of vesting Shares with a fair market value (determined on the date of their vesting) equal to the minimum amount the Company is required to withhold for income and employment taxes. If Participant makes an Election, then Participant must, prior to making the Election, pay in cash (or check) to the Company an amount equal to the amount the Company is required to withhold for income and employment taxes.

7.      Section 83(b) Election .  Participant hereby acknowledges that he or she has been informed that, with respect to the purchase of the Shares, an election may be filed by the Participant with the Internal Revenue Service, within 30 days of the purchase of the Shares, electing pursuant to Section 83(b) of the Code to be taxed currently on any difference between the purchase price of the Shares and their Fair Market Value on the date of purchase (the “ Election ”). Making the Election will result in recognition of taxable income to the Participant on the date of purchase, measured by the excess, if any, of the Fair Market Value of the Shares over the purchase price for the Shares. Absent such an Election, taxable income will be measured and recognized by Participant at the time or times on which the Company’s Repurchase Right lapses. Participant is strongly encouraged to seek the advice of his or her own tax consultants in connection with the purchase of the Shares and the advisability of filing of the Election. PARTICIPANT ACKNOWLEDGES THAT IT IS SOLELY PARTICIPANT’S RESPONSIBILITY, AND NOT THE COMPANY’S RESPONSIBILITY, TO TIMELY FILE THE

ELECTION UNDER SECTION 83(b) OF THE CODE, EVEN IF PARTICIPANT REQUESTS THE COMPANY, OR ITS REPRESENTATIVE, TO MAKE THIS FILING ON PARTICIPANT’S BEHALF.


The parties have executed this Agreement as of the date first set forth above.

 

AMYRIS BIOTECHNOLOGIES, INC.

By:                                                                                                  

Its:                                                                                                   

RECIPIENT:

Signature                                                                                     

Please Print Name                                                                


RECEIPT

Amyris Biotechnologies, Inc. hereby acknowledges receipt of (check as applicable):

¨   A check in the amount of $                                 

¨   The cancellation of indebtedness in the amount of $                                 

given by                                                   as consideration for Certificate No.-                          for                          shares of Common Stock of Amyris Biotechnologies, Inc.

Dated:                                         

 

AMYRIS BIOTECHNOLOGIES, INC.
By:    
Its:    


RECEIPT AND CONSENT

The undersigned Participant hereby acknowledges receipt of a photocopy of Certificate No.-                      for                              shares of Common Stock of Amyris Biotechnologies, Inc. (the “ Company ”).

The undersigned further acknowledges that the Secretary of the Company, or his or her designee, is acting as escrow holder pursuant to the Restricted Stock Agreement that Participant has previously entered into with the Company. As escrow holder, the Secretary of the Company, or his or her designee, holds the original of the aforementioned certificate issued in the undersigned’s name. To facilitate any transfer of Shares to the Company pursuant to the Restricted Stock Agreement, Participant has executed the attached Assignment Separate from Certificate.

Dated:                                          , 20         

Signature                                                                                                       

Please Print Name                                                                                       


STOCK POWER AND ASSIGNMENT

SEPARATE FROM STOCK CERTIFICATE

FOR VALUE RECEIVED and pursuant to that certain Restricted Stock Agreement dated as of                                          ,              , [ COMPLETE AT THE TIME OF PURCHASE ] (the “ Agreement ”), the undersigned Participant hereby sells, assigns and transfers unto                                                   ,                      shares of the Common Stock $0.000 [              ] , par value per share, of Amyris Biotechnologies, Inc., a Delaware corporation (the “ Company ”), standing in the undersigned’s name on the books of the Company represented by Certificate No(s).                  [ COMPLETE AT THE TIME OF PURCHASE ] delivered herewith, and does hereby irrevocably constitute and appoint the Secretary of the Company as the undersigned’s attorney-in-fact, with full power of substitution, to transfer said stock on the books of the Company. THIS ASSIGNMENT MAY ONLY BE USED AS AUTHORIZED BY THE AGREEMENT AND ANY EXHIBITS THERETO.

Dated:                                          ,             

 

PARTICIPANT
   
(Signature)
   
(Please Print Name)

Instructions to Participant :     Please do not fill in any blanks other than the signature line. The purpose of this document is to enable the Company and/or its assignee(s) to acquire the shares upon exercise of its “Repurchase Right” set forth in the Agreement without requiring additional action by the Participant.

Exhibit 10.47

AMYRIS BIOTECHNOLOGIES, INC.

2010 E MPLOYEE S TOCK P URCHASE P LAN

1.     Establishment of Plan.  Amyris Biotechnologies, Inc. (the “Company”) proposes to grant options for purchase of the Company’s Common Stock to eligible employees of the Company and its Participating Corporations (as hereinafter defined) pursuant to this Employee Stock Purchase Plan (this “Plan”). For purposes of this Plan, “Parent” and “Subsidiary” shall have the same meanings as “parent corporation” and “subsidiary corporation” in Sections 424(e) and 424(f), respectively, of the Internal Revenue Code of 1986, as amended (the “Code”), and “Corporate Group” shall refer collectively to the Company and all its Parents and Subsidiaries. “Participating Corporations” are the Company and any Parents or Subsidiaries that the Board of Directors of the Company (the “Board”) designates from time to time as corporations that shall participate in this Plan. The Company intends this Plan to qualify as an “employee stock purchase plan” under Section 423 of the Code (including any amendments to or replacements of such Section), and this Plan shall be so construed. Any term not expressly defined in this Plan but defined for purposes of Section 423 of the Code shall have the same definition herein. Subject to Section 14, a total of 168,627 shares of the Company’s Common Stock is reserved for issuance under this Plan. In addition, on each January 1 for each calendar year after the Effective Date, the aggregate number of shares of the Company’s Common Stock reserved for issuance under the Plan shall be increased automatically by the lesser of one (1%) percent of the number of shares of the Company’s Common Stock issued and outstanding on each December 31 immediately prior to the date of increase or (ii) such number of shares of the Company’s Common determined by the Board or the Committee provided that the aggregate number of shares issued over the term of this Plan shall not exceed 10,000,000 shares of Common Stock.

2.     Purpose.  The purpose of this Plan is to provide eligible employees of the Company and Participating Corporations with a means of acquiring an equity interest in the Company through payroll deductions, to enhance such employees’ sense of participation in the affairs of the Company and Participating Corporations, and to provide an incentive for continued employment.

3.     Administration.  The Plan will be administered by the Compensation Committee of the Board or by the Board (either referred to herein as the “Committee”). Subject to the provisions of this Plan and the limitations of Section 423 of the Code or any successor provision in the Code, all questions of interpretation or application of this Plan shall be determined by the Committee and its decisions shall be final and binding upon all Participants. The Committee will have full and exclusive discretionary authority to construe, interpret and apply the terms of the Plan, to determine eligibility and decide upon any and all claims filed under the Plan. Every finding, decision and determination made by the Committee will, to the full extent permitted by law, be final and binding upon all parties. Notwithstanding any provision to the contrary in this Plan, the Committee may adopt rules and/or procedures relating to the operation and administration of the Plan to accommodate requirements of local law and procedures outside of the United States. Members of the Committee shall receive no compensation for their services in connection with the administration of this Plan, other than standard fees as established from time to time by the Board for services rendered by Board members serving on Board committees. All expenses incurred in connection with the administration of this Plan shall be paid by the Company.

4.     Eligibility.  Any employee of the Company or the Participating Corporations is eligible to participate in an Offering Period (as hereinafter defined) under this Plan except the following:

(a) employees who are not employed by the Company or a Participating Corporation prior to the beginning of such Offering Period or prior to such other time period as specified by the Committee; except that employees who are employed on the Effective Date of the Registration Statement


filed by the Company with the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”) registering the initial public offering of the Company’s Common Stock shall be eligible to participate in the First Offering Period;

(b) employees who are customarily employed for twenty (20) hours or less per week;

(c) employees who are customarily employed for five (5) months or less in a calendar year;

(d) employees who, together with any other person whose stock would be attributed to such employee pursuant to Section 424(d) of the Code, own stock or hold options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any of its Participating Corporations or who, as a result of being granted an option under this Plan with respect to such Offering Period, would own stock or hold options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any of its Participating Corporations;

(e) employees who do not meet any other eligibility requirements that the Committee may choose to impose (within the limits permitted by the Code);

(f) employees who have been an employee of the Company for less than one (1) month prior to the first day of an Offering Period (except as set forth in (a) above); and

(g) individuals who provide services to the Company or any of its Participating Corporations as independent contractors who are reclassified as common law employees for any reason except for federal income and employment tax purposes.

5.     Offering Dates.

(a) The offering periods of this Plan (each, an “Offering Period”) may be of up to six (6) months duration (except the Initial Offering Period, which may be longer than six (6) months as described below) and shall commence and end at the times designated by the Committee. Each Offering Period is itself a purchase period (a “Purchase Period”) during which payroll deductions of Participants are accumulated under this Plan.

(b) The initial Offering Period shall commence on the date on which the Registration Statement covering the initial public offering of shares of the Company’s Common Stock is declared effective by the U.S. Securities and Exchange Commission (the “Effective Date”), and shall end with the Purchase Date that occurs on or prior to February 14th or August 14th that first occurs six months or more after the Effective Date. The initial Offering Period shall consist of a single Purchase Period. Thereafter, a six-month Offering Period shall commence on each February 15 th and August 15 th , with each such Offering Period also consisting of a single six-month Purchase Period.

(c) The first business day of each Offering Period is referred to as the “Offering Date,” however, for the initial Offering Period this shall be the Effective Date. The last business day of each Purchase Period is referred to as the “Purchase Date.” The Committee shall have the power to change these terms as provided in Section 25 below.

6.     Participation in this Plan.

(a) Any employee who is an eligible employee determined in accordance with Section 4 immediately prior to the initial Offering Period will be automatically enrolled in the initial Offering Period under this Plan. With respect to subsequent Offering Periods, any eligible employee determined in accordance with Section 4 will be eligible to participate in this Plan, subject to the requirement of Section 6(b) hereof and the other terms and provisions of this Plan. Eligible employees who meet the eligibility requirements set forth in Section 4 and who are either automatically enrolled in the initial offering period


or who elect to participate in the this Plan pursuant to Section 6(b) are referred to herein as a “Participant” or collectively as “Participants.”

(b) Notwithstanding the foregoing, (i) an eligible employee may elect to decrease the number of shares of Common Stock that such employee would otherwise be permitted to purchase for the initial Offering Period under the Plan and/or purchase shares of Common Stock for the initial Offering Period through payroll deductions by delivering a subscription agreement to the Company within thirty (30) days after the filing of an effective registration statement pursuant to Form S-8 and (ii) the Committee may set a later time for filing the subscription agreement authorizing payroll deductions for all eligible employees with respect to a given Offering Period. With respect to Offering Periods after the initial Offering Period, a Participant may elect to participate in this Plan by submitting a subscription agreement prior to the commencement of the Offering Period (or such earlier date as the Committee may determine) to which such agreement relates.

(c) Once an employee becomes a Participant in an Offering Period, then such Participant will automatically participate in the Offering Period commencing immediately following the last day of such prior Offering Period unless the Participant withdraws or is deemed to withdraw from this Plan or terminates further participation in the Offering Period as set forth in Section 11 below. Such Participant is not required to file any additional subscription agreement in order to continue participation in this Plan.

7.     Grant of Option on Enrollment.  Becoming a Participant with respect to an Offering Period will constitute the grant (as of the Offering Date) by the Company to such Participant of an option to purchase on the Purchase Date up to that number of shares of Common Stock of the Company determined by a fraction, the numerator of which is the amount accumulated in such Participant’s payroll deduction account during such Purchase Period and the denominator of which is the lower of (i) eighty-five percent (85%) of the fair market value of a share of the Company’s Common Stock on the Offering Date (but in no event less than the par value of a share of the Company’s Common Stock), or (ii) eighty-five percent (85%) of the fair market value of a share of the Company’s Common Stock on the Purchase Date (but in no event less than the par value of a share of the Company’s Common Stock) provided, however , that for the Purchase Period within the initial Offering Period the numerator shall be fifteen percent (15%) of the Participant’s compensation for such Purchase Period and provided , further , that the number of shares of the Company’s Common Stock subject to any option granted pursuant to this Plan shall not exceed the lesser of (x) the maximum number of shares set by the Committee pursuant to Section 10(b) below with respect to the applicable Purchase Date, or (y) the maximum number of shares which may be purchased pursuant to Section 10(a) below with respect to the applicable Purchase Date. The fair market value of a share of the Company’s Common Stock shall be determined as provided in Section 8 below.

8.     Purchase Price.  The purchase price per share at which a share of Common Stock will be sold in any Offering Period shall be eighty-five percent (85%) of the lesser of:

(a) The fair market value on the Offering Date; or

(b) The fair market value on the Purchase Date.

The term “fair market value” means, as of any date, the value of a share of the Company’s Common Stock determined as follows:

(i) if such Common Stock is publicly traded and is then listed on a national securities exchange, its closing price on the date of determination on the principal national securities exchange on which the Common Stock is listed or admitted to trading as reported in The Wall Street Journal or such other source as the Board or the Committee deems reliable; or


(ii) if such Common Stock is publicly traded but is neither listed or admitted to trading on a national securities exchange, the average of the closing bid and asked prices on the date of determination as reported in The Wall Street Journal or such other source as the Board or the Committee deems reliable; or

(iii) with respect to the initial Offering Period, “fair market value” on the Offering Date shall be the price at which shares of Common Stock are offered to the public pursuant to the Registration Statement covering the initial public offering of shares of the Company’s Common Stock; and

(iv) if none of the foregoing is applicable, by the Board or the Committee in good faith.

9.     Payment of Purchase Price; Payroll Deduction Changes; Share Issuances.

(a) The purchase price of the shares is accumulated by regular payroll deductions made during each Offering Period. The deductions are made as a percentage of the Participant’s compensation in one percent (1%) increments not less than one percent (1%), nor greater than fifteen percent (15%) or such lower limit set by the Committee. Compensation shall mean all W-2 cash compensation categorized by the Company as base salary or regular hourly wages, and expressly excluding commissions, overtime, shift premiums, bonuses and incentive compensation, plus draws against commissions, provided , however , that for purposes of determining a Participant’s compensation, any election by such Participant to reduce his or her regular cash remuneration under Sections 125 or 401(k) of the Code shall be treated as if the Participant did not make such election. Payroll deductions shall commence on the first payday following the last Purchase Date (first payday following the effective date of filing with the U.S. Securities and Exchange Commission a securities registration statement for the Plan with respect to the initial Offering Period) and shall continue to the end of the Offering Period unless sooner altered or terminated as provided in this Plan.

(b) A Participant may increase or decrease the rate of payroll deductions during an Offering Period by filing with the Company a new authorization for payroll deductions, with the new rate to become effective for the next payroll period commencing after the Company’s receipt of the authorization and continuing for the remainder of the Offering Period unless changed as described below. Such change in the rate of payroll deductions may be made at any time during an Offering Period, under rules determined by the Committee. A Participant may increase or decrease the rate of payroll deductions for any subsequent Offering Period by filing with the Company a new authorization for payroll deductions prior to the beginning of such Offering Period, or such other time period as specified by the Committee.

(c) A Participant may reduce his or her payroll deduction percentage to zero during an Offering Period by filing with the Company a request for cessation of payroll deductions. Such reduction shall be effective beginning with the next payroll period after the Company’s receipt of the request and no further payroll deductions will be made for the duration of the Offering Period. Payroll deductions credited to the Participant’s account prior to the effective date of the request shall be used to purchase shares of Common Stock of the Company in accordance with Section (e) below. A reduction of the payroll deduction percentage to zero shall be treated as such Participant’s withdrawal from such Offering Period, and the Plan, effective as of the day after the next Purchase Date following the filing date of such request with the Company.

(d) All payroll deductions made for a Participant are credited to his or her account under this Plan and are deposited with the general funds of the Company. No interest accrues on the payroll deductions. All payroll deductions received or held by the Company may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such payroll deductions.

(e) On each Purchase Date, so long as this Plan remains in effect and provided that the Participant has not submitted a signed and completed withdrawal form before that date which notifies the Company that the Participant wishes to withdraw from that Offering Period under this Plan and have all


payroll deductions accumulated in the account maintained on behalf of the Participant as of that date returned to the Participant, the Company shall apply the funds then in the Participant’s account to the purchase of whole shares of Common Stock reserved under the option granted to such Participant with respect to the Offering Period to the extent that such option is exercisable on the Purchase Date. The purchase price per share shall be as specified in Section 8 of this Plan. Any amount remaining in a Participant’s account on a Purchase Date which is less than the amount necessary to purchase a full share of the Company’s Common Stock shall be carried forward, without interest, into the next Purchase Period or Offering Period, as the case may be. In the event that this Plan has been oversubscribed, all funds not used to purchase shares on the Purchase Date shall be returned to the Participant, without interest. No Common Stock shall be purchased on a Purchase Date on behalf of any employee whose participation in this Plan has terminated prior to such Purchase Date.

(f) As promptly as practicable after the Purchase Date, the Company shall issue shares for the Participant’s benefit representing the shares purchased upon exercise of his or her option.

(g) During a Participant’s lifetime, his or her option to purchase shares hereunder is exercisable only by him or her. The Participant will have no interest or voting right in shares covered by his or her option until such option has been exercised.

10.     Limitations on Shares to be Purchased.

(a) No Participant shall be entitled to purchase stock under any Offering Period at a rate which, when aggregated with such Participant’s rights to purchase stock, that are also outstanding in the same calendar year(s) (whether under other Offering Periods or other employee stock purchase plans of the Corporate Group), exceeds $25,000 in fair market value, determined as of the Offering Date, (or such other limit as may be imposed by the Code) for each calendar year in which such Offering Period is in effect (hereinafter the “Maximum Share Amount”). The Company shall automatically suspend the payroll deductions of any Participant as necessary to enforce such limit provided that when the Company automatically resumes such payroll deductions, the Company must apply the rate in effect immediately prior to such suspension.

(b) The Committee may, in its sole discretion, set a lower maximum number of shares which may be purchased by any Participant during any Offering Period than that determined under Section 10(a) above, which shall then be the Maximum Share Amount for subsequent Offering Periods; provided, however, in no event shall a Participant be permitted to purchase more than [            ] Shares during any one Offering Period, irrespective of the Maximum Share Amount set forth in (a) and (b) hereof. If a new Maximum Share Amount is set, then all Participants must be notified of such Maximum Share Amount prior to the commencement of the next Offering Period for which it is to be effective. The Maximum Share Amount shall continue to apply with respect to all succeeding Offering Periods unless revised by the Committee as set forth above.

(c) If the number of shares to be purchased on a Purchase Date by all Participants exceeds the number of shares then available for issuance under this Plan, then the Company will make a pro rata allocation of the remaining shares in as uniform a manner as shall be reasonably practicable and as the Committee shall determine to be equitable. In such event, the Company shall give written notice of such reduction of the number of shares to be purchased under a Participant’s option to each Participant affected.

(d) Any payroll deductions accumulated in a Participant’s account which are not used to purchase stock due to the limitations in this Section 10, and not covered by Section 9(e), returned to the Participant as soon as practicable after the end of the applicable Purchase Period.


11.     Withdrawal.

(a) Each Participant may withdraw from an Offering Period under this Plan by signing and delivering to the Company a written notice to that effect on a form provided for such purpose by the Company. Such withdrawal may be elected at any time prior to the end of an Offering Period, or such other time period as specified by the Committee.

(b) Upon withdrawal from this Plan, the accumulated payroll deductions shall be returned to the withdrawn Participant, without interest, and his or her interest in this Plan shall terminate. In the event a Participant voluntarily elects to withdraw from this Plan, he or she may not resume his or her participation in this Plan during the same Offering Period, but he or she may participate in any Offering Period under this Plan which commences on a date subsequent to such withdrawal by filing a new authorization for payroll deductions in the same manner as set forth in Section 6 above for initial participation in this Plan.

12.     Termination of Employment.  Termination of a Participant’s employment for any reason, including retirement, death, disability, or the failure of a Participant to remain an eligible employee of the Company or of a Participating Corporation, immediately terminates his or her participation in this Plan. In such event, accumulated payroll deductions credited to the Participant’s account will be returned to him or her or, in the case of his or her death, to his or her legal representative, without interest. For purposes of this Section 12, an employee will not be deemed to have terminated employment or failed to remain in the continuous employ of the Company or of a Participating Corporation in the case of sick leave, military leave, or any other leave of absence approved by the Company; provided that such leave is for a period of not more than ninety (90) days or reemployment upon the expiration of such leave is guaranteed by contract or statute.

13.     Return of Payroll Deductions.  In the event a Participant’s interest in this Plan is terminated by withdrawal, termination of employment or otherwise, or in the event this Plan is terminated by the Board, the Company shall deliver to the Participant all accumulated payroll deductions credited to such Participant’s account. No interest shall accrue on the payroll deductions of a Participant in this Plan.

14.     Capital Changes.  If the number of outstanding Shares is changed by a stock dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in the capital structure of the Company, without consideration, then the Committee shall adjust the number and class of Common Stock that may be delivered under the Plan, the purchase price per share and the number of shares of Common Stock covered by each option under the Plan which has not yet been exercised, and the numerical limits of Sections 1 and 10 shall be proportionately adjusted, subject to any required action by the Board or the stockholders of the Company and in compliance with applicable securities laws; provided that fractions of a Share will not be issued.

15.     Nonassignability.  Neither payroll deductions credited to a Participant’s account nor any rights with regard to the exercise of an option or to receive shares under this Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in Section 22 below) by the Participant. Any such attempt at assignment, transfer, pledge or other disposition shall be void and without effect.

16.     Use of Participant Funds and Reports.  The Company may use all payroll deductions received or held by it under the Plan for any corporate purpose, and the Company will not be required to segregate Participant payroll deductions. Until Shares are issued, Participants will only have the rights of an unsecured creditor. Each Participant shall receive promptly after the end of each Purchase Period a report of his or her account setting forth the total payroll deductions accumulated, the number of shares purchased, the per share price thereof and the remaining cash balance, if any, carried forward to the next Purchase Period or Offering Period, as the case may be.


17.     Notice of Disposition.  Each Participant shall notify the Company in writing if the Participant disposes of any of the shares purchased in any Offering Period pursuant to this Plan if such disposition occurs within two (2) years from the Offering Date or within one (1) year from the Purchase Date on which such shares were purchased (the “Notice Period”). The Company may, at any time during the Notice Period, place a legend or legends on any certificate representing shares acquired pursuant to this Plan requesting the Company’s transfer agent to notify the Company of any transfer of the shares. The obligation of the Participant to provide such notice shall continue notwithstanding the placement of any such legend on the certificates.

18.     No Rights to Continued Employment.  Neither this Plan nor the grant of any option hereunder shall confer any right on any employee to remain in the employ of the Company or any Participating Corporation, or restrict the right of the Company or any Participating Corporation to terminate such employee’s employment.

19.     Equal Rights And Privileges.  All eligible employees shall have equal rights and privileges with respect to this Plan so that this Plan qualifies as an “employee stock purchase plan” within the meaning of Section 423 or any successor provision of the Code and the related regulations. Any provision of this Plan which is inconsistent with Section 423 or any successor provision of the Code shall, without further act or amendment by the Company, the Committee or the Board, be reformed to comply with the requirements of Section 423. This Section 19 shall take precedence over all other provisions in this Plan.

20.     Notices.  All notices or other communications by a Participant to the Company under or in connection with this Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof.

21.     Term; Stockholder Approval.  This Plan will become effective on the Effective Date. This Plan shall be approved by the stockholders of the Company, in any manner permitted by applicable corporate law, within twelve (12) months before or after the date this Plan is adopted by the Board. No purchase of shares that are subject to such stockholder approval before becoming available under this Plan shall occur prior to stockholder approval of such shares and the Board or Committee may delay any Purchase Date and postpone the commencement of any Offering Period subsequent to such Purchase Date as deemed necessary or desirable to obtain such approval. This Plan shall continue until the earlier to occur of (a) termination of this Plan by the Board (which termination may be effected by the Board at any time pursuant to Section 25 below), (b) issuance of all of the shares of Common Stock reserved for issuance under this Plan, or (c) the tenth anniversary of the first Purchase Date under the Plan.

22.     Designation of Beneficiary.

(a) A Participant may file a written designation of a beneficiary who is to receive any shares and cash, if any, from the Participant’s account under this Plan in the event of such Participant’s death subsequent to the end of a Purchase Period but prior to delivery to him of such shares and cash. In addition, a Participant may file a written designation of a beneficiary who is to receive any cash from the Participant’s account under this Plan in the event of such Participant’s death prior to a Purchase Date.

(b) Such designation of beneficiary may be changed by the Participant at any time by written notice. In the event of the death of a Participant and in the absence of a beneficiary validly designated under this Plan who is living at the time of such Participant’s death, the Company shall deliver such shares or cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such shares or cash to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.


23.     Conditions Upon Issuance of Shares; Limitation on Sale of Shares.  Shares shall not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such shares pursuant thereto shall comply with all applicable provisions of law, domestic or foreign, including, without limitation, the Securities Act, the Securities Exchange Act of 1934, as amended, the rules and regulations promulgated thereunder, and the requirements of any stock exchange or automated quotation system upon which the shares may then be listed, and shall be further subject to the approval of counsel for the Company with respect to such compliance.

24.     Applicable Law.  The Plan shall be governed by the substantive laws (excluding the conflict of laws rules) of the State of Delaware.

25.     Amendment or Termination.  The Committee, in its sole discretion, may amend, suspend, or terminate the Plan, or any part thereof, at any time and for any reason. If the Plan is terminated, the Committee, in its discretion, may elect to terminate all outstanding Offering Periods either immediately or upon completion of the purchase of shares of Common Stock on the next Purchase Date (which may be sooner than originally scheduled, if determined by the Committee in its discretion), or may elect to permit Offering Periods to expire in accordance with their terms (and subject to any adjustment pursuant to Section 14). If an Offering Period is terminated prior to its previously-scheduled expiration, all amounts then credited to Participants’ accounts for such Offering Period, which have not been used to purchase shares of the Company’s Common Stock, shall be returned to those Participants (without interest thereon, except as otherwise required under local laws) as soon as administratively practicable. Further, the Committee will be entitled to change the Offering Periods, limit the frequency and/or number of changes in the amount withheld during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the administration of the Plan, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of the Company’s Common Stock for each Participant properly correspond with amounts withheld from the Participant’s base salary or regular hourly wages, and establish such other limitations or procedures as the Committee determines in its sole discretion advisable which are consistent with the Plan. Such actions will not require stockholder approval or the consent of any Participants. However, no amendment shall be made without approval of the stockholders of the Company (obtained in accordance with Section 21 above) within twelve (12) months of the adoption of such amendment (or earlier if required by Section 21) if such amendment would: (a) increase the number of shares that may be issued under this Plan; or (b) change the designation of the employees (or class of employees) eligible for participation in this Plan.

26.     Corporate Transactions.

(a) In the event of a Corporate Transaction (as defined below), each outstanding right to purchase Company Common Stock will be assumed or an equivalent option substituted by the successor corporation or a parent or a subsidiary of the successor corporation. In the event that the successor corporation refuses to assume or substitute for the purchase right, the Offering Period with respect to which such purchase right relates will be shortened by setting a new Purchase Date (the “New Purchase Date”) and will end on the New Purchase Date. The New Purchase Date shall occur on or prior to the consummation of the Corporate Transaction.

(b) “Corporate Transaction” means the occurrence of any of the following events: (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities; or (ii) the consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets; or (iii) the consummation of a merger or


consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.


AMYRIS BIOTECHNOLOGIES, INC. ( THE “C OMPANY ”)

2010 E MPLOYEE S TOCK P URCHASE P LAN (“ESPP”)

   E NROLLMENT /C HANGE  F ORM

 

S ECTION 1:

 

A CTIONS

      

C HECK D ESIRED A CTION :

¨     Enroll in the ESPP

¨     Change Contribution Percentage

¨     Discontinue Contributions

  

AND C OMPLETE S ECTIONS :

2 + 3 + 4 + 6

2 + 4 + 6

2 + 5 + 6

              

S ECTION  2:

 

P ERSONAL D ATA

      

Name:                                                                                                                   

 

        Department:  

 

    
      

Home Address:                                                                                                   

 

            
                 
       Social Security No.:     ¨ ¨ ¨ - ¨ ¨ - ¨ ¨ ¨ ¨           

S ECTION 3:

 

E NROLL

      

I hereby elect to participate in the ESPP, effective at the beginning of the next Offering Period (or with the first Offering Period). I elect to purchase shares of the Common Stock of the Company pursuant to the ESPP. I understand that the stock certificate(s) for the shares purchased on my behalf will be issued in street name and deposited directly into my brokerage account. I hereby agree to take all steps, and sign all forms, required to establish an account with [                      ] for this purpose.

 

My participation will continue as long as I remain eligible, unless I withdraw from the ESPP by filing a new Enrollment/Change Form with the Company. I understand that I must notify the Company of any disposition of shares purchased under the ESPP.

S ECTION  4:

 

E LECT C ONTRIBUTION P ERCENTAGE

      

I hereby authorize the Company to withhold from each of my paychecks such amount as is necessary to equal at the end of the applicable Offering Period              % of my compensation (as defined in the ESPP) paid during such Offering Period as long as I continue to participate in the ESPP. That amount will be applied to the purchase of shares of the Company’s Common Stock pursuant to the ESPP. The percentage must be a whole number (from 1%, up to a maximum of 15%).

 

Please ¨ -increase ¨ -decrease my contribution percentage.

 

Note:    You may change your contribution percentage only once within an Offering Period to be effective during such Offering Period and such change can only be to decrease your contribution percentage. An increase in your contribution percentage can only take effect with the next Offering Period . Each change will become effective as soon as reasonably practicable after the form is received by the Company.

S ECTION  5:

 

D ISCONTINUE C ONTRIBUTIONS

      

¨        I hereby elect to stop my contributions under the ESPP , effective as soon as reasonably practicable after this form is received by the Company. Please ¨ -refund all contributions to me in cash, without interest OR ¨ - use my contributions to purchase shares on the next Purchase Date. I understand that I cannot resume participation until the start of the next Offering Period and must timely file a new enrollment form to do so.

S ECTION  6:

 

A CKNOWLEDGMENT   AND S IGNATURE

      

I acknowledge that I have received a copy of the ESPP and of the Prospectus (which summarizes the major features of the ESPP). I have read the Prospectus and my signature below (or my clicking on the Accept box if this is an electronic form) indicates that I hereby agree to be bound by the terms of the ESPP.

        

Signature:                                                                                                            

 

        Date:                                     

 

    

Exhibit 23.01

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the use in this Amendment No. 2 to the Registration Statement on Form S-1 of our report dated April 16, 2010, except for the eleventh paragraph of Note 19 to the consolidated financial statements as to which the date is June 22, 2010, relating to the consolidated financial statements of Amyris Biotechnologies, Inc., which appears in such Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.

 

/s/ PricewaterhouseCoopers LLP

San Jose, California

June 22, 2010

Exhibit 24.02

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that the person whose signature appears below hereby constitutes and appoints John G. Melo, Jeryl L. Hilleman and Tamara L. Tompkins, and each of them, as his true and lawful attorney-in-fact and agent with full power of substitution, for him in any and all capacities, to sign any and all amendments to the registration statement filed by Amyris Biotechnologies, Inc. on April 16, 2010, file No. 333-166135 (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

 

By:   /s/  Arthur Levinson        
 

Arthur Levinson, Ph.D., Director

Date: 6-14-2010